<SEC-DOCUMENT>0002007919-26-000006.txt : 20260319
<SEC-HEADER>0002007919-26-000006.hdr.sgml : 20260319
<ACCEPTANCE-DATETIME>20260319160048
ACCESSION NUMBER:		0002007919-26-000006
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260319
DATE AS OF CHANGE:		20260319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inhibrx Biosciences, Inc.
		CENTRAL INDEX KEY:			0002007919
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				990613523
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42031
		FILM NUMBER:		26774114

	BUSINESS ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 140
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 795-4220

	MAIL ADDRESS:	
		STREET 1:		11025 N. TORREY PINES ROAD, SUITE 140
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ibex SpinCo, Inc.
		DATE OF NAME CHANGE:	20240111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inbx-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b,d:8fac7241aa424916b2e0582fb85490ec-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:inbx="http://inhibrx.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>inbx-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0002007919</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-37">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-40" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-288">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="inbx-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="right"><xbrli:measure>inbx:right</xbrli:measure></xbrli:unit><xbrli:unit id="distribution"><xbrli:measure>inbx:distribution</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>inbx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>inbx:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>inbx:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>inbx:program</xbrli:measure></xbrli:unit><xbrli:unit id="contract"><xbrli:measure>inbx:contract</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-30</xbrli:startDate><xbrli:endDate>2024-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inbx:AventisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-30</xbrli:startDate><xbrli:endDate>2024-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inbx:AventisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-30</xbrli:startDate><xbrli:endDate>2024-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:MergerConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:LoansAssumedByAcquirerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:NetAssetsAndLiabilitiesAssumedByAcquirerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:TransactionCostsPaidByAcquirerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inbx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inbx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:ClassOfWarrantOrRightExpirationDate1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:ClassOfWarrantOrRightExpirationDate2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inbx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inbx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-30</xbrli:startDate><xbrli:endDate>2024-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2017PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2017PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:SeverancePaymentsToFormerEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:OxfordTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-13</xbrli:startDate><xbrli:endDate>2025-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-18</xbrli:startDate><xbrli:endDate>2026-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0002007919</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8fac7241aa424916b2e0582fb85490ec_1"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.932%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.993%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Mark one)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-42031</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.932%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.993%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">INHIBRX BIOSCIENCES, INC.</ix:nonNumeric> </span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) &#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">99-0613523</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">11025 N. Torrey Pines Road,</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 140</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">795-4220</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.218%"><tr><td style="width:1.0%"/><td style="width:33.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.018%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.943%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">INBX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#9744;  <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#9744;  <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> &#160;&#9746;  No &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> &#160;&#9746;  No &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:564.75pt"><tr><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:24.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:265.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:120.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:24.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="f-27">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;      <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).&#160;&#160;&#160;&#160;      &#9744;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;            &#160;&#160;&#160;&#160; Yes &#160;&#9744;  No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-31">174.6</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $14.27 per share. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;11, 2026, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">14,607,036</ix:nonFraction> shares of common stock outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Documents Incorporated By Reference</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#8217;s Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</span></div></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INHIBRX BIOSCIENCES, INC.<br/>ANNUAL REPORT ON FORM 10-K<br/>For the Year Ended December&#160;31, 2025</span></div><div style="margin-bottom:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_10">Special Note Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_13">Part I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_16">Item 1. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_85">Item 1A. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_85">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_112">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_115">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_115">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_118">Item 2. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_118">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_118">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_121">Item 3. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_121">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_124">Item 4. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_124">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_124">89</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_127">Part II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_127">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_130">Item 5. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_130">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases&#160;of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_130">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_133">Item 6. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_133">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_136">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_136">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_136">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_163">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_163">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_163">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_166">Item 8. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_166">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_166">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_223">Item 9. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_223">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_223">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_226">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_226">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_226">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_232">Item 9B. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_232">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_232">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_235">139</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_238">Part III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_238">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_241">Item 10. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_241">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_241">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_253">Item 11. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_253">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_253">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_268">Item 12. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_268">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_268">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_277">Item 13. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_277">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_277">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_283">Item 14. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_283">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_283">140</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_289">Part IV.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_289">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_292">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_292">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_292">141</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_295">Item 16. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_295">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_295">144</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_298">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i8fac7241aa424916b2e0582fb85490ec_298">144</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or this Annual Report, contains express and implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Except as otherwise indicated by the context, references in this Annual Report to &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to the consolidated business of Inhibrx Biosciences, Inc., or the Company or Inhibrx. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;design,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design, initiation, timing, progress, results and costs of our research and development programs as well as our preclinical studies and clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance therapeutic candidates into, and successfully complete, clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding disease control and disease response; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of regulatory designations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and therapeutic benefits of our therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing, coverage and reimbursement of our therapeutic candidates, if approved; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize our technology platform to generate and advance additional therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategic plans for our business and therapeutic candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into strategic partnerships and the potential benefits of such partnerships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future results of operations and financial position and our estimates regarding expenses, capital requirements and needs for additional financing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise funds needed to satisfy our capital requirements, which may depend on financial, economic and market conditions and other factors, over which we may have no or limited control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our third-party partners&#8217; and service providers&#8217; ability to continue operations and advance our therapeutic candidates through clinical trials, as well as the ability of our third party manufacturers to provide the required raw materials, antibodies and other biologics for our preclinical research and clinical trials, in light of the current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled &#8220;Risk Factors&#8221; elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our current beliefs and opinions on the relevant subject. These statements are </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part I.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_16"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_19"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation from Former Parent</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, Inhibrx, Inc., or the Former Parent, effected the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, upon which the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of our common stock, or the Distribution. On May 30, 2024, the Former Parent completed a series of internal restructuring transactions, or the Separation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2024, the Former Parent completed the merger, or the Merger, of Art Acquisition Sub, Inc., a wholly-owned subsidiary of Aventis Inc., or the Acquirer, a wholly-owned subsidiary of Sanofi S.A., or Sanofi, with and into the Former Parent with the Former Parent continuing as the surviving entity. Pursuant to the Merger (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer; and (ii) by way of the Separation, we acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105. From and after the closing, Inhibrx continues to operate as a stand-alone, publicly traded company focused on ozekibart and INBRX-106, both of which are clinical-stage programs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the spin-off, descriptions of historical business activities are presented as if the spin-off had already occurred, and the Former Parent&#8217;s activities related to such assets and liabilities had been performed by us. Refer to Note 1 to our consolidated financial statements included elsewhere in this Annual Report for further discussion of the underlying basis used to prepare the consolidated financial statements. The operating results presented in our historical financial statements prior to the Merger and in connection with the Separation and the Merger may not be indicative of our results following the Merger and Separation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Clinical Pipeline</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize our multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function:</span></div><div style="margin-bottom:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:308.25pt"><tr><td style="width:1.0pt"/><td style="width:150.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:150.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:152pt"><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g1.jpg" alt="INBRX-109 Blank.jpg" style="height:175px;margin-bottom:5pt;vertical-align:text-bottom;width:192px" id="i-1"/></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g2.jpg" alt="INBRX-106 Blank.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:192px" id="i-2"/></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ozekibart (INBRX-109)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-106</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Tetravalent DR5 agonist</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Hexavalent OX40 agonist</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:15.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.699%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Target(s)/Format</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">STAGE OF DEVELOPMENT</span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Preclinical</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="6" style="border-right:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">ozekibart (INBRX-109)*</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">DR5<br/>Tetravalent Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"/><td colspan="9" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">INBRX-106**</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">OX40<br/>Hexavalent Agonist</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*     Currently being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer, and certain other solid tumor types.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">**   Currently being investigated in patients with non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma, or HNSCC.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i8fac7241aa424916b2e0582fb85490ec_22"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Leadership Team </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a team with deep scientific, manufacturing, and clinical experience in discovering and developing protein therapeutics, as well as an accomplished commercial team with the expertise we believe to successfully bring our therapeutic candidates, if approved, to market. Our in-house capabilities span the disciplines of discovery, protein engineering, cell biology, translational research, chemistry, manufacturing and controls, or CMC, clinical development, and commercialization. Members of our team bring experience from multiple organizations including Genentech, Inc., Gilead Sciences, Inc., Merck &amp; Co., Novartis AG, Pfizer Inc., and Roche. Our board of directors is comprised of individuals with proven business and scientific accomplishments and significant operating knowledge of our company.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_25"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions. We are a biopharmaceutical company aiming to develop a differentiated and sustainable product portfolio by focusing on the following: </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly advance and optimize the clinical development of our lead programs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since entering the clinic, we have made great strides in our clinical programs, with the successful completion of two registration-enabling trials. In May 2024, we completed a successful Merger and Separation with Sanofi for the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">purchase of our INBRX-101 program for alpha-1 antitrypsin deficiency disorder. Positive data from that registrational program read out in October 2025. In October 2025, we announced positive data from our ozekibart (INBRX-109) registration-enabling trial in advanced or metastatic, unresectable chondrosarcoma. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Both ozekibart and INBRX-106 have key data or milestone events expected in 2026. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apply our protein engineering platforms to create differentiated, next-generation therapeutics in focused disease areas with a high unmet medical need. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus our internal clinical development where we believe we can create effective and flexible solutions to address the challenges of validated targets in areas with a high unmet medical need. Our modular protein engineering platforms enable us to efficiently identify optional therapeutic formats customized to the target biology. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maintain our culture of innovation, execution and efficiency. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have successfully built an innovative culture that encourages scientific risk-taking within the bounds of our data-driven philosophy. This enables our research and development team to discover numerous promising preclinical candidates cost effectively, from which we select what we believe are highly differentiated programs for clinical development. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maximize the potential of our therapeutic pipeline. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a disciplined strategy to maximize the potential of our therapeutic pipeline in order to bring the greatest value to our stockholders and the most significant impact to patients. We are continuously looking to streamline operations to increase efficiency and to ensure maximum value is achieved with the capital we raise. Additionally, we will enter into strategic partnerships and transactions in instances where we believe partnering will accelerate our development timelines and/or maximize the commercial potential of any approved therapeutic candidate. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_28"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_31"></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ozekibart (INBRX-109)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ozekibart is a precisely engineered tetravalent therapeutic candidate targeting death-receptor 5, or DR5, a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand, or TRAIL, receptor 2. DR5 activation induces cancer-specific programmed cell death. The valency of ozekibart was selected to maximize the therapeutic index. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background on DR5 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Apoptosis is a critical process for maintaining healthy tissue homeostasis, but this process is frequently altered in cancer patients leading to the accumulation of malignant cells. Apoptotic signaling pathways are tightly regulated by the balance of pro- and anti-apoptotic factors, and their therapeutic modulation has the potential to be exploited for the treatment of cancer. Targeting the anti-apoptotic proteins has been a clinically successful strategy. For example, Venetoclax, an inhibitor of B-cell lymphoma 2, or Bcl-2, was approved by the FDA for the treatment of chronic lymphocytic leukemia in 2016.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we believe therapeutically targeting pro-apoptotic proteins such as DR5 is a promising oncology treatment strategy. DR5 signaling is induced by clustering of multiple receptors, which initiates an apoptotic signaling pathway resulting in cell death. The strength of apoptotic signaling is proportional to the degree of DR5 clustering. Importantly, although DR5 is expressed throughout the body, cancer cells have been shown to be more sensitive to DR5 signaling compared to healthy cells of normal tissues.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The promise of inducing cancer-specific cell death has led to extensive efforts by pharmaceutical and biotechnology companies to therapeutically exploit the DR5 pathway for the treatment of cancer. These initial efforts centered around developing recombinant versions of the DR5 ligand, TRAIL, and agonistic bivalent DR5 antibodies. Despite demonstrated clinical safety as single agents and in combination with chemotherapies, these first generation DR5 agonists failed to meet clinical efficacy endpoints. We believe these failures were caused by insufficient clustering of DR5, which is necessary for activation of this pathway.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unmet Medical Need </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently investigating ozekibart in chondrosarcoma, Ewing sarcoma, and colorectal cancer. These are some of the most aggressive diseases, some of which are also orphan oncology indications that have shown signs of activity in preclinical studies. These indications, particularly in advanced or refractory settings, often do not respond well to currently approved therapies and represent a significant unmet need.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chondrosarcoma is a rare malignant bone tumor composed of cartilage matrix-producing cells. It is reported to be the second most common primary bone sarcoma with an incidence of 1 in 200,000 per year globally. The incidence in the United States is reported to be about 1,400 cases per year. There is currently no approved systemic treatment for patients with unresectable or metastatic disease. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ewing sarcoma is a rare type of cancer that occurs in bones or in the soft tissue around the bones and is more commonly found in children. The incidence of Ewing sarcoma for all ages is approximately 1.3 cases per 1 million people in the U.S., corresponding to approximately 430 new patients diagnosed per year in the U.S. The median age at diagnosis of patients with Ewing sarcoma is 15. Current treatment for Ewing sarcoma typically includes a combination of chemotherapy, surgery, and/or radiation therapy. Despite aggressive treatment, outcomes remain poor for patients with metastatic or relapsed disease, with five-year survival rates dropping below 30% in these cases, highlighting the need for more efficacious options.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Colorectal adenocarcinoma, or CRC, is the third most frequent cancer globally and the second leading cause of cancer-related death. According to the World Health Organization, there were nearly 2,000,000 new cases of CRC in 2020, with nearly 1,000,000 deaths. Effective therapies beyond the second-line setting are limited. In the U.S., the five-year relative survival rate in patients with metastatic CRC is 15.7%, underscoring the need for better treatments.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution&#8201;&#8212;&#8201;ozekibart</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ozekibart is a tetravalent agonist of DR5 that we designed with our proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. We believe ozekibart has the potential to overcome the limitations of previous DR5 agonists. As shown in the diagram below, ozekibart is comprised of four DR5 targeted sdAbs fused to an Fc region that has been modified to prevent Fc receptor interactions. In preclinical studies, we have observed that ozekibart has the ability to potently agonize DR5 through efficient receptor clustering, causing cancer cell death. Based upon experience with earlier generation DR5 agonists, hepatocytes appear to be a non-cancerous cell type particularly sensitive to DR5 agonism. We have engineered ozekibart with our proprietary sdAb modifications to reduce recognition by pre-existing anti-drug antibodies in humans, which can lessen the potential for hyper-clustering and thereby reduce potential hepatotoxicity.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ozekibart: Tetravalent DR5 Agonistic Antibody </span></div><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g3.jpg" alt="Image_4.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:345px" id="i-3"/></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1/2 Clinical Trial of ozekibart</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase&#160;1 clinical trial in the United States in November&#160;2018. This Phase&#160;1 clinical trial was designed as an open-label, three-part trial in patients with locally advanced or metastatic solid tumors. Part 1 of the trial completed in August 2019 and enrolled 20 patients, utilizing a traditional 3+3 dose escalation design escalating ozekibart as a single agent from 0.3 mg/kg to 30 mg/kg. Ozekibart was observed to be well-tolerated without significant toxicities observed at doses up to and including the maximum administered dose of 30 mg/kg. No MTD was reached. In September&#160;2019, we commenced Part 2, single agent dose expansion cohorts, which enrolled 121 patients in single agent dose cohorts in the following tumor types: colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, chondrosarcoma, synovial sarcoma, and solid tumors. In February&#160;2021, we initiated chemotherapy combination cohorts in Part&#160;3 of this trial, of which we are still investigating in Ewing sarcoma and colorectal adenocarcinoma.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Primary objectives of the Phase 1 trial were safety, tolerability, and determination of the maximum tolerated dose, or MTD, and recommended Phase 2 dose. For some of the expansion cohorts in Part 2 and Part 3, clinical anti-tumor efficacy, such as response rate, was also included as one of the primary objectives. Secondary objectives were serum exposure and immunogenicity, as measured by frequency of anti-drug antibodies. Exploratory objectives included clinical anti-tumor efficacy, based on response rate, duration of response, disease control rate, progression-free survival and overall survival, as well as evaluation of potential predictive diagnostic and pharmacodynamic biomarkers.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Colorectal Adenocarcinoma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we announced interim efficacy and safety data from the cohort of the Phase 1/2 trial evaluating ozekibart in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma, or CRC. Efficacy was assessed in 10 of the 13 evaluable patients as of the cutoff date of December 2, 2024, who received at least one dose of ozekibart, based on RECIST v1.1 criteria. Results demonstrated one complete response, or CR, three partial responses, or PR, and six cases of stable disease, or SD. Durable disease control lasting &#8805;180 days was observed in 46.2% of patients, with a median progression-free survival, or PFS, of 7.85 months. All patients had received at least one prior line of systemic therapy (median: two; range: 1&#8211;6). Notably, the patient achieving a CR had undergone three prior lines of therapy, and two PRs occurred in patients who had failed prior FOLFIRI-based treatments.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the interim data observed above, we initiated an expansion cohort enrolling 44 patients, as a fourth line of therapy for approximately 70% of patients and as a third line of therapy for approximately 30% of patients. 80% of patients had been previously treated with regimens containing irinotecan. Efficacy was assessed in 26 evaluable patients who had at least one post-baseline scan as of the cutoff date of October 15, 2025. Based on RECIST v1.1 criteria, a 23% overall response rate, or ORR, was observed and an overall disease control rate of 92% was observed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In general, ozekibart in combination with FOLFIRI was well tolerated. The most common treatment-emergent adverse events included anemia, diarrhea, nausea, and fatigue, with the majority being low-grade and consistent with the known safety profile of FOLFIRI.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to provide an update on the expansion cohort during the second quarter of 2026 when the PFS data is mature. If the current response and duration trends observed continue, we plan to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for this indication.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ewing Sarcoma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced interim efficacy and safety data from the cohort of the Phase&#160;1/2 trial evaluating ozekibart in combination with Irinotecan, or IRI, and Temozolomide, or TMZ, for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Among the 13 patients evaluable as of the data cut of September&#160;8, 2023, the observed disease control rate was 76.9%, or 10 out of 13&#160;patients as measured by RECISTv1.1, with seven patients achieving partial responses (53.8%) and three patients achieving stable disease (23.1%). Four of the 13 evaluable patients at that time had prior IRI exposure, including two out of the four responses.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on this preliminary data, the ongoing Phase 1/2 trial in the Ewing sarcoma cohort was expanded to enroll up to an additional 50 patients. In March 2026, we provided an update at the European Society for Medical Oncology (ESMO) Sarcoma and Rare Cancers Congress. Of the 31 patients evaluable based on a cutoff date of January 15, 2026, we observed a 64.5% ORR and a disease control rate of 87.1%. At the time of the presentation, responses were ongoing in eight patients, one of which had been on treatment and progression free for more than two years. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ozekibart in combination with IRI/TMZ was well tolerated. The most common adverse events were diarrhea, nausea, anemia, and fatigue, all consistent with the known safety profile of IRI/TMZ.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to complete enrollment in the Phase 1/2 trial of ozekibart in combination with IRI/TMZ for advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma in the second half of 2026.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the current response and duration trends observed continue, we plan to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for this indication.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chondrosarcoma </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase&#160;1 ozekibart in Chondrosarcoma </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January&#160;2021, the FDA granted Fast Track designation to ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. In November&#160;2021, the FDA granted orphan drug designation for ozekibart for the treatment of chondrosarcoma. In August&#160;2022, the European Commission granted orphan designation for ozekibart for the treatment of chondrosarcoma. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2024, we announced efficacy and safety data from the Phase&#160;1 expansion cohort evaluating ozekibart for the treatment of chondrosarcoma. Among the 54 patients evaluable, the observed disease control rate was 77.8%, or 42 out of 54 patients as measured by RECISTv1.1, with two patients achieving partial responses (3.7%) and 40 patients achieving stable disease (74.1%). Disease control was observed in patients with and without IDH1/IDH2 mutations. Of those achieving stable disease, 55.0% had decreases from baseline in tumor size. 23 of 42&#160;patients (54.8%) who achieved disease control maintained control for longer than 6&#160;months, and the longest duration of stable disease observed was 27&#160;months. The median progression-free survival, or PFS, was 7.42&#160;months.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ChonDRAgon Trial</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2021, we initiated a randomized, blinded, placebo-controlled, registrational trial in patients with metastatic, unresectable conventional chondrosarcoma, which enrolled over 200 patients in total at 68 different sites worldwide. The primary objective of the trial was the evaluation of the efficacy of ozekibart as measured by median PFS, assessed by central real-time independent radiology review per RECIST 1.1. Secondary objectives were the evaluation of overall survival, median PFS by investigator assessment, quality of life, objective response rate, duration of response, disease control rate, safety and tolerability, pharmacokinetics and anti-drug antibodies to ozekibart.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Key enrollment criteria in order for patients to qualify for inclusion in the trial were grade 2 or 3 unresectable or metastatic conventional chondrosarcoma. Patients received either ozekibart or placebo every three weeks at a randomization of 2:1, stratified by the line of therapy, grade and IDH1/2 mutation status. Patients randomized to the placebo arm were allowed to crossover to receive ozekibart upon confirmation of progression as reported by central independent radiology review. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, we announced ChonDRAgon met its primary endpoint of a statistically significant and clinically meaningful median PFS for patients with advanced or metastatic chondrosarcoma treated with ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio 0.479; 95% CI: 0.33, 0.68); P&lt;0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The benefit of ozekibart was consistent across all pre-specified subgroups, including patients with isocitrate dehydrogenase, or IDH, -wild-type and IDH-mutant tumors. Other key secondary endpoints, including disease control rate (54% vs 27.5%), and delay to deterioration in pain and physical function, further supported the clinical benefit observed with ozekibart.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ozekibart was generally well tolerated, with a manageable safety profile. The most common treatment-related adverse events were fatigue, constipation, and nausea. Hepatotoxicity, a known risk for this mechanism of action, occurs during the first treatment cycle and is in patients with underlying hepatic impairment. One hepatotoxicity-related fatal event occurred early in the study, prior to the implementation of mitigation measures. Over the course of the ChonDRAgon study, this risk was effectively mitigated by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, allowing for prompt management of liver enzyme elevations. This approach resulted in a low overall incidence of treatment-related hepatic adverse events, 11.8% compared to 4.5% in the placebo arm, the majority of which were Grade 1 or 2 in severity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following recent regulatory interactions, we plan to submit a biologics license application, or BLA, early in the second quarter of 2026. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Data for ozekibart </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e 273 patients studied and evaluable in our Phase 1 trial as of the cutoff date of August 2, 2025, the treatment</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">-related serious adverse events observed in more than one patient were (i) abnormal laboratory findings of increased alanine aminotransferase (8 or 2.9%), increased aspartate aminotransferase (8 or 2.9%), (ii) gastrointestinal disorders, which included diarrhea (4 or 1.5%), (iii) blood and lymphatic system disorders, which included anemia (3 or 1.1%), febrile neutropenia, a condition where the body has a reduced number of a certain type of white blood cells in conjunction with a fever (2 or 0.7%), (iv) hepatobiliary (liver, bile duct or gallbladder) disorders which included acute hepatic failure (3 or 1.1%). </span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Of the 180 patients studied and evaluable in the ChonDRAgon study as of the primary endpoint cutoff date of September 30, 2025, the se</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rious adverse events related to study drug (ozekibart during the double blind or crossover period) that occurred in more than one patient were (i) abnormal laboratory findings of increased alanine aminotransferase (6 or 3.3%), increased aspartate aminotransferase (5 or 2.8%), (ii) hepatobiliary disorders, which included hepatic failure (2 or 1.1%).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INBRX-106 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-106 is a hexavalent OX40 agonist, currently being investigated as a single agent and in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background on Immunotherapy </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A notable recent success in cancer treatment is the approval of checkpoint inhibitor immunotherapies as therapeutic agents. Immune checkpoints are key mechanisms that fine-tune and control the body&#8217;s immune response. In the cancer setting, tumors have developed strategies for hijacking these checkpoints, preventing an immune response to the cancer and allowing the tumor cells to proliferate unchecked. Checkpoint inhibitor immunotherapies were developed to overcome this phenomenon by relieving immune cell inhibition, resulting in a potentially long-lasting amplification of the anti-tumor immune response. Therapies against checkpoint proteins, such as PD-1 and PD-L1, produced impressive results in clinical development, resulting in marketing approvals in a number of malignancies. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Background on OX40 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OX40, a member of the TNFRSF, is predominately expressed and is a key co-stimulatory receptor on activated T-cells. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. The natural mechanism of OX40 activation is via the interaction with its trimeric ligand, OX40L, which serves to effectively cluster multiple OX40 molecules and facilitate downstream signaling leading to nuclear factor kappa-light-chain-enhancer of activated B cells, or NFkB, activation. Based on the capacity for OX40 signaling to enhance anti-tumor immunity in preclinical studies, there have been many efforts to therapeutically exploit this pathway for cancer immunotherapy. Most previously developed agents were bivalent OX40 agonists, the configuration of which we believe to be poorly suited for efficient receptor clustering, evidenced by the lack of clinical responses observed for such molecules. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unmet Medical Need </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite unprecedented clinical response rates, the majority of patients fail to respond to therapies targeting PD-1 and PD-L1. We believe this is in part because T-cells require co-stimulation for full functionality. Thus, checkpoint inhibition alone is likely insufficient to fully enable the immune system to attack a tumor, and we believe further benefit could be derived by the addition of immune co-stimulatory agents. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Solution </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor. As shown in the diagram below, INBRX-106 is composed of six OX40 targeting sdAbs and a functional Fc domain. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g4.jpg" alt="Image_8.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:336px" id="i-4"/></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a hexavalent therapeutic candidate, INBRX-106 is designed to bind six OX40 molecules on the cell surface to mediate efficient receptor clustering and downstream signaling. In preclinical studies, we observed that INBRX-106 elicited superior OX40 agonism when compared to the bivalent antibodies, 1A7 (analog of MOXR-0916) or 1D10 using an OX40 expressing NFkB reporter cell line, wherein clustering of OX40 receptor mediated signaling culminated in luciferase expression. We also observed that INBRX-106 can mediate T-cell co-stimulation and reduce the suppressive activity of regulatory T-cells. Additionally, INBRX-106 is able to exploit IgG-mediated effector function via the Fc domain. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Data </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase&#160;1/2 clinical trial in December&#160;2019 for INBRX-106. This trial was designed as an open-label, four-part trial in patients with locally advanced or metastatic solid tumors. Primary objectives of the trial were safety and tolerability, and the determination of the MTD and recommended Phase&#160;2 dose of INBRX-106 as a single agent and in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. For some of the expansion cohorts in part 4, clinical anti-tumor efficacy, such as response rate, was also included as one of the primary objectives. Secondary objectives were serum exposure, immunogenicity, as measured by the frequency of anti-drug antibodies, and clinical anti-tumor efficacy per RECIST (version 1.1) and immune RECIST based on response rate, duration of response, disease control rate, progression-free survival and overall survival. Exploratory objectives included evaluation of potential predictive diagnostic and pharmacodynamic biomarkers. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;1 of the trial utilized a traditional 3+3 algorithm for single agent dose escalation from 0.0003&#160;mg/kg to 3 mg/kg in twenty patients. INBRX-106 was observed to be generally well tolerated in humans. The most common adverse events, or AEs, reported for INBRX-106 were Grade 1 and 2 and notably, cutaneous toxicities, which are common immune-related AEs associated with immune checkpoint inhibitors. These AEs, which were mostly mild or moderate non-serious adverse events and likely immune-related toxicities were in line with the mechanism of action of this candidate therapeutic. The maximum administered dose was 3 mg/kg and the MTD level was not reached. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;2 of the trial, single agent dose expansion, administered INBRX-106 in different dosing schedules to patients with tumor types responsive to checkpoint inhibitors. Part&#160;2 treatment cohorts of this trial were in the following tumor types: NSCLC, melanoma, HNSCC, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In Parts 3 and 4 of this trial, INBRX-106 was evaluated in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. In the all-comer Part&#160;3 of the trial, INBRX-106 was escalated in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> and enrolled patients with locally </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">advanced or metastatic solid tumors. It was observed to be well tolerated, with predominantly mild or moderate non-serious immune-related toxicities noted. We observed durable responses across multiple tumor types. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In Part&#160;4, INBRX-106 combination expansion cohorts, we enrolled patients with NSCLC and HNSCC, both in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The patients had to be positive for PD-L1 expression, as determined by immunohistochemistry, and possess adequate hematologic and organ function, to qualify for enrollment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The initial data with a cutoff date of August 2024 was observed from 24 NSCLC patients who all had previous checkpoint inhibitor exposure was tumor reduction or stabilization of target lesions in more than half the patients. Of those patients, one complete response and four partial responses were observed. The initial data with a cutoff date of August 2024 was observed from 14 HNSCC patients, seven of which were checkpoint failures and seven of which were checkpoint naive, was tumor reduction of target lesions in half the patients. Of those patients, two complete responses and five partial responses were observed. These cohorts have been expanded to recruit additional patients, and a new cohort was added in NSCLC patients with any PD-L1 status to evaluate the safety of chemotherapy when used in conjunction with the INBRX-106 and KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> combination. Early evaluation of the data indicate INBRX-106 in combination with pembrolizumab can be safely combined with chemotherapy, which supports further evaluation of this combination in indications where checkpoint inhibitors are used in conjunction with chemotherapy. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we completed enrollment of the Phase 1/2 trial evaluating 34 patients in checkpoint inhibitor refractory or relapsed NSCLC in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Primary endpoints for this cohort are objective response rate, or ORR, disease control rate, duration of response, or DOR, and safety. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, a seamless Phase 2/3 clinical trial was initiated for INBRX-106 in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as a first-line treatment for patients with locally advanced recurrent or metastatic HNSCC. This trial recruited patients who had not received prior checkpoint inhibitors and whose tumors expressed a PDL-1 combined positive score, or CPS, equal to or greater than 20. During the first quarter of 2026, we completed enrollment of 68 patients in the Phase 2 portion with a primary endpoint of ORR, supported by secondary endpoints of DOR, PFS, and safety. We plan to provide initial results from the Phase 2 trial in the second quarter of 2026. We plan to announce PFS data from this trial in the fourth quarter of 2026 at the European Society for Medical Oncology 2026 Congress.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If positive, we anticipate this data may ungate the Phase 3 portion, where we expect approximately 350 patients will be randomized to INBRX-106 or placebo in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The co-primary endpoints for the Phase 3 portion of the study are expected to be PFS and overall survival. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Data for INBRX-106</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Of the 272 patients studied and evaluable in our Phase 1/2 clinical trial for INBRX-106 as of the cutoff date of June 13, 2025, the treatment-related serious adverse events observed in more than one patient were (i) pyrexia, or fever (4 or 1.5%), (ii) diarrhea (3 or 1.1%), (iii) cytokine release syndrome (3 or 1.1%), (iv) infusion-related reactions (3 or 1.1%), (v) pneumonia (2 or 0.7%), and rash (2 or 0.7%). </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_55"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technology and information commercially or strategically important to our business. We seek to obtain and maintain, patent rights intended to cover the technologies incorporated into, or used to produce, our therapeutic candidates, the compositions of matter of our therapeutic candidates and their methods of use and manufacture, as well as other inventions that are important to our business. We also seek to obtain strategic or commercially valuable patent rights in the United States and other jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, our patent estate contains 31 patent families that we solely own, 2 patent families that we co-own with Regeneron Pharmaceuticals, Inc. (formerly 2Seventy Bio, Inc.) and 2 patent families that we co-own with Poplar Therapeutics, Inc., formerly Phylaxis BioScience, LLC. The patent estate is comprised of 32 issued U.S. patents, 164 issued foreign patents in various countries around the world, including Australia, Canada, China, Europe (validated in France, Germany, Italy, Spain, the United Kingdom and other European countries), Russia, India, Israel, Japan, Mexico, New Zealand, Singapore, South Korea, South Africa and other countries as further described below, 28 pending U.S. patent applications, 3 pending Patent Cooperation Treaty, or PCT, applications, 1 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pending US provisional application, and 348 pending patent applications in various jurisdictions outside of the U.S., as further described below. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INBRX-106</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With regard to INBRX-106, as of December&#160;31, 2025, we solely own 3 patent families relating to the composition of matter of INBRX-106, its methods of use for the treatment of cancer and/or its alternative dosing regimens for the treatment of cancer. These patent families are comprised of: 3 issued U.S. patents, 11 issued patents in various countries around the world, including Australia, Chile, Indonesia, Israel, Japan, Mexico, New Zealand, Russia and Vietnam, 1 pending U.S. patent application, 2 pending PCT applications and 31 pending patent applications in various countries around the world, including Argentina, Australia, Brazil, Canada, China, Europe, Gulf Cooperation Council, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Philippines, Singapore, South Africa, South Korea, Taiwan, and Thailand. These patents and patents issuing from these applications, if any, are expected to expire between 2037 and 2044, absent any patent term adjustments or extensions or terminal disclaimers. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ozekibart (INBRX-109)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With regard to ozekibart, as of December&#160;31, 2025, we solely own 4 patent families relating to the composition of matter of ozekibart, its methods of use for the treatment of cancer, its formulations, and/or its use in combination with select compounds. These patent families are comprised of: 3 issued U.S. patents, 53 issued patents in various countries around the world, including Australia, Brazil, China, Europe (validated in France, Germany, Italy, Spain, the United Kingdom and other European countries), Hong Kong, India, Indonesia, Israel, Japan, Mexico, New Zealand, Russia, Singapore, South Korea, and South Africa, 4 pending U.S. patent applications and 61 pending patent applications in various countries around the world, including Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, India, Israel, Japan, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea, Taiwan and Thailand. These patents and patents issuing from these applications, if any, are expected to expire between 2036 and 2043, absent any patent term adjustments or extensions or terminal disclaimers.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Single Domain Antibody and Multispecific Technologies</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our single domain antibody and multispecific technologies, as of December&#160;31, 2025, we solely own 6 patent families relating to non-immunogenic single domain antibodies, multispecific molecules having a constrained CD3 binding, molecules comprising modified IL-2 variants, and/or methods of using such molecules to treat diseases (e.g., cancer). These patent families are comprised of: 4 issued U.S. patents, 26 issued patents in Australia, Canada, China, Hong Kong, Indonesia, India, Israel, Japan, Malaysia, Mexico, New Zealand, Russia, Singapore, South Korea, and Taiwan, 6 pending U.S. patent applications and 83 pending patent applications in various countries around the world, including Argentina, Australia, Brazil, Canada, Chile, China, Europe, Gulf Cooperation Council, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Russia, Saudi Arabia, Singapore, South Africa, South Korea and Taiwan. These patents and patents issuing from these applications, if any, are expected to expire between 2036 and 2041, absent any patent term adjustments or extensions or terminal disclaimers.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property strategy, to adapt to competition or to seize potential opportunities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the USPTO. For example, the Hatch-Waxman Act permits a patent term extension for FDA-approved drugs of up to five&#160;years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our therapeutic candidates receive FDA approval, we expect to apply for patent term extensions on </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">patents covering those therapeutic candidates. We intend to seek patent term extensions in any jurisdiction where these are available and where we also have a patent that may be eligible; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect this intellectual property, in part, by requiring our employees, consultants, sponsored researchers and other service providers and advisors to execute confidentiality agreements upon the commencement of employment or other relationship with us. In general, these agreements provide that confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements further provide that inventions and discoveries conceived or reduced to practice by the individual that are related to our business, or actual, or demonstrably anticipated, research or development, or made during normal working hours, on our premises or using our equipment, supplies, or proprietary information, are our exclusive property. In many cases our agreements with consultants, sponsored researchers and other service providers and advisors require them to assign, or grant us licenses to, inventions resulting from the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, we expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We seek trademark protection in the United States and in certain other jurisdictions where available and when we deem appropriate. We currently have a registration for &#8220;Inhibrx&#8221; in the United States and have filed trademark applications for &#8220;Inhibrx Biosciences&#8221; in the United States. We intend to file applications for trademark registrations in connection with our therapeutic candidates in various jurisdictions, including the United States. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_58"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement. Our primary competitors fall into the following groups: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Crescendo Biologics Ltd., Molecular Partners AG, Precirix NV, Affibody Medical AB, Numab Therapeutics AG, GT Biopharma, Inc., and Sanofi;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., Numab Therapeutics AG, Amgen, Inc., Xencor, Inc., and Zymeworks Inc.; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing therapeutics for the treatment of autoimmune diseases, including Sanofi, Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Merck &amp; Co., Inc., Novartis AG, Candid Therapeutics, Inc., Hinge Bio, Inc., and Apogee Therapeutics, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors also include other large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other marketing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_61"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of product candidates such as those we are developing. Our therapeutic candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining marketing approvals in the U.S. and in foreign countries and jurisdictions, and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations, require the expenditure of substantial time and financial resources. Failure to comply with the applicable FDA requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a biologic may be marketed in the United States generally involves the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of certain preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other applicable requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug application, or IND, which must become effective before human clinical trials may begin; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice regulations, or GCPs, to evaluate the safety, purity and potency, or efficacy, of the therapeutic candidate for its intended use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of a BLA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA advisory committee review, if applicable; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice requirements, or cGMPs, to assure that the facilities, commercial manufacturing process, testing methods and controls are adequate to ensure manufacturing robustness and to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of potential inspection of selected clinical investigation sites to assess compliance with GCPs; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once a therapeutic candidate is identified for development, it enters the preclinical testing stage. Preclinical tests generally include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for allowance from the FDA to administer an investigational drug or biological product to humans. An IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the trial includes an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may therefore not result in FDA allowance to begin a clinical trial. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due in response to safety concerns or due to non-compliance with specific FDA requirements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and any safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and a separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and preclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, an independent IRB or ethics committee at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries, including clinicaltrials.gov.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1: The therapeutic candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2: The therapeutic candidate is administered to a limited patient population with a specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the therapeutic candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3: The therapeutic candidate is administered to an expanded patient population to further evaluate dosage, to provide substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the therapeutic candidate and provide an adequate basis for product labeling. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the approved therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the therapeutic candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Review and Approval Process </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the therapeutic candidate, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product. Such information can come from company-sponsored clinical studies, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under the PREA, BLAs and certain supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been submitted, the FDA conducts a preliminary review of the application within the first 60 days after submission, before accepting it for filing, to determine whether it is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information from the application sponsor. In this event, the BLA must be resubmitted with the requested information. The resubmitted application also is subject to review before the FDA accepts it for filing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Once filed, FDA reviews a BLA to determine, among other things, whether a therapeutic candidate is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal to complete a standard review of an original BLA within ten months after the filing date, or, if the application qualifies for priority review, within six months after the filing date.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCPs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA and conducts any required inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the BLA identified by the FDA and may require additional clinical data, including additional clinical trials, or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the BLA addressing all of the deficiencies identified in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the letter or withdraw the application. Even if such data and information are submitted, the FDA may decide that the resubmitted application does not satisfy the criteria for approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-market studies or surveillance programs to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications &#8211;including full BLAs&#8211; to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the disease or condition for which the orphan product has exclusivity, or obtain approval for the same product but for a different disease or condition for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of a competing product for seven years if a competitor obtains approval of the &#8220;same drug,&#8221; as defined by the FDA, or if the active ingredient of the therapeutic candidate is determined to be contained within the competitor&#8217;s product for the same disease or condition. In addition, if an orphan designated product receives marketing approval for a disease or condition broader than what is designated, it may not be entitled to orphan exclusivity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has a number of programs intended to expedite the development or review of a marketing application for an investigational drug or biologic. For example, the Fast Track designation program is intended to expedite or facilitate the process for developing and reviewing therapeutic candidates that meet certain criteria. Specifically, investigational biologics are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the specified disease or condition. The sponsor of a Fast Track therapeutic candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. With regard to a Fast Track candidate, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A therapeutic candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A therapeutic candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the therapeutic candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the therapeutic candidate, including involvement of senior managers.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any therapeutic candidate submitted to the FDA for approval, including a therapeutic candidate with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. A BLA is eligible for priority review if the therapeutic candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of a BLA designated for priority review in an effort to expedite the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of original BLAs under its current PDUFA review goals. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, depending on the design of the applicable clinical trials, a therapeutic candidate may be eligible for accelerated approval. Specifically, biologics intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the therapeutic candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials, and may require that such confirmatory trials be underway prior to granting accelerated approval. Drugs or biologics receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory trials in a timely manner or if such trials fail to verify the predicted clinical benefit. In addition, the FDA requires as a condition of accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a therapeutic candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval Requirements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Drug and biologic manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws and regulations. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw or limit approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of requirements for post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences for non-compliance include, among other things:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on ongoing or planned clinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of biological products. A sponsor can make only those claims relating to safety, potency, purity and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and failure to comply with these requirements may lead to enforcement action. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars and Exclusivity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009. or BPCIA, created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active ingredient and to patent terms. This six-month exclusivity, which runs from the end of an existing period of non-patent regulatory exclusivity protection or patent term, may be granted based on the voluntary completion of a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of exclusivity or patent term remaining. Pediatric exclusivity does not require the sponsor to obtain approval for the applicable product in the studied pediatric indication. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval and Regulation of Companion Diagnostics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the safe and effective use of a therapeutic product depends on an in vitro diagnostic medical device, then the FDA generally will require approval or clearance of that diagnostic, known as an in vitro companion diagnostic device, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostic devices. According to the guidance, for novel drugs, an in vitro companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Accordingly, if the FDA determines that an in vitro companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the in vitro companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the in vitro companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, in vitro diagnostics, including in vitro companion diagnostic devices, are generally regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution, and the FDA has generally required companion diagnostics for cancer therapies to obtain approval of a premarket approval, or PMA, application.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The PMA involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA order for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After an in vitro device is authorized by the FDA and placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which currently covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Manufacturing sites for devices also remain subject to periodic unscheduled inspections by the FDA.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation&#160;Outside of the United States </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, or the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-clinical Studies and Clinical Trials </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similarly to the United States, the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice, or GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While the EU Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice, or GMP. Other national and EU-wide regulatory requirements may also apply.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a marketing authorization, or MA. To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application, or MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The centralized procedure provides for the grant of a single MA issued by the European Commission based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and is valid throughout the EU. The centralized procedure is compulsory for (i) medicines derived from biotechnology, (ii) designated orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs (such as gene therapy, somatic cell therapy and tissue engineered products) and (iv) those medicines with an active substance not authorized in the EU on or before May 20, 2004 indicated for the treatment of certain diseases, such as autoimmune diseases, cancer, neurodegenerative disorders or diabetes. The centralized procedure is optional for those medicines containing a new active substance not authorized in the EU on or before May 20, 2004, for products that constitute a significant therapeutic, scientific or technical innovation, or medicines to which the granting of a MA under the centralized procedure would be in the interest of patients at the EU-level. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The decentralized procedure provides for recognition by EU national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for MA is submitted simultaneously to the national authorities of several EU member states, one of them being chosen as the &#8220;Reference Member State,&#8221; and the remaining being the &#8220;Concerned Member States.&#8221; The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the MA on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data and Marketing Exclusivity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, new products authorized for marketing (i.e., reference products) generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Medicinal Products</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition (2) either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Orphan designation must be requested before submitting an MAA. An EU orphan designation entitles a party to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to ten years of market exclusivity for the approved indication, which means that the competent authorities cannot accept another MAA, or grant a MA, or accept an application to extend a MA for a similar medicinal product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan, or PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (i) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the applicant consents to a second orphan medicinal product application; or (iii) the applicant cannot supply enough orphan medicinal product. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product candidate for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all the EU member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity is granted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Framework in the United Kingdom</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;31, 2020, the United Kingdom formally withdrew from the EU, also known as Brexit. The United Kingdom and the EU entered into a trade agreement known as the Trade and Cooperation Agreement, which went </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">into effect on January&#160;1, 2021. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, is the United Kingdom&#8217;s standalone medicines regulatory body. As a result of the Northern Ireland Protocol, different rules applied in Northern Ireland than in Great Britain (England, Wales, and Scotland); broadly, Northern Ireland continued to follow the EU regulatory regime. However, a new arrangement called &#8220;the Windsor Framework&#8221; went into effect on January 1, 2025 and has changed the existing system under the Northern Ireland Protocol, including the regulation of pharmaceutical products in the United Kingdom. Specifically, the MHRA is now responsible for approving all medicines intended to be marketed in the United Kingdom (i.e., Great Britain and Northern Ireland), while the EMA is no longer involved in approving medicines intended for sale in Northern Ireland. In addition, an international recognition procedure has been in place since January 1, 2024, whereby the MHRA will have regard to decisions on the approval of marketing authorizations made by the EMA and certain other regulatory bodies when determining an application for a new United Kingdom marketing authorization.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing and Reimbursement </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products for which we receive approval will depend, in part, on the extent to which they will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage for our product candidates for which we receive approval may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. For example, the U.S. Department of Health and Human Services, or HHS, imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source biologics that have been on the market for at least eleven (11) years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to twenty (20) products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the EU do not follow price structures of the United States and generally tend to be significantly lower. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product and therapeutic candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted in March&#160;2010 and has had a significant impact on the health care industry in the United States. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, certain provisions of the ACA have been subject to judicial, executive, and legislative challenges. For example, on July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, and related agencies. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform, or TrumpRx, U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, physician sunshine and drug pricing transparency laws and regulations such as: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is broadly interpreted and aggressively enforced with the result that beneficial commercial arrangements can be penalized in the healthcare industry. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on a variety of arrangements, including sham consulting and other financial arrangements with physicians. Penalties for violating the federal Anti-Kickback Statute include imprisonment, fines and possible exclusion from federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing practices. If an entity is found to have violated the False Claims Act, it must pay three times the actual damages sustained by the government, plus mandatory and substantial civil penalties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The Health Insurance Portability and Accountability Act of 1996 and its accompanying regulations, or HIPAA, created new federal, civil and criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also imposes certain obligations with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information on their behalf and their covered subcontractors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The Physician Payments Sunshine Act, enacted as part of the ACA, among other things, imposes reporting requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), teaching hospitals and certain advanced non-physician healthcare practitioners, as well as ownership and investment interests held by physicians and their immediate family members. The law provides for the imposition of civil monetary penalties, and payments reported also have the potential to draw scrutiny on payments and relationships with physicians, which may have implications under the Anti-Kickback Statute and other healthcare laws; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; and state and local laws which require certain regulatory licenses to manufacture or distribute products commercially and/or the registration of pharmaceutical sales representatives. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. and European Data Privacy and Security Laws</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">health-related data. For example, the European Union General Data Protection Regulation, or the EU GDPR, and the United Kingdom General Data Protection Regulation and Data Protection Act 2018, or collectively, the UK GDPR (the EU GDPR and UK GDPR together referred to as the &#8220;GDPR&#8221;), impose comprehensive data privacy compliance obligations in relation to the collection and use of data relating to an identifiable living individual or &#8220;personal data&#8221;, including a principle of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit, as well as regulating cross-border transfers of personal data out of the European Economic Area, or the EEA, and the UK. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered &#8220;foreign persons&#8221; and are majority owned by, organized under the laws of, a primary resident in, or a contractor of, a covered person or country of concern, as applicable) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to engage in certain transactions or agreements with certain third parties in the future.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Laws and Regulations </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our present business is, and our future business may be, subject to regulation under the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations. See &#8220;Risk Factors&#8201;&#8212;&#8201;Risks Related to Government Regulation&#8201;&#8212;&#8201;If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.&#8221; </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_64"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We presently have relationships with suppliers for the manufacture of supplies for all of our required raw materials, antibodies, and other biologics for our preclinical research, clinical trials, and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_67"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are a key factor in our ability to achieve our mission to discover and develop effective biologic therapeutics for people with life-threatening conditions. We believe that our future success depends on our continued ability to identify, recruit, retain, and incentivize our management team and our clinical, scientific, and other employees. Our ability to do so depends on factors including our company culture, compensation and benefits, growth and development opportunities, and prioritization of employee safety. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Profile</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had 110 employees, 109 of whom were full-time, 84 of whom were engaged in research and development activity, and 51 of which hold advanced degrees, including but not limited to Ph.D., M.D., PharmD, J.D., MBA, and other master&#8217;s degrees. None of the employees are represented by a labor union and we believe we maintain good relations with our employees. Our employees represent a broad range of backgrounds and bring a wide array of perspectives and experiences. We believe this allows us to better drive innovation and achieve our mission.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Conduct &amp; Ethics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted corporate policies, including a Corporate Code of Conduct and Ethics and Whistleblower Policy, or Code of Conduct, which apply to all of our employees. All employees complete a mandatory public company </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">training session and are required to abide by, review and confirm compliance with our Code of Conduct, as well as our Insider Trading Policy governing trading by our personnel in our securities. We have established a whistleblower reporting hotline to enable our employees to anonymously report any suspected violations of these policies. In addition, we require employees to complete Anti-Harassment Training, with employees who work in a management capacity required to complete additional trainings in Harassment Prevention. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Compensation and Benefits</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to reward and support our employees in order to continue to attract and retain top talent. Our compensation includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee base salaries that are competitive and consistent with employee positions, skill levels, experience, and knowledge;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation awards which help to align the interests of our stockholders with those of our employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bonus award plans for all full-time employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retirement savings options and matching contributions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fully covered healthcare benefits for all full-time employees and their dependents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unlimited vacation benefit for all full-time employees; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Parental leave and other leave options available to all employees.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Growth and Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to fostering and growing talent within the biopharmaceutical and life sciences space. We provide internship opportunities for students interested in biotechnology and science within our research and development departments. Many of our interns have continued on to join us in a full-time position after graduation. Our hiring process is transparent and we are an equal opportunity employer and prohibits all forms of unlawful discrimination in accordance with applicable law. Many of our employees hold advanced degrees, as well as professional licenses and certifications; however, we equally commit resources to advancing all of our employees with a range of educational backgrounds. We offer tuition reimbursement aimed at growth and career development, as well as the opportunity for employees to attend relevant conferences and symposiums. In addition, we offer in-house coaching opportunities to refine or develop professional skills as our employees become managers and plan their career growth. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Wellness, Health, and Safety</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are strongly committed to the health and safety of our employees and strive to maintain the highest possible level of safety in our workplace. We require annual workplace safety training to reinforce workplace safety procedures that may be useful in the event of emergency situations and to assist our employees in helping to prevent workplace accidents. Our Environmental Health and Safety Committee, which is comprised of numerous cross-departmental members, meets regularly to review workplace safety and adherence to safety policies. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_70"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our company was incorporated as Ibex SpinCo, Inc. on January&#160;8, 2024 under the laws of the State of Delaware as a direct, wholly-owned subsidiary of the Former Parent. We changed our name from Ibex SpinCo, Inc. to Inhibrx Biosciences, Inc. on January&#160;25, 2024. Our corporate headquarters are located at 11025 N.&#160;Torrey Pines Road, Suite 140, La&#160;Jolla, CA 92037, and our telephone number is (858) 795-4220. Our website address is www.inhibrx.com. Information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_73"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports are and will be available to you free of charge through the &#8220;Investors&#8221; section on our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the SEC. The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Properties </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters are located in La Jolla, California where we currently lease approximately 43,000&#160;square feet of laboratory and office space under a lease that expires in 2028. We have an option to extend the lease an additional three&#160;years. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_79"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_82"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions generally include, but are not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us as long as we qualify as an emerging growth company, except that we have irrevocably elected not to take advantage of the extension of time to comply with new or revised financial accounting standards available under Section&#160;102(b) of the JOBS Act. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will, in general, remain as an emerging growth company for up to five full fiscal&#160;years following the completion of the Distribution. We would cease to be an emerging growth company and, therefore, become ineligible to rely on the above exemptions, if we: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;have more than $1.235&#160;billion in annual revenue in a fiscal year; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;issue more than $1&#160;billion of non-convertible debt during the preceding three-year period; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;become a &#8220;large accelerated filer&#8221; as defined in Exchange Act Rule&#160;12b-2, which would occur after: (i)&#160;we have filed at least one annual report pursuant to the Exchange Act; (ii)&#160;we have been an SEC-reporting company for at least twelve&#160;months; and (iii)&#160;the market value of our shares of common stock that is held by non-affiliates exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; as defined by applicable rules of the SEC. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report, including our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results, financial condition, and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_88"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section of this Annual Report titled &#8220;Risk Factors&#8221;. These risks include, among others, the following:</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, have incurred significant operating losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable in the future, or if we achieve profitability in the future, we may not be able to sustain it. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be adversely affected by the effects of inflation.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend heavily on the success of our therapeutic candidates, which are currently in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed. Even if our therapeutic candidates receive regulatory approval and are commercialized, there is no assurance that our commercialization efforts will be successful. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct a portion of our clinical trials and certain of our preclinical studies and contract manufacturing. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to obtain and enforce intellectual property protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain marketing approval for any product that we may develop and the marketing approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not know whether an active, liquid and orderly trading market will continue to develop or be sustained for our common stock and as a result it may be difficult for you to sell your shares of our common stock. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our stock price may fluctuate significantly. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our executive officers, directors and holders of more than 5% of our capital stock own a significant&#160;percentage of our stock and are able to exercise significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_94"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, have incurred significant operating losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable in the future, or if we achieve profitability in the future, we may not be able to sustain it. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. To date, we have financed our operations through equity and debt financings, license and milestone revenue and grants. We have incurred significant recurring operating losses since our inception. We expect to incur additional losses in future&#160;years as we execute our plan to continue our discovery, research and development activities, including the manufacturing of and ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates. We are unable to predict the extent of any future losses or when we will become profitable in the future, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our Company could also cause you to lose all or part of your investment. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted substantially all of our financial resources and efforts to developing our therapeutic candidates, identifying potential therapeutic candidates and conducting preclinical studies and clinical trials. We are still in the development stage for all of our therapeutic candidates, and while we have demonstrated an ability to successfully conduct and complete certain of our clinical trials, we have yet to demonstrate an ability to obtain marketing approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had more experience developing therapeutic candidates. Our ability to generate revenue and achieve profitability depends in large part on our ability, alone or with license partners, to achieve milestones and to successfully complete the development of, obtain the necessary marketing approvals for, and commercialize, our therapeutic candidates. Even if we achieve development or commercial milestones, generate product royalties or generate product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our ability to generate future revenue from product sales depends heavily on our success in: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing clinical trials through all phases of clinical development of our current therapeutic candidates, including ozekibart (INBRX-109) and INBRX-106; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancing preclinical therapeutic candidates into clinical development; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking and obtaining marketing approvals for our therapeutic candidates that successfully complete clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining satisfactory acceptance, formulary placement coverage and adequate reimbursement for our approved products from third-party payors, including private health insurers, managed care providers and governmental payor programs, including Medicare and Medicaid; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing products for which we obtain marketing approval successfully establishing a sales force, marketing and distribution infrastructure; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of any approved products by physicians, patients, third-party payors and the medical community; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, expanding and enforcing our intellectual property portfolio; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing additional internal systems and infrastructure, as needed; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA or other comparable foreign authorities to perform preclinical studies or clinical trials in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our therapeutic candidates, our expenses could increase and revenue could be further delayed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $124.2 million in cash and cash equivalents. We expect our expenses to increase in future&#160;years as we execute our plan to continue our discovery, research and development activities, including the ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates. Identifying potential therapeutic candidates and conducting preclinical testing and clinical trials are time consuming, expensive and uncertain processes that take&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our therapeutic candidates, if approved, may not achieve commercial success. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents will be sufficient to fund our planned operations through at least the 12-month period following the date of this Annual Report. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our current and planned preclinical studies and clinical trials for our current therapeutic candidates or other therapeutic candidates we may seek to develop may encounter technical, enrollment or other issues that could cause our development costs to increase more than we expect, or we could expand our clinical trials to additional indications which could increase clinical trial expenses. Because successful development of our therapeutic candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our therapeutic candidates. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. In addition, our ability to obtain future funding when needed through equity financings, debt financings or strategic collaborations may be challenging in light of recent market and macroeconomic conditions, which have been particularly challenging for research and development life science companies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or clinical therapeutic candidates, or we may be unable to take advantage of future business opportunities. In addition, any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital by issuing equity or debt securities may cause dilution to existing stockholders, and raising funds through lending and licensing or collaboration agreements may restrict our operations or require us to relinquish proprietary rights. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic collaborations and license and development agreements. We do not have any committed external source of funds. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures or declaring dividends. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants therein, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely affect our ability to conduct our business. For example, we entered into a loan and security agreement with Oxford Finance LLC and other lenders, or collectively, Oxford, which contains certain restrictive covenants as discussed below in &#8220;Risk Factors &#8211; We have a significant amount of debt which may affect our ability to operate our business and secure additional financing in the future. If we fail to comply with the terms of our loan agreement with Oxford, our business, prospects and results of operations could be materially and adversely affected.&#8221;</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through collaborations, strategic alliances or third-party licensing agreements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or therapeutics candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market therapeutic candidates that we would otherwise develop and market ourselves. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the effects of inflation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, shipping costs, supply shortages, increased costs of labor, weakening exchange rates and other similar effects. Recently, inflation has increased throughout the U.S. economy. Inflation can adversely affect us by increasing the costs of clinical trials and research, the development of our therapeutic candidates, administration and other costs of doing business. We may experience increases in the prices of labor and other costs of doing business. In an inflationary environment, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If this happens, we may need to raise additional capital to fund our operations, which may not be available in sufficient amounts or on reasonable terms, if at all, sooner than expected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We maintain our cash and cash equivalents at financial institutions. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Previous and potential future disruptions in access to bank deposits or lending commitments due to bank failure have contributed to increased volatility and could materially and adversely affect our liquidity, our business and financial condition. The closures of financial institutions and their placement into receivership with the Federal Deposit Insurance Corporation, or FDIC, created bank-specific and broader financial institution liquidity risk and concerns. Future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages. The failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of our therapeutic candidates, which are currently in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed. Even if our therapeutic candidates receive regulatory approval and are commercialized, there is no assurance that our commercialization efforts will be successful. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products on the market and our ability to achieve and sustain profitability depends on obtaining marketing approvals for and successfully commercializing our therapeutic candidates. Our two therapeutic candidates are still currently in clinical trials (ozekibart (INBRX-109) and INBRX-106). While we plan to submit a BLA to the FDA for the approval of ozekibart in patients with metastatic or unresectable chondrosarcoma early in the second quarter of 2026, there is no assurance that we will be successful in our efforts to submit a BLA on the timeline we expect or at all. Even if we are able to make such submission, the FDA may not accept our submission as complete, or may not agree that the clinical and preclinical data we have generated to date are sufficient to gain regulatory approval to commercialize ozekibart in the United States. The FDA may, despite prior advice, determine that additional trials or data are necessary in order to submit or obtain approval. Regulatory authorities may find fault with the data generated at one of our clinical sites or with the activities of our trial monitor or may disagree with our analyses of the results of our trials. Regulatory authorities may also identify deficiencies or other issues with our manufacturing or quality systems or processes. Any such findings or issues could require additional data or analyses or the need for changes to our systems or processes that could delay or prevent us from gaining approval of ozekibart.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and preclinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials or preclinical studies will be conducted as planned, including whether we will be able to meet expected timeframes for data readouts, or completed on schedule, if at all, and failure can occur at any time during the trial or study process. Despite promising preclinical or clinical results, any therapeutic candidate can unexpectedly fail at any stage of clinical or preclinical development. The historical failure rate for therapeutic candidates in our industry is high, particularly in the earlier stages of development.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval for the commercial distribution of our therapeutic candidates, we must conduct extensive preclinical tests and clinical trials to demonstrate sufficient safety, purity, and potency (or efficacy) of our therapeutic candidates in patients. Before we can initiate clinical trials for any therapeutic candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about the candidate&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an Investigational New Drug Application, or IND, or similar regulatory submission. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any therapeutic candidate before it allows us to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our development programs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. If we experience additional delays or fail to develop or again terminate development of a therapeutic candidate in our pipeline, we may not have the financial resources to continue development of, or to modify existing or to enter into new license or collaboration for, a therapeutic candidate. Other issues that may again delay or potentially prevent us from completing our ongoing and planned clinical trials, include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate sufficient preclinical toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with regulatory authorities on trial design; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in identifying, recruiting and training suitable clinical investigators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining approval from one or more institutional review boards, or IRBs, or ethics committees at clinical trial sites; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or amendments to the clinical trial protocol; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from the trial protocol or dropping out of a trial; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our CROs to perform in accordance with Good Clinical Practice, or GCP, requirements or applicable regulatory rules and guidelines in other countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of our therapeutic candidates, or in obtaining sufficient quantities of combination therapies for use in clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects failing to remain in our trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative product for the indications for which we are developing our therapeutic candidates, or participating in competing clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue a clinical trial, or costs being greater than we anticipate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjects experiencing severe or serious unexpected drug-related adverse effects; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies that could be considered similar to our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting data; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failure by our contract manufacturers or us to make any necessary changes to such manufacturing process, or failure of our contract manufacturers to produce clinical trial materials in accordance with cGMPs, regulations or other applicable requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The therapeutic candidates we pursue may not demonstrate the necessary safety or efficacy requirements for marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may be suspended, partially suspended or terminated by us, the IRBs overseeing such trials, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations, administrative actions or lack of adequate funding to continue the clinical trial. Clinical holds may be placed prior to a clinical trial even beginning, in order to address potential safety and risk concerns of regulatory authorities, and partial or complete clinical holds can be imposed at any time during a trial. For example, in early 2023, the ChonDRAgon trial of ozekibart was placed on partial clinical hold by the FDA, and the Former Parent paused patient enrollment in the trial, following the occurrence of a fatal serious adverse event (grade 5) of hepatotoxicity (or hepatic failure) triggering the predefined stopping rules built into the protocol. The FDA lifted the hold in April&#160;2023 after the Former Parent amended the trial protocol to include additional screening criteria and to make other changes to address patients who may be at risk of significant hepatotoxicity. Furthermore, while we perform certain similar functions internally, we expect to rely on contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our clinical trials and while we expect to enter into and have entered into agreements governing those CROs&#8217; committed activities, we have limited influence over their actual performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenue or receive royalties from any of these therapeutic candidates may be delayed. Any delays in completing our clinical trials may increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. If we were to cancel the development of any of our therapeutic candidates, we may still be required to pay certain non-cancellable commitments to our CROs under the terms of our various CRO contracts. Any of these occurrences may materially and adversely affect our business, financial </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain approval of ozekibart, we may never be able to successfully commercialize the product or to meet our expectations with respect to revenues or profits. We have never marketed, sold or distributed for commercial use any pharmaceutical product. We are in the process of building the teams, infrastructure, systems, processes, policies, relationships and materials necessary for launch of ozekibart in the United States in chondrosarcoma. If we receive regulatory approval to market or sell ozekibart or any of our other therapeutic candidates, if successfully developed and approved, but are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects will be materially adversely affected. There is no guarantee that we will be successful in our launch or commercialization efforts with respect to ozekibart or with respect to any other therapeutic candidate that may be approved in the future. We may encounter issues, delays or unexpected challenges in launching or commercializing ozekibart or any of our other therapeutic candidates, if approved. For example, our results may be negatively impacted if we have not adequately sized our field teams or our physician segmentation and targeting strategy is inadequate or if we encounter deficiencies or inefficiencies in our infrastructure or processes. We may encounter unexpected limitations in the scope, breadth, availability or amount of reimbursement covering ozekibart or our other therapeutic candidates, if approved, or other limitations or issues related to the price. We may face issues related to market acceptance and use of any of our therapeutic candidates, if approved. Any of these issues could impair our ability to successfully commercialize the product or to generate substantial revenues or profits or to meet our expectations with respect to revenues or profits. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of therapeutic candidates is based on our proprietary modular protein engineering platforms and is novel and unproven, and the cost and time to develop them and the likelihood of success may be more uncertain than if we had employed more established drug development approaches. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to identify, develop and commercialize therapeutics and therapeutic candidates (including ozekibart and INBRX-106) based on our proprietary modular protein engineering platforms, which leverage a novel and unproven therapeutic approach. Our research methodology and novel approach to oncology and rare disease using our proprietary modular protein engineering platforms may be unsuccessful in identifying additional therapeutic candidates, and any therapeutic candidates based on our technology may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing that would extend development timelines and be more costly, or make the therapeutic candidates unmarketable or unlikely to receive marketing approval. If any of our therapeutic candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, and it may prove to be difficult or impossible to finance or further continue development of our pipeline. We have observed serious adverse events in our Phase 1/2 clinical trial of INBRX-106, as well as our Phase 1 and Phase 2 clinical trials of ozekibart for chondrosarcoma, for which we have been subject to a prior partial clinical hold.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As noted in the risk factor &#8220;We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted,&#8221; the life science industry is highly competitive, and development of products, even therapeutic candidates with novel and unproven technology such as our therapeutic candidates, is highly competitive. If we fail to stay at the forefront of technological change in utilizing our protein engineering platforms to create and develop therapeutic candidates, we may be unable to compete effectively. Our competitors may render our protein engineering platforms obsolete or may limit the commercial value of our therapeutic candidates, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By contrast, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our proprietary modular protein engineering platforms and potential of our proprietary modular protein engineering platforms-based therapeutic candidates. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, advancing our therapeutic candidates as novel candidates creates other significant challenges for us, including educating medical personnel regarding a novel class of modular protein therapeutics, as well as the challenges of incorporating our therapeutic candidates, if ever approved, into treatment regimens. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any of these challenges, events or circumstances occur, we may be forced to abandon our development efforts for a program or programs, which would harm our business, financial condition, results of operation and prospects.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early stage clinical trials of our therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial results or observations in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical studies and early clinical trials does not ensure that later and pivotal clinical trials will generate the same results, or otherwise provide adequate data to demonstrate the safety and efficacy of a therapeutic candidate. Frequently, therapeutic candidates that have shown promising results in preclinical studies or early clinical trials have subsequently suffered significant setbacks in later or pivotal clinical trials. Our therapeutic candidates in clinical trials, including ozekibart and INBRX-106, may ultimately fail to show the desired safety and efficacy in clinical trials despite having progressed through preclinical studies and despite any initial observations of single agent activity, stable disease or partial responses. While the registrational trial was successful for ozekibart in patients with metastatic or unresectable chondrosarcoma, there can be no assurance that our other clinical trials will be successful or support further clinical development, including development in trials, of any of our therapeutic candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies or trials, and any of these setbacks in our clinical development could have a material adverse effect on our business and operating results. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our therapeutic candidates, whether used alone on in combination with other therapies, have in the past caused, could cause us or regulatory authorities to interrupt, delay or halt clinical trials or the delay or denial of marketing approval by regulatory authorities, or, if such therapeutic candidates are approved, result in a more restrictive label and other post-approval requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials, when used alone or in combination with other approved products or investigational drugs, we may also need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Results of our clinical trials could reveal a high and unacceptable severity of adverse side effects and it is possible that patients enrolled in these clinical trials could respond in unexpected ways. For instance, ozekibart and INBRX-106 are therapeutic candidates targeting oncology indications that are clinically evaluated in very sick populations. Certain trial participants, including participants evaluated in our trials for ozekibart, have in the past and others may in the future experience side effects or serious adverse events that could be related to one of our therapeutic candidates. We have observed treatment related serious adverse events in our Phase 1/2 clinical trial of INBRX-106 which consisted of administration site conditions, metabolism and nutrition disorders, gastrointestinal disorders, blood and lymphatic system disorders, cardiac disorders, cytokine release syndrome, infusion-related reactions, primary adrenal insufficiency, increased blood bilirubin, myositis, toxic encephalopathy, and acute kidney injury, and in our Phase 1 and Phase 2 clinical trials of ozekibart in chondrosarcoma which consisted of abnormal laboratory findings, gastrointestinal disorders, blood and lymphatic disorders, hepatobiliary disorders, and administration site conditions, infections, metabolism and nutrition disorders, tachycardia, posterior reversible encephalopathy syndrome, muscular weakness and renal and urinary disorders.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It may be difficult to establish safety in relatively small patient populations with rare diseases. Further, we intend to develop certain of our therapeutic candidates in combination with one or more cancer therapies. This combination </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">may have additional side effects that were not present in preclinical studies or clinical trials of our therapeutic candidates conducted as a monotherapy or in combination with other cancer therapies. The uncertainty resulting from the use of our therapeutic candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, clinical trials by their nature utilize a sample of the potential patient population. Rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our therapeutic candidates receives marketing approval and we or others identify undesirable side effects caused by our product (or potentially other therapeutics with similar mechanisms of action), any of the following adverse events could occur: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to suspend marketing of a product, or we may decide to remove such product from the marketplace</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw or modify their approval of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component of the product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of safety-related labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients or to implement other aspects of a risk evaluation and mitigation strategy, or REMS, such as a restricted distribution program or educational programs for prescribers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or could be sued and held liable for harm caused to patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse side effects caused by any therapeutics that may be similar in nature to our therapeutic candidates could delay or prevent marketing approval of our therapeutic candidates, limit the commercial profile of an approved label for our therapeutic candidates, or result in significant negative consequences for our therapeutic candidates following marketing approval, if any. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above described events could prevent us from achieving or maintaining market acceptance of our therapeutic candidates, if approved, and could delay, impede and/or substantially increase the costs of commercializing our therapeutic candidates thus significantly impacting our ability to successfully commercialize our therapeutic candidates and generate revenue. Any of the above described occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to develop certain of our therapeutic candidates in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop certain of our therapeutic candidates in combination with one or more approved or investigational cancer therapies. Even if any therapeutic candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our therapeutic candidates are replaced as the standard of care for the indications we choose for any of our therapeutic candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. Developing combination therapies using approved therapeutics also exposes us to additional clinical risks, such as the requirement that we demonstrate the safety, purity, potency or efficacy of each active component of any combination regimen we may develop.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also may evaluate our therapeutic candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell any therapeutic candidate we develop in combination with an unapproved cancer therapy if that unapproved cancer therapy does not ultimately obtain marketing approval. In addition, unapproved cancer therapies face the same risks described with respect to our therapeutic candidates currently in development and clinical trials, including the potential for serious adverse events, delay in their clinical trials and lack of FDA approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination our therapeutic candidates, we may be unable to obtain approval of or market any such therapeutic candidate. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our therapeutic candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Should any competitors have ongoing clinical trials for therapeutic candidates treating the same indications as our therapeutic candidates, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; therapeutic candidates. The conditions for which we currently plan to evaluate our therapeutic candidates include orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by other factors including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility criteria for the study in question; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the therapeutic candidate under study; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability and efficacy of available therapies for the disease or condition under investigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the therapeutic candidate under investigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our payments for conducting clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult for us to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for any of our clinical trials could result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates and in delays to commercially launching our therapeutic candidates, if approved, which would materially harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">From time to time we evaluate and pursue potential alternatives for monetizing our assets, which may not result in the consummation of any transaction, or achieve the desired objectives of such a transaction. Our efforts may create a distraction for our management team and adversely affect our business operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we evaluate and pursue potential alternatives for monetizing our assets, with a focus on tax efficiency and enhancing stockholder value while minimizing dilution. Our ability to successfully execute a transaction is dependent on a variety of factors, a large number of which are out of our control, and we may not be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">able to implement a transaction on favorable terms, or within an advantageous timeframe, or on terms that recognize significant value for our assets. The timing and process of evaluating and pursuing such transactions is often unpredictable. For example, in 2025 we announced that we were pursuing an ozekibart transaction; however, in view of potential additional value creation in 2026, an ozekibart transaction is currently not being actively pursued, as we focus on the completion of key INBRX-106 milestones. Additionally, the negotiation and consummation of a transaction may be costly and time-consuming. A transaction may not be as efficient from a tax perspective as we desire, or enhance stockholder value, or result in any other anticipated or intended benefits. We also could incur total costs and expenses that are greater than expected, and our efforts could make it more difficult to attract and retain qualified personnel or disrupt our operations, each of which could have a material adverse effect on our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The current market price of our common stock may reflect an assumption that a transaction involving ozekibart or our other assets will occur, and any perceived delay or failure to complete a transaction could result in negative investor perceptions and could cause a decline in the market price of our common stock, which could adversely affect our ability to access the equity and financial markets, as well as our ability to explore and enter into potential transactions. We cannot guarantee that any transaction involving ozekibart or our other assets will be negotiated, signed or completed, be on attractive terms, enhance stockholder value or deliver any anticipated benefits.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our therapeutic candidates may be delayed, and our business may be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have provided, and will continue to provide, a number of timing estimates regarding the initiation of clinical trials and clinical development milestones, and the expected availability of data resulting from these trials for certain of our therapeutic candidates. We expect to continue to estimate the timing of these types of development milestones and our expected timing for the accomplishment of various other scientific, clinical, regulatory and other product development objectives. From time to time, we may publicly announce the expected timing of some of these events. We have had in the past, and may need in the future, to adjust our previously announced timing for certain of our therapeutic candidates. The achievement of many of these milestones and events may be outside of our control. All of these timing estimations are based on a variety of assumptions we make, which may cause the actual timing of these events to differ from the timing we expect, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our available capital resources and our ability to obtain additional funding as needed; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress, costs and results of our clinical trials and research and development activities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of clinical trial allowances or approvals by the FDA and other regulatory authorities and the timing of these allowances and approvals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts of our licensees with respect to the commercialization of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the securing of, costs related to, and timing issues associated with, manufacturing our therapeutic candidates and, if any of our therapeutic candidates are approved, associated with sales and marketing activities and the commercial manufacture of our therapeutic candidates; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances arising from or relating to pandemics, regional conflicts, sanctions, geopolitical events, natural disasters or extreme weather events, including potential effects on the global supply chain, our manufacturers and the availability of raw materials needed for the research and development of our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to achieve announced milestones in the timeframes we expect, the future marketing approval and commercialization of any of our therapeutic candidates may be delayed, and our business, financial condition, results of operations, and prospects may be harmed and our stock price may decline. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial, interim, topline and preliminary data from our clinical trials that we may announce, observe or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish initial, interim, topline or preliminary data from our clinical trials. These initial, interim, topline and preliminary data from our clinical trials that we may publish from time to time or that we may observe on an ongoing basis in our open-label trials may change as more data become available and, accordingly, they are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues, more participant data become available and we issue our final clinical trial report. Initial, interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim, topline and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for any current or future therapeutic candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small or smaller than we may expect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first-, second-, or third-line. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to initially seek approval of certain of our therapeutic candidates as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that therapeutic candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The number of patients who have the cancers we are targeting may turn out to be small or smaller than expected. Additionally, the potentially addressable patient population for our current programs or future therapeutic candidates may be limited, if and when approved. Even if we obtain significant market share for any therapeutic candidate, if and when approved, if the potential target populations are small or smaller than expected, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second- or third-line therapy. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct a portion of our clinical trials and certain of our preclinical studies and contract manufacturing. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we expect to continue our current clinical trials and expect to initiate clinical trials in the near term for other therapeutic candidates, we do not independently conduct clinical trials. As such, while we perform certain functions internally, we currently rely on third-party CROs, clinical data management organizations and consultants to help us design, conduct, supervise and monitor clinical trials of our therapeutic candidates. As a result, we have less control over the timing, quality and other aspects of our clinical trials than we would have had we conducted them on our own. There is a limited number of third party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs or investigators or to do so on commercially reasonable terms. Further, these investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines for any reason, our clinical development programs could be delayed and otherwise adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the relevant study or trial. Our reliance on third parties we do not control will not relieve us of these responsibilities and requirements. In addition, we and our CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities with the respect to the conduct of preclinical studies and clinical trials. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP, GCP or other requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies clinical trials before approving our marketing applications, if ever. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our therapeutic candidates.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not track our research and development expenses on a program-by-program basis, which may impact our ability to efficiently allocate resources and could adversely affect our financial condition and results of operation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting and regulatory requirements, we track all research and development expenses in the aggregate and do not measure or track such expenses on a program-by-program basis. As a result, we evaluate the effectiveness of any particular research and development expense using qualitative metrics such as patient data and discussions with our employees overseeing the particular program. Our approach to research and development expenses may limit our ability to accurately assess the cost-effectiveness and progress of individual programs, which could impact our strategic decision-making process. For instance, if our qualitative observations are inaccurate or if the CRO fails to adequately oversee the research and development activities of any program, we may continue to allocate resources to a program that is not cost-effective or underperforming, or conversely, we may underfund a program that could potentially yield significant returns. This could result in inefficient use of our resources and potentially impact our financial condition and results of operations. Moreover, our approach to tracking research and development expenses could potentially impact our ability to attract investors who scrutinize the allocation of research and development expenses as a measure of a company&#8217;s management efficiency and strategic focus. If any such risk were to materialize, it could potentially impact our financial condition, results of operations, and ability to attract investments.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular therapeutic candidate and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on specific therapeutic candidates, development programs and specific indications. As a result, we may forgo or delay pursuit of opportunities with other therapeutic candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable potential commercial therapeutics or profitable market opportunities. Our spending on current and future research and development programs and therapeutic candidates for specific indications may not yield any commercially viable therapeutic candidates. If we do not accurately evaluate the commercial potential or target market for a particular therapeutic candidate, we may relinquish valuable rights to that therapeutic candidate through collaborations, licenses and other similar arrangements in cases in which it would </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">have been more advantageous for us to retain sole development and commercialization rights to such therapeutic candidate.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have existing collaborations with third parties, and may in the future enter into additional collaborations, to develop or commercialize our therapeutic candidates. If these collaborations are not successful, our business could be harmed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have existing collaborations with third parties, and may in the future enter into additional collaborations, to develop or commercialize our therapeutic candidates. Any collaborations that we are party to may pose several risks, including the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical trials conducted as part of these collaborations may not be successful; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any therapeutic candidates that achieve marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding therapeutic candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our therapeutic candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own therapeutic candidates or products, which may cause collaborators to cease to devote, or limit, resources to the commercialization of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our therapeutic candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of any such therapeutic candidate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have disagreements with these collaborators, including disagreements over proprietary rights, collaborator performance, contract interpretation or the preferred course of development of any therapeutic candidates. Any disagreement we may have with our collaborators, may cause delays or termination of the research, development or commercialization of our therapeutic candidates pursuant to the applicable agreement, may lead to additional responsibilities for us with respect to our therapeutic candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive and which would likely divert the attention of our management from our core research and development activities. These types of disputes could materially harm our financial condition and our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third party manufacturers encounter such difficulties, or otherwise fail to comply with their contractual obligations, the development or commercialization of our therapeutic candidates could be delayed or stopped. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we have found that our therapeutic candidates can be readily manufactured at high yields with established processes used to produce therapeutic proteins, the manufacture of biotechnology products is generally complex and requires significant expertise and capital investment. We and our contract manufacturers must comply with cGMPs, and similar foreign regulations and guidelines for clinical trial product manufacture and for commercial product manufacture. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up, addressing product quality, product comparability, validating production processes and mitigating potential sources of contamination. These problems include difficulties with raw material procurement, production costs and yields, quality control, product quality, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our therapeutics or in the manufacturing facilities in which our therapeutics are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that manufacturing problems, including supply chain disruptions of any of our therapeutic candidates or products will not occur in the future. Any delay or interruption in the supply of preclinical or clinical trial supplies or supply chain disruptions could delay the completion of these trials, increase the costs associated with maintaining these trial programs and, depending upon the period of delay, require us to commence new trials at additional expense or terminate trials completely. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we were to experience an unexpected loss of supply of, or if any supplier were unable to meet our demand for any of our therapeutic candidates or future approved products we seek to commercialize, if any, we could experience delays in our research or planned clinical studies or be forced to stop our development or commercialization efforts. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods needed to switch manufacturers and suppliers, if necessary, would significantly delay our clinical studies and the commercialization of our therapeutics, if approved, which would materially adversely affect our business, prospects, financial condition and results of operation. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to supply and manufacture our therapeutic candidates, and we expect to continue to rely on third parties to manufacture and supply our therapeutics, if approved. The development of therapeutic candidates and the commercialization of any therapeutic candidates, if approved, could be stopped, delayed or made less profitable if any of these third parties fail to provide us with sufficient quantities of therapeutic candidates or therapeutics, fail to do so at acceptable quality levels or prices, or fail to maintain or achieve satisfactory regulatory compliance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to develop and manufacture our therapeutic candidates for use in the conduct of our trials or for commercial supply, if our therapeutics are approved. Instead, we rely on, and expect to continue to rely on third-party providers to manufacture the supplies for our preclinical studies and clinical trials. We currently rely on a limited number of third-party contract manufacturers for our required raw materials, antibodies, and other biologics for our preclinical research and clinical trials, as well as for the manufacture of supplies for our therapeutic candidates. To the extent any of our manufacturing partners are unable to fulfill these obligations in a timely manner, our clinical trials may be delayed, and our business may be adversely affected. In general, reliance on third party providers may expose us to more risk than if we were to manufacture our therapeutic candidates ourselves. In addition, the facilities used by our third-party manufacturers must be approved for the manufacture of our therapeutic candidates by the FDA, or any comparable foreign regulatory authority, pursuant to inspections that will be conducted after we submit a BLA to the FDA, or submit a comparable marketing application to a foreign regulatory authority. We do not control the operational processes of the contract manufacturing organizations with whom we contract and are dependent on these third parties for the production of our therapeutic candidates in accordance with relevant regulations (such as cGMPs), which include, among other things, quality control and the maintenance of records and documentation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on foreign CROs and CMOs. Such foreign CROs and CMOs may be subject to U.S. legislation, sanctions, trade restrictions and foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, on December 18, 2025, President Trump signed the National Defense Authorization Act for Fiscal Year 2026 into law, which includes the BIOSECURE Act. The BIOSECURE Act prohibits the U.S. Government from procuring or obtaining biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; (&#8220;BCC&#8221;); entering into, extending, or renewing government contracts with an entity that directly or indirectly uses biotechnology equipment or services from a BCC in performance of that federal contract; and/or issuing grants or loans to purchase, obtain, or use biotechnology equipment or services produced by a BCC. The BIOSECURE Act also prohibits U.S. government loan and grant recipients from using federal loan or grant money to enter into contracts with entities that use equipment or services from BCCs in the performance of any federal prime contract or subcontract. Companies designated as a BCC include those that are identified on the U.S. Department of Defense&#8217;s annual List of Chinese Military Companies, also known as the 1260H List. The U.S. Government also has the ability to designate entities as BCCs through a separate designation process. There is a &#8220;safe harbor&#8221; provision providing that the restrictions do not apply to equipment or services that were formerly but are no longer provided by a BCC, as well as a &#8220;grandfathering&#8221; provision providing that the prohibitions shall not apply for a five-year period to biotechnology equipment or services produced or provided under a contract or agreement entered into before the applicable effective date. Given the BIOSECURE Act, we may be restricted in our ability to work with certain Chinese biotechnology companies to the extent we would contract with, or otherwise receive funding from, the U.S. Government. Such disruption could have adverse effects on the development of our therapeutic candidates if we are unable to find alternative suppliers.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have no control over the ability of third-party manufacturers and testing, packaging and labeling, and storage facilities to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture our therapeutic candidates, or if such authorities withdraw any such approval in the future, we may be required to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our therapeutic candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial position. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not have any long-term commitments or supply agreements with any third-party manufacturers. We may be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our therapeutic candidates or such quantities at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breach of the manufacturing agreement by the third party;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to manufacture our therapeutic candidates according to our specifications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to manufacture our therapeutic candidates according to our schedule or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences could have a material adverse effect on our business.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may be unable to successfully scale up manufacturing of our therapeutic candidates in sufficient quality and quantity, which would delay or prevent us from developing our therapeutic candidates and commercializing any approved therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing partners may be unable to successfully increase the manufacturing capacity for our therapeutic candidates in a timely or cost-effective manner, or at all, as needed for our development efforts or, if our therapeutic candidates are approved, our commercialization efforts. Quality issues may also arise during scale-up activities. If </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we, or any manufacturing partners, are unable to successfully scale up the manufacture of our therapeutic candidates in sufficient quality and quantity, the development, testing, and clinical trials of our therapeutic candidates may be delayed or infeasible, and marketing approval or future commercial launch of any resulting therapeutic may be delayed or not obtained, which could significantly harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully identify, develop and commercialize additional therapeutics or therapeutic candidates could impair our ability to grow. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our therapeutic candidates in our current pipeline, we continue to innovate and expect to expand our portfolio. Because we have limited financial and managerial resources, research programs to identify therapeutic candidates may require substantial additional technical, financial and human resources, whether or not any new potential therapeutic candidates are ultimately identified. Our success may depend in part upon our ability to identify, select and develop promising therapeutic candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional therapeutic candidates suitable for further development. All therapeutic candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a therapeutic candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA and other comparable foreign regulatory authorities or to achieve market acceptance. If we do not successfully develop and commercialize new therapeutic candidates we have identified and explored, our business, prospects, financial condition and results of operations could be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of biotechnology treatments of any therapeutic candidates for which we may conduct clinical trials. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing any approved products, these claims could result in an FDA investigation of the safety and effectiveness of our future commercial products, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturers) or our marketing programs, a recall of our products or more serious enforcement action, limitations on the approved indications for which the product may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to clinical trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by potential product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our therapeutic candidates are approved for marketing and commercialization and we are unable to establish effective sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are currently establishing capabilities for sales, marketing, and distribution. We will need to establish our own internal sales, marketing, and distribution capabilities to commercialize our approved therapeutic candidates, if any, in the United States and other worldwide territories, or will need to enter into collaborations with third parties to perform these services. Internal efforts are expensive and time-consuming, requiring the commitment of significant financial and managerial resources to establish an effective internal marketing and sales force with technical expertise and the related supporting distribution, administration and compliance capabilities. If we were to rely on additional third parties with these capabilities to market our future therapeutics or were to decide to co-promote products with any of our future collaborators, we would need to establish and maintain or revise existing marketing and distribution arrangements with these partners, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. Any revenue we receive in connection with third-party license, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">marketing or distribution arrangements, will depend upon the efforts of these third parties, and there can be no assurance these third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The future commercial success of our therapeutic candidates will depend on the degree of market acceptance of our therapeutic candidates among physicians, patients, healthcare payors and the medical community. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are still in clinical development and our emerging pipeline is still in preclinical development; although we plan to submit a BLA to the FDA early in the second quarter of 2026 for the approval of ozekibart in patients with metastatic or unresectable chondrosarcoma, we may never have an approved product that is commercially successful. Due to the inherent risk in the development of biopharmaceutical products, it is probable that not all or none of the therapeutic candidates in our pipeline, including any that are or may be licensed to third parties, will successfully complete development and be commercialized. Furthermore, even when available on the market, our products may not achieve an adequate level of acceptance by physicians, patients and the medical community, and we may not become profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of any approved products by physicians, patients and healthcare payors will depend on a number of factors, many of which are beyond our control, including, but not limited to: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for any approved product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">wording in the FDA- or EMA-approved prescribing information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales, marketing and distribution support; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, patients and healthcare payors of each product as safe, effective and cost-effective; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience, ease of use, ease of administration and other perceived advantages over alternative products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of adverse events or publicity; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment with our therapeutics in relation to alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which products are approved for inclusion and adequately reimbursed on formularies of hospitals and third-party payors, including managed care organizations; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our products are designated in the label, under physician treatment guidelines or under reimbursement guidelines as a first, second, third or last line therapy. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_100"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Organization and Operations </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive. We are currently developing therapeutic candidates that will compete, if approved, with other products and therapies that currently exist or are being developed. Our primary competitors fall into the following groups: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Crescendo Biologics Ltd., Molecular Partners AG, Precirix NV, Affibody Medical AB, Numab Therapeutics AG, GT Biopharma, Inc., and Sanofi;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., Numab Therapeutics AG, Amgen, Inc., Xencor, Inc., and Zymeworks Inc.; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Companies developing therapeutics for the treatment of autoimmune diseases, including Sanofi, Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Merck &amp; Co., Inc., Novartis AG, Candid Therapeutics, Inc., Hinge Bio, Inc., and Apogee Therapeutics, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors also include other large pharmaceutical and biotechnology companies who already have marketing approval for, or may be developing therapeutic candidates with, mechanisms similar to or targeting the same indications as our therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the therapeutic candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the therapeutic candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our therapeutic candidates obsolete, less competitive or not economical. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Mark P. Lappe, our Chief Executive Officer, David Matly, our President, and Kelly D. Deck, our Chief Financial Officer, who are all employed at will and for whom we do not have &#8220;key man&#8221; insurance coverage. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies and the specialized nature of the marketing approval process. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(many of whom have substantially greater financial resources than us), and we might not be able to attract or retain these key employees on conditions that are economically acceptable. Our inability to attract and retain these key employees could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant amount of debt which may affect our ability to operate our business and secure additional financing in the future. If we fail to comply with the terms of our loan agreement with Oxford, our business, prospects and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we borrowed a total of $100.0 million from Oxford under a loan and security agreement, or the 2025 Loan Agreement. In March 2026, we amended the 2025 Loan Agreement and borrowed an additional $75.0 million, for a total of $175.0 million. Our obligations under the 2025 Loan Agreement, as amended, are secured by substantially all of our assets. The 2025 Loan Agreement, as amended, requires us, and any debt arrangements or instruments we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">dispose of assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete mergers or acquisitions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur or guarantee indebtedness; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or encumber any assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make specified investments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in different lines of business; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with our affiliates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may limit our flexibility in operating our business. A failure by us to comply with the covenants could result in an event of default, which could adversely affect our business. Upon the occurrence of an event of default, including the occurrence of a material adverse change, the lender could elect to declare all amounts outstanding to be due and payable and exercise other remedies. If the indebtedness were to be accelerated, our future financial condition could be materially adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may incur additional indebtedness in the future. The instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. Our obligations pursuant to the 2025 Loan Agreement, as amended, are secured by substantially all of our assets, including our intellectual property. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against this collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation. Further, if our business is subject to liquidation, the right to repayment of Oxford and any other holders of indebtedness would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to continuing contingent liabilities of the Former Parent following the Separation and Distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There are several significant areas where the liabilities of the Former Parent may become our obligations, notwithstanding the Separation and Distribution. For example, under the Internal Revenue Code of 1986, as amended, or the Code, and the related rules and regulations, each corporation that was a member of the Former Parent&#8217;s consolidated U.S. federal income tax reporting group during any taxable period or portion of any taxable period ending on or before the effective time of the Distribution is jointly and severally liable for the U.S. federal income tax liability of the entire Former Parent consolidated tax reporting group for that taxable period. In addition, the Separation and Distribution Agreement, dated as of January 22, 2024, by and among the Former Parent, the Company and Aventis, Inc., a Pennsylvania corporation, or the Separation and Distribution Agreement, allocates the responsibility for taxes between the Former Parent and us. Pursuant to this allocation, we may be responsible for taxes that we would not have otherwise incurred, or that we would have incurred but in different amounts or at different times, on a standalone basis outside of the Former Parent consolidated group, and the amount of such taxes could be significant. If the Former Parent is unable to pay any prior period taxes for which it is responsible, we could be required to pay the entire amount of such taxes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of any net operating loss carryforwards and other tax attributes may be limited.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will incur significant losses for the foreseeable future. Our ability to utilize net operating loss, or NOL, carryforwards and certain other tax attributes (if any) to offset future taxable income or tax liabilities (if any) may be limited as a result of ownership changes. Under Sections 382 and 383 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is generally defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. It is possible that the Company has experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which shifts are outside our control). Corresponding rules may apply under state tax laws. Even if there is no limitation on utilization of our NOL carryforwards as the result of an ownership change, utilization of U.S. federal NOL carryforwards is limited and may reduce taxable income in a given year by no more than 80% of the pre-NOL taxable income in such year. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited. If we earn taxable income in a future year, such limitations on utilization of NOL carryforwards could result in increased future tax liability to us and our future cash flows could be adversely affected. Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including non-compliance with governmental and regulatory bodies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors. Misconduct by these parties could include intentional failures to comply with state and federal securities laws, FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish for our therapeutic candidates, comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain marketing approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance may not provide adequate levels of coverage against claims which may adversely affect our financial condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain insurance that we believe is adequate for businesses of our size and type. However, there are types of losses that we believe are not economically reasonable to insure or that cannot be insured against. For instance, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">because directors and officers, or D&amp;O, liability insurance has become cost prohibitive with high retentions providing minimal coverage, we have not renewed our D&amp;O policy. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we may be subject to securities litigation in the future, including potential class action or stockholder derivative actions. Our indemnification agreements with our directors and certain officers, as well as Delaware General Corporation Law, or DGCL, may require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Without D&amp;O insurance, the amounts we would pay to defend any such litigation or indemnify our officers and directors should they be subject to legal action based on their service to us could have a material adverse effect on our financial condition, results of operations and liquidity. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As we expand our development and regulatory capabilities, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development and regulatory affairs, as well as sales and marketing in connection with the commercialization of any of our therapeutic candidates, if approved. To manage our future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to integrate efficiently or achieve the expected benefits of any acquisitions of complementary businesses, therapeutic candidates or technologies. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Should we in the future acquire any complementary business, therapeutic candidates or technologies, our ability to integrate and manage acquired businesses, therapeutic candidates or technologies effectively will depend upon a number of factors including the size of the acquired business, the complexity of any therapeutic candidate or technology and the resulting difficulty of integrating the acquired business&#8217;s operations, if any. Our relationship with current employees or employees of any acquired business may become impaired. We may also be subject to unexpected claims and liabilities arising from such acquisitions. These claims and liabilities could be costly to defend, could be material to our financial condition and might exceed either the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties. There can also be no assurance that we will be able to assess ongoing profitability and identify all actual or potential liabilities of a business, therapeutic candidate or technology prior to its acquisition. If we acquire businesses, therapeutic candidates or technologies that result in assuming unforeseen liabilities in respect of which it has not obtained contractual protections or for which protection is not available, this could materially adversely affect our business, prospects, financial condition and results of operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected as a result of major computer system failures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors&#8217; operations could result in a material disruption of our development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our partners&#8217; marketing approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, our development programs, reputation and competitive position may be adversely affected and the further development of our therapeutic candidates may be delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security incidents or other compromises of our information technology environment could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain sensitive company data on our computer networks and third-party cloud services, including personal information, intellectual property, and proprietary business information. We face a number of threats to our networks from unauthorized access, accidental acts or omissions that expose us to vulnerabilities, security breaches and other system disruptions. Our third-party partners, including CROs and providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third-party service providers, face similar risks, which could affect us directly or indirectly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies. A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability, negatively impact the operation of our business, result in regulatory investigations or actions, litigation, fines and penalties, reputational harm, or other adverse consequences. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets, personal information or preclinical or clinical trial data, may be exposed to unauthorized persons or to the public. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists,&#8221; or employees or other inside actors. Cyberattacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, the use of social engineering (such as phishing) and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our business partners and other third parties with whom we work face similar risks and any security breach of their systems or data could adversely affect us. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption, or loss of confidential or propriety information. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state and foreign government requirements include obligations of companies to notify individuals and others of security breaches involving certain personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, prompt regulatory scrutiny and enforcement, cause us to incur significant costs, including legal expenses, or cause us to incur remediation costs that could, under such circumstances, materially harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any such security breach may materially compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information, it may also subject us to litigation, investigations, significant fines, penalties or liabilities for any noncompliance with certain privacy and security laws or obligations. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from security incident impacting our systems. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">reproduce the data. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. Further, a data breach could result in regulatory investigations and negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities in La Jolla, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents, that results in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. Earthquakes, medical epidemics or pandemics or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. Certain of these natural disasters, including fires and severe weather events may be exacerbated by the effects of climate change. If a natural disaster, pandemic, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or if similar events occurred elsewhere effecting the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material and adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_103"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce intellectual property protection for our technologies or therapeutic candidates, the development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to obtain, maintain, and enforce our intellectual property rights. We rely on a combination of patents, trademarks, and trade secrets to protect our current and future therapeutic candidates and methods for treating patients using our therapeutic candidates. Our patent portfolio includes various issued United States patents, United States pending non-provisional patent applications, United States pending provisional applications, pending Patent Cooperation Treaty, or PCT, applications, issued foreign patents, and foreign patent applications currently pending in various foreign jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we will endeavor to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining, maintaining, and enforcing patents is time-consuming, expensive and sometimes unpredictable, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and enforce any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or may in-license may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to any patents we may license to or from third </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">parties. Therefore, such patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to provide meaningful protection from any competitors. Our competitors may be able to circumvent our patents by developing similar or alternative therapeutic candidates in a non-infringing manner. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which non-compliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent&#160;years been the subject of much litigation. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether, e.g., due to a determination that the claims are invalid or unenforceable. In addition, there can be no assurance that: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or will not be able to legally make, use or sell products or therapeutic candidates that are the same as or similar to our therapeutic candidates despite the claims of the patents that we own or license; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors are the first to file patent applications covering certain aspects of our inventions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any issued patents that we own or have licensed will provide us with any competitive advantage; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining valid and enforceable issued or granted patents covering our therapeutic candidates in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors or third parties may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Third-party or competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">other types of intellectual property protection, particularly that relating to biotechnology. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, could provoke third parties to assert claims against us, and, whether or not successful, could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the PCT is usually filed within 12&#160;months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in one, several or all of Brazil, China, India, Israel, Mexico, New Zealand, Russia or Eurasian Patent Organization, Singapore, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When a patent is granted by a regional patent office (e.g., Europe or Eurasia), the patent must be validated in individual countries in order to be in effect in those countries. We may decide not to validate regional patents in every available country or at all in any country in the region. In addition, we may decide to abandon national and regional patent applications before or after grant. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or any licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, geopolitical actions in the U.S. and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. For example, the U.S. and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the U.S. without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions in which we file patent applications could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Act, or the America Invents Act, enacted in September&#160;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. In contrast, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, assuming that other requirements for patentability were met. Furthermore, United States patent law under the America Invents Act allows for post issuance challenges to United States patents, including ex parte reexaminations, inter parte reviews and post grant oppositions. If our United States patents are challenged using such procedures, we may not prevail, possibly resulting in altered or diminished claim scope or loss of patent rights altogether. Similarly, some countries, notably members of the European Union, also have post grant opposition proceedings that can result in changes in scope and/or cancellation of patent claims. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The United States Supreme Court has also ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As another example, the complexity and uncertainty of European patent laws have increased in recent&#160;years. In Europe, a new unitary patent system was launched on June&#160;1, 2023, which significantly impacted European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications now have the option, upon grant of a patent, of becoming a Unitary Patent, which are subject to the jurisdiction of the Unitary Patent Court, or UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We have opted our current European patents and patent applications out of the UPC and may opt out our future European patents and patent applications. However, if certain formalities and requirements for opting-out are not met, our current or future European patents could be subject to the jurisdiction of the UPC. We may decide to opt out certain European patents and patent applications from the UPC. However, if certain formalities and requirements for opting-out are not met, our current or future European patents could be subject to the jurisdiction of the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, doing so may preclude us from realizing the benefits of the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision. We cannot predict with certainty the long-term effects of any potential changes. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO, the European Patent Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">the European Patent Office and foreign patent agencies in several stages over the lifetime of the patent. Some jurisdictions also require payment of annuity fees during pendency of a patent application. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our therapeutic candidates, our competitors might better be able to enter the market, which would have an adverse effect on our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to reduce the scope of our intellectual property due to intellectual property claims included in the patents or patent applications of others. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may have filed, and may in the future file, patent applications covering technology similar to ours. It is also possible that we have failed to identify relevant third-party patents or applications. For example, United States applications filed before November&#160;29, 2000 and certain United States applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with this earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutic candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover any future approved products or our therapeutic candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies, if possible, or block us from practicing certain aspects of our technology if we are unable to successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed prior to March&#160;16, 2013, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. Similarly, if another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed after March&#160;16, 2013, we may have to participate in a derivation proceeding to determine whether that party derived the claimed invention from an inventor listed on our application and then filed the third-party application without authorization. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our United States patent position with respect to such inventions. In addition, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Further, changes enacted on March&#160;15, 2013 to the United States patent laws under the America Invents Act resulted in the United States changing from a &#8220;first to invent&#8221; country to a &#8220;first to file&#8221; country. As a result, we may lose the ability to obtain a patent if a third party files with the USPTO first and could become involved in proceedings before the USPTO to resolve disputes related to inventorship. We may also become involved in similar proceedings in other jurisdictions. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, licensees or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our current and any future therapeutic candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. We or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">our licensors, licensees or any future strategic partners may in the future become party to, or be threatened with, adversarial proceedings or litigation by third parties regarding intellectual property rights with respect to our current and any future therapeutic candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO or similar proceedings before corresponding foreign patent offices. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future therapeutic candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we or our licensors, licensees or any future strategic partners believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future therapeutic candidates. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this is a high burden and requires us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. For example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing or, in some cases, not at all. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our technology. This loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. Moreover, we may face patent infringement claims from nonpracticing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the actual or threatened suit.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we, our licensees or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we, our licensees or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give any competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, the holders of any such patents may be able to block us or our licensees from marketing therapeutic candidates based on our technology until such patents expire, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property licensed to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements under which we are granted rights to third-party intellectual property, and we expect that we may need to enter into additional license agreements in the future. License agreements may impose various development obligations, payment of royalties and fees based on achieving certain milestones, as well as other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing therapeutic candidates covered by the licensed intellectual property or otherwise adversely affect our business. Our license agreements may involve sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we would rely on our licensor to comply with its obligations under the primary license agreements, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which we may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize any of our therapeutic candidates incorporating the relevant intellectual property. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property agreements with our licensors, licensees, and third parties may be subject to disagreements over contract interpretation, which could narrow the scope of, or result in termination of, our rights to the relevant intellectual property or technology or increase our financial or other obligations to such third parties, or reduce the financial or other obligations our licensees have to us. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. For example, we may disagree with our licensors or licensees regarding whether, when and to what extent various obligations under these agreements apply to certain of our/their therapeutic candidates and products, including various payment, development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement. In either case, such disagreement could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable, generally expensive, time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. For example, although we were successful in the trade secrets case brought by I-Mab Biopharma, we were required to expend resources litigating and settling the case. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material and adverse effect on our ability to compete in the marketplace. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to our business. We rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. Trade secrets and confidential know-how are difficult to maintain as confidential. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, partners, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to us. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. We may need to share our proprietary information, including trade secrets, with our current and future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. The failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if relevant agreements are entered into, despite these efforts, any of these parties may breach the agreements and unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Moreover, a competitor who independently develops substantially equivalent proprietary information may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. Under certain circumstances, we may also decide to publish some know-how to attempt to prevent others from obtaining patent rights covering such know-how. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our employees can use generative artificial intelligence (&#8220;AI&#8221;) technologies in certain circumstances to perform portions of their work. There can be no assurance that employees will not inadvertently or improperly input information that is proprietary, confidential, or sensitive, including trade secrets, into AI systems in a manner that results in unauthorized disclosure or loss of confidentiality. Many generative AI tools are provided by third-party vendors, and we may have limited ability to control or verify how information submitted by employees is processed, stored, retained, or used by such providers, including whether such information may be incorporated into model training or otherwise accessed or disclosed. Any failure to adequately prevent the disclosure or misuse of our proprietary or confidential information, whether due to employee error, inadequate controls, evolving AI system functionality, or third-party practices, could result in the loss of trade secret protection and the disclosure of confidential information related to our inventions and product candidates, which could preclude us from obtaining patents covering disclosed inventions and product candidates, all of which could adversely affect our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or confidential information of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or biotechnology companies, including potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We have in the past and may again be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or clients, or our competitors. Litigation has been and may again be necessary to defend against such claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Our trademarks may not be approved by one or more governmental trademark offices or may not be approved for use on our products by regulatory agencies, such as the FDA. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our patent terms expire before or soon after our therapeutic candidates are approved, or if manufacturers of biosimilar drugs successfully challenge our patents, our business may be materially harmed. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United States non provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our therapeutic candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive medications, including biosimilar medications. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our therapeutic candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the European Union. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, and only one patent applicable to an approved drug may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. Also, the scope of our right to exclude during any patent term extension period may be limited or may not cover a competitor&#8217;s product or product use. As a result, our revenue from applicable therapeutic candidates, if approved, could be reduced, possibly materially. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our patents and patent applications may not provide us with sufficient rights to exclude </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">others from commercializing products similar or identical to ours. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of biosimilar drugs may challenge the scope, validity, or enforceability of our patents in court or before a patent office, and we may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential sales of that product. Upon the expiration of our issued patents or patents that may issue from our pending patent applications, we will not be able to assert such patent rights against potential competitors and our business, financial condition, results of operations, and prospects may be adversely affected. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business nor permit us to maintain our competitive advantage. The following examples are illustrative: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may be able to make therapeutic candidates that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or may have exclusively licensed; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not develop additional technologies that are patentable. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_106"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain marketing approval for any product that we may develop and the marketing approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we may attempt to develop, manufacture or market in the United States will be subject to extensive regulation by the FDA, including regulations relating to development, preclinical testing, performance of clinical trials, manufacturing and post-approval commercialization. Preclinical testing, clinical trials and manufacturing, among other activities, will be subjected to an extensive review process before a new therapeutic product may be sold in the United States. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. The time required to obtain FDA approval, and any other required approvals for biological products is unpredictable but typically requires several&#160;years and may never be obtained. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we may wish to develop, manufacture or market in countries other than the United States will also be subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing, pricing and third-party reimbursement among other things in such countries. The foreign marketing approval process includes all of the risks and uncertainties associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in such foreign jurisdictions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In particular, obtaining marketing approval for biological products requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the therapy candidate&#8217;s safety and efficacy, or with respect to biological products in the United States, such therapeutic candidate&#8217;s safety, purity and potency. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the regulatory authorities. Our therapeutic candidates may not be effective, may be only </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMPs or similar foreign requirements compliance by us or by our contract development and manufacturing organizations, or CDMOs, that could result in the candidate not being approved. Moreover, we have not obtained marketing approval for any therapeutic candidate in any jurisdiction and it is possible that none of our existing therapeutic candidates or any therapeutic candidates we may seek to develop in the future will ever obtain marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates could fail to receive, or could be materially delayed in receiving, marketing approval for many reasons, including any one or more of the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a therapeutic candidate is safe, pure, potent and/or effective for its proposed indication; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our therapeutic candidates may not be sufficient to support the submission of a BLA or other submission or to obtain marketing approval in the United States or elsewhere; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate or may identify other GCP deficiencies related to the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing processes, facilities and testing sites of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA or comparable foreign regulatory authorities; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medical standard of care or the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even though we plan to submit a BLA to the FDA for the approval of ozekibart in patients with metastatic or unresectable chondrosarcoma early in the second quarter of 2026, it may not be approved and it is possible that none of the other therapeutic candidates we may develop will obtain the marketing approvals necessary for us to sell the products either in the United States or any other country. Furthermore, approval by the FDA of a therapeutic product does not assure approval by regulatory authorities outside the United States or vice versa. Even if approval for a therapeutic product is obtained, such approval may be subject to limitations on the indicated uses or appropriate patient population that could result in a significantly reduced potential market size for the product. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to obtain the appropriate marketing approvals necessary for us to sell our therapeutic candidates, or if the approvals are more limited than those that we intend to seek, our business, financial condition and results of operations would be materially harmed. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek accelerated approval for one or more of our therapeutic candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a drug or biologic designed to treat a serious or life-</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the drug or biologic has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway may be used in cases in which the advantage of a new drug or biologic over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional confirmatory studies to verity and describe the drug&#8217;s predicted clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, the Food and Drug Omnibus Reform Act of 2022 provided FDA with stronger statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to seeking accelerated approval for any of our therapeutics candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for our therapeutic candidates, there can be no assurance that such application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. For instance, we plan to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway if the current response and duration trends observed in our Phase 1/2 trial of ozekibart in patients with Ewing sarcoma continue, but there is no guarantee it will be accepted as an approvable pathway. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidates would result in a longer time period to commercialization of such therapeutic candidates, if any, could increase the cost of development of such candidate and could harm our competitive position in the marketplace.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to stringent domestic and foreign therapeutic and drug regulation with respect to any potential products. Even if we receive marketing approval for any of our therapeutic candidates, we will still be subject to ongoing regulatory obligations and continued review, which may result in significant additional expense. If we fail to comply with United States and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties. Any unfavorable regulatory action may materially and adversely affect our future financial condition and business operations. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive marketing and commercialization approval for a therapeutic candidate, we will be subject to continuing post-marketing regulatory requirements. Our potential products, further development activities and manufacturing and distribution of a future product, once developed and determined, will be subject to extensive and rigorous regulation by numerous government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and the safety and effectiveness of our therapeutic candidates and, if approved, our future products. The process of obtaining marketing approval or clearance from the FDA and comparable foreign bodies for new products, or for enhancements, expansion of the indications or modifications to existing products, could: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take a significant, indeterminate amount of time; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the expenditure of substantial resources; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">involve rigorous preclinical and clinical testing, and possibly post-market surveillance; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require design changes of our potential products; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in our never being granted the marketing approval we seek. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may cause our operations or potential for success to suffer, harm our competitive standing and result in further losses that adversely affect our financial condition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, as well as its foreign regulatory counterparts, also have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. Additionally, the FDA regulates the promotional claims that may be made about prescription products, such as our products, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, we may share truthful and not misleading information with healthcare providers and payors that is otherwise consistent with the product&#8217;s FDA approved labeling. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will have ongoing responsibilities under these and other FDA and international regulations, both before and after a product is approved and commercially released. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory agencies. If we or our manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, adverse regulatory inspection finding, holds on clinical trials, delay of approval or refusal by the FDA or applicable authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of marketing approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, exclusion of eligibility from government contracts, injunctions, civil penalties or criminal prosecution. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively commercializing our potential products and harm our business. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications that are specifically approved by the FDA and comparable regulatory authorities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion any therapeutic candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted outside of their respective jurisdictions. While we have previously formed partnerships in China designed to provide access to patient populations outside of the United States and in the future may conduct clinical trials in other foreign jurisdictions, there can be no assurance these data will be accepted by the FDA or EMA or other comparable foreign regulatory authorities as a basis for a product&#8217;s marketing approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To augment our U.S.-centric clinical strategy, we have previously formed partnerships in China designed to provide access patient populations for clinical trials not readily available in the United States and to facilitate rapid patient enrollment with the goal of generating more robust early clinical data from patients in China. We may in the future pursue partnerships to conduct clinical trials outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will not accept the data as support for an application for regulatory approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Many foreign regulatory bodies have similar approval requirements. In addition, any foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, including any trials conducted in China. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding or staffing shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, review, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, may also slow the time necessary for new biologics or modifications to approved and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities from March 2020 until July 2021. If a prolonged government shutdown occurs, or if funding issues, staffing shortages, or renewed global health concerns otherwise hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partnerships in China subject us to risks and uncertainties relating to the laws and regulations of China and the changes in relations between the United States and China. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The government of China has pursued economic reform policies, including by encouraging foreign trade and investment. However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be significantly altered, or that such policies will be beneficial to our partnerships in China. China&#8217;s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade. The U.S. government has called for substantial changes to foreign trade policy with China and has raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on U.S. goods. Moreover, China&#8217;s legislature adopted a national security law to substantially change the way Hong Kong has been governed since the territory was handed over by the United Kingdom to China in 1997. This law increased the power of the central government in Beijing over Hong Kong, limited the civil liberties of residents of Hong Kong and could restrict the ability of businesses in Hong Kong to continue to conduct business as previously conducted. The U.S. State Department previously enacted sanctions related to China&#8217;s governing of Hong Kong, and the United States has and may in the future impose the same tariffs and other trade restrictions on exports from Hong Kong that it places on goods from mainland China. Any further changes in United States trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars. For example, the Uyghur Forced Labor Prevention Act, or UFLPA, imposes a rebuttable presumption that the importation of any goods produced or manufactured wholly or in part in the UFLPA-designated region, or produced by certain entities, is prohibited and that such goods are not permitted entry to the United States. This legislation may have an adverse effect on global supply chains which could adversely impact our business and results of operations. Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations affecting biopharmaceutical companies are also unpredictable. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our partnerships in China which could materially harm our business and financial condition. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of any product candidates for which we obtain approval will depend in part on the extent to which governmental authorities, private health insurers, and other third-party payors provide coverage and adequate reimbursement. Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully commercialize any product candidates for which we obtain approval will depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from government authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and provide reimbursement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing pressure on biotechnology companies to reduce healthcare costs. In the United States, these pressures come from a variety of sources, such as managed care groups and institutional and government purchasers. Increased purchasing power of entities that negotiate on behalf of federal healthcare programs and private sector beneficiaries could increase pricing pressures in the future. Such pressures may also increase the risk of litigation or investigation by the government regarding pricing calculations. The biotechnology industry will likely face greater regulation and political and legal actions in the future. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adverse pricing limitations may hinder our ability to recoup our investment in one or more future therapeutic candidates, even if our future therapeutic candidates obtain marketing approval. Adverse pricing limitations prior to approval will also adversely affect us by reducing our commercial potential. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. For example, the U.S. Department of Health and Human Services, or HHS, imposes rebates on many Medicare Part B and Medicare Part D products to penalize price increases that outpace inflation on an annual basis. HHS has also been empowered to negotiate the price of certain single-source biologics that have been on the market for at least eleven (11) years covered under Medicare as part of the Medicare Drug Price Negotiation Program. Each year up to twenty (20) </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products will be selected by HHS for the Medicare Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage for our product candidates for which we receive approval may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for approved products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize potential products and our overall financial condition. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize in the future and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval in the future. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any therapeutic candidate that we successfully develop. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to commercialize our product candidates, may adversely affect the prices we may obtain and may have a material and adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. In addition, third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our therapeutic candidates, if we obtain marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive or set a price that we believe is fair for our products; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has significantly changed the way healthcare is financed by both governmental and private insurers in the United States. It also included the Biologics Price Competition and Innovation Act, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, certain provisions of the ACA have been subject to judicial, executive, and legislative challenges. For example, on July 4, 2025, the One Big Beautiful Bill Act, or the OBBBA, was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, the current administration is pursuing policies to reduce regulations and expenditures across government agencies including at HHS, the FDA, the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. For example, the current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct-to-consumer platform, or TrumpRx, U.S. patients and Medicaid programs prescription drug Most-Favored Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-patient discounts and repatriation of foreign revenues. Other recent actions, for example, include (1) directing agencies to reduce agency workforce and cut programs; (2) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives; (3) imposing tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission&#8217;s Strategy Report released in September 2025, working across government agencies to increase enforcement on direct-to-consumer pharmaceutical advertising. Additionally, the current administration recently called on Congress to enact "The Great Healthcare Plan," to codify and expand Most-Favored Nation pricing, lower government subsidies to private insurance companies, increase healthcare price transparency, expand pharmaceutical drugs available for over-the-counter purchase, and enact restrictions on pharmacy benefit manager payment methodologies, among other things. These actions and policies may significantly reduce U.S. drug prices, potentially impacting manufacturers&#8217; global pricing strategies and profitability, while increasing their operational costs and compliance risks. In June 2024, the U.S. Supreme Court&#8217;s Loper Bright decision greatly reduced judicial deference to regulatory agencies, which could increase successful legal challenges to federal regulations affecting our operations. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these as well as other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our therapeutic candidates, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. For instance, the European Commission launched its Pharmaceutical Strategy for Europe initiative in November 2020. The European Commission published its proposals for revision related to medicinal products (potentially reducing the duration of regulatory data protection and revising the eligibility for expedited pathways, among other potential revisions) in April 2023. There may be substantial revisions before the European Parliament and European Council adopts any of the proposals which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future products, if any, might not be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, an adequate level of reimbursement might not be available for such products and third-party payors&#8217; reimbursement policies might adversely affect our ability to sell any future products profitably. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our therapeutic candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the U.S. federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and the civil monetary penalties laws, which prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. federal False Claims Act; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 and its accompanying regulations, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also imposes certain obligations with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information on their behalf and their covered subcontractors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the United States Department of Health and Human Services, or HHS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain advanced non-physician healthcare practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and local laws that require certain regulatory licenses to manufacture or distribute products commercially and/or the registration of pharmaceutical sales representatives; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; and state and local laws that require the registration of pharmaceutical sales representatives. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgements, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations, any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We received orphan drug status for ozekibart for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek orphan drug status for additional therapeutic candidates, but even if it is granted, we may be unable to maintain any benefits associated with orphan drug status, including the potential for market exclusivity. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or for which there is no reasonable expectation that the cost of developing and making available in the United </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">States a drug or biologic for a disease or condition will be recovered from sales in the United States for that drug or biologic. In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same drug or biologic for the same disease or condition for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We received orphan drug status for ozekibart for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek orphan drug status for additional therapeutic candidates, but the FDA may not grant any such request. Even with orphan drug status, exclusive marketing rights in the United States may be limited if we seek FDA marketing approval for an indication broader than the therapeutic candidate&#8217;s orphan designated disease or condition. Additionally, any therapeutic candidate that initially receives orphan drug status designation, may lose such designation if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same disease or condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care, or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We received Fast Track designation for ozekibart for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek Fast Track designation for other of our therapeutic candidates. Even if received, Fast Track designation may not actually lead to a faster review process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for ozekibart for the treatment of patients with metastatic or unresectable chondrosarcoma. Depending on the data from our preclinical and clinical studies, we may decide to seek such designation for some or all of our other therapeutic candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing candidates that meet certain criteria. Specifically, drugs and biologics are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the candidate and the specific indication for which it is being studied. The sponsor of a Fast Track therapeutic candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and under Fast Track designation, the FDA may initiate a rolling review of sections of a BLA before the application is complete, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the BLA is submitted. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion whether or not to grant Fast Track designation. Even if we believe a particular therapeutic candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track designation for any of our other therapeutic candidates, such therapeutic candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that ozekibart or any other therapeutic candidate that may be granted Fast Track designation will receive marketing approval in the U.S. Many therapeutic candidates that have received Fast Track designation have ultimately failed to obtain approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates for which we intend to seek approval may face competition sooner than anticipated. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving marketing approval to commercialize a therapeutic candidate ahead of our competitors, our future therapeutic candidates may face direct competition from biosimilar products. In the United States, our therapeutic candidates are regulated by the FDA as biological products, and we intend to seek approval for these therapeutic candidates pursuant to the BLA pathway. The BPCIA created an abbreviated pathway for the FDA approval of biosimilar biological products based on a previously licensed innovator, or reference, biological product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12&#160;years after the original reference biological product was approved under a BLA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA, potentially creating the opportunity for follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the European Commission has granted marketing authorizations for many biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few&#160;years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our therapeutic candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our therapeutic candidates may have received approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions and an uncertain geopolitical environment could have an adverse effect on our business, financial condition, results of operations and prospects</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party partners&#8217; and service providers&#8217; ability to continue operations and advance our therapeutic candidates could be adversely affected by general conditions in the global economy or disruption of global financial markets, including the impacts of uncertain trade policy and inflation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The current federal government administration has increased, and may continue to increase, the use of tariffs by the United States to accomplish certain policy goals. For example, on April 2, 2025, the United States imposed substantial tariffs on most countries throughout the world. Such tariffs and any countermeasures by the United States&#8217; trading partners could increase the cost of raw materials for the manufacture of drug product and may impact our ability to import drug product and cause uncertainty in our ability to supply drug product for our clinical trials. Such conditions may increase the costs for us to run our business, disrupt global supply chains, create additional operational challenges and cause widespread uncertainty in the financial markets.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible the administration may implement trade policy directly impacting the biopharmaceutical industry, which, along with related uncertainty about such policy changes, could reduce our ability to access capital and could increase volatility in the market valuation of companies in the healthcare industry. Because of such uncertainty, we cannot predict the impact of any future changes to international trading relationships or the ultimate impact recently adopted tariff policies will have on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a global economy, which includes utilizing third-party suppliers in several countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects. The Bureau of Industry and Security, U.S. Department of Commerce, has initiated an investigation to determine whether pharmaceutical ingredients, including finished drug product, manufactured outside the United States pose a national security risk and should be subject to additional tariffs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for clinical testing, as well as for manufacture of any products that we may commercialize, if approved. Currently, several of our suppliers are located outside of the United States and we rely on specialized laboratory equipment, supplies, materials, and precursor compounds, all or part of which we believe may be ultimately sourced from multiple countries outside the United States, to advance our research and development efforts.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Unlike consumer goods, pharmaceuticals face unique regulatory constraints that make rapid supply chain adjustments particularly difficult and costly. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward commercialization in the future, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities, negatively impacting our growth prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">condition and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described elsewhere in this report.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable privacy, data protection and information security laws, regulations and standards and other requirements could adversely affect our business, results of operations, and financial performance. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the United States and abroad. We are subject to numerous U.S. federal and state laws and non-U.S. regulations, including in Europe and China, governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to health-related information and other personal information. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations. HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Numerous states have also adopted comprehensive consumer privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. These comprehensive privacy laws impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act, or collectively, the CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines and allows private litigants affected by certain data breaches to recover significant statutory damages. The CCPA provides for fines and allows private litigants affected by certain data breaches to recover </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">significant statutory damages. Similar laws have been passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The CCPA and other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties with whom we work. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In Europe and the UK, we are subject to the GDPR, which comprehensively regulates our use of personal data, including cross-border transfers of personal data out of the EEA and the UK. In addition, some of the personal data we process in respect of clinical trial participants is special category or sensitive personal data under the GDPR, and subject to additional compliance obligations and to local law derogations. We may be subject to diverging requirements under EU member state laws and UK law, such as whether consent can be used as the legal basis for processing and the roles, responsibilities and liabilities as between sites and sponsors. As these laws develop, we may need to make operational changes to adapt to these diverging rules, which could increase our costs and adversely affect our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In relation to such cross border transfers of personal data, we expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the European Commission approval of the current EU-US Data Privacy Framework for data transfers to certified entities in the United States to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes; we may have to implement alternative data transfer mechanisms under the GDPR and/ or take additional compliance and operational measures; and/or it could otherwise affect the manner in which we provide our services, and could adversely affect our business, operations and financial condition.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the GDPR could result in penalties for noncompliance. Since we are subject to the supervision of relevant data protection authorities under multiple legal regimes (including under both the EU GDPR and the UK GDPR), we could be fined under those regimes independently in respect of the same breach. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/or civil claims (including class actions). </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Where we rely on third parties to carry out a number of services for us, including processing personal data on our behalf, we are required under GDPR and the U.S. state privacy laws to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our partnerships in China may expose us to stringent Chinese data security and personal information protection laws and regulations. The Cybersecurity Law of the People&#8217;s Republic of China, or the PRC Cybersecurity Law, which took effect on June 1, 2017, established a cybersecurity and data protection framework in China. Notably, the PRC Cybersecurity Law introduced data localization and cross-border data transfer requirements for operators of critical information infrastructures. The Data Security Law of the People&#8217;s Republic of China, or the PRC Data Security Law, took effect on September&#160;1, 2021 and applies extraterritorially, and to a broad range of activities that involve &#8220;data&#8221; (not only personal or sensitive data). The PRC Data Security Law requires data processing, which includes the collection, storage, use, processing, transmission, provision and publication of data, to be conducted in a legitimate and proper manner. Moreover, the PRC Data Security Law (together with its implementing regulations) provides a national security review procedure for those data processing activities which affect or may affect national security and requires &#8216;important data&#8217; to be stored locally in China unless one complies with certain data transfer restrictions, such as passing a security assessment organized by the relevant authorities. In addition, the PRC Data Security Law also provides that any organization or individual within the territory of the PRC shall not provide any foreign judicial body and law enforcement body with any data stored in the territory of the PRC without the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval of the competent PRC governmental authorities. Also in China, the Personal Information Protection Law of the People&#8217;s Republic of China, or PIPL, which took effect on November 1, 2021, introduced stringent protection requirements for processing personal information. Notably, a data export mechanism, such as a security assessment, entering into a standard contract with the overseas recipient and obtaining a personal information protection certification, must be relied on in order for a &#8216;personal information processor&#8217; (defined under the PIPL as an organization or individual that independently determines the purposes and methods of personal information processing activities) to export personal information out of China, unless an exemption applies. In addition to the PRC Cybersecurity Law, the PRC Data Security Law and the PIPL, the PRC government authorities promulgated several regulations to provide further implementation guidance in accordance with the laws mentioned above. For example, the Regulations on Network Data Security Management, or the Regulations, which took effect on January 1, 2025 in China, have extraterritorial effect and apply broadly to any network data processing activities (not only personal information processing activities). The Regulations reiterate and expand on the existing obligations on &#8216;network data processors&#8217; (defined under the Regulations as individuals or organizations that independently determine the purposes and methods of network data processing activities) as imposed under the PRC Cybersecurity Law, PRC Data Security Law and the PIPL and introduce new data security obligations, such as a requirement to report any risks arising from network products and services that may endanger national security or public interest to the relevant authorities within 24 hours. We cannot predict what impact the new laws and regulations or the increased costs of compliance, if any, will have on our operations in China. We may also be required to make further significant adjustments to our business practices to comply with data security and personal information protection laws in China. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered persons (i.e., individuals and entities who are designated as such by the U.S. Attorney General or considered &#8220;foreign persons&#8221; and are majority owned by, organized under the laws of, a primary resident in, or a contractor of, a covered person or country of concern, as applicable) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to engage in certain transactions or agreements with certain third parties in the future.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended (the FCPA), the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit individuals, companies, and their respective employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed on other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our supply chain.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain quantities of various flammable and toxic chemicals in our facilities in La Jolla, California required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these hazardous materials in our La Jolla facilities comply with the relevant guidelines of La Jolla, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Any insurance coverage we have may not be sufficient to cover these liabilities. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations which would adversely affect our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize our therapeutic candidates, if approved, in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our therapeutic candidates before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our therapeutic candidates. To obtain separate marketing approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our therapeutic candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our therapeutic candidates and ultimately commercialize our therapeutic candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. We may need to rely on third parties to market, distribute and sell our products in foreign markets. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_109"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not know whether an active, liquid and orderly trading market will continue to develop or be sustained for our common stock and as a result it may be difficult for you to sell your shares of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock was listed on the Nasdaq Global Market on May 30, 2024. Although trading in our common stock has developed, we cannot assure you that an active trading market will continue to develop or be sustained or that any trading market will be liquid. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our stock price may fluctuate significantly. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of shares of our common stock may be highly volatile and could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of our clinical trials and preclinical studies or those of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical events, such as global conflicts or hostilities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to our therapeutic candidates or development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; actual or anticipated fluctuations in our financial condition and operating results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our partners or our competitors of new therapeutics or therapeutic candidates, significant contracts, strategic partnerships, joint ventures, collaborations, commercial relationships or capital commitments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of new or updated research or reports by securities analysts or recommendations for our stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing disputes or delays; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any future sales of our common stock, including upon the exercise of the warrants to purchase our common stock, or other securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any change to the composition of the board of directors or key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expiration of contractual lock-up agreements with our executive officers, directors and security holders; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional debt or equity financing efforts; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">circumstances and market conditions relating to pandemics and natural disasters. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. In addition, the stock market in general, and life science companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have on occasion instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and holders of more than 5% of our capital stock own a significant&#160;percentage of our stock and are able to exercise significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, our executive officers, directors and holders of more than 5% of our capital stock beneficially owned approximately 59.1% of our shares of common stock outstanding. Accordingly, this group of stockholders will continue to have significant control over our operations. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock in the public market could cause our stock price to fall. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had 14,577,609 shares of common stock outstanding. All of our shares of common stock issued in the Distribution are freely tradable without restriction or further registration under the Securities Act unless the shares are owned by our &#8220;affiliates&#8221; as that term is defined in the rules under the Securities Act or are subject to other contractual restrictions. Shares held by &#8220;affiliates&#8221; may be sold in the public market only if registered or if they qualify for an exemption from registration or in compliance with Rule&#160;144 under the Securities Act, or Rule&#160;144. Shares held by the Former Parent may be sold, subject to compliance with applicable securities laws. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have reserved approximately 4,000,000 shares for future grants under our 2024 Omnibus Incentive Plan. Any common stock that we issue, including under our 2024 Omnibus Incentive Plan or other equity incentive plans that we may adopt in the future, would dilute the&#160;percentage ownership held by our existing stockholders. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, issued and outstanding warrants to purchase shares of our common stock consisted of pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-38">991,849</ix:nonFraction> shares of common stock. To the extent any of these warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our shares of common stock and an increase in the number of shares eligible for resale in the public market, subject to compliance with applicable securities laws. The holders of warrants have certain registration rights with respect to our common stock. In addition, in January 2025, in connection with the 2025 Loan Agreement, we issued to the lenders warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-39">140,741</ix:nonFraction> shares of our common stock, and in March 2026, in connection with an amendment to the 2025 Loan Agreement, we issued to the lenders warrants to purchase an additional 21,518 shares of our common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued in the Distribution, shares retained by the Former Parent, shares issued under our 2024 Omnibus Incentive Plan or shares issued upon exercise of the warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or therapeutic candidates, or grant licenses on terms unfavorable to us. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, our stock price and trading volume could decline. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price could decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the public markets, which could cause our stock price or trading volume to decline. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Nasdaq Stock Market may delist our securities from its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on the Nasdaq Global Market on May 30, 2024. We cannot assure you that, in the future, our securities will meet the continued listing requirements to be listed on the Nasdaq Global Market. If Nasdaq delists our common stock, we could face significant material adverse consequences, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and analyst coverage for our company; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities or obtain additional financing in the future. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the 2025 Loan Agreement, as amended, restrict our ability to pay dividends without the prior written consent of Oxford. Future debt financing agreements may also limit or require us to have the lender&#8217;s permission before declaring dividends on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial statements and other public reporting, which would harm our business and the trading price of our common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, our management will be required to report upon the effectiveness of our internal control over financial reporting. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that there will not be material weaknesses or significant deficiencies identified in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. In the future, if we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we become an &#8220;accelerated filer,&#8221; as defined in the Exchange Act, our independent registered public accounting firm will be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we would not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July&#160;2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. If the rules and regulations applicable to public companies divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, bylaws and Delaware law contains provisions that could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing our board of directors to issue up to 15,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as our board of directors may determine; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specifying that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors or our Chief Executive Officer and that our stockholders may not act by written consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may create new directorships and that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing that our board of directors is divided into three classes&#8201;&#8212;&#8201;Class&#160;I, Class&#160;II, and Class&#160;III&#8201;&#8212;&#8201;with each class serving staggered three-year terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that our board of directors may amend our bylaws without stockholder approval; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring a super-majority of votes to amend certain of the above-mentioned provisions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As a Delaware corporation, we are also subject to provisions of Delaware law, including Section&#160;203 of the DGCL, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation designates the Court of Chancery of the State of Delaware, or the Chancery Court, or the federal district court for the District of Delaware, or the District Court of Delaware, or the other federal district courts of the United States as the exclusive forum for certain types of actions and proceedings that </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation requires, unless we otherwise consent, that the Chancery Court will, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law (subject to the Chancery Court having personal jurisdiction over the indispensable parties named as defendants): (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers or employees of the Company, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws, (iv)&#160;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws, (v)&#160;any action or proceeding as to which the DGCL confers jurisdiction to the Chancery Court, or (vi)&#160;any action or proceeding asserting a claim against us, or our directors, officers or employees, governed by the internal affairs doctrine. If the Chancery Court does not have jurisdiction for these actions or proceedings, then the actions or proceedings must be brought in a state court located in the State of Delaware. If these state courts also do not have jurisdiction, these actions or proceedings must be brought in the federal district court for the District of Delaware. These limitations in our certificate of incorporation will not apply to actions brought to enforce a duty or liability created by the Securities Act, the Exchange Act or to any claim for which the federal courts have exclusive jurisdiction. However, our certificate of incorporation also provides that, unless we otherwise consent in writing, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In addition, any person holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to these provisions of our certificate of incorporation. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation that materially diverts the attention of our management or pursuant to which we incur substantial costs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. Securities litigation against us could result in substantial costs and materially divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to &#8220;emerging growth companies&#8221; will make our Common Sock less attractive to investors. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an &#8220;emerging growth company,&#8221; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including not being required to comply with the auditor attestation requirements of Section&#160;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an &#8220;emerging growth company,&#8221; we are required to report only two&#160;years of financial results in certain Securities Act registration statements. We may take advantage of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an &#8220;emerging growth company&#8221; for up to five&#160;years after the completion of the Distribution, although we will lose that status sooner if our revenues exceed $1.235&#160;billion, if we issue more than $1&#160;billion in non-convertible debt in a three-year period, or if the market value of our common stock </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that are held by non-affiliates exceeds $700&#160;million as of June&#160;30 of a fiscal year. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile than that of an otherwise comparable company that does not avail itself of the same or similar exemptions. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; as defined in Rule&#160;12b-2 under the Exchange Act. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced financial statement and other financial information disclosure, and reduced disclosure obligations regarding executive compensation in our annual and periodic reports and proxy statements. We will remain a smaller reporting company as long as either (i)&#160;the market value of our common stock held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700&#160;million. Our public float is measured as of the last business day of our most recently completed second fiscal quarter, and annual revenues are as of the most recently completed fiscal year for which audited financial statements are available. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile than that of an otherwise comparable company that does not avail itself of the same or similar exemptions. </span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_115"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-42" continuedAt="f-42-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-40" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-41">Our cybersecurity policies, standards, processes and practices are designed to align with recognized frameworks, such as those established by the National Institute of Standards and Technology, or NIST, and the International Organization for Standardization. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use such frameworks as a guide to help us identify, assess and manage cybersecurity risks relevant to our business. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is designed to preserve the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents when they occur.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program designed to ensure our systems are effective and prepared for information security risks, including monitoring for internal and external threats. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services depending on the sensitivity of the information and systems, including network and endpoint monitoring, audits, vulnerability assessments, penetration testing, and threat modeling, which are designed to inform our risk identification and assessment. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our audit committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer, General Counsel, and Director of Information Technology.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also identify cybersecurity risks by engaging experts to attempt to test our information systems. Depending on the sensitivity of the data and systems in question, we may also undertake activities such as:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">monitoring emerging data protection laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">implementing relevant policies, practices, and contracts (as applicable);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">employing technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">providing training for our employees and contractors regarding cybersecurity threats;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">conducting phishing simulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">conducting annual cybersecurity management and incident response training; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">carrying information security risk insurance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our incident response plan is designed to coordinate the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, and includes processes to triage, assess severity for, escalate, contain, investigate and remediate incidents, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the above processes, we engage with consultants, internal auditors and other third parties, including annually having an independent <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-43">third-party</ix:nonNumeric> review of our cybersecurity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-44" continuedAt="f-44-1">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, depending on the nature and sensitivity of the data or systems in question, and monitor cybersecurity threat risks identified through such diligence. Additionally, we generally require certain third parties to agree by contract to </ix:nonNumeric></span></div></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-42-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-44-1">manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we may conduct as appropriate.</ix:continuation></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-45">materially affected</ix:nonNumeric> or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity breaches could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; which disclosures are incorporated by reference herein.</span></div></ix:continuation><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Governance; Management</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-46" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-47" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-48">Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-49" escape="true">The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-50" escape="true">At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-52" escape="true">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led primarily by our Director of Information Technology, who has</ix:nonNumeric> several years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, and implementing effective information and cybersecurity programs. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-53" escape="true">Our Director of Information Technology is informed with regard to and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through his management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our management team <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-54">reports to the audit committee of our board of directors about cybersecurity threat risks, among other cybersecurity related matters</ix:nonNumeric>, at least annually.</ix:nonNumeric></span></div></ix:nonNumeric><div id="i8fac7241aa424916b2e0582fb85490ec_118"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters are located in La Jolla, California where we currently lease approximately 43,000 square feet of laboratory and office space under a lease that expires in 2028. We have an option to extend the lease an additional three years. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_121"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_124"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part II. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_130"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the ticker symbol &#8220;INBX.&#8221;</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;11, 2026, we had 14,607,036 outstanding shares of common stock and approximately 6 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects, restrictions in our debt agreements and other factors that our board of directors may deem relevant. In addition, the terms of the 2025 Loan Agreement restrict our ability to pay dividends without the prior written consent of Oxford. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, we did not issue or sell any unregistered securities not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any of our equity securities during the three months ended December 31, 2025.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report contains forward-looking statements that involve risk and uncertainties, including those described in the section of this Annual Report titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; As a result of many factors, including those factors set forth in the section of this Annual Report titled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_139"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation from Former Parent</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, Inhibrx, Inc., or the Former Parent, effected the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, upon which, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of our common stock, or the Distribution. On May 30, 2024, the Former Parent completed a series of internal restructuring transactions, or the Separation. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2024, the Former Parent completed the merger, or the Merger, of Art Acquisition Sub, Inc., a wholly-owned subsidiary of Aventis Inc., or the Acquirer, a wholly-owned subsidiary of Sanofi S.A., or Sanofi, with and into the Former Parent with the Former Parent continuing as the surviving entity. Pursuant to the Merger (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer; and (ii) by way of the Separation, we acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing, each Former Parent stockholder received: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every four shares of the Former Parent&#8217;s common stock held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From and after the closing, Inhibrx continues to operate as a stand-alone, publicly traded company focused on ozekibart and INBRX-106, both of which are clinical-stage programs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the spin-off, descriptions of historical business activities are presented as if the spin-off had already occurred, and the Former Parent&#8217;s activities related to such assets and liabilities had been performed by us. Refer to Note 1 to our consolidated financial statements included elsewhere in this Annual Report for further discussion of the underlying basis used to prepare the consolidated financial statements. The operating results presented in our historical financial statements prior to the Merger and in connection with the Separation and the Merger may not be indicative of our results following the Merger and Separation.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Related Parties</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Separation and Distribution Agreement and various agreements relating to transition services, licenses and certain other matters with the Former Parent, which govern our relationship with the Former Parent prior to, at and after the Former Parent completed the Distribution. These agreements include the allocation of employee benefits, taxes and certain other liabilities and obligations attributable to periods prior to, at and after the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Distribution. The terms of these agreements, including amounts billed during the period, are discussed in greater detail in Note 7 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Clinical Pipeline</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize our multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function:</span></div><div style="margin-bottom:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:288.75pt"><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0pt"/><td style="width:140.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:140.50pt"/><td style="width:1.0pt"/></tr><tr style="height:164pt"><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g1.jpg" alt="INBRX-109 Blank.jpg" style="height:219px;margin-bottom:5pt;vertical-align:text-bottom;width:240px" id="i-5"/></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt;vertical-align:middle"><div style="margin-bottom:9.5pt;text-align:center"><img src="inbx-20251231_g2.jpg" alt="INBRX-106 Blank.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:240px" id="i-6"/></div></td></tr><tr style="height:17pt"><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ozekibart (INBRX-109)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-106</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Tetravalent DR5 agonist</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Hexavalent OX40 agonist</span></div></td></tr></table></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:15.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.699%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Target(s)/Format</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;border-top:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">STAGE OF DEVELOPMENT</span></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Preclinical</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="6" style="border-right:1pt solid #dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#ededed;border-left:1pt solid #dbdbdb;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">ozekibart (INBRX-109)*</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="background-color:#ededed;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">DR5<br/>Tetravalent Agonist</span></td><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"/><td colspan="9" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="24" style="background-color:#ededed;border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">INBRX-106**</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#00497f;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">OX40<br/>Hexavalent Agonist</span></td><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="15" style="background-color:#80a035;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="24" style="border-right:1pt solid #dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*     Currently being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer, and certain other solid tumor types.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">**   Currently being investigated in patients with non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma, or HNSCC.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ozekibart (INBRX-109)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ozekibart is a precisely engineered tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with colorectal cancer, Ewing sarcoma, and chondrosarcoma. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colorectal adenocarcinoma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we announced interim efficacy and safety data from the cohort of the Phase 1/2 trial evaluating ozekibart in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma, or CRC. Efficacy was assessed in 10 of the 13 patients evaluable as of the cutoff date of December 2, 2024, who received at least one dose of ozekibart, based on RECIST v1.1 criteria. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the interim data observed above, we initiated an expansion cohort enrolling 44 patients, as a fourth line of therapy for approximately 70% of patients and as a third line of therapy for approximately 30% of patients. 80% of patients had been previously treated with regimens containing irinotecan. Efficacy was assessed in 26 evaluable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">patients who had at least one post-baseline scan as of the cutoff date of October 15, 2025. Based on RECIST v1.1 criteria, a 23% overall response rate, or ORR, was observed and an overall disease control rate of 92% was observed.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We plan to provide an update on the expansion cohort during the second quarter of 2026 when the PFS data is mature. If the current response and duration trends observed continue, we plan to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for this indication.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ewing sarcoma </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced interim efficacy and safety data from the cohort of the Phase 1/2 trial evaluating ozekibart in combination with Irinotecan, or IRI, and Temozolomide, or TMZ, for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Overall, ozekibart in combination with IRI/TMZ was well tolerated from a safety perspective. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on this preliminary data, the ongoing Phase 1/2 trial in the Ewing sarcoma cohort was expanded to enroll up to an additional 50 patients. In March 2026, we provided an update at the European Society for Medical Oncology (ESMO) Sarcoma and Rare Cancers Congress. Of the 31 patients evaluable based on a cutoff date of January 15, 2026, we observed a 64.5% ORR and a disease control rate of 87.1%. At the time of the presentation, responses were ongoing in eight patients, one of which had been on treatment and progression free for more than two years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to complete enrollment in the Phase 1/2 trial of ozekibart in combination with IRI/TMZ for advanced or metastatic, unresectable, relapsed, or refractory Ewing sarcoma in the second half of 2026. If the current response and duration trends observed continue, we plan to meet with the FDA in the second half of 2026 to discuss an accelerated approval pathway for this indication.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chondrosarcoma</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we initiated a randomized, blinded, placebo-controlled, registrational trial in patients with metastatic, unresectable conventional chondrosarcoma, which enrolled over 200 patients in total at 68 different sites worldwide and for which the United States Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA, granted orphan drug designation for the treatment of chondrosarcoma in November 2021 and August 2022, respectively. The primary endpoint for this trial is progression-free survival, or PFS. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025, we announced this trial met its primary endpoint of a statistically significant and clinically meaningful median PFS for patients with advanced or metastatic chondrosarcoma treated with ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio 0.479; 95% CI: 0.33, 0.68); P&lt;0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following recent regulatory interactions, we plan to submit a biologics license application early in the second quarter of 2026. </span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INBRX-106</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">INBRX-106 is a hexavalent OX40 agonist currently being investigated as a single agent and in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2025, we completed enrollment of the Phase 1/2 trial evaluating 34 patients in checkpoint inhibitor refractory or relapsed NSCLC, in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Primary endpoints for this cohort are objective response rate, or ORR, disease control rate, or DCR, duration of response, or DOR, and safety. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, a seamless Phase 2/3 clinical trial was initiated for INBRX-106 in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> as a first-line treatment for patients with locally advanced recurrent or metastatic HNSCC. This trial recruited patients who had not received prior checkpoint inhibitors and whose tumors expressed a PDL-1 combined positive score </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equal to or greater than 20. During the first quarter of 2026, we completed enrollment of 68 patients in the Phase 2 portion with a primary endpoint of ORR supported by secondary endpoints of DOR, PFS, and safety. We plan to provide initial results from the Phase 2 trial in the second quarter of 2026. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If positive, we anticipate this data may ungate the Phase 3 portion, where we expect approximately 350 patients will be randomized to INBRX-106 or placebo in combination with KEYTRUDA</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The co-primary endpoints for the Phase 3 portion of the study are expected to be PFS and overall survival.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_142"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products to date.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, our research and development expenses have related primarily to research activities, including our discovery efforts, and preclinical and clinical development and the manufacturing of our therapeutic candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting and regulatory requirements, we track all research and development expenses in the aggregate and do not manage or track either external or internal expenses on a program-by-program basis. External research and development expenses are instead managed and tracked by the nature of the activity, and primarily consist of contract manufacturing and clinical trial expenses. Internal research and development expenses primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development. We manage and prioritize our research and development expenses based on scientific data, probability of successful technical development and regulatory approval, market potential and unmet medical need, among other considerations. We regularly review our research and development activities and, as necessary, reallocate resources that we believe will best support the long-term growth of our overall business. We review expenses incurred by vendor and by contract as benchmarked against the progression of our clinical and other milestones. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">External research and development expenses consist of:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with the preclinical development of our programs; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our therapeutic candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with the manufacturing of our therapeutic candidates under agreements with contract development and manufacturing organizations, or CDMOs;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory requirements, including fees and other expenses related to our Scientific Advisory Board; and</span></div><div style="margin-bottom:9.5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other external expenses, such as laboratory services related to our discovery and development programs and other shared services.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internal research and development expenses consist of:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including non-cash stock-based compensation under the former Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, and the 2024 Omnibus Incentive Plan, or the 2024 Plan, for personnel engaged in research and development functions; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other internal expenses, such as laboratory supplies and other shared research and development costs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development and support our preclinical programs. In particular, clinical development of our therapeutic candidates, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our CDMOs to manufacture our therapeutic candidates and future commercial products is also much more costly as compared to early-stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, and our ongoing assessments as to each therapeutic candidate&#8217;s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development costs may vary significantly based on factors such as: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the per patient trial costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of trials required for approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the trials are conducted;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of time required to enroll eligible patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to identify patients eligible for our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of doses that patients receive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drop-out or discontinuation rates of patients; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential additional safety monitoring requested by regulatory agencies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient participation in the trials and follow-up; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing, and successful manufacturing of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the phase and development of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety profile of our therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our therapeutic candidates following approval, if any;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation and regulatory guidance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to attract and retain personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties related to potential economic downturn, inflation, interest rates, geopolitical events and widespread health events on capital and financial markets, the supply chain and our expenses; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional strategic collaborations or other arrangements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative, or G&amp;A, expenses consist primarily of: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including non-cash stock-based compensation under the former 2017 Plan and 2024 Plan, for personnel engaged in G&amp;A functions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with accounting, audit, and tax services, legal services, including costs associated with obtaining and maintaining our patent portfolio, investor relations and consulting expenses under agreements with third parties, such as consultants and contractors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with pre-commercialization and business development activity; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we incurred increased G&amp;A expenses in connection with the Merger, including stock compensation expense upon acceleration of options, and other transaction costs, including legal, advisory, and consulting services. We do not expect these expenses to recur in future years. We expect certain of our G&amp;A expenses will continue to increase in the future to support our continued research and development activities, including costs related to pre-commercialization and business development activities. Additionally, we will continue to incur other professional service fees, including but not limited to, legal costs associated with the filing, prosecution, and maintenance of our patents for our therapeutic candidates, and other legal matters, as well as costs associated with services for compliance, accounting, legal, regulatory, tax, investor and public relations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense) </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain related to transaction with Acquirer. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gain related to transaction with Acquirer consists of our gain recorded in connection with the completion of the Merger during the second quarter of 2024. We do not expect future gains in connection with the Merger in future periods.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense consists of interest on our former loans with Oxford incurred prior to the Merger, upon which the outstanding debt was assumed by the Acquirer. In future periods, we expect to incur interest expense in connection with our loan and security agreement with Oxford Finance LLC and other lenders, or collectively, Oxford, entered into in January 2025, or the 2025 Loan Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on cash and cash equivalents, which include sweep and money market account balances as well as investments held in highly liquid debt securities with original maturities of less than three months from our date of acquisition.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_145"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2025 and December&#160;31, 2024 </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations for each of the periods indicated (in thousands, except percentages):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:39.896%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">203,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">127,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(104,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">136,325&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">331,648&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(195,323)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(135,025)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(331,448)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">196,423&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to transaction with Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,021,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,021,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(13,491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,028)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,019,022&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,024,050)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,827,627)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fee Revenue</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License fee revenue during the year ended December 31, 2025 was $1.3 million and consisted of revenue related to Scithera License Agreement which we recognized following the completion of the transfer of all licenses, related materials, and know-how. License fee revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million. See Note 6 to our consolidated financial statements included elsewhere in this Annual Report for additional information on our license and collaboration agreements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">CHANGE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">External expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(12,326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(36,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other external research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Internal expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(37,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other internal research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(3,298)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">113,028&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">203,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(90,715)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$90.7 million from $203.7 million during the year ended December 31, 2024 to $113.0 million during the year ended December 31, 2025. The overall decrease was primarily due to the following factors:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial expense decreased by $12.3 million primarily due to decreased expenses following the spin-off of our INBRX-101 program, which occurred during the second quarter of 2024, and the termination of our INBRX-105 program during 2024, in addition to decreases in expenses in our ozekibart (INBRX-109) registration-enabling trial for the treatment of unresectable or metastatic conventional chondrosarcoma as the trial approached completion of enrollment ahead of our data readout. These decreases in expenses were offset in part by increases in our ongoing trials for INBRX-106, in which we opened additional sites and increased enrollment during the period;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing expense decreased by $36.1 million compared to the prior year, primarily attributable to increased expense in the prior year associated with the purchase of raw materials for our drug substance manufacturing and process development and manufacturing activities with one of our CDMO partners for our ozekibart program, as well as decreased expenses following the spin-off of our INBRX-101 program, which occurred during the second quarter of 2024;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expense decreased by $37.4 million, which was primarily related to $25.9 million in stock option expense recognized during 2024 upon the acceleration of outstanding options in connection with the close of the Merger, in addition to a decrease in headcount during the current period;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility and equipment-related expense increased by $0.5 million, which was primarily related to our operating lease expense; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research and development expense decreased by $5.5 million, which was primarily attributable to a decrease in certain non-recurring sponsored research and preclinical activities, as well as a decrease in purchases of lab supplies and travel expenses following the decrease in headcount during the current period.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">G&amp;A Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expense decreased by $104.6 million from $127.9 million during the year ended December 31, 2024 to $23.3 million during the year ended December 31, 2025. The overall decrease was primarily due to the following factors:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one-time expenses incurred in the prior year related to the Merger of $68.1 million, consisting of legal, advisory, and consulting services performed in connection to the transaction, and SEC filing fees in connection with filings related to the transaction; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses decreased by $23.2 million, which was primarily related to $15.2 million in stock option expense recognized during 2024 upon the acceleration of outstanding options in connection with the close of the Merger, in addition to a decrease in headcount during the current period;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">professional services-related expenses related to legal services, decreased by $9.6 million, primarily attributable to the conclusion of legal proceedings and other intellectual property matters. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain related to transaction with Acquirer. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we earned $2.0 billion of other income, consisting of gains recorded in connection with the completion of the Merger. We recorded a gain of $1.7 billion related to Merger consideration for our outstanding common stock, warrants, and stock options, in addition to $211.3 million related to the extinguishment of our loan under an amended loan agreement with Oxford, or the Amended 2020 Loan Agreement, which was assumed by the Acquirer. In addition to the Acquirer assuming our outstanding debt, the Acquirer assumed outstanding assets and liabilities related to INBRX-101 upon the transaction, resulting in a gain of $14.5 million. The Acquirer also reimbursed us for or paid on our behalf $68.0 million of transaction costs related to the Merger, resulting in a gain. We did not earn income or gains in connection with the Merger during the year ended December 31, 2025 and do not expect to in future periods.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was $12.2 million during the year ended December 31, 2025, all of which related to interest incurred and the amortization of debt discounts related to the 2025 Loan Agreement, under which we had $100.0 million in outstanding principal during the period. Interest expense was $13.5 million during the year ended December 31, 2024, all of which related to interest incurred and the amortization of debt discounts related to the Amended 2020 Loan Agreement, under which we had $200.0 million in outstanding principal during the period prior to its extinguishment upon the Merger. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> During the years ended December 31, 2025 and December&#160;31, 2024, we earned $7.5 million and $10.9 million, respectively, of interest income related to interest earned on our sweep and money market account balances.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was approximately $2,000 during each of the years ended December 31, 2025 and December&#160;31, 2024, respectively. For the years ended December 31, 2025 and December&#160;31, 2024, we have applied a 100% valuation allowance against our federal deferred tax assets since it is more likely than not that the deferred tax assets will not be realized.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_148"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, sources of capital raised to fund our operations have been comprised of the sale of equity securities, borrowings under loan and security agreements, payments received from commercial partners for licensing rights to our therapeutic candidates under development, grants, and proceeds from the sale and issuance of convertible promissory notes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we entered into the 2025 Loan Agreement with Oxford, upon which we received gross proceeds of $100 million. On March&#160;18, 2026, we entered into the First Amendment to Loan and Service Agreement with Oxford, or the March 2026 Amendment. The March 2026 Amendment provides for an additional tranche, or the Term B Loans, in an aggregate principal amount of $75.0 million, upsized from $50.0 million originally available </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">under the 2025 Loan Agreement prior to the March 2026 Amendment, $75.0 million of which was funded on the date of the March 2026 Amendment.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of our therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing our intellectual property portfolio, and raising capital to support and expand these activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Our net income or losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities, as well as the timing of other corporate transactions. During the year ended December 31, 2025, our net loss was $140.1 million. As of December&#160;31, 2025, we had an accumulated deficit of $246.2 million and cash and cash equivalents of $124.2 million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date of filing of this Annual Report. Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. Though we had net income during the year ended December 31, 2024 following the Merger, we expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it. We expect our research and development expenses to increase as we continue our development of, and seek marketing approvals for, our therapeutic candidates (especially as we move more candidates into later stages of clinical development), and begin to commercialize any approved products, if ever. At this time, we are preparing to proceed with the commercialization of certain of our therapeutic candidates, if ever approved. As a result, we will incur significant pre-commercialization expenses in preparation for launch, the outcome of which is uncertain. Additionally, if approved, we will incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Until such time we, if ever, can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, we engage in discussions with potential acquirers regarding the disposition of one or more of our therapeutic candidates. If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future liquidity and capital funding requirements will depend on numerous factors, including: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, costs and timing of preclinical studies and clinical trials for our current or future therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and when we are able to obtain marketing approval to market any of our therapeutic candidates and the outcome of meetings with applicable regulatory agencies, including the FDA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize, including the costs and timing of manufacturing, any therapeutic candidates that receive marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence and effect of competing or complementary therapeutics or therapeutic candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing or securing sales and marketing capabilities if any current or future therapeutic candidate is approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any strategic licensing, collaboration or other similar agreement that we have established or may establish; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved therapeutics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repay, refinance or restructure when payment is due any indebtedness we might incur, including in the event such indebtedness is accelerated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of our capital stock; and </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing or future effects of a potential economic downturn, inflation, interest rates, geopolitical events, and widespread health events on capital and financial markets, the supply chain and our expenses. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing and testing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product, and employ internal resources to manage our manufacturing relationships with these third parties.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, our material cash requirements from known contractual and other obligations primarily relate to our lease obligations and services provided by our third party CROs and CDMOs.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our lease for our laboratory and office space expires in 2028, with an option to extend for an additional three years. As of December&#160;31, 2025, we have future minimum rental obligations under these leases of $7.3 million, of which $2.9 million and $4.4 million are current and non-current, respectively. For more information regarding these lease agreements, refer to Note 9 to the consolidated financial statements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with CROs related to our ongoing preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $16.4 million in our consolidated balance sheets for expenditures incurred for R&amp;D services performed at CROs, CDMOs, and other third-party organizations as of December&#160;31, 2025. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments. Depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from the cost of work performed to date up to twelve months of future committed manufacturing costs. As of December&#160;31, 2025, the noncancellable portion of these contracts totaled in aggregate, excluding amounts recorded in accounts payable and accrued expenses as of this date, approximately $15.9 million. The noncancellable purchase commitments relate to future contract manufacturing of drug supply for one of our therapeutic candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the net cash flow activity for each of the periods indicated&#160;(in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(129,794)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(194,409)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">71,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,376)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(125,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $129.8 million during the year ended December 31, 2025 and consisted primarily of a net loss of $140.1 million, adjusted for non-cash items, including accretion on our debt discount and the non-cash portion of interest expense related to our debt of $2.4 million, stock-based compensation expense of $11.1 million, depreciation and amortization of $2.5 million, and non-cash lease expense of $1.8 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, including a decrease in operating lease liability of $1.6 million as a result of lease payments made throughout the period and decreases in accounts payable of $3.3 million and accrued expenses of $4.4 million due to the timing of payments to our CRO and CDMO partners during the period. These uses of cash were offset in part by a decrease in prepaid expenses and other current assets of $1.4 million as a result of the timing of payments to our CRO and CDMO partners during the period, as well as a decrease in accounts receivable and other receivables of $0.2 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $194.4 million during the year ended December&#160;31, 2024 and consisted primarily of a net income of $1.7 billion, adjusted for non-cash items. Non-cash adjustments primarily related to gains recorded upon the Merger of $2.0 billion. Other non-cash adjustments included accretion on our debt discount and the non-cash portion of interest expense related to our debt of $2.1 million, stock-based compensation expense, including expense related to the acceleration of options upon the Merger, of $58.5 million, depreciation and amortization of $2.3 million, and non-cash lease expense of $1.9 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, primarily related to an increase in other non-current assets of $3.7 million due to prepayments and additional deposits we made to our CRO partners during the period. Additionally, the operating lease liability decreased by $1.4 million as a result of lease payments made throughout the period. These uses of cash were offset by increases in accrued expenses and other current liabilities of $35.9 million, an increase in accounts payable of $17.9 million, and a decrease in prepaid expenses of $3.0 million due to the timing of payments to our CRO and CDMO partners during the period, each of which excludes the liabilities related to INBRX-101 which were assumed by the Acquirer in the Merger.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $28,000 and&#160;$2.6 million during the years ended December 31, 2025 and December&#160;31, 2024, respectively, and was related to capital purchases of software, leasehold improvements, and laboratory and office equipment. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $101.4 million during the year ended December 31, 2025, which consisted primarily of net proceeds of $99.8 million from the 2025 Loan Agreement which we entered into in January 2025, in addition to $1.6 million from the proceeds from the exercise of stock options. Net cash provided by financing activities was $71.7 million during the year ended December&#160;31, 2024, which consisted of proceeds from the exercise of stock options.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_154"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles, or GAAP, which requires management to make estimates and assumptions </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">that affect the amounts reported. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management&#8217;s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from these estimates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 1 to our consolidated financial statements included elsewhere in this Annual Report, we believe that the following critical accounting policies and estimates have a higher degree of inherent uncertainty and require our most significant judgments: </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts for research and development activities, including with CDMOs for clinical supplies and manufacturing scale-up activities related to our therapeutic candidates and with CROs for our preclinical studies and clinical trials. The financial terms of these agreements vary and may result in payment flows that do not match the periods over which materials or services are provided, resulting in either an accrual or a prepaid expense.</span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These accruals of research and development expenses require us to estimate expenses incurred, including estimates of the time period over which services will be performed, completion of contract components, the enrollment of subjects, and the status of our clinical trials. Such estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. If the actual timing of the performance of services varies from our estimates, we adjust the accrual or prepaid expense accordingly. </span></div><div style="margin-bottom:9.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_157"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in 2012. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, presenting only two years of audited financial statements, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation, and an exemption from the requirements to obtain a non-binding advisory vote on executive compensation or golden parachute arrangements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an emerging growth company can take advantage of an extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Exchange Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will remain a smaller reporting company as long as either: (i) the market value of the shares of our common stock held by non-affiliates is less than $250.0 million as of the last business day of our most recently completed second fiscal quarter; or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">year and the market value of the shares of our common stock held by non-affiliates is less than $700.0 million as of the last business day of our most recently completed second fiscal quarter.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_160"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For information with respect to recently issued accounting standards and the impact of these standards, if any, on our consolidated financial statements, refer to Note 1 in our consolidated financial statements in Part II, Item 8 of this Annual Report. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_169"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:92.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_172">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-55">BDO USA, P.C.</ix:nonNumeric>; <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-56">San Diego, California</ix:nonNumeric>; PCAOB ID No. <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-57">243</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_172">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_175">Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_175">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_178">Consolidated Statements of Operations for the Years Ended December 31, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_178">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_181">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_181">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_184">Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_184">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_187">Notes to the Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8fac7241aa424916b2e0582fb85490ec_187">112</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx Biosciences, Inc. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">La Jolla, California</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Inhibrx Biosciences, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2025 and 2024, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, P.C.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;19, 2026</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_175"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx Biosciences, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data and par value)&#160;</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-58">124,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-59">152,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-61">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-62">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-63">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-65">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">8,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">7,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">132,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">160,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-70">3,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-71">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-72">5,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-73">7,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">6,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-76">146,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-77">180,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">5,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">9,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">25,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">33,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">40,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including final payment fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">100,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-90">138,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-91">47,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-92"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-93"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-95">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-97">15,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-99">no</ix:nonFraction></ix:nonFraction> shares outstanding as of December&#160;31, 2025 and December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-102"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-103">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-105">120,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-107">14,577,609</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-109">14,475,904</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-110">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-111">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-112">254,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-113">239,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-114">246,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-115">106,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">7,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">133,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">146,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-119">180,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_178"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx Biosciences, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">License fee revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-120">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-121">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-122">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-123">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">113,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">203,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">23,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">127,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-128">136,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-129">331,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">135,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">331,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to transaction with Acquirer</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-133">2,021,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-134">12,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-135">13,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:InterestIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-136">7,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:InterestIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-137">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-138">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-139">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">5,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">2,019,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-142">140,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-143">1,687,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-144">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-145">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">140,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">1,687,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-148">9.04</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-149">114.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-150">9.04</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-151">112.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-152">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-153">14,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-154">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-155">14,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_181"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.177%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.474%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock<br/>(Shares)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock (Amount)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-156">47,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-157">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">657,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">613,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">43,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">58,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">58,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-163">3,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-164">71,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-165">71,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of warrants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-166">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Former Parent&#8217;s common stock, stock options, and warrants by the Acquirer</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="inbx:StockholderEquitySpinoffTransactionDecreaseInCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-167">53,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="3" id="f-168">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="3" id="f-169">563,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="3" id="f-170">1,179,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="3" id="f-171">1,743,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in Distribution</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-172">14,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-173">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-174">16,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-175">16,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">1,687,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">1,687,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-178">14,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-179">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">239,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">106,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">133,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">11,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-184">11,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of warrants in connection with 2025 Loan Agreement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-185">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-186">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-187">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-188">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-189">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">140,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-191">140,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-192">14,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-193">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">254,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">246,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">7,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_184"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx Biosciences, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER&#160;31, &#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">140,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">1,687,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-199">2,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-200">2,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount and non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-201">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-202">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-203">11,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-204">58,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-205">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-206">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash gain on transaction with Acquirer</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet" format="ixt:num-dot-decimal" scale="3" id="f-208">1,998,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-209">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-210">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-211">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-212">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="f-213">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="f-214">566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="f-215">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="f-216">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-217">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-218">2,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-220">3,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-221">3,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-222">17,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-223">4,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-224">35,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-225">1,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-226">1,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-227">129,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-228">194,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-229">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-230">2,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-231">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-233">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-234">2,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-235">99,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="f-236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payment of third-party fees associated with debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:PaymentsOfDebtIssuanceCostsSecuredDebt" scale="3" id="f-237">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:PaymentsOfDebtIssuanceCostsSecuredDebt" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-239">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-240">71,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-241">101,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-242">71,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-243">28,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-244">125,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-245">152,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-246">277,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-247">124,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-248">152,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-249">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-250">11,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-251">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-252">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-254">6,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-255">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_187"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Inhibrx Biosciences, Inc. </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_190"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-257" continuedAt="f-257-1" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="f-257-1" continuedAt="f-257-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx Biosciences, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#8217;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-258" continuedAt="f-258-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-258-1">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-259" continuedAt="f-259-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-259-1">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.</ix:continuation> </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Distribution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, Inhibrx, Inc., or the Former Parent, announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. The Former Parent and the Company signed an Agreement and Plan of Merger, dated as of January 22, 2024, or the Merger Agreement, with Aventis Inc., a Pennsylvania corporation, or the Acquirer, and a wholly-owned subsidiary of Sanofi S.A., or Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation, or the Merger Sub, and a wholly-owned subsidiary of Acquirer, along with a Separation and Distribution Agreement, dated as of January 22, 2024, by and among the Former Parent, the Company and Acquirer. The Merger Agreement provided for the acquisition by Acquirer of the Former Parent, or the Merger, to be accomplished through the merger of Merger Sub with and into the Former Parent with the Former Parent continuing as the surviving entity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, the Former Parent completed a distribution to holders of its shares of common stock of <ix:nonFraction unitRef="number" contextRef="c-31" decimals="2" name="inbx:MergerExchangeRatioProRateBasisPercentage" scale="-2" id="f-260">92</ix:nonFraction>% of the issued and outstanding shares of common stock of the Company, or the Distribution. On May 30, 2024, the Former Parent completed the Merger, pursuant to which (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer, a wholly-owned subsidiary of Sanofi; and (ii) by way of a series of internal restructuring transactions, or the Separation, the Company acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105. Upon the closing of the Merger, the Company became a stand-alone, publicly traded company.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the foregoing transactions, each Former Parent stockholder received: (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" scale="0" id="f-261">30.00</ix:nonFraction> per share in cash, (ii) <ix:nonFraction unitRef="right" contextRef="c-32" decimals="INF" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" format="ixt-sec:numwordsen" id="f-262">one</ix:nonFraction> contingent value right per share, representing the right to receive a contingent payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" scale="0" id="f-263">5.00</ix:nonFraction> in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-2" continuedAt="f-257-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="INF" name="inbx:MergerExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="f-264">four</ix:nonFraction> shares of the Former Parent&#8217;s common stock held. The Acquirer retained an equity interest in the Company of <ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="inbx:MergerOwnershipPercentage" scale="-2" id="f-265">8</ix:nonFraction>% upon the Distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Acquirer paid transaction consideration of $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="f-266">1.9</ix:nonFraction> billion, including the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" scale="0" id="f-267">30.00</ix:nonFraction> per share consideration and the assumption of the Company&#8217;s third-party debt. See Note 3 for further discussion on the extinguishment of the Company&#8217;s Amended 2020 Loans with Oxford (as defined below). In addition, the Acquirer assumed all assets and liabilities under contracts primarily related to INBRX-101 upon close of the Merger. The Acquirer also reimbursed the Company or paid on behalf of the Company $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" scale="6" id="f-268">68.0</ix:nonFraction>&#160;million in transaction costs. The Acquirer may pay an additional $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-269">300.0</ix:nonFraction>&#160;million in consideration under the contingent value rights issued upon the achievement of a regulatory milestone.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the legal form of the spin-off, the Separation and Distribution is being treated as a reverse spin-off for financial accounting and reporting purposes in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 505-60,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spinoffs and Reverse Spinoffs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">because (i) a wholly-owned subsidiary of the Acquirer merged with and into the Former Parent immediately following the Distribution; (ii) no senior management of the Former Parent were retained by the Former Parent following the Distribution; and (iii) the size of the Company&#8217;s operations relative to the 101 Business. As a reverse spin-off, the Company considers Inhibrx as the accounting spinnor of the Former Parent, and the accounting successor to the Former Parent. Therefore, for periods prior to the spin-off, the Company&#8217;s financial statements are the historical financial statements of the Former Parent. For such periods, descriptions of historical business activities are presented as if the spin-off had already occurred, and the Former Parent&#8217;s activities related to such assets and liabilities had been performed by the Company. In addition, for all periods prior to the spin-off, all outstanding shares referenced in these financial statements are those shares outstanding of the Former Parent at each respective date, unless otherwise indicated as adjusted for the distribution ratio. Following the spin-off, all outstanding shares referenced are those of the Company, which, as discussed above, were issued on a four-to-one ratio of the Former Parent&#8217;s outstanding shares.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the sale of the 101 Business in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 205-20, Discontinued Operation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s, and determined that the Separation does not represent a strategic shift and thus does not qualify as a discontinued operation. The Company next evaluated the sale of the 101 Business in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that the 101 Business does not meet the definition of a business, given that substantially all of the fair value of the gross assets transferred is concentrated in one asset. The Company then evaluated the transaction under </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 845, Nonmonetary Transactions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which contains guidance on the accounting for the distribution of nonmonetary assets to stockholders of an entity in a spin-off. In accordance with this guidance, the disposal of the 101 Business has been accounted for as a dividend-in-kind, with a gain recognized for the difference between the fair value and carrying value of the disposed assets. </span></div><ix:nonNumeric contextRef="c-1" name="inbx:ScheduleOfMergerTransactionTableTextBlock" id="f-270" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain on the transaction of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-8" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" scale="9" id="f-271">2.0</ix:nonFraction> billion during the year ended December 31, 2024, which consisted of the following components (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration for common stock, warrants, and stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-272">1,727,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of Amended 2020 Loans assumed by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-273">211,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-274">14,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs paid by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-275">68,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total gain recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-276">2,021,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the Merger consideration payable to shareholders of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-8" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" scale="9" id="f-277">1.7</ix:nonFraction>&#160;billion was recorded, net of consideration allocated to the shares issued to Acquirer, through a reduction to retained earnings of $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-8" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="9" id="f-278">1.2</ix:nonFraction>&#160;billion, representing the amount of retained earnings available at the closing of the Merger, with the remaining amount of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="f-279">563.8</ix:nonFraction>&#160;million recorded through additional paid-in capital.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-3" continuedAt="f-257-4"><ix:nonNumeric contextRef="c-1" name="inbx:LiquidityPolicyTextBlock" id="f-280" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-281">246.2</ix:nonFraction> million and cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-282">124.2</ix:nonFraction> million. From its inception and through December&#160;31, 2025, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents, including proceeds from the March 2026 Amendment (see Footnote 11), will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. The Company expects to continue to incur net losses for the foreseeable future until, if ever, the Company has an approved product and can successfully commercialize it. Until such time the Company, if ever, can generate substantial product revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, the Company engages in discussions with potential acquirers regarding the disposition of one or more of its therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its intellectual property on less favorable terms than it would otherwise choose. These actions could materially impact its business, results of operations, financial condition, and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-283" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, and the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-4" continuedAt="f-257-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-284" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-285" continuedAt="f-285-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company&#8217;s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-285-1">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2025 and December&#160;31, 2024, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for credit losses was recorded.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-286" continuedAt="f-286-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company has never declared or paid any dividends on its common stock. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-286-1">Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-287" continuedAt="f-287-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and office equipment: <span style="-sec-ix-hidden:f-288">three</span> to <ix:nonNumeric contextRef="c-41" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-289">five years</ix:nonNumeric>; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture, fixtures and other: <ix:nonNumeric contextRef="c-42" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-290">five years</ix:nonNumeric>; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: <ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-291">three years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-287-1">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-292" continuedAt="f-292-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-292-1">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-293" continuedAt="f-293-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception based on the unique facts and circumstances present in the contract. The Company evaluates classification of leases as either operating or finance at commencement and, as necessary, at modification.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-5" continuedAt="f-257-6"><ix:continuation id="f-293-1" continuedAt="f-293-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At lease commencement for leases with terms greater than 12 months, the Company records a lease liability determined as the present value of future lease payments over the expected lease term. The Company calculates the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The Company also records an operating right-of-use asset based on the liability as adjusted for any lease incentives or prepaids. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably certain of exercise.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After lease commencement, assumptions made by the Company at the commencement date are re-evaluated upon the occurrence of certain events, including a lease modification. The Company evaluates any change to an existing lease to determine if it constitutes a separate contract or a single contract with the existing lease. For modifications treated as a single contract, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate as of the effective date of the modification, and recognizes the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding right-of-use asset under the lease modification guidance pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional right-of-use asset that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional right-of-use asset. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. </span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-293-2">The Company accounts for lease and non-lease components in its lease agreements as a single lease component in determining lease assets and liabilities. In addition, the Company does not recognize the right-of-use assets and liabilities for leases with lease terms of twelve months or less, instead recognizing lease payments as operating expenses on a straight-line basis over the lease term.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-294" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Poplar Therapeutics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a <ix:nonFraction unitRef="number" contextRef="c-44" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-295">10</ix:nonFraction>% equity interest as consideration in a series of agreements with Poplar Therapeutics, Inc, or Poplar Therapeutics, formerly Phylaxis Bioscience, LLC., which was later increased to <ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-296">15</ix:nonFraction>% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company&#8217;s proportionate share of the net income or loss of Poplar Therapeutics is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The investment had been reduced to <ix:nonFraction unitRef="usd" contextRef="c-46" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-297">zero</ix:nonFraction> prior to the beginning of 2021 as a result of the allocation of the Company&#8217;s share of prior losses of the investee. Following the Company&#8217;s increase in equity interest of <ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="inbx:EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" scale="-2" id="f-298">5</ix:nonFraction>% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company&#8217;s investment in Poplar Therapeutics as of December&#160;31, 2025 and December&#160;31, 2024 is <ix:nonFraction unitRef="usd" contextRef="c-48" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-299"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-300">zero</ix:nonFraction></ix:nonFraction>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-301" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments held during the periods presented consisted principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximated their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximated fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s warrants are equity-classified and carried at the instruments&#8217; fair value upon classification into equity.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-6" continuedAt="f-257-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-302" continuedAt="f-302-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-302-1">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-303" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-304">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-307">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-308">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-311">5,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-312">5,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-315">5,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-316">5,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-319">5,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term outstanding debt is not measured at fair value on a reoccurring basis. As of December&#160;31, 2025 and December&#160;31, 2024, the fair value of the Company&#8217;s long-term outstanding debt approximates fair value using Level 2 inputs. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-320" continuedAt="f-320-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><ix:continuation id="f-320-1" continuedAt="f-320-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 835-30, Imputation of Interest</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-320-2">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="inbx:WarrantsPolicyPolicyTextBlock" id="f-321" continuedAt="f-321-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments with Characteristics of Both Liabilities and Equity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 480-10, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-7" continuedAt="f-257-8"><ix:continuation id="f-321-1"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company&#8217;s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company&#8217;s outstanding warrants are classified as equity as of and for the years ended December&#160;31, 2025 and December&#160;31, 2024.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-322" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company&#8217;s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-323" continuedAt="f-323-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-8" continuedAt="f-257-9"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-323-1">marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-324" continuedAt="f-324-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-324-1">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change occurs, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-325" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the same period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive common shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net earnings (loss) per share when the effect is anti-dilutive.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of shares of common stock used in the basic and diluted net income (loss) per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.</span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, outstanding shares during the period consist both of shares of the Former Parent and of the Company. For purposes of computing earnings (loss) per share only, for all periods presented in its consolidated statements of operations, the Company adjusted all outstanding shares of the Former Parent, including potentially dilutive securities, by the <ix:nonFraction unitRef="distribution" contextRef="c-14" decimals="INF" name="inbx:EarningsDistributionRatio" format="ixt-sec:numwordsen" scale="0" id="f-326">four</ix:nonFraction>-to-one distribution ratio used in the Distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company has a net loss, basic loss per share and diluted loss per share are identical since the effect of potentially dilutive common shares is anti-dilutive and therefore excluded. Accordingly, for the year ended December 31, 2025, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-327" continuedAt="f-327-1" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-9" continuedAt="f-257-10"><ix:continuation id="f-327-1"><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.458%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-328">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-329">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-330">3,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.342%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.458%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-331">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-332">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-333" continuedAt="f-333-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company&#8217;s market-traded shares best represents its expected volatility. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><ix:continuation id="f-333-1" continuedAt="f-333-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-333-2">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-334" continuedAt="f-334-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-334-1">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-335" continuedAt="f-335-1" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM, in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM has been identified as the Chief </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-257-10" continuedAt="f-257-11"><ix:continuation id="f-335-1" continuedAt="f-335-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer, who reviews financial results at a consolidated level only. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="f-336"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-337">one</ix:nonFraction></ix:nonFraction> operating and reportable segment as the Company has devoted substantially all of its resources to drug discovery and development activities through conducting preclinical studies and clinical trials associated with its programs, all of which aim to discover and develop biologic therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM assesses performance for the biologic therapeutic segment and decides how to allocate resources based on the consolidated net income (loss) as reported on its consolidated income statement. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The segment depreciation expense, interest expense, interest income, and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. </span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-335-2">The Company&#8217;s revenues to date under this segment have been derived from licenses with collaboration partners and grant awards, and the Company has not generated any revenue from the commercial sale of approved therapeutic products (see Note 6). As a result, the Company has incurred operating losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its therapeutic candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval. The CODM evaluates the Company's operating results and allocates resources using net income (loss) and the components of operating expense, together with information on the progression and results of clinical trial activities, to advance the Company's therapeutic pipeline and to best support the long-term growth of the Company&#8217;s overall business.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-338" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-339">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-340">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:ResearchAndDevelopmentExpensePersonnel" format="ixt:num-dot-decimal" scale="3" id="f-341">35,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:ResearchAndDevelopmentExpensePersonnel" format="ixt:num-dot-decimal" scale="3" id="f-342">72,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseClinicalTrials" format="ixt:num-dot-decimal" scale="3" id="f-343">35,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseClinicalTrials" format="ixt:num-dot-decimal" scale="3" id="f-344">47,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseContractManufacturing" format="ixt:num-dot-decimal" scale="3" id="f-345">19,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseContractManufacturing" format="ixt:num-dot-decimal" scale="3" id="f-346">55,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" format="ixt:num-dot-decimal" scale="3" id="f-347">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" format="ixt:num-dot-decimal" scale="3" id="f-348">9,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-349">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-350">17,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:GeneralAndAdministrativeExpenseMergerRelated" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:GeneralAndAdministrativeExpenseMergerRelated" format="ixt:num-dot-decimal" scale="3" id="f-352">68,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="inbx:GeneralAndAdministrativeExpensePersonnel" format="ixt:num-dot-decimal" scale="3" id="f-353">14,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="inbx:GeneralAndAdministrativeExpensePersonnel" format="ixt:num-dot-decimal" scale="3" id="f-354">37,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-355">8,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-356">22,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-357">5,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-358">2,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer" format="ixt:num-dot-decimal" scale="3" id="f-360">2,021,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-361">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="f-362">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-363">140,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-364">1,687,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Other segment items consist of the gain on transaction from the Merger, discussed above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other segment expenses include provision for income taxes.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-365" escape="true"><ix:continuation id="f-257-11"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvement to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to enhance the transparency and decision usefulness of income tax disclosures. Two primary enhancements related to this ASU include disaggregating existing income tax disclosures relating to the effective tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025 and applied it prospectively, as disclosed in Note 8, Income Taxes. The adoption did not have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued but Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires additional disclosure about specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this accounting standard update on the Company&#8217;s consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:nonNumeric><div id="i8fac7241aa424916b2e0582fb85490ec_193"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-366" continuedAt="f-366-1" escape="true">OTHER FINANCIAL INFORMATION </ix:nonNumeric></span></div><ix:continuation id="f-366-1" continuedAt="f-366-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-367" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:ClinicalTrailsPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-368">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:ClinicalTrailsPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-369">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-370">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-371">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:PrepaidLicenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-372">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:PrepaidLicenseCurrent" scale="3" id="f-373">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" scale="3" id="f-374">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" scale="3" id="f-375">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-376">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-377">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-378">8,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-379">7,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company&#8217;s therapeutics. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-366-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-380" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-381">9,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-382">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-383">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-384">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-385">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-386">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-387">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-388">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-389">14,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-390">15,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-391">11,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-392">8,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-393">3,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-394">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for each of the years ended December 31, 2025 and December&#160;31, 2024, and consisted of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-395">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-396">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-397">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-398">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-399">2,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-400">2,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-401" escape="true"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:AccruedClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-402">10,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:AccruedClinicalTrialsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-403">14,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-404">7,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-405">7,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="f-406">5,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="f-407">5,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent" scale="3" id="f-408">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent" scale="3" id="f-409">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-410">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-411">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:AccruedInterestExpenseCurrent" scale="3" id="f-412">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:AccruedInterestExpenseCurrent" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-414">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-415">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-416">25,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-417">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s usage of third-party CROs for management of clinical trials. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i8fac7241aa424916b2e0582fb85490ec_196"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-418" continuedAt="f-418-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC and other lenders, or collectively, Oxford. Under the original 2020 Loan Agreement and subsequent amendments between November 2020 and October 2022, or collectively, the Amended 2020 Loan Agreement, the Company received an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="f-419">200.0</ix:nonFraction> million over <ix:nonFraction unitRef="tranche" contextRef="c-81" decimals="INF" name="inbx:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-420">seven</ix:nonFraction> tranches, or Terms A-G.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-418-2" continuedAt="f-418-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Separation, the outstanding term loans were to mature on January&#160;1, 2027, or the Amended Maturity Date. Under the Amended 2020 Loan Agreement, and through the Separation, the repayment schedule provided for interest-only payments through February 1, 2025, followed by <ix:nonNumeric contextRef="c-82" name="inbx:DebtInstrumentPrincipalAndInterestTerm" format="ixt-sec:durmonth" id="f-421">23</ix:nonNumeric> months of principal and interest payments. Upon the Amended Maturity Date, a final payment of <ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" scale="-2" id="f-422">9.0</ix:nonFraction>% of the original principal amount would be due to Oxford. This final payment of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="f-423">18.0</ix:nonFraction> million was being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="c-84" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="f-424">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-85" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="f-425">3.0</ix:nonFraction>%, depending upon the timing of the prepayment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company&#8217;s outstanding debt was assumed by the Acquirer. Prior to the close of the Merger, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="f-426">200.0</ix:nonFraction> million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The Acquirer assumed the outstanding debt balance in full, consisting of the $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="f-427">200.0</ix:nonFraction> million in gross principal, the $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="inbx:DebtInstrumentBalloonPaymentWriteOff" scale="6" id="f-428">18.0</ix:nonFraction> million final payment fee, and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="6" id="f-429">2.3</ix:nonFraction>&#160;million, net of debt discounts of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" scale="6" id="f-430">9.0</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the Acquirer&#8217;s assumption and subsequent repayment of the outstanding debt constitutes an extinguishment of the debt as the Company has been legally released from being the primary obligor under the liability. The Company did not make any payment upon the extinguishment of the debt and did not incur any prepayment penalties. Upon the Acquirer&#8217;s assumption of the outstanding debt, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-431">211.3</ix:nonFraction>&#160;million, the net carrying amount of the Amended 2020 Loans upon extinguishment, within the gain related to transaction with Acquirer in its consolidated statements of operations during the year ended December 31, 2024. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Separation, interest expense was calculated using the effective interest method and was inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2024, interest expense was $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-432">13.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="inbx:AmortizationOfDebtDiscountPremiumAndAccretion" scale="6" id="f-433">2.1</ix:nonFraction> million of which related to non-cash amortization of the debt discount and accretion of the final payment. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2025 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, the Company entered into a Loan and Security Agreement, or the 2025 Loan Agreement, with Oxford, pursuant to which it received $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-434">100.0</ix:nonFraction> million in gross proceeds. The 2025 Loan Agreement provides for an additional tranche of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="inbx:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" scale="6" id="f-435">50.0</ix:nonFraction> million to be funded upon the Company's request and at Oxford&#8217;s sole discretion. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding term loan will mature on January 1, 2030, or the Maturity Date, and bears interest at (1) <ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-436">5.61</ix:nonFraction>% plus (2) the greater of (i) the 1-Month Term Secured Overnight Financing Right as published by the CME Group or (ii) <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-437">4.34</ix:nonFraction>%. The repayment schedule provides for interest-only payments through February 1, 2028, with principal payments beginning on March 1, 2028. The interest-only period is followed by <ix:nonNumeric contextRef="c-87" name="inbx:DebtInstrumentPrincipalAndInterestTerm" format="ixt-sec:durmonth" id="f-438">23</ix:nonNumeric> months of equal payments of principal plus interest. Upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of any term loan under the Term Loan Facility, or (iii) prepayment of any term loan under the Term Loan Facility, the Company will be required to make a final payment of <ix:nonFraction unitRef="number" contextRef="c-88" decimals="INF" name="inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" scale="-2" id="f-439">9.0</ix:nonFraction>% of the total principal amount. This final payment of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="f-440">9.0</ix:nonFraction> million will be accreted over the life of the 2025 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Maturity Date, subject to a prepayment fee ranging from <ix:nonFraction unitRef="number" contextRef="c-90" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="f-441">2.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-91" decimals="INF" name="inbx:DebtInstrumentPrepaymentFee" scale="-2" id="f-442">5.0</ix:nonFraction>%, depending on the timing of the prepayment. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-443" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company&#8217;s outstanding debt balance under the 2025 Loan Agreement consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-444">109,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-445">8,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount and final payment fee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-446">100,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-418-3" continuedAt="f-418-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-447" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest-only period will continue through February 2028, with principal payments beginning in March 2028. Future principal payments and final fee payments will be made as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-448">43,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-449">52,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="inbx:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-450">13,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-451">109,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-452">8,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-453">100,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the 2025 Loan Agreement are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. The 2025 Loan Agreement also requires the Company to maintain a minimum liquidity threshold in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="inbx:LongTermDebtLiquidityThreshold" scale="6" id="f-454">20.0</ix:nonFraction>&#160;million, tested at all times, with such liquidity threshold subject to increase to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="inbx:LongTermDebtLiquidityThreshold" scale="6" id="f-455">50.0</ix:nonFraction>&#160;million or $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="inbx:LongTermDebtLiquidityThreshold" scale="6" id="f-456">75.0</ix:nonFraction>&#160;million based on certain pipeline development changes. As of December&#160;31, 2025, the Company is in compliance with all covenants under the 2025 Loan Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance in January 2025, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s common stock equal to <ix:nonFraction unitRef="number" contextRef="c-96" decimals="INF" name="inbx:ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" scale="-2" id="f-457">2.0</ix:nonFraction>% of the funded amount, or $<ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="6" id="f-458">2.0</ix:nonFraction>&#160;million, or the 2025 Oxford Warrants. Upon issuance, the warrants were exercisable for <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-459">140,741</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-460">14.21</ix:nonFraction> per share. The 2025 Oxford Warrants are immediately exercisable, and the exercise period will expire <ix:nonNumeric contextRef="c-97" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-461">10</ix:nonNumeric> years from the date of issuance. Upon issuance, the warrants were classified as equity and recorded at their fair value of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="f-462">1.7</ix:nonFraction> million as additional paid-in-capital and as a debt discount which will be accreted over the life of the 2025 Loan Agreement using the effective interest method. See Note 4 for further discussion of these warrants.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-418-4">Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-463">12.9</ix:nonFraction>%. During the year ended December 31, 2025, interest expense was $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-464">12.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="f-465">2.4</ix:nonFraction> million of which related to non-cash amortization of the debt discount and accretion of the final payment.</ix:continuation> </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_199"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-466" continuedAt="f-466-1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="f-466-1" continuedAt="f-466-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, upon effecting the Separation, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-467">120,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-468">15,000,000</ix:nonFraction> shares of preferred stock, each with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-469"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-470">0.0001</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Distribution and as of May 29, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-471">14,475,904</ix:nonFraction> shares of common stock outstanding. The Company issued one SEC-registered, publicly listed, share of Inhibrx for every <ix:nonFraction unitRef="number" contextRef="c-31" decimals="INF" name="inbx:MergerExchangeRatio" format="ixt-sec:numwordsen" scale="0" id="f-472">four</ix:nonFraction> shares of the Former Parent&#8217;s common stock held, resulting in <ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-473">13,316,140</ix:nonFraction> shares of common stock issued to common stockholders of the Former Parent. Upon the Distribution, the Former Parent retained an equity interest in the Company of <ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="inbx:MergerOwnershipPercentage" scale="-2" id="f-474">8</ix:nonFraction>%, or <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="0" name="us-gaap:StockOrUnitsAvailableForDistributions" format="ixt:num-dot-decimal" scale="0" id="f-475">1,157,926</ix:nonFraction> shares. The Company issued <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-476">1,838</ix:nonFraction> shares of common stock to Oxford in connection with the Oxford Warrants (as defined below) in the Distribution.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-466-2" continuedAt="f-466-3"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with certain institutional and other accredited investors, or Purchasers, pursuant to which the Company sold and issued <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-477">3,621,314</ix:nonFraction> shares of the Company&#8217;s common stock for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-478">19.35</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-479">6,714,636</ix:nonFraction> shares of the Company&#8217;s common stock in a private placement transaction, or the Private Placement. The purchase price of the pre-funded warrants was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="INF" name="inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="f-480">19.3499</ix:nonFraction> per pre-funded warrant, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-481">0.0001</ix:nonFraction> per share. The pre-funded warrants were equity-classified and carried at the instruments&#8217; fair value upon issuance. During the second quarter of 2024, certain Purchasers exercised <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="inbx:ClassOfWarrantsOrRightsWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-482">2,747,245</ix:nonFraction> pre-funded warrants on a cashless basis for a net of <ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-483">2,746,454</ix:nonFraction> shares of the Former Parent&#8217;s common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Merger Agreement, the Former Parent entered into an Agreement Relating to the Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated as of January 22, 2024, by and between the Former Parent and each holder of the pre-funded warrants purchased in the Private Placement so that on the date of the Distribution, any remaining pre-funded warrants of the Former Parent not already exercised to purchase the Former Parent&#8217;s common stock became exercisable for an equivalent number of shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-484">0.0001</ix:nonFraction> per share, pursuant to certain beneficial ownership limitations. The Company has evaluated the amendment and accounted for this as a modification to the original Purchase Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Separation and Distribution, each holder of outstanding pre-funded warrants received (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-485">30.00</ix:nonFraction> per pre-funded warrant in cash, less the applicable exercise price per share, (ii) <ix:nonFraction unitRef="right" contextRef="c-32" decimals="INF" name="inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant" format="ixt-sec:numwordsen" id="f-486">one</ix:nonFraction> contingent value right per share, representing the right to receive a contingent payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue" scale="0" id="f-487">5.00</ix:nonFraction> in cash upon the achievement of a regulatory milestone, and (iii) one pre-funded warrant of Inhibrx for every <ix:nonFraction unitRef="number" contextRef="c-33" decimals="INF" name="inbx:MergerExchangeRatio" format="ixt-sec:numwordsen" id="f-488">four</ix:nonFraction> of the Former Parent&#8217;s pre-funded warrants held. Following the Separation and Distribution, pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-489">991,849</ix:nonFraction> shares of the Company&#8217;s common stock are outstanding at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-490">0.0001</ix:nonFraction> per share. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement, as amended, and will remain outstanding until exercised in full.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oxford Warrants</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended 2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Amended 2020 Loan Agreement, the Company issued equity-classified warrants to Oxford, or the 2020 Oxford Warrants, in <ix:nonFraction unitRef="tranche" contextRef="c-108" decimals="INF" name="inbx:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-491">two</ix:nonFraction> tranches: (i) <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-492">7,354</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-493">17.00</ix:nonFraction> and (ii) <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-494">40,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-495">45.00</ix:nonFraction>. As part of the Separation and Distribution, each holder of eligible outstanding warrants received (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-496">30.00</ix:nonFraction> per warrant in cash, less the applicable exercise price per share (ii) <ix:nonFraction unitRef="right" contextRef="c-6" decimals="INF" name="inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant" format="ixt-sec:numwordsen" id="f-497">one</ix:nonFraction> contingent value right per share, representing the right to receive a contingent payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue" scale="0" id="f-498">5.00</ix:nonFraction> in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="inbx:MergerExchangeRatio" format="ixt-sec:numwordsen" id="f-499">four</ix:nonFraction> of the Former Parent&#8217;s warrants held. All outstanding warrants with an exercise price which exceeded the total consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice" scale="0" id="f-500">35.00</ix:nonFraction> were canceled upon the Merger for no consideration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Separation, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt-sec:numwordsen" id="f-501">no</ix:nonFraction> Oxford Warrants were outstanding.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2025 Loan Agreement, the Company issued warrants to Oxford, or the 2025 Oxford Warrants. The Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-502">140,741</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-503">14.21</ix:nonFraction> per share. The 2025 Oxford Warrants are exercisable upon issuance and will expire on January&#160;13, 2035. The 2025 Oxford Warrants are equity-classified and carried at the instruments&#8217; fair value upon classification into equity, with no subsequent remeasurements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-466-3"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="c-1" name="inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="f-504" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance as of December&#160;31, 2025 and December&#160;31, 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-505">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-506">3,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-507">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-508">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future equity grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-509">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-510">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="f-511">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-513">5,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-514">4,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8fac7241aa424916b2e0582fb85490ec_202"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-515" continuedAt="f-515-1" escape="true">EQUITY COMPENSATION PLAN </ix:nonNumeric></span></div><ix:continuation id="f-515-1" continuedAt="f-515-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company&#8217;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provided for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. The 2017 Plan was terminated in connection with the Merger. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, the Company granted options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options were subject to <ix:nonNumeric contextRef="c-119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-516">four-year</ix:nonNumeric> vesting with a <ix:nonNumeric contextRef="c-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-517">one-year</ix:nonNumeric> cliff and had a contractual term of <ix:nonNumeric contextRef="c-119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-518">10</ix:nonNumeric> years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-519">65.3</ix:nonFraction>&#160;million. Aggregate intrinsic value of stock options exercised is calculated using the fair value of common stock on the date of exercise. The total fair value of stock options vested during the year ended December 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-520">42.5</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Merger, there was no activity under the 2017 Plan and no stock options remained outstanding under the 2017 Plan.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Settlement of Stock Options Upon Merger</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding options with an exercise price less than or equal to the total consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" scale="0" id="f-521">35.00</ix:nonFraction> vested immediately upon the Merger and were settled for the consideration of: (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" scale="0" id="f-522">30.00</ix:nonFraction> per share in cash, less the applicable exercise price of their stock option and (ii) <ix:nonFraction unitRef="right" contextRef="c-32" decimals="INF" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" format="ixt-sec:numwordsen" id="f-523">one</ix:nonFraction> contingent value right per share, representing the right to receive a contingent payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" scale="0" id="f-524">5.00</ix:nonFraction> in cash upon the achievement of a regulatory milestone. In connection with the acceleration of the eligible stock options, affecting 160 grantees, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-525">39.3</ix:nonFraction>&#160;million in stock compensation expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding options with an exercise price which exceeded the total consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" scale="0" id="f-526">35.00</ix:nonFraction> were canceled upon the Merger for no consideration. In connection with the cancellation of all unvested options with an exercise price above $<ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice" scale="0" id="f-527">35.00</ix:nonFraction>, affecting 7 grantees, the Company recognized all remaining stock compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-528">1.8</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company adopted the 2024 Omnibus Incentive Plan, or the 2024 Plan, which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2025, an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-529">4.0</ix:nonFraction> million shares of common stock were authorized for issuance under the 2024 Plan, of which <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-530">0.4</ix:nonFraction> million remained available for issuance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-515-2" continuedAt="f-515-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. All options granted to employees are subject to <ix:nonNumeric contextRef="c-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-531">four-year</ix:nonNumeric> vesting with a <ix:nonNumeric contextRef="c-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-532">one-year</ix:nonNumeric> cliff. All options granted to non-employee directors are subject to a <ix:nonNumeric contextRef="c-125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-533">one-year</ix:nonNumeric> vesting term. All options have a contractual term of <ix:nonNumeric contextRef="c-123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-534">10</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="f-535" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2024 Plan for the year ended December 31, 2025 is as follows (in thousands, except for per share data and years):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term <br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-536">3,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-537">15.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-538">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-539">17.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-540">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-541">15.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-542">435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-543">15.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-544">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-545">16.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-546">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-547">220,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-548">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-549">15.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-550">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-551">81,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-552">4.7</ix:nonFraction> million. The total fair value of stock options vested during the year ended December 31, 2025 was $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="f-553">17.4</ix:nonFraction> million. <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt-sec:numwordsen" id="f-554">No</ix:nonFraction> stock options were exercised or vested during the year ended December 31, 2024. The Company expects all outstanding stock options to vest. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-555" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock options granted under the 2024 Plan using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the years ended December 31, 2025 and December&#160;31, 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-556">3.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-557">4.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-558">86.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-559">86.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-562">5.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-563">6.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-564">13.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-565">11.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-566"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-567">no</ix:nonFraction></ix:nonFraction>t grant any stock options under the 2017 Plan during the years ended December 31, 2025 and December&#160;31, 2024. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 for further discussion in how the Company determines the assumptions used in the option pricing model.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-515-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-568" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options under the 2024 Plan and 2017 Plan consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-569">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-570">36,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-571">4,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-572">21,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-573">11,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-574">58,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-575">25.9</ix:nonFraction> million of total unrecognized stock-based compensation expense related to its stock options under the 2024 Plan, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-125" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-576">2.56</ix:nonNumeric> years. As of December&#160;31, 2025, the Company had <ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt-sec:numwordsen" id="f-577">no</ix:nonFraction> remaining unrecognized stock-based compensation expense related to its stock options under the 2017 Plan following the termination of the plan subsequent to the Merger.</span></div></ix:continuation><div id="i8fac7241aa424916b2e0582fb85490ec_205"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="inbx:LicenseAndGrantRevenueTextBlock" id="f-578" continuedAt="f-578-1" escape="true">LICENSE REVENUE</ix:nonNumeric></span></div><ix:continuation id="f-578-1" continuedAt="f-578-2"><ix:nonNumeric contextRef="c-1" name="inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock" id="f-579" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Scithera, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-580">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-583">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-584">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-585">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scithera License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2025, the Company entered into a License and Assignment Agreement, or the Scithera License Agreement, with Scithera, Inc., or Scithera, a newly formed biotechnology company that focuses on antibody-based molecules.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Scithera License Agreement, the Company licensed to Scithera the right to use certain assets in the Company&#8217;s antibody library to research, develop, and commercialize antibody-based molecules to certain targets. Additionally, the Company assigned to Scithera its agreement with NorthStar Medical Technologies, LLC for the development of radiopharmaceuticals for the treatment of cancer. The Company also agreed to make available to Scithera certain research materials useful for identifying, generating, and developing antibodies from antibody libraries to enable Scithera&#8217;s use of the assets licensed under the Scithera License Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contingent upon Scithera&#8217;s achievement of specified funding events, Scithera was required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="inbx:CollaborativeArrangementNonrefundablePayment" scale="6" id="f-586">1.3</ix:nonFraction> million as a non-refundable payment. In addition, Scithera may make additional future milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-4" name="inbx:MaximumPotentialMilestonePayments" scale="6" id="f-587">41.25</ix:nonFraction> million per target upon the achievement of certain milestone events, and potential royalty payments on net sales in the low- to mid-single digits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-1" decimals="INF" name="inbx:RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" format="ixt-sec:numwordsen" id="f-588">one</ix:nonFraction> performance obligation, which was the transfer of licenses to Scithera for the specified assets and all related materials and know-how. During the second quarter of 2025, Scithera achieved the specified funding event and made a non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="inbx:CollaborativeArrangementNonrefundablePayment" scale="6" id="f-589">1.3</ix:nonFraction> million to the Company. Upon notice of the achievement of such funding event, the Company re-assessed the transaction price to be $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="inbx:CollaborativeArrangementNonrefundablePayment" scale="6" id="f-590">1.3</ix:nonFraction> million, which was allocated to the single performance obligation. All remaining consideration under the agreement is variable consideration associated with the achievement of specified development milestones, and as a result, has been fully constrained (excluded) from the transaction price until such time that the Company </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-578-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company completed its single performance obligation and recognized $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" scale="6" id="f-591">1.3</ix:nonFraction>&#160;million at the point in time upon the completion of the transfer of all licensed materials and know-how. During the year ended December 31, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="f-592">1.3</ix:nonFraction> million of revenue and received a payment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="inbx:CollaborativeArrangementNonrefundablePayment" scale="6" id="f-593">1.3</ix:nonFraction>&#160;million under the Scithera License Agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Option and License Agreement with bluebird bio, Inc., or bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of <ix:nonFraction unitRef="program" contextRef="c-145" decimals="INF" name="inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement" format="ixt-sec:numwordsen" id="f-594">two</ix:nonFraction> initial programs and up to an additional 8 programs. The Company retained all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy, and subsequently in April 2024, this agreement, or the 2020 Regeneron Agreement, was assigned to Regeneron Pharmaceuticals, Inc., or Regeneron, in connection with the divestiture of 2seventy&#8217;s oncology and autoimmune pipeline to Regeneron.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee in exchange for a development license and an option in which Regeneron may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which Regeneron exercises its option, Regeneron will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="inbx:CollaborativeArrangementDevelopmentMilestoneReceivable" scale="6" id="f-595">51.5</ix:nonFraction>&#160;million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, pursuant to the option extension terms in the 2020 Regeneron Agreement, Regeneron requested to extend the option term for its third program by an additional six months in exchange for an option extension fee of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="f-596">0.1</ix:nonFraction>&#160;million. The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="f-597">0.1</ix:nonFraction>&#160;million of revenue related to this extension at the point in time in which the extension was granted. In November 2024, Regeneron requested a second extension of the option term for an additional six months in exchange for an option extension fee of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="f-598">0.1</ix:nonFraction>&#160;million. The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="inbx:CollaborativeArrangementNonrefundableUpfrontPayment" scale="6" id="f-599">0.1</ix:nonFraction>&#160;million of revenue related to this extension at the point in time in which the extension was granted. The $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-600">0.2</ix:nonFraction>&#160;million related to the option extensions is recorded as accounts receivable in the Company&#8217;s consolidated balance sheet as of December&#160;31, 2024 and was collected in full during the first quarter of the year ended December 31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-601">0.2</ix:nonFraction>&#160;million of revenue related to this agreement. The Company did <ix:nonFraction unitRef="usd" contextRef="c-139" decimals="0" name="us-gaap:Revenues" format="ixt-sec:numwordsen" id="f-602">no</ix:nonFraction>t recognize any revenue under this agreement during the year ended December 31, 2025.</span></div></ix:continuation><div id="i8fac7241aa424916b2e0582fb85490ec_208"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-603" continuedAt="f-603-1" escape="true">RELATED PARTY TRANSACTIONS </ix:nonNumeric></span></div><ix:continuation id="f-603-1" continuedAt="f-603-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Distribution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, as discussed in Note 1, the Former Parent completed a distribution to holders of its shares of common stock of <ix:nonFraction unitRef="number" contextRef="c-33" decimals="2" name="inbx:MergerExchangeRatioProRateBasisPercentage" scale="-2" id="f-604">92</ix:nonFraction>% of the issued and outstanding shares of common stock of the Company, or the Distribution. The Former Parent retained an equity interest in the Company of <ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="inbx:MergerOwnershipPercentage" scale="-2" id="f-605">8</ix:nonFraction>%, or <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="us-gaap:StockOrUnitsAvailableForDistributions" format="ixt:num-dot-decimal" scale="0" id="f-606">1,157,926</ix:nonFraction> shares upon the Distribution. Accordingly, the Company identified the Acquirer as a related party following the Merger with the Former Parent.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-603-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Services Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company also entered into the Transition Services Agreement with the Former Parent under which the Company or one of its affiliates provide the Former Parent or other Sanofi entities with certain transition services for a limited time to ensure an orderly transition following the Separation. The services that the Company agreed to provide to the Former Parent or other Sanofi entities under the Transition Services Agreement include certain finance and accounting, including payroll, tax, and procurement, information technology, legal and intellectual property, clinical study support, technical operations, regulatory, quality assurance, commercial and medical affairs, and other services. The Former Parent pays the Company for any such services received by the Former Parent or other Sanofi entities, as applicable, at agreed amounts as set forth in the Transition Services Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company substantially completed all obligations under the Transition Services Agreement. The Company has not billed the Former Parent for any services under the Transition Services during the year ended December 31, 2025 and does not expect any future billings. During the year ended December 31, 2024, the Company billed the Former Parent for $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-607">0.3</ix:nonFraction> million for services performed under the Transition Services Agreement, which was recognized as other income. The Company received approximately $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-608">0.2</ix:nonFraction> million in cash during the year ended December 31, 2024, with the remaining balance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-609">23,000</ix:nonFraction> received during the year ended December 31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Transition Services Agreement required the Former Parent to reimburse the Company for certain severance payments made by the Company to certain Company employees whose employment was terminated as a result of the Merger. During the year ended December 31, 2024, the Company billed the Former Parent for $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-610">1.0</ix:nonFraction> million of severance payments to former employees, all of which was received as of December&#160;31, 2024. No further activity occurred during the year ended December 31, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacovigilance Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company entered into a Pharmacovigilance Agreement with the Former Parent, pursuant to which the parties agreed to implement processes and procedures for sharing information as required for each party&#8217;s compliance with its regulatory and pharmacovigilance responsibilities.</span></div></ix:continuation><div id="i8fac7241aa424916b2e0582fb85490ec_211"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-611" continuedAt="f-611-1" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="f-611-1" continuedAt="f-611-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-612" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income (loss) before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-613">140,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-614">1,687,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss provision for before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-617">140,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-618">1,687,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-619" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense were as follows for the years ended December 31, 2025 and December&#160;31, 2024, respectively (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-620">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-621">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-622">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-623">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision for the years ended December 31, 2025 and December&#160;31, 2024 was related to state income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company made no material income tax payments during 2025 for Federal, state, and foreign jurisdictions.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-611-2" continuedAt="f-611-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on January 1, 2025 on a prospective basis. As a result, the Company's rate reconciliation for 2025 is presented in accordance with the new disclosure requirements, while the reconciliation for 2024 continues to be presented under disclosure requirements in effect for that period.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-624" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-625">29,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-626">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-627">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-629">29,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-630">21.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-631">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-632">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-633">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) 50% or more of our state tax provision relates to the California state jurisdiction.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:31.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense at federal statutory rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-635">354,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense, net of federal benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-636">10,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationPermanentItems" format="ixt:num-dot-decimal" scale="3" id="f-637">6,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-638">28,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-639">4,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of deferred tax assets and liabilities upon Transaction with Acquirer </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" format="ixt:num-dot-decimal" scale="3" id="f-640">195,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable gain related to Transaction with Acquirer</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" format="ixt:num-dot-decimal" scale="3" id="f-641">410,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">336(e) election</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="inbx:EffectiveIncomeTaxRateReconciliation336eElectionAmount" scale="3" id="f-642">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-643">124,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-644">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-611-3" continuedAt="f-611-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-645" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-646">40,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-647">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 research and development capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-648">8,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-649">15,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-650">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="f-651">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-652">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" id="f-653">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="inbx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-654">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="inbx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-655">1,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-656">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-657">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="f-658">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-660">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-661">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-662">53,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-663">23,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-664">52,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-665">21,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets after valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-666">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-667">2,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-669">575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-670">1,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-671">1,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-672">1,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-673">2,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-674"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-676"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Former Parent retained all rights associated with the unused federal and state NOLs and research tax credit carryforwards as of the date of the transaction to offset its future taxable income. As of December&#160;31, 2025, the Company had unused federal and state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-678">183.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-679">32.8</ix:nonFraction> million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2034 if not utilized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. Following the Separation, the Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company may incur ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2025. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2025, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-680">52.5</ix:nonFraction> million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-611-4"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-681" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-683">4,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-685">4,651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company did not have any gross unrecognized tax benefits. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-688"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-689">no</ix:nonFraction></ix:nonFraction> accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2025 or December&#160;31, 2024, and has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-690"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-691">no</ix:nonFraction></ix:nonFraction>t recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2025 and December&#160;31, 2024 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in the United States and various state jurisdictions. Following the Separation, the Company&#8217;s tax years from 2024 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law. The OBBBA includes significant changes to U.S. tax and related laws. Some of the provisions of the OBBBA affecting corporations include the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, or TCJA, modifications to the Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income international tax provisions, an increase in the limit of the deduction of interest expense to 30% of earnings before interest, taxes, depreciation, and amortization, and reinstatement of 100% bonus depreciation deduction from the TCJA for eligible property acquired after January 19, 2025. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA&#8217;s financial reporting implications have been recognized in our income tax provision for 2025. The incorporation of these effects resulted in no material impact on the Company&#8217;s effective tax rate.</span></div></ix:continuation><div id="i8fac7241aa424916b2e0582fb85490ec_214"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-692" continuedAt="f-692-1" escape="true">LEASES </ix:nonNumeric></span></div><ix:continuation id="f-692-1" continuedAt="f-692-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a <ix:nonNumeric contextRef="c-155" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-693">seven-year</ix:nonNumeric> lease agreement as its sole location in La Jolla, California, which contains an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" scale="6" id="f-694">0.1</ix:nonFraction> million per month with <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="inbx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="f-695">2</ix:nonFraction>% annual escalations. In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020, which contained an initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth" format="ixt:num-dot-decimal" scale="0" id="f-696">30,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="inbx:LesseeOperatingLeaseAnnualEscalations" scale="-2" id="f-697">2</ix:nonFraction>% annual escalations. Each of these leases expired in June 2025 with an option to extend the lease an additional <ix:nonNumeric contextRef="c-155" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-698">five years</ix:nonNumeric>, which was not included in the right-of-use asset and lease liabilities. Payments under each of the lease agreements included base rent plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-692-2" continuedAt="f-692-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company entered into a new lease agreement for its existing facilities, or the 2024 Lease Agreement, for the period following the expiration of its <ix:nonFraction unitRef="contract" contextRef="c-157" decimals="INF" name="inbx:LesseeOperatingLeaseNumberOfContracts" format="ixt-sec:numwordsen" id="f-699">two</ix:nonFraction> existing leases through June 2028, with an option to extend the lease an additional <ix:nonNumeric contextRef="c-158" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-700">three years</ix:nonNumeric>, which is not included in the right-of-use asset and lease liabilities. This agreement did not include any additional square footage. The 2024 Lease Agreement contains initial base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-701">0.2</ix:nonFraction> million per month with <ix:nonFraction unitRef="number" contextRef="c-157" decimals="INF" name="inbx:OperatingLeaseAnnualEscalationsPercentage" scale="-2" id="f-702">3</ix:nonFraction>% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. The 2024 Lease Agreement also provided for <ix:nonNumeric contextRef="c-157" name="inbx:OperatingLeasesContractAbatementPeriod" format="ixt-sec:durwordsen" id="f-703">four months</ix:nonNumeric> of base rent abatement of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="inbx:OperatingLeaseAbatementPeriodAmount" scale="6" id="f-704">0.2</ix:nonFraction>&#160;million per month for the period of October 2024 through January 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the 2024 Lease Agreement contains a lease which should be accounted for as a single modified contract with its existing lease agreements. As a result, the Company remeasured the operating lease liability, resulting in an increase to its operating lease liability and right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" scale="6" id="f-705">6.3</ix:nonFraction> million as of the lease&#8217;s commencement date, which was determined to be the effective date of the 2024 Lease Agreement. The Company utilized an estimated incremental fully collateralized borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-706">10.2</ix:nonFraction>% in its present value calculation as the 2024 Lease Agreement, which does not have a stated rate and did not have a readily determinable implicit rate. The estimated rate was determined using the rate of the 2025 Loan Agreement (as defined below) with Oxford entered into in January 2025.</span></div><ix:nonNumeric contextRef="c-1" name="inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" id="f-707" escape="true"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The operating right-of-use asset and operating lease liability as of December&#160;31, 2025 and December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-708">5,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-709">7,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-710">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-711">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-712">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-713">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-714">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-715">8,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2025 and December&#160;31, 2024, the Company recognized operating lease expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-716">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-717">3.4</ix:nonFraction> million, respectively. During the years ended December 31, 2025 and December&#160;31, 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" scale="6" id="f-718">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" scale="6" id="f-719">1.7</ix:nonFraction> million for amounts included in the measurement of the operating lease liability, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and December&#160;31, 2024, the Company&#8217;s operating lease had a remaining term of <ix:nonNumeric contextRef="c-6" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-720">2.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-7" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-721">3.5</ix:nonNumeric> years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-722"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-723">10.2</ix:nonFraction></ix:nonFraction>% as of December&#160;31, 2025 and December&#160;31, 2024.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-724" escape="true"><ix:continuation id="f-692-3"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental commitments for the Company&#8217;s operating leases reconciled to the operating lease liability are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-725">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-726">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-727">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-728">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-729">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-730">6,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-731">2,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-732">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i8fac7241aa424916b2e0582fb85490ec_217"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-733" continuedAt="f-733-1" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="f-733-1" continuedAt="f-733-2"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div></ix:continuation><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-733-2">Additionally, as of December&#160;31, 2025 and December&#160;31, 2024, Mark P. Lappe, the Company&#8217;s Chief Executive Officer, David Matly, the Company&#8217;s President, and Kelly D. Deck, the Company&#8217;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.</ix:continuation> </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_220"></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-734" continuedAt="f-734-1" escape="true">SUBSEQUENT EVENTS </ix:nonNumeric></span></div><ix:continuation id="f-734-1" continuedAt="f-734-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2026, the Company entered into the First Amendment to Loan and Service Agreement with Oxford, or the March 2026 Amendment. The March 2026 Amendment provides for an additional tranche, or the Term B Loans, in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-735">75.0</ix:nonFraction>&#160;million, upsized from $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-736">50.0</ix:nonFraction> million originally available under the 2025 Loan Agreement, prior to the March 2026 Amendment, collectively with the prior $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-737">100.0</ix:nonFraction> million under the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><ix:continuation id="f-734-2"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025 Loan Agreement, the Oxford Term Loans. $75.0 million of the Term B Loans was funded on the date of the March 2026 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the 2025 Loan Agreement, as amended, and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement, as amended, includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. The March 2026 Amendment updated the minimum liquidity threshold covenant, tested at all times, to $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="inbx:LongTermDebtLiquidityThreshold" scale="6" id="f-738">40.0</ix:nonFraction>&#160;million, not subject to future increases. All other terms of the 2025 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the March 2026 Amendment tranche of funding, the Company issued warrants to Oxford to purchase <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-739">21,518</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-740">69.71</ix:nonFraction> per share. The warrants are immediately exercisable, and the exercise period will expire <ix:nonNumeric contextRef="c-163" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="f-741">10</ix:nonNumeric> years from the date of issuance.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_223"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_226"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report, our disclosure controls and procedures were designed and operating effectively at the reasonable assurance level.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in its 2013 Internal Control-Integrated Framework.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management believes that, as of December&#160;31, 2025, our internal control over financial reporting is effective based on those criteria.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_232"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter ended December&#160;31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="c-164" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-742"><ix:nonNumeric contextRef="c-164" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-743">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-164" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-744"><ix:nonNumeric contextRef="c-164" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-745">terminated</ix:nonNumeric></ix:nonNumeric> any &#8220;Rule 10b5-1 trading arrangement&#8221; or any &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2026, we entered into the First Amendment to Loan and Service Agreement with Oxford Finance, LLC, or the March 2026 Amendment. The March 2026 Amendment provides for an additional tranche, or the Term B Loans, in an aggregate principal amount of $75.0 million, upsized from $50.0 million originally available under the 2025 Loan Agreement prior to the March 2026 Amendment, $75.0 million of which was funded on the date of the March 2026 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the 2025 Loan Agreement, as amended, and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all of our present and future assets, subject to certain exceptions. The 2025 Loan Agreement, as amended, includes customary events of default, including instances of a material adverse change in our operations, that may require prepayment of the outstanding term loans. The March 2026 Amendment updated the minimum liquidity threshold covenant, tested at all times, to $40.0&#160;million, not subject to future increases. All other terms of the 2025 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $75.0 million in funding on the date of the March 2026 Amendment, we issued to Oxford Finance LLC warrants, or the Term B Warrants, to purchase 21,518 shares of Common Stock, at an exercise price of $69.71 per share. The Term B Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and the number of shares of Common Stock issuable upon exercise of the Term B Warrants will be subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. The issuance of the Term B Warrants is exempt from the registration requirements of the Securities Act, pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. Each lender represented that it is an accredited investor, and that it was acquiring the securities for investment for its own account, not as nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the March 2026 Amendment and the Term B Warrants contained herein does not purport to be complete and is qualified in its entirety by reference to the March 2026 Amendment and the form of Term B Warrant, which is filed as Exhibit 10.12 and Exhibit 4.2, respectively, to this Annual Report and is incorporated herein by reference.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_235"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_238"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part III. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_241"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item not otherwise set forth below is incorporated by reference from the discussion responsive thereto under the caption &#8220;Management and Corporate Governance&#8221; and, if applicable, &#8220;Delinquent Section 16(a) Reports&#8221; in our proxy statement for the 2026 annual meeting of stockholders.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insider Trading Policy</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-746">adopted</ix:nonNumeric> an insider trading policy and procedures governing the purchase, sale, and/or other dispositions of our securities by our directors, officers, employees and other covered persons that are designed to promote compliance with insider trading laws, rules and regulations, and the Nasdaq Stock Market LLC listing rules, as applicable. A copy of our Insider Trading Policy is filed as Exhibit 19 to this Annual Report. It is our policy to comply with U.S. insider trading laws and regulations, including with respect to transactions in our own securities.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_253"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in our proxy statement for the 2026 annual meeting of stockholders.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_268"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our proxy statement for the 2026 annual meeting of stockholders.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_277"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Management and Corporate Governance&#8221; in our proxy statement for the 2026 annual meeting of stockholders.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_283"></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Fees for Independent Registered Public Accounting Firm&#8221; and &#8220;Pre-Approval Policies and Procedures&#8221; in our proxy statement for the 2026 annual meeting of stockholders.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_289"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Part IV. </span></div><div id="i8fac7241aa424916b2e0582fb85490ec_292"></div><div style="-sec-extract:summary;margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the accompanying &#8220;Index to Exhibits&#8221; below are filed or incorporated by reference as part of this Annual Report.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Index to Consolidated Financial Statements&#8221; at Item 8 to this Annual Report. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.</span></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Filed Herewith</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated By Reference File No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Date Filed</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex2-1.htm">Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis Inc., and Art Acquisition Sub, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1/23/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex2-2.htm">Separation and Distribution Agreement, dated as of January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc., and Aventis Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-39452</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1/23/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000093/amendmenttoseparationanddi.htm">Amendment to Separation and Distribution Agreement, dated as of September 23, 2025, by and among Inhibrx Biosciences, Inc., Sanofi AATD Inc., and Aventis Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11/14/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex3-1.htm">Amended &amp; Restated Certificate of Incorporation of Inhibrx Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex3-2.htm">Amended &amp; Restated Bylaws of Inhibrx Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924051494/tm243190d7_ex4-1.htm">Form of Warrant to Purchase Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4/25/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/exhibit41-formofwarrantoxf.htm">Form of Warrant to Purchase Stock by and between Inhibrx Biosciences, Inc. and entities affiliated with Oxford Finance LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1/13/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000019/inbx-descriptionofregister.htm">Description of Registered Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex10-3.htm">Transition Services Agreement, dated as of May 29, 2024, by and between Inhibrx Biosciences, Inc. and Inhibrx, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924051494/tm243190d7_ex10-2.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4/25/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#x5E;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex10-1.htm">Registration Rights Agreement, dated as of May 29, 2024, by and among Inhibrx Biosciences, Inc. and the parties thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791924000011/exhibit104-inhibrxbioscien.htm">Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Mark Lappe. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-280127</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791924000011/exhibit106-inhibrxbioscien.htm">Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Kelly Deck. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-280127</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000081/inhibrxbiosciencesaremploy.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000081/inhibrxbiosciencesaremploy.htm">mended and Restated Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000081/inhibrxbiosciencesaremploy.htm">, effective as of April 1, 2025, by and between Inhibrx Biosciences, Inc. and David Matly. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066732/tm243190d16_ex10-1.htm">2024 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-279840</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex10-4.htm">Form of Stock Option Grant Notice under the 2024 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000110465924066732/tm243190d16_ex10-3.htm">Form of Restricted Stock Unit Agreement under the 2024 Omnibus Incentive Plan. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-279840</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5/30/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791924000029/inhibrxbiosciencesnon-empl.htm">Nonemployee Director Compensation Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/exhibit101-oxfordlsa.htm">Loan and Security Agreement, dated January 13, 2025, among Inhibrx Biosciences, Inc., Oxford Finance LLC, and the other lenders party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1/13/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-oxfordfirstame.htm">First Amendment to the Loan and Security Agreement, dated March 18, 2026, among Inhibrx Biosciences, Inc., Oxford Finance LLC, and the other lenders party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000019/inhibrxbiosciencesinsidert.htm">Inhibrx Biosciences, Inc. Insider Trading Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791924000011/exhibit211-listofsubsidiar.htm">Subsidiaries of the Registrant. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-280127</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231q42025.htm">Consent of BDO USA, P.C., independent registered public accounting firm. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i99fdaf1655e04bb7b2ddd4bf5fe167f6_2263">Power of Attorney (see signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q42025.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q42025.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q42025.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q42025.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/2007919/000200791925000019/inhibrxbiosciences-clawbac.htm">Inhibrx Biosciences, Inc. Clawback Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-42031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#x5E;&#160;&#160;&#160;&#160;Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. Pursuant to Item 601(a)(6) of Regulation S-K, certain information from this exhibit have been redacted as their disclosure would constitute a clearly unwarranted invasion of personal privacy.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">+</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Management compensation plan or arrangement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*       This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><div id="i8fac7241aa424916b2e0582fb85490ec_295"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9.5pt"><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8fac7241aa424916b2e0582fb85490ec_298"></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.75pt"><tr><td style="width:1.0pt"/><td style="width:223.75pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">INHIBRX BIOSCIENCES, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:&#160;&#160;Mark P. Lappe</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:&#160;&#160;Chief Executive Officer and Chairman</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;19, 2026</span></div></td></tr></table></div><div style="margin-bottom:18pt;text-align:center"><span id="i99fdaf1655e04bb7b2ddd4bf5fe167f6_2263"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark P. Lappe and Kelly D. Deck, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:34.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark P. Lappe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">principal executive officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kelly D. Deck, C.P.A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(principal financial officer and</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">principal accounting officer</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jon Faiz Kayyem, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Jon Faiz Kayyem, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglas G. Forsyth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Douglas G. Forsyth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kimberly Manhard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kimberly Manhard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">March 19, 2026</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kristiina Vuori, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>exhibit1012-oxfordfirstame.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i546fbdc6f043463c9e44229093d28a3a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">THIS FIRST AMENDMENT to Loan and Security Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into as of March 18, 2026, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (&#8220;Oxford&#8221;), as collateral agent (in such capacity, &#8220;Collateral Agent&#8221;), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defied herein) or otherwise a party to the Loan Agreement from time to time, including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA  22314 and OXFORD FINANCE CREDIT FUND III LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA  22314 (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Lender</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;Lenders&#8221;), and INHIBRX BIOSCIENCES, INC., a Delaware corporation with an office located at 11025 North Torrey Pines Road, Suite 140, La Jolla, CA 92037 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of January 13, 2025 (as amended, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement entered into pursuant to the Loan Agreement as provided herein and subject to the terms and conditions   set forth herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and  other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 2.2(a) of the Loan Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Availability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the Effective Date in an aggregate amount of One Hundred Million Dollars ($100,000,000.00) according to each Lender&#8217;s Term A Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a &#8220;Term A Loan&#8221;, and collectively as the &#8220;Term A Loans&#8221;).  After repayment, no Term A Loan may be re borrowed.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the First Amendment Date in an aggregate amount of Seventy Five Million Dollars ($75,000,000.00) according to each Lender&#8217;s Term B Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Term B Loans</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#59; each Term A Loan and Term B Loan is hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and the Term A Loans and Term B Loans are hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  After repayment, no Term B Loan may be re borrowed.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 3.2(d) of the Loan Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes (if requested by the applicable Lender) and Warrants, in number, form and content reasonably acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date&#59; and</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 8 of the Loan Agreement is hereby amended by deleting &#8220;or&#8221; at the end of Section 8.12, replacing   &#8220;.&#8221; at the end of Section 8.13 with &#8220;&#59; or&#8221; and adding the following Section 8.14 thereto&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8.14  Active Development</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.  Both of Borrower&#8217;s drug candidates INBRX-106 and INBRX-109 are no longer under Active Development.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Active Development</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means with respect to a given drug candidate, such drug candidate being actively developed and its clinical trials being actively pursued by Borrower, Borrower continuing to intend to invest meaningful additional resources into the development of such drug candidate with the ultimate goal of either (a) seeking approval and commercializing the drug candidate or (b) monetizing the asset through partnership or a sale of the asset and the proceeds of which in Borrower&#8217;s and Lender&#8217;s mutual good faith estimation will be sufficient to fulfill all of Borrower&#8217;s Obligations. In the event a drug candidate receives a Complete Response Letter or there is a clinical hold, the borrower must continue to invest meaningful resources with the intent to remediate any negative findings in order to resubmit the application and&#47;or lift the clinical hold to continue the development of such drug candidate with the goal of either (a) seeking approval and commercializing the drug candidate or (b) monetizing the asset through partnership or a sale of the asset and the proceeds of which in Borrower&#8217;s and Lender&#8217;s mutual good faith estimation will be sufficient to fulfill all of Borrower&#8217;s Obligations.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Minimum Required Balance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is Forty Million Dollars ($40,000,000.00).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is March 18, 2026.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Section 13.1 of the Loan Agreement is hereby amended by deleting therefrom the definition of &#8220;Increased Minimum Balance Requirements.&#8221;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Schedule 1.1 to the Loan Agreement is hereby amended and restated as set forth on Schedule 1.1 attached hereto.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Limitation of Amendment.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing&#59; </font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The execution, delivery and performance by Borrower of this Amendment and the Loan Agreement as amended by this Amendment have been duly authorized&#59; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect&#59;  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The execution, delivery and performance by Borrower of this Amendment have been duly authorized, and do not (i) conflict with any of Borrower&#8217;s organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower, or any of its property or assets may be bound or affected&#59; or (iv) constitute an event of default under any material agreement by which Borrower or any of its property, is bound&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to Section 6.1(b) of the Loan Agreement&#59; and </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(&#8220;Releasees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity (other than claims relating to fraud), which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof and through the date hereof.  Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest&#58; (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents&#59; (b) any provision of this Amendment or the Loan Documents&#59; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment shall be deemed effective as of the First Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower&#8217;s payment of all Lenders&#8217; Expenses incurred by the Borrower and owing on the date hereof but not otherwise paid or satisfied, which may be debited (or ACH&#8217;d) from any of Borrower&#8217;s accounts.</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#93;</font></div><div style="height:67.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i546fbdc6f043463c9e44229093d28a3a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the parties hereto have caused this Agreement to be executed as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">INHIBRX  BIOSCIENCES, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly Deck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kelly Deck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">COLLATERAL AGENT AND LENDER&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC, as Agent</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE CREDIT FUND III LP, as</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lender</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Advisors, LLC, as manager</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE LLC, as Lender</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE CREDIT FUND III 2024-A,</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">LP, as Lender</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Advisors, LLC, as servicer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE FUNDING IX, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE FUNDING XIII, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE FUNDING TRUST 2023-1, as Lender</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE CREDIT FUND III 2025-A,</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">LP, as Lender</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance LLC, as servicer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Advisors, LLC, as servicer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE FUNDING TRUST 2025-1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">OXFORD FINANCE CREDIT FUND IV LP,</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">as Lender</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance LLC, as servicer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Advisors, LLC, as manager</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND FUNDING TRUST II, as Lender</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Credit Fund II LP, as servicer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Oxford Finance Advisors, LLC, its manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:10.00pt">&#91;Signature Page to 1st Amendment to Loan and Security Agreement&#93;</font></div><div><font><br></font></div></div></div><div id="i546fbdc6f043463c9e44229093d28a3a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE&#160;1.1<br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Lenders and Commitments</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;A Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$62,500,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">62.50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND II LP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12,500,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12.50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND III LP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$25,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25.00%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$100,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;B Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$48,750,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">65.00%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND III LP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$26,250,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35.00%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$75,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate (all Term Loans)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$111,250,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">63.57%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND II LP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$12,500,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7.14%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE CREDIT FUND III LP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$51,250,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29.29%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">$175,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit231q42025.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id3c31ce414004df28ae13f35cfbba473_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-279840) of Inhibrx Biosciences, Inc. of our report dated March&#160;19, 2026, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; BDO USA, P.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">San Diego, California</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;19, 2026</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311q42025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i974003542e7d4d67ba399d6bde4b9394_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark P. Lappe, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Inhibrx Biosciences, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;19, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312q42025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i21c6e5188ec94b55a5ae265aaa666534_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Kelly D. Deck, certify that&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Inhibrx Biosciences, Inc&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9.5pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;19, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321q42025.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i959452ab8c3640659417f79b40203d9a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report of Inhibrx Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark P. Lappe, Chief Executive Officer and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;19, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mark P. Lappe</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322q42025.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="if62f24a366284affb220467c4d136218_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report of Inhibrx Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kelly D. Deck, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.571%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;19, 2026</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kelly D. Deck</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kelly D. Deck, C.P.A.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:9.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>inbx-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:inbx="http://inhibrx.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://inhibrx.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inbx-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://inhibrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://inhibrx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>9952157 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://inhibrx.com/role/DEBT">
        <link:definition>9952158 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952159 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLAN" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN">
        <link:definition>9952160 - Disclosure - EQUITY COMPENSATION PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEREVENUE" roleURI="http://inhibrx.com/role/LICENSEREVENUE">
        <link:definition>9952161 - Disclosure - LICENSE REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>9952162 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://inhibrx.com/role/INCOMETAXES">
        <link:definition>9952163 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://inhibrx.com/role/LEASES">
        <link:definition>9952164 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952165 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952166 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>9955513 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://inhibrx.com/role/DEBTTables">
        <link:definition>9955514 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955515 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANTables" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables">
        <link:definition>9955516 - Disclosure - EQUITY COMPENSATION PLAN (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEREVENUETables" roleURI="http://inhibrx.com/role/LICENSEREVENUETables">
        <link:definition>9955517 - Disclosure - LICENSE REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://inhibrx.com/role/INCOMETAXESTables">
        <link:definition>9955518 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://inhibrx.com/role/LEASESTables">
        <link:definition>9955519 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9955520 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails">
        <link:definition>9955521 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails">
        <link:definition>9955522 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails">
        <link:definition>9955523 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails">
        <link:definition>9955524 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails">
        <link:definition>9955525 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails">
        <link:definition>9955526 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails">
        <link:definition>9955527 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails" roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails">
        <link:definition>9955528 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://inhibrx.com/role/DEBTNarrativeDetails">
        <link:definition>9955529 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofLongTermDebtDetails" roleURI="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails">
        <link:definition>9955530 - Disclosure - DEBT - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofMaturitiesofLongTermDebtDetails" roleURI="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails">
        <link:definition>9955531 - Disclosure - DEBT - Schedule of Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955532 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>9955533 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANNarrativeDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails">
        <link:definition>9955534 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955535 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails">
        <link:definition>9955536 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails" roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails">
        <link:definition>9955537 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEREVENUEScheduleofTotalRevenueDetails" roleURI="http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails">
        <link:definition>9955538 - Disclosure - LICENSE REVENUE - Schedule of Total Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEREVENUENarrativeDetails" roleURI="http://inhibrx.com/role/LICENSEREVENUENarrativeDetails">
        <link:definition>9955539 - Disclosure - LICENSE REVENUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>9955540 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>9955541 - Disclosure - INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955542 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9955543 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955544 - Disclosure - INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9955545 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>9955546 - Disclosure - INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://inhibrx.com/role/LEASESNarrativeDetails">
        <link:definition>9955547 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" roleURI="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails">
        <link:definition>9955548 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails">
        <link:definition>9955549 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1">
        <link:definition>9955549 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955550 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="inbx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inbx_InterestIncomeNonoperating" abstract="false" name="InterestIncomeNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" abstract="false" name="StockholderEquitySpinoffTransactionDecreaseInCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inbx_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" abstract="false" name="NonmonetaryTransactionGainLossRecognizedOnTransferNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" abstract="false" name="PaymentsOfDebtIssuanceCostsSecuredDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" abstract="false" name="RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" abstract="false" name="OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inbx_LicenseAndGrantRevenueTextBlock" abstract="false" name="LicenseAndGrantRevenueTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_ScheduleOfMergerTransactionTableTextBlock" abstract="false" name="ScheduleOfMergerTransactionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" abstract="false" name="ScheduleOfLicenseAndGrantRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" abstract="false" name="RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="inbx_PhylaxisBioScienceLLCMember" abstract="true" name="PhylaxisBioScienceLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_AventisIncMember" abstract="true" name="AventisIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_MergerConsiderationMember" abstract="true" name="MergerConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_MergerExchangeRatioProRateBasisPercentage" abstract="false" name="MergerExchangeRatioProRateBasisPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" abstract="false" name="ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" abstract="false" name="ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" abstract="false" name="ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_MergerExchangeRatio" abstract="false" name="MergerExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="inbx_MergerOwnershipPercentage" abstract="false" name="MergerOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" abstract="false" name="EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_EarningsDistributionRatio" abstract="false" name="EarningsDistributionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_LoansAssumedByAcquirerMember" abstract="true" name="LoansAssumedByAcquirerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" abstract="true" name="NetAssetsAndLiabilitiesAssumedByAcquirerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_TransactionCostsPaidByAcquirerMember" abstract="true" name="TransactionCostsPaidByAcquirerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ResearchAndDevelopmentExpensePersonnel" abstract="false" name="ResearchAndDevelopmentExpensePersonnel" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ResearchAndDevelopmentExpenseClinicalTrials" abstract="false" name="ResearchAndDevelopmentExpenseClinicalTrials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ResearchAndDevelopmentExpenseContractManufacturing" abstract="false" name="ResearchAndDevelopmentExpenseContractManufacturing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" abstract="false" name="ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_GeneralAndAdministrativeExpenseMergerRelated" abstract="false" name="GeneralAndAdministrativeExpenseMergerRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_GeneralAndAdministrativeExpensePersonnel" abstract="false" name="GeneralAndAdministrativeExpensePersonnel" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ClinicalTrailsPrepaidExpenseCurrent" abstract="false" name="ClinicalTrailsPrepaidExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" abstract="false" name="ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_PrepaidLicenseCurrent" abstract="false" name="PrepaidLicenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" abstract="false" name="OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AccruedClinicalTrialsCurrent" abstract="false" name="AccruedClinicalTrialsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" abstract="false" name="AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" abstract="false" name="AccruedOutsideResearchAndDevelopmentOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AccruedInterestExpenseCurrent" abstract="false" name="AccruedInterestExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_A2020OxfordTermLoansMember" abstract="true" name="A2020OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2025LoanAgreementMember" abstract="true" name="A2025LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_DebtInstrumentPrincipalAndInterestTerm" abstract="false" name="DebtInstrumentPrincipalAndInterestTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_DebtInstrumentPrepaymentFee" abstract="false" name="DebtInstrumentPrepaymentFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_DebtInstrumentBalloonPaymentWriteOff" abstract="false" name="DebtInstrumentBalloonPaymentWriteOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_AmortizationOfDebtDiscountPremiumAndAccretion" abstract="false" name="AmortizationOfDebtDiscountPremiumAndAccretion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_LongTermDebtLiquidityThreshold" abstract="false" name="LongTermDebtLiquidityThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" abstract="false" name="ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_WarrantsPreFundedMember" abstract="true" name="WarrantsPreFundedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightExpirationDate1Member" abstract="true" name="ClassOfWarrantOrRightExpirationDate1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightExpirationDate2Member" abstract="true" name="ClassOfWarrantOrRightExpirationDate2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_ClassOfWarrantsOrRightsWarrantsExercised" abstract="false" name="ClassOfWarrantsOrRightsWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" abstract="false" name="ClassOfWarrantOrRightContingentValueRightPerWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" abstract="false" name="ClassOfWarrantOrRightContingentValueRightPerWarrantValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" abstract="false" name="ClassOfWarrantOrRightCancelledThresholdExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_Plan2017Member" abstract="true" name="Plan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2024PlanMember" abstract="true" name="A2024PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2017PlanMember" abstract="true" name="A2017PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ScitheraLicenseAgreementMember" abstract="true" name="ScitheraLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseNonAffiliateMember" abstract="true" name="LicenseNonAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" abstract="false" name="ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="inbx_ScitheraInc.Member" abstract="true" name="ScitheraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_RegeneronPharmaceuticalsInc.Member" abstract="true" name="RegeneronPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_A2seventyBioIncMember" abstract="true" name="A2seventyBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseAgreementInitialProgramsAuthorizedMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" abstract="true" name="LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_CollaborativeArrangementNonrefundablePayment" abstract="false" name="CollaborativeArrangementNonrefundablePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_MaximumPotentialMilestonePayments" abstract="false" name="MaximumPotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" abstract="false" name="CollaborativeAgreementNumberOfRelatedProgramsToAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" abstract="false" name="CollaborativeArrangementDevelopmentMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_CollaborativeArrangementNonrefundableUpfrontPayment" abstract="false" name="CollaborativeArrangementNonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_ServicesPerformedUnderTransitionServicesAgreementMember" abstract="true" name="ServicesPerformedUnderTransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_SeverancePaymentsToFormerEmployeesMember" abstract="true" name="SeverancePaymentsToFormerEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliation336eElectionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" abstract="false" name="LesseeOperatingLeaseInitialBaseRentExpensePerMonth" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseAnnualEscalations" abstract="false" name="LesseeOperatingLeaseAnnualEscalations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_LesseeOperatingLeaseNumberOfContracts" abstract="false" name="LesseeOperatingLeaseNumberOfContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inbx_OperatingLeaseAnnualEscalationsPercentage" abstract="false" name="OperatingLeaseAnnualEscalationsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="inbx_OperatingLeasesContractAbatementPeriod" abstract="false" name="OperatingLeasesContractAbatementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inbx_OperatingLeaseAbatementPeriodAmount" abstract="false" name="OperatingLeaseAbatementPeriodAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" abstract="false" name="OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inbx_OxfordTermLoansMember" abstract="true" name="OxfordTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>inbx-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1260b96-73a2-42e6-be11-61aafe61fa16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_81dd1c8b-95b9-49ce-bd59-1a9158584ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1260b96-73a2-42e6-be11-61aafe61fa16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_81dd1c8b-95b9-49ce-bd59-1a9158584ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e7759481-7eca-46d6-8c6d-d0385bbfdf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1260b96-73a2-42e6-be11-61aafe61fa16" xlink:to="loc_us-gaap_LiabilitiesCurrent_e7759481-7eca-46d6-8c6d-d0385bbfdf6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7c86b213-2d2c-4e28-80fd-771988191b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f1260b96-73a2-42e6-be11-61aafe61fa16" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7c86b213-2d2c-4e28-80fd-771988191b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5da2cc0-c63e-4d49-93ef-e2d9e211eb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb0e2393-d126-46d1-8d6a-05847b27def8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5da2cc0-c63e-4d49-93ef-e2d9e211eb33" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb0e2393-d126-46d1-8d6a-05847b27def8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_74ff3630-ecaf-4875-b88f-2cd92b563665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5da2cc0-c63e-4d49-93ef-e2d9e211eb33" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_74ff3630-ecaf-4875-b88f-2cd92b563665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a689438-5333-4ba7-a142-a292019ce7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5da2cc0-c63e-4d49-93ef-e2d9e211eb33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9a689438-5333-4ba7-a142-a292019ce7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a10249ef-4c00-44dd-b0d9-22ed243574b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5da2cc0-c63e-4d49-93ef-e2d9e211eb33" xlink:to="loc_us-gaap_AssetsCurrent_a10249ef-4c00-44dd-b0d9-22ed243574b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_64277e1f-dc90-494e-9245-2a007f58c117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70441a4a-ded4-43d6-a881-022eff757941" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_64277e1f-dc90-494e-9245-2a007f58c117" xlink:to="loc_us-gaap_Liabilities_70441a4a-ded4-43d6-a881-022eff757941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_78ac5b93-bc91-4485-9134-9233c770246d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_64277e1f-dc90-494e-9245-2a007f58c117" xlink:to="loc_us-gaap_StockholdersEquity_78ac5b93-bc91-4485-9134-9233c770246d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac595bde-da60-46e4-8ba8-392beb627c68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_64277e1f-dc90-494e-9245-2a007f58c117" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac595bde-da60-46e4-8ba8-392beb627c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_75090982-f058-4cdc-a937-b4eaa57b702e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_367982e8-c662-43df-bb5e-6b8ca030068d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_75090982-f058-4cdc-a937-b4eaa57b702e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_367982e8-c662-43df-bb5e-6b8ca030068d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1c6c6603-9f5e-4a5c-a8b0-33a809180267" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_75090982-f058-4cdc-a937-b4eaa57b702e" xlink:to="loc_us-gaap_PreferredStockValue_1c6c6603-9f5e-4a5c-a8b0-33a809180267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4649f3a7-c0ef-49b0-9c5f-39297d21a3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_75090982-f058-4cdc-a937-b4eaa57b702e" xlink:to="loc_us-gaap_CommonStockValue_4649f3a7-c0ef-49b0-9c5f-39297d21a3b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0167a113-6bd7-4bee-992f-1ede1f840567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_75090982-f058-4cdc-a937-b4eaa57b702e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0167a113-6bd7-4bee-992f-1ede1f840567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84ab310c-4531-4018-960b-b8be757c47db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a465de6a-82a4-48be-80b6-600183a546b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_84ab310c-4531-4018-960b-b8be757c47db" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a465de6a-82a4-48be-80b6-600183a546b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_33a3f0c8-9a8f-4fd4-a682-0446c58e70c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_84ab310c-4531-4018-960b-b8be757c47db" xlink:to="loc_us-gaap_AccountsPayableCurrent_33a3f0c8-9a8f-4fd4-a682-0446c58e70c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d47294d-4096-4ee1-a6c6-f03a484fe214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_84ab310c-4531-4018-960b-b8be757c47db" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d47294d-4096-4ee1-a6c6-f03a484fe214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c6fa15d4-4510-4fc6-bb9e-26862a9d3852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c721d3b3-f9f6-42ce-90a1-8d4203573609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c6fa15d4-4510-4fc6-bb9e-26862a9d3852" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c721d3b3-f9f6-42ce-90a1-8d4203573609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_32cf2cd1-2c2a-4f71-8844-ec2a0b9a42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c6fa15d4-4510-4fc6-bb9e-26862a9d3852" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_32cf2cd1-2c2a-4f71-8844-ec2a0b9a42e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_019b0689-c16a-7716-90ed-f525ad072a43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c6fa15d4-4510-4fc6-bb9e-26862a9d3852" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_019b0689-c16a-7716-90ed-f525ad072a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0ae87592-e67f-49f2-bd19-97dc76673de6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c6fa15d4-4510-4fc6-bb9e-26862a9d3852" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0ae87592-e67f-49f2-bd19-97dc76673de6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_98424bc8-9a86-4fc5-8ad0-27af36dd20c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a86f6576-594d-4dd7-a921-4e07a4b2b349" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_98424bc8-9a86-4fc5-8ad0-27af36dd20c7" xlink:to="loc_us-gaap_OperatingExpenses_a86f6576-594d-4dd7-a921-4e07a4b2b349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d28f12e3-b62e-4ef4-bc5c-9c23a2a104b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_98424bc8-9a86-4fc5-8ad0-27af36dd20c7" xlink:to="loc_us-gaap_Revenues_d28f12e3-b62e-4ef4-bc5c-9c23a2a104b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_58e3ce84-2bec-46f6-bb68-a2d253433bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_eb28ab24-d9d4-4ccc-ba43-4bb42e78f71c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_58e3ce84-2bec-46f6-bb68-a2d253433bd4" xlink:to="loc_us-gaap_InterestExpenseNonoperating_eb28ab24-d9d4-4ccc-ba43-4bb42e78f71c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestIncomeNonoperating_5d7c1c8e-ce19-4365-a15b-0b1e6ad79445" xlink:href="inbx-20251231.xsd#inbx_InterestIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_58e3ce84-2bec-46f6-bb68-a2d253433bd4" xlink:to="loc_inbx_InterestIncomeNonoperating_5d7c1c8e-ce19-4365-a15b-0b1e6ad79445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_03c432e6-b989-4060-9f2c-55f562b0dd89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_58e3ce84-2bec-46f6-bb68-a2d253433bd4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_03c432e6-b989-4060-9f2c-55f562b0dd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_340d9a25-0029-444b-994f-64e8f3ef3529" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_58e3ce84-2bec-46f6-bb68-a2d253433bd4" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_340d9a25-0029-444b-994f-64e8f3ef3529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3ff9be6f-97b8-4fbe-97d1-106fae723f27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d5865ae7-184a-43aa-880b-ac477900d9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3ff9be6f-97b8-4fbe-97d1-106fae723f27" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d5865ae7-184a-43aa-880b-ac477900d9f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e5d95bb7-a601-40bd-9daa-9215d1eec405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3ff9be6f-97b8-4fbe-97d1-106fae723f27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e5d95bb7-a601-40bd-9daa-9215d1eec405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4ec5476-40b0-4012-9a92-a4da934a6414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d077b6ac-3701-400e-b353-9a9a3eaa78e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4ec5476-40b0-4012-9a92-a4da934a6414" xlink:to="loc_us-gaap_OperatingIncomeLoss_d077b6ac-3701-400e-b353-9a9a3eaa78e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61f408e8-755f-4d26-8b07-89d1d4858d05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4ec5476-40b0-4012-9a92-a4da934a6414" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61f408e8-755f-4d26-8b07-89d1d4858d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc33dc1e-7291-4e40-8415-367cc7d402b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67f753e2-7abc-4d02-b69d-d71ea9c92707" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cc33dc1e-7291-4e40-8415-367cc7d402b9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67f753e2-7abc-4d02-b69d-d71ea9c92707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cd89b121-c746-42a1-bfb6-3d7014f0f652" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cc33dc1e-7291-4e40-8415-367cc7d402b9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cd89b121-c746-42a1-bfb6-3d7014f0f652" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f393ae11-bcc8-48db-9301-253346c3dc53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f393ae11-bcc8-48db-9301-253346c3dc53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_706e8ee7-ef92-4bc0-80e6-5c7f27dea04f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_NetIncomeLoss_706e8ee7-ef92-4bc0-80e6-5c7f27dea04f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_d99a52fb-d6ff-4227-b470-2caa2a5306c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_d99a52fb-d6ff-4227-b470-2caa2a5306c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3951672a-3b07-432a-afa1-e0050f311bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3951672a-3b07-432a-afa1-e0050f311bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense_8a262b9c-b3e0-4084-847e-0cdfebe2e9dc" xlink:href="inbx-20251231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_inbx_NoncashOperatingLeaseExpense_8a262b9c-b3e0-4084-847e-0cdfebe2e9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a48e131f-f2b6-40c9-99fa-a181bd99c435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a48e131f-f2b6-40c9-99fa-a181bd99c435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb26efb8-c8dc-4480-8537-aecdaaaa1c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb26efb8-c8dc-4480-8537-aecdaaaa1c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0ce48f4f-e495-4107-a908-57f26f2db63d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_ShareBasedCompensation_0ce48f4f-e495-4107-a908-57f26f2db63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8faf2c8d-07a2-4e95-af04-490e7a51ca62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8faf2c8d-07a2-4e95-af04-490e7a51ca62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478d1c6b-caac-4bce-819a-3758b200e497" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_478d1c6b-caac-4bce-819a-3758b200e497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_019b06da-29b8-765d-adc3-6a6434c443f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_019b06da-29b8-765d-adc3-6a6434c443f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_05a481f8-f771-43e9-91d2-f0e7b849f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_05a481f8-f771-43e9-91d2-f0e7b849f6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b5a56b13-2745-4af2-a704-64817afaa613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b5a56b13-2745-4af2-a704-64817afaa613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_02162dbd-e707-4868-8739-3495011bdaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_02162dbd-e707-4868-8739-3495011bdaa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_e1225d3f-fe69-45cf-b699-56e841480304" xlink:href="inbx-20251231.xsd#inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a197741-2d39-4d9c-98a5-47ef3ebd0e06" xlink:to="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_e1225d3f-fe69-45cf-b699-56e841480304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff966914-4544-4ef3-9e74-5b97c2f6ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ee56d60-1d73-46de-bbba-4ac3aff1c2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff966914-4544-4ef3-9e74-5b97c2f6ad96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ee56d60-1d73-46de-bbba-4ac3aff1c2d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18486399-a802-4dac-bf01-fb107fe134dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff966914-4544-4ef3-9e74-5b97c2f6ad96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_18486399-a802-4dac-bf01-fb107fe134dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6272c34-6f3e-498d-a8af-af7bed248a67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff966914-4544-4ef3-9e74-5b97c2f6ad96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6272c34-6f3e-498d-a8af-af7bed248a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb3f2bf5-159e-4418-a806-550ac3d17ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62861d8e-306a-4780-a537-c68c31fe1eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb3f2bf5-159e-4418-a806-550ac3d17ae8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_62861d8e-306a-4780-a537-c68c31fe1eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019b06d9-2104-7c04-9c1e-76f2bb170779" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb3f2bf5-159e-4418-a806-550ac3d17ae8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019b06d9-2104-7c04-9c1e-76f2bb170779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1feaaca7-45ba-463f-8706-bb514365ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019b06b0-8e89-74d0-95e4-a86277f63fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1feaaca7-45ba-463f-8706-bb514365ac5d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019b06b0-8e89-74d0-95e4-a86277f63fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_019b06b0-6202-7b23-9f8e-8748e73b452e" xlink:href="inbx-20251231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1feaaca7-45ba-463f-8706-bb514365ac5d" xlink:to="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_019b06b0-6202-7b23-9f8e-8748e73b452e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f942e995-9cd2-469d-bcee-998fd12b229f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1feaaca7-45ba-463f-8706-bb514365ac5d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f942e995-9cd2-469d-bcee-998fd12b229f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_df01ecbc-1608-4283-ad82-a08752072b37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_Revenues_df01ecbc-1608-4283-ad82-a08752072b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpensePersonnel_46443380-4ae6-4080-be65-1b92b726d994" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpensePersonnel"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_ResearchAndDevelopmentExpensePersonnel_46443380-4ae6-4080-be65-1b92b726d994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_04cc8b8a-f6a7-45e7-8444-2cfeb4dce6c6" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseClinicalTrials"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_04cc8b8a-f6a7-45e7-8444-2cfeb4dce6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_b32d4125-24f2-419b-a693-918de1a35e8e" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseContractManufacturing"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_b32d4125-24f2-419b-a693-918de1a35e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_349d6b16-603d-4691-94fc-8caf5b255b89" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_349d6b16-603d-4691-94fc-8caf5b255b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_7b9b4109-4a16-4dae-8556-f275104ef85b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_7b9b4109-4a16-4dae-8556-f275104ef85b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_df626467-ce8a-46ec-a028-72d9d0eb5b9b" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpenseMergerRelated"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_df626467-ce8a-46ec-a028-72d9d0eb5b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpensePersonnel_45def5a0-9f87-436f-9b28-51e057596e76" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpensePersonnel"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_inbx_GeneralAndAdministrativeExpensePersonnel_45def5a0-9f87-436f-9b28-51e057596e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_e10b0203-7afb-4f7c-9f6e-995017732afa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_e10b0203-7afb-4f7c-9f6e-995017732afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_07ea5129-0a39-427b-8185-0a08e6b15eda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_07ea5129-0a39-427b-8185-0a08e6b15eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cda1e-a120-73e8-b2a3-b808320518e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cda1e-a120-73e8-b2a3-b808320518e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019cda1e-a120-765b-aeb1-f9651483513f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_abac904e-6126-411e-a5fd-b47efcb035e9" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019cda1e-a120-765b-aeb1-f9651483513f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_8f3726ec-d228-4983-b46e-3f03bdd5733e" xlink:href="inbx-20251231.xsd#inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:to="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_8f3726ec-d228-4983-b46e-3f03bdd5733e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_68a315f6-be0a-492d-a889-785b58603ff1" xlink:href="inbx-20251231.xsd#inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:to="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_68a315f6-be0a-492d-a889-785b58603ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PrepaidLicenseCurrent_69fcdd77-6851-4481-b680-064164c06729" xlink:href="inbx-20251231.xsd#inbx_PrepaidLicenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:to="loc_inbx_PrepaidLicenseCurrent_69fcdd77-6851-4481-b680-064164c06729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c7710836-1d05-4806-b0a8-7afdfec5056d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:to="loc_us-gaap_OtherAssetsCurrent_c7710836-1d05-4806-b0a8-7afdfec5056d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent_5e126b99-c7a8-429f-a80a-27d2b83b017f" xlink:href="inbx-20251231.xsd#inbx_ClinicalTrailsPrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cbf97fe9-4c48-484f-8b96-e32aeedb1aac" xlink:to="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent_5e126b99-c7a8-429f-a80a-27d2b83b017f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b4fcc763-3bff-44f1-b596-291675b12847" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a47cdc65-d576-4ac8-a2e5-33909ca75656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b4fcc763-3bff-44f1-b596-291675b12847" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a47cdc65-d576-4ac8-a2e5-33909ca75656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_df76d18f-7968-465d-97fc-3677d853ee75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_b4fcc763-3bff-44f1-b596-291675b12847" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_df76d18f-7968-465d-97fc-3677d853ee75" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_bc41e4aa-798d-4270-a558-3390693c4a9d" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_bc41e4aa-798d-4270-a558-3390693c4a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_d1e20eb7-3bc2-4eb4-8a66-c1b4d0bccdca" xlink:href="inbx-20251231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_d1e20eb7-3bc2-4eb4-8a66-c1b4d0bccdca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c90632d-8c57-4ae3-81f9-9699727aa3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0c90632d-8c57-4ae3-81f9-9699727aa3ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0dbac994-2c67-4c3c-8afb-6135f7d17588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0dbac994-2c67-4c3c-8afb-6135f7d17588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedInterestExpenseCurrent_e25bde68-a696-4961-b98f-bbe50f75eafd" xlink:href="inbx-20251231.xsd#inbx_AccruedInterestExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_inbx_AccruedInterestExpenseCurrent_e25bde68-a696-4961-b98f-bbe50f75eafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalTrialsCurrent_9194523b-0694-4f24-a8b1-4f6250c959b2" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalTrialsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_inbx_AccruedClinicalTrialsCurrent_9194523b-0694-4f24-a8b1-4f6250c959b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aec6cc78-4414-4cf5-9628-abb6904fb9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ad5d3c09-8089-4beb-82ef-e52da6917b1a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_aec6cc78-4414-4cf5-9628-abb6904fb9f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019b0710-80ee-7979-b5a9-f5dc364dc6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-71df-8240-1918d0ef3991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019b0710-80ee-7979-b5a9-f5dc364dc6c4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-71df-8240-1918d0ef3991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7d2a-94ca-8d17e273b52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019b0710-80ee-7979-b5a9-f5dc364dc6c4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7d2a-94ca-8d17e273b52f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-7132-bacd-4f952e59f50a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-79f0-b8f7-f2d819fd9aec" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-7132-bacd-4f952e59f50a" xlink:to="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-79f0-b8f7-f2d819fd9aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-707b-abe2-d64c4df1bc31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-7132-bacd-4f952e59f50a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-707b-abe2-d64c4df1bc31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7044-97ae-3b7a3bad3492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-7132-bacd-4f952e59f50a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7044-97ae-3b7a3bad3492" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd3a6-faf9-7343-8bde-30edfe8482ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019cd3a6-faf9-771c-bad2-4bfa5d942f24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd3a6-faf9-7343-8bde-30edfe8482ee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019cd3a6-faf9-771c-bad2-4bfa5d942f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019cd3a6-faf9-7c11-b08e-f731febea50d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd3a6-faf9-7343-8bde-30edfe8482ee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019cd3a6-faf9-7c11-b08e-f731febea50d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_126859db-1c4c-4c88-aa24-6fcf5362221f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d19f9420-9eee-42b8-b577-11fc8f738610" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_126859db-1c4c-4c88-aa24-6fcf5362221f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d19f9420-9eee-42b8-b577-11fc8f738610" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ebfa3123-ee8e-45f5-a9ac-4f62dc6e1072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ebfa3123-ee8e-45f5-a9ac-4f62dc6e1072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_900238fa-5dcc-49b5-926c-ca30864095e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_900238fa-5dcc-49b5-926c-ca30864095e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0eadcdc4-8f1e-42d5-9c7f-deaeed699bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0eadcdc4-8f1e-42d5-9c7f-deaeed699bcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a7a3bef6-1c14-40c6-86a3-c80340f964d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a7a3bef6-1c14-40c6-86a3-c80340f964d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8330bec7-7388-4600-8ebe-2ba418b08226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8330bec7-7388-4600-8ebe-2ba418b08226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_a2b964a2-80a0-44d7-ba15-5be9df32be30" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_a2b964a2-80a0-44d7-ba15-5be9df32be30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_f1fc5a9f-114b-4f25-adb5-b5c648c176c1" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_f1fc5a9f-114b-4f25-adb5-b5c648c176c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_19d5d9cd-83bc-4a1f-bfaa-2474b1cecf1a" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_19d5d9cd-83bc-4a1f-bfaa-2474b1cecf1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_bf8351b3-3edc-423e-88a0-919b59b58685" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e191d46d-1944-4d77-b284-b7a4e6c64329" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_bf8351b3-3edc-423e-88a0-919b59b58685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7301-9647-0cfdff6666ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019cb486-6f11-7e93-8e90-4c8305adf6af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7301-9647-0cfdff6666ff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019cb486-6f11-7e93-8e90-4c8305adf6af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019cb486-6f11-7903-a906-7ba9e5befc60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7301-9647-0cfdff6666ff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019cb486-6f11-7903-a906-7ba9e5befc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019cb486-6f11-7d10-8c5a-f77b76f682b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7301-9647-0cfdff6666ff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019cb486-6f11-7d10-8c5a-f77b76f682b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_019cb486-6f11-7878-b10c-c2b25361eca7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7301-9647-0cfdff6666ff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_019cb486-6f11-7878-b10c-c2b25361eca7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_835d1525-6ddd-4961-87c3-b3525b4beb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_835d1525-6ddd-4961-87c3-b3525b4beb2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9adbcc9b-a729-4ec1-856a-7ae6ffd76ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9adbcc9b-a729-4ec1-856a-7ae6ffd76ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_8a494533-7879-4998-bf6e-b5ee77d83cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_8a494533-7879-4998-bf6e-b5ee77d83cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_53e99e0b-8c80-4072-a4dc-f5475084674f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_53e99e0b-8c80-4072-a4dc-f5475084674f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_bedfd16d-3e65-45f3-8703-e72b460b8586" xlink:href="inbx-20251231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_bedfd16d-3e65-45f3-8703-e72b460b8586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5c957553-fe82-4c92-a32f-f2c80fc4db72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_5c957553-fe82-4c92-a32f-f2c80fc4db72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d24a4ff8-77ee-4505-b555-676c1e851159" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d24a4ff8-77ee-4505-b555-676c1e851159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d48b781a-0f08-4a4d-a5fd-b81755d2388e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_17234d69-2b07-4c54-b09b-e54156c2ceef" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d48b781a-0f08-4a4d-a5fd-b81755d2388e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_aefbda72-06c9-4115-9fc2-25b5bcd79a20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b25dddb1-9dc2-485b-8f30-5485a3e520a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_aefbda72-06c9-4115-9fc2-25b5bcd79a20" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b25dddb1-9dc2-485b-8f30-5485a3e520a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_954b4d0a-b338-4698-81b2-1f1dc5f05d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_aefbda72-06c9-4115-9fc2-25b5bcd79a20" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_954b4d0a-b338-4698-81b2-1f1dc5f05d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1e656ed7-6bf5-4e03-abdc-6f071f1ab128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5fecd496-6285-436b-8926-c291de0543d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1e656ed7-6bf5-4e03-abdc-6f071f1ab128" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5fecd496-6285-436b-8926-c291de0543d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c242acf2-7383-405a-bf78-c62b794d6372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1e656ed7-6bf5-4e03-abdc-6f071f1ab128" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c242acf2-7383-405a-bf78-c62b794d6372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_be2e91bf-dbbf-4b6b-950b-f6ecdd51e883" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a73aba90-bbbf-46f4-9673-056cc3200d94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_be2e91bf-dbbf-4b6b-950b-f6ecdd51e883" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a73aba90-bbbf-46f4-9673-056cc3200d94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_39635b5f-227b-4542-8803-4e5e4a8258b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_be2e91bf-dbbf-4b6b-950b-f6ecdd51e883" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_39635b5f-227b-4542-8803-4e5e4a8258b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3cc07e1b-9ef5-4421-925a-bc51f294f384" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0dbc9ccf-0e3b-4d7c-bfaa-43627acfb52e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3cc07e1b-9ef5-4421-925a-bc51f294f384" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0dbc9ccf-0e3b-4d7c-bfaa-43627acfb52e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fb1119a6-8e86-40c2-bcfc-ba146fb6b9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_3cc07e1b-9ef5-4421-925a-bc51f294f384" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fb1119a6-8e86-40c2-bcfc-ba146fb6b9b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83ffe2f7-5ae2-441f-bbed-2fe755bacf68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_999c819c-1341-447d-a8c5-541f25bad418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83ffe2f7-5ae2-441f-bbed-2fe755bacf68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_999c819c-1341-447d-a8c5-541f25bad418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63c628cc-686c-48ad-bb07-215cf0495999" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83ffe2f7-5ae2-441f-bbed-2fe755bacf68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63c628cc-686c-48ad-bb07-215cf0495999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7181dce7-78e6-4b46-bb69-23d5e2e178b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83ffe2f7-5ae2-441f-bbed-2fe755bacf68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7181dce7-78e6-4b46-bb69-23d5e2e178b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7110234b-d549-4bde-b9cb-798c5165214b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_09798aff-a347-4a78-a89d-7e26d2504060" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7110234b-d549-4bde-b9cb-798c5165214b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_09798aff-a347-4a78-a89d-7e26d2504060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2046380c-dd0a-4dd8-8060-12d18e612e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_7110234b-d549-4bde-b9cb-798c5165214b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2046380c-dd0a-4dd8-8060-12d18e612e51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef5dc52e-9241-40ce-abe3-b39503e54fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2a4647de-9931-4a21-9a5a-992cb5a6de83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef5dc52e-9241-40ce-abe3-b39503e54fe5" xlink:to="loc_us-gaap_OperatingLeaseLiability_2a4647de-9931-4a21-9a5a-992cb5a6de83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2560a805-ba1a-498e-a30b-efe012fc48aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef5dc52e-9241-40ce-abe3-b39503e54fe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2560a805-ba1a-498e-a30b-efe012fc48aa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>inbx-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:to="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:to="loc_us-gaap_RelatedPartyDomain_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:to="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_83ea89fc-6136-4233-8430-522f3b90ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:to="loc_us-gaap_NonrelatedPartyMember_83ea89fc-6136-4233-8430-522f3b90ebda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6c7e9a20-89d2-4ec2-bc7f-8ea83a446627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:to="loc_us-gaap_RelatedPartyMember_6c7e9a20-89d2-4ec2-bc7f-8ea83a446627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:to="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646f60f-3879-4968-b00a-eaee1d5b050b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646f60f-3879-4968-b00a-eaee1d5b050b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0e26c8ba-c3fe-406c-b04c-12868eb1a04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0e26c8ba-c3fe-406c-b04c-12868eb1a04e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_019b0688-e1ea-759f-b04d-c963e7f62e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_019b0688-e1ea-759f-b04d-c963e7f62e10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5f66882-fe73-46f0-9dd3-403402f9d588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5f66882-fe73-46f0-9dd3-403402f9d588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_47882cee-3033-45e2-b42d-9831d122b94d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_AssetsCurrent_47882cee-3033-45e2-b42d-9831d122b94d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ceb8b5c3-2f6b-48cb-a13d-ff77e10c6fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ceb8b5c3-2f6b-48cb-a13d-ff77e10c6fc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdc71fbd-a71c-46e8-90c9-0e544673ff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdc71fbd-a71c-46e8-90c9-0e544673ff8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b89748bf-7708-4713-8b38-2d62801a1a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b89748bf-7708-4713-8b38-2d62801a1a64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9da27281-dc28-44ca-b2c8-4404088f1cba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_Assets_9da27281-dc28-44ca-b2c8-4404088f1cba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_50243546-c2cb-46aa-99b0-6402a0bcd289" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_AccountsPayableCurrent_50243546-c2cb-46aa-99b0-6402a0bcd289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1a4099a4-9248-4c07-800e-3545036b5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1a4099a4-9248-4c07-800e-3545036b5e37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_43967ad5-46c1-4c09-856f-968a5cbbcafa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_43967ad5-46c1-4c09-856f-968a5cbbcafa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_452928cc-c968-477e-aa2a-9087f0224593" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_LiabilitiesCurrent_452928cc-c968-477e-aa2a-9087f0224593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c5069c72-07c2-4f03-8bc4-cddb7b5fa7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c5069c72-07c2-4f03-8bc4-cddb7b5fa7ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ae6dd2-9d1a-4dfa-af50-4ee93b518e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ae6dd2-9d1a-4dfa-af50-4ee93b518e1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1b73a5d8-cdc5-4467-bc78-9cd63ba2d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_Liabilities_1b73a5d8-cdc5-4467-bc78-9cd63ba2d5e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5a6fe1a7-06b7-48f1-b4a0-79bd02a0813b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5a6fe1a7-06b7-48f1-b4a0-79bd02a0813b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4095f99f-78cd-4b20-9ab2-58ec7d6f95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_PreferredStockValue_4095f99f-78cd-4b20-9ab2-58ec7d6f95c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96bce565-e220-4af4-b0b9-77929b4872c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_CommonStockValue_96bce565-e220-4af4-b0b9-77929b4872c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8039ca35-0cf3-45d9-ba63-5692638fbff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8039ca35-0cf3-45d9-ba63-5692638fbff5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1df726c-5e2f-4e1f-bfe1-255d0a8f8859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1df726c-5e2f-4e1f-bfe1-255d0a8f8859" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d363a33-fa98-4b89-902a-c042875d0f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_StockholdersEquity_5d363a33-fa98-4b89-902a-c042875d0f41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff596f53-8d4f-455b-8bf8-561dd6712e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff596f53-8d4f-455b-8bf8-561dd6712e7f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:to="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_69d50d97-344b-4a6d-9748-3786d6f6ec31_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:to="loc_srt_ProductsAndServicesDomain_69d50d97-344b-4a6d-9748-3786d6f6ec31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:to="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_acec0f13-018a-45dd-8436-2f8ec1084e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:to="loc_us-gaap_LicenseMember_acec0f13-018a-45dd-8436-2f8ec1084e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d74db658-2c2e-4d8d-8f8b-9534dbf8b4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:to="loc_us-gaap_Revenues_d74db658-2c2e-4d8d-8f8b-9534dbf8b4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_215cc034-c93d-4d20-9206-36a4b540924e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_215cc034-c93d-4d20-9206-36a4b540924e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f55c1c06-7870-49eb-9f05-14393076d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f55c1c06-7870-49eb-9f05-14393076d7a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_64d575da-7d60-488f-9551-b29a6fd7c7df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_OperatingExpenses_64d575da-7d60-488f-9551-b29a6fd7c7df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e7210159-1782-426b-9f62-c5176591c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OperatingIncomeLoss_e7210159-1782-426b-9f62-c5176591c31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_c641ec72-8b56-434f-a5f0-15f532961b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_c641ec72-8b56-434f-a5f0-15f532961b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1d09aed6-0189-4e18-b7cf-c19caaa39ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1d09aed6-0189-4e18-b7cf-c19caaa39ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestIncomeNonoperating_131d45f2-1946-4cbb-a6e4-64b690270900" xlink:href="inbx-20251231.xsd#inbx_InterestIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_inbx_InterestIncomeNonoperating_131d45f2-1946-4cbb-a6e4-64b690270900" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_999a2032-44ff-4eb9-82b3-4bce08cf1588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_999a2032-44ff-4eb9-82b3-4bce08cf1588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b8dda759-9520-4a5e-a76f-6cbb1663cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b8dda759-9520-4a5e-a76f-6cbb1663cbb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c6639e6-21ae-49f9-818f-e122f8617475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c6639e6-21ae-49f9-818f-e122f8617475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19cfa4b0-9fba-47b1-b7bf-0a972debb455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19cfa4b0-9fba-47b1-b7bf-0a972debb455" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_929a322a-65fd-42a6-ac97-000538967c92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_NetIncomeLoss_929a322a-65fd-42a6-ac97-000538967c92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9986a14-9cd6-4b02-8c68-0f0f4baf0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9986a14-9cd6-4b02-8c68-0f0f4baf0ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b83e54cc-ac95-4038-9976-aa559d8df41c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b83e54cc-ac95-4038-9976-aa559d8df41c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c3f2791-2149-4e6a-9d58-010839f40180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c3f2791-2149-4e6a-9d58-010839f40180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_726b82f1-3d9d-4364-a280-a07e9bd9cc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_726b82f1-3d9d-4364-a280-a07e9bd9cc1a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:to="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:to="loc_us-gaap_EquityComponentDomain_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:to="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d2c17a37-cd7d-4de5-a3e2-bc9a098bf759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_CommonStockMember_d2c17a37-cd7d-4de5-a3e2-bc9a098bf759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_919614c9-9789-40d4-afaa-f989b7b57765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_919614c9-9789-40d4-afaa-f989b7b57765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dce1a236-6b57-4482-8876-49290ef9de5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_RetainedEarningsMember_dce1a236-6b57-4482-8876-49290ef9de5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14382118-34a9-4b3c-84eb-707269546a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14382118-34a9-4b3c-84eb-707269546a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59065b2b-ab3b-4bcc-befb-c022e551dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockholdersEquity_59065b2b-ab3b-4bcc-befb-c022e551dd48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_55a14f70-9126-4c23-be0c-2780e6bd417a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_55a14f70-9126-4c23-be0c-2780e6bd417a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b069c-a754-7825-ab2d-951f40f51272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b069c-a754-7825-ab2d-951f40f51272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d992e0-c571-4f53-a972-0e20e0d9ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d992e0-c571-4f53-a972-0e20e0d9ca2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dac18509-9b2a-4252-b70c-a62455cfeece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dac18509-9b2a-4252-b70c-a62455cfeece" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e4a8fbee-766f-4368-a067-64cac0f74d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e4a8fbee-766f-4368-a067-64cac0f74d6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_72502252-2330-4ecd-abc2-c687dc55d369" xlink:href="inbx-20251231.xsd#inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_72502252-2330-4ecd-abc2-c687dc55d369" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_92968289-2e08-4fec-bdf3-1b2cb4eb21fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_92968289-2e08-4fec-bdf3-1b2cb4eb21fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ee37464-bb70-4dae-b1f5-9caac7be4ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ee37464-bb70-4dae-b1f5-9caac7be4ea4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb858dc4-761b-4166-81e2-0f5436fbc5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb858dc4-761b-4166-81e2-0f5436fbc5b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ed866dc-5fab-4c3a-ad0f-4546702537db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_NetIncomeLoss_8ed866dc-5fab-4c3a-ad0f-4546702537db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c0484af-d7e6-4a53-b7c0-986539aa6451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bdff1d85-9a8f-471b-a4c6-dc4af9eb7e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_226c337b-d875-4d57-a88f-cf5e5fa3df71_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:to="loc_srt_RangeMember_226c337b-d875-4d57-a88f-cf5e5fa3df71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:to="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_195787d9-c60c-4cf1-978b-afc539219bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:to="loc_srt_MinimumMember_195787d9-c60c-4cf1-978b-afc539219bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ddec267e-21a3-4ecd-992d-7a2f1a18b94b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:to="loc_srt_MaximumMember_ddec267e-21a3-4ecd-992d-7a2f1a18b94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e26a0f3a-419e-43e5-9ec3-967bd6103823_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e26a0f3a-419e-43e5-9ec3-967bd6103823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_67795f54-9a69-4b02-915d-44157daef8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_67795f54-9a69-4b02-915d-44157daef8b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ddb1834a-3242-46a3-87ba-197255b6e590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ddb1834a-3242-46a3-87ba-197255b6e590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d2001894-ed33-4159-a18c-b2fcdbc1b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d2001894-ed33-4159-a18c-b2fcdbc1b16c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_339d34ac-45d0-4801-8ae9-d1e74cdf73de_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_339d34ac-45d0-4801-8ae9-d1e74cdf73de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_3d13b31e-d9ce-488c-bc20-e4aacd98ebcb" xlink:href="inbx-20251231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_3d13b31e-d9ce-488c-bc20-e4aacd98ebcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:to="loc_dei_EntityDomain_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:to="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AventisIncMember_54645d40-9945-47d4-ad73-d7cf1fad64eb" xlink:href="inbx-20251231.xsd#inbx_AventisIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:to="loc_inbx_AventisIncMember_54645d40-9945-47d4-ad73-d7cf1fad64eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_95a16845-c286-49fd-8553-a3e429fd84c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_95a16845-c286-49fd-8553-a3e429fd84c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerConsiderationMember_53387671-56bd-4a0d-b82a-d454b6621bd5" xlink:href="inbx-20251231.xsd#inbx_MergerConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:to="loc_inbx_MergerConsiderationMember_53387671-56bd-4a0d-b82a-d454b6621bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1b11a63-0107-41f7-bc71-9429f9a5f639_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:to="loc_us-gaap_EquityComponentDomain_d1b11a63-0107-41f7-bc71-9429f9a5f639_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:to="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21833b8e-7f6c-441d-9e39-825b56c4aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:to="loc_us-gaap_RetainedEarningsMember_21833b8e-7f6c-441d-9e39-825b56c4aebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f28200e4-594c-4739-9eca-97208bdeaa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f28200e4-594c-4739-9eca-97208bdeaa8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8ddf4f6e-6609-445f-baae-53ad302409ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8ddf4f6e-6609-445f-baae-53ad302409ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51aad08a-84ff-4bc3-a6cb-5e26c3eda7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51aad08a-84ff-4bc3-a6cb-5e26c3eda7a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41685aae-50dd-4cdf-bfa5-688fcf40e578_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_41685aae-50dd-4cdf-bfa5-688fcf40e578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cfc6179-b4e6-46b8-b8a6-54474500025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cfc6179-b4e6-46b8-b8a6-54474500025d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatioProRateBasisPercentage_650b4a05-5c7b-46f2-af64-4934087c4640" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatioProRateBasisPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerExchangeRatioProRateBasisPercentage_650b4a05-5c7b-46f2-af64-4934087c4640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_e6295e3d-e65b-4762-a4ac-a8521c3cb2c8" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_e6295e3d-e65b-4762-a4ac-a8521c3cb2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_2bfecc02-d5d2-4905-bfb3-a90c60ddcddf" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_2bfecc02-d5d2-4905-bfb3-a90c60ddcddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_182db282-ba89-405f-a235-906399c9b0d6" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_182db282-ba89-405f-a235-906399c9b0d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatio_fc16a102-ff30-4c78-9883-5d207e55cf9b" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerExchangeRatio_fc16a102-ff30-4c78-9883-5d207e55cf9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_688e7f17-b6a1-4f5b-9ec5-beb75d763d4d" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerOwnershipPercentage_688e7f17-b6a1-4f5b-9ec5-beb75d763d4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fb49f798-78e4-40bd-a247-6df9bf26474f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fb49f798-78e4-40bd-a247-6df9bf26474f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7a6fa495-932c-424a-ac51-50e075aab59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7a6fa495-932c-424a-ac51-50e075aab59c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_1943dacb-fbb3-4a0b-b735-a5862259595e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_1943dacb-fbb3-4a0b-b735-a5862259595e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a9ca35b6-5c53-43f0-89b6-989c2d0fb435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a9ca35b6-5c53-43f0-89b6-989c2d0fb435" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94ebebd-8dac-45c1-8b5f-61c50e25c057" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94ebebd-8dac-45c1-8b5f-61c50e25c057" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a47dbb5c-5b0b-470f-930a-405a01766487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a47dbb5c-5b0b-470f-930a-405a01766487" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f8b11470-e446-4247-a328-70bf9d83b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f8b11470-e446-4247-a328-70bf9d83b7c8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dd85227-aa20-43a0-82a7-361b75c8beea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dd85227-aa20-43a0-82a7-361b75c8beea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c21354c8-b7cb-4711-83a6-69a80901fedb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_EquityMethodInvestments_c21354c8-b7cb-4711-83a6-69a80901fedb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_c82f8847-d9c8-445b-ba25-1194e26e633a" xlink:href="inbx-20251231.xsd#inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_c82f8847-d9c8-445b-ba25-1194e26e633a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_725ae0a9-4606-44b8-8856-c39ab0df0607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_725ae0a9-4606-44b8-8856-c39ab0df0607" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EarningsDistributionRatio_32145c75-d905-41d2-8b1d-88d312e2a951" xlink:href="inbx-20251231.xsd#inbx_EarningsDistributionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_EarningsDistributionRatio_32145c75-d905-41d2-8b1d-88d312e2a951" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cf638915-f4ee-4c06-970a-34e97acf4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cf638915-f4ee-4c06-970a-34e97acf4fe0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_bf35a80c-6663-4aa1-a0da-fdd27e61d174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NumberOfReportableSegments_bf35a80c-6663-4aa1-a0da-fdd27e61d174" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_79f500f0-b817-4ed9-a2f9-538b05cfab61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_79f500f0-b817-4ed9-a2f9-538b05cfab61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerConsiderationMember_c4daa904-7d83-48b9-9e45-dca50a43e36f" xlink:href="inbx-20251231.xsd#inbx_MergerConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_MergerConsiderationMember_c4daa904-7d83-48b9-9e45-dca50a43e36f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LoansAssumedByAcquirerMember_2ad5a774-b533-49b7-accd-67232a3f1eae" xlink:href="inbx-20251231.xsd#inbx_LoansAssumedByAcquirerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_LoansAssumedByAcquirerMember_2ad5a774-b533-49b7-accd-67232a3f1eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_c8f43969-810c-4cbd-876a-43309e1c0621" xlink:href="inbx-20251231.xsd#inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_c8f43969-810c-4cbd-876a-43309e1c0621" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TransactionCostsPaidByAcquirerMember_79213ee3-ad89-450c-976b-e9560f7eadad" xlink:href="inbx-20251231.xsd#inbx_TransactionCostsPaidByAcquirerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_TransactionCostsPaidByAcquirerMember_79213ee3-ad89-450c-976b-e9560f7eadad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_6fb47b8b-0101-4dfb-b859-b38d68d12f03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_6fb47b8b-0101-4dfb-b859-b38d68d12f03" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7183-b0e0-cc2342b807a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7183-b0e0-cc2342b807a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cb439-931b-7099-b39b-703773c673b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cb439-931b-7099-b39b-703773c673b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7271-870a-d131a8bc5308_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7271-870a-d131a8bc5308_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cb439-931b-74fd-9bd6-b7592f541609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cb439-931b-74fd-9bd6-b7592f541609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cb439-931b-7409-a628-42837eb5141e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cb439-931b-7409-a628-42837eb5141e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cb439-931b-7bee-a9d6-17b6383339d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cb439-931b-7bee-a9d6-17b6383339d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb439-931b-7320-8097-ca1b5e950e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb439-931b-7320-8097-ca1b5e950e4e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82e24050-b47b-4992-831d-6d279b516958_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_82e24050-b47b-4992-831d-6d279b516958_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f234c61d-b0e5-41d9-885e-d017ce4d8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f234c61d-b0e5-41d9-885e-d017ce4d8b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fe5ec883-66e8-444f-b999-41130b3afef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:to="loc_us-gaap_WarrantMember_fe5ec883-66e8-444f-b999-41130b3afef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d394a40f-25b8-434f-a4b2-734f5814e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d394a40f-25b8-434f-a4b2-734f5814e5b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c9001184-d7af-47b7-b83b-8c36853d5525_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:to="loc_us-gaap_SegmentDomain_c9001184-d7af-47b7-b83b-8c36853d5525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:to="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReportableSegmentMember_1ecb8c91-033b-4383-87a2-a470c717c234" xlink:href="inbx-20251231.xsd#inbx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:to="loc_inbx_ReportableSegmentMember_1ecb8c91-033b-4383-87a2-a470c717c234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d4b8d74-da3b-449e-82ac-d30c84603a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_Revenues_3d4b8d74-da3b-449e-82ac-d30c84603a3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpensePersonnel_21e1bc9a-7322-4f85-a987-3b9ee4bd23b9" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpensePersonnel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpensePersonnel_21e1bc9a-7322-4f85-a987-3b9ee4bd23b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_025ca0d0-8957-4c2e-9851-4e7346d92493" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseClinicalTrials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_025ca0d0-8957-4c2e-9851-4e7346d92493" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_d1826dc8-00b9-4c8d-b857-d17ff8e6aa5e" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseContractManufacturing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_d1826dc8-00b9-4c8d-b857-d17ff8e6aa5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_48069b13-7698-4d2e-8918-01b2c44a6752" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_48069b13-7698-4d2e-8918-01b2c44a6752" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_fd63db64-0ba8-4d7e-aa33-a7fa88599ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_fd63db64-0ba8-4d7e-aa33-a7fa88599ea4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_126cfdbc-f5c8-44b1-933a-859cac724be0" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpenseMergerRelated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_126cfdbc-f5c8-44b1-933a-859cac724be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpensePersonnel_2321f1c3-f3c0-404b-a288-6b90877785e6" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpensePersonnel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_inbx_GeneralAndAdministrativeExpensePersonnel_2321f1c3-f3c0-404b-a288-6b90877785e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_f2e2eb30-43b5-436f-a74a-cdae4a96fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_f2e2eb30-43b5-436f-a74a-cdae4a96fcf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8fba34d5-4d0e-4dd3-91f7-8d5a88b69e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8fba34d5-4d0e-4dd3-91f7-8d5a88b69e9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cb44d-7694-73f8-b29f-c8cd42f818a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cb44d-7694-73f8-b29f-c8cd42f818a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_4ec99416-8238-4cb9-8970-84366d8e92d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_4ec99416-8238-4cb9-8970-84366d8e92d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96720281-b045-46b3-b30a-f12282003d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NetIncomeLoss_96720281-b045-46b3-b30a-f12282003d20" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40df653f-2b82-4585-a000-ed8186682385_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40df653f-2b82-4585-a000-ed8186682385_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c28537ba-b78b-47be-a832-38f9cb656b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c28537ba-b78b-47be-a832-38f9cb656b7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_f8c7d01e-e47c-49af-a0ae-7fd5cb63b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_f8c7d01e-e47c-49af-a0ae-7fd5cb63b34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e7457793-81db-49e4-a806-f44838b5d9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e7457793-81db-49e4-a806-f44838b5d9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a35ac162-4eee-49ee-8563-d31f3ac9d21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a35ac162-4eee-49ee-8563-d31f3ac9d21b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7d63dcb0-94b0-4a32-a806-9e7eac0041a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7d63dcb0-94b0-4a32-a806-9e7eac0041a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7f2d41b6-549d-4c9c-a75a-efe24c2dcdda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7f2d41b6-549d-4c9c-a75a-efe24c2dcdda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44214a85-9793-4400-89b1-9f1b5757a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44214a85-9793-4400-89b1-9f1b5757a3b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eb70b5e9-1b7b-455c-a2da-1869c2c83785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eb70b5e9-1b7b-455c-a2da-1869c2c83785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa741f45-a5f4-4142-8d99-b221bb95eea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa741f45-a5f4-4142-8d99-b221bb95eea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_09dbd71d-a7ac-48ce-9e8f-2ed9e70b5ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_09dbd71d-a7ac-48ce-9e8f-2ed9e70b5ca3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_534e0c9a-c112-4198-8243-ce94b8c97dab" xlink:href="inbx-20251231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:to="loc_inbx_A2020OxfordTermLoansMember_534e0c9a-c112-4198-8243-ce94b8c97dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2025LoanAgreementMember_019cb45a-bda5-7509-9f3f-cc5127ae787a" xlink:href="inbx-20251231.xsd#inbx_A2025LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:to="loc_inbx_A2025LoanAgreementMember_019cb45a-bda5-7509-9f3f-cc5127ae787a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6346d5e7-d768-4906-ae0f-3926ec294e82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6346d5e7-d768-4906-ae0f-3926ec294e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d2c7d0f2-321e-43c7-b5df-ceaee19f6c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:to="loc_us-gaap_SecuredDebtMember_d2c7d0f2-321e-43c7-b5df-ceaee19f6c9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b071b-de0c-7d6e-a737-003bb8fe020f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:to="loc_us-gaap_LineOfCreditMember_019b071b-de0c-7d6e-a737-003bb8fe020f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dba8968-8d5b-4a3c-a792-e18f893664d1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:to="loc_srt_RangeMember_6dba8968-8d5b-4a3c-a792-e18f893664d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:to="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd5db87f-d78c-4bda-98f7-8418e60995e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:to="loc_srt_MinimumMember_fd5db87f-d78c-4bda-98f7-8418e60995e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29d56404-d75e-42b8-bde3-db88db35d31e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:to="loc_srt_MaximumMember_29d56404-d75e-42b8-bde3-db88db35d31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-767a-9a70-30887ed553e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:to="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-767a-9a70-30887ed553e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:to="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b071b-de0c-7706-87c6-3cac03b54770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:to="loc_us-gaap_SecuredDebtMember_019b071b-de0c-7706-87c6-3cac03b54770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4712c15e-9fc0-4679-a732-650e28ef71aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4712c15e-9fc0-4679-a732-650e28ef71aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfTranches_611fbda9-7a33-42d5-9ee9-2e95e5bffc0a" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentNumberOfTranches_611fbda9-7a33-42d5-9ee9-2e95e5bffc0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrincipalAndInterestTerm_f0791263-f8a2-41e1-b3f3-fc1c2712736b" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrincipalAndInterestTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPrincipalAndInterestTerm_f0791263-f8a2-41e1-b3f3-fc1c2712736b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_557da7d4-20b6-4e57-9793-5d7d5e102540" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_557da7d4-20b6-4e57-9793-5d7d5e102540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_8959b63c-80f4-43ee-b935-0ee110fca736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_8959b63c-80f4-43ee-b935-0ee110fca736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_e727293b-c8d0-467a-a5ad-e4c1ce9722f5" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_e727293b-c8d0-467a-a5ad-e4c1ce9722f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentBalloonPaymentWriteOff_3f2440dd-e5b2-4ad0-8bb5-626e29be5a26" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentBalloonPaymentWriteOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentBalloonPaymentWriteOff_3f2440dd-e5b2-4ad0-8bb5-626e29be5a26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_f73ecb99-4ce1-4c55-badd-701ee44d46e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_f73ecb99-4ce1-4c55-badd-701ee44d46e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_97ff23b0-1017-45c3-8006-e4fbc43bb179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_97ff23b0-1017-45c3-8006-e4fbc43bb179" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_595ca36c-c887-45e0-a65a-3eca3c11aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_595ca36c-c887-45e0-a65a-3eca3c11aaf0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_dbe62183-9515-4dff-8a0d-f51f75cf3f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_InterestExpenseDebt_dbe62183-9515-4dff-8a0d-f51f75cf3f6e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_9c68bfd3-7f55-4065-9828-301239ebfe64" xlink:href="inbx-20251231.xsd#inbx_AmortizationOfDebtDiscountPremiumAndAccretion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_9c68bfd3-7f55-4065-9828-301239ebfe64" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019b071b-de0c-708a-afd5-93d6191a73b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019b071b-de0c-708a-afd5-93d6191a73b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_019b071c-69d3-75d8-a9ca-6ffda534e64d" xlink:href="inbx-20251231.xsd#inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_019b071c-69d3-75d8-a9ca-6ffda534e64d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b071d-14d3-7209-a0a3-1cd0fc8b8875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b071d-14d3-7209-a0a3-1cd0fc8b8875" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b0722-1361-7248-9419-75faaae71aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b0722-1361-7248-9419-75faaae71aa9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_019b0723-c3fc-7ea1-b2f4-4507954ca429" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_019b0723-c3fc-7ea1-b2f4-4507954ca429" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtLiquidityThreshold_019cb461-7c02-725e-a092-16afb3de92c1" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtLiquidityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_LongTermDebtLiquidityThreshold_019cb461-7c02-725e-a092-16afb3de92c1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_019b0726-7b2a-765d-a842-7a62f28549e7" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_019b0726-7b2a-765d-a842-7a62f28549e7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019b0726-430a-7935-8adf-52eb9f694051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019b0726-430a-7935-8adf-52eb9f694051" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019b0729-7627-7e48-891d-41f4ba9f2080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019b0729-7627-7e48-891d-41f4ba9f2080" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b072a-011d-74f6-8920-8dcf880128bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b072a-011d-74f6-8920-8dcf880128bd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019b0727-5774-7926-8ea6-48ee42892610" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019b0727-5774-7926-8ea6-48ee42892610" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b072a-9738-77e7-80df-d500c15c08ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b072a-9738-77e7-80df-d500c15c08ae" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019b0727-b889-7b84-b52a-f14c2fc9da2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019b0727-b889-7b84-b52a-f14c2fc9da2d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_019b072b-4b15-7b95-9907-a244c406437c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_019b072b-4b15-7b95-9907-a244c406437c" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:to="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7113-b148-4d8470db689c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7113-b148-4d8470db689c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0710-80ee-7b2c-b0ad-0aac700cbf05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:to="loc_us-gaap_SecuredDebtMember_019b0710-80ee-7b2c-b0ad-0aac700cbf05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-7e7b-86d8-c74e8157e460_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-7e7b-86d8-c74e8157e460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b0710-80ee-705b-b172-e67c24bfb81c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:to="loc_us-gaap_LineOfCreditMember_019b0710-80ee-705b-b172-e67c24bfb81c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-7efa-a432-5021157b2f29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-7efa-a432-5021157b2f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7170-9c40-f12c4281bf33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7170-9c40-f12c4281bf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019b0710-80ee-76c7-8fd4-39072dd67df1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_LongTermDebt_019b0710-80ee-76c7-8fd4-39072dd67df1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:to="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-75ec-86fa-5f6ecba7d330_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-75ec-86fa-5f6ecba7d330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0710-a3a0-731a-903e-d2767d1a661b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:to="loc_us-gaap_SecuredDebtMember_019b0710-a3a0-731a-903e-d2767d1a661b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-7453-8357-9835e5f1b53c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-7453-8357-9835e5f1b53c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b0710-a3a0-7290-859b-155db65dbd29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:to="loc_us-gaap_LineOfCreditMember_019b0710-a3a0-7290-859b-155db65dbd29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7d33-817e-a9e936ce14eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7d33-817e-a9e936ce14eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-7d7b-beea-63be6c9c8065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-7d7b-beea-63be6c9c8065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-777a-80b2-4c52fb16de5b" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtMaturityAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-777a-80b2-4c52fb16de5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-767f-8459-6957df4b44a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-767f-8459-6957df4b44a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-a3a0-742e-a1c7-c351d25e886c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-a3a0-742e-a1c7-c351d25e886c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019b0710-a3a0-7835-82bc-e484c9d657ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebt_019b0710-a3a0-7835-82bc-e484c9d657ce" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1355aa1-becf-4907-84c9-119624bf23d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1355aa1-becf-4907-84c9-119624bf23d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b2e829eb-e6dc-41ce-8bec-3fa5beebe8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:to="loc_us-gaap_PrivatePlacementMember_b2e829eb-e6dc-41ce-8bec-3fa5beebe8a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_81fdb48a-bf7f-446d-98b0-44ac8add1205_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_81fdb48a-bf7f-446d-98b0-44ac8add1205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsPreFundedMember_557334d8-d7ac-4ab0-88db-7484cb7c20e9" xlink:href="inbx-20251231.xsd#inbx_WarrantsPreFundedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_WarrantsPreFundedMember_557334d8-d7ac-4ab0-88db-7484cb7c20e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member_2e09f81a-fb9b-4b6a-8fbb-5b60210c4267" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member_2e09f81a-fb9b-4b6a-8fbb-5b60210c4267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member_c93fa0b5-d30b-408c-b62f-cc5137f43326" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member_c93fa0b5-d30b-408c-b62f-cc5137f43326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_9c975714-4a86-42f1-8167-41953a08cd18" xlink:href="inbx-20251231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:to="loc_inbx_A2020OxfordTermLoansMember_9c975714-4a86-42f1-8167-41953a08cd18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-72d5-90cd-efc36f57626f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-72d5-90cd-efc36f57626f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0738-232d-755f-996b-ef00d26735ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:to="loc_us-gaap_SecuredDebtMember_019b0738-232d-755f-996b-ef00d26735ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b435a114-d548-42f4-a6db-15faac4ac01c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b435a114-d548-42f4-a6db-15faac4ac01c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2c8a71a5-9ed8-4c0f-86d3-bc8971ca4a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2c8a71a5-9ed8-4c0f-86d3-bc8971ca4a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_054c7f0a-d537-40b7-86bc-4c1c94b778e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_054c7f0a-d537-40b7-86bc-4c1c94b778e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_192af4d2-54a2-4fcc-8b30-80aeb8f4e554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_192af4d2-54a2-4fcc-8b30-80aeb8f4e554" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_839ec48f-a2bc-40ab-9b4e-90e08fb32e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_839ec48f-a2bc-40ab-9b4e-90e08fb32e69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatio_d7be7864-40cd-4631-b7cf-a3a7b8e62c05" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_MergerExchangeRatio_d7be7864-40cd-4631-b7cf-a3a7b8e62c05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a37b33df-2a3f-425c-8113-3854dd3e605d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesIssued_a37b33df-2a3f-425c-8113-3854dd3e605d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_5141553e-1ef9-4dbb-a854-7995488dcee9" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_MergerOwnershipPercentage_5141553e-1ef9-4dbb-a854-7995488dcee9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOrUnitsAvailableForDistributions_c01b91a1-29b3-4e28-90e4-36ae58a0f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOrUnitsAvailableForDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_StockOrUnitsAvailableForDistributions_c01b91a1-29b3-4e28-90e4-36ae58a0f7bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3c0c707-06b5-4407-9515-ba74f10df90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3c0c707-06b5-4407-9515-ba74f10df90f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1d3b6f50-16e9-42d5-9303-cc6cc3800ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1d3b6f50-16e9-42d5-9303-cc6cc3800ac9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8cb85bda-2a44-4b29-9738-86943d6ba80e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8cb85bda-2a44-4b29-9738-86943d6ba80e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_3aded936-c43c-40ac-9a3f-bd6cff639403" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_3aded936-c43c-40ac-9a3f-bd6cff639403" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6665578c-7540-44f3-bcee-dbeeb082381f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6665578c-7540-44f3-bcee-dbeeb082381f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised_f6204d4b-117c-4c52-b645-c49e417d9a5c" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantsOrRightsWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised_f6204d4b-117c-4c52-b645-c49e417d9a5c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_066ae19a-bc1c-4c3b-89da-52d06334b938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_066ae19a-bc1c-4c3b-89da-52d06334b938" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_ea9cc06e-a9da-4510-be62-9f1110c0d350" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_ea9cc06e-a9da-4510-be62-9f1110c0d350" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_524fb9e7-6975-4850-9303-5a3c3f03d23f" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_524fb9e7-6975-4850-9303-5a3c3f03d23f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_2e87b902-c31b-4786-8e90-b4996600f45c" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_2e87b902-c31b-4786-8e90-b4996600f45c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfTranches_d4ebd4c3-58c7-42ba-96e3-ae930b651677" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_DebtInstrumentNumberOfTranches_d4ebd4c3-58c7-42ba-96e3-ae930b651677" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_95a40c06-d932-416e-b2d5-54f59e57c54d" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_95a40c06-d932-416e-b2d5-54f59e57c54d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf596b0-8504-485d-bc55-f52d5a621a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf596b0-8504-485d-bc55-f52d5a621a40" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:to="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55d027af-3145-4a64-8ece-1e012c7b8546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55d027af-3145-4a64-8ece-1e012c7b8546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PreFundedWarrantsMember_54f4db6c-d948-416b-9bf4-0133bf90cde5" xlink:href="inbx-20251231.xsd#inbx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_inbx_PreFundedWarrantsMember_54f4db6c-d948-416b-9bf4-0133bf90cde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7009c336-ae01-4ce4-93ea-851defc98d95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_StockCompensationPlanMember_7009c336-ae01-4ce4-93ea-851defc98d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3bdf5837-f5a1-4cf5-b74e-c243a7892a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_WarrantMember_3bdf5837-f5a1-4cf5-b74e-c243a7892a29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_573a0c3e-8a0c-4ca3-a045-76cfe0537838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_573a0c3e-8a0c-4ca3-a045-76cfe0537838" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4251fe1-be22-4896-94e2-84710c6bfc7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4251fe1-be22-4896-94e2-84710c6bfc7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39c6ab55-3fa9-4bd2-ac3e-2e1f0a33f372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39c6ab55-3fa9-4bd2-ac3e-2e1f0a33f372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_07314d1d-ec22-4c42-98b7-3d8d40a85a94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:to="loc_us-gaap_PlanNameDomain_07314d1d-ec22-4c42-98b7-3d8d40a85a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:to="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Plan2017Member_78c6f728-1754-4cc6-aba8-c855355dbec3" xlink:href="inbx-20251231.xsd#inbx_Plan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_Plan2017Member_78c6f728-1754-4cc6-aba8-c855355dbec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b074f-23fa-7ce5-aee9-955d42f4c5e9" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_A2024PlanMember_019b074f-23fa-7ce5-aee9-955d42f4c5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2017PlanMember_019ce1a2-4f46-7c74-87ff-e2c657bf27e3" xlink:href="inbx-20251231.xsd#inbx_A2017PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_A2017PlanMember_019ce1a2-4f46-7c74-87ff-e2c657bf27e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c7276e51-647d-4eba-a146-96a985d58054_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:to="loc_us-gaap_VestingDomain_c7276e51-647d-4eba-a146-96a985d58054_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:to="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aae4fd69-21bb-444e-826e-2752802160bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aae4fd69-21bb-444e-826e-2752802160bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-70a1-83ff-e9544cc2d7fb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-70a1-83ff-e9544cc2d7fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraLicenseAgreementMember_019d056e-d799-748c-abad-13c3829ff456" xlink:href="inbx-20251231.xsd#inbx_ScitheraLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:to="loc_inbx_ScitheraLicenseAgreementMember_019d056e-d799-748c-abad-13c3829ff456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d056e-d799-784c-924d-31b950c783ca_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:to="loc_srt_ProductsAndServicesDomain_019d056e-d799-784c-924d-31b950c783ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:to="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_019d056e-d799-796b-aa12-4da61f25f3a5" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:to="loc_inbx_LicenseNonAffiliateMember_019d056e-d799-796b-aa12-4da61f25f3a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9a643bf3-6b9a-43b0-8e71-e3d9ac36a08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9a643bf3-6b9a-43b0-8e71-e3d9ac36a08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09efb4c1-ccf6-4e23-ab94-af30c159f5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09efb4c1-ccf6-4e23-ab94-af30c159f5d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0ff4eb2d-b58e-4cc2-978d-059698138aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0ff4eb2d-b58e-4cc2-978d-059698138aa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_377e05a7-41e8-476e-9636-ccd6f779202e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_377e05a7-41e8-476e-9636-ccd6f779202e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_a2d3ce02-e6da-44e9-b1fe-f13698785eb6" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_a2d3ce02-e6da-44e9-b1fe-f13698785eb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_963c7913-6a95-4e1a-8d9d-1738d4d57b4f" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_963c7913-6a95-4e1a-8d9d-1738d4d57b4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_031e7a76-dc54-4122-93db-1923e15c7541" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_031e7a76-dc54-4122-93db-1923e15c7541" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_8f7cb120-4c8b-4c14-97ab-a172f20c8f6a" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_8f7cb120-4c8b-4c14-97ab-a172f20c8f6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d225a391-0db0-4bd5-89ef-3fbfdf3deb60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d225a391-0db0-4bd5-89ef-3fbfdf3deb60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d056e-d799-7f95-94bb-03ec0b23f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d056e-d799-7f95-94bb-03ec0b23f10c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_7551149c-0b2d-4c96-ba1b-b59cdc5bc6db" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_7551149c-0b2d-4c96-ba1b-b59cdc5bc6db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b0740-c441-7bd7-a853-044bbc332a01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b0740-c441-7bd7-a853-044bbc332a01" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c7a1662e-4321-41cf-a5bb-aa1227bdaa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c7a1662e-4321-41cf-a5bb-aa1227bdaa9a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c7594bf-bf07-40b6-9f2d-c94e3a2621a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c7594bf-bf07-40b6-9f2d-c94e3a2621a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0baeb27-833f-41d7-8994-a2c2488dec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0baeb27-833f-41d7-8994-a2c2488dec2e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ebf84066-ed02-4b34-a8cf-816fd77452d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ebf84066-ed02-4b34-a8cf-816fd77452d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afb5aae2-a05d-4bfe-8aad-acd63da145c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afb5aae2-a05d-4bfe-8aad-acd63da145c7" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-7e07-82a2-2d9c37821dae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-7e07-82a2-2d9c37821dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b0748-3fdf-7eaf-8de0-f5623fd07292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b0748-3fdf-7eaf-8de0-f5623fd07292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-7f01-a7f2-c7afad69639c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-7f01-a7f2-c7afad69639c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b0748-3fdf-7fc9-8d50-f6a971cdb3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b0748-3fdf-7fc9-8d50-f6a971cdb3ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b0748-3fdf-734e-8ad3-04152657aa91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b0748-3fdf-734e-8ad3-04152657aa91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7808-a799-76eb72ebe659_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:to="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7808-a799-76eb72ebe659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:to="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b0748-3fdf-72e7-9113-dd7fa398418f" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:to="loc_inbx_A2024PlanMember_019b0748-3fdf-72e7-9113-dd7fa398418f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Plan2017Member_019b0773-38eb-76e6-ab0b-09222a123db3" xlink:href="inbx-20251231.xsd#inbx_Plan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:to="loc_inbx_Plan2017Member_019b0773-38eb-76e6-ab0b-09222a123db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b0748-3fdf-742d-b12a-d8b163213591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b0748-3fdf-742d-b12a-d8b163213591" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:to="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7ff1-85b7-781207d90c69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7ff1-85b7-781207d90c69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b0755-5d47-75e2-8712-e09c42c484e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b0755-5d47-75e2-8712-e09c42c484e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b0755-5d47-77dc-8828-620f38797eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b0755-5d47-77dc-8828-620f38797eb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b0755-5d47-7f13-8ef6-6b069995f58f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b0755-5d47-7f13-8ef6-6b069995f58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b0755-5d47-7b56-9110-8282be810f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b0755-5d47-7b56-9110-8282be810f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b0755-5d47-7e96-8d2f-50c7512820c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b0755-5d47-7e96-8d2f-50c7512820c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b0755-5d47-7708-87e7-d27a4125414c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b0755-5d47-7708-87e7-d27a4125414c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:to="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b074a-30bb-70ab-9d8a-34d834cf73b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:to="loc_us-gaap_PlanNameDomain_019b074a-30bb-70ab-9d8a-34d834cf73b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:to="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b074a-30bb-7ca7-865e-32ea6099da26" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:to="loc_inbx_A2024PlanMember_019b074a-30bb-7ca7-865e-32ea6099da26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-766b-a8cd-cd3825f8cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-766b-a8cd-cd3825f8cc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b074a-30bb-72c0-9e9d-a8282be2eb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b074a-30bb-72c0-9e9d-a8282be2eb33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b074a-30bb-7fed-8431-9d21b95702ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b074a-30bb-7fed-8431-9d21b95702ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019b074a-30bb-74e7-b3ae-553609c1dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019b074a-30bb-74e7-b3ae-553609c1dc55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-7a5d-bd7c-59416d0907ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019b074a-30bb-7892-b134-fedb8185fb07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019b074a-30bb-7892-b134-fedb8185fb07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7530-bbc8-fab6387a2f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7530-bbc8-fab6387a2f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b074a-30bb-7afe-95c0-41a30044eb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b074a-30bb-7afe-95c0-41a30044eb4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b074a-30bb-745d-b485-f746462fcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b074a-30bb-745d-b485-f746462fcd14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019b074a-30bb-7193-9dca-d1e897d12efa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019b074a-30bb-7193-9dca-d1e897d12efa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7d8c-ad48-5a1a4f7e3109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019b074a-30bb-7906-ad5e-53f8308e5597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019b074a-30bb-7906-ad5e-53f8308e5597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b074a-30bb-76a5-9b4b-c555deb7c886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b074a-30bb-76a5-9b4b-c555deb7c886" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b074a-30bb-7201-8d9f-12eacaeab0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b074a-30bb-7201-8d9f-12eacaeab0b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019b074a-30bb-710f-bac6-a4286261c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019b074a-30bb-710f-bac6-a4286261c2af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019b074a-30bb-7b75-b453-184c92ddcfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019b074a-30bb-7b75-b453-184c92ddcfea" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUEScheduleofTotalRevenueDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:to="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_317eaa1d-c5b6-4ebc-9043-c8852956a8f8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:to="loc_srt_ProductsAndServicesDomain_317eaa1d-c5b6-4ebc-9043-c8852956a8f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:to="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_c58ee50c-1fd0-4133-b06f-05e7e0ff9553" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:to="loc_inbx_LicenseNonAffiliateMember_c58ee50c-1fd0-4133-b06f-05e7e0ff9553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:to="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:to="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraInc.Member_019b0743-4d3d-7629-84fa-f9ef4a01e696" xlink:href="inbx-20251231.xsd#inbx_ScitheraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:to="loc_inbx_ScitheraInc.Member_019b0743-4d3d-7629-84fa-f9ef4a01e696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RegeneronPharmaceuticalsInc.Member_2018dec8-23e8-444f-b993-b38417f1757c" xlink:href="inbx-20251231.xsd#inbx_RegeneronPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:to="loc_inbx_RegeneronPharmaceuticalsInc.Member_2018dec8-23e8-444f-b993-b38417f1757c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06347ba1-639d-41d9-a5c5-1a6317897adb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:to="loc_us-gaap_Revenues_06347ba1-639d-41d9-a5c5-1a6317897adb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUENarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/LICENSEREVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_92a84aa9-e289-4c10-95e0-028c2acfebb3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:to="loc_srt_NameOfMajorCustomerDomain_92a84aa9-e289-4c10-95e0-028c2acfebb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:to="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_bca1e79f-2765-4a1b-83bc-c88f713dffb6" xlink:href="inbx-20251231.xsd#inbx_A2seventyBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_A2seventyBioIncMember_bca1e79f-2765-4a1b-83bc-c88f713dffb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RegeneronPharmaceuticalsInc.Member_39c80992-c30a-4d16-adcd-229ef58912e1" xlink:href="inbx-20251231.xsd#inbx_RegeneronPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_RegeneronPharmaceuticalsInc.Member_39c80992-c30a-4d16-adcd-229ef58912e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraLicenseAgreementMember_019d0585-1d50-77a4-ba44-8fc7310ae3e4" xlink:href="inbx-20251231.xsd#inbx_ScitheraLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_ScitheraLicenseAgreementMember_019d0585-1d50-77a4-ba44-8fc7310ae3e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_413124fd-73ec-425c-96f6-ac4d2d19d41e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:to="loc_srt_ProductsAndServicesDomain_413124fd-73ec-425c-96f6-ac4d2d19d41e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:to="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_04eecce2-0807-4035-9f90-b3734043694d" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:to="loc_inbx_LicenseNonAffiliateMember_04eecce2-0807-4035-9f90-b3734043694d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58021c47-1869-46f4-94ab-bb6143a1bd53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58021c47-1869-46f4-94ab-bb6143a1bd53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_480d18b3-5197-47cd-ae7e-c46588de0692" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_480d18b3-5197-47cd-ae7e-c46588de0692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_a6947fdf-a723-46d2-b0e0-2ae006db1f72" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_a6947fdf-a723-46d2-b0e0-2ae006db1f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundablePayment_019b074d-e3e3-7d54-966d-8eabbd6a6b68" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundablePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementNonrefundablePayment_019b074d-e3e3-7d54-966d-8eabbd6a6b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MaximumPotentialMilestonePayments_019b074d-e3e3-7a39-b91e-3254f821c7fa" xlink:href="inbx-20251231.xsd#inbx_MaximumPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_MaximumPotentialMilestonePayments_019b074d-e3e3-7a39-b91e-3254f821c7fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_019b074d-e3e3-7ce7-85e6-6969bed70498" xlink:href="inbx-20251231.xsd#inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_019b074d-e3e3-7ce7-85e6-6969bed70498" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_019b074d-e3e3-7fd0-846d-489fb9e6f720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_019b074d-e3e3-7fd0-846d-489fb9e6f720" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d0585-1d50-7618-a52e-356b2426d766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d0585-1d50-7618-a52e-356b2426d766" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_019b074e-1e01-7f59-b460-89c7a7f9dd11" xlink:href="inbx-20251231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_019b074e-1e01-7f59-b460-89c7a7f9dd11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_019b074e-6e68-7655-b19c-a4433c06835b" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_019b074e-6e68-7655-b19c-a4433c06835b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_019b074e-6e68-740a-94ec-985967e55a39" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_019b074e-6e68-740a-94ec-985967e55a39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019b074e-6e68-7dca-86f3-c4711b551549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019b074e-6e68-7dca-86f3-c4711b551549" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019b074e-6e68-7d7e-b2d0-82b646626eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_Revenues_019b074e-6e68-7d7e-b2d0-82b646626eb2" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_01cf9d96-ab73-4570-b794-b825b4fab555" xlink:href="inbx-20251231.xsd#inbx_ServicesPerformedUnderTransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:to="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_01cf9d96-ab73-4570-b794-b825b4fab555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SeverancePaymentsToFormerEmployeesMember_7ddb57db-5d73-4464-915d-b04f7c29033f" xlink:href="inbx-20251231.xsd#inbx_SeverancePaymentsToFormerEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:to="loc_inbx_SeverancePaymentsToFormerEmployeesMember_7ddb57db-5d73-4464-915d-b04f7c29033f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f6ba5f43-005a-486e-88b0-e52ff8f2c728_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:to="loc_us-gaap_RelatedPartyDomain_f6ba5f43-005a-486e-88b0-e52ff8f2c728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:to="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ece2e4a7-60c5-4285-a1bc-53146d78933a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:to="loc_us-gaap_RelatedPartyMember_ece2e4a7-60c5-4285-a1bc-53146d78933a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatioProRateBasisPercentage_62d6f155-daa4-4196-859d-7cf81adcd0ea" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatioProRateBasisPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_inbx_MergerExchangeRatioProRateBasisPercentage_62d6f155-daa4-4196-859d-7cf81adcd0ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_eedda25d-ba57-45ae-b396-f85a600931a0" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_inbx_MergerOwnershipPercentage_eedda25d-ba57-45ae-b396-f85a600931a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOrUnitsAvailableForDistributions_6a90c784-19fe-44d5-895d-c357fd5572ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOrUnitsAvailableForDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_StockOrUnitsAvailableForDistributions_6a90c784-19fe-44d5-895d-c357fd5572ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0087cf24-516b-46a6-a255-3399bd1227ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0087cf24-516b-46a6-a255-3399bd1227ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db0fbfdd-99f1-463d-aefc-a5ff7f7c0f09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db0fbfdd-99f1-463d-aefc-a5ff7f7c0f09" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b1c1e678-f6a0-48ad-9886-08ac2a44699e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b1c1e678-f6a0-48ad-9886-08ac2a44699e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019d515a-6438-46c7-b2fd-ced1b053799e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:to="loc_us-gaap_DomesticCountryMember_019d515a-6438-46c7-b2fd-ced1b053799e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_30a9f32a-3fef-4d04-9251-52a15e6ab941" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_30a9f32a-3fef-4d04-9251-52a15e6ab941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_881613b0-7def-4298-9db5-8c48350c7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_881613b0-7def-4298-9db5-8c48350c7b92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0b6736f7-6419-4450-bdd7-b89ff8179d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0b6736f7-6419-4450-bdd7-b89ff8179d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6d1f4a33-61ab-4279-9944-631fb24d4919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6d1f4a33-61ab-4279-9944-631fb24d4919" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5124de83-117c-44bc-8bd0-36523629e17d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5124de83-117c-44bc-8bd0-36523629e17d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_18fcde54-9f78-40ad-96de-98262f33c16f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:to="loc_us-gaap_CreditFacilityDomain_18fcde54-9f78-40ad-96de-98262f33c16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:to="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_07217f95-13d5-4d4b-83ee-bb451d8bf259" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:to="loc_us-gaap_SecuredDebtMember_07217f95-13d5-4d4b-83ee-bb451d8bf259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OxfordTermLoansMember_12c544dd-da3d-46a5-be71-c775230e5333" xlink:href="inbx-20251231.xsd#inbx_OxfordTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:to="loc_inbx_OxfordTermLoansMember_12c544dd-da3d-46a5-be71-c775230e5333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2025LoanAgreementMember_019cdda2-a3a5-793f-8775-f7d5d5ef592e" xlink:href="inbx-20251231.xsd#inbx_A2025LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:to="loc_inbx_A2025LoanAgreementMember_019cdda2-a3a5-793f-8775-f7d5d5ef592e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ea6a67a-b87d-4744-8734-f2cf9864f7b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ea6a67a-b87d-4744-8734-f2cf9864f7b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6414392d-4c4a-41e5-a494-1145d569b7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:to="loc_us-gaap_LineOfCreditMember_6414392d-4c4a-41e5-a494-1145d569b7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cdda2-a3a5-7941-b9f0-8ee99225513f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:to="loc_us-gaap_SecuredDebtMember_019cdda2-a3a5-7941-b9f0-8ee99225513f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b89ffedc-328c-45bc-8d38-05455cfabe3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b89ffedc-328c-45bc-8d38-05455cfabe3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37fc497d-06c4-469a-879b-34c05958a976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:to="loc_us-gaap_SubsequentEventMember_37fc497d-06c4-469a-879b-34c05958a976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_debb40c7-b40e-4600-ba60-e089303d1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_debb40c7-b40e-4600-ba60-e089303d1b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3828ef86-3fc0-4cf9-96c4-2a006823f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3828ef86-3fc0-4cf9-96c4-2a006823f08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtLiquidityThreshold_019cdda2-a3a5-7875-8993-78c22e336f22" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtLiquidityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_inbx_LongTermDebtLiquidityThreshold_019cdda2-a3a5-7875-8993-78c22e336f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019d0562-e462-7d34-b3f7-d2136db82375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019d0562-e462-7d34-b3f7-d2136db82375" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d0563-c9b7-7327-95b2-d15270b68fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d0563-c9b7-7327-95b2-d15270b68fb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_cb97a1d0-d6e0-4ecd-8dee-ae9642279f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_cb97a1d0-d6e0-4ecd-8dee-ae9642279f1e" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>inbx-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_inbx_DebtInstrumentNumberOfTranches_32c593c7-3d77-40da-8a8f-0fbd95a49b5b_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_inbx_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfTranches" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentNumberOfTranches" xlink:to="lab_inbx_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e6e4b8f5-27f8-421d-9872-fda7ff54cbf2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RegeneronPharmaceuticalsInc.Member_c4d4835c-946c-4565-b3c3-459faeb76825_terseLabel_en-US" xlink:label="lab_inbx_RegeneronPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_inbx_RegeneronPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_inbx_RegeneronPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_inbx_RegeneronPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_inbx_RegeneronPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RegeneronPharmaceuticalsInc.Member" xlink:href="inbx-20251231.xsd#inbx_RegeneronPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RegeneronPharmaceuticalsInc.Member" xlink:to="lab_inbx_RegeneronPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_0e3a4eaf-f144-4de7-8794-e1571e91138d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d0dc15e2-3a33-4782-82f4-c971e9e8dfa3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d15a3c84-83af-47dd-a229-425aa8aa5c5a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_27ba9620-9715-4000-a59e-18bbbd47cefc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ddada874-4d98-442e-bc12-5c2fb2680c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized related to performance obligation</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_11d586ae-4285-4a5d-8566-d439a01f9283_terseLabel_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_inbx_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_inbx_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense" xlink:href="inbx-20251231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NoncashOperatingLeaseExpense" xlink:to="lab_inbx_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_1a4e61a1-6245-441b-8172-8139c2b75117_terseLabel_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, right per share, contingency</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_label_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_documentation_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:to="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c5886254-79fc-4181-817b-8461028b23d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_91f2d515-1f19-4451-a6a3-f50749181bfc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_d2b618ee-e40f-45f8-8d81-a8f8012c73f5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">R&amp;D credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_ae56c047-675f-49f1-996d-9e7ff7509ed3_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future equity grants</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_37b50758-d9e7-41b6-803f-3e18b6087a73_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d56663e8-9c74-4bf2-8992-abf8ae96089a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon exercise of warrants, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1d057c0f-218b-4f0e-bc4e-8d71d8af1ebb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ff633542-6fa5-4161-b27e-1b7021246386_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_929b2aea-17a1-4acb-93c0-bfe511bd6d97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_019b074d-e3e3-7c7d-9489-00974607143e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to performance obligation</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_401809b9-2cb7-477e-81fb-f1f496e1ec17_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_8e8b4cbf-8bc6-4efb-96c5-a20b00dc3149_terseLabel_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3)</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_label_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:label id="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_documentation_en-US" xlink:label="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:href="inbx-20251231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:to="lab_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1fb30fea-c7c6-4e32-99f4-38ba65accae1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ReportableSegmentMember_43fea6b1-eaea-479e-a61f-4e21a633cd7e_terseLabel_en-US" xlink:label="lab_inbx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_inbx_ReportableSegmentMember_label_en-US" xlink:label="lab_inbx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_inbx_ReportableSegmentMember_documentation_en-US" xlink:label="lab_inbx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReportableSegmentMember" xlink:href="inbx-20251231.xsd#inbx_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ReportableSegmentMember" xlink:to="lab_inbx_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing_85c0d3da-e725-4044-abbb-b189beeb9001_terseLabel_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing_label_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Contract Manufacturing</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing_documentation_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseContractManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:to="lab_inbx_ResearchAndDevelopmentExpenseContractManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_50d3c419-8a86-4977-8af8-e9588ffc4527_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_85a18b66-790f-4d54-a38b-f8fcae9a5e0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_a99b60a8-edb2-4d39-8671-bc5d06774fbe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b5e27083-f793-44cc-9aac-faf95c57de20_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_43f56093-4dad-4a91-9c92-04902d5a2ed8_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0086af9a-1cf5-45c9-91ee-ce46abb0dfd3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_0c851944-c5b8-456f-b321-ab8032659682_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other general and administrative</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38bb317c-82a6-4a5f-b9e6-767814ae19f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9079b6f4-273c-4975-9c4a-aa701fef4349_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Research and Development and Clinical Trial Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ceab9cc2-daad-4c88-a2c0-08bd5e183474_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-73de-9390-281d8248cd71_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_7d3a2457-7583-46bc-a3d3-e4478bf6b7e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment terms, final payment amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b9c26fda-7f92-43c0-bea0-7a32c485bce5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_26f8cd5b-80b4-46cc-b299-1df10db52709_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e5de96c5-7836-46db-a247-0792bb77a668_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_042ed622-3e1b-4f8f-82cc-a29e6f7545dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6307ace4-87f5-477a-b29c-48b4e5c9d769_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b1fd039d-384c-4a35-9c9e-1b1ffd898558_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0881fa7e-8fa3-42bf-aec5-2cb9311236d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_072c96b2-0d76-4759-9240-8068389027c9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares in Distribution (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0d915c88-1fa1-4d83-a6d8-78a2121993e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_290fe454-3aaa-47a2-adeb-da512a178b82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8914ae44-98f8-47c2-a3f8-bbc896fb8f56_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c60a4109-7cee-47a3-8765-4f397af48e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4ac3c634-bded-4b83-a073-eba8b00d35b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_4554d05d-5e4b-4c9b-80e4-1d5e41bba4f7_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrefundable, upfront payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:to="lab_inbx_CollaborativeArrangementNonrefundableUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dfa6aa4f-718e-4d0c-bb6d-66c98f767d4e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_7937c154-ebad-4029-afb5-6ce3eb80bd7e_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_dd112a53-9cdc-4a1f-8fba-d521a3caad84_terseLabel_en-US" xlink:label="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3a54466e-4a22-4c68-856f-f19f5cb2c39e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_c7bc38d1-e8e4-404c-ab88-38fbe0d19fba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a6e4a099-9aec-4cfd-905e-ff422ef6d879_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_85691853-0dd1-41b7-9988-7a41aebef35d_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ba8b60a4-d786-4c6d-8391-6a5fb887c731_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_d981fba0-6324-4acc-a807-beb8df47ba7b_terseLabel_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment, depreciation, and facility</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_label_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Equipment, Depreciation, And Facility</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_documentation_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Equipment, Depreciation, And Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:to="lab_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScheduleOfMergerTransactionTableTextBlock_9eaddb12-b34b-49b3-b309-2395e46d16f6_terseLabel_en-US" xlink:label="lab_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Merger Transaction</link:label>
    <link:label id="lab_inbx_ScheduleOfMergerTransactionTableTextBlock_label_en-US" xlink:label="lab_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Merger Transaction [Table Text Block]</link:label>
    <link:label id="lab_inbx_ScheduleOfMergerTransactionTableTextBlock_documentation_en-US" xlink:label="lab_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Merger Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfMergerTransactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:to="lab_inbx_ScheduleOfMergerTransactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c125e473-77bd-4471-8543-a89a75076194_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_cb03bf2e-a23d-47eb-94c3-8188274a469b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4187e007-04e0-45e5-93be-c43dd7bb31e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_e19ff1d8-aae3-4262-8e17-c68de7d96125_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled, threshold exercise price (in dollars per share)</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Cancelled, Threshold Exercise Price</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Cancelled, Threshold Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:to="lab_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_8a011ab8-1492-4010-a6b5-9e51111bdbf2_terseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">336(e) election</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 336(e) Election, Amount</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 336(e) Election, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_892be9b8-24b2-4e8c-9944-2681dfd24285_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4620cfce-b5da-432c-a78b-c0b56125bef5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsPreFundedMember_5abd10c3-8aa8-4825-8494-9a592109fd9b_terseLabel_en-US" xlink:label="lab_inbx_WarrantsPreFundedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, Pre-Funded</link:label>
    <link:label id="lab_inbx_WarrantsPreFundedMember_label_en-US" xlink:label="lab_inbx_WarrantsPreFundedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Pre-Funded [Member]</link:label>
    <link:label id="lab_inbx_WarrantsPreFundedMember_documentation_en-US" xlink:label="lab_inbx_WarrantsPreFundedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Pre-Funded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsPreFundedMember" xlink:href="inbx-20251231.xsd#inbx_WarrantsPreFundedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsPreFundedMember" xlink:to="lab_inbx_WarrantsPreFundedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_090923a4-0b32-4533-afcb-76f6ecaffb26_terseLabel_en-US" xlink:label="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage, increase during period (as a percent)</link:label>
    <link:label id="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_label_en-US" xlink:label="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period</link:label>
    <link:label id="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_documentation_en-US" xlink:label="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:href="inbx-20251231.xsd#inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:to="lab_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScitheraLicenseAgreementMember_019d056e-d799-762a-8949-f40f40ea19ba_terseLabel_en-US" xlink:label="lab_inbx_ScitheraLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scithera License Agreement</link:label>
    <link:label id="lab_inbx_ScitheraLicenseAgreementMember_label_en-US" xlink:label="lab_inbx_ScitheraLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scithera License Agreement [Member]</link:label>
    <link:label id="lab_inbx_ScitheraLicenseAgreementMember_documentation_en-US" xlink:label="lab_inbx_ScitheraLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scithera License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraLicenseAgreementMember" xlink:href="inbx-20251231.xsd#inbx_ScitheraLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScitheraLicenseAgreementMember" xlink:to="lab_inbx_ScitheraLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019b0691-1197-78fc-bc39-fc9b117494ce_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_adf7df03-14dd-49fb-97f3-a66087c93ecb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_019b0723-c3fc-7016-bba7-bd98f886a018_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of principal amount for final payment</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_label_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:to="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_72ff800a-92d0-490f-ad0e-10a50bb89f51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_96f488ad-e482-4719-b9a0-0698db306ffd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9bdfa46c-cbda-477c-be42-bece09f23db5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining term of operating lease (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_4a13860a-3aec-495f-9aa2-b5e8718dd50b_terseLabel_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_inbx_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_inbx_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LiquidityPolicyTextBlock" xlink:href="inbx-20251231.xsd#inbx_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LiquidityPolicyTextBlock" xlink:to="lab_inbx_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_43613862-08fb-456b-8e10-e72bc0887a29_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member_987c1b0b-a4be-47c9-b8c1-193089ec36f4_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 1</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 1 [Member]</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:to="lab_inbx_ClassOfWarrantOrRightExpirationDate1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_MergerConsiderationMember_7ccbb38c-d289-4d8e-865b-2a2946f7b838_terseLabel_en-US" xlink:label="lab_inbx_MergerConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger consideration for common stock, warrants, and stock options</link:label>
    <link:label id="lab_inbx_MergerConsiderationMember_label_en-US" xlink:label="lab_inbx_MergerConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger Consideration [Member]</link:label>
    <link:label id="lab_inbx_MergerConsiderationMember_documentation_en-US" xlink:label="lab_inbx_MergerConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerConsiderationMember" xlink:href="inbx-20251231.xsd#inbx_MergerConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_MergerConsiderationMember" xlink:to="lab_inbx_MergerConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019cd3a7-e1fb-7ba9-b4c9-a0e889ae0ba4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019cb47a-7d2f-7909-894c-780fdc83ff64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d76fa714-c8bd-4a57-aaa9-07d6051ac09c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_5ad5408e-fca7-4dc1-a706-6c46212a3cfa_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_baac1ea1-c03e-4612-9ecf-ff958cf31c3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_bb69ac5b-f967-4b0c-aa95-279d22c814f9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e99e0f37-bde5-44b4-a38a-704f1a1091b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7074f67f-4a56-47b8-ae2b-f6018f0e3d26_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f99efadc-bb5b-4cdb-a24e-a04fed66c15e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_405448c4-8ac0-4dda-b356-1f0812ef3148_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (in shares)</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights1</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:to="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_eb269c5e-bbde-4c6b-b961-544a43108eea_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3ecea95b-6808-4f5f-9849-ab0810562a60_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1c6169e2-114a-4a9c-bc31-4b3199206923_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, including debt discount and final payment fee</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_020175fa-94b2-4897-afb1-cdce0cf46fa4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_94e63277-62fd-447d-804c-f9cd4ffa82e5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_aa5c5817-77bd-4ff1-9338-ed6cf4ef8239_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4f482db7-b535-4111-8a67-dd2fe7fe0ab0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_64cae40a-e59d-421f-8560-1217ac9c090f_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a37a4fe0-dc19-4684-ab2a-2ebeb5b46ea4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Stock-Based Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_efdc25fa-f538-4766-9156-84fba5fc4e9e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent_86a62feb-6041-474b-b534-122f40d6a269_terseLabel_en-US" xlink:label="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent_label_en-US" xlink:label="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trails, Prepaid Expense Current</link:label>
    <link:label id="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent_documentation_en-US" xlink:label="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trails, Prepaid Expense Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:href="inbx-20251231.xsd#inbx_ClinicalTrailsPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:to="lab_inbx_ClinicalTrailsPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_4cd3d093-dbd9-484f-b649-bfbfbe8cf0f5_terseLabel_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share, contingency (in dollars per share)</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_label_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_documentation_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:to="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" xlink:to="lab_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019cb483-c6b1-70f8-ae62-e2ed337dbc7f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_baec446b-a29e-469d-aaed-dd9dd3d9b1f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_019b071c-69d3-78ab-871a-3831aef5ed37_terseLabel_en-US" xlink:label="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility maximum borrowing capacity accordion feature</link:label>
    <link:label id="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_label_en-US" xlink:label="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility Maximum Borrowing Capacity Accordion Feature</link:label>
    <link:label id="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_documentation_en-US" xlink:label="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line Of Credit Facility Maximum Borrowing Capacity Accordion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:href="inbx-20251231.xsd#inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:to="lab_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a8484487-bf5c-499a-958a-ec46f8921fe8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_48d3f924-ff87-4d33-9460-4b812d42f6bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9a09eb55-344c-4f2f-aac6-02c5b904dd85_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_177c8679-13ba-4c33-a257-434e029ebef3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expenses</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_8cd208b0-2822-4929-804a-96313142782d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets after valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_9602bbe6-9651-46bb-ba1a-74e8182c3337_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_label_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrepaymentFee_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPrepaymentFee" xlink:to="lab_inbx_DebtInstrumentPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a1e88f33-fbb7-400e-b2cf-5a901d280f20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_bb444abf-a326-46c8-a77c-ace063759e0b_terseLabel_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease, by Balance Sheet Location</link:label>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_label_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability [Table Text Block]</link:label>
    <link:label id="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset And Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:href="inbx-20251231.xsd#inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:to="lab_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_2e93ba13-79db-49f6-9021-29f298da00d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundablePayment_019b074c-2e42-7d12-ae11-1f1d15103e21_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundablePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrefundable, payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundablePayment_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundablePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Payment</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementNonrefundablePayment_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementNonrefundablePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Nonrefundable Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundablePayment" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundablePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementNonrefundablePayment" xlink:to="lab_inbx_CollaborativeArrangementNonrefundablePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9af39e91-6e42-4176-9011-94280d8954bd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d2f71d66-a4ae-40ac-b367-fac5b387d255_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_ec05c03e-527d-4a92-be9b-2c73c1b43a47_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_50eb1bba-ee87-4508-8aed-5d54025b8f57_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued and outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6863126c-8d26-400d-8731-625efddb92dc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8847a17-9b33-4415-af68-794e66735391_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_de5a1a58-4e04-4ce3-8bce-242b3910db4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ffa21eea-eecd-4070-96c8-d4b94a469604_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_29d9a4db-3330-4567-bc3f-861c793026f5_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_46eed3b4-3e46-4297-a13e-1f3afa4390c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax expense, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_25b36a61-55d5-4ee5-b2d1-3c26d0f7ef1a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_f2499f45-678b-4a77-bc5a-5dcfcf607502_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c12d42ea-b2f1-40e7-868a-7ec2e91e3c18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aef44ac5-12b7-486e-ab3e-2ff9fd4b007e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_26499c84-f6e2-4760-ba6e-e476ce61237d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8aa792e7-47ce-4c39-9e28-d24bc26d530d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8aa4e5a8-bd9c-4723-a637-4f559d460293_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d5ca32f0-ba6c-42dc-b718-32d0e7cae5c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionTypeDomain_59ef22fc-5f4c-4ac3-8e25-b6e7dc472d62_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionTypeDomain_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="lab_us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_102d3773-fbd8-42a0-ad6d-1267760973af_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d1f5c4a-3c3d-4939-a199-84e749617cc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f02bbad9-27b9-4a5b-82d8-e6a9bffa7f27_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_889eec5f-1228-4cf1-b8b0-51e57f25f60c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_59af96ac-c66b-44b7-9e90-653fbda58465_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee5d80be-ae5d-4f89-b4bf-cbd243bb2dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_51508e60-605e-499f-a1ca-815e6638a470_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c25ff5fc-7b1e-44b0-926a-3d9165c06814_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_83739bdc-61fd-43f7-a952-b6e431623f50_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9dcd4f15-ffde-4ddd-bc7b-b82f17ae64ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LoansAssumedByAcquirerMember_791d8c60-507c-4a8f-8696-880c8153d60e_terseLabel_en-US" xlink:label="lab_inbx_LoansAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book value of Amended 2020 Loans assumed by Acquirer</link:label>
    <link:label id="lab_inbx_LoansAssumedByAcquirerMember_label_en-US" xlink:label="lab_inbx_LoansAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Assumed By Acquirer [Member]</link:label>
    <link:label id="lab_inbx_LoansAssumedByAcquirerMember_documentation_en-US" xlink:label="lab_inbx_LoansAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans Assumed By Acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LoansAssumedByAcquirerMember" xlink:href="inbx-20251231.xsd#inbx_LoansAssumedByAcquirerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LoansAssumedByAcquirerMember" xlink:to="lab_inbx_LoansAssumedByAcquirerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019b0727-b889-7027-9558-4f7b721c4afd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_be05a628-21e5-4ad8-a260-a65a745f81c9_terseLabel_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_label_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_documentation_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:to="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_df5738eb-9066-4ff2-a3fd-085988ce1883_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e6b0cb9e-b719-4656-8877-4a9ede3acfeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5ab858d-60ed-4fda-a2ee-6cd1a4606db2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_abafd577-70e4-45ca-8e77-fb04886fec32_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9428536a-c9e0-4ba1-9f46-31e00219139e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e7f68a70-102c-40da-9908-9af7f60b097a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4873c7d1-1e5d-46a5-95c4-5419300e55a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7a73cfae-be20-4bd3-a221-3eb6386842f4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_87f10a57-7d87-4fbe-95f6-6e9d61154e09_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_92cd559c-8261-45ec-bb8e-847cc1489ccb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c4cad671-ae15-45b7-83b7-594074efcae9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6fd5d6e0-9e94-43f5-8840-e728655537eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_479c3dbe-f1c5-4612-a429-ebe08a8bec74_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_c1279d8d-a5a9-4e0f-929f-d28003188f21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_f86ed66b-b711-445e-9fb4-1a85970c84de_terseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6dad1805-a26f-4fa0-b9a2-76543f98f189_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6b45a7ed-2756-42dc-a8eb-2ab4e35d0310_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_TransactionCostsPaidByAcquirerMember_47771671-4a76-4c31-a834-5489416854ca_terseLabel_en-US" xlink:label="lab_inbx_TransactionCostsPaidByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs paid by Acquirer</link:label>
    <link:label id="lab_inbx_TransactionCostsPaidByAcquirerMember_label_en-US" xlink:label="lab_inbx_TransactionCostsPaidByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs Paid By Acquirer [Member]</link:label>
    <link:label id="lab_inbx_TransactionCostsPaidByAcquirerMember_documentation_en-US" xlink:label="lab_inbx_TransactionCostsPaidByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Costs Paid By Acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TransactionCostsPaidByAcquirerMember" xlink:href="inbx-20251231.xsd#inbx_TransactionCostsPaidByAcquirerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_TransactionCostsPaidByAcquirerMember" xlink:to="lab_inbx_TransactionCostsPaidByAcquirerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9fc30722-17c3-45c6-b2a0-6108f48d531d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7c8012fe-d937-4077-b7c0-df802a99493f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_60438aa3-9a22-4f8d-a49c-dcaeb51caa39_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_5d692f4d-ca30-440b-9dd5-b2f7d46356c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits (FIN 48)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2seventyBioIncMember_26944dc3-e2dd-4f11-989b-59059504284d_terseLabel_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2seventy bio, Inc.</link:label>
    <link:label id="lab_inbx_A2seventyBioIncMember_label_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2seventy bio, Inc. [Member]</link:label>
    <link:label id="lab_inbx_A2seventyBioIncMember_documentation_en-US" xlink:label="lab_inbx_A2seventyBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2seventy bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember" xlink:href="inbx-20251231.xsd#inbx_A2seventyBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2seventyBioIncMember" xlink:to="lab_inbx_A2seventyBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_efa81043-f06b-45a6-8456-7a5ac510226a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c1757747-642d-4b39-9620-50888cda6afb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3aae1187-4b72-4b46-aeb9-0aa25cfde302_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3fdb1855-b0a6-4457-a27d-08450534b32b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PreFundedWarrantsMember_227a50ee-512c-4d6a-b416-597c675bc738_terseLabel_en-US" xlink:label="lab_inbx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants issued and outstanding</link:label>
    <link:label id="lab_inbx_PreFundedWarrantsMember_label_en-US" xlink:label="lab_inbx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_inbx_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_inbx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PreFundedWarrantsMember" xlink:href="inbx-20251231.xsd#inbx_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PreFundedWarrantsMember" xlink:to="lab_inbx_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_863f72c9-7971-4f9e-b228-f78230b9c1ea_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_e1befe6f-1306-4850-b4d5-a032d6fb1388_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_34bcd18b-b6c3-4242-a819-01734c249272_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_48a510c0-f11c-43a3-a7c0-66f2de4f1c08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d71d5532-d279-4789-ab1b-d0e1a83660a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1fb943e0-7fed-4730-9c13-8a63dae78415_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OperatingLeaseAbatementPeriodAmount_40bf0cb7-500b-4a23-ac48-fbccb72a4305_terseLabel_en-US" xlink:label="lab_inbx_OperatingLeaseAbatementPeriodAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, abatement period amount</link:label>
    <link:label id="lab_inbx_OperatingLeaseAbatementPeriodAmount_label_en-US" xlink:label="lab_inbx_OperatingLeaseAbatementPeriodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Abatement Period Amount</link:label>
    <link:label id="lab_inbx_OperatingLeaseAbatementPeriodAmount_documentation_en-US" xlink:label="lab_inbx_OperatingLeaseAbatementPeriodAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Abatement Period Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeaseAbatementPeriodAmount" xlink:href="inbx-20251231.xsd#inbx_OperatingLeaseAbatementPeriodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OperatingLeaseAbatementPeriodAmount" xlink:to="lab_inbx_OperatingLeaseAbatementPeriodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_099e1b0b-19e6-4338-bfc7-c35d39a996c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c4b7d4df-7834-4d71-823a-b7e41613554d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0f3ccd80-5374-4691-b663-6e45a9fcee5e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a7702aa0-7cdb-42c0-bec5-6d5313242334_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_c4363a71-577e-4e71-91a0-9eda19fcab52_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3f142e1d-d949-4b12-93d9-57a46b3649a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_21ef9251-8aca-4106-a03d-17c9e26d57cc_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_2748c73f-7a35-4095-9bdf-8fb92ab31005_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_12ec4ffd-0c30-4a18-9681-4299834b1634_terseLabel_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other outside research and development</link:label>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_label_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outside Research And Development, Other, Current</link:label>
    <link:label id="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Outside Research And Development, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:href="inbx-20251231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:to="lab_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_6ffc6f71-afca-417c-b8cf-26889e631f5c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised_3214c99b-2021-4bf9-b1d7-f83c235c9cb3_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised_label_en-US" xlink:label="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights, Warrants Exercised</link:label>
    <link:label id="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantsOrRightsWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:to="lab_inbx_ClassOfWarrantsOrRightsWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_45e6edf8-bb9a-4806-b575-763bb87590e3_terseLabel_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_label_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phylaxis BioScience, LLC [Member]</link:label>
    <link:label id="lab_inbx_PhylaxisBioScienceLLCMember_documentation_en-US" xlink:label="lab_inbx_PhylaxisBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phylaxis BioScience, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember" xlink:href="inbx-20251231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PhylaxisBioScienceLLCMember" xlink:to="lab_inbx_PhylaxisBioScienceLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_6f7973a4-bf62-4822-add8-921fd210e5b0_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercise period</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4203eb89-4ddf-436c-83b9-8bdd2e803300_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8fa8667f-b508-45a4-b48b-3eddeea9fcd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_310446e6-a044-4e88-a296-66ba7ed2497d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2b3e61ce-826c-4e2d-812c-0c29dc77f8ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_29347811-c093-4df6-9e2a-f805a52d996e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_532ada3a-f318-4d9a-ba32-1571b0f99d80_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-76cc-bb17-f18f5918aac9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedClinicalTrialsCurrent_7048511c-27a3-4c1c-bcf8-afb1933454a2_terseLabel_en-US" xlink:label="lab_inbx_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_inbx_AccruedClinicalTrialsCurrent_label_en-US" xlink:label="lab_inbx_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:label id="lab_inbx_AccruedClinicalTrialsCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedClinicalTrialsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trials, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalTrialsCurrent" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalTrialsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedClinicalTrialsCurrent" xlink:to="lab_inbx_AccruedClinicalTrialsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_eb371950-d4a0-4cf9-829b-eac6be53df26_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_88cc1e54-1f78-4b1f-9aae-3c9b0352360b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OxfordTermLoansMember_00978642-e5cf-44f0-9e75-94406541f556_terseLabel_en-US" xlink:label="lab_inbx_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_inbx_OxfordTermLoansMember_label_en-US" xlink:label="lab_inbx_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inbx_OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inbx_OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OxfordTermLoansMember" xlink:href="inbx-20251231.xsd#inbx_OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OxfordTermLoansMember" xlink:to="lab_inbx_OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_019b06a5-79da-74a0-abe6-679dba6c3909_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b2cc9566-677b-44cd-b81c-a3b3ebce8097_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_16cae314-24d5-4b11-9c77-c5ed295338f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e8e19597-9f6a-42ab-87ef-453f4ce7af14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d269efea-317e-4fd7-8025-f94cba6590b2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2c034339-e40d-44b0-87dd-c2af497def7b_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_91b4527c-ccd3-4f2f-bd9f-d59ee850ca64_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_40497043-718c-4d2d-9482-38fa01214b6e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8fe507b4-d238-4f4d-a702-76477e75a772_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_2cd56675-6b93-41b9-b8eb-8d1b5788ac3e_terseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elimination of deferred tax assets and liabilities upon Transaction with Acquirer</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Elimination Of Deferred Tax Assets And Liabilities Upon Transaction With Acquirer, Amount</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Elimination Of Deferred Tax Assets And Liabilities Upon Transaction With Acquirer, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cdd1281c-37b0-4279-af9c-a8582461ae5e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5937848e-bc4e-4bd9-95fa-1ecd3a61de21_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4ebda7be-d18d-427e-9949-42de10721f4b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7546c73d-3e38-485f-8d68-2c2fc7868409_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_999024d5-ded6-4324-a7e4-840a5ff74d52_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb486-6f11-7938-b590-592c8eeeb2ab_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bb0eedc6-d5e0-4c58-9d90-5746b298fc4a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2921ad5f-9acf-40b8-bc92-514ab1dcc8db_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ba8f2e2c-b6d5-44b7-8d99-e2791f0ab90a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_844b20a4-4aca-4a0a-a403-021a40b47226_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ab4e2566-d70c-484f-ac54-a89a151887c6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b074a-30bb-7e1b-81c1-34c11ded29b1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ca581cac-c34e-4e08-a49d-cde74589fc42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_aa257ac4-dc5b-4b7e-af7f-b3d0143b8230_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_cad90b00-26dc-4f43-aa38-ea47d057d6e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOrUnitsAvailableForDistributions_1d90f482-f642-4907-8ac7-cc596476589e_terseLabel_en-US" xlink:label="lab_us-gaap_StockOrUnitsAvailableForDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockOrUnitsAvailableForDistributions_label_en-US" xlink:label="lab_us-gaap_StockOrUnitsAvailableForDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock or Units Available for Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOrUnitsAvailableForDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOrUnitsAvailableForDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOrUnitsAvailableForDistributions" xlink:to="lab_us-gaap_StockOrUnitsAvailableForDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c1d4fb5-2b59-4c28-8a8b-ba59d915266b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5564c138-ef08-4266-8282-37cf5fb2f6c9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScitheraInc.Member_019b0743-4d3d-73a9-98a6-2063ecbc14c1_terseLabel_en-US" xlink:label="lab_inbx_ScitheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scithera, Inc.</link:label>
    <link:label id="lab_inbx_ScitheraInc.Member_label_en-US" xlink:label="lab_inbx_ScitheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scithera, Inc. [Member]</link:label>
    <link:label id="lab_inbx_ScitheraInc.Member_documentation_en-US" xlink:label="lab_inbx_ScitheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scithera, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraInc.Member" xlink:href="inbx-20251231.xsd#inbx_ScitheraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScitheraInc.Member" xlink:to="lab_inbx_ScitheraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d53dc150-3828-4766-8d3b-aa7111117acd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8d4b71a-4921-496b-865f-45a4cea90a35_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OperatingLeaseAnnualEscalationsPercentage_8db3c7df-5b79-47f2-8c88-ca83cdb61534_terseLabel_en-US" xlink:label="lab_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual escalations percentage</link:label>
    <link:label id="lab_inbx_OperatingLeaseAnnualEscalationsPercentage_label_en-US" xlink:label="lab_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Escalations Percentage</link:label>
    <link:label id="lab_inbx_OperatingLeaseAnnualEscalationsPercentage_documentation_en-US" xlink:label="lab_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Escalations Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:href="inbx-20251231.xsd#inbx_OperatingLeaseAnnualEscalationsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:to="lab_inbx_OperatingLeaseAnnualEscalationsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63945b3b-b206-4d4a-874d-e11a72e0f8fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_20fdafe6-60c0-4211-b353-b93385efa90b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_01d5f653-a41a-406c-8c5e-52648c5b4715_terseLabel_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee revenue</link:label>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_label_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Non-Affiliate [Member]</link:label>
    <link:label id="lab_inbx_LicenseNonAffiliateMember_documentation_en-US" xlink:label="lab_inbx_LicenseNonAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Non-Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseNonAffiliateMember" xlink:to="lab_inbx_LicenseNonAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b58d3a39-2c64-4c10-ac9f-c1f6977972df_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1570e724-b37e-4e33-bb01-4cec978cd6c6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e97c01b5-331a-4915-b547-92b912325f8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bf26a849-9a3c-43b3-8304-bbeab997a83b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2132ddd9-345d-4375-8acd-51ecd26b9ddc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2024PlanMember_019b0748-3fdf-7042-91e8-6c4c5c776718_terseLabel_en-US" xlink:label="lab_inbx_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Plan</link:label>
    <link:label id="lab_inbx_A2024PlanMember_label_en-US" xlink:label="lab_inbx_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Plan [Member]</link:label>
    <link:label id="lab_inbx_A2024PlanMember_documentation_en-US" xlink:label="lab_inbx_A2024PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2024PlanMember" xlink:to="lab_inbx_A2024PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_de7b9df3-0854-4893-a8a4-289605f77b3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_38a170c9-584e-48ed-8f01-218396538943_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_afdad39b-e624-4f80-9514-7a43fb32809c_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total license fee revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_f92f244c-dcb3-4547-aac3-d25faec6ae09_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Debt Issuance Cost, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_0723a37d-ede9-480d-87b3-308cdd70bfe8_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain related to transaction with Acquirer</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_d151d05f-0f86-45a2-8f06-a0df5c3fb6aa_verboseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nonmonetary transaction, gain</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_8f67604f-b311-4206-b078-f7eb57133f82_netLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total gain recognized</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction, Gain (Loss) Recognized on Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:to="lab_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2025LoanAgreementMember_019cb45a-bda5-76d1-a26b-317fd13795f7_terseLabel_en-US" xlink:label="lab_inbx_A2025LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Loan Agreement</link:label>
    <link:label id="lab_inbx_A2025LoanAgreementMember_label_en-US" xlink:label="lab_inbx_A2025LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Loan Agreement [Member]</link:label>
    <link:label id="lab_inbx_A2025LoanAgreementMember_documentation_en-US" xlink:label="lab_inbx_A2025LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2025LoanAgreementMember" xlink:href="inbx-20251231.xsd#inbx_A2025LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2025LoanAgreementMember" xlink:to="lab_inbx_A2025LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c6cc885f-6885-4d1c-ad35-0e320d6a70db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f566c4aa-2a51-45bf-9c05-ee801479bbca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cliff Vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fa6286e3-84b9-4fb6-8ef9-91f5623cb196_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c7e2b1e1-1b5a-4a08-9144-f7ed2a755c0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5901d6fd-dd81-4fe5-83dd-50e58223195b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f854b6ca-e1f5-4df3-b73a-ac9f47194cdc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9cec5ee5-c35f-4092-8e3f-bf3200606f2b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_c2c30dba-bffe-4ec8-80cb-1526d5d9389b_negatedTerseLabel_en-US" xlink:label="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash gain on transaction with Acquirer</link:label>
    <link:label id="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_label_en-US" xlink:label="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net</link:label>
    <link:label id="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_documentation_en-US" xlink:label="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:href="inbx-20251231.xsd#inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:to="lab_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d02da614-7bff-4b39-8e07-03376e969e34_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019cb481-f20e-7e0f-8751-740f0a2eecc4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income taxes at 21%</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_eae699fc-809b-4da1-96b8-14d84f3f194a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_98fbad1b-0158-4d93-b369-35cd72a03d07_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY COMPENSATION PLAN</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0156aa96-0e12-4e06-b129-eb122b80da15_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_121ebf4e-1a58-4387-a0f1-00d64bc27232_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, including final payment fee</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_65108ad2-0579-42d6-bd28-22224130bd56_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_d987aa5a-def4-4b54-89cf-d60a01db81f4_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_12773aaf-6b55-43f2-9210-f4dd9e844422_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_795e47f0-909a-45c2-89be-1563a011ef01_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of programs related to collaborative agreement</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_label_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:label id="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_documentation_en-US" xlink:label="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number Of Related Programs To Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:href="inbx-20251231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:to="lab_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_dc391369-c386-4b0c-a644-2dfa201c2a64_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_bc4cb9eb-c539-4285-b795-20d3af377629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_843f2059-361f-4c20-abf9-4027060f4008_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4fdbcbe6-a578-47cb-8645-f1137096cb23_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EarningsDistributionRatio_02f68105-e6f0-4408-b8d6-e8f1a2162c7b_terseLabel_en-US" xlink:label="lab_inbx_EarningsDistributionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution ratio</link:label>
    <link:label id="lab_inbx_EarningsDistributionRatio_label_en-US" xlink:label="lab_inbx_EarningsDistributionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Distribution Ratio</link:label>
    <link:label id="lab_inbx_EarningsDistributionRatio_documentation_en-US" xlink:label="lab_inbx_EarningsDistributionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Distribution Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EarningsDistributionRatio" xlink:href="inbx-20251231.xsd#inbx_EarningsDistributionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EarningsDistributionRatio" xlink:to="lab_inbx_EarningsDistributionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_2ff8dd02-e6d9-4e55-95f9-7dc51b4ac3aa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9d647c13-759d-4c46-9f77-d288bdc67d89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d0ddd376-ddc7-4a86-9c81-7806d83c1dd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6f5fc268-1c6b-4cb2-8b1b-9fa91689ac0e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_92c411d7-5ace-40e9-9676-53a68d409e32_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, right per share, contingency</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Contingent Value Right Per Warrant</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Contingent Value Right Per Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:to="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3026e97c-1681-48ba-8796-bd94a4f02bae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_0bb9156c-2d80-416c-97cf-01604dead96d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5799f25c-a475-49f3-b2f3-8c743ec92ea7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_f334dab1-373d-46d3-a2f7-a929d658b1f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs and Other Debt-Related Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5f9b0c77-e59e-415a-b04c-80cc50b99133_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1bfe23ec-6da1-4310-ab9e-e8e6b6490463_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_18939c39-0e81-46de-a65f-91e0b0c556e0_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7bec9488-f561-4371-bfc4-bcbac96bd452_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9d325f65-0aff-42f0-b53a-5b5ec66b19a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares in conversion of convertible securities (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ff3a599e-4f67-4ed0-94cc-76a13dff715e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5b81352c-b5c4-4f8e-b8e2-44bbed662ade_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_d4d8dd01-3e98-46ae-b0bf-d70802adbbbb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_bf6ad074-ea7e-49eb-9bef-8d8ee6430f81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_97fdc3a8-5be8-4891-909f-8438f461c864_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_32c9078e-c902-4dad-8893-9038c87962ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Former Parent&#8217;s common stock, stock options, and warrants by the Acquirer</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_3067e520-d492-474d-9224-8f9248376075_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Spinoff transaction</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b49fab35-07db-4b80-9dee-313d19886e66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9876675b-2c83-4b77-a328-4187fb0db867_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_2a2b9f44-e915-40db-a611-14f0de254058_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PrepaidLicenseCurrent_f86f7d4c-d744-4e38-bf35-74f428510ba0_terseLabel_en-US" xlink:label="lab_inbx_PrepaidLicenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_inbx_PrepaidLicenseCurrent_label_en-US" xlink:label="lab_inbx_PrepaidLicenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid License Current</link:label>
    <link:label id="lab_inbx_PrepaidLicenseCurrent_documentation_en-US" xlink:label="lab_inbx_PrepaidLicenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid License Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PrepaidLicenseCurrent" xlink:href="inbx-20251231.xsd#inbx_PrepaidLicenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PrepaidLicenseCurrent" xlink:to="lab_inbx_PrepaidLicenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_019b074c-2e42-7766-825b-a3888f69985b_terseLabel_en-US" xlink:label="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, number of performance obligation,</link:label>
    <link:label id="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_label_en-US" xlink:label="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Number Of Performance Obligation</link:label>
    <link:label id="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_documentation_en-US" xlink:label="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Number Of Performance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:href="inbx-20251231.xsd#inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:to="lab_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_Plan2017Member_ca1ecffd-4655-4cbe-b958-f38dde817a43_terseLabel_en-US" xlink:label="lab_inbx_Plan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_inbx_Plan2017Member_label_en-US" xlink:label="lab_inbx_Plan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan 2017 [Member]</link:label>
    <link:label id="lab_inbx_Plan2017Member_documentation_en-US" xlink:label="lab_inbx_Plan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Plan2017Member" xlink:href="inbx-20251231.xsd#inbx_Plan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_Plan2017Member" xlink:to="lab_inbx_Plan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b72a9195-dab8-4ba0-ab12-77ebc0602543_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4db7c201-a22b-4dbd-a992-9163c0ab97b5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_04f014ab-85d3-4b90-9507-edad0713a53c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_518d5809-3044-47e6-8c11-ab6b5bd31f6d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_2b2eccba-3b65-4a29-8bdc-8a0d058b3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c62b8cab-6868-4faa-89e9-319154bcd4a3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8ca5f331-de8b-4d08-9e65-3bce32b750db_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AventisIncMember_add591a0-32fa-4565-b944-f851680fff48_terseLabel_en-US" xlink:label="lab_inbx_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aventis Inc</link:label>
    <link:label id="lab_inbx_AventisIncMember_label_en-US" xlink:label="lab_inbx_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aventis Inc [Member]</link:label>
    <link:label id="lab_inbx_AventisIncMember_documentation_en-US" xlink:label="lab_inbx_AventisIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aventis Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AventisIncMember" xlink:href="inbx-20251231.xsd#inbx_AventisIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AventisIncMember" xlink:to="lab_inbx_AventisIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9674569-8ed5-491d-93c0-80b1273806b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_2e576701-7a82-4480-8666-1d8b559ab8a2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_05f123a8-21a6-4e4e-ae03-68578951114f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_35435e7a-e150-4ebb-8445-a809620becaa_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_c156ec32-c4b4-4f62-98b3-a0309bec6362_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_4c28e401-5f6f-4510-b669-ba903278132a_negatedTerseLabel_en-US" xlink:label="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Former Parent&#8217;s common stock, stock options, and warrants by the Acquirer (in shares)</link:label>
    <link:label id="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_label_en-US" xlink:label="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholder Equity, Spinoff Transaction, Decrease In Common Stock</link:label>
    <link:label id="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_documentation_en-US" xlink:label="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholder Equity, Spinoff Transaction, Decrease In Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:href="inbx-20251231.xsd#inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:to="lab_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_845765f8-c1bc-442a-b244-021b4246c4b6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LongTermDebtLiquidityThreshold_019cb461-7c02-747d-8a48-80f4446a8417_terseLabel_en-US" xlink:label="lab_inbx_LongTermDebtLiquidityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term debt, minimum liquidity threshold</link:label>
    <link:label id="lab_inbx_LongTermDebtLiquidityThreshold_label_en-US" xlink:label="lab_inbx_LongTermDebtLiquidityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt, Liquidity Threshold</link:label>
    <link:label id="lab_inbx_LongTermDebtLiquidityThreshold_documentation_en-US" xlink:label="lab_inbx_LongTermDebtLiquidityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Debt, Liquidity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtLiquidityThreshold" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtLiquidityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LongTermDebtLiquidityThreshold" xlink:to="lab_inbx_LongTermDebtLiquidityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69329982-4b7b-4186-bb69-5beaffd87c34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_61767bca-0bf0-4669-8d48-4c9275a4d85e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4f9230ac-71a4-49e8-9ab9-272043b3f5e2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_019cb484-6e5c-70fb-bcaf-b97ef92e39ed_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4ab7d988-9ef2-4947-929a-20db2994f37f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4c75ba5c-8718-422f-b4a4-70bc0d1c0c5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019cb489-9e98-750c-824a-267562dfbc41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member_f4aa772e-3fc2-4f1c-85fd-228596b0d055_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 2</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 2 [Member]</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expiration Date 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:to="lab_inbx_ClassOfWarrantOrRightExpirationDate2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_2a630a95-f845-4b64-9cd9-66393565efbd_terseLabel_en-US" xlink:label="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer</link:label>
    <link:label id="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_label_en-US" xlink:label="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Assets And Liabilities Assumed By Acquirer [Member]</link:label>
    <link:label id="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_documentation_en-US" xlink:label="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Assets And Liabilities Assumed By Acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:href="inbx-20251231.xsd#inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:to="lab_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8bc895aa-bcd5-4c94-ac84-d89915ba2f52_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3f2e73b0-beb4-4173-82cf-389175a105a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2e445e51-0a82-402b-870c-f265027eb508_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_85f31b6d-3d3c-432a-822e-8c2f93867459_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_019b0741-2984-7735-bb2f-c138335a9fd7_terseLabel_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LICENSE REVENUE</link:label>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_label_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Grant Revenue [Text Block]</link:label>
    <link:label id="lab_inbx_LicenseAndGrantRevenueTextBlock_documentation_en-US" xlink:label="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAndGrantRevenueTextBlock" xlink:href="inbx-20251231.xsd#inbx_LicenseAndGrantRevenueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAndGrantRevenueTextBlock" xlink:to="lab_inbx_LicenseAndGrantRevenueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedInterestExpenseCurrent_b975380c-1b25-4503-a94b-cdbdb9768087_terseLabel_en-US" xlink:label="lab_inbx_AccruedInterestExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_inbx_AccruedInterestExpenseCurrent_label_en-US" xlink:label="lab_inbx_AccruedInterestExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest Expense, Current</link:label>
    <link:label id="lab_inbx_AccruedInterestExpenseCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedInterestExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Interest Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedInterestExpenseCurrent" xlink:href="inbx-20251231.xsd#inbx_AccruedInterestExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedInterestExpenseCurrent" xlink:to="lab_inbx_AccruedInterestExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_f13a627b-d86b-4c94-8145-83bb54796a85_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_8e8afebc-9c48-45cc-8e13-70ee47bbcd13_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_f2fea479-8c1f-4c5c-bf16-f412d91c2f2d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bf656a75-22fd-496b-8435-7bfe62fb60bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019cb47a-7d2f-74cf-aa9b-0f467b55e78a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6520bb5f-a562-49ad-a4ce-2ad4e84d772b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8e8c4d88-04cf-4854-9b84-d6a8255c8c8c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of debt discount and non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60261a09-dc0f-4244-aedb-ee38f34126ce_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_565e8650-11c6-48c1-8dba-9684dac4e692_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issuable upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_67bb06b3-3488-4b27-8bf5-4c1f9ba0bb4d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_aad844f4-fb1a-470c-807f-793173ce507d_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Programs, Program 3</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Three [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Initial Programs Authorized, Program Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:to="lab_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_872a9836-9cde-4f21-bfd5-3b2ffa54351e_terseLabel_en-US" xlink:label="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and accretion</link:label>
    <link:label id="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_label_en-US" xlink:label="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium) and Accretion</link:label>
    <link:label id="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_documentation_en-US" xlink:label="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium) and Accretion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:href="inbx-20251231.xsd#inbx_AmortizationOfDebtDiscountPremiumAndAccretion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:to="lab_inbx_AmortizationOfDebtDiscountPremiumAndAccretion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1d51eeea-431c-471e-aff8-65a0ac128f63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_43795ae8-bfd3-412d-bb08-44d06deda4ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_cf8ff0ba-de0c-41be-8e2a-314427362754_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_3773ba15-c911-4b7e-a5f6-6c9ee61390a9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_ce87513e-9143-4991-add8-73ffda0a90ee_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Purchase Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:to="lab_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_72587581-f4a4-4902-b491-35c7210d8d53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6f887f15-0d49-4a1b-910b-6531d5392517_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December&#160;31, 2025 and December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5b63630b-22d4-4dec-ac26-1ccce2b8f578_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_a4e1221f-d831-49e0-8efd-7b3a291ef049_terseLabel_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger consideration exercise price (in dollars per share)</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_label_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Exercise Price</link:label>
    <link:label id="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_documentation_en-US" xlink:label="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:to="lab_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_e8a1ab4e-c533-4f1b-87e5-e4631fe2fb5e_terseLabel_en-US" xlink:label="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside research and development services</link:label>
    <link:label id="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_label_en-US" xlink:label="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outside Research And Development Services, Prepaid Expense Current</link:label>
    <link:label id="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_documentation_en-US" xlink:label="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outside Research And Development Services, Prepaid Expense Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:href="inbx-20251231.xsd#inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:to="lab_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_127210b9-8107-439a-b906-b042e74cc8c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cfa532e8-45b0-40a4-a2fa-782292189da9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value, 120,000,000 shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; 14,577,609 and 14,475,904 shares issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseNumberOfContracts_e70f4162-abff-4bc3-bffb-169ce9c7bea3_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, number of contracts</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseNumberOfContracts_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseNumberOfContracts_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:to="lab_inbx_LesseeOperatingLeaseNumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_07246f1f-8f62-48d0-983d-8cd1dd8106a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials_27bdf474-d443-47e4-af85-23831045a50d_terseLabel_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials_label_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Clinical Trials</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials_documentation_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:to="lab_inbx_ResearchAndDevelopmentExpenseClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_996d807a-92bf-447b-92d0-c1ecf2bbbaac_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f8674426-6d4c-473f-9c73-068b74728fbb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_32aa8c3c-5f37-4108-b22a-a0fdf7525ef9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c3310ee1-4881-4037-b4ff-6b11f9dea692_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_08a51070-322e-40a8-ba97-c3326825e236_terseLabel_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Loan Agreement</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_label_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Oxford Term Loans [Member]</link:label>
    <link:label id="lab_inbx_A2020OxfordTermLoansMember_documentation_en-US" xlink:label="lab_inbx_A2020OxfordTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Oxford Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember" xlink:href="inbx-20251231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2020OxfordTermLoansMember" xlink:to="lab_inbx_A2020OxfordTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OperatingLeasesContractAbatementPeriod_0868bc2e-cdbc-45f3-a6aa-a0fe896f9cd2_terseLabel_en-US" xlink:label="lab_inbx_OperatingLeasesContractAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, contract abatement period</link:label>
    <link:label id="lab_inbx_OperatingLeasesContractAbatementPeriod_label_en-US" xlink:label="lab_inbx_OperatingLeasesContractAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Contract Abatement Period</link:label>
    <link:label id="lab_inbx_OperatingLeasesContractAbatementPeriod_documentation_en-US" xlink:label="lab_inbx_OperatingLeasesContractAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Contract Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeasesContractAbatementPeriod" xlink:href="inbx-20251231.xsd#inbx_OperatingLeasesContractAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OperatingLeasesContractAbatementPeriod" xlink:to="lab_inbx_OperatingLeasesContractAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_05faced0-b12c-4d89-be22-ab71624d92ed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_c4bb9ce3-4db7-497c-a06c-a76f38bba9d4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_70d1bf91-d0d0-4bbe-a39a-b154f307452e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b031ed9d-ca49-4baa-b700-f08778963ace_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a8f8f629-00b3-4f6b-83f0-6bcb29df0bb7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_d85e4eee-fe58-45ad-b073-a3c93ea5b418_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Poplar Therapeutics</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AuditInformationAbstract_label_en-US" xlink:label="lab_inbx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_inbx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_inbx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AuditInformationAbstract" xlink:href="inbx-20251231.xsd#inbx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AuditInformationAbstract" xlink:to="lab_inbx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_081977f3-e2e3-4f13-a2b8-935b424eb1e4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a28851cb-5319-496e-b0fb-115a5ccd2111_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_MaximumPotentialMilestonePayments_019b074c-2e42-7778-a7a1-b5215b10c86f_terseLabel_en-US" xlink:label="lab_inbx_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_inbx_MaximumPotentialMilestonePayments_label_en-US" xlink:label="lab_inbx_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_inbx_MaximumPotentialMilestonePayments_documentation_en-US" xlink:label="lab_inbx_MaximumPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MaximumPotentialMilestonePayments" xlink:href="inbx-20251231.xsd#inbx_MaximumPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_MaximumPotentialMilestonePayments" xlink:to="lab_inbx_MaximumPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_be38d9bf-41b7-417b-ac77-5793b9c63002_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ee2c80f9-b91c-4b5e-ae31-0ebafca0fb0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_47b00c69-b7b6-4828-8e35-5c39d8bfa3b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_05b84507-0bfe-4cbb-b924-6004ef5f73e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a04a544c-876a-4433-9c12-65a35d1efddb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_019ce1a5-34ee-700f-8b2f-703b1af6c141_negatedTerseLabel_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of third-party fees associated with debt</link:label>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_label_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:label id="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_documentation_en-US" xlink:label="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs, Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:href="inbx-20251231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:to="lab_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7b3e80ac-66ea-4e4b-92f2-6b946d044d67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e1906952-b30b-460e-aa86-f0b55316fb22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_bdcc2666-6073-4f6b-a065-93df336324ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3c36937b-fdef-4fbc-a51e-6ce9e7b02746_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_81e57f35-bed4-481d-ba96-1ca7a12f4662_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019cb439-931b-7de5-809d-f8698b24b725_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_012a6692-b3be-4c14-8bd6-073f91594a34_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_713138ae-694b-4b0f-98c3-59f62217ccdd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_d4b35ce6-8507-4d03-b3ff-3d0e1cf93733_terseLabel_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Programs</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_label_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement, Initial Programs Authorized [Member]</link:label>
    <link:label id="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember_documentation_en-US" xlink:label="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Initial Programs Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:to="lab_inbx_LicenseAgreementInitialProgramsAuthorizedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpensePersonnel_44fba65b-c0dd-477f-a9d6-9857dbe86cfb_terseLabel_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel</link:label>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpensePersonnel_label_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Personnel</link:label>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpensePersonnel_documentation_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Personnel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpensePersonnel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:to="lab_inbx_GeneralAndAdministrativeExpensePersonnel" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1930b8ff-3d13-45ed-b5cb-ac317885fefa_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e1958ca4-b9f1-46d2-ba07-0f41db67fb99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ddb1da9d-4260-4ff8-9a44-aa206b1ccb19_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5a726b2a-5227-48ea-be1e-aece2ad0d4b0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4764fe30-08c6-4ede-a6a9-8a1b189135fa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_MergerExchangeRatioProRateBasisPercentage_535b9115-69f9-4c6c-9473-95faedba8d4c_terseLabel_en-US" xlink:label="lab_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange ratio, pro-rate basis</link:label>
    <link:label id="lab_inbx_MergerExchangeRatioProRateBasisPercentage_label_en-US" xlink:label="lab_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger, Exchange Ratio, Pro-Rate Basis, Percentage</link:label>
    <link:label id="lab_inbx_MergerExchangeRatioProRateBasisPercentage_documentation_en-US" xlink:label="lab_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger, Exchange Ratio, Pro-Rate Basis, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatioProRateBasisPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:to="lab_inbx_MergerExchangeRatioProRateBasisPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_019b0688-e1ea-7005-b2ed-cc9e21d4ce8c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a82b01a9-c7cf-4298-a697-523f00170853_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_SeverancePaymentsToFormerEmployeesMember_7d8cb46b-5529-4c42-a5bf-a194b51725f9_terseLabel_en-US" xlink:label="lab_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Payments To Former Employees</link:label>
    <link:label id="lab_inbx_SeverancePaymentsToFormerEmployeesMember_label_en-US" xlink:label="lab_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Payments To Former Employees [Member]</link:label>
    <link:label id="lab_inbx_SeverancePaymentsToFormerEmployeesMember_documentation_en-US" xlink:label="lab_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Severance Payments To Former Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:href="inbx-20251231.xsd#inbx_SeverancePaymentsToFormerEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:to="lab_inbx_SeverancePaymentsToFormerEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_06826b49-b652-4d70-ab43-255f6677c13a_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_MergerOwnershipPercentage_2ffda854-c385-444e-953c-457f6728535d_terseLabel_en-US" xlink:label="lab_inbx_MergerOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_inbx_MergerOwnershipPercentage_label_en-US" xlink:label="lab_inbx_MergerOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger, Ownership Percentage</link:label>
    <link:label id="lab_inbx_MergerOwnershipPercentage_documentation_en-US" xlink:label="lab_inbx_MergerOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_MergerOwnershipPercentage" xlink:to="lab_inbx_MergerOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6bafe4fa-9716-4495-8b4f-32b3be1440b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_90ea0661-d1ea-406d-b395-66b92f38849a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 research and development capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_e6d6df02-b39b-4527-a0c8-c06f07eb328c_terseLabel_en-US" xlink:label="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical drug substance and product manufacturing</link:label>
    <link:label id="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_label_en-US" xlink:label="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current</link:label>
    <link:label id="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_documentation_en-US" xlink:label="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:href="inbx-20251231.xsd#inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:to="lab_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_744d06e4-d98b-49b3-869f-54dd13e4c7be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonmonetaryTransactionTypeAxis_6fe1545b-210d-4b22-bf15-be7c3196dac0_terseLabel_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:label id="lab_us-gaap_NonmonetaryTransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_NonmonetaryTransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="lab_us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c4d45939-3b84-4f18-840a-d18d08eca374_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_49f62d6f-570c-4042-8554-305238f62e8c_terseLabel_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone payment receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_label_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:label id="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_documentation_en-US" xlink:label="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Milestone Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:to="lab_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_83ef4ad8-1ae6-4959-ae9f-9eed7a75bbf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d3ade904-7f3b-4546-a5a8-9e7bf2d63929_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b399a6cc-36fa-491e-9a5d-f2b52995970c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cf25e8d3-634a-431c-9f38-ce5478d19f3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_be02b90d-25c0-4d6d-a7b9-ffd209a51824_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_88fffdab-a557-467c-b420-5dfc2e5a520e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_75d314a4-da44-49ab-94ad-0d770725f70b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_019cb480-a21d-7d61-9e39-f9586fa81c53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9ee3bd6c-0df0-4b1b-a36c-f30cd81e5761_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, shares issued/sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_51bbecba-2a24-4c61-a596-d7fcfe08f8d7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0b388760-d814-4455-8d1b-6679438d3f10_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019cd3a2-2b43-7675-8bde-c141ec0f58f3_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_029c19fc-4ecb-4736-9e36-1dcbb2835d09_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_fb9ce2bb-6b63-48ba-a2df-ee4257dd6e76_terseLabel_en-US" xlink:label="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services Performed Under Transition Services Agreement</link:label>
    <link:label id="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_label_en-US" xlink:label="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Services Performed Under Transition Services Agreement [Member]</link:label>
    <link:label id="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Services Performed Under Transition Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:href="inbx-20251231.xsd#inbx_ServicesPerformedUnderTransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:to="lab_inbx_ServicesPerformedUnderTransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_efd7f447-afb5-40cf-949f-7088d642e392_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5054d8f8-005b-4116-ba63-a82f9f1e2e52_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_c4575ef4-f1cf-460e-a04e-9958056f2108_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_72d85cf0-8154-4e91-a19f-e663f1975491_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_c92852fd-6324-4022-833d-a144f0f87235_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payment in cash (in dollars per share)</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Contingent Value Right Per Warrant, Value</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Contingent Value Right Per Warrant, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:to="lab_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentBalloonPaymentWriteOff_2daa1f9b-ae04-4411-8582-b61667f98dab_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment fee</link:label>
    <link:label id="lab_inbx_DebtInstrumentBalloonPaymentWriteOff_label_en-US" xlink:label="lab_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Balloon Payment, Write-Off</link:label>
    <link:label id="lab_inbx_DebtInstrumentBalloonPaymentWriteOff_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Balloon Payment, Write-Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentBalloonPaymentWriteOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:to="lab_inbx_DebtInstrumentBalloonPaymentWriteOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c38b20eb-2d6f-43ae-bb47-6e1f9bc1145c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4271102e-5d01-4769-8281-1b84a7e7d630_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_c848ea67-6522-46bd-b35f-4da928cdb627_terseLabel_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="inbx-20251231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_inbx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_921a48d3-15bf-4d2a-b92f-43e6a865121b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_687430aa-b7a3-4f68-8a52-e9bae6544fa8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_16df2695-c573-4e69-a18a-d1075839ec48_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1a99841e-7c53-4d88-aa06-a0b598e7d16d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_34738a38-c609-40db-b183-a7f22dcf7ff0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9ccfe890-5568-4859-99da-249a034b8a0e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8cdf86b8-79ed-44bb-b6d6-0bb1735d2c80_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_48c1efb4-1906-4ad9-b816-bb1093ba33a5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease extension term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_f83998c7-2dd3-4a35-b6f3-a32dc4a67b17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3e9bca11-cf8a-44a4-8ab8-bcc6531fca04_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_22a99b2f-e63b-49e1-bb6f-e2ad89b5fe95_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_59f59974-d687-45e5-8796-6d229b654050_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_29b7196d-1f14-42e4-9c22-571057c59891_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_32e797e4-83a4-4e24-8bd6-cf3924411bdd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_b135ca8e-70d2-4560-8850-15a0a8a87464_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_WarrantsPolicyPolicyTextBlock_b5bf349c-5e14-4f8f-b0c3-81f1f5488ec1_terseLabel_en-US" xlink:label="lab_inbx_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments with Characteristics of Both Liabilities and Equity</link:label>
    <link:label id="lab_inbx_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_inbx_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_inbx_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_inbx_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsPolicyPolicyTextBlock" xlink:href="inbx-20251231.xsd#inbx_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_WarrantsPolicyPolicyTextBlock" xlink:to="lab_inbx_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_57160e61-445e-43b5-ae90-b22ef9b736fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_e5315160-564b-47e1-b9f8-9ec73b502b1a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction service amount</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8ecaba91-b389-43a7-bd88-314a9162b4e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23890f3e-5787-475b-90ba-bbe031f95c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d1fc681d-830d-460e-b991-fe7e99ae4f7a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c1516c32-d883-4eb1-b67b-7deb8121d89f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c71c23d4-3235-4631-a14c-b1704a29bc0d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a3228d09-d54f-4e08-894d-8eeabb8d44c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7d9e7123-63f2-436c-bee6-a5f8e1a2835e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c46bc3aa-a330-4de0-b4f2-f6564872846a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_InterestIncomeNonoperating_c3e6bf14-6603-42d9-ad42-dffeeeb1e7ed_terseLabel_en-US" xlink:label="lab_inbx_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_inbx_InterestIncomeNonoperating_label_en-US" xlink:label="lab_inbx_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:label id="lab_inbx_InterestIncomeNonoperating_documentation_en-US" xlink:label="lab_inbx_InterestIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestIncomeNonoperating" xlink:href="inbx-20251231.xsd#inbx_InterestIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_InterestIncomeNonoperating" xlink:to="lab_inbx_InterestIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_4a4b9d7c-57a8-4e8f-9dbf-80aa664d5a7c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f6748c90-2a7f-45fc-b941-2b598a20dbb4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_fedc60cb-bbc5-4f28-90fa-fc1b943e635e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease agreement term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f69cd1ae-bd87-4b8e-abde-507c47a56668_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3f55e492-d2f7-48bc-aac6-009554ca739b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8912e83b-5f64-4988-97f3-c28b300a96b5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f952686-e4cb-4286-8cd8-281eef677286_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f97245a6-4c4a-46e2-a072-aecd7f3c5927_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability_c0be65ef-6f44-4775-b9ee-c7f6c8bbf44c_terseLabel_en-US" xlink:label="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments included in measurement of lease liability</link:label>
    <link:label id="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability_label_en-US" xlink:label="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments Included in Measurement of Lease Liability</link:label>
    <link:label id="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability_documentation_en-US" xlink:label="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments Included in Measurement of Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:href="inbx-20251231.xsd#inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:to="lab_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7f64457e-9f41-4cfa-87be-c7df95b71a4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected income tax expense at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_386ab592-2380-44e4-9a79-dcf78691a107_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_12a2673d-372f-42ea-8011-5c9fc69295f0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019cb482-542e-7b07-843e-e12250deb6c4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_a30213fd-8a35-401a-bd78-0d813c093b24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt funded</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d0f07415-41ac-4f17-8987-698b5590ef57_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8960eb7f-dc74-4b9b-8462-2aba2ec083b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e29a3700-d34f-48f3-8947-6b4c33d7a490_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_112f13bc-8289-4c7f-9881-8fea130c8421_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized, currently available (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_07929aa5-a914-4472-8633-61d1056bc335_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8a52ab61-c947-4274-a82b-317a34a0d937_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_41b2825b-e11d-4205-9dd1-a8b88185053b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a2b6cc94-5300-495d-8f3d-24904e935cf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d7c8deff-5e01-4613-8527-417dd03e662e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants in connection with 2025 Loan Agreement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_A2017PlanMember_019b0740-c441-7f71-bdf1-48a41041a119_terseLabel_en-US" xlink:label="lab_inbx_A2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_inbx_A2017PlanMember_label_en-US" xlink:label="lab_inbx_A2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Plan [Member]</link:label>
    <link:label id="lab_inbx_A2017PlanMember_documentation_en-US" xlink:label="lab_inbx_A2017PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2017PlanMember" xlink:href="inbx-20251231.xsd#inbx_A2017PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_A2017PlanMember" xlink:to="lab_inbx_A2017PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_MergerExchangeRatio_2e379214-cbc9-4c32-8e35-a5ee49a4683e_terseLabel_en-US" xlink:label="lab_inbx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_inbx_MergerExchangeRatio_label_en-US" xlink:label="lab_inbx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger, Exchange Ratio</link:label>
    <link:label id="lab_inbx_MergerExchangeRatio_documentation_en-US" xlink:label="lab_inbx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatio" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_MergerExchangeRatio" xlink:to="lab_inbx_MergerExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_554fa919-ec27-48a4-9b97-4149e912ddac_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9b97f5d7-870b-4ba0-bd91-6cace75a3bd8_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_263788a8-ed21-4743-9254-5ce21d7de9a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_efa5151a-1acd-475a-b301-f09d8fdf8015_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ad428bf7-b889-406d-b60e-d8ae5bc128e5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_758bd3b6-b353-4cd6-a205-b61b02cfd5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_6f41ecc9-877d-4d5f-8e68-f32e3e70e843_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_08732086-fdfb-4657-838b-c8cc6b8dcc36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ba8bbfb-73d5-428e-ab42-8d1b2c867eab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_82c842b8-3b1b-4ef3-bcb8-aff0ca2eb394_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of principal amount for final payment</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_label_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:label id="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:to="lab_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e1163d7c-ecc2-41f0-9f01-3628465e635e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_DebtInstrumentPrincipalAndInterestTerm_7ac3ac9c-1f4a-4df4-8766-03b8487fe711_terseLabel_en-US" xlink:label="lab_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, principal and interest term</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrincipalAndInterestTerm_label_en-US" xlink:label="lab_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal And Interest Term</link:label>
    <link:label id="lab_inbx_DebtInstrumentPrincipalAndInterestTerm_documentation_en-US" xlink:label="lab_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Principal And Interest Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrincipalAndInterestTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:to="lab_inbx_DebtInstrumentPrincipalAndInterestTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f71fd46c-95dd-49f6-9cb8-0f13c97cce8d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_558f5e76-1f6e-473a-b706-2f96ebfda9c2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_019cb42c-64e1-71cc-b915-782ff052201c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurements On a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_492f0032-b5eb-49cb-bf15-7face4267dc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables from related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7f3926c-c780-4162-915f-36feeeba4ba0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_1a39a590-56ce-47f2-a64e-f5f643a638ce_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial base rent per month</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Initial Base Rent Expense Per Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:to="lab_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_437304da-ccb5-4c94-bd86-87c15d58a566_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_fbfde4e8-b4ac-4545-b4dc-8ed6ff8070c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_5358b424-1961-4a5c-bf1e-35dc1f26889a_negatedTerseLabel_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-taxable gain related to Transaction with Acquirer</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_label_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-Taxable Gain Related to Transaction With Acquirer, Amount</link:label>
    <link:label id="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_documentation_en-US" xlink:label="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-Taxable Gain Related to Transaction With Acquirer, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:to="lab_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_863064b4-2259-4adf-93e0-2976b28d28e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_19aa3576-dae0-47b5-8fb3-2a37a5233df9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_7411f795-62d7-4d3e-b2b1-a99eb19a8eb8_terseLabel_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of License and Grant Revenue</link:label>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_label_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of License And Grant Revenue [Table Text Block]</link:label>
    <link:label id="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_documentation_en-US" xlink:label="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of License And Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:to="lab_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-73cf-8752-5983c6411522_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-a3a0-7a5a-b9f6-303c42e9d366_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad22dd98-ec98-4874-9a59-33c15145a87a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4d928687-9edd-4789-b066-c6b60d89f84a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a3c8030c-838e-40c3-b033-4fecd50399be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bb9b2ef2-dc6d-47e9-a735-dd5a3d8faa37_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7b5c8157-80e0-4d08-861f-82257a29d494_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-7e59-8c06-1dc8a3fb8c46_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_abe1a83e-81fe-469e-ae9d-430cb2e4368f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9684fc15-9659-4e6d-97b4-2726d8b53e5b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_8b4c6d39-8217-43de-916a-c658d1f8d62b_terseLabel_en-US" xlink:label="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement</link:label>
    <link:label id="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_label_en-US" xlink:label="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement</link:label>
    <link:label id="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_documentation_en-US" xlink:label="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:href="inbx-20251231.xsd#inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:to="lab_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d2ab03f1-bc29-4fb1-bbce-b20040ca73d7_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_d97b102f-08a0-44f1-95e9-2355e60c1c35_terseLabel_en-US" xlink:label="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical drug substance and product manufacturing</link:label>
    <link:label id="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_label_en-US" xlink:label="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Drug Substance and Product Manufacturing, Current</link:label>
    <link:label id="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_documentation_en-US" xlink:label="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Drug Substance and Product Manufacturing, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:to="lab_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated_ccf45040-92e7-47ac-acfe-32cd610687b6_terseLabel_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger-related</link:label>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated_label_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Merger-Related</link:label>
    <link:label id="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated_documentation_en-US" xlink:label="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense, Merger-Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpenseMergerRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:to="lab_inbx_GeneralAndAdministrativeExpenseMergerRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_e7ad797a-4843-435a-a0a2-fcd9ce64cd77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3961b735-2cd2-4ce1-839c-baa3e4a2a6a2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1a90a5fc-1dc2-4c72-a7f2-ebb214df5fbf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7f3c5df9-5deb-4fc5-a917-c855cf13127d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ee3497c5-920e-409b-a7f3-82bc642d3fd2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_935786e6-c3f3-47a5-89c5-161d1895163e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_ed338335-2e20-468f-bfe2-fe5000840644_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bb7b67c6-d865-4955-b22c-5ba86f4fbd1a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-79c2-bee9-c1bc5df425ac_terseLabel_en-US" xlink:label="lab_inbx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_inbx_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_inbx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_inbx_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_inbx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtMaturityAfterYearFour" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LongTermDebtMaturityAfterYearFour" xlink:to="lab_inbx_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_019c55da-ba5d-754b-b0ae-35b2f016fc67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a2b90c8a-e980-4844-9728-bb01c9daba6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpensePersonnel_3e0c8c51-e1bb-4eec-b624-b48cb1a7a219_terseLabel_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpensePersonnel_label_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Personnel</link:label>
    <link:label id="lab_inbx_ResearchAndDevelopmentExpensePersonnel_documentation_en-US" xlink:label="lab_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Personnel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpensePersonnel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:to="lab_inbx_ResearchAndDevelopmentExpensePersonnel" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_019b0726-7b2a-7d18-bd45-1ed6076ee131_terseLabel_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of common stock outstanding</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_label_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issuance As A Percent Of Common Stock Outstanding</link:label>
    <link:label id="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_documentation_en-US" xlink:label="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issuance As A Percent Of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:to="lab_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_30987414-2d8b-403d-ab6d-dc615b06fa86_terseLabel_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual escalations (as a percent)</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_label_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:label id="lab_inbx_LesseeOperatingLeaseAnnualEscalations_documentation_en-US" xlink:label="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Escalations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:to="lab_inbx_LesseeOperatingLeaseAnnualEscalations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_62b2befc-bc59-46e3-bbb2-e78a8b5e49bb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares in Distribution</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ff0ec6ac-26c5-44cd-8301-7c78a70767cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0faeb32-112b-4243-9bfa-092c9045b45b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_83b57ffc-cb01-45aa-924e-2553230e2f7c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7253a4ce-aabf-4484-856d-54232dfa0e59_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1463baef-aa3e-48ba-bfde-7aa9f5eb9252_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd82c26e-6312-4405-94e8-647c2c7f72d0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_028de10a-9b24-4075-bbda-27953f78bb75_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>inbx-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:811e73b3-aa5b-4218-a502-6be03cab6029,g:0b6704c1-8003-4b6f-9055-5dd09bdc0e3b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://inhibrx.com/role/Cover" xlink:type="simple" xlink:href="inbx-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a966a1f5-3e0b-48cd-85ef-57fb212f6686" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentType_a966a1f5-3e0b-48cd-85ef-57fb212f6686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_e783ee3f-f153-49fc-9f41-ae67a553a6ce" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentAnnualReport_e783ee3f-f153-49fc-9f41-ae67a553a6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_881273a0-699b-4bc5-8a2d-8055a1c9f3d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentPeriodEndDate_881273a0-699b-4bc5-8a2d-8055a1c9f3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_12b20c1b-cbf9-4362-886b-54d698d86955" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_CurrentFiscalYearEndDate_12b20c1b-cbf9-4362-886b-54d698d86955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6bc949a7-6fef-4e94-9ec7-09828797f136" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentTransitionReport_6bc949a7-6fef-4e94-9ec7-09828797f136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1769d944-5c41-4aba-8222-dd09bf723e93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityFileNumber_1769d944-5c41-4aba-8222-dd09bf723e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_55bba755-3275-4d4c-830b-0ea28dd75fa7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityRegistrantName_55bba755-3275-4d4c-830b-0ea28dd75fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_200a0e43-b31e-494f-80e3-f1095b6cda35" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_200a0e43-b31e-494f-80e3-f1095b6cda35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebb47270-ade0-4fcc-9441-8949c0320c64" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebb47270-ade0-4fcc-9441-8949c0320c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_254eb910-61eb-495e-9f2e-d627dca04d35" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityAddressAddressLine1_254eb910-61eb-495e-9f2e-d627dca04d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1786a566-7478-4773-9508-a234c27aa2bb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityAddressAddressLine2_1786a566-7478-4773-9508-a234c27aa2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_43f8aae7-99ab-4959-ba37-72c4b4b07a34" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityAddressCityOrTown_43f8aae7-99ab-4959-ba37-72c4b4b07a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2f2b3f29-e2ad-4d23-8d3d-9e96c73b7355" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityAddressStateOrProvince_2f2b3f29-e2ad-4d23-8d3d-9e96c73b7355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b4fb8f36-5186-416b-88b7-15aa039f2bc3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityAddressPostalZipCode_b4fb8f36-5186-416b-88b7-15aa039f2bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3d25303b-a83c-4caf-8127-973dada3399e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_CityAreaCode_3d25303b-a83c-4caf-8127-973dada3399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_519c2dcc-cecc-467f-a1ec-509223dd54d2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_LocalPhoneNumber_519c2dcc-cecc-467f-a1ec-509223dd54d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2fb848e4-e8d8-4e5a-9347-250aee2acc38" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_Security12bTitle_2fb848e4-e8d8-4e5a-9347-250aee2acc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7028c241-c592-47c0-b199-6997bd42f784" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_TradingSymbol_7028c241-c592-47c0-b199-6997bd42f784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b3bf3e2d-1702-4065-98ff-d3d6f01030de" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_SecurityExchangeName_b3bf3e2d-1702-4065-98ff-d3d6f01030de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8bfbbf7d-8667-4f8d-a5a6-fdf9f591871e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8bfbbf7d-8667-4f8d-a5a6-fdf9f591871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_a1acd327-c7dd-497e-b4ae-36b82ff0b359" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityVoluntaryFilers_a1acd327-c7dd-497e-b4ae-36b82ff0b359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ff0dc904-84d8-442e-9adc-06cc37f74d41" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityCurrentReportingStatus_ff0dc904-84d8-442e-9adc-06cc37f74d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_428c1f6c-bf85-4a17-b6f3-c90e62c1abce" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityInteractiveDataCurrent_428c1f6c-bf85-4a17-b6f3-c90e62c1abce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5c34b63d-a6ae-4267-9034-08af5dfefe87" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityFilerCategory_5c34b63d-a6ae-4267-9034-08af5dfefe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_86ddb979-30af-4026-8c16-8a653b9e7fbf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntitySmallBusiness_86ddb979-30af-4026-8c16-8a653b9e7fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bb24c1b4-5464-41e4-9df4-48dd7ca9b78e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityEmergingGrowthCompany_bb24c1b4-5464-41e4-9df4-48dd7ca9b78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_d9e1df9f-5fef-41e9-9688-25fc3ebb4a26" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityExTransitionPeriod_d9e1df9f-5fef-41e9-9688-25fc3ebb4a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ccfb7b78-0c5e-4190-a44e-5daa6532f5f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ccfb7b78-0c5e-4190-a44e-5daa6532f5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_0863e507-1575-4a5f-8128-cc39858b1158" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_0863e507-1575-4a5f-8128-cc39858b1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e1880993-28b2-4f69-9687-c2bafdfa35c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityShellCompany_e1880993-28b2-4f69-9687-c2bafdfa35c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4c5f992e-fe4b-4327-85a0-4c9b3ceee24b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityPublicFloat_4c5f992e-fe4b-4327-85a0-4c9b3ceee24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0073ee7d-3b72-444b-9a69-9f20f46dcde2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0073ee7d-3b72-444b-9a69-9f20f46dcde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ba607a8d-e2c2-492a-ac9d-49e4d7a33488" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ba607a8d-e2c2-492a-ac9d-49e4d7a33488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9a14bf53-3d9d-4d92-95ab-66c3973edfd3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_AmendmentFlag_9a14bf53-3d9d-4d92-95ab-66c3973edfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b41e8c41-3385-4582-acb0-44d06e3baaeb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_EntityCentralIndexKey_b41e8c41-3385-4582-acb0-44d06e3baaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a9aee028-2940-4c82-992c-e0a9b0314055" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentFiscalYearFocus_a9aee028-2940-4c82-992c-e0a9b0314055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2bfee386-75f0-4a34-92bf-746fb19a8fa8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0cf0338c-3577-479a-8099-be569f3e2041" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2bfee386-75f0-4a34-92bf-746fb19a8fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/AuditInformation" xlink:type="simple" xlink:href="inbx-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AuditInformationAbstract_1c02849e-eaaf-4de3-9a5d-a1d7503da64f" xlink:href="inbx-20251231.xsd#inbx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_413a3ab4-0fe5-4557-8def-70095f42145a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_1c02849e-eaaf-4de3-9a5d-a1d7503da64f" xlink:to="loc_dei_AuditorName_413a3ab4-0fe5-4557-8def-70095f42145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_86971ab4-3300-4e34-87d4-3332073f9dcb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_1c02849e-eaaf-4de3-9a5d-a1d7503da64f" xlink:to="loc_dei_AuditorLocation_86971ab4-3300-4e34-87d4-3332073f9dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_9e89a47f-ee8d-4681-8ef3-cf05da2279ee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_AuditInformationAbstract_1c02849e-eaaf-4de3-9a5d-a1d7503da64f" xlink:to="loc_dei_AuditorFirmId_9e89a47f-ee8d-4681-8ef3-cf05da2279ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_941e17dc-7875-499a-881d-2125da531018" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_941e17dc-7875-499a-881d-2125da531018" xlink:to="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ec56d0ab-5ee1-4059-9d0e-7f77a2cb015a" xlink:to="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_83ea89fc-6136-4233-8430-522f3b90ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:to="loc_us-gaap_NonrelatedPartyMember_83ea89fc-6136-4233-8430-522f3b90ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_6c7e9a20-89d2-4ec2-bc7f-8ea83a446627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a468c082-a96b-4425-b557-598bab939ac9" xlink:to="loc_us-gaap_RelatedPartyMember_6c7e9a20-89d2-4ec2-bc7f-8ea83a446627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fbd0765-53c8-4e83-ac34-d3966fd8425b" xlink:to="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:to="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646f60f-3879-4968-b00a-eaee1d5b050b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1646f60f-3879-4968-b00a-eaee1d5b050b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0e26c8ba-c3fe-406c-b04c-12868eb1a04e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0e26c8ba-c3fe-406c-b04c-12868eb1a04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_019b0688-e1ea-759f-b04d-c963e7f62e10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_019b0688-e1ea-759f-b04d-c963e7f62e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5f66882-fe73-46f0-9dd3-403402f9d588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c5f66882-fe73-46f0-9dd3-403402f9d588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_47882cee-3033-45e2-b42d-9831d122b94d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ac765eb-6ad8-4e0c-b7f3-16b5d9347f0e" xlink:to="loc_us-gaap_AssetsCurrent_47882cee-3033-45e2-b42d-9831d122b94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ceb8b5c3-2f6b-48cb-a13d-ff77e10c6fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ceb8b5c3-2f6b-48cb-a13d-ff77e10c6fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdc71fbd-a71c-46e8-90c9-0e544673ff8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdc71fbd-a71c-46e8-90c9-0e544673ff8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b89748bf-7708-4713-8b38-2d62801a1a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b89748bf-7708-4713-8b38-2d62801a1a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9da27281-dc28-44ca-b2c8-4404088f1cba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71884f92-dfeb-4389-ba10-bf5563fb0deb" xlink:to="loc_us-gaap_Assets_9da27281-dc28-44ca-b2c8-4404088f1cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_806edd91-d49b-481e-b262-f5d76ebe293f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_50243546-c2cb-46aa-99b0-6402a0bcd289" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_AccountsPayableCurrent_50243546-c2cb-46aa-99b0-6402a0bcd289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1a4099a4-9248-4c07-800e-3545036b5e37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1a4099a4-9248-4c07-800e-3545036b5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_43967ad5-46c1-4c09-856f-968a5cbbcafa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_43967ad5-46c1-4c09-856f-968a5cbbcafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_452928cc-c968-477e-aa2a-9087f0224593" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_36c37a2b-d6f0-4bc7-b71c-09c0ba5913a2" xlink:to="loc_us-gaap_LiabilitiesCurrent_452928cc-c968-477e-aa2a-9087f0224593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c5069c72-07c2-4f03-8bc4-cddb7b5fa7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c5069c72-07c2-4f03-8bc4-cddb7b5fa7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ae6dd2-9d1a-4dfa-af50-4ee93b518e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_75ae6dd2-9d1a-4dfa-af50-4ee93b518e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1b73a5d8-cdc5-4467-bc78-9cd63ba2d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_Liabilities_1b73a5d8-cdc5-4467-bc78-9cd63ba2d5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5a6fe1a7-06b7-48f1-b4a0-79bd02a0813b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5a6fe1a7-06b7-48f1-b4a0-79bd02a0813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4095f99f-78cd-4b20-9ab2-58ec7d6f95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_PreferredStockValue_4095f99f-78cd-4b20-9ab2-58ec7d6f95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96bce565-e220-4af4-b0b9-77929b4872c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_CommonStockValue_96bce565-e220-4af4-b0b9-77929b4872c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8039ca35-0cf3-45d9-ba63-5692638fbff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8039ca35-0cf3-45d9-ba63-5692638fbff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1df726c-5e2f-4e1f-bfe1-255d0a8f8859" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1df726c-5e2f-4e1f-bfe1-255d0a8f8859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d363a33-fa98-4b89-902a-c042875d0f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d41aa264-c5fb-4144-abe8-404c147f9c1e" xlink:to="loc_us-gaap_StockholdersEquity_5d363a33-fa98-4b89-902a-c042875d0f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff596f53-8d4f-455b-8bf8-561dd6712e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4343c0c4-9db6-4dbc-9259-cd554f58cd57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ff596f53-8d4f-455b-8bf8-561dd6712e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90a7097b-29b5-45f2-88aa-cf7b019d21ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_90a7097b-29b5-45f2-88aa-cf7b019d21ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9ac82594-57ef-43bb-81ad-e19f9bea6bae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9ac82594-57ef-43bb-81ad-e19f9bea6bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_edb39bab-9646-4f99-9fdc-8f219f89069f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_edb39bab-9646-4f99-9fdc-8f219f89069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7da2016-02d3-421c-8f48-9e3899ad4476" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7da2016-02d3-421c-8f48-9e3899ad4476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3b30641f-3b06-4990-83ad-aa8f1eb970d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3b30641f-3b06-4990-83ad-aa8f1eb970d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_827ece25-406e-4aef-8c26-73bcfb085d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_CommonStockSharesIssued_827ece25-406e-4aef-8c26-73bcfb085d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b2086be-1aa2-43a1-b87f-86b3ae6e8cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f8d9bb2-736c-4f1b-a718-284c8644a384" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b2086be-1aa2-43a1-b87f-86b3ae6e8cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_befca9a3-6fc5-4314-956f-b1a0d17ef89e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_befca9a3-6fc5-4314-956f-b1a0d17ef89e" xlink:to="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:to="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_69d50d97-344b-4a6d-9748-3786d6f6ec31" xlink:to="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_acec0f13-018a-45dd-8436-2f8ec1084e12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a429d54e-3048-4c86-8383-205d6db6e73c" xlink:to="loc_us-gaap_LicenseMember_acec0f13-018a-45dd-8436-2f8ec1084e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5b454a03-5d7c-4fe7-aa15-2246c591768a" xlink:to="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d74db658-2c2e-4d8d-8f8b-9534dbf8b4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e68f57d0-ba16-4173-a27e-0cc37e0a146f" xlink:to="loc_us-gaap_Revenues_d74db658-2c2e-4d8d-8f8b-9534dbf8b4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_215cc034-c93d-4d20-9206-36a4b540924e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_215cc034-c93d-4d20-9206-36a4b540924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f55c1c06-7870-49eb-9f05-14393076d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f55c1c06-7870-49eb-9f05-14393076d7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_64d575da-7d60-488f-9551-b29a6fd7c7df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_203320cd-6c56-41c5-aa99-4b7c6b6645e6" xlink:to="loc_us-gaap_OperatingExpenses_64d575da-7d60-488f-9551-b29a6fd7c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e7210159-1782-426b-9f62-c5176591c31c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OperatingIncomeLoss_e7210159-1782-426b-9f62-c5176591c31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_c641ec72-8b56-434f-a5f0-15f532961b70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_c641ec72-8b56-434f-a5f0-15f532961b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1d09aed6-0189-4e18-b7cf-c19caaa39ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1d09aed6-0189-4e18-b7cf-c19caaa39ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_InterestIncomeNonoperating_131d45f2-1946-4cbb-a6e4-64b690270900" xlink:href="inbx-20251231.xsd#inbx_InterestIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_inbx_InterestIncomeNonoperating_131d45f2-1946-4cbb-a6e4-64b690270900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_999a2032-44ff-4eb9-82b3-4bce08cf1588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_999a2032-44ff-4eb9-82b3-4bce08cf1588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b8dda759-9520-4a5e-a76f-6cbb1663cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_290e3d45-ac78-44b6-b782-b715e61b3315" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b8dda759-9520-4a5e-a76f-6cbb1663cbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c6639e6-21ae-49f9-818f-e122f8617475" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c6639e6-21ae-49f9-818f-e122f8617475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19cfa4b0-9fba-47b1-b7bf-0a972debb455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19cfa4b0-9fba-47b1-b7bf-0a972debb455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_929a322a-65fd-42a6-ac97-000538967c92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_NetIncomeLoss_929a322a-65fd-42a6-ac97-000538967c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9986a14-9cd6-4b02-8c68-0f0f4baf0ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9986a14-9cd6-4b02-8c68-0f0f4baf0ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b83e54cc-ac95-4038-9976-aa559d8df41c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5dd59bde-1990-494e-b3ca-af9d2b19cfc6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b83e54cc-ac95-4038-9976-aa559d8df41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c4d8119-8bc0-4986-8c5f-488f33173eb2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c3f2791-2149-4e6a-9d58-010839f40180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c3f2791-2149-4e6a-9d58-010839f40180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_726b82f1-3d9d-4364-a280-a07e9bd9cc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_299eecd3-a240-4c60-9136-1880bf678244" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_726b82f1-3d9d-4364-a280-a07e9bd9cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5bb9e4be-3f29-48be-a7d4-892d302032c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5bb9e4be-3f29-48be-a7d4-892d302032c0" xlink:to="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcab4b9b-4310-4184-aeb6-ccbdf71a38ca" xlink:to="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d2c17a37-cd7d-4de5-a3e2-bc9a098bf759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_CommonStockMember_d2c17a37-cd7d-4de5-a3e2-bc9a098bf759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_919614c9-9789-40d4-afaa-f989b7b57765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_919614c9-9789-40d4-afaa-f989b7b57765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dce1a236-6b57-4482-8876-49290ef9de5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_eea3d2d1-aca0-4948-a1f6-51a48c71a178" xlink:to="loc_us-gaap_RetainedEarningsMember_dce1a236-6b57-4482-8876-49290ef9de5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1652d85b-9014-4f63-877e-d5cc5e85614f" xlink:to="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2c320932-373a-47ee-a3f5-a2021d0f8874" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14382118-34a9-4b3c-84eb-707269546a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14382118-34a9-4b3c-84eb-707269546a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_59065b2b-ab3b-4bcc-befb-c022e551dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockholdersEquity_59065b2b-ab3b-4bcc-befb-c022e551dd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_55a14f70-9126-4c23-be0c-2780e6bd417a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_55a14f70-9126-4c23-be0c-2780e6bd417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b069c-a754-7825-ab2d-951f40f51272" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b069c-a754-7825-ab2d-951f40f51272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d992e0-c571-4f53-a972-0e20e0d9ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62d992e0-c571-4f53-a972-0e20e0d9ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dac18509-9b2a-4252-b70c-a62455cfeece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_dac18509-9b2a-4252-b70c-a62455cfeece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e4a8fbee-766f-4368-a067-64cac0f74d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e4a8fbee-766f-4368-a067-64cac0f74d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_72502252-2330-4ecd-abc2-c687dc55d369" xlink:href="inbx-20251231.xsd#inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock_72502252-2330-4ecd-abc2-c687dc55d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_92968289-2e08-4fec-bdf3-1b2cb4eb21fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_92968289-2e08-4fec-bdf3-1b2cb4eb21fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ee37464-bb70-4dae-b1f5-9caac7be4ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ee37464-bb70-4dae-b1f5-9caac7be4ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb858dc4-761b-4166-81e2-0f5436fbc5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb858dc4-761b-4166-81e2-0f5436fbc5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ed866dc-5fab-4c3a-ad0f-4546702537db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_NetIncomeLoss_8ed866dc-5fab-4c3a-ad0f-4546702537db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c0484af-d7e6-4a53-b7c0-986539aa6451" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c0484af-d7e6-4a53-b7c0-986539aa6451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bdff1d85-9a8f-471b-a4c6-dc4af9eb7e40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9bb4f735-51da-45fb-af03-818326b042a8" xlink:to="loc_us-gaap_StockholdersEquity_bdff1d85-9a8f-471b-a4c6-dc4af9eb7e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inbx-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43147aa9-7ec8-4d22-8f52-378c9e572458" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43147aa9-7ec8-4d22-8f52-378c9e572458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_650d065e-50e0-4bd5-b42b-44d02b157a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43147aa9-7ec8-4d22-8f52-378c9e572458" xlink:to="loc_us-gaap_NetIncomeLoss_650d065e-50e0-4bd5-b42b-44d02b157a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43147aa9-7ec8-4d22-8f52-378c9e572458" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c6442d35-db95-4218-84f8-8f1aae4d2546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c6442d35-db95-4218-84f8-8f1aae4d2546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9d3b22b7-0d6d-4232-8256-ae6cffa32003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9d3b22b7-0d6d-4232-8256-ae6cffa32003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_80e6b52a-e4e5-4aef-a743-d6f1b9527e60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_us-gaap_ShareBasedCompensation_80e6b52a-e4e5-4aef-a743-d6f1b9527e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NoncashOperatingLeaseExpense_2361cde9-b1b8-4d2e-8c67-ca576ca80aaf" xlink:href="inbx-20251231.xsd#inbx_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_inbx_NoncashOperatingLeaseExpense_2361cde9-b1b8-4d2e-8c67-ca576ca80aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_67d3037b-d740-4c03-9e7d-4e9478e7dde8" xlink:href="inbx-20251231.xsd#inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet_67d3037b-d740-4c03-9e7d-4e9478e7dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_50256d5b-347a-429b-8553-d6950087ba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_50256d5b-347a-429b-8553-d6950087ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1217a734-6335-4f74-84e7-e8c68982e555" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8f2e504-f0fb-42b9-b9d4-242a0ef842d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8f2e504-f0fb-42b9-b9d4-242a0ef842d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_019b06a5-79da-7fe0-9d46-f6548f5b7d30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_019b06a5-79da-7fe0-9d46-f6548f5b7d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_22e2e3c8-0934-4cec-9171-d290b27a9890" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_22e2e3c8-0934-4cec-9171-d290b27a9890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aabc6103-f2b2-40c8-b473-f8aa8a0f586e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aabc6103-f2b2-40c8-b473-f8aa8a0f586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_66b3efff-729a-405b-ad02-ecad09e821e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_66b3efff-729a-405b-ad02-ecad09e821e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7d33ca2a-1206-46f3-a57a-de4c77fc83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7d33ca2a-1206-46f3-a57a-de4c77fc83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_416c9ccb-7b22-4991-ba9c-7bb23877b49f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_416c9ccb-7b22-4991-ba9c-7bb23877b49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4c15ab7d-a9cf-4d75-b699-3556e7a21f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f66694cb-a25f-4d40-870d-b95acaf8806a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4c15ab7d-a9cf-4d75-b699-3556e7a21f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b407f15-97b9-4b66-bd6c-0d36d821a6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_43147aa9-7ec8-4d22-8f52-378c9e572458" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6b407f15-97b9-4b66-bd6c-0d36d821a6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c17c2e3-eb07-488b-9c23-6763b978e8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c17c2e3-eb07-488b-9c23-6763b978e8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a92799e-8e34-4666-ae4e-0c20dd4b0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c17c2e3-eb07-488b-9c23-6763b978e8f9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a92799e-8e34-4666-ae4e-0c20dd4b0a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019b06a6-c6a7-7d98-a6b1-7da9602f8421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c17c2e3-eb07-488b-9c23-6763b978e8f9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_019b06a6-c6a7-7d98-a6b1-7da9602f8421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab864f70-f6cc-4ffa-b296-47de9c5b73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6c17c2e3-eb07-488b-9c23-6763b978e8f9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab864f70-f6cc-4ffa-b296-47de9c5b73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019b06a7-8295-70b4-b794-9ccd51a5ccef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019b06a7-8295-70b4-b794-9ccd51a5ccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_019b06a8-7087-709d-ab9a-14c541ce29ea" xlink:href="inbx-20251231.xsd#inbx_PaymentsOfDebtIssuanceCostsSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:to="loc_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt_019b06a8-7087-709d-ab9a-14c541ce29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f38f06cc-418e-41f9-b49f-aa8f68482f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f38f06cc-418e-41f9-b49f-aa8f68482f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a99a382c-b886-44d8-af42-6f63c4ff644e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86fe4904-824a-4f6a-9f1a-dab1c63efdbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a99a382c-b886-44d8-af42-6f63c4ff644e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25eb0072-11d1-4ec7-af4a-e3d0737a268d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25eb0072-11d1-4ec7-af4a-e3d0737a268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4a012dd-8ca0-44c5-b0df-6c01cda86655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4a012dd-8ca0-44c5-b0df-6c01cda86655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_87c61ebc-159a-4f92-8e1a-b5995e73631a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_87c61ebc-159a-4f92-8e1a-b5995e73631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2667a145-8bf5-4994-8dfb-08fc69de2dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2667a145-8bf5-4994-8dfb-08fc69de2dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_6496fc78-d53a-4771-9c2f-91649b902e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2667a145-8bf5-4994-8dfb-08fc69de2dbb" xlink:to="loc_us-gaap_InterestPaidNet_6496fc78-d53a-4771-9c2f-91649b902e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_125fcd91-e315-4d2b-afe4-233f4e14a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2667a145-8bf5-4994-8dfb-08fc69de2dbb" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_125fcd91-e315-4d2b-afe4-233f4e14a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d0075235-70b6-4685-aa2b-2075b266adae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0938f496-c7ae-4a41-a1be-7761b89efb7c" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d0075235-70b6-4685-aa2b-2075b266adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_3ccb34cd-6ccf-4450-8ee4-30c542bb067d" xlink:href="inbx-20251231.xsd#inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d0075235-70b6-4685-aa2b-2075b266adae" xlink:to="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_3ccb34cd-6ccf-4450-8ee4-30c542bb067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_019b06a9-d606-7ce3-8f9d-56db12cbce69" xlink:href="inbx-20251231.xsd#inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d0075235-70b6-4685-aa2b-2075b266adae" xlink:to="loc_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred_019b06a9-d606-7ce3-8f9d-56db12cbce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_497baf3f-3be2-49c0-884d-117f03eedfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f7ce618c-4758-48da-a8df-1edeb81a7b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_497baf3f-3be2-49c0-884d-117f03eedfb1" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f7ce618c-4758-48da-a8df-1edeb81a7b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0003341b-d48b-4186-8111-6b287db044e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f85017ff-f61c-42ce-9092-9380fee2c0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0003341b-d48b-4186-8111-6b287db044e4" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f85017ff-f61c-42ce-9092-9380fee2c0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBT" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8a8c9c62-69cb-4fdf-b87b-fc15e10da2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1e3ad6d7-a9a1-46cb-84d8-341ae6ae440f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8a8c9c62-69cb-4fdf-b87b-fc15e10da2f3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1e3ad6d7-a9a1-46cb-84d8-341ae6ae440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9c9ba173-fc17-4a17-a10a-59aa45899c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3e52d7cc-caae-45a5-91d8-dcdbd1b9ead5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9c9ba173-fc17-4a17-a10a-59aa45899c8b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3e52d7cc-caae-45a5-91d8-dcdbd1b9ead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLAN"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c68052a-5d5e-43d4-ad6d-d9749bb24498" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3356d7e-148e-48e6-8148-0ce8baa69da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c68052a-5d5e-43d4-ad6d-d9749bb24498" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3356d7e-148e-48e6-8148-0ce8baa69da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUE" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUE"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEREVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_63f19550-0ca7-4dd1-9db7-2e4aacbf6b17" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAndGrantRevenueTextBlock_019b0741-2984-78e5-8762-a6473f62b9b9" xlink:href="inbx-20251231.xsd#inbx_LicenseAndGrantRevenueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_63f19550-0ca7-4dd1-9db7-2e4aacbf6b17" xlink:to="loc_inbx_LicenseAndGrantRevenueTextBlock_019b0741-2984-78e5-8762-a6473f62b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="inbx-20251231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d097fa54-b6e8-45eb-b67f-eb99a053799c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f88ab50c-5afd-45a3-bffe-cfcfc25523dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d097fa54-b6e8-45eb-b67f-eb99a053799c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_f88ab50c-5afd-45a3-bffe-cfcfc25523dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXES" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c96471e0-b8e9-42c6-b539-cf3cfd1134cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_48d6bb58-3b21-4ad1-9b59-bd85f86e6f12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c96471e0-b8e9-42c6-b539-cf3cfd1134cb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_48d6bb58-3b21-4ad1-9b59-bd85f86e6f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASES" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c86fd09a-8f4d-4f42-9a8c-f8d24f98f481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_44002f2a-f34b-409c-8bce-029a4d2aa906" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c86fd09a-8f4d-4f42-9a8c-f8d24f98f481" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_44002f2a-f34b-409c-8bce-029a4d2aa906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="inbx-20251231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c18c277-f0fc-439b-bd77-536b9bd2d781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8fab5745-a3de-49b9-a548-6e678d858908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c18c277-f0fc-439b-bd77-536b9bd2d781" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8fab5745-a3de-49b9-a548-6e678d858908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="inbx-20251231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_190a4d26-3829-48a8-8d90-828ea0bfadc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_0f70d917-e1a6-41d8-ac73-a07781bb4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_190a4d26-3829-48a8-8d90-828ea0bfadc9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_0f70d917-e1a6-41d8-ac73-a07781bb4e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bc65132b-1a3c-4868-ab06-7f7f35d9ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bc65132b-1a3c-4868-ab06-7f7f35d9ef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d9cc7b79-1b86-467f-bca8-99f95952ad0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d9cc7b79-1b86-467f-bca8-99f95952ad0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LiquidityPolicyTextBlock_33c28023-a1c3-42aa-a188-421ec1ff5cd5" xlink:href="inbx-20251231.xsd#inbx_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_inbx_LiquidityPolicyTextBlock_33c28023-a1c3-42aa-a188-421ec1ff5cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_623bf8ba-caeb-4c7d-b98c-5d9c13d7e7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_UseOfEstimates_623bf8ba-caeb-4c7d-b98c-5d9c13d7e7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b305980f-dba9-4bfa-a00a-45f8977e05c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b305980f-dba9-4bfa-a00a-45f8977e05c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9b2a4a1e-6b99-40cd-81ec-f2c7934499a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9b2a4a1e-6b99-40cd-81ec-f2c7934499a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_9a95a297-9146-4a6c-8366-7ba37a489576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_9a95a297-9146-4a6c-8366-7ba37a489576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9430831e-0fee-4f14-aa48-507a5f841084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9430831e-0fee-4f14-aa48-507a5f841084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8a4f437e-275c-40ef-a8ea-ba926c29793b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8a4f437e-275c-40ef-a8ea-ba926c29793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3eaa7a23-b228-4ceb-91ab-2f1da1f00371" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_3eaa7a23-b228-4ceb-91ab-2f1da1f00371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_d09553c4-16c3-4c1b-82c9-f3c444c947b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_d09553c4-16c3-4c1b-82c9-f3c444c947b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_30d56c1f-c461-4626-bd15-aed82c7c6de8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_30d56c1f-c461-4626-bd15-aed82c7c6de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9d4501b7-8f83-43c5-b445-46bece4bb48b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9d4501b7-8f83-43c5-b445-46bece4bb48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_c7e477ef-222a-4808-a139-95f2e6596e29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_c7e477ef-222a-4808-a139-95f2e6596e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsPolicyPolicyTextBlock_caaf92e8-7b39-4c66-b17c-efcdb1e29045" xlink:href="inbx-20251231.xsd#inbx_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_inbx_WarrantsPolicyPolicyTextBlock_caaf92e8-7b39-4c66-b17c-efcdb1e29045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_80a6be3e-b649-4cf6-8db9-467fe091820b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_80a6be3e-b649-4cf6-8db9-467fe091820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_920385b6-be79-452d-b917-03b68264a585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_920385b6-be79-452d-b917-03b68264a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2c443fef-ae5d-4e61-80bd-2d71b6524530" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2c443fef-ae5d-4e61-80bd-2d71b6524530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_302aba3a-189f-4707-a5a0-a68b3cbca003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_302aba3a-189f-4707-a5a0-a68b3cbca003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_530a58dc-3d15-48ca-a758-c31e8d22f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_530a58dc-3d15-48ca-a758-c31e8d22f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8cbd104a-7131-486f-8456-5767ee5862d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8cbd104a-7131-486f-8456-5767ee5862d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cd30b249-486a-49db-b0fe-7523afaf169b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cd30b249-486a-49db-b0fe-7523afaf169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ca9e3fd-adb7-4472-963d-9765efe76304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37292c48-58d9-4300-9a2c-990a8a29f6a5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4ca9e3fd-adb7-4472-963d-9765efe76304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dbb9c46-3d03-4d9b-99c4-ece48a8d9484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfMergerTransactionTableTextBlock_c834b119-001c-41d1-ad54-2949239ca684" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfMergerTransactionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dbb9c46-3d03-4d9b-99c4-ece48a8d9484" xlink:to="loc_inbx_ScheduleOfMergerTransactionTableTextBlock_c834b119-001c-41d1-ad54-2949239ca684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_019cb42c-64e1-74ce-adfa-226772a8ed22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dbb9c46-3d03-4d9b-99c4-ece48a8d9484" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_019cb42c-64e1-74ce-adfa-226772a8ed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f6d75b55-f6c5-45a7-a7dc-f8b234033810" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dbb9c46-3d03-4d9b-99c4-ece48a8d9484" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f6d75b55-f6c5-45a7-a7dc-f8b234033810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d00efe17-39a0-4c4f-91df-08474d411f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dbb9c46-3d03-4d9b-99c4-ece48a8d9484" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d00efe17-39a0-4c4f-91df-08474d411f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91c22f1a-f0ca-46a7-9657-0aacf16fb02e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_cd41954f-b25b-460a-985d-d5648aa4931d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91c22f1a-f0ca-46a7-9657-0aacf16fb02e" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_cd41954f-b25b-460a-985d-d5648aa4931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9b9ec78f-e25a-4e7b-b2de-af838163ebe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91c22f1a-f0ca-46a7-9657-0aacf16fb02e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9b9ec78f-e25a-4e7b-b2de-af838163ebe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_aaa44854-04f1-43fd-9104-b040f3a024b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_91c22f1a-f0ca-46a7-9657-0aacf16fb02e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_aaa44854-04f1-43fd-9104-b040f3a024b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_28fb0496-3459-4dfb-889b-b9b41dcceca6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0973788d-8afa-4c5d-afd8-072381ab18c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_28fb0496-3459-4dfb-889b-b9b41dcceca6" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0973788d-8afa-4c5d-afd8-072381ab18c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_79b3e718-abbe-4bd2-a629-baab571ca511" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_28fb0496-3459-4dfb-889b-b9b41dcceca6" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_79b3e718-abbe-4bd2-a629-baab571ca511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6058142c-f1cb-4b4a-8fff-5c00552982f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_4fc2a6b1-31f6-4f3a-b45c-4faf3992d2f7" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6058142c-f1cb-4b4a-8fff-5c00552982f9" xlink:to="loc_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_4fc2a6b1-31f6-4f3a-b45c-4faf3992d2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_610b6ba1-6570-4c25-9df4-9efa1fdb8e79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_908a72a7-f50e-4eec-a9e9-ea1eee21a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_610b6ba1-6570-4c25-9df4-9efa1fdb8e79" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_908a72a7-f50e-4eec-a9e9-ea1eee21a14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8cf3daab-93ef-4cbe-9d13-a38100f2c33e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_610b6ba1-6570-4c25-9df4-9efa1fdb8e79" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8cf3daab-93ef-4cbe-9d13-a38100f2c33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_43704ad5-f8cc-4b7e-9a5d-b965d1223685" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_610b6ba1-6570-4c25-9df4-9efa1fdb8e79" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_43704ad5-f8cc-4b7e-9a5d-b965d1223685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUETables" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUETables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEREVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_f0b02c86-fc65-47f3-97a5-a8617ed5e382" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_c252a675-53c5-449c-bf87-7e0ea44a0554" xlink:href="inbx-20251231.xsd#inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_f0b02c86-fc65-47f3-97a5-a8617ed5e382" xlink:to="loc_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock_c252a675-53c5-449c-bf87-7e0ea44a0554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019cb477-5cca-7c08-9f22-92c9d9a27b36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_019cb477-5cca-7c08-9f22-92c9d9a27b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_955b49f9-13c7-4926-adbf-b46e07f36371" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_955b49f9-13c7-4926-adbf-b46e07f36371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_decc6d0e-3d90-4f56-8581-74c9f3245018" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_decc6d0e-3d90-4f56-8581-74c9f3245018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_47dd51e0-5c91-473e-9701-6454b8cc5098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_47dd51e0-5c91-473e-9701-6454b8cc5098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4a3c05e1-ecdd-4c95-9a03-91e6a855c57c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c70bcad-e2bd-4778-ac4a-341b59b67cfb" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4a3c05e1-ecdd-4c95-9a03-91e6a855c57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESTables" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2fab1942-5f74-4cd5-97a0-aa46799f4a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_9b36e361-2dc5-4fee-ab54-f497236bca32" xlink:href="inbx-20251231.xsd#inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fab1942-5f74-4cd5-97a0-aa46799f4a40" xlink:to="loc_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock_9b36e361-2dc5-4fee-ab54-f497236bca32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_765c8b93-6218-4026-8b63-44866a045767" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fab1942-5f74-4cd5-97a0-aa46799f4a40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_765c8b93-6218-4026-8b63-44866a045767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7afa5776-3d1f-4ffd-9c56-ba94b6401b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7afa5776-3d1f-4ffd-9c56-ba94b6401b06" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_226c337b-d875-4d57-a88f-cf5e5fa3df71" xlink:to="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_195787d9-c60c-4cf1-978b-afc539219bf0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:to="loc_srt_MinimumMember_195787d9-c60c-4cf1-978b-afc539219bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ddec267e-21a3-4ecd-992d-7a2f1a18b94b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b9774947-c326-4761-b177-ecb888fe86a2" xlink:to="loc_srt_MaximumMember_ddec267e-21a3-4ecd-992d-7a2f1a18b94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e26a0f3a-419e-43e5-9ec3-967bd6103823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_67795f54-9a69-4b02-915d-44157daef8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_67795f54-9a69-4b02-915d-44157daef8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ddb1834a-3242-46a3-87ba-197255b6e590" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ddb1834a-3242-46a3-87ba-197255b6e590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d2001894-ed33-4159-a18c-b2fcdbc1b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_099d747c-a3d8-4bae-8c5d-2782f15d0dcd" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d2001894-ed33-4159-a18c-b2fcdbc1b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_339d34ac-45d0-4801-8ae9-d1e74cdf73de" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PhylaxisBioScienceLLCMember_3d13b31e-d9ce-488c-bc20-e4aacd98ebcb" xlink:href="inbx-20251231.xsd#inbx_PhylaxisBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_22b2c833-ee8f-4933-9190-a58b5882946a" xlink:to="loc_inbx_PhylaxisBioScienceLLCMember_3d13b31e-d9ce-488c-bc20-e4aacd98ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1cafbfa0-b2d3-4aa6-b27f-ae90649c8d39" xlink:to="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AventisIncMember_54645d40-9945-47d4-ad73-d7cf1fad64eb" xlink:href="inbx-20251231.xsd#inbx_AventisIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9aa651f2-63fd-465a-96eb-1e8701789f82" xlink:to="loc_inbx_AventisIncMember_54645d40-9945-47d4-ad73-d7cf1fad64eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_95a16845-c286-49fd-8553-a3e429fd84c6" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerConsiderationMember_53387671-56bd-4a0d-b82a-d454b6621bd5" xlink:href="inbx-20251231.xsd#inbx_MergerConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_4f0d33fb-8a12-4aad-bb2c-ba4fe45243cd" xlink:to="loc_inbx_MergerConsiderationMember_53387671-56bd-4a0d-b82a-d454b6621bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1b11a63-0107-41f7-bc71-9429f9a5f639" xlink:to="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_21833b8e-7f6c-441d-9e39-825b56c4aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:to="loc_us-gaap_RetainedEarningsMember_21833b8e-7f6c-441d-9e39-825b56c4aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f28200e4-594c-4739-9eca-97208bdeaa8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04d9b1d7-ff3e-418b-b94f-d21eb46219fb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f28200e4-594c-4739-9eca-97208bdeaa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8ddf4f6e-6609-445f-baae-53ad302409ef" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51aad08a-84ff-4bc3-a6cb-5e26c3eda7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2236cf3f-f093-4883-a672-e2cc38a8420a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51aad08a-84ff-4bc3-a6cb-5e26c3eda7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_41685aae-50dd-4cdf-bfa5-688fcf40e578" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cfc6179-b4e6-46b8-b8a6-54474500025d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb58560-6294-40f9-bd01-9fd34856d11d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cfc6179-b4e6-46b8-b8a6-54474500025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aba868af-77a4-445e-aef4-728cdfd06eab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatioProRateBasisPercentage_650b4a05-5c7b-46f2-af64-4934087c4640" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatioProRateBasisPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerExchangeRatioProRateBasisPercentage_650b4a05-5c7b-46f2-af64-4934087c4640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_e6295e3d-e65b-4762-a4ac-a8521c3cb2c8" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_e6295e3d-e65b-4762-a4ac-a8521c3cb2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_2bfecc02-d5d2-4905-bfb3-a90c60ddcddf" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_2bfecc02-d5d2-4905-bfb3-a90c60ddcddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_182db282-ba89-405f-a235-906399c9b0d6" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_182db282-ba89-405f-a235-906399c9b0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatio_fc16a102-ff30-4c78-9883-5d207e55cf9b" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerExchangeRatio_fc16a102-ff30-4c78-9883-5d207e55cf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_688e7f17-b6a1-4f5b-9ec5-beb75d763d4d" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_MergerOwnershipPercentage_688e7f17-b6a1-4f5b-9ec5-beb75d763d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fb49f798-78e4-40bd-a247-6df9bf26474f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fb49f798-78e4-40bd-a247-6df9bf26474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7a6fa495-932c-424a-ac51-50e075aab59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_7a6fa495-932c-424a-ac51-50e075aab59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_1943dacb-fbb3-4a0b-b735-a5862259595e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_1943dacb-fbb3-4a0b-b735-a5862259595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a9ca35b6-5c53-43f0-89b6-989c2d0fb435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a9ca35b6-5c53-43f0-89b6-989c2d0fb435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94ebebd-8dac-45c1-8b5f-61c50e25c057" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94ebebd-8dac-45c1-8b5f-61c50e25c057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a47dbb5c-5b0b-470f-930a-405a01766487" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a47dbb5c-5b0b-470f-930a-405a01766487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f8b11470-e446-4247-a328-70bf9d83b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f8b11470-e446-4247-a328-70bf9d83b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dd85227-aa20-43a0-82a7-361b75c8beea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8dd85227-aa20-43a0-82a7-361b75c8beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_c21354c8-b7cb-4711-83a6-69a80901fedb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_EquityMethodInvestments_c21354c8-b7cb-4711-83a6-69a80901fedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_c82f8847-d9c8-445b-ba25-1194e26e633a" xlink:href="inbx-20251231.xsd#inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod_c82f8847-d9c8-445b-ba25-1194e26e633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_725ae0a9-4606-44b8-8856-c39ab0df0607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_725ae0a9-4606-44b8-8856-c39ab0df0607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EarningsDistributionRatio_32145c75-d905-41d2-8b1d-88d312e2a951" xlink:href="inbx-20251231.xsd#inbx_EarningsDistributionRatio"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_inbx_EarningsDistributionRatio_32145c75-d905-41d2-8b1d-88d312e2a951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cf638915-f4ee-4c06-970a-34e97acf4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cf638915-f4ee-4c06-970a-34e97acf4fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_bf35a80c-6663-4aa1-a0da-fdd27e61d174" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9ec66b47-20e0-4222-a26c-bbc00909b757" xlink:to="loc_us-gaap_NumberOfReportableSegments_bf35a80c-6663-4aa1-a0da-fdd27e61d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c6902-d048-4a5b-b51f-a5db85e8e7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_876c6902-d048-4a5b-b51f-a5db85e8e7c5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeAxis_79f500f0-b817-4ed9-a2f9-538b05cfab61" xlink:to="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerConsiderationMember_c4daa904-7d83-48b9-9e45-dca50a43e36f" xlink:href="inbx-20251231.xsd#inbx_MergerConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_MergerConsiderationMember_c4daa904-7d83-48b9-9e45-dca50a43e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LoansAssumedByAcquirerMember_2ad5a774-b533-49b7-accd-67232a3f1eae" xlink:href="inbx-20251231.xsd#inbx_LoansAssumedByAcquirerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_LoansAssumedByAcquirerMember_2ad5a774-b533-49b7-accd-67232a3f1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_c8f43969-810c-4cbd-876a-43309e1c0621" xlink:href="inbx-20251231.xsd#inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember_c8f43969-810c-4cbd-876a-43309e1c0621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_TransactionCostsPaidByAcquirerMember_79213ee3-ad89-450c-976b-e9560f7eadad" xlink:href="inbx-20251231.xsd#inbx_TransactionCostsPaidByAcquirerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonmonetaryTransactionTypeDomain_6b17eadc-7c20-4cf8-9920-48aae131bebb" xlink:to="loc_inbx_TransactionCostsPaidByAcquirerMember_79213ee3-ad89-450c-976b-e9560f7eadad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ae5b679d-63f5-4792-ad3f-d88447a48e08" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_6fb47b8b-0101-4dfb-b859-b38d68d12f03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c802377e-5648-4224-b07f-1b6a1381e720" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_6fb47b8b-0101-4dfb-b859-b38d68d12f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cb430-5fc7-722a-8800-9e81b1995ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cb430-5fc7-722a-8800-9e81b1995ee4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_019cb439-931b-7183-b0e0-cc2342b807a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cb439-931b-7099-b39b-703773c673b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_019cb439-931b-7d57-b2d8-1007f2e56cf1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cb439-931b-7099-b39b-703773c673b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cb439-931b-7271-870a-d131a8bc5308" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cb439-931b-74fd-9bd6-b7592f541609" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cb439-931b-74fd-9bd6-b7592f541609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cb439-931b-7409-a628-42837eb5141e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cb439-931b-7409-a628-42837eb5141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cb439-931b-7bee-a9d6-17b6383339d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cb439-931b-7548-b22e-2be99da120a6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cb439-931b-7bee-a9d6-17b6383339d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_019cb439-931b-73e1-8e35-a763660384dd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb439-931b-7320-8097-ca1b5e950e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_019cb439-931b-74d6-83e1-78ba12c5e44b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cb439-931b-7320-8097-ca1b5e950e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0320448e-ac14-405e-8eed-9f9c4250cbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0320448e-ac14-405e-8eed-9f9c4250cbe8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82e24050-b47b-4992-831d-6d279b516958" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f234c61d-b0e5-41d9-885e-d017ce4d8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f234c61d-b0e5-41d9-885e-d017ce4d8b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fe5ec883-66e8-444f-b999-41130b3afef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_221d55ed-7459-42fb-bdee-3c85a7b07e33" xlink:to="loc_us-gaap_WarrantMember_fe5ec883-66e8-444f-b999-41130b3afef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_95b46803-fbc5-4da1-b3b4-9936210e6479" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d394a40f-25b8-434f-a4b2-734f5814e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e527ffaf-a65b-4ecf-83f5-7eff9ec06148" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d394a40f-25b8-434f-a4b2-734f5814e5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_179e9f7d-1a2f-404f-b063-746b09e28108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_179e9f7d-1a2f-404f-b063-746b09e28108" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9001184-d7af-47b7-b83b-8c36853d5525" xlink:to="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ReportableSegmentMember_1ecb8c91-033b-4383-87a2-a470c717c234" xlink:href="inbx-20251231.xsd#inbx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2bb00db1-013f-46cd-8f49-15f4aeca035f" xlink:to="loc_inbx_ReportableSegmentMember_1ecb8c91-033b-4383-87a2-a470c717c234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d7fac9b7-b56d-468a-9384-f8d2703bf2ea" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3d4b8d74-da3b-449e-82ac-d30c84603a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_Revenues_3d4b8d74-da3b-449e-82ac-d30c84603a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpensePersonnel_21e1bc9a-7322-4f85-a987-3b9ee4bd23b9" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpensePersonnel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpensePersonnel_21e1bc9a-7322-4f85-a987-3b9ee4bd23b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_025ca0d0-8957-4c2e-9851-4e7346d92493" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseClinicalTrials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseClinicalTrials_025ca0d0-8957-4c2e-9851-4e7346d92493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_d1826dc8-00b9-4c8d-b857-d17ff8e6aa5e" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseContractManufacturing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseContractManufacturing_d1826dc8-00b9-4c8d-b857-d17ff8e6aa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_48069b13-7698-4d2e-8918-01b2c44a6752" xlink:href="inbx-20251231.xsd#inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility_48069b13-7698-4d2e-8918-01b2c44a6752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_fd63db64-0ba8-4d7e-aa33-a7fa88599ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fc98ccd8-a4da-4a73-8914-22b4a66c3f3a" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_fd63db64-0ba8-4d7e-aa33-a7fa88599ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_126cfdbc-f5c8-44b1-933a-859cac724be0" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpenseMergerRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_inbx_GeneralAndAdministrativeExpenseMergerRelated_126cfdbc-f5c8-44b1-933a-859cac724be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_GeneralAndAdministrativeExpensePersonnel_2321f1c3-f3c0-404b-a288-6b90877785e6" xlink:href="inbx-20251231.xsd#inbx_GeneralAndAdministrativeExpensePersonnel"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_inbx_GeneralAndAdministrativeExpensePersonnel_2321f1c3-f3c0-404b-a288-6b90877785e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_f2e2eb30-43b5-436f-a74a-cdae4a96fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_2ce242ca-cb2a-4818-a92f-49423f5709ee" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_f2e2eb30-43b5-436f-a74a-cdae4a96fcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8fba34d5-4d0e-4dd3-91f7-8d5a88b69e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8fba34d5-4d0e-4dd3-91f7-8d5a88b69e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cb44d-7694-73f8-b29f-c8cd42f818a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer_019cb44d-7694-73f8-b29f-c8cd42f818a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_4ec99416-8238-4cb9-8970-84366d8e92d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_4ec99416-8238-4cb9-8970-84366d8e92d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96720281-b045-46b3-b30a-f12282003d20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3ff33b7-0696-4b19-874e-fcc4e73e7576" xlink:to="loc_us-gaap_NetIncomeLoss_96720281-b045-46b3-b30a-f12282003d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent_1866e521-b0d0-4fdb-b6fc-c7e4413eb8fb" xlink:href="inbx-20251231.xsd#inbx_ClinicalTrailsPrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_inbx_ClinicalTrailsPrepaidExpenseCurrent_1866e521-b0d0-4fdb-b6fc-c7e4413eb8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_d492a393-fd98-48d6-8875-e62f7769b2b9" xlink:href="inbx-20251231.xsd#inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent_d492a393-fd98-48d6-8875-e62f7769b2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PrepaidLicenseCurrent_7cf1a0ae-0bf4-4d3e-b1c2-d617dc3856d0" xlink:href="inbx-20251231.xsd#inbx_PrepaidLicenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_inbx_PrepaidLicenseCurrent_7cf1a0ae-0bf4-4d3e-b1c2-d617dc3856d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_0ecf1f6d-1412-4bcf-bb34-4d4cb994c7ac" xlink:href="inbx-20251231.xsd#inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent_0ecf1f6d-1412-4bcf-bb34-4d4cb994c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_311fe7b2-64f2-4d2c-9efd-7d34634502e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_us-gaap_OtherAssetsCurrent_311fe7b2-64f2-4d2c-9efd-7d34634502e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ae31c4b-70e8-42ea-ab30-fc580fe8a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833bc8c6-02ee-430d-b646-0f8426900d4e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ae31c4b-70e8-42ea-ab30-fc580fe8a7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d62aaf3c-e0ff-4d8b-8628-f89a0dec012f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d62aaf3c-e0ff-4d8b-8628-f89a0dec012f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_40df653f-2b82-4585-a000-ed8186682385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c28537ba-b78b-47be-a832-38f9cb656b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c28537ba-b78b-47be-a832-38f9cb656b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_f8c7d01e-e47c-49af-a0ae-7fd5cb63b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_f8c7d01e-e47c-49af-a0ae-7fd5cb63b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e7457793-81db-49e4-a806-f44838b5d9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e7457793-81db-49e4-a806-f44838b5d9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a35ac162-4eee-49ee-8563-d31f3ac9d21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d2c91499-af61-4e47-96a0-1ca265fd6008" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a35ac162-4eee-49ee-8563-d31f3ac9d21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_338e80f7-2d29-44d9-9694-6dcaf05a2e47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7d63dcb0-94b0-4a32-a806-9e7eac0041a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7d63dcb0-94b0-4a32-a806-9e7eac0041a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7f2d41b6-549d-4c9c-a75a-efe24c2dcdda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7f2d41b6-549d-4c9c-a75a-efe24c2dcdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44214a85-9793-4400-89b1-9f1b5757a3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_efb8e996-59e7-4666-b42f-80f46376dcf1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44214a85-9793-4400-89b1-9f1b5757a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cd619ef-3692-4357-b764-2fa90517bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cd619ef-3692-4357-b764-2fa90517bdf2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7a93dbb-643a-470e-ac91-8df9e9cc9cf5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eb70b5e9-1b7b-455c-a2da-1869c2c83785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_eb70b5e9-1b7b-455c-a2da-1869c2c83785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa741f45-a5f4-4142-8d99-b221bb95eea2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_28b9dfd6-ab05-41a7-8f73-28e2c91d9c72" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_aa741f45-a5f4-4142-8d99-b221bb95eea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6437f3ae-86ea-445e-8181-faec5bec4ba8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_09dbd71d-a7ac-48ce-9e8f-2ed9e70b5ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00f35746-98f2-4bc6-a89d-03c0a7d6bdc9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_09dbd71d-a7ac-48ce-9e8f-2ed9e70b5ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalTrialsCurrent_327e230a-3296-476c-b25e-fb1180f36e65" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalTrialsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_inbx_AccruedClinicalTrialsCurrent_327e230a-3296-476c-b25e-fb1180f36e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0852c80c-d893-445b-94ff-3f663722c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0852c80c-d893-445b-94ff-3f663722c40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_1bb897d2-c41f-4be8-aa48-cea8f53a9088" xlink:href="inbx-20251231.xsd#inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent_1bb897d2-c41f-4be8-aa48-cea8f53a9088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_11aa63cf-6d5b-45fc-aa52-b88572da40d9" xlink:href="inbx-20251231.xsd#inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent_11aa63cf-6d5b-45fc-aa52-b88572da40d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5e393c01-3834-42c8-abfa-7a4e5dbf773a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5e393c01-3834-42c8-abfa-7a4e5dbf773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AccruedInterestExpenseCurrent_60ef060e-4bfb-4bed-ae4c-525e4b64e428" xlink:href="inbx-20251231.xsd#inbx_AccruedInterestExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_inbx_AccruedInterestExpenseCurrent_60ef060e-4bfb-4bed-ae4c-525e4b64e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79e00a13-25f6-41e4-8954-0532b43fcc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_79e00a13-25f6-41e4-8954-0532b43fcc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_376cbbd7-8c78-447d-adbc-acee52114106" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f21c86f1-4c0a-40da-8f73-85af141e040b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_376cbbd7-8c78-447d-adbc-acee52114106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e8782819-6c5c-4a4b-abde-a378fe0b4f54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e8782819-6c5c-4a4b-abde-a378fe0b4f54" xlink:to="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af3c7848-ce5d-4f55-ba08-ecc7ccdd8a3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_534e0c9a-c112-4198-8243-ce94b8c97dab" xlink:href="inbx-20251231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:to="loc_inbx_A2020OxfordTermLoansMember_534e0c9a-c112-4198-8243-ce94b8c97dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2025LoanAgreementMember_019cb45a-bda5-7509-9f3f-cc5127ae787a" xlink:href="inbx-20251231.xsd#inbx_A2025LoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6b6b033d-4457-4f56-9ea5-4b50b5e4b430" xlink:to="loc_inbx_A2025LoanAgreementMember_019cb45a-bda5-7509-9f3f-cc5127ae787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6346d5e7-d768-4906-ae0f-3926ec294e82" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d2c7d0f2-321e-43c7-b5df-ceaee19f6c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:to="loc_us-gaap_SecuredDebtMember_d2c7d0f2-321e-43c7-b5df-ceaee19f6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b071b-de0c-7d6e-a737-003bb8fe020f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9c94e8b8-48cb-4a7f-b08d-6c2a28dc165c" xlink:to="loc_us-gaap_LineOfCreditMember_019b071b-de0c-7d6e-a737-003bb8fe020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6dba8968-8d5b-4a3c-a792-e18f893664d1" xlink:to="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fd5db87f-d78c-4bda-98f7-8418e60995e5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:to="loc_srt_MinimumMember_fd5db87f-d78c-4bda-98f7-8418e60995e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29d56404-d75e-42b8-bde3-db88db35d31e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_798da016-0db6-4e6d-b4af-91991475b837" xlink:to="loc_srt_MaximumMember_29d56404-d75e-42b8-bde3-db88db35d31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019b071b-de0c-767a-9a70-30887ed553e3" xlink:to="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b071b-de0c-7706-87c6-3cac03b54770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019b071b-de0c-7c19-abe4-7c4e28424a8c" xlink:to="loc_us-gaap_SecuredDebtMember_019b071b-de0c-7706-87c6-3cac03b54770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67145b72-b353-4abf-8494-86a17ab1a207" xlink:to="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4712c15e-9fc0-4679-a732-650e28ef71aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4712c15e-9fc0-4679-a732-650e28ef71aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfTranches_611fbda9-7a33-42d5-9ee9-2e95e5bffc0a" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentNumberOfTranches_611fbda9-7a33-42d5-9ee9-2e95e5bffc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrincipalAndInterestTerm_f0791263-f8a2-41e1-b3f3-fc1c2712736b" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrincipalAndInterestTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPrincipalAndInterestTerm_f0791263-f8a2-41e1-b3f3-fc1c2712736b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_557da7d4-20b6-4e57-9793-5d7d5e102540" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue_557da7d4-20b6-4e57-9793-5d7d5e102540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_8959b63c-80f4-43ee-b935-0ee110fca736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_8959b63c-80f4-43ee-b935-0ee110fca736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPrepaymentFee_e727293b-c8d0-467a-a5ad-e4c1ce9722f5" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPrepaymentFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPrepaymentFee_e727293b-c8d0-467a-a5ad-e4c1ce9722f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentBalloonPaymentWriteOff_3f2440dd-e5b2-4ad0-8bb5-626e29be5a26" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentBalloonPaymentWriteOff"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentBalloonPaymentWriteOff_3f2440dd-e5b2-4ad0-8bb5-626e29be5a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_f73ecb99-4ce1-4c55-badd-701ee44d46e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_f73ecb99-4ce1-4c55-badd-701ee44d46e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_97ff23b0-1017-45c3-8006-e4fbc43bb179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_97ff23b0-1017-45c3-8006-e4fbc43bb179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_595ca36c-c887-45e0-a65a-3eca3c11aaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_595ca36c-c887-45e0-a65a-3eca3c11aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_dbe62183-9515-4dff-8a0d-f51f75cf3f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_InterestExpenseDebt_dbe62183-9515-4dff-8a0d-f51f75cf3f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_9c68bfd3-7f55-4065-9828-301239ebfe64" xlink:href="inbx-20251231.xsd#inbx_AmortizationOfDebtDiscountPremiumAndAccretion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_AmortizationOfDebtDiscountPremiumAndAccretion_9c68bfd3-7f55-4065-9828-301239ebfe64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019b071b-de0c-708a-afd5-93d6191a73b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_019b071b-de0c-708a-afd5-93d6191a73b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_019b071c-69d3-75d8-a9ca-6ffda534e64d" xlink:href="inbx-20251231.xsd#inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature_019b071c-69d3-75d8-a9ca-6ffda534e64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b071d-14d3-7209-a0a3-1cd0fc8b8875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_019b071d-14d3-7209-a0a3-1cd0fc8b8875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b0722-1361-7248-9419-75faaae71aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_019b0722-1361-7248-9419-75faaae71aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_019b0723-c3fc-7ea1-b2f4-4507954ca429" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent_019b0723-c3fc-7ea1-b2f4-4507954ca429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtLiquidityThreshold_019cb461-7c02-725e-a092-16afb3de92c1" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtLiquidityThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_LongTermDebtLiquidityThreshold_019cb461-7c02-725e-a092-16afb3de92c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_019b0726-7b2a-765d-a842-7a62f28549e7" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding_019b0726-7b2a-765d-a842-7a62f28549e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019b0726-430a-7935-8adf-52eb9f694051" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_019b0726-430a-7935-8adf-52eb9f694051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019b0729-7627-7e48-891d-41f4ba9f2080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019b0729-7627-7e48-891d-41f4ba9f2080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b072a-011d-74f6-8920-8dcf880128bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b072a-011d-74f6-8920-8dcf880128bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019b0727-5774-7926-8ea6-48ee42892610" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_019b0727-5774-7926-8ea6-48ee42892610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b072a-9738-77e7-80df-d500c15c08ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_019b072a-9738-77e7-80df-d500c15c08ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019b0727-b889-7b84-b52a-f14c2fc9da2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019b0727-b889-7b84-b52a-f14c2fc9da2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_019b072b-4b15-7b95-9907-a244c406437c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25fe4c5d-9005-4ff3-b89f-d09c42e45933" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_019b072b-4b15-7b95-9907-a244c406437c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019b0710-80ee-7ad4-8930-b62e303bd276" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019b0710-80ee-7ad4-8930-b62e303bd276" xlink:to="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:to="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-80ee-7113-b148-4d8470db689c" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0710-80ee-7b2c-b0ad-0aac700cbf05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019b0710-80ee-7d4d-83bc-ef4bf3958fcd" xlink:to="loc_us-gaap_SecuredDebtMember_019b0710-80ee-7b2c-b0ad-0aac700cbf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-80ee-7e7b-86d8-c74e8157e460" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b0710-80ee-705b-b172-e67c24bfb81c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0710-80ee-731f-9b36-80cbfeebac9d" xlink:to="loc_us-gaap_LineOfCreditMember_019b0710-80ee-705b-b172-e67c24bfb81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-80ee-705d-b1c4-79e59dbf2054" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-7efa-a432-5021157b2f29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-80ee-7efa-a432-5021157b2f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7170-9c40-f12c4281bf33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-80ee-7170-9c40-f12c4281bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019b0710-80ee-76c7-8fd4-39072dd67df1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-80ee-76a5-a7db-856ba593b997" xlink:to="loc_us-gaap_LongTermDebt_019b0710-80ee-76c7-8fd4-39072dd67df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#DEBTScheduleofMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019b0710-a3a0-7b7e-9671-2195b5208030" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019b0710-a3a0-7b7e-9671-2195b5208030" xlink:to="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:to="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_019b0710-a3a0-75ec-86fa-5f6ecba7d330" xlink:to="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0710-a3a0-731a-903e-d2767d1a661b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_019b0710-a3a0-7675-9cbd-cd9df22262e5" xlink:to="loc_us-gaap_SecuredDebtMember_019b0710-a3a0-731a-903e-d2767d1a661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0710-a3a0-7453-8357-9835e5f1b53c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_019b0710-a3a0-7290-859b-155db65dbd29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0710-a3a0-722a-a179-580f769df61e" xlink:to="loc_us-gaap_LineOfCreditMember_019b0710-a3a0-7290-859b-155db65dbd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019b0710-a3a0-7d69-aa12-8012d4cd17dd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7d33-817e-a9e936ce14eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_019b0710-a3a0-7d33-817e-a9e936ce14eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-7d7b-beea-63be6c9c8065" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_019b0710-a3a0-7d7b-beea-63be6c9c8065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-777a-80b2-4c52fb16de5b" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_inbx_LongTermDebtMaturityAfterYearFour_019b0710-a3a0-777a-80b2-4c52fb16de5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-767f-8459-6957df4b44a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019b0710-a3a0-767f-8459-6957df4b44a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-a3a0-742e-a1c7-c351d25e886c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_019b0710-a3a0-742e-a1c7-c351d25e886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019b0710-a3a0-7835-82bc-e484c9d657ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019b0710-a3a0-7472-9c24-9fadbfc594a4" xlink:to="loc_us-gaap_LongTermDebt_019b0710-a3a0-7835-82bc-e484c9d657ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0999b44b-5d9d-4654-8eec-ae65c07e4c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0999b44b-5d9d-4654-8eec-ae65c07e4c5f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1355aa1-becf-4907-84c9-119624bf23d2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b2e829eb-e6dc-41ce-8bec-3fa5beebe8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e0162d60-81f2-48b3-92ca-3fb64ad702f4" xlink:to="loc_us-gaap_PrivatePlacementMember_b2e829eb-e6dc-41ce-8bec-3fa5beebe8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81fdb48a-bf7f-446d-98b0-44ac8add1205" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_WarrantsPreFundedMember_557334d8-d7ac-4ab0-88db-7484cb7c20e9" xlink:href="inbx-20251231.xsd#inbx_WarrantsPreFundedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_WarrantsPreFundedMember_557334d8-d7ac-4ab0-88db-7484cb7c20e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member_2e09f81a-fb9b-4b6a-8fbb-5b60210c4267" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_ClassOfWarrantOrRightExpirationDate1Member_2e09f81a-fb9b-4b6a-8fbb-5b60210c4267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member_c93fa0b5-d30b-408c-b62f-cc5137f43326" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightExpirationDate2Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_eb954007-0304-4fde-bccb-df6796bbde43" xlink:to="loc_inbx_ClassOfWarrantOrRightExpirationDate2Member_c93fa0b5-d30b-408c-b62f-cc5137f43326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1c53bb7b-0cc5-409d-8c2f-e23e6b62bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2020OxfordTermLoansMember_9c975714-4a86-42f1-8167-41953a08cd18" xlink:href="inbx-20251231.xsd#inbx_A2020OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7ab31f9a-5827-40fe-a91d-064d6746c5ab" xlink:to="loc_inbx_A2020OxfordTermLoansMember_9c975714-4a86-42f1-8167-41953a08cd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019b0738-232d-72d5-90cd-efc36f57626f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019b0738-232d-755f-996b-ef00d26735ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019b0738-232d-7895-bfff-f78427875aa0" xlink:to="loc_us-gaap_SecuredDebtMember_019b0738-232d-755f-996b-ef00d26735ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_128d4c15-d756-403f-baf7-2efb254ea1fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b435a114-d548-42f4-a6db-15faac4ac01c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b435a114-d548-42f4-a6db-15faac4ac01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2c8a71a5-9ed8-4c0f-86d3-bc8971ca4a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2c8a71a5-9ed8-4c0f-86d3-bc8971ca4a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_054c7f0a-d537-40b7-86bc-4c1c94b778e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_054c7f0a-d537-40b7-86bc-4c1c94b778e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_192af4d2-54a2-4fcc-8b30-80aeb8f4e554" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_192af4d2-54a2-4fcc-8b30-80aeb8f4e554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_839ec48f-a2bc-40ab-9b4e-90e08fb32e69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_839ec48f-a2bc-40ab-9b4e-90e08fb32e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatio_d7be7864-40cd-4631-b7cf-a3a7b8e62c05" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_MergerExchangeRatio_d7be7864-40cd-4631-b7cf-a3a7b8e62c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a37b33df-2a3f-425c-8113-3854dd3e605d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_CommonStockSharesIssued_a37b33df-2a3f-425c-8113-3854dd3e605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_5141553e-1ef9-4dbb-a854-7995488dcee9" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_MergerOwnershipPercentage_5141553e-1ef9-4dbb-a854-7995488dcee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOrUnitsAvailableForDistributions_c01b91a1-29b3-4e28-90e4-36ae58a0f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOrUnitsAvailableForDistributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_StockOrUnitsAvailableForDistributions_c01b91a1-29b3-4e28-90e4-36ae58a0f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3c0c707-06b5-4407-9515-ba74f10df90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d3c0c707-06b5-4407-9515-ba74f10df90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1d3b6f50-16e9-42d5-9303-cc6cc3800ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1d3b6f50-16e9-42d5-9303-cc6cc3800ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8cb85bda-2a44-4b29-9738-86943d6ba80e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8cb85bda-2a44-4b29-9738-86943d6ba80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_3aded936-c43c-40ac-9a3f-bd6cff639403" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_3aded936-c43c-40ac-9a3f-bd6cff639403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6665578c-7540-44f3-bcee-dbeeb082381f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6665578c-7540-44f3-bcee-dbeeb082381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised_f6204d4b-117c-4c52-b645-c49e417d9a5c" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantsOrRightsWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantsOrRightsWarrantsExercised_f6204d4b-117c-4c52-b645-c49e417d9a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_066ae19a-bc1c-4c3b-89da-52d06334b938" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_066ae19a-bc1c-4c3b-89da-52d06334b938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_ea9cc06e-a9da-4510-be62-9f1110c0d350" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant_ea9cc06e-a9da-4510-be62-9f1110c0d350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_524fb9e7-6975-4850-9303-5a3c3f03d23f" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue_524fb9e7-6975-4850-9303-5a3c3f03d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_2e87b902-c31b-4786-8e90-b4996600f45c" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1_2e87b902-c31b-4786-8e90-b4996600f45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DebtInstrumentNumberOfTranches_d4ebd4c3-58c7-42ba-96e3-ae930b651677" xlink:href="inbx-20251231.xsd#inbx_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_DebtInstrumentNumberOfTranches_d4ebd4c3-58c7-42ba-96e3-ae930b651677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_95a40c06-d932-416e-b2d5-54f59e57c54d" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_95a40c06-d932-416e-b2d5-54f59e57c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf596b0-8504-485d-bc55-f52d5a621a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61903fee-3193-4460-8270-7d7584ff423e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf596b0-8504-485d-bc55-f52d5a621a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f8132a6a-2244-4248-9ee0-6731938f1ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f8132a6a-2244-4248-9ee0-6731938f1ce7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:to="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c7003eb-4a8f-4dc2-8ca1-e80617dd4b7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_55d027af-3145-4a64-8ece-1e012c7b8546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_EmployeeStockOptionMember_55d027af-3145-4a64-8ece-1e012c7b8546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_PreFundedWarrantsMember_54f4db6c-d948-416b-9bf4-0133bf90cde5" xlink:href="inbx-20251231.xsd#inbx_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_inbx_PreFundedWarrantsMember_54f4db6c-d948-416b-9bf4-0133bf90cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7009c336-ae01-4ce4-93ea-851defc98d95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_StockCompensationPlanMember_7009c336-ae01-4ce4-93ea-851defc98d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3bdf5837-f5a1-4cf5-b74e-c243a7892a29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67877465-c422-4663-bbfa-925e8b1e3052" xlink:to="loc_us-gaap_WarrantMember_3bdf5837-f5a1-4cf5-b74e-c243a7892a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fd2444f-7f03-4d4f-8393-6a873fdd27e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_573a0c3e-8a0c-4ca3-a045-76cfe0537838" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9587a179-2cea-4933-a28e-a178c3a3e178" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_573a0c3e-8a0c-4ca3-a045-76cfe0537838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a740299-8da4-4426-adbc-7051332e7b29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a740299-8da4-4426-adbc-7051332e7b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e4251fe1-be22-4896-94e2-84710c6bfc7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39c6ab55-3fa9-4bd2-ac3e-2e1f0a33f372" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5980f171-c0de-4ab1-8c22-2812ae27dcac" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39c6ab55-3fa9-4bd2-ac3e-2e1f0a33f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_07314d1d-ec22-4c42-98b7-3d8d40a85a94" xlink:to="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Plan2017Member_78c6f728-1754-4cc6-aba8-c855355dbec3" xlink:href="inbx-20251231.xsd#inbx_Plan2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_Plan2017Member_78c6f728-1754-4cc6-aba8-c855355dbec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b074f-23fa-7ce5-aee9-955d42f4c5e9" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_A2024PlanMember_019b074f-23fa-7ce5-aee9-955d42f4c5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2017PlanMember_019ce1a2-4f46-7c74-87ff-e2c657bf27e3" xlink:href="inbx-20251231.xsd#inbx_A2017PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2b11ce64-f684-4c69-a639-e042bfc1a1e0" xlink:to="loc_inbx_A2017PlanMember_019ce1a2-4f46-7c74-87ff-e2c657bf27e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c7276e51-647d-4eba-a146-96a985d58054" xlink:to="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aae4fd69-21bb-444e-826e-2752802160bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_c19508eb-81c0-4e16-a390-668b5e77a858" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aae4fd69-21bb-444e-826e-2752802160bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_019d056e-d799-70a1-83ff-e9544cc2d7fb" xlink:to="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraLicenseAgreementMember_019d056e-d799-748c-abad-13c3829ff456" xlink:href="inbx-20251231.xsd#inbx_ScitheraLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_019d056e-d799-725c-b626-651165e444be" xlink:to="loc_inbx_ScitheraLicenseAgreementMember_019d056e-d799-748c-abad-13c3829ff456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019d056e-d799-784c-924d-31b950c783ca" xlink:to="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_019d056e-d799-796b-aa12-4da61f25f3a5" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d056e-d799-7880-a7ab-edc1aec95ad6" xlink:to="loc_inbx_LicenseNonAffiliateMember_019d056e-d799-796b-aa12-4da61f25f3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f9eb7c-c77e-4f5f-9a52-d5510dc687fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9a643bf3-6b9a-43b0-8e71-e3d9ac36a08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9a643bf3-6b9a-43b0-8e71-e3d9ac36a08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09efb4c1-ccf6-4e23-ab94-af30c159f5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09efb4c1-ccf6-4e23-ab94-af30c159f5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0ff4eb2d-b58e-4cc2-978d-059698138aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0ff4eb2d-b58e-4cc2-978d-059698138aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_377e05a7-41e8-476e-9636-ccd6f779202e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_377e05a7-41e8-476e-9636-ccd6f779202e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_a2d3ce02-e6da-44e9-b1fe-f13698785eb6" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice_a2d3ce02-e6da-44e9-b1fe-f13698785eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_963c7913-6a95-4e1a-8d9d-1738d4d57b4f" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare_963c7913-6a95-4e1a-8d9d-1738d4d57b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_031e7a76-dc54-4122-93db-1923e15c7541" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare_031e7a76-dc54-4122-93db-1923e15c7541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_8f7cb120-4c8b-4c14-97ab-a172f20c8f6a" xlink:href="inbx-20251231.xsd#inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare_8f7cb120-4c8b-4c14-97ab-a172f20c8f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d225a391-0db0-4bd5-89ef-3fbfdf3deb60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d225a391-0db0-4bd5-89ef-3fbfdf3deb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d056e-d799-7f95-94bb-03ec0b23f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d056e-d799-7f95-94bb-03ec0b23f10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_7551149c-0b2d-4c96-ba1b-b59cdc5bc6db" xlink:href="inbx-20251231.xsd#inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice_7551149c-0b2d-4c96-ba1b-b59cdc5bc6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b0740-c441-7bd7-a853-044bbc332a01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b0740-c441-7bd7-a853-044bbc332a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c7a1662e-4321-41cf-a5bb-aa1227bdaa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c7a1662e-4321-41cf-a5bb-aa1227bdaa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c7594bf-bf07-40b6-9f2d-c94e3a2621a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9c7594bf-bf07-40b6-9f2d-c94e3a2621a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0baeb27-833f-41d7-8994-a2c2488dec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d0baeb27-833f-41d7-8994-a2c2488dec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ebf84066-ed02-4b34-a8cf-816fd77452d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ebf84066-ed02-4b34-a8cf-816fd77452d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afb5aae2-a05d-4bfe-8aad-acd63da145c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c43cc20-46ea-4cb0-97a6-4e4b456d2f94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_afb5aae2-a05d-4bfe-8aad-acd63da145c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b0748-3fdf-77ea-be28-cedcd44539d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b0748-3fdf-77ea-be28-cedcd44539d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019b0748-3fdf-7e07-82a2-2d9c37821dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b0748-3fdf-7eaf-8de0-f5623fd07292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0748-3fdf-74aa-98df-05cb58274285" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b0748-3fdf-7eaf-8de0-f5623fd07292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019b0748-3fdf-7f01-a7f2-c7afad69639c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b0748-3fdf-7fc9-8d50-f6a971cdb3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019b0748-3fdf-7fc9-8d50-f6a971cdb3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b0748-3fdf-734e-8ad3-04152657aa91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019b0748-3fdf-766f-b8f9-627565b84399" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019b0748-3fdf-734e-8ad3-04152657aa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019b0748-3fdf-7808-a799-76eb72ebe659" xlink:to="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b0748-3fdf-72e7-9113-dd7fa398418f" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:to="loc_inbx_A2024PlanMember_019b0748-3fdf-72e7-9113-dd7fa398418f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_Plan2017Member_019b0773-38eb-76e6-ab0b-09222a123db3" xlink:href="inbx-20251231.xsd#inbx_Plan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b0748-3fdf-7b13-ba16-e44790727852" xlink:to="loc_inbx_Plan2017Member_019b0773-38eb-76e6-ab0b-09222a123db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0748-3fdf-7e6c-8264-7e936e258eea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b0748-3fdf-742d-b12a-d8b163213591" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0748-3fdf-77b1-8e7c-14713cc62989" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019b0748-3fdf-742d-b12a-d8b163213591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b0755-5d47-7e93-b6d8-2405a1171a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b0755-5d47-7e93-b6d8-2405a1171a57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:to="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_019b0755-5d47-7ff1-85b7-781207d90c69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_019b0755-5d47-75e2-8712-e09c42c484e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_019b0755-5d47-7b87-b9b5-11601663193e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_019b0755-5d47-75e2-8712-e09c42c484e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b0755-5d47-76a5-92d8-751a545c4961" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b0755-5d47-77dc-8828-620f38797eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_019b0755-5d47-77dc-8828-620f38797eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b0755-5d47-7f13-8ef6-6b069995f58f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_019b0755-5d47-7f13-8ef6-6b069995f58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b0755-5d47-7b56-9110-8282be810f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_019b0755-5d47-7b56-9110-8282be810f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b0755-5d47-7e96-8d2f-50c7512820c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_019b0755-5d47-7e96-8d2f-50c7512820c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b0755-5d47-7708-87e7-d27a4125414c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b0755-5d47-736c-a05f-b3b6f6b8250d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_019b0755-5d47-7708-87e7-d27a4125414c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b074a-30bb-7be2-9b97-aab4f5829b52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019b074a-30bb-7be2-9b97-aab4f5829b52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:to="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019b074a-30bb-70ab-9d8a-34d834cf73b5" xlink:to="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2024PlanMember_019b074a-30bb-7ca7-865e-32ea6099da26" xlink:href="inbx-20251231.xsd#inbx_A2024PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019b074a-30bb-7b6f-b40f-b5446e775ed2" xlink:to="loc_inbx_A2024PlanMember_019b074a-30bb-7ca7-865e-32ea6099da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019b074a-30bb-7254-828a-6b3fc080ca5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-766b-a8cd-cd3825f8cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-766b-a8cd-cd3825f8cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b074a-30bb-72c0-9e9d-a8282be2eb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019b074a-30bb-72c0-9e9d-a8282be2eb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b074a-30bb-7fed-8431-9d21b95702ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_019b074a-30bb-7fed-8431-9d21b95702ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019b074a-30bb-74e7-b3ae-553609c1dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_019b074a-30bb-74e7-b3ae-553609c1dc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-7a5d-bd7c-59416d0907ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_019b074a-30bb-7bdb-82f1-0203a4d0694d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_019b074a-30bb-7a5d-bd7c-59416d0907ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019b074a-30bb-7892-b134-fedb8185fb07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_019b074a-30bb-7892-b134-fedb8185fb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7530-bbc8-fab6387a2f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7530-bbc8-fab6387a2f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b074a-30bb-7afe-95c0-41a30044eb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_019b074a-30bb-7afe-95c0-41a30044eb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b074a-30bb-745d-b485-f746462fcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_019b074a-30bb-745d-b485-f746462fcd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019b074a-30bb-7193-9dca-d1e897d12efa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_019b074a-30bb-7193-9dca-d1e897d12efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7d8c-ad48-5a1a4f7e3109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_019b074a-30bb-7ba0-b5af-e030c34166bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_019b074a-30bb-7d8c-ad48-5a1a4f7e3109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019b074a-30bb-7906-ad5e-53f8308e5597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_019b074a-30bb-7906-ad5e-53f8308e5597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b074a-30bb-76a5-9b4b-c555deb7c886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_019b074a-30bb-76a5-9b4b-c555deb7c886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b074a-30bb-7201-8d9f-12eacaeab0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_019b074a-30bb-7201-8d9f-12eacaeab0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019b074a-30bb-710f-bac6-a4286261c2af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_019b074a-30bb-710f-bac6-a4286261c2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019b074a-30bb-7b75-b453-184c92ddcfea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_019b074a-30bb-7baf-a444-6825d8fb62a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_019b074a-30bb-7b75-b453-184c92ddcfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUEScheduleofTotalRevenueDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_b22539b1-f60e-4317-a69a-36417b026ada" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_b22539b1-f60e-4317-a69a-36417b026ada" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:to="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_317eaa1d-c5b6-4ebc-9043-c8852956a8f8" xlink:to="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_c58ee50c-1fd0-4133-b06f-05e7e0ff9553" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f69a2d8-9c93-440b-85ff-16bc439107a7" xlink:to="loc_inbx_LicenseNonAffiliateMember_c58ee50c-1fd0-4133-b06f-05e7e0ff9553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:to="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0edb52ea-adef-4e1d-a0ee-38eff5dcd37f" xlink:to="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraInc.Member_019b0743-4d3d-7629-84fa-f9ef4a01e696" xlink:href="inbx-20251231.xsd#inbx_ScitheraInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:to="loc_inbx_ScitheraInc.Member_019b0743-4d3d-7629-84fa-f9ef4a01e696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RegeneronPharmaceuticalsInc.Member_2018dec8-23e8-444f-b993-b38417f1757c" xlink:href="inbx-20251231.xsd#inbx_RegeneronPharmaceuticalsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d63c7695-a4e3-4fef-a894-1c572acc8a83" xlink:to="loc_inbx_RegeneronPharmaceuticalsInc.Member_2018dec8-23e8-444f-b993-b38417f1757c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f9478514-9765-4f16-85ab-364c347ff109" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_06347ba1-639d-41d9-a5c5-1a6317897adb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7cf74491-1a1c-4125-a515-7f7a4fa14bc0" xlink:to="loc_us-gaap_Revenues_06347ba1-639d-41d9-a5c5-1a6317897adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LICENSEREVENUENarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LICENSEREVENUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LICENSEREVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_edebdfaf-d337-46dc-a5a8-7e67ea1c635d" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract_edebdfaf-d337-46dc-a5a8-7e67ea1c635d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_92a84aa9-e289-4c10-95e0-028c2acfebb3" xlink:to="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2seventyBioIncMember_bca1e79f-2765-4a1b-83bc-c88f713dffb6" xlink:href="inbx-20251231.xsd#inbx_A2seventyBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_A2seventyBioIncMember_bca1e79f-2765-4a1b-83bc-c88f713dffb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RegeneronPharmaceuticalsInc.Member_39c80992-c30a-4d16-adcd-229ef58912e1" xlink:href="inbx-20251231.xsd#inbx_RegeneronPharmaceuticalsInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_RegeneronPharmaceuticalsInc.Member_39c80992-c30a-4d16-adcd-229ef58912e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ScitheraLicenseAgreementMember_019d0585-1d50-77a4-ba44-8fc7310ae3e4" xlink:href="inbx-20251231.xsd#inbx_ScitheraLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_25ddc60b-178e-454d-8edf-7a2aa9931ef0" xlink:to="loc_inbx_ScitheraLicenseAgreementMember_019d0585-1d50-77a4-ba44-8fc7310ae3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_413124fd-73ec-425c-96f6-ac4d2d19d41e" xlink:to="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseNonAffiliateMember_04eecce2-0807-4035-9f90-b3734043694d" xlink:href="inbx-20251231.xsd#inbx_LicenseNonAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fab3bbb1-b738-44dc-a741-01be566695b4" xlink:to="loc_inbx_LicenseNonAffiliateMember_04eecce2-0807-4035-9f90-b3734043694d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_58021c47-1869-46f4-94ab-bb6143a1bd53" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_480d18b3-5197-47cd-ae7e-c46588de0692" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedMember_480d18b3-5197-47cd-ae7e-c46588de0692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_a6947fdf-a723-46d2-b0e0-2ae006db1f72" xlink:href="inbx-20251231.xsd#inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0043b6fe-8b2d-4a17-a45d-618edff9095d" xlink:to="loc_inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember_a6947fdf-a723-46d2-b0e0-2ae006db1f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1116dc18-d612-4e37-9aec-668ccf11378b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundablePayment_019b074d-e3e3-7d54-966d-8eabbd6a6b68" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundablePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementNonrefundablePayment_019b074d-e3e3-7d54-966d-8eabbd6a6b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MaximumPotentialMilestonePayments_019b074d-e3e3-7a39-b91e-3254f821c7fa" xlink:href="inbx-20251231.xsd#inbx_MaximumPotentialMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_MaximumPotentialMilestonePayments_019b074d-e3e3-7a39-b91e-3254f821c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_019b074d-e3e3-7ce7-85e6-6969bed70498" xlink:href="inbx-20251231.xsd#inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation_019b074d-e3e3-7ce7-85e6-6969bed70498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_019b074d-e3e3-7fd0-846d-489fb9e6f720" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_019b074d-e3e3-7fd0-846d-489fb9e6f720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d0585-1d50-7618-a52e-356b2426d766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_019d0585-1d50-7618-a52e-356b2426d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_019b074e-1e01-7f59-b460-89c7a7f9dd11" xlink:href="inbx-20251231.xsd#inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement_019b074e-1e01-7f59-b460-89c7a7f9dd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_019b074e-6e68-7655-b19c-a4433c06835b" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementDevelopmentMilestoneReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable_019b074e-6e68-7655-b19c-a4433c06835b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_019b074e-6e68-740a-94ec-985967e55a39" xlink:href="inbx-20251231.xsd#inbx_CollaborativeArrangementNonrefundableUpfrontPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_inbx_CollaborativeArrangementNonrefundableUpfrontPayment_019b074e-6e68-740a-94ec-985967e55a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019b074e-6e68-7dca-86f3-c4711b551549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019b074e-6e68-7dca-86f3-c4711b551549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019b074e-6e68-7d7e-b2d0-82b646626eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_040ea3ed-3b8f-4dac-af1b-2bb1a79a6167" xlink:to="loc_us-gaap_Revenues_019b074e-6e68-7d7e-b2d0-82b646626eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_40b875b1-82b3-4395-8ff1-c856f85f95e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_40b875b1-82b3-4395-8ff1-c856f85f95e9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_44503b5d-daf2-4a12-9c11-aa0e49c2aa9a" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_01cf9d96-ab73-4570-b794-b825b4fab555" xlink:href="inbx-20251231.xsd#inbx_ServicesPerformedUnderTransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:to="loc_inbx_ServicesPerformedUnderTransitionServicesAgreementMember_01cf9d96-ab73-4570-b794-b825b4fab555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_SeverancePaymentsToFormerEmployeesMember_7ddb57db-5d73-4464-915d-b04f7c29033f" xlink:href="inbx-20251231.xsd#inbx_SeverancePaymentsToFormerEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_fdba18e5-f83b-4cb6-bda6-bb6b52e29283" xlink:to="loc_inbx_SeverancePaymentsToFormerEmployeesMember_7ddb57db-5d73-4464-915d-b04f7c29033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6ba5f43-005a-486e-88b0-e52ff8f2c728" xlink:to="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_ece2e4a7-60c5-4285-a1bc-53146d78933a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9c49d38f-dc62-497f-815c-d53f3bcef079" xlink:to="loc_us-gaap_RelatedPartyMember_ece2e4a7-60c5-4285-a1bc-53146d78933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f6de555b-3d03-4e04-85d5-9ec3a7d59a64" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerExchangeRatioProRateBasisPercentage_62d6f155-daa4-4196-859d-7cf81adcd0ea" xlink:href="inbx-20251231.xsd#inbx_MergerExchangeRatioProRateBasisPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_inbx_MergerExchangeRatioProRateBasisPercentage_62d6f155-daa4-4196-859d-7cf81adcd0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_MergerOwnershipPercentage_eedda25d-ba57-45ae-b396-f85a600931a0" xlink:href="inbx-20251231.xsd#inbx_MergerOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_inbx_MergerOwnershipPercentage_eedda25d-ba57-45ae-b396-f85a600931a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOrUnitsAvailableForDistributions_6a90c784-19fe-44d5-895d-c357fd5572ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOrUnitsAvailableForDistributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_StockOrUnitsAvailableForDistributions_6a90c784-19fe-44d5-895d-c357fd5572ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0087cf24-516b-46a6-a255-3399bd1227ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_0087cf24-516b-46a6-a255-3399bd1227ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db0fbfdd-99f1-463d-aefc-a5ff7f7c0f09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_26364628-b481-49c2-9a96-82c9ad122fa2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db0fbfdd-99f1-463d-aefc-a5ff7f7c0f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019cb479-f5c3-7e96-ad4c-477ccbb96bab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019cb47a-7d2f-79af-a2be-00194b52201c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cb479-f5c3-7e96-ad4c-477ccbb96bab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_019cb47a-7d2f-79af-a2be-00194b52201c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019cb47a-7d2f-77a0-bd09-8c798c93475c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cb479-f5c3-7e96-ad4c-477ccbb96bab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_019cb47a-7d2f-77a0-bd09-8c798c93475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb47a-7d2f-7954-924e-6409dd6a3c30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cb479-f5c3-7e96-ad4c-477ccbb96bab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cb47a-7d2f-7954-924e-6409dd6a3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d832e76a-f7a5-4897-a102-f6a442d78bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_809f4e1b-7ff8-4fe0-938f-9724484460cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d832e76a-f7a5-4897-a102-f6a442d78bcb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_809f4e1b-7ff8-4fe0-938f-9724484460cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_477d7fc0-b2cc-4281-940e-c7a0fd1be721" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d832e76a-f7a5-4897-a102-f6a442d78bcb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_477d7fc0-b2cc-4281-940e-c7a0fd1be721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f8c3a189-3c93-4fe5-ae82-77921d0d5379" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f8c3a189-3c93-4fe5-ae82-77921d0d5379" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_929a486f-1e40-4687-8156-2ec0c342c672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_929a486f-1e40-4687-8156-2ec0c342c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_84587dc1-2aa4-4161-954e-ad742d4b43b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_84587dc1-2aa4-4161-954e-ad742d4b43b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_68fdd5d8-d8e0-4ba2-94dc-9b0e23d94f4a" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems_68fdd5d8-d8e0-4ba2-94dc-9b0e23d94f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1b048c13-3af8-4e66-9a85-40f8754d9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1b048c13-3af8-4e66-9a85-40f8754d9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_32cf69ea-5a48-437a-ba3f-93af382ca6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_32cf69ea-5a48-437a-ba3f-93af382ca6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_2b4968ae-c0ef-4342-aa7c-90a75f45dc2e" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount_2b4968ae-c0ef-4342-aa7c-90a75f45dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_c6cc3e5a-e83c-4d60-b422-e57e1c2a9f52" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount_c6cc3e5a-e83c-4d60-b422-e57e1c2a9f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_cbd440b9-aac7-4f45-a5c2-eb0a6431faf7" xlink:href="inbx-20251231.xsd#inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount_cbd440b9-aac7-4f45-a5c2-eb0a6431faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_56c2a0bb-906f-4c72-bddc-89efbf721636" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_56c2a0bb-906f-4c72-bddc-89efbf721636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_019cb480-a21d-717c-95cd-a96f082c69a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_019cb480-a21d-717c-95cd-a96f082c69a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ff1ac8a-9cea-4913-8bd3-3e2bc25bb983" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019cb47e-7680-732d-a55e-df91316ea3fb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ff1ac8a-9cea-4913-8bd3-3e2bc25bb983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f8c3a189-3c93-4fe5-ae82-77921d0d5379" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019cb481-f20e-7ec8-b6a1-57b0166d8785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019cb481-f20e-7ec8-b6a1-57b0166d8785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019cb482-542e-72f7-a49e-c4406d87e32e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019cb482-542e-72f7-a49e-c4406d87e32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019cb483-c6b1-7cdf-8f7b-71c2c869bfca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019cb483-c6b1-7cdf-8f7b-71c2c869bfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_019cb484-6e5c-77c1-81fc-45a5d936b879" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_019cb484-6e5c-77c1-81fc-45a5d936b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb484-bb9f-7f2c-8526-37dbee0de71b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019cb47f-15df-77cb-b847-b7d83e9739ae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019cb484-bb9f-7f2c-8526-37dbee0de71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_552954dd-8afd-4a16-94f6-9741a7594297" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552954dd-8afd-4a16-94f6-9741a7594297" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8a24182a-94a3-48c3-a0cc-e29f4f0ed323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8a24182a-94a3-48c3-a0cc-e29f4f0ed323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7aa32372-73e6-4aa3-ab8f-14a515e954ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7aa32372-73e6-4aa3-ab8f-14a515e954ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d2822094-1f91-4953-ba9e-9dbb5f5bbb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d2822094-1f91-4953-ba9e-9dbb5f5bbb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a830aa2d-1c1d-40f4-84dd-c6e4b96b8fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_a830aa2d-1c1d-40f4-84dd-c6e4b96b8fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_912edb12-1050-4884-a7f7-1e7595693209" xlink:href="inbx-20251231.xsd#inbx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_inbx_DeferredTaxAssetsOperatingLeaseLiabilities_912edb12-1050-4884-a7f7-1e7595693209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3a22db02-ab8f-4697-be94-0077dc7d6931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3a22db02-ab8f-4697-be94-0077dc7d6931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019cb489-9e98-7f16-adef-210b142053eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_019cb489-9e98-7f16-adef-210b142053eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_09a1a0f4-1488-446a-af84-8b69c308deb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_09a1a0f4-1488-446a-af84-8b69c308deb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_faa03b92-c373-4503-acc9-0ab803d066d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_faa03b92-c373-4503-acc9-0ab803d066d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6b18ac4-0161-4474-8a86-360e53a60a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6b18ac4-0161-4474-8a86-360e53a60a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_48694e8c-3c9f-4703-a5db-20dc88b23385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_5277023c-d5cf-4275-92cb-e63cdbfe131e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_48694e8c-3c9f-4703-a5db-20dc88b23385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fbae91e-8a8e-4e5b-b1b7-b8256613a612" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552954dd-8afd-4a16-94f6-9741a7594297" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fbae91e-8a8e-4e5b-b1b7-b8256613a612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae4cd5b3-d3d9-431a-957b-aa44cd0c6617" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fbae91e-8a8e-4e5b-b1b7-b8256613a612" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae4cd5b3-d3d9-431a-957b-aa44cd0c6617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_57f12c11-d7e7-463b-9812-f5d4c6574793" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fbae91e-8a8e-4e5b-b1b7-b8256613a612" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_57f12c11-d7e7-463b-9812-f5d4c6574793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f8485e72-0d29-4ed7-a612-00fc7d7f1ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5fbae91e-8a8e-4e5b-b1b7-b8256613a612" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f8485e72-0d29-4ed7-a612-00fc7d7f1ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_89de26cc-f415-49b4-acad-c9d42f868482" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552954dd-8afd-4a16-94f6-9741a7594297" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_89de26cc-f415-49b4-acad-c9d42f868482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5a80a8a1-07d5-46d1-b042-b64adfb26f04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552954dd-8afd-4a16-94f6-9741a7594297" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5a80a8a1-07d5-46d1-b042-b64adfb26f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2b44cb0-e37a-4bbb-b6b0-f7efafbaa5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2b44cb0-e37a-4bbb-b6b0-f7efafbaa5ed" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b1c1e678-f6a0-48ad-9886-08ac2a44699e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_019d515a-6438-46c7-b2fd-ced1b053799e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:to="loc_us-gaap_DomesticCountryMember_019d515a-6438-46c7-b2fd-ced1b053799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_30a9f32a-3fef-4d04-9251-52a15e6ab941" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3b71c8a9-612d-454b-9277-953f9d6feb1b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_30a9f32a-3fef-4d04-9251-52a15e6ab941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_705e3f2a-cf9a-4fda-b82f-64e81491425c" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_881613b0-7def-4298-9db5-8c48350c7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_OperatingLossCarryforwards_881613b0-7def-4298-9db5-8c48350c7b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0b6736f7-6419-4450-bdd7-b89ff8179d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0b6736f7-6419-4450-bdd7-b89ff8179d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6d1f4a33-61ab-4279-9944-631fb24d4919" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6d1f4a33-61ab-4279-9944-631fb24d4919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5124de83-117c-44bc-8bd0-36523629e17d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48caacfa-2046-4417-b50a-c5163ef51bdd" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5124de83-117c-44bc-8bd0-36523629e17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43d72c35-78a2-4c43-bdd5-cd64fcb2269a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43d72c35-78a2-4c43-bdd5-cd64fcb2269a" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8c9f20b1-6e1c-42d8-bdcb-3769c173317e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8c9f20b1-6e1c-42d8-bdcb-3769c173317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_87bfbae0-b97f-4910-b421-91d07d2e82cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_87bfbae0-b97f-4910-b421-91d07d2e82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_65971226-7b9f-4b82-b97d-fc1d6c91b583" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_65971226-7b9f-4b82-b97d-fc1d6c91b583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f4d4ec66-554a-4fb7-b8dd-558de6398688" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5053e4d7-67f6-4292-b4d7-55afd786d494" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f4d4ec66-554a-4fb7-b8dd-558de6398688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4672df3a-e1fd-4787-a77d-f20b4176d2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4672df3a-e1fd-4787-a77d-f20b4176d2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_5a3f5509-0e7a-4f71-818c-b40f546aa2ee" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth_5a3f5509-0e7a-4f71-818c-b40f546aa2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseAnnualEscalations_4081f5fd-e61c-4084-9d2e-43a4d38a132f" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseAnnualEscalations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_LesseeOperatingLeaseAnnualEscalations_4081f5fd-e61c-4084-9d2e-43a4d38a132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_98b2320c-9ea0-4e47-a52a-12e95c76b329" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_98b2320c-9ea0-4e47-a52a-12e95c76b329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LesseeOperatingLeaseNumberOfContracts_112177b5-bda9-42c4-a0cf-8450dcc9cf53" xlink:href="inbx-20251231.xsd#inbx_LesseeOperatingLeaseNumberOfContracts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_LesseeOperatingLeaseNumberOfContracts_112177b5-bda9-42c4-a0cf-8450dcc9cf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6297a336-7a66-47f7-81d0-3dfdaf23dbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_OperatingLeaseExpense_6297a336-7a66-47f7-81d0-3dfdaf23dbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeaseAnnualEscalationsPercentage_e5a489f2-32e1-46c0-bb01-d003500e7396" xlink:href="inbx-20251231.xsd#inbx_OperatingLeaseAnnualEscalationsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_OperatingLeaseAnnualEscalationsPercentage_e5a489f2-32e1-46c0-bb01-d003500e7396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeasesContractAbatementPeriod_41c164a2-c3fd-4569-9408-17e5299c3d4f" xlink:href="inbx-20251231.xsd#inbx_OperatingLeasesContractAbatementPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_OperatingLeasesContractAbatementPeriod_41c164a2-c3fd-4569-9408-17e5299c3d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeaseAbatementPeriodAmount_e7d5d863-18d2-4a6b-95c7-e6948c27c4a5" xlink:href="inbx-20251231.xsd#inbx_OperatingLeaseAbatementPeriodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_OperatingLeaseAbatementPeriodAmount_e7d5d863-18d2-4a6b-95c7-e6948c27c4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_b2a7ba19-3b34-4f8f-b09d-32e5e917dd96" xlink:href="inbx-20251231.xsd#inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement_b2a7ba19-3b34-4f8f-b09d-32e5e917dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_e2bf20b8-5372-4bb0-b241-e953a842a8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_e2bf20b8-5372-4bb0-b241-e953a842a8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability_33fa0436-711f-4d9f-9896-18e0ba3fa147" xlink:href="inbx-20251231.xsd#inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability_33fa0436-711f-4d9f-9896-18e0ba3fa147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e30d9fca-c005-4030-9ef8-e6ba5b89bd84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e30d9fca-c005-4030-9ef8-e6ba5b89bd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_929ada8a-b799-4042-9f8f-ade13083d00a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6305f1e-63f7-4c60-98f3-35f115e97290" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_929ada8a-b799-4042-9f8f-ade13083d00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bcf10196-b342-408a-9256-7ab153d8f2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_efac5e42-ca2a-44fd-b803-ee6b6842ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcf10196-b342-408a-9256-7ab153d8f2d7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_efac5e42-ca2a-44fd-b803-ee6b6842ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_a27768e6-f88e-4217-807b-f82fffd8d6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bcf10196-b342-408a-9256-7ab153d8f2d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_a27768e6-f88e-4217-807b-f82fffd8d6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96d5939d-3c89-4c98-98c2-5fc1f67545ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a27768e6-f88e-4217-807b-f82fffd8d6cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96d5939d-3c89-4c98-98c2-5fc1f67545ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48c0de18-0b98-4487-b2f6-0b6f7b190557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a27768e6-f88e-4217-807b-f82fffd8d6cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48c0de18-0b98-4487-b2f6-0b6f7b190557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0c1b6ebf-ea26-46fe-881d-081acfab2d60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_a27768e6-f88e-4217-807b-f82fffd8d6cd" xlink:to="loc_us-gaap_OperatingLeaseLiability_0c1b6ebf-ea26-46fe-881d-081acfab2d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e6a89e86-a8de-4a4d-a1b1-5e73a9cb5ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e6a89e86-a8de-4a4d-a1b1-5e73a9cb5ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c3fc3ae-2bd8-4537-abfd-c713af4c33a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9c3fc3ae-2bd8-4537-abfd-c713af4c33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e42cec3-de83-4a1c-87da-f1dc55b614ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e42cec3-de83-4a1c-87da-f1dc55b614ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8929e4-9015-46de-85e9-0deb444ec595" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0b8929e4-9015-46de-85e9-0deb444ec595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca06547d-5a60-475a-ab7f-27483fe42ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca06547d-5a60-475a-ab7f-27483fe42ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e98eca95-252c-425f-8062-6ae8a8c30916" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_OperatingLeaseLiability_e98eca95-252c-425f-8062-6ae8a8c30916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_21828627-763c-4c3b-9689-cbef3b5ff672" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_21828627-763c-4c3b-9689-cbef3b5ff672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1c8c624-2872-4a99-bc0f-e10454a81fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d002053a-a350-4580-889f-bd49f1d36c44" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1c8c624-2872-4a99-bc0f-e10454a81fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="inbx-20251231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e4861198-b7db-41f1-859e-89f99e14abb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e4861198-b7db-41f1-859e-89f99e14abb4" xlink:to="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_18fcde54-9f78-40ad-96de-98262f33c16f" xlink:to="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_07217f95-13d5-4d4b-83ee-bb451d8bf259" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d608ac0a-b715-412c-9299-2e972339c9c9" xlink:to="loc_us-gaap_SecuredDebtMember_07217f95-13d5-4d4b-83ee-bb451d8bf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b57c0b2-e3a2-46ef-a312-fcc370d68f2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_OxfordTermLoansMember_12c544dd-da3d-46a5-be71-c775230e5333" xlink:href="inbx-20251231.xsd#inbx_OxfordTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:to="loc_inbx_OxfordTermLoansMember_12c544dd-da3d-46a5-be71-c775230e5333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_A2025LoanAgreementMember_019cdda2-a3a5-793f-8775-f7d5d5ef592e" xlink:href="inbx-20251231.xsd#inbx_A2025LoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5702e65f-f3d6-45b8-97fa-f53ef0f29a2a" xlink:to="loc_inbx_A2025LoanAgreementMember_019cdda2-a3a5-793f-8775-f7d5d5ef592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9ea6a67a-b87d-4744-8734-f2cf9864f7b2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6414392d-4c4a-41e5-a494-1145d569b7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:to="loc_us-gaap_LineOfCreditMember_6414392d-4c4a-41e5-a494-1145d569b7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019cdda2-a3a5-7941-b9f0-8ee99225513f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7c4f844b-e3b7-4ae4-bc51-06a49d381167" xlink:to="loc_us-gaap_SecuredDebtMember_019cdda2-a3a5-7941-b9f0-8ee99225513f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b89ffedc-328c-45bc-8d38-05455cfabe3c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37fc497d-06c4-469a-879b-34c05958a976" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_73dcdcc3-becd-4c27-9c5d-944d18850e73" xlink:to="loc_us-gaap_SubsequentEventMember_37fc497d-06c4-469a-879b-34c05958a976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a1030da5-4059-459a-a8dd-eb4e978ff440" xlink:to="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_debb40c7-b40e-4600-ba60-e089303d1b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_debb40c7-b40e-4600-ba60-e089303d1b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3828ef86-3fc0-4cf9-96c4-2a006823f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3828ef86-3fc0-4cf9-96c4-2a006823f08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inbx_LongTermDebtLiquidityThreshold_019cdda2-a3a5-7875-8993-78c22e336f22" xlink:href="inbx-20251231.xsd#inbx_LongTermDebtLiquidityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_inbx_LongTermDebtLiquidityThreshold_019cdda2-a3a5-7875-8993-78c22e336f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019d0562-e462-7d34-b3f7-d2136db82375" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_019d0562-e462-7d34-b3f7-d2136db82375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d0563-c9b7-7327-95b2-d15270b68fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019d0563-c9b7-7327-95b2-d15270b68fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_cb97a1d0-d6e0-4ecd-8dee-ae9642279f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4088455e-5419-4e56-85b9-f5ebeecbc8e4" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_cb97a1d0-d6e0-4ecd-8dee-ae9642279f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>inbx-20251231_g1.jpg
<TEXT>
begin 644 inbx-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$ C@".  #_X1$N17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  ,   $Q
M  (    -    <@$R  (    4    @(=I  0    !    E    *@   9L
M'0  !FP    =1TE-4" R+C$P+C$T   R,#(P.C W.C$Y(#$U.C,Y.C(W   !
MH $  P    $  0            L!   $     0   0 ! 0 $     0   .H!
M @ #     P   3(! P #     0 &   !!@ #     0 &   !%0 #     0 #
M   !&@ %     0   3@!&P %     0   4 !*  #     0 "   " 0 $
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M8V+6@?\ "=^,/^AKUS_P8S?_ !5'_"=^,/\ H:]<_P#!C-_\55 '_"=^,/\
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M_P!MH ]OT+3/[$\/:9I/G>=]AM(K;S=NW?L0+NQDXSC.,FM"@ HH ** "B@
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M6B 'Y  ' !, %  F !)A8W-P35-&5
M    ]M8  0    #3+6QC;7,
M                          UD97-C   !(    $!C<')T   !8    #9W
M='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![
M !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "
M%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C
M          $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0
M+0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,    :    ' !0
M '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3
M+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N
M6%E:(        &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B
M      !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3T
M"EMC:')M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C
M      $    ,96Y54P    @    < $< 20!- %!M;'5C          $    ,
M96Y54P    @    < ', 4@!' $+_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 54!=0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=&VG7'B.Y&69HO4]ZZSP[X2CBA&Y555')/%/T#6M'\&V*W>KS1VMJ.-Q[FN
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M);L0D3L<!![U]+_MJ>%U\8_ 379+?_7P6YV'T-?DOI&MWNCZUY-YN\R-\9[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0C/W:_.+QYKUFVMR21XFW<G!SS7;_MS?M"7U[\7-2T63S((K.4QQA^.37/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J.ZNX[*$R2,$5>I-2%MHYKP?XX_$VYU#Q))I%G<-"L7+,#U%<.
M88Z&$HNK,F<U%79VWQ%^.^E>'=/DCMIX[B=@5*@],UXK+XP6YM9(LX\UR_7U
MJK?:'%<Q;I&620\EC6#>Z>\=QY:-R37Y[F&92S!KGT2V1Y\ZCF]3H)]6A2P:
M%<-(_%>+^+=9T?X%_'_1+JX2%5OHV>3</6O<-!^']U<6@G\MI HSNQTKXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***CN[N.RMVED;;&@R3Z4 ><_M*?$63P7
MX5^SPL%EU!2BFOF2WT.2]MVN+G<\TGWB>:V_VCOC;)X_^(2Z;#M-OILV%/J*
MAAU%?[);/\*U\+Q!BIRK*,-D<=>6NA\-_P#!36SN+_0+'3[?<%:<+Q[U\GZ'
M^SA)9ZC#>+)/'/&5=61CG(YK]%OVFO@[)\5=%\ZWC\QK4F5L#H!7G?P4_9AU
M;XF3[K>US;Q\,3P<BOY_\4LYQN!Q\)4FU&459KNCS,74FIV1RGP\_:#U;P=X
M6CM-6C,MO"0HD"%FP*]<^$W[3WA?Q;-&L=Q(LV=N#Q2?$[]FN/P;X>FCG3#*
MI/-?'ETBZ%XMFC@8QJKGE7*_RKAX;\5,R5!T\2E-1[[D4\942M(_0?\ :1C_
M +1^ 6H36,T;&1005;GFN%_9G\&K\._"WG*NV34$$CGU-?->C_M$:E%I;:%'
M=-<03<MYKEL8[5]1?#_Q1_:O@FSQM#QP@$#UQ7Z'PCQ%'-\S<E%QM#9]'=W.
MC#U>>I?R.TU68ZU>6\:-G)PU=OH/@E9+&-"O05PW@FP:.Y6:7/S'(S7L/AF\
MC\A>G2OM\QJ.FE&'0ZJFFB.0\1> XX86^3MZ5F^#M%B@U+RV%>C>(IXGMVZ=
M*X6P=8M<++Z]JPP^(G.DTR8R;1O?$C3&MOAS>-"OS-$PX^E?CS^T)\/;B_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&?XHM#?:#=1+PSH0*^3I='N-)\<ZENY^?J*^F?BSXI7PUX3N64_OG0[*\E^&
MOA3_ (2N::^NOO2_,QKXOB[%0A&-/J<N(=[16YC^'[>;6K@0[FYXP36/\3?
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M:\'^(U@$97'\)S7V.4<L)\BT.F*<96D6HHE&C;O]FO.+F_\ *\9VK?PK,O\
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MO -O&H#PJWU%>C?L@-+\.OC;8R0MY-K<38E4< UX7#.88'#XCV$E[L]'\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^BM=\9/Y>V23.WWK];R>K+&82E76MTCMIRYH'!_%S0=#^&OA<:AH]]#X;FM
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M2RA5;C4 MR/[C5TD?@;2_''CZSTVVMXX4E^8X%<CX%OF=5CDSD<5UWP_U/\
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ME?OV1Y?%3EC,0V[I13>[MJW\[G;1A]IF[\1?BZ+[X>7EG=.)(VCP!7RK\&?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%U_QU;QV,43QQN#G;TK\GR'C3-Y8V.!CRVG+56O;75>74QC*<6H\RU['/\
M[*R7%IXXUC0)F*-9K\JYQUKV^_T.\TK:LP.VO*/&^DK\$_C[IOB"3='9ZW=J
MDA'3;D5]1_$2\TKQ!I:7VFLLEO(@VGWQ7[CE.-G2G/ S7P/\'JCLIR:]UECX
M%?%J3P?=1V-RV;%N%^IKZ,MYUNH$D4Y610PQ[U\=:%;M/8JR]8FW _2OH?X
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MPU;Z9-)"H5EV]:\9U+0YK+5));<?*N2Q/85]1E]6%1<RT9T4['FW[95E;O\
M#V$?Q+/'R.O6OI'X+7$,'P\T7=CY;1!S]*^3?B?JS_&#XG6_A>RS)'Q(Y[ @
M\U]'66J'PAX>L;-<LUO"L94<].*\.-)U\=6G3=UI'U:W_,QMS3=CO/%.H0FV
M8@J%Q6U^QI)<3:_JICW>5YG/O7G.A^$/$OQ/N$@LX"(9.,L,<5]1?!#X20?"
MWPZL8'^ESJ#-[&OM^'<KJTJGM9Z(Z\/3:=V=Q1117VIV!1110 4444 %%%%
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MU*RY;)GD?QE\!V_B_P 'PVPD?=:H) ?H*ZS]@*YD\:W*Z+YC-<1R-D$]@?\
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MS)\/6>.C./<UI1?/<^B(W\Q%;U&:=0!@45^G'I!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=F?1U%5])U%=6TV&Y3[LRAA5BOJD[JZ.D**** "BBB@ HHHH **** "BBB@
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MNS7X$2UB?&_P5T76OC?K\?AZ[DF73_#\GF%3R'&:^J/!W@BWTS44M+.-8X4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'P*\#ZQ\2/$=OH\4;S6\KA2%0_)DXK]8_P!GO]F_3?V>OA#'8Q0QR7L@\UY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBO=-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B>/? MGX_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME=WV.A\$_&74/#&JI8ZLFV%CCS&/->TVETM[:QS)RLBA@?:ODWXE>+5U,K,
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M^<GV1RQC8[#X#W/AO]F'X.Z?!<21V]TD>)F ^8C'>NO\$?M3^%?B)=-::=J
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M/]G/X96/@#P':K%#']I89:7'S'->AU]Q@,#3H1O'=G93@HH****] T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!E^-M6;0O"U[=IPT$985\*_%5+KQIKUUJ
M32,S,Q8#/2ONSQ=HG_"1^&[RQ_Y^(RE?%7CC2)_AYXRO;&^0K;E]L9QUKY_/
M%52C.&RW,:U['D]Y?20LJR=8SR".#7"?%;]G?2/BZW]J0QFVU6V_>HT/R D=
M.E>P>+-'MK@M)&5^:I?AEX:\_4-I&4/!KQJ\J-7#M5%IV,96<=3YAT3]K?QA
M\(;RXT'6OWUJL9B ";C@\"MO]E?XGZ5;_%'[3=,T,-PQ8@G:,FMG]NS]GJ32
M_$/_  D$,+"UDVH=H[U\]0Z5<6$OF;)(P.XRM?SQG?%V-R_,O8U?>C3=XWWM
MZGCU*TE*W8_6OX8^#=,\>6!875K):S*3M#@M7PY_P4+\&-^SYXGDM[(LMGJ6
MZ0E3\HKSGX-_M.^(OA3JL$=G?22*S@%9'/ KZ2_;)\._\-#_   CNHVCN-8D
MM05VG."17JRE3XJPDG"+4X:_\ TNJT;):H_../XH-I?BF&:-CYB2;B1ZU[M\
M"TM_VBM8FM=;7S(;<CZD&OE_Q/X<F\+7-U#=96\MG*.#V(KZ&_8#U(1:\WF-
M@S!1R>M>;P])X;%4\/\ 8<K23ZLFGHTCN?BU^PG=:#YFH>'8U>Q7+F,GYB*\
M,U30[C19FAN(I(9$.-K @U^DGAGQ3'::G);R!9(\ 889%<K\=_V6_#_QDTV6
M[M5\C4E7</+^5<U]/Q9P"JM25? Z-ZVZ/T-JV&UO$^%OAY\<=2^%FNQW5O<,
MFT@;,DAN?2NO^-7[5=MK?B*QU^/?'JF8X&P,<'@\5Q7Q)^"%_P##OQ9<VVJ
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M/RNK?0TZOHCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*,8N]D>I'86BBBNHH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-JU,4J>+TBFI6^6B_4X)-N7O&?\ LXZ1_P )[XKCL;A=C7L@C1L=,GK7Z6_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDTN3&V5RU?5=?)_["'A[[7JK:DWWE)45]85^@9=?V"N=U/X0HHHKN+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMDMO:QK%"G117'@<MG3G[2H_0SC3L[LLT445[!L%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT<;##1FO=8M%M89_,6&,/G.=M6JX,#DE##2YEJR(48Q(K2RBL(5CAC6-5&
M*EHHKV34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILDJQ+EF51ZDXH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.[N
MDLK62:1@L<2EF)/0"I*\/_X*"_%IO@[^SMJ6I1R^5))^Z!!P>0: /GO]L+_@
ML9I_PD\33:/X4^SWMS#E',BYPPZU\O\ C_\ X+*_$;QEH=Q9K;6\*S?QH<$5
M\@ZYJ<FN^)M0OKES-)<7#2!GY/)S4T>MHRJGEJN!C- 'H4?[8'CO1?$7]M)J
MU\TRN'\LSG;U^M?L3_P3R_:4F_:'^#%E<7C*U]:P+YV#SFOQ*\.:!9^(TD6X
MF:-?:ONK_@BM\<I/#?C;6_#/^NMII%BC+&@#]3**** "BBB@ HHHH **** "
MBBB@ HHH)P* ,+QU_8]AHTUWK$L-K;1@EY7.,5^='[=/_!0[PKX.@N])\!7@
MOKWE68CHW?!JK_P6U_:WU;0_$"^!M'NI;>.:)9'DB<JV>]?G+X?M&U?4E^US
M/)))RSL>2:!W8_QSXGU;XHZ_)J&MWT\C2,6\MI"RC/:J4>VVB\N-555[CO6M
MXLT2'2)XUAD+AASDUBZE?0^'=+FU"\=8[6W&YV)Z"@1Y/^V1K*0Z%I=BS;I+
M[Y$4G-=K\$=*;1/A%I=M("KQKR*\0T];[]IOXU?:,,-'T"X\R!QTD7-?2IBC
MMHUCB 6-   * %0\X;[K<$>HKR7Q_P#"W7-'^*-IX@\+P&5Y9521!]T+GDXK
MVKP[X7N_$MXL=O'N7/S'/05]&? 7X(Z7X9D6_O=MQ)C_ %<@R : /8?V2?CU
MX?\  OPTM;'Q$K0WAB!8"/OBNG\,_MBC3/B5'#X?W26\I*X=<+S7*OIFG:Y,
MNVQMQCY1A:V+;X8'3[9KRWT^-=BDAPO0T -_;7^!=Q)H:>*KJZ=9;B/SO*BD
MR#N]J^<_@I\$;[PI:ZEJFH3.L5\WFQ"1^U6/B'^U#XF^'OBZ3_A)U>73[=RL
M44K%E9>W%>5_%_\ :*\9?&RW:UT>Q6ST^081X3MPM 'HWB/]H[P_X.\1PZ2U
MXS74S^7A3D9KN_"-C<>)I3=PEFC'S*:^4OAS^S'>2:O#J.I3S37,;;R9#G!K
M[N_9F\-0)H9AGX 0 $T ?1G_  3?^*%]+XPO-'GD>2&&+A6/2OMP'(KX+_91
MU:S^'GQJN NW;=8C4_6OO*-MT:GU&: '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7YN?\%T?BC?6&@KX>C:1;614D.#QFOTCKXN_X
M+%?LWK\3/@C<:U:KNOK9E!P.=HH _&X-F)/<#-=IX6^%:^(?"%SJ/VAE>#HO
MK7$E?(N9(&^];MY;?45Z?X>U*&S^&5VJ78CD8CY >M 'GRSR:;<R1J[#:<<'
MK7W1_P $1M,T7_A.M:OM4NTAN(G#1;OXC7S#XJ\"Z=I'P^6]9D:ZN(MX]2:Y
M+X7>(?$NC:KM\/:I<:=-(?F,1QNH _H3U7XP>'-%D5;G5+:-F.!ENM;FD:Q;
M:[8I<VDR30R?=93D&OYX_&7QL^(JZXUK?>*=0\R%L99SQ7U!_P $UO\ @HGX
MD\!?%.W\-^(M0N-7L;UUMXC*_"DG&10!^PU%,MIOM%O'(.DBAA^-/H ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115
M:75[6"X\E[B)9.FTMS0!9KPC_@H?\1--^'W[.NI7&H21JLOR*K'J2#7N[-M7
M)Z#G-? /_!<@RZK\"6:SO4DA650T2-GF@#\G+YOMOB+4YH^8Y[AI%QZ$UQGQ
M._:(TSX:6K01S1ZA>$<6R-\Q/I2?&WQ^WPS^&,NH1;OM"XC&.O/%<'\ _P!G
M^WUX-XF\38O+JX/GP,3]Q3SB@!FJ_MF>,]?@CSX9U)K.$81<'&*Z'X;_ +:G
MV"]C6_L9-#DS_K)3BNN?XF>%='O5TW^T-/C(.PJ6&5JOXO\ @QX5^).GEI;6
M.Z:4?)*AXH [30_$EO\ %?5(I[?4([UKIAF53G%=??\ @V]^#.OZ;KD<S3?8
MYEF0J.XYKXC\?WNN_L6:Q#?6^H^9I=V^(+9/O)7TA\+?CUJWQL^&5E?7C2+#
M)]U7'(H _3?]G;_@LQ>--8V^K6=Q/#\L1+-PH'&:_1;X0_%?3?C'X.@UC3)$
MDAEZ[6SM/I7\\7A&\:W;"MVX K]/O^"-_P :99[3_A$YI\\-*%)H _0BBBB@
M"KK=Q)::5<20C,BH2N/7%?S\_MS:U>>(?VH_%/\ :#.WDWK>6&/W>:_H08;A
M@]#UK\0O^"O?PGA^&_Q^DU"%E_XG%RSL!VH ^=/!^C6VL>=]HF2/:.-W>H;&
M6^\+^)RVBW36]P&&)$)K+21H_NG%:'AG54TO4/-D4R4 :GQ$\7>)O$\BQ:[J
MDVH!<$*Q/%<TD1B/"XQ6GXE^,'AG2]?:74[RU5L#]PS@-7F?QJ_:FL;.X_XD
M7AV]N(\<-"-P- 'KME<-J.AM',V2#P#7EWQ[^(EK\,O 5W.TRK>9VI#GYF!K
MR:7]I/Q;XA4PV.CZE9LW 9HSQ5GPE\ O$GQ-U^+5O&&H"[LT.?L[#!Q0!O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5%N?WDD*A17Q3K/B);+6KVU/W8)2@/TKTS]D;]HC4/ WC&.RM6=UN)/X3TH
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M66/ :OEO]I;Q(OB_XY^&]+LR)6;Y9"O.PY[U[II-F=,T.UM6^]"NTT ?5O\
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M_P!M/X7SVWPZ,L:D%7+=.E?>7P:\9^&C\,(X95#2,A"G/>O$_P!JKPU:^)O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(9E5XY 0014U% 'PO\>O U]\,_'MQ(D3_9;N0R J. ,UQNIZFWBS1IM/;/\
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M6=\IGTK[(O?#L/B(01V\?^N .2*P_P!K?]G[3_#?A;3=2TQ9'N(X-TP49YH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M13HY1&F?2K&A>&=2\8W8AL;>20$X+*.E=YH7[)VLZC*@GEDA5CSD4 <K\,?
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MN - 'T)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;25&=GUH ^>?A#\*M0^+GB^WT^SAD:+S LK@9 !]:_3GX ^!V^ G@JUTRSD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_B('2@#<U/4(=+L)IKB1(XHT+,6.!@"OR?\ ^"AOQ(T?X@_')YM)V-!$AC?
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MFW$.HRE6$111VS7RW^SAJUSX)^&T$D4\S,P(9R>35WQ!\5]4N)6^REN.3[T
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M[)=1QV-_&N3&6YKV('(H \=_;BTEM8^!5Y&J[F616K\R_B9X:_X2GP7>"/\
MUL+[<#MBOU._:0^,/A?X8^!KL^(;JU42(0L4AZDCBORS\7_$B&[U_4&T^!6L
M+B9G4K]W!H Y?X)^ H[Z4_:/F,+;<&O5=9\%VMII^(XU7CL*\\^#^N>9JMPJ
M_P 4A->G:QJ+)9G=PN.3Z4 >!_&32M/CT.^\R"(7$:GRY"/F4^U9_P (O&EQ
MXL\*V/AZ*:2Z=_W3Y/3->3_M:?'O[=XXC\/Z5^\DFD,4A0]*^A/V0/!ECX'\
M,6M[=;);Z103N'S*: /=O"'[/LWAGP#:V[1[NYS[U8N_V=+IM):\6S BP?F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBG8?%'P['>V<G7AE/7-=37R7^Q/KLD?Q*N+"%V:S",0.U?6E !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444CN$4LW 49-
M 'AW_!0+Q_%\/_@%?7$DWE&;,0YZY%?ACXA'G^(+Z251(LT[. >^37Z ?\%>
M/VCKCQ%X[D\&VLC?8X0),@]37POJFD+>C/\ %B@#:\#?%F;1/"TFBP0HJW#
MY%>I>'OA7<ZU\-+Y=2A$WVL;HU<Y!%?/DUA-I4ZR8.%.<UZ!I?[5=UI?A&33
MG7<RKL1LG([4 >7>,/A3HR:Q<6LVE6:M&Y7/EBL+_A0VB,<_8;7'8>6*]GL_
M@KXL\0Z+/XDDTN9M/8>:9B#C%81A4<;>G:@#A-(^"6@V$RR'3;5B.QC%=5#I
M5O9VRQ6\*0Q+T5!@"KSQTJ0;Z ,#5$^R#VJCH^DW?B:],%JNZ0 MC/:MWQ7I
M+166\<US>D:O-H=V9869'QC(- '.?&'QI??"GP[-=I;^9-"V"IYKEOAU^U-;
M>)Y8X=55;65_N@"O>_AMI^D^-M7:'7(H9H9%.1*,C-?/OQN^#NE^&/B@VDVH
MCAM]09I$N%&#$.P% 'J5HS:[-&MKB03_ .KYZTWQ3HLUKI%U:WB^6LBX8^E>
M2_L]>.[S0O&%WI+2R78MYMD+L><"O;O%^KMK7A#58;J/RYFC(1SU!Q0!\.?M
M&_M!-X&NI-'TZX8);$K(%;[P]Z^E/^"?OQ?3X@?#^&W\F*)H$+,ZCYFK\[OC
M[%):_%+6H9)&DVN>6KZH_P""96N,--GMXV*E8><4 ??]O<6-]HMQ)<>7(+>)
MI$#>HKF_A=\3%\;^'9F8+&89F0 >@-<A9Z_<6,%S'O9Q-&4P3ZUYM\/O&,WA
M/XD2Z-,3#!(#)GU)H ^B;SQ%#"3^\YK!U'Q;(S'9]WUS6$;IIGR6R&Y!JM=W
M6WY5H P?CE\5)O"'@^ZDAW/<LN445RO[.]Y'KNGW5^O%Y<#=*#QM-=Y)8Z?,
MRS:I%%+;Q]1)TKYW\>?%#6G^),FD^&M+$%K-(45H?ER* /8/VCRU[\+;Y[AU
M(M8&8#=FN6_X)_W-Y>^&;AF+_9KN,H@SQWKF$_9X\6?$"Y6/6-2OK6W<X:/=
MD,/2OHG]GK]FS6OA'8(VF6;ZA:X^4'H* -3]G>^D\-_&VXTC4&:&QVCR\]"3
M7Z&_!KX&VOC)%A581^[W@Y'-?GO\4M;FM;^%+BQ73=21P=ZCYF/:O1/A]\7_
M !1H6FV\TNL7EBV0J[7/S#L* /H+XB? N:#XRM&T"_9XX&Y'3(KF/@MXCLO!
MM]J=G>8AG\Y]@QU%>O?"CXDW&N_#?_B:6XDOG/RSN<NRUR7Q%^"T?BJT>\M5
M^SW3, -@Y.: )?V7_&$:^/K[6;@+,UE.1$'Z8KGOVY_$7V7Q78>*+=_L\-NQ
MEF2,X4UZ)=_LF2_#KX6&[:^GM[R[B$JJ!RW%>)^-?"6G_&33&TG4M:DM9+,>
M65S_ *SZT ?0O[(GCW2?&O@S[=<3K_ID>0*POC1H45WK%U]G^:'^$UY?^R9X
M O?A?XBN=-GNII--8A+=VZ8]J^K/B=\)+73/A]::E'+YAN!S0!\L>&M,^QZO
MM/8UZMX=M898-S'[HR:Y";P_G5&>/U[5UV@:%=7-A<+$K,XB.!^% '@/[0L4
M?C+XH26**LD,=N6QVR*^1/%7A>[U+QI)-<B1/LLA1&QT -?>+_!F^T/PC>>,
M=3C:-HY6CPW<5\V_%OXD:+XBM;B&UM[>*;?M)4<DT =3\&=?C\26MNEI(?,M
M4V'%=#X>UN]G^.&CW%NSJ]C+AF4U@? O38O ?P^O-4F4*V=RY'7->Z?L6?!G
M_A,M7O-6OEVK<R>9"6';VH Z+Q9X@NO%.M(]Q\PB;+,QYKH[B:[O_"S0^'8_
MMU\J?,A[&O)/VI?'"^'?B-;>&;)O):\E\EI%X*UZC\(]?B^"GA1Y'E%Y*L>9
M)'/- 'E'PK^.WB;X+_&\P>*M+@CAO95B4,=V,FOHGXW:S9Z]=+-:1HJ,BM\H
M]J^4;WQ"_P ;/V@KS4&7S+:%A(@ZJ"/2OL3X0>"+'XCP^7>3_9UCC!S]* /.
M/#_BJ_DB&GPR2*CM@+G KN_#OPFU'0]0AO+^+9')AMY/8US?Q?T;3_ 7B8?V
M?<"5(R#N'J*AU_\ :/NM;T5;4Y41@*&!]* .Q_:1\+:7IUG:SP^7<2>3D[AG
M%?.'AKXF6/ACQ0\C6Z[HWX(2NYTK6]1^+_BJUT&WDDN9KC '/2OKOX;_ /!.
MWPOIGA:/^T5$UY<QAI"T8)1B* /D77?CO:^*K6./>(V X J/PM?)<W6[=N4G
M/6I_VN_V-]4^#'BF:ZL(Y9-/F<LC <**\U^'/C)K:_-K*S;H^#F@#['\/?!Z
MS\4_#E=0LFW74,9=U';%>7:SXKU".W326DDW._EJF>]=;^SK\5F\.W[0W$W^
MB7 "$$_*!4/Q;.ECXL:?<6'ER0M<)P/K0!]!?L:?!"3P+X=75+Y66^F!X([&
MO=JH>%W5_#UF578/)7@?2K] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]2NKA89(IFAN"ORS#JE>LW5MY%R\8YVG%>"?MO\ B)H_#_V>S.ZXV#!7JN*
M/8/V4/!FG?##3[/5M3CCU2:\42EI!R#7JWQ,\9Z3XR3R[.QAM=V0=O>O@O\
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MH&C#  /C[U 'V5^SUX4F^*'PXM]0MY&:6TB#L16SXQ^+FHV>CKI%S)(T=OP
M37E_[,/Q(NOA3;:GH;W1A6%=ASWK5U7Q)9>)=</F74;,6Y.: -3PUJJWLF?4
MU1\>?%Z\T#4H=(TF%IKQG ;8>0IKJ/&VBZ?X(^&5OJ=G-'<75X3&J)U4UZ+^
MRM\$]'D^'Z>*O$$,4VI,YXD^]M[4 <!\5=!\2:C\!)+-;:XFCF^<KZ$BOC/P
M#^R%JWBGQ1+]NAELX6FW%F'3FOTE^.W[0^CZ7\,+NRL=-7SHPV&7'&*_/#P9
M^U%JWB7XC75C]HDAC\QAM- 'I7Q*^'UKX<U[1?#=K.LUK/"!,1TR/6O3O _C
MR/P#80V=K,(OLX"?*<5\W7_Q2DG^*EG;WDWER-G;(QZ"N9^+?[0:^$M1FAMK
MC[3)NQE&Z4 >G?MC7MOXCL&U:SF6/5[8&2-E^\[5S/ASQ9XMU#X$-->K=>=+
M;G,C'FN+^"_A7Q%^T5XUL5CN)I(FD&Z(#/X5]C>-O@E=^&?A1?:3]E=9K6V(
M(V\YQ0!Y;^QGX5CL_ *:E<MYEW.&#%NM>N6OQ$O-!9X[.9H^,':>U>=_LW6$
MMAX+6QD#+/'NRIZBN<^-WBN]L;^'2=*9EOII0C,G4 T =_KOB.Y\37FQI6D9
MCR<UJ3>%&ATG=MZKG-4_#_[#OC.P\!1Z\VO2,\F'V8Z9KG;KQOK?PU9K75H9
MKR%3@R'H* /5/V%];T_P5\=[.?5FC51(=LC_ ,-?IK97D>H6D<\++)%*H96'
M0BOQVTSQ1:ZY,MW8SHLJD'<I^X?2ONC]C;]KW3[_ ,+KI?B#4([>2U CB>5L
M9 H ^D?%?@K2_&UB;?4[.&[CQ@!QG%?&W[;/["*:?81:YX/L]LD+&2:*%<9K
MZ4\6_M5^$/#,64U6TNF_NI)6K\/?C5X?^*MBT=M=6[NRX:+=F@#\Q_#WB76-
M#46]Y82V]S&<;".:]Q_9A^#.O?%7QI!>:C9S6^GP,)$D8?*Q!K[(U']GGP;J
MU\;FXT.SDF)R7*\UTV@>&['PQ9+;V-O';PKT510!:L[=;2TBB7A8T"C\!4E%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\1_ 'Q4? 'Q;-GI,A:VG=4*J=V :^VHSN13[4 .HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_:*^*<&GZ O[FV7]ZRCC*]>:ZSX=?M=V7@_5=/\ "-PB6[6JBWD*KMR1QUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M01ZTS1RW"[5 &>37COA[3XY_&S3, TF1D>@KZS_8PT-/$GQ6\G.U(8PX^HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXA_X
M+A^'[_6OV?M.:S5V6&X)?'88K[>KY,_X*]_$*R\$?L[*EU&DC7CM&@;L2.M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-0FE4;5D8G%5<\TX(2N[^'N: /(OVE?V:+'XN6/F6,<=K>*OW\<DU\:?'_\
M8WU?X0Z8+^69KB,J68A>E?HM>>.-+T:7;)>6^_T+=*P=6\$VOQXTJ\TZZDBF
MAN 5C/84 ?E'HBW.HWT-G#(RFX8( .^:_1/]EGX?Q^"/A):V<NGM)+=1^7*V
M.H-?*GCK]GEOA'\>Y+5IHH[6SN08O>OOK]G_ %23QIX?TW3+*WDDNF(1I%&0
M* /"_P!HC]@:Q\2>'O[4T.)+/4%8R?*/F/>O%_ 7Q]^('[+EZMIK=KJ%SI<;
M[1N!"FOOWXR^"]1^&FN-;7FN6MJV <2'&,U\^_M->&]/\9?#S-QKVFW$D<FX
MJK#)Q0!Z=\ OCU;_ !W\-KJ$-FUIM&"#ZUHZCKD<NJM?7#*MK:Y5L],UXM^R
MY\3O#_@OX?R0Q>7"%DV%BW!KT779+;Q=\/KFTT^ZBFN;N4,J(<MR: /./BYI
MWB?XXZH\=BUQ#IL!*;0/E85R3_L:^*DMUE\JX$/7=L."*_1#]GW]DJ]M/A[:
MW%TOEK)$K-N7K79?&FWTOP5\/_)7R8VABPQP* /BKX!_LY:7X8LXYM2LXYKI
M0"&8<@UZ].JV2+'#A8UZ #I7$:C\;+&'5HX!'D,V"X/ KK+2]CU.U6:)E=6Y
M&.U %J'.HWT,1^](X7/UKZP^%7P/M]+^'\4C1CSY!UQZU\GZ3=K8:G#.R[A$
MX;'TKTG5OVGO$$YCATR:2WA0 !,>E '9?$_]FVSNI6N)+/\ ?=1)CI7#:1XM
MUKX(3L]W=27.G(#A?X5]*[/X>?M2K-<BP\5-C<N1YAVY]*K?$SP))\;+W[/I
MZ_V;I<@W,\@^5OQH \$DFN/VE_B[;ZE=;FTVSDVLA^Z1FOO_ /9[^)FE_"_P
MG'8Z<L<85 K*IZU\O_"?X,KH?B^/2M+DC:W9ML[KRI/K7U)\+/V>(=-D>2=?
M.R<C':@"Y-HE]X[\4_V@6:&WD?<0?XA7IEEI7_$J6VC^ZHQQ6?81IIS_ &';
MY:_=3/:M;0[@Z5=O'-RO1: /K;]E"RM]/^'%M&FWS@/F]:]4KQO]E6VN#IS3
M,&%NZ?+7LE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#?W
MBZ?923O]R)2Q^E?AO_P5D^+S?$W]J;6+%&)MK<@JN>E?N1J-BNIV$UO)]R92
MK8]#7XV_\%0?V#?%/ACXY:EXHTBUDN=-O3A BEFH ^:?A1\4SX!G^;<T>,8%
M=MXH_:!L?%/@^33G1OF.[FO*-<^'GB#PM:^??:7?1PYQN:$@5D+*"/O8]L]*
M +%U-FXDVE@I/ IT&HR6\+1JQVM55I0#Q\Q]!UIOGL#\T<B>[#% $RJ9I/<U
MX?\ M,?$;4;[Q#I?A719/*?4W\F<U[A;3B.4,"#CTKYZ_:)TN[^'GQ0T7Q(L
M3S6*3>;/M7<0* /4?@-\ ]%^#=Y:WL\)FU0,'N'8[@W>NJ_;'@_X6MX4M;KP
MVJV>H::WG.0NW=CM6?X*^)^D_%#3([ZQGC0R#)C=L,/PK:4^6W/3N/6@#S'X
M _&UO&D/]CZQNAUBWSN,GRY Z5Z81@UXC^TOX(/@K5[/Q;I7[FZGG5)=O"[>
M_%>N>"_$:>+O"]O>1_-\BJWUQ0!J1)O?]34OQ7\:Z#H_PZGCL&1=490!\W?Z
M5'&,1R,S!5$;')Z5\>_$/XVZ3X?^+XM[ZX>2%9#N"OD#F@#O](^!6K^+YI-0
MOKC;'(VY26Q7K&G_  *\6?!K0;;6ENHY=/9?,VJ,DBH_#WQ$T7XC?#Z,:/<1
M>9"@&S<-Q-=QX9^+MYXO\+1Z#=M'Y-FGE$-U- 'Q?^W1H<GB\:;KFDQLMTC^
M9<8ZBN\_8^_:EO?AKX?M?LNGW<VH2 +YBQE@I]:ZWQ+X/L6\776GRKNCU%O+
M /.,^E8W[/4[>"?CCKOAEH[?[%91CR0R@G- '0?$7X?^+OVD/&$FM>(KY&LY
ME&V,':PK&N?V'M'O()$8R'<IQF0]:]OD^5N, >@INXT ?!OC_P"!6K?"'QDV
MDSB1M'D!<,F=H/;FKWP7^)<OP.^)=G>:M>QW6G*<A%?.T=@:^T/&'@K3?'VE
M-9ZE$&C;^)1\WYUX/\0_^"?FCZI'-)I[3>6P+'<_.: /JB7_ (*V:'H?@>W@
M+K-'Y0"+&1E17"ZY^U[H?[0'AF_59O+DVX52_-?$?@OX2:7X1UZ]L=6DN-D,
MA5=S]A7+>*(M4T'7KFZ\'1W@L[5\SNP)4T ?3\FFV[NRK/&-O3+<UV?PF\:R
M:9>_89'\Z,D*@7G%?(<>C_$S6O#AUJSEADA";V4<D4_]G;]J35O"OQ0MK/Q!
MN;S9UCP%^Z2>] 'Z&S0-%]Y2N1WKI/AYXAT/PG/-?:W&TD,<9* 'N*PIM?CU
M_3(9HO\ 5LH.?PKD/C%.\?A*%8]VYY-O'>@"MX[\:Q?&;XC1:E;QRIID,@C6
M%>')!X-?:O@#PMKWC/PC8VX98=-6%5*,,,>/6O)?V!?V,KKQQ)#KFI6KM8J>
M %[U]\Z#\)FM;*.&&%EAA7:#MQP* /%_!/P^TGX=2_Z/$5E8Y=F/4U[+X*\8
MVUA:@^9&3CIFL/Q'\+Y-<U5;6WQN8X)SWK9N/V9-4\,Z#]J9^,9ZT &LZK#J
M&HK<1_.ZG("GDUZS\ /@O<?%K4?.O87BMH"&.\;=PK5_94_90L]:@75-8_>8
MPR!6KZHT'P[:>&[%;>TA6.-1C@<F@"/PIX6M?!^CQ65FFR&,<5I444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI*^CNO$%CX/@\^XUW**2NW;GTKV;]B[]C6XT&\NO%OBXM_:MTOF;7;=ANO%
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MKB?@/X.D\'^ +**9=L[1C>/2NVH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#.FVZ:?=1PQPS>5DD#EC7/\ _!-CX*W5]JTWB"ZA:.*$B2%B/O"@#US]E_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWC6-/114U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>,_MD?!^U\=
M?#^XU0QYO-,B+1[1R:]FJOJVEPZUITUK<+NAF7:P]10!^=/@B9FL?)E(62,8
M(;K4FKW:VL_^L7KZU[]X_P#V'WG\37%YH[-Y=PV2"V,53?\ 8%%[IYDFED^U
M8R 'XS0!Y;X8\2S:78N\4@&Y3GFO2/V:OA')\0_$HUB_W/9KRN3W%4-'_8L\
M3V^K)#(J?85;EM_45]/?"[X?6_PV\+0Z?;CA>6)ZDT =!;P+;0)&HPL:A1]!
M3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>inbx-20251231_g2.jpg
<TEXT>
begin 644 inbx-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$ C@".  #_X1$R17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  ,   $Q
M  (    -    <@$R  (    4    @(=I  0    !    E    *@   9L
M'0  !FP    =1TE-4" R+C$P+C$T   R,#(P.C W.C$Y(#$U.C,W.C4Q   !
MH $  P    $  0            L!   $     0   0 ! 0 $     0   0 !
M @ #     P   3(! P #     0 &   !!@ #     0 &   !%0 #     0 #
M   !&@ %     0   3@!&P %     0   4 !*  #     0 "   " 0 $
M 0   4@" @ $     0  #^$       @ "  (    D     $   "0     ?_8
M_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R B
M+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<(3(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R_\  $0@ > !X P$A  (1 0,1 ?_$ !\   $% 0$! 0$!           !
M @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-1
M80<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$
M149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;G
MZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*
M"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"
MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V
M]_CY^O_:  P# 0 "$0,1 #\ T-=_:'_L3Q#J>D_\(MYWV&[EMO-_M#;OV.5W
M8\LXSC.,FL__ (::_P"I1_\ *E_]JH /^&FO^I1_\J7_ -JKH/!'QR_X3+Q=
M9:#_ ,([]C^U"3]_]M\S;M1G^[Y8SG;CKWH ]?HH ** "B@ KQ[QK\=?^$/\
M77^@_P#".?:_LA3]_P#;O+W;D5_N^6<?>QU[4 8/_#37_4H_^5+_ .U4?\--
M?]2C_P"5+_[50!H:%^T/_;?B'3-)_P"$6\G[==Q6WF_VANV;W"[L>6,XSG&1
M10!ZG/X,\*W5Q+<7'AG1IIY7+R226$3,[$Y))*Y))[UAZ/\ "7P?I&HZI>?V
M7!>_;Y?-\F]MX9([;ECMA78-B_-C'/"KZ4 ;'_"">#_^A4T/_P %T/\ \34+
M:/X4\/2&^L-#TBVOH5;9);V<:.F1@DLH!48)R<CC-3.2BKL&[%NQ\10WMYY(
M\M4"Y+^8",Y('/KQTK;J*-55(\PD[A16HPJ*>XBMT#2MM#,%'!.2>@XI-I*[
M X^;Q=)::@MO+.C!Y56,[,;\[<+G&,G<>A/;WJM=^ O 7C35KG5;[2A<ZC+C
MSW%W,.5 4#Y'"] !7'A\4IR<)/4E2N-_X4E\//\ H7O_ "=N/_CE'_"DOAY_
MT+W_ ).W'_QRNTHL6'P@\":9J-M?V>A>7=6LJS0O]KG.UU(*G!?!P0.M% '<
M44 %>5^)H1:2:C+.TES+-$8ML/S_ +QEW%NP7 !/;'S=<X/%C4G"[V1,MB]H
M>F*EZ]@+J/R)($5D:%E*C:5P,,""3ECW^<>]>BJ-J!1C@8X&*6!@E%L4-A:*
M[BPJ&ZC62V</OP!GY.O'\Z4DFK,#R_4TC::]N%,L]TMQ"XC:10)!&P'.%^3&
M6'..%!Z9KI?"<227LUR\4UO/(?,*28W$<Y!P3QDDX/.2>A.*\C"\LJENW_!,
MX[G8T5[!H%% !10 5Q'BW36MKB"\A\R99)U:6/8&(4,"< #)!;9D>@^H/-BH
M\U-DR6A-X1@B\]BQ61PH8_,6*-A0P.2<'*D_EWKL:6$CRTK!'8**ZB@IKR)&
MNZ1U0>K'%)M+5@<#K=A<3ZA=P0VQ9I5.V/&"P 88S@C'[P].F#UR<=/X<T9-
M)TV,2(?MC#,\C.6+-WQD].!T]!7#AZ'+5<FB$M39HKO+"B@#YT\2_'SQ5HWB
MK5]+M]/T9H+*]FMXVDAE+%4<J"<2 9P/05E_\-'>,/\ H&Z'_P!^)O\ X[0
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MZ./_ .%V_$/_ *&'_P DK?\ ^-T?\+M^(?\ T,/_ ))6_P#\;KH&;'A/XO\
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M0B!865H@!^0 !P 3 !0 )  U86-S<$U31E0
M         /;6  $     TRUL8VUS
M                               -9&5S8P   2    ! 8W!R=    6
M   V=W1P=    9@    48VAA9    :P    L<EA96@   =@    48EA96@
M >P    49UA96@   @     4<E120P   A0    @9U120P   A0    @8E12
M0P   A0    @8VAR;0   C0    D9&UN9    E@    D9&UD9    GP    D
M;6QU8P         !    #&5N55,    D    ' !' $D 30!0 "  8@!U &D
M; !T "T :0!N "  <P!2 $< 0FUL=6,          0    QE;E53    &@
M !P 4 !U &( ; !I &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6  $
M    TRUS9C,R       !#$(   7>___S)0  !Y,  /V0___[H?___:(   /<
M  # ;EA96B        !OH   ./4   .06%E:(        "2?   /A   ML18
M65H@        8I<  +>'   8V7!A<F$       ,    "9F8  /*G   -60
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !11FC- !1110 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*YG1/C#X=UV*,PZI:>9( =A?D'TKI(9EN(E>-@RL,@CO7UD9QE\+.H=1115
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBE'F:/J/P[$8="M4/58E%7*;'&(HU5?NJ,"G5^JK16/3"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4.H>5]BE\[;Y6T[MW3%35Y+^T-XYFAGM])M
M)MJS ^:5/*FN3'8R&&HNM/9$SDHJ[/G[Q]'_ &+\2+K['_QXW#%>.@)/->-?
M#^X?X<_'G6M/OE:-/$4YGMY,<$*/6OH?Q;I-O'8( 0TA/XYKG?B7\-;'Q/\
M#6:XN%6WU2TA/V:<\;>*_(LVQ$ZW+BJ*]^+O;NNJ^X\NH^;WEN?)O[1/C"?X
MV_M#:+HX=FTVRNHR%!R"P.*^R-#T9?#MC:6J#:MNH 'I7QE^P?\ !3Q%XD^)
M>J^(M>O(+O3[.XD6WVKR&5N.:^TXM>ADO_WS*JD\UY644:C=3%2WJ._R78SI
MQ>LGU-V_U]3I+0R*&B8893W%?.?BOQ#/^S3\6(?$UCN70KQS)>(OW4]*]_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !14=Y>1V%L\TS+''&"S,3T%>3^(_VI+.VU5[;3[:6Y6,X,B?,K
M5SXC%4J$>:J[(F4E'5GKA.!7&_'3QM)X(^'-_>6[8G6/Y"#TKQOX@_M*:YJU
MTL.GK]CAV_,9%ZFO.OB'\:/$7B+P_-IMS-'+"PPV%KRZF>8>5X4WTWZ&?MH[
M(Y+XBZK=:UI_VRZN))I)VWDD] :\W^*?Q/O/AU\)-8U73X_,N--BWHF<;S78
M7VNIJ>D?9_XHQMQ7(^+_  ;+KOP_U6WG7;;SQX9F' KPHQM3DZF^KU,5MJ>8
M?LG_ +<.I>('^V>--%%C:S3B&.>-3)UZ9K],_@\+%? "ZU:R+-#<1[T<5^?'
M[)^M^&=1^#GB70KZ&U_T*65HRP&[*C@@U[G^QA\4[L_!MK%IF;3X0P@+'/&3
MWKX*MBJ]6O"+?-&:;7E;]#EC4]^[U['J'C7Q<MGJ=QJ$G^KM\R-@9X')KYZ^
M)O[1LW[4?BJQ\.:'-(=+M9-M\PR,+7KOB'4$GT+4)I&'EO"Z9/3D5\]_ CP3
MJ'P:\=Q:K>&%M)\8S&.(A/N;3ZUPYS.,*E+#3=HR^+T]>B;LGZF57HNG4^GO
MAQ]E\(Z'#I]BBI'"@1L#&XCO5C5)3?7JM[U4T>6VTG4E:9O]'8Y!SU%6?$GB
M+3WN_P#0V#)]:]Z-)0FE26G3L:\JZ'QK^V3X:F^&GQ]T?7M/S!<,H+,O&Y2>
M>:]'^-/Q.'C+X56%K:?Z1>^)T^S(J?-M(Q6I^VK\%KSXU?"ZXN-,N(;74K%=
MRRN. JC.*R/^";?P^63X:+>:]<0ZIJT!818Y$; D9Q7SLZ-?#XBK1I;5=7KM
MM>R,>5IM+J=IX6T6]T3P9H>CC<&CAC\\#MCK7VK\"6LHOA[9PV>T;!\RCKFO
MF_2]-2W\1R?:EV&0DC(Z"NU^'_BEO!'C"V$<Q6SN'"R9/"BOT+(\RIX2K&A;
MW6DKG;1J*+43Z.HJ*TNX[ZV6:)P\<@R"*EK]&.\**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "D9PO4@?6L[Q9XEA\*:+->3=(U) _O&O"_%/Q1\3>(VDN+5OL]I_
M!E>U>7F&;8?!V55ZOH9U*L8;GT!+J-O!]^:%?JXIDNL6L4+2-<0[5&2=XKXZ
MU?5-7O+AY+R_D2->68.5 KE=4^+.EZ5.8Y/$2.,X8"X/%>-6XNPU+6>G:[2,
M7BHK<^AOC)^TL=.NI+#2#NP.9@<$5X7??$6ZU+5))7N)KJ=CDENU1Z5KVA^)
MHE^SZK:R22<8\S+&O0O 7P476K9I(E7=U)(ZU\YBLZAB;U)RYET2>ABZO/YG
M*^&M72XO5N+Z1F5#G8>AK@/VZ/CTOA'X83QV6V&:Z3$8!Q7M]U\(FL=26-HV
M.TY..AKX+_X*BF[M]:\N5FAALPRQ1]"U?%\39M3P^$<Z5^:7NKROU.6M*T=#
MLO\ @F?\0%UK3-0T-KCS+CS))VY]37U%J>B6=K!B1HPWJQQ7YM_\$Q_&K^!/
MC)<27LWEQWT.Q2QXR37U+XZ3QM^U+\4;CPKX,NEL;2R8I=73J2BG&1R*PX?S
M&%/+Z:E*[3Y;+=L5.24;'3^//C/HOPH\0JM]J(3H=@P5JC^S;XXL_BW\<=0\
M0_:H9+?2W(MMSCH17PW^V7X+\8?#/Q_-H?B;4H]4FMXN)H,A<=!7)_LO^(_%
M#^)6T[1;Z2&23GEB<\5EF'$5/$XI8?V3DH/INW;KZ"G4YGML?HUX=\<VW@7X
MMZW;ZE-LL9$DG#)\PR3[5WF@6D?CC1!>:>S7%C=J2IQU%?G_ .%OVD+[PE=W
MUKJA6XF=GAE,@W$<D'K7W1^PA\>]%U?X ZAY,+7%YI<6$B4Y9B<]!7E<,\4U
M9XF>!=.T%=KOOL31K-RY6?(/[5WAV3X;^*;KP_8ZE,MI=EKB2$?=W-U%>C_\
M$W[DW%S=:'<*/+FP(1V%>(?%_P 7W/CGXJZE)>1R)/)<LJJW55W' KZF_8_\
M 6OA[3K6^MHY%U/ 9>?Z5\7_ *S5X9VJU)/DBVE'RZV7XV,*<I2J>Z>P>+?@
MK').X3='SC '6L:7X?W'ANPQ&I8+ZU[&/CK\.M+T=)M8UK3[:\A.R6*28!@P
MZ\5A:_\ $SPK\0X'D\/:A:WD:]1$X;%?N&#SQU5%1DFGJ>CS-:-H\^\"ZVDN
MI^7<<.IQ@UZ)J,5OJ6G;516&*\;U&Y%KXQ'E<9../K7LG@K3YK^&-=K/O':N
M_,J:BU505%U)O@7\6(?A/J]U:ZE,ZV3AF1>V[M79S_M93_:#)%8Q-:@]<\XK
MRSXG>!F"LS(R2+\PS7*^$O$K7-VUC-C>IQTZU[&'SG$_5XJB_AW-HU9<NA]=
M>!?CAHOC6Q$B3K',#AD/&#786UW'=QAHY%D4\Y4YKY7M/AZ'TTW"S-&,=$;%
M:GP:^*%_X+\?6^DSS--97K[%#'<5_&O7RWB:.(J*C-6?<UIXCF=F?3%%-C<2
M(&7HPR*=7U9TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8X3?36L=]/Y4RKT8,<$FOT/^&?PIB\(> K6WT\M]BCCW;P.&SR:^ ?B79?\
M"(^,)ECC9,290=QSQ7WQ^SY^T N@_L775UKML\<UG:DQR.,;Z^2\/\ZJQC4I
M5$VXJZ?9=5Y'+A9V;3.1^*7QDTO4/!D^FZ7,S7D=WY$@VX ['FKGQ;ELK/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3C/%>]&CAEB?:5Y:1IK?I??\BN:\KOL=+H?Q@L?!7BM?"MW8PSZ?J ,D);^
M= !7%_';]EF\U35VU;P_KEYHLEQSY4 ^6O-?A!\5IOCS^T= \,172='S SD=
MP>.:^S/B7J>GW?AR'R9(S(JX(!Y'%<&6T:%?F</>IJ7N/K;K9[VOL$+5(MO9
M;'SS^S)^QE9KXW76/%&I3>(M2C#>6;I<^7]*]\\'P1Z!\6/L[<*VU8ZYOP%X
MF7P]J/FD]L5H>*WNY]5AUVW4[;=@^0/2OJ\ME3PF*C-+1/4VI\L;=[GT%16+
MX"\3KXK\.P7/_+0J-_UK:K]HIU%.*G'9GJ)W5T%%%%4 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]>
MMGO-&NHH_OR1E5^M?-L7C63P/K6H6,R^7)YA!)XS7T]7!_$_X!:/\2#YTRM%
M==F4X!^M>'GF4?7J:2>J,:U/G1\U^*?'L27#?O%RQSUIVD>+%\GS%FVMU'->
MN:5^P_X?6Z\R\DGE]-LAH\0_L3Z/<J_V":6'@X#.?PKP_P#5>HJ=DU<Q^K.Q
MX)\2-5MO'.AW&EWQ62&Z0QEF.=F>]?*E[\;O$/[#GB633HV<:'J3[K:;=P4'
M8^E?27C?X3ZGX2\4S6-UYBJI^5CG##M7$_&?]GF'XR^"KC1[Z/S-R?NY/XD(
MY&#7Q_$G">&Q])0YN6K#6,EHTSGK8=25NI\O_$?]LG5C^T3I?B2W7[+I\WE+
M+L;[_(SFO0_VVM)O?V@M#T?4M'D\R.^MBY ;ITKQ+PE^S)>:!\1CX6\50W($
MDNRRNFR(SD_*,^M>U:YX-USX"ZI9Z7J@D_L]$*P2$':5QZU^*X[,*].K/+,9
M\?,G>VCL]UZGGV?-RR*?_!,GP=)X5^(NHQW'^N@B.\^F#7-_\%:/'^G>(IOL
M,=POG6ZL%&>AXKT[]CJ&/1/B%XLO#(KQ+822Y';G-? O[8$FL?%'XZWRZ9,U
MQ]KNBD48);CCM7V3CSY50PRE9RE?Y+7\S=QT4?,^Q/\ @AMX/^P:K>>))ANV
M[HE8^QXK]//B#XQL_$6A0_=\Y5^;V-?"_P"Q/\);WX!?"/3]/\MH[R95N)..
MNX5[5K'Q-N;&TQ-#,IQUQBOO</D;ITX0I[VU]3KC3:7*NIY'^WQH^H7VDZ3J
MFG_O!I-\ES+'G@HO)KPO]J+X]^"_%G@K1=;TB1;/6EC/VV&-,;FZ<FO<?CWX
MDU+4/A[J5U;P/(K1N"-N=HQUKX=^)/P;NK3P-8^(I/F^T*T@"_=//I7S'',8
MX6$:=2*<*BM)]GLG^AS8E*-D^IM_LT?#6/XJ_M1Z?=RPBXL(8TN#D9&[-?IM
MK_BI=%T[[);Q"*WA4*B+T'%?F3^P-\?U\#?$R&.:'<LSB&0E?N*37ZG2Z#9^
M*-!CU"WVR6]PFY&!SGBGP55P]/"^PFO>@[/O;H.A)6LSR6SL+GQ+KC3?,HSQ
M76WGP_N+BPWC<L@&015_PAID5KJSQE57:QQFO0+E(%T\?=SBON\9F$HS2@CI
ME-WT/$;_ %.73H_L]SD,A_,5X_\ '+7YOA(?^$@T'_1[B\R9RAV_G7T-XJT&
M'5KU_E_&O /VI?"<UUX(O885:3R5P%'7GTKAX@PCQV65(T=*D5S*W==OD*M'
MG@TMSY!^(GQ.AU2]FOKY]MQ)(79R<[FS7T)^Q/\ M3WLBPZ;IUN;K4$PL:]O
MSKQSQ=^P?XB^)7@-M:\-:C:Z@(?GEM$R\R,!DY^E4OV#OV@I/V=/C8NC>(])
MFAF:81W4KQX6+WYZ5^'QX+C74(XUM1D[N2U_J_7L>;&CHKG[&^"[I-5\'QW6
MM+NU22/N,[ >U>:_$'PXT=T;F!3NC.1[UZI\&_$.D>+].ANFFCDM;B/S$8'C
M!Z54^*<6FAW6TV[>_.:_5LIHT\!&-##JT5HD=T;_ !'DBZD/$.CM"W^L4;2*
MC^ VJ)X$^,6FFY;9&TW6J=O>1V'B"8;@L>"37/>(;UM3UL2VY(,+ AAVK[;
MR=*I=;;G13T9^C-M<+=VZ2QG<DBAE/J*DK@_V=/%%QXG^&UH]Q]^W41 ^H K
MO*^^ISYHJ2ZG<%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOQOB+%X>69_6H135.R2[R9Y]647+FZ(^R/A-XHD^/_[4B^*+-1:^'M/MVM8
MGW6 /'%?=_PI\06VC7D,TFWY<=:_/K]C73M8T:75+%8\VME<.GF(O&1VS7TO
MX7^)5VH\CR9FD7C@5^H9?@:E? 0JOXI:R\F=M.+<5)%[_@J+9Q_&3X ZE;QA
M6:WS*H]E%?E!^P]XNL_ GQEAN;V;:R7('/;&17ZH^.Q>>+]&NK.Z1O+NXFB"
M$=V&*_(O]I+X ZU\#/VBKJUD9K>QDFWPMRN>]?/\3Y,EA564K-;_ "=U^1G6
MIMJ[W/U#_;"O(/&W[-XO("&CDVX(]Q7R9^R[\!]2T;X@:9K$CE;.:<-DMC
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP3\8M)U[08PUQ=;C/M&=W-?B?'V4PQ.&6)I?Q:=K/]'Y'FXB+<;HY/\ 8/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9/1['33E>-S<HJ*TO8=0@$D,BRQMT93D&I:](T"BBB@ HHHH **** "BBB@
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MG'%?1<*8FA>=*#U>MCHP\E>QV%%%%?:G6%%%% !1110 4444 %%%% !1110
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M1^-OA:W3Q_K"K\K?:'.W'^T:]@_8X\=Z=\0_ &H>"=6CCN%LT$*HXZ9KQ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/->S@\OI9)@*F*Q-O:<KU[7V2-(QY(\TMSP73H8];EDU"Y;Y[V7S#GJ2Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.K^,]4\:WL>+73W>"'>/X>QKSC]L'Q?)\0?B1-;V/[^/=Y<6#U.,8K[/\?\
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MZ\3^*AXU^'=]$A_?10N^,^@KR[6OCM;Z/^S)'IZP)-=^6R2!CR#FOG#]E/\
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MS9Q^]OI/O/G(&>N*]$K[;+\/*C04)[G73BTK,****[BPHHHH **** "BBB@
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MJ.@ I:_2,#@:6%I^SI+0]"$%%604445V%!1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !45Y>1V%LTTS!(T&23VJ6O+?VE-<N+;3[:QA=HUNA\S X[URXS%1P]&5
M:70F4N57*?Q/_:;T_3=.N+72/],O&!3'3::^?])U.^O->FN+Z+;->$DKZ5ZU
MHWPJL;&T2YNIH3N4,>?F)KSWX@"/2/$/G6^&AC;C%?G>(SR>.ER-:=#AG5<M
MSS_P-H>F_ [XVWNI:E-]ET_4X-D?R_+YA-<!X4\/KXA_:2\1:W:MYD-K=?(X
M[@BO5?BWHEE\7/!DUC)((Y(T+1.IPP?''->>?LEV'_"#P>(-+UO=&R2 1W$I
MP'_$U\%*3R[,*=/$22IRDW&_1M?#^J..SC-)['MVO?L\Z?\ 'WPPT>H0QF:%
M=T<Y^]&W8CZ5\P_$_P#9,\>R^(8?#\WB*\N/!Z/B0-C;M!R.*^E_"7QBM["&
M6WM[I&525W*W!KFO'_Q":]9EC\QBQ[&OHZ>5^VK\[6CZKJO/N;>SNRS-K%OX
M3^']MI<:JUK:P+%MQPV!C-?-OQA^!UK\0O,U'19/[&U:$[HI(1\S&O9#8WGB
MN#RV#1Q=R:=IWABS\-W"M-(&QVS7T$,'AE3=.HKO\O1]#?EBM&?&7Q6^,/CK
MP-X'N/#OB"QDAN-I6.]+Y>1>@XKXSN;:]\1:Q-&UW-,V[@,<U]Y_\%!?!_B3
MQ9K:WFFVOVRR6((JPH68&OD_X:_LV^-O%?CF..'1[JS#2<R3Q,%6OR_./[3Q
M&,J0Y9.*TC?JCCESN3-+X<?#*^@AC5=S;ADXZU]E?L.?LNZPGC[3_$%S;RPV
M-FPDRP_UE=E^SQ^SAH?P^CM)M4476H;5+DG<F?QKZJ\-:M9P6<<-K'#'"HQA
M!BN/ \#XFE6CB\R>NZBOU9FL/)/FF>E0>/H+GP]]GF1<HFP9]*\5^*<D,ME+
MMQN)X ^M=;KEYYMN3&,#%<Y\/?#:_$'XGV-C<'_1UD^<>M?HF4X5U*Z43KI\
MTI:GTA^SU;W-O\-;/[5NW,H*Y_NXXKN*@TVPCTNPAMXAMCA0(H]A4]?KT(\L
M5$]0****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'<!*<[ >P!Z5ZB^L_P#"2:O'L^Y&02:SX?P]9Q^NUMY)6\DMOFR:49?$SO\
MX,?'W4O %JMCJ]N9+/\ @E)^Z*^@/!?CS3_'6GBXL9EDXRP[BO&=)\':/XBT
MB%?,C$P49W&CX81R>"OB8EG;R;H;A@K '(Q7WV3<23G5CAJJT>AVTZTKV9]
M4445]X=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>,O&<6M:O%#:JJ$$ E?3(%>L>%_"UK;Z!'(NU69<DU\LZ#K=_:7T:R65SO\
M,"D%#D\BOJGX:^"_$7C_ $VWCBMI+2%@ QF4CBOJ:.58F*]A13L:U*<M$B"R
MOKZ34_LVF1O<3=,#I7LOP1^%%]87O]K:N&2X8 HA_AKKOAM\*['P#I*QK$DE
MTW,DC#<<^QKJP,"OM\KX?I4&JU76?Y&].@HZO<***;+.D"[G95'J37TAT#J*
MY?QI\6])\&VC/).LTF.$C8$YKSVT_:%UG5I&EM;16MUYP8^<5YN,S;"X;2K(
MSE4C'<]JHKE_AS\2[7QW9G;^[N8^'1N#FNHKNHUH58*I3=TRXR35T%%%%:#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#QO]J_QRNCZ=96*R;6DE&\ ]0:X>P\>(OAI;%8UVL!\U7/VR
MM"N&UVSN_F\EV51['%<'X9L9%*[C\GKVK\ZXF@JF);GTV.'$?$=EX4\%1^*;
MEF63RIARI%:.O:CXD^&+(T=]-+&O(3L15#PQXS\-V)\F37M/MKB/JK3A34GB
MGQPGBRU:UL9%O!'\HE4[E/XU\SA<=6A5_<SM;S.>,NQ[!\&/BM%\3- \QML=
MU'PZ9Y^M=I7QSINMZQ\-=;^W6;;3GYD_A(^E>I>&/VM&D2-M0@W#H_EITK])
MP.?T9TU[9V??H=U.LFO>/=*1T61"K ,K<$'O6?X8\46GBW2H[NSD62-QV.=M
M:-?0QDFKHZ#Q7X]_!_PY+J$>H2Z3;M)(=K-CJ37$>%=!LX;"XL88(XD88  K
MU_XYG[1:VL Y+.,^PKS:[T^.Q'VB%OF7]:GD2=TBNECYU\6^$(] UVYM[N'8
M6<LIQU!->=>*M-AM[YDLX?,N7/R@#K7V'J?AS2_']M_I4(+KP648;\ZS+'X2
MZ!X:U&.6& 2S!2?W@W=J^2?#,_K#G&I[E]CGC1?,>,_L^WNM6$#P_8)-H<[0
M<UZ5J,NNZT!;V^GR/,W %?1WP9T&Q/A59/L-H'WD9$0KL$T>TC?<MK;JWJ(Q
MFNJ7#.'E)2;82PZYKGEG[,GP/F^'&G2:AJ'_ "$+K/!'*J>U>MT45]%1HQI0
M4(;(U2LK!1116@PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAQ-87E6R>AWX?X1]%%%?0&X4444 %%%% !1110 4444 %%%% !1110 4444
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MWXGT.\T35%8ZQHY\ER!P[5V97BJM'$?5L7*Z?POOY/S+IR?,HL]F^!WQFO/
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M<R$CZ5UU0Z?8QZ=9QPQKM5% J:J)"BBB@ HHHH **** "BBB@ HHHH ****
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MW(8>M4K_ ,":AI6G^:Q;:PR/>K/@T3S7-FL[>;(H4.1TSWKU3XI0(G@VWVJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+%MDUTDF!]<?2F_M4?$73?V@/V>I=R_\3"Q1VD@(.Z,]*T_^"3_[1^D>"O\
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MH>!!J<?R0M%E7;@8(]:PO GPD\*^*O!4>IW-R[:DLSD2(_<&OKLZCB)8JG#
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M)6/0IU.>-PHHHKT30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:Z;]@+XC3:]\=M'L9"QAW%F4GC@5B_\ !0/PBNG>/O[0M=NR95,@'?&:WO\
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MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWN(KB-8Y0;>["\-WK]B=:TE-&NX9$4*J\5L:O\#O!_QST1K3Q38Q3#;^[FV
MN#]37C\08:&,H)QT?1DU$I*Q\;ZMX=O/VV_V5!KFGMY/B3P[&D (^_*N,L:\
M9\&7VM_#7X3V]O)=2*UQ<-"X/<@FO9/$.K:Y_P $\?C/<0K9S7G@;4W=0\:%
M]@;A0W:N9^(FEV/Q;NQ]CDBL[>W;[6J,=F2>?ZU^&\38C$?6:.'QD?>4D^;I
M**_5'GUMU$^WO@AX<NO$'P5\-SJ&+"R7+"IKFWNH[]K>1FR.,U>_99^)UOIW
MP6TVUA\N3[+ L3$\]JS_ !MK^_4A+#MW;MQQ7[IE=9UJ<7'9I69W4]4CI/"]
MYJ'A8&:TOFAYR5]:]V^#7Q,_X3S2=LW_ !]0CY^>M?+4$^K:RN8U;;["NS^$
MNNZQ\,;Z2Z6)I8Y!B0$9XKZC*,QEA*MJ]3W7T[&]*HXO5Z'U116#X!\=VWCO
M2!<0<,O$BG^$UO5^@TZD9Q4X.Z9WIW5T%%%%6 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%(S;%+'H!DT >;?M&^-?[$\/1V,+_OKPE&4'H*X?PO)'H'A$FXM-[2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(TE;E3,SP!I%MIOB^]U.0KY-NCL!ZXYKQ34?AU??M ?'0^*H8&EL-(E$G3(
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MI9;?=6MSL&>I%=;^T;X'CUKX8:HG5[>!GC [&O/X9R:G2R*.$:M-7;_Q)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>?$FUO? <-C(H?5+IBEB ?F23L:\D^#O[?\ X?\ B9KMW9_OH(;?<8VD7;N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.?VH+XVGPKOE
M#;?,C(^M>C5Y3^URK'X;.5!VC=NP.@Q6.(=J4GY,F6QX3\'],6X-L&4;7 W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M71K=&Z[ :NT.,6[M$B*H1<*, = *6BBJ **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<=\9M+BO/#9E:/<T.3GTKL:IZ[I2:UI<UN_25<4 MS
MYYT>V4:U,5[,0*@^*OB*+PUX+O&DD"R3QE$&>]5OC3K[?!R=E\M1."?*4_\
M+0$UX3XN\9ZA\1-519Y&V@Y\L'BO#S;.:6$BZ6\VON]3.M-)FO\ "S78-.U3
M[1</@R'<6/->AZ[XJLM7LY+JZO85MHUY#=L5YO=2:?X+\/M<WX$85?E!'+'M
M7D]WX5U?XQ:@UQ>:E)H^C[B(T27RS)^%?B..Q\95_8T4Y5):VZ+S;Z(\V536
MR/46^)GA?6=4DL=/U2-KC. @;K4^C>)7\(>,],NIIE:VAN%9U)YQFO%_%O[+
MUC86AN-+U*^2_A'F)(K8#8YY-7/A-XOO/B)X2\N^&;[3W991ZJO ->EE.*KX
M?$PIXFR;U36SMT*A)J5I'ZG>$/$MKXF\-V=];21^3<1AEP>E:@.17Q_\'=4U
M-?!-O%'J$T<:H-HWXVUV$'Q\UGP';&%FCNL\!I&R:_4,/Q5AZDN2::9V1Q,;
MV9](51\0^(;7PQI<EW=R+'%&">3UKYAU/]IO7-2N1Y;QQMGD*U8OC;XD:MXN
MTIIM3NF@LK<;G ?@@=:VK<1T(1;2?SV"6(BCIOBC^T!JWCJ]EM=+9K:Q#8R/
MXQZU6^'5G;PWBR7J[U/+DMU]:\*C\?>)?B%=36/@NPADA@.PSSJ54^X-9FNV
M?Q=^&=A+J[16-U#; R31"4M\HZX%?FN.XC^O.3BI22ZI:?+N<$Z_,[[GTGXX
MU.W\/ZQ'?:6WE>4PQ@^]?0W@+Q!_PDWA>UNN[( ?KBOC[X6>*_\ A=WPK36%
M'E7$(7[5#T,;9Z8KZP^#WDKX&M5A(*KP<>M?8<%XB,XR4)76YUX65SJ:***^
M\.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/%^N#
MP[X?N+H_\LT./KBIE))78":]XRTWPT/],NHX6[ GFO.?&?QOD\0!M/T.-G:3
MY3,O(Q7$Z#J<?Q"U*XO-6N'PQ.U<\"MWPC?:5X5O)G558*3MR.M?GN9<5U9.
M5*@K+OU.*6(;=EHCQC]M*;5_A;\#;CR9&C?5D9)VQT&<U<_9WT.UM?AAH4<*
MH&OK9)96 ^^V.M=!^T/8Q_'CPS?:/<%EBN$V1%?X#[5X[\'!\1/@GJUOHMUI
M\%]HMN0L$H!>38.E? UZBP]66)JIM25KI7MZG')I2NMCZLMOAB]Y8&WF$;VL
MRX=67J*^:OC!X%L_V5OBA!<:?)NTO6#NFC!X5V.*]QT[]HAM<UY=+GL[JQ50
MNZ1HBJ\^YKS[]O'P]9W_ (+TV:"X2ZF:XB8;6#,/F%>9C,;AZU#ZQ1E[U-IK
MH[]K=F.JH<G-#IU'WWPME\0:<+J,-Y<B!]P'KS7,IH%QX>OEB\P]>&]*]^^#
MFK6]QX'ALYD7S?)4<CVKB_B'X.C6>:24B&)26WG@"OKZ.827NU'I^1IS66K,
MK2-#U36K-E\T^6!\QQVKSCX]^ ;3PU\-=3N+R2-+1W#RRG^'O7._%?\ ;;T/
MX,V[VEK>27%X,J%!W FO$]#^,7BS]MWQ@?#C?Z+H,F3.T9(_SQ7S^99QA9WP
M=.?-*6B4?/NS&55?"CGY_P!JF#1= 33_  K;>:L;D1S(<@M]*Z3X#Z1X^\2>
M*%\0:]J3I9-DK;NGW@:]>^%W[!W@GX33-Y$DU\S?,%F4,%;O74:OX(FTZ8+'
M RVZ'"*G3'TK&EE>*A5A4Q53W8[);?,J,'?WF<S<>&(O#?B)/%4*[8X,-<Q
M_?45M:[XDL/BK#'=::BJD@RT8.=M;R>'UU/P[<6DD,N)HRI!Z8_*O,?V;].G
MM?%WB'3RO[NWN"L8_N@"L\/1]EF4?9Z1J-W7FM;_ #ZE*T9>IW?PUM5\+^(;
M"Z9O.ELIA(<'H/2ON?P-XVL_&.B6]Q!-&9'0%T!Y4^E?"OAV"=?$$R]"AR0>
M_->@:-XGOO#<RRPSRP]]JG"U^K8',HX&7LTKQ>OF=4:O(]3[&HKYRT[XH^(-
M3B79,N,=GZUUOPR^.MU+XACTC5EC5I/N..]>YA>(L)7JJC&Z;[FT<1&3L>P4
M4BMO4,.AY%+7O&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !117._$_QPO@'PG<WW654/E@]S4RDHQ<I;(#P/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLKSJACD_9Z-=&=5.LI[&U1117L&P4444 %%%% !1110 4444 %%%% !1110
M5XK^T3\2)+J[30].FW;N967L>XKT3XM^)7\*> [^[B)$T<9V8KYY^&NI1W&J
MR7VH[I6F;?EN<9KYGB3,I8>C[.&\OR.?$5+*R.N\+^%D\)>%Q?K,L<^,@-U)
MK&F^(DD,TDEQB0-G/%,^(_BK[1.?)=EME'"CI7AGCCQ]=:SJ1LK'=UP2*^!P
M.!EB7=G'&/-L=?XQUVVUO5&\L*N3TJ_X)\2'39=JMM\ODGT%>6S:>WANV^VW
MVH1PLHW$22@&O*?B;^VUI^DO<:/I/F2WK1MNE"Y4>O(K;-L1A,#A95*LTU%;
M7U;\D%1QC'<[?]N'XO6OQGA;PFNJ1VZVHQ,Q/#@]J\O^#\G@;P);QOXNN;7^
MS=-(=$D;:)67D?G7S/=>,=0\6^*;^\:XF_>D$'=U-?;GP(_8'T?XN^!-/U_Q
M#=O-;I$A\@$,LAQGD5_.]:IB<YS>E#FY6VVO[J1YMW.:/(_VF_'_ (M_;T;R
M?AWH]XNA::<0I;H/+('!Y'6N)^'7_!'/5O%%HU_XTOEMXR=S6K*5;Z9K]./A
M3X T_P"#WAN2UT#2;.QM0FTM&FPD5S/C;6I-6O\ [*C,S2-D\]*_7LDX=HT*
MEZC<VNK9W1@F[]3Y_P#V;/V8O"7[/]Q;PZ3IL<;*V/,?YLG\:^QO WQ#A\.Z
M+(BJNZ0<$<8KQ_QCX973=!\Z,;9(1N&.]<IIGQ<FMHO*FW*R\9(K[:KA?K<%
M*CHET1T:O6)VOQ[\7:.WA35#KTD2V,\9#[S]X5\2_!'QAKUWXPUKP[X7N39Z
M/?3-+#(1N78/2NF_:Z^)L7CGQYX1T/\ M!$L9+\"\V2?*R'L:/C3XLT/X6^/
M=!B\.&W2.&P97: CYCZG%?"\4XA8:G*HI65+1V>KOTOV./$:+T/(?VB_V7;W
MQ=?V<<S-=PK/ONY!_=[\U\Y_M5^)[J]LK3POIL[6NBZ0HMS"IXE*GJ:]N\<?
MM@7V@-J%ON6XFOD,(7.[9[BO%=$^$^M?''Q.([>"222[D!; /RY/)KX'AW'8
MBA1C1A=*6_=M]/0RI2Y4K&E^RU^SQJOQ9U6#3=$@:>Y(#.%&=H/&:^Y/AC\
M/%7[&^CS:QJ&JQVLQX1'3ID8Q7??LR_#;PS^PW\$4U)E6X\17,>%+*"S-V'K
M6]X6^%6O_M!:G'XG\874\>FS?O;>S5LQLIY&5/<5]=3R54ZMJJ<JSUO>RBN[
M+E3UL]S/^!G[8/C+X37JZ]XDTJZU#0M5?R#,!M6!?[Y]J^J-:\<:!\1_!]KJ
MVDM')'>Q>8&4],U\V_M*^)K#X>_#:71VMHI1?(;>VM]N0K8ZXH^"'B"3P/\
M">QMKAF622$$1CI'["OHLNRN5&JL+1ES)*[?9O\ S-H<W\.]T=-XJE%OXC58
MQD,0 !73:5X?O UO=QL5:$AAQ7#^&EG\3:]]J8-Y:G(KV#2[K['I.&48QUKZ
M;&5)4.6,-T;2NMCW3X0_%>U\>Z>MOCR[RW0*Z$\\<9KMJ^8_V?;R:;XKS?95
M;R]@W[>F*^G*_0LIQ4\1AHU*FYW4I.4;L****](T"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>_[5O[!OB7X$Z(U_JF;JQ8?Z\(0!GIFOE;X:7M[\._BFFH:?=-"L;@N@/RR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9KQI' 'UKQ#3O#=QXLNVFNF<1N>%K\)J97/+<>ZDWR\KNC@Y6I7>A^B'@/\
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-_BG?>%?#DC-"V$GE4XV ^AKB[KP.W@7X6'3].F>.:\D$<TG1B3P37Y1QEQ
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M6ISNR/JW]@[]GY?AY\*+.]NHS]OOF8R%NI'45\?_ /!0IQ??&FX$*E8[?<C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS]#7MOQ"B3QG+):K"L]O("'##@U\^>!?AE_P@'CO5]'6>9]/NHFD:)_NY.>
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MLO@YXQCL?!NCW2WMK$LELFTM,%(R*];"TXPQ=:I3=K)6]-V[^H15I.P[XK>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP_%<U6.D68SHZ71QGQ._:4U:P^(=U)YD?E6Y'&P9Q7:?#SXDFRU6SU!G"R3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5#V%>"C#=M[_ "7^9$J4IJS1^=-MI'CGQ1J0L;7PYJBLQVL6CX3ZU]!?!/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRLN/F% $WPZ^%=MXVT[S]0U@PE1DJ\QR:Z;Q3\(Q\.="CUK0KUY)+=U+8D+
MCO7B,'Q .EW>U9BB@],]:]$\'?%W^W]+DTN6;;;R*23GH: /HKX)_'G3_B!I
M%O;W$Z1:D!M9&."Q^E>D5\)^"[V2S^+6GV6EM))-YWWU'\S7W)I E72[<3?Z
M[8-_UH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^^&MK%^T%?7>GKYD.@3&*6Z(PUP3W-?3^IB^N(U^T-(8V/RE^@H _7_XY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!KV+6=6AT+2[B\N)$CAMXVD8L<# &: +5%? _P 3_P#@H7KGQ#\?W6G^&?\
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M%U+(J3,H;'S<5]L_\%!/'C>%/@=>PI)MFN"N,'DU^<_@_0FUKQ5I]MMRUU<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@KXAOM'M;RSOKRQ8Q+<(FY#V-?/NM>++SX]?%6'4M:N$%QJ,RQRNW"JI/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/B/XG;6/$]]=0J#-?RET51]T&OO?_@B]X>TC0X[BZGL%OM992<NH=1SQP:^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:1YF"Y49"YKZ&^&7[(]GH<AFUB0WK=HW&17J6A?#O1?#4@>QTZWMY!_$J\T
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MD6,KO+%17TQ&_F(&'1N:^4/V6_ =]\3_ !O_ ,)%>^8MG:L'B+?QD5]8@8%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%;#P9X?FU18UFNKJ9P'*\@$\4 4/BE\&[;P+^RCJ&CV^YI@BB0L<Y(]*\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M52!0BE5P<"OG&+6M5^'OB>+0_$&[-RP2%W/()K3O_P"T;/65AM6>61^47VH
M^G?@?>#P5\3-"OX9%D%S<!60')Q7Z!6%U]NLXY@NWS%#8/:ORS^%-IXBTG6;
M'5IHVD.GN)5B+<-7Z(_L\_&:V^+OA!956.&ZM<1RQ ]#B@#T&BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQJ5]M<O&<KFN@\8?LY:7/H%KXAUF+S)G;]W[$=*+";6/B5]CD_>W$:J/++=
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M $N$ED :0^PKWKP5\5=!^(*'^R]1MKJ1>J(X9A7X1Z?#JO@"[M[IXY88IN0
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MZ US4WQ'\)?$$W3306]Q'(Q8O"!NQ]:^._#/PROOC]XUGO$L_.,K?*<U]'?
MG]FW6/AQH-]<ZI92"U^:- W0$CB@#C=*_95T'XY_$/Q##:V\\=CL'D,YX![U
MX!\9?V(O%OP3URXEM8;B\L\ML\H%EV]N*_0OX'>&CX*T%99(?+DN"=QQU&:T
MOBE<OJ.F[5'G*>JD4 ?G+^S5^S]X@^*NO6NEKI^H?:+J0("T;;1]:_3;X::$
MWPC\)VGAS4K<QS6T(1LKC) JC^SSJ^F> M9M+^.SAAN;=]Y.,9KJOCY\2+/Q
MQKD=Y%''#-M^;:>M %K0OV;/%7QDTFXU#P_<1_9[<;VB()9A[5[=^QY^QAKF
MC>+;?6O$BHL=H-JQ%<,3VKJ/^":DTT_AW4&(;R&C78Q'4YKZFH 1%\M%4=%&
M!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!#J-ZNG:?/<-]V"-I#] ,U^(?_!1_P#:4N?VE/VD;JT679H]C($A
M!Z*PX-?M5X_O[?3/!.JS73;(5M9=Q/\ NFOYZ_C7J-C_ ,++UZ_AF5;".XD)
MD)QCYCF@#V#X8^-;;P+=VNFW$]G-;S6[?, #MX]:^5_VF?&VAZ]\:=#T2-1>
MR0WXDE6,AO+4GJ?2N)\7_M*77C+49-#\#6K:I?9\N2=B8_*]2":Z+X1? 4>
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M>7N48]]QH ZK]DO3?B-\%-2>UU_5+:_TN4\!<LP'U->N>.O%D>O12F0*JLI
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M$5^C7C>63Q/<03RYDM[C&YNH<5NZG_P3D\#_ !+^'<FK&UMHKAAEF"\YQUH
M^)- ^)/V^P6ZU*XBNK6!<QIG.*\G\36%Y\4]?N+BUCVV,<A V# %?27C3]C*
MP\-7TNFVFH2&.1MJ@)]VN^\,_LK:7X;^%<FEVS 7EPP<SA?F'M0!\\_L^_$R
M?X.:M&88X2RD9W+G-?H-=_'G1_BI^SK'';VL<=S&Z2S,$ R0.:_/WXB_LQ:]
MX6\:V-FMQ-Y=]+L24C&*^AO@_P#"_6O!'A,Z9+<-,)F!+%NU '::I\7O#NM^
M$H5LIHX;J#/F1,WS#\*SO NO6'BMI5DF3Y3CDUSDG[)+:_XW2;3[SR;@L#)
M&P)?8U<9/#_@OQ&VBZU(NBWJY4/$N_?COF@"YXRTV/3)F>UF5=OH>M>J?L[_
M +"7BKXZK#JMQ/':Z3N!/F@JS#V-<EX5^&^BZFAEM]:;5U SAEQBO;/A/\9O
M&WP_@6TTV>XNK"'D0=%51VH ^S?@O\(=.^"_@FVT?3U^2$?,YY+'ZUUU>>?L
M_?'&'XP>']TBK#J%N/WT0_AKT.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY':O4/%'@_1?&/A!I[!ECGU(FXVJO^K=N?TH \2TK]F_2/ '@_3UM[B[%U<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6/\ NHN* )="TQ=&TBWM5Z0H%_'%6Z** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ^7I=SH[>5(YZS$=ZPO$_P ;M7^+UI/8^'?#*ZQI+,T33,VW=V- 'PAIM_\
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M*^3(OVV-<\=ZRMU;W<EK;PG]U&K=J]M_94^(TOB36+J2>#[4R*TK7#'[O?%
M'3?'CXB>'_"WB6Q35K;[0LQ(<!06%>8:1\.M*^(7Q'6\T6WE:P4>;@C.U@<U
M>^*/BSP_X]\1Z]]K=6NH<?9QC.T^U>X?\$V/!&B^(?AIK$UQ,L=Y#,X0$<D
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M?LK^#/A-J+7FDZ1;PW6?E<#E1Z4 =QX9M&L= LXF^\D2@CTX%7J** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?C-)XT\12,;..4BW4G  SD5ZCXY\+Z;\:-.M]:U3;INBL-\=NHW"X'I[5O\
M[.'P'AUFSDCD'V>Q6<^1'C@KV- 'T'XG^(B_$#PK8Z7H]O&KVJX#QIQ^E=+X
M#T&71/#_ )!;==2#YR#T/>H]'^'<'P[T2&6SA51CDC^*MBS9K1X[J/+B3 *C
MU- 'UA^Q[HMOI?@-655^TL/WC?Q=:]@KR7]E+1+RR\+R7EPK1QW2C8I[8KUJ
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6UA(9&8?>^E?5%8G@#P/9^ /#=OI]I&JK$N"0/O&MN@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPHTWY?WUX_WY&.<>N*[JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>inbx-20251231_g3.jpg
<TEXT>
begin 644 inbx-20251231_g3.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MK3K]$I1<(*+=['IK8****U&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHK884444 %%%% !1110 4444 %%%% !1110 5P/Q)FF-QI<46V1%9I'A[G
MX./05WU>>_$..YTN^M]5C^>V=?L\F>J$]"/8UY^/YOJ\N4F6QY5\4)EL-'.K
MW4Z?9+<?:)D+<8'1?KGM7SM#'-\3/ _BSQ?) YN(MD,-Q*_RKN891%Z#"]:]
MX^)%G/XF32O#L/DC[9)(Y%RA*$*O#,1SP3TKQ_Q]I-QX!^'-OX6-["\#WJW4
M,L8V.^.) R_7H?2OSRM.<UR25E"R^;[GFUFY79VWP6N)+/Q.]C-:,Z-HUNT8
M4?*I*YR?4UZ'XZU0:(UI<W\BQ7PR;>TACWRS>JJHSR?>O%]0DUSP_P",[>\\
M/AI;@:% %8]%4J/F*G&<5VOP#\=7NJZ')J.O"&2_>^ECCN=GSLH/5B?TK+!M
MQJ2HT][_ )HJE)? SQG]H+QQXDN;JWM+JR6TO;[;<2VLC@FWMU!$2$_WB26-
M6OV<?BM=276N^&+F*3SF@2ZMHB.X.'P>^.M3ZW]F^)?Q@N6=]R7<LUM$>N&1
M&VG_ +Z%>+W&K:MX \8)KE@'&IZ1*5FMER3*G1X\>X%=6'E"I-.4?ZV.;FM5
MYNFQ]P6>L2PV26US/'&#]XYSCVKR3XM:3?\ B"W@MM,ECMHYI'*2W+[$>55)
M5"W12V, GBNS\):IH7C3P?I^N:9<)>17L8E!!RRM_$C>A%:EPMKJMM)9S&.2
MU(Q)"T.]..Y^E>U5IJ<&HK?KTW.]I3C8\N_9-TJ\\66.J378M3##<-;W=JR%
MI4D"\@ <?C7M$.BV?AZYETZQB^SV@B<X[LW4D^YJY\.O!&HZ1#>:OX>T-8([
M@JK.K",S!1@,JGKC]:J^++C4=,UA/[4T][6:2$M$I^ZWJ<^H]*XZ66.A4G74
M-9=1PIJ*21ZE\#=0DO/![0R,[_9IWC0MS\O4 '\:](K@/@K:RVG@6#SH_+:6
M620=LJ2.:[^OO*=^57.I;!1116@PHHHH **** "BBB@ HHHH **** "BBB@
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M'7(]<T>%T&R2,".2/T(']:WZ_5**BJ<5#8]%;!1116XPHHHH **** "BBB@
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MQVC3/*VV,N?N\^M>P?!WP=J?PQ\ ^(=0U\V\&J7]U<ZQ<6UJX:*VRN0BD<'
M7J*RPV(G.6LN96UTM;YD4JCG;6^G8]?'?FG#ZU\X_"OPKXY^(G@C2?$UU\3M
M7L7U &<V<-O$RHH=@J\\\J*]@NM0\3Q_$#2K*UTJVE\*O:R/=ZF9@)8IQD*B
MIGD'C)Q7H4ZTIQYG!K[OT-XRYE<ZYN.^* V>_P!*X'XW:]KGA?X:ZSJ?AV S
MZM!&OE[8_,:-2P#.$'WBJDG%<3\&=0L-2OC?V?Q2U'Q8L=LSWFE:AM#*Q ._
M80&3!XVU4JZ57V8<VMCVZ5BL;,#RH)%<3\'_ !]<?$OP7%KMQ:K92/<30F&-
MRZX1RH.3W.*\Q\#VOC/XQ:;>>+_^$SOO#5O-<3II.GV$:M D4;E0TRG_ %A;
M;TK5_9IU:'P]\!?[2OI56ULYKV>:3&U0J.Q;&?<&N2.(=2I%V:BT_P!#.,^9
MIK9H[>;XP:''\4X_ 9>8:N]O]I$@4>4#C(C)SG<1SBE^,'Q N/AGX(GUZ"U6
M]D2XAA$$C[1AW"DY'H#FOE";QIH%UX&O/&PUNS3XB/X@&NPV9+&18E;8MOG'
M_//G&:]T_:,UZV\4?L^KJ^GRAK>^FLKB%^H&Z12,X]#UKECC7.E4E?5*Z]'M
M\T0JO,I>6I[I;MNC!+9R ?TJ:OG#QY9^-/@WI%IXS7QM>>(8HKF!=4TN^A5;
M>6*1@K>2HYC(W<"OHBSN$N;6&9"2DB!USZ$9%>M2K.HW%JS1NI7=CR'XN>"?
M%VI?$7PGXI\)P:?=SZ-#<1M#J$[1H?-7;V&3QFLK5OA?\0/BL]M:>/M2TO2_
M#$4JRRZ1HFYGNRIR%>1@,)Z@5[P8U8Y(YI&C5NU93PL92<FWKTOH3[--N_4\
MQ^)?@&_\4ZY\/I],6"*VT'5DNYUD<J1"$(PH Y/;%4?B7\,]7G\8:/XX\%O;
MV_B2U(@O8+ES'#?VN?FC<@?>'8D5ZWY*\';R#D4[RUXXZ=*MX:$KWZV_ ;A%
MW//?&7P>\*?$?48=2UZRDEU*& 0J8KMXVB4G. 5([GKWKA/@;J>M+:_$30-)
MU1]=L]$O7M]%O+^0N-Q0GRVD_C56XS7=^-/@7X1\>:P^J:K93F_D18Y9+>[E
MB\U5&%5@K8( ]JZCPOX/T;P7H\6EZ)IT&G6$>=L$*X&3U)/4GW-8?5Y.MSV2
M6NW7\">5\UTBMX.&OCPOIQ\3"U_X2#RO]-%GGR=^3]W/;&*X+XC6OQ"UV35-
M&L?"GAW5='N%,=M?7UT<QAEPQ>,J<D'IBO7UC5>@I=H]*Z:E'VD>6]ON_P C
M1JZL>"W_ ,"-;T3P7X"/AW4K>;Q1X1)>%KO(@NU<YDB8C)5><*>U3IX5^(GC
M'XB>#/$7B'3M'T;3]%GF9K.VNFFEP\14N6V@')P HZ5[GM IOEKR<=>M9?58
M]';5-KO8ATTSR7P3\,+MO'WC/Q1XKM;*\N=4G6&QB($RPV<>0@.1@,>":3X@
M?"RZD\6^$/$O@^VL;+4]'O&%S$ L"7%I(,2*2HY([5ZVL*+VZ4C6Z-U6J^JT
MU#D\[WZ[W*Y8GB.K>#?'_AWXK>*?%WAJRTG5;'58;: V%Y=-%(WEQ@;PP&%P
M<C!ZBM_X2_#[6M&UCQ#XK\536[^)-=9!)!:$M#:PH"$B5CRV,UZ@(U7H!3MB
M]<<T+#14^?Y_,2A&.PHX%+11786%5;^PBU*QFM9ANBE4HP]C5JBD]= /+Q\"
M=(E:7SKVYDW?=Q@%1Z$]ZJ-\"UAO-EKJ&+%OO"49=1Z+CBO6Z3;7/+#TI*SC
M<GE78\NNO@OIEEIMS_Q-;\0K&S .Z[!@9R<#I7QE\:/ASK>M>+-$U>74Y;;P
M_<0QV1G''V>3<>">P(Y!K]"?%$,DWAS4XX5+2-;N%4=22IKQ6SM=.USP?<Z1
M>0K<)=1"*2-N"K 8S[$=J\'-Z?)22I*S,:L4URGSOKGQ0\"_#.UBT:VU&34(
MK5"J"V@+>:P')8G +$]ZET[QE'\7ELK:PMYGT.$+=:BLW&6'W(OSY.*G\>?L
MYZ'I>GRM#J$DLS#;&LL>X@GITK!^%_PDN/ J3W=WK4LDD@*(@^10I]J\>%6I
M.$5.&FVWXZ'/!S;LTCV.&WTR;Q#8:_-HF-3@4*C*"J#'"DJ.#CL<9IGC/Q99
M>(O$EOX=N+/[3-+-%<3*IPUN5.5SZ$]3[4_3?#^I:KX5O&MM8F@N0K1Q3\,Z
M''50>,CM3/!GA>#3=*2S1$GN68&ZOYGWW-T^1NRWOZ"E6H1KQY*.B;L^]BY1
M;T3.PL[BSDU*>.W_ ']Q<,$MXU.YF[9'M7N'A?08O#^DPVR+B3&Z5NI9CUYJ
M#0_!VBZ,T=U::;#;W)09D"Y89'/7I70U];A,&L.W)N[9U1CRA1117IEA1110
M 4444 %%%% !1110 4444 %%%% $3('&#RO0@\@BO-_&WPUT*STG4-2M;5[>
M[QN7RW(16)Z[>F*]-J*:%+B-DD4.C#:RGH1652'/%H#X\\1>%[N'5;2\\/2+
MHFLL5CN)50/!>0YRRLO8_P"U5[Q/8ZCI[VT+7BQ)(-Y 0'GH*]]USX;^&WC2
M4G^RYM^Y)XY-I!].>HKA/&'PM>XNK":_U%;VSYVQ6Z;6D Y&6_PKYWZA5I\L
M*27GJ8*#3L?'OQ(^#FO:]XM&H2ZI'<6,K;I!-EBHZ84C/&.GI7I'@G]F"Q1[
M.[DU%#: AWMH4(WC^[GC@]Z]GUSX7V-_#YVEW+:<=OS1\NF1W&>0:U=)\#ZC
MX=TF.:UCFU>"8_=CP'0CMCT-<5?+*B@XM;=F93P\6^:P[58[1-0T"#3XU5(9
MX8XX(P   >@ [#O7NE<%\/?!1TV-]2U2W']I2L3&C<^0G91VR>]=[7T&7X>5
M"E:1TQ3W84445ZA852U*-KK3KJ&,*7DC9%!.!D@@9-7:8T:MP1Q4M7 ^=/ 7
MA'XR> ?!MKX9TVR\+P6ULSK'>W-S+(V&8G<5  XSTKT'X4?"=_ ;:KJNJ:F^
MN>*-7<27^I2IM!P,+'&O\*#]:]*6-5;..?6E"!>@KDI86%*UFW;8SC!1M;H>
M/_#GX.FS^$>I^#O%<-O=1WMS=/(EN^Y0DDA*L"1PPZ^QJY\,_"/B'0_!NI>%
M/&,MOJ&EP*UI9:A',1+<6A4@+*#@JP!VYS7JBH%X XK,\0>';#Q/H]WI>I6Z
MW-A=1F*:$DKN7TR""/PI_5H12<=TK?+LP4(QM;H?.?Q;^'NB_ ZQT/7O ]U=
MZ)K@U&WM8=,6\>2.^1G :,QLQ!X[CI7N-X/%G_"P-,^S"P'A#[(YO0V?M/VC
M^#;VV^M8?A7X >"O".KPZI::5)-?P?ZB>^G><P_[@=B ??%>D^6O''3I6.'P
M[@Y.UD[:+;0(QY6[:&#XQN-=M=#EE\.6EG?:LA4Q6]](T<;C/S#< 2#CI7EW
MA7X=^)M>^*EIXT\2Z1I/AN.SLY;5;'39/-DNVD&&:9PH! '2O<&4-UIJQJO(
M'(K>I0]I-3;VZ?J7RH\"\+^"OB7\+[:^\,^&[71]6\/S7$LUAJ%]<M')9*Y)
M*,@!+X)XP:JQ_!?QA;_ ^R\!QW5FD]SJ3'4KJ.4JHM3*7;9QDEO3\*^B=B^E
M)Y2^E9?4X6MS/:VYFJ45MZ'.P_#_ ,.Q:<MF-%L/(6+R0/LR;MF,=<9Z5XK)
M\$_%[?!K5O BSV16'51+I$\DI(^RB7> PQP1_=KZ-V@=J;Y:JV<5I4PM.:2M
MTMVT93A&1X+XF\$_$KXH06'ASQ+!I&D^'H+E)KZ^T^=I)+]8V#*J(0/+R1SD
MU[S BQ0HB+M10 JKT ["G>6NW&./2G*-HP*TI452;E=MON.,>46BBBN@H***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\Y\:> [BXU2/5-
M'MXVE<%;F#=LWGLP/K7HU%8U:4:T7">PFKJS/"O%GPP:]M;>YU.66WO)B42*
MW<%8Q[GN:BM?A_HNGV$MFUL+^>=<-+<\M^'8"O4?'UC)=:7'-&0/(8LV?0BN
M"U6^AL-)DU*=#^YC&%SC))P%_&L8T*%!:1062#PW\.-+TC14>\U6XAT^1R#;
M-P<],;AR1]*]"T#P[X?M;>&;3;.WVQC"2*-S?F>]>0V^H726T5]<2^>?OK #
M\D /89X)K>^%WB>:?QA<V3.%BN8C)Y1X&Y>Z^O'I7CX;&4*E=TJ4$D9J4>:U
MCV->E+3?:L_6M=LO#]F;F^F6&+H,]2?0#N:^C;45=FII45PUO\2/.7[2]B8K
M L%WLV' /1BOI7:QNLD:.IRK $'VZUC2KTZWP.XDT]B2BBBMQA1110 4444
M%%%% !1136[>E %>_OX--M9;F=]D48RQKF8_B-8QW"I>12V4,GW)Y!E3]<=*
M3Q]?VLVC2V+SKYDA#%8SDJBG<S'V %>':7'XD\;*^H6>H6]MIC,RVMM);^9O
MC5B [L3D9([5\]C\QEAJL8P5T93DXNR/IV.>.9$>-@Z,,JPY!'L:DS7S[X=\
M9^(=%M;C3@C6]W:,!-92#?L!Z,I/.P]JW8?B-JVJ1.'D>VG0,OEPQ\DX[UO'
M-:,H<]@52)3\0>,I+OQA?K,/-CMV,$,.-RJ!U./4FJ=QKUUI,-I)/(SZ6K;1
M#_';LW7D]<^E>,>++R33]6E@UK5YM*L(U%Q(T3[)KB5R3Q_%@8K:\,ZE-K5C
M!'<W=U>6-TI^RW=X/+>+'1)!WSV:ODIYE*&(=6.U_P"KF*J69[9<1BWM2L3L
MYE.=_KD9KTCPW:R6>C6T;_?*AB,],UXG\-=7NM9U:VT:_91!'D1W!X)V\A??
M-?0*J%  & !Q7W]"M&O!3B=2=T.HHHKH&%%%% !1110 4444 %%%% !1110
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M,+;.<<]^?I4RT38'S'XG\1^'?AOXH'GWGD17-Y)%9PX+N^#]Q5'4UT7B*_\
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ME?.&^Z373'V=:D^3KOZG4K37,?.-KJ6E?#_Q98:O::=?>&Q8SN\VG7<9^\P
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MD4N6 Y+'^$'TKO['PW:>&/$^E6-I;QC0H;22\4+SYLX8!2QS\VT= :YWP_\
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M6U]J!$,BX"G8/F0=\YY-<]^TUI-CJ&AP16U_;Z?Y,N&EN,_.#T10 26)Z"O
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MXT\Q@<R #+'ZU[LRB9,$!D8<CJ"*Y./X9:)%J9O%AD5?,\S[-YG[K=G.0O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***2@#SOX]?$5_A?\--4UN"-I;W MK90<
M8EDX5C].M?G1X?U[4]+\06FKVEVR:M!.;I;H$ERY.22>X->U?M-?M!0_%:Z;
MPUH]G);:=H]XSS75R^T7#H=N OH#ZU\U:'\0M'NFUR:1WM(]'NA:7;2C W$
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M5U$DR1SH4D4, 0&4]",]*OT %%%% !156_OH=-L;F[N'\NWMXFED?T5023^
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MM9TD5@T95&9E4 $DXJEX9\%:OI?[/L'A.>&-=<717LC$) 4\UD8!=W3&3UH
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MG7,\=O#_ ,])7"K^9-/BN(YHEDC=9(V&Y74@J1ZYZ4 2;%]*-HZXYJM)JEG
M\*27<$;3?ZI6D4%_]W)Y_"K0.: %HHHH **** "BBB@ HHHH **** "BBB@
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ME(4*HX51DX44 >,?#GX.^&_$W[/,NOZM!<:AJ[V%U+#=S7#[[7RVDV+#AL(
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M^([B;4+":'RIM0DX,$@Y$8'8'OBOHGQ@I\0:7#;VIFM(_.5$N3\C<]=N?44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #&59%*L RG@@\@UP_QJFTK3/A'XGFU2T2YTZ&PD)@V#&2,+@=L,17=U
MYM^T5,UI\#_&DJ1QRM_9[@)+]WD@?US]: /R,AA?Q-XBN&NSLT_1[A!#:_\
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MF?8;*/RH?.?>^W)/)QSUH VJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>inbx-20251231_g4.jpg
<TEXT>
begin 644 inbx-20251231_g4.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M$.A@*QOK=6F3:Q #?("<9/7M6Q'J]G)IZWRW,9LFB\Y;C<-A3&=V?3'->&_
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MC.^YZNK C(Z4M-7I3J[UL:!1113 **** "BBB@ HHHH **** "BBB@ HHHH
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MA]322BI;)KY,ET[]3QNQ_96^'5OI-O;7&BFXE2%4EG^U3#<P4!GP&QDGGI7
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M^U)0"7V\F,< "O2J^NP+;HIRE=G1&]M0HHHKT"@HHHH **** "BBB@ HHHH
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M"#S4]?:)WU.T****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBNATA1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QD61"K
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R/B?QO\
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MT/1!<^;<W>OM<V]O(_V"QE0*(MV0 Y/WMN>*R_!^CQW%K9GRR'TX26%N9?\
MELS/EI >NT8Q7(OI6J^+;F1+W5)IT2X*6L%G&L:,-WR[FZD^]>M?#_PKXAU/
M5;F"XTKREAC6%;B1QY:@<9!')-<,,/6G6_=P:2_%]/D'([W1[1X.UH7D2V,M
MFME<6Z+\B8*,,8+*174YK \.>%[?PW"2'>>X? >:0\_0#L*;JWC33]/W)&QN
MYPVPQP]C[GH*^UIU)4J2>(:3.M>9T5%96BZW#K5N[Q@H\;;)(R<E3]>]:M=D
M9*<5*.S&%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-;[IH
MAO+Z"QA,L\BQ1CJS<4EG?0:A");>5)8VZ,IS7"_%*ZNK9M(:&0)"96W[CCD+
MD$^PK@-'\>:7=*D>E:CY>H,VY9E#)'(1U&2 K9]J\;$YA'"UE":T,Y3478]2
M\9^'[Z^D2]L/+EN(XRGE2]QUROO7@7CR\M;"\CM+HL[N3-'%("'AN%/RG _I
M7N_ASXB6VI74=A>PM87S<?.1M9AUP?>H?B!_9DEQ8-(;7[8"Q5W"E]H[ ]:Q
MQ&#P^-3FI6N$HJ6[/ENW\9^(HOL\&M:>^J0SS!8I;&95(R<99>/E'?%=IK7@
M&VU[2O[-UE/,M+LJ%MH0020> ,<YK=U+X8V.MZE'.+Q[2*6;?LCC =6R/NM7
ML&B_#NST>_@O)+B>^F@&(O.(PG&,X ZUST<NKP2IR=XW_ GV?0\3^'_P7N?!
MK#3?#VC2:1$"7:2X&%/U8Y)S7IWAGP?J<?BBWO;ZW2W@M58;MX;>QX&!^M>E
M_A1P>U>K3P-*FU+JBU!1V%YI:**](L**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BJ6J:E;Z18SWMY<1VMI IDEFF;:JJ!DDGM7D3_M5^$=LEQ#8:]=Z
M0C;3K$&FLUKC^]OSG ]<5C4K4Z7QNQ+E%;L]JHKB=6^*6B:;X%;QA%,^IZ J
M"0W&GQF8A"<%\ YP._<5NP^)+"YT6/6(KV!])>W^U+=!OE\O&=V>F,4_:Q>B
M?G\NX[KHS9HKF/ OCJQ^(7A^'6]*6X&GS.R0O<0F,R!3C>H)Y4GH:Z7FK4E)
M<RV&.HIK-MH7YEJ@'44F:0Y]J5P'44QF*]/QKB?&7Q&'A+Q;X.T/[&;EO$-U
M+;"97"B#:@;<1WSFHE.,=9";45=G<T5B^)?$MGX4T._UC4I1!8641FF?J0H]
M!W)Z >M0>"_&FG>/?#-AK^D2--I]['OC,@VN,$@JR]F!&"*?/'FY;ZA=7MU.
MAHKB-#^(?]L?$SQ!X2-EY9TFV@N/M>\$2>8,[=O48KM.]*%2-17C_5@3N/K.
MOM!T_4FWW=E!</C&Z1 QQ]35]6W#-#+N7%-I26NHSQ-/#.DZ5?WEQ;V$-M-"
MS'(X55'<+VQ6SX-^(6C6/VB*X>2V65@T<L@RKXX.*V/&&A%;RYNV0O97$128
MH.4&,$G^=?/6@Z?=:AK;V27.^WC+BWD/(* _*2.U>9C:\L*E*G97WT)D^78]
MFU[XG7&J7=W:Z;/'96,>%:YEP&([XSZ]JX*Y\>3V%K/:VNE_:[:&/SW$DZQ7
M!C!YD"'DC@XS7.V$UC;>,],TN0M)<CS+J19/E1W7A=OJ1Z5?^(O@]?$T+W^G
M7;66MV,;R)>1)N!7&6A<'JIQCVKY#$XJKBFY)Z1_IG*YMZGK'P=O[2X74)X[
MQG%RZ-$DG!9=N00/QKU%CM[9KY;^'?C2T\?Z'!)X>'V2X0K%-;\9MW QP1SV
MKJ;C5/%$ES<Z%:7SW=U$%:Y+R82(-]T$CDD]=HKV\+FE*E1BI1T_4UC4TV/=
M_M4/F>4)4\SKL##=^52K\RU\]^$[_54UR31[FVACU%/+GBNH9&960MCC=R".
MXKZ#C7:@!.3W/O7L8+%_6XN7+:QI&7,/HHHKTBPHHHH **** "BBB@ HHHH
M**** "HVRJ$CG&3CUI]9>MZPFCVJN5:25SMCC7^(X[^@K.<E%.3Z >6>)/BI
M=Z5=1B.[F%W-(RQ6,5OYK%0<'Y1Z>M3VGQFOKRW*PZ>DEY%Q+&^Y']OD//XU
M@^(;+44\76>K:?';WY:!H[JW9]@B!;=N5O0=#3[JZ?4O$.D7]O;K&T.Y%NH3
MNB>,CF/U)R,YKX2>9UZ4VN;2_P"9SW=WJ4/&>O1:]HM[=:W=_8((EDWR2/@(
M2N,*OK7*?#W3=7UN%-1UZ+[-9-"D5IHN05BB R)6Q_&1R/2O.?CQXAE^(OC^
MS\-Z1N-K8R"2[6W).2#EMV..!6]\2_C%J7POU#3+6_T2&,W"HT,5O<$S)$<
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MT[Q]HFI:'X:T9;F&*#"W'E[$0GG<H')[UZQ^SG$-*\,^&_\ A(8XYQ$!9D7
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MS2>6,<DFI**8B/;\N,FD\D>IJ6BE8")80.Y/UJ3I2T4P"BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !36Z4ZBDP/*?B1IMXNL2WT]J]Y8&$+'*OS+ PSR5[?6O'/AK8F.S;3H
M$2W_ 'CQW7F#K*6)W?B*^J->:9='O3;Q">?RFV1-R&..F*^6;FU\36^JP7NF
MZ>IV0M!=&6%L/\V5; 'WATKYS'X>I&?M*6M]_)&$XO=%W2[BT\/^/+NZN$AD
MGT\0V,)#@XMW!).W_?/->9_M$:W:^.-4@TBTGFMY[(F>X2VC# )D#+,2 #W
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MG2W=4,T8;Y@W8,#6AH?Q"N_B1HLNAZ_X36Y:_55MS:R,H$I^[)C!QS[U])?
M/X,V/P]EL_#6IK_:$C027$@D)*K*V"0/8#BIHX>CB,6XQ?X&2BJD[IZ?J>,^
M'O$_CFX\;61_LNZTZTL99&E\Z-658V;+#)/+'I7H5UXDM?&6N2O-;W0MK)4F
MC\Z,H9IRW7Z*O;UKZ/NOA3X<N%4)9?95!RRP.0&^N:L/\,_#3A!_94*A&##;
MD<CUYKV:.2^R?Q'7&ERO<M^%--TVST>V?3[98HIHE;)'SMD9^8]SFMZHH8U@
MC6-%"(HP%'  J6OJ(KE5D= 44450!1110 4444 %%%% !1110 4444 %%%%
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ML,&8HHY)QQ7 Z/\ $+2/#_QJ\+:GH^F:MH^BWMG'H-]_:5FUO&6'$# G@D8
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M+8+(<1QWKJN8V;^[GH:J#P3X[^&?BKQ%>>#+/3->T77;HW[6E_.T#VEPPP[
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M;55;7+BXU4&PDC'V>Q$TP&X'EI6)[D\5]??!?0].TKPC'/96R027)W2N.2Y
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M,3'A3$W<@]<<5[=.G&E%0ALC<V/#_P"T-<>/-4U'2;W0&M->U1FO8+V.0DS
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M2)N W SN]10!\MV#P6NFV]S]M2*53DQ2NJ$C<,!,_P 7O7Z ?!O]J[P]X_\
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M>MOC)IR1223F.W,+;20J#/S-CU%5=^D:Q\:H++7+VXA$]D\,;%=XW$$ X.,
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M.H7-[#%]KM+Y0JR2<B"4=%/^R<5[C7FWQHU _P!F6>GQGYY9/.=?]E>!^IH
M^>&OTOK^[NIM.>"Y@S 1Y?R;A]XY'!]J^;/$5^WA7Q_;O9V\UI!=L)[B11L:
M%@2"Z>AS7U+-X-UC5IKR+P]/_I,R-)+;RGY0 ,E@W;/O7SW\3IK6Q\'V^HSE
M$OH9FVJW+-G^'U)R* .9D\676J^+-/OH7:XU"*?RYHY/]7,I8'=QTQWKMOCY
MX'OD\3:)XA2.WM]1ME6<):_=\LX.[<.W/->>^7&OA[3O%NCR(T=X"7B(PD$I
M.&4_7K2:]XDDAFT[1/$\M]IUJ!YL=Q&^^.=&'(4GMZ8H WVM[[P9\14\8Q0/
M;6MS+&Y$)^1I  2..Y!KVK5?'.D>+K/1M<30I+"6\GDM_*DG^1IL\.2?N?6O
M.]2\6GQE\)1;:99S:?K$ 2.TA6#>EZJ@\DG[CGUJAX#U:U\/_#G2)M3N7DU:
MUE>XO+6\^ZJ;L-$!].] 'N'A/Q5=_;M+AGE6">+5UA:%2)00K &59!U'.*^S
MZ^3/V>Y/"VK:]9W]KI?V?3;,-Y4T@9T\Z1LKUX! [U]9T <K\3_^1+O/^NMO
M_P"CTKJJY/XH?\B7>?\ 76W_ /1Z5UE( HHHI@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'YO?M7?!/7/ ?Q U;7O+N-1T#
M6IVN5O@C.87;EHI".@';VKQ2WTNY\,V<4-OI;:/'>1;U*PF(W$9..IY*FOV#
MO%MVM91=",VV"9/.P4QWSGC%?GC^UEXF\-ZMXXNM6TF]DN[*VC2#]T,HT@X\
MN$>G'&.,T ? OQK\1Z]XP\;/X$T55: >7#<W,2%VY&2CM_"@ZXKEO&7A>V\)
MZEIGA[P;]HN]:>';/,I^:1SPSIZ>E>YIX_T+P9X5U%%DD>YDEE%U?V=KYBI,
MV2JR2\;V X/:L+]G7X;HNJ2Z]?:@FNWTBA;.>(DK!O/S*0>C^W:@#D/AK\)]
M1\/^(M7BN8U\O3;*0W-T<[?,=/E52>^37H_[/WPYNOAUX9N+S4MLFH:HH>:W
M;E84 .WGKN/6N]328+S4/$.A7-PME':W0N;J60@+<IQB*-CC/(Y(Z=*^G?V3
M_ _@KQ=XDN1XAMH;Z[C:.73HW<F)MH)/ ^5L #@T =]X$_9K\.?&[X7^!M<U
MJ.\T?4+>S^SW'V4",WL(<[0^1W'\77%?47A_0;'POHMEI.FPK;6%G$L,$*]%
M4#@5=AC2WC6.-%CC0!510  .@  Z"I: "L?Q!X7T[Q-"D=_!YFPY5U)5E^A%
M;%% ')>(O!<+^#]7TS188["[NK5X4EC^5B2. 6Z\U\,?%3P+"L-SIGB'3I-/
MF>'RS%,"NUQ]V5&Z'![CK7Z*5\L_M3>*[;6=;T[P]-;)$MC/YC7,W5@R<@#T
MP: /DZW\/0/X%B\)6-SYDKD_:)H_XI5)+#V)%0+I6F?$#P9%X9U.6X36=/E
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M):M'XU\(AY95)DU&T"9 ;."5QU4CJ.U>0:]\0CJ/Q4L_%?ANQ:"\2))+JT.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV?B:QO;.VA#L+J I*S'@J, C&>G-??%<;\6+"\U#P'JD5BJO)A7D0@DL@(+
M>^!0!\=?!_\ 9=L9M8TR_P!?F=KB*4"0Q!2D 8?* V.IKZQL?@=H&DR1FSDO
M(H>/-A,NX3X.?F)%>2Z#KDL,+Z9;RS(+C:RQPXWR.#\HR?0]:^E=,%PNGVPN
MRINO+7S2.F['- $T<:PQK&@"(H "C@ #L*EHHH **** "N<U+5?$4-])%9:'
M:W-N/N32WXC+?\!V$C\ZZ.DVB@#B+_1_$_BJ%;/4O[,TS3F='E6U=YYFVLK!
M02%4 E>>*[BDVBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M11ZDGJ: /?KB=;:"69_NQJ7..N ,UXW:_M2>'[RT%\GA[Q0VFDM_IT>EEXL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 11, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INHIBRX BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">99-0613523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11025 N. Torrey Pines Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">795-4220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INBX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,607,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#8217;s Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002007919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 124,220<span></span>
</td>
<td class="nump">$ 152,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,435<span></span>
</td>
<td class="nump">7,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">132,832<span></span>
</td>
<td class="nump">160,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">7,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">6,831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">146,478<span></span>
</td>
<td class="nump">180,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,944<span></span>
</td>
<td class="nump">9,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">25,529<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,799<span></span>
</td>
<td class="nump">40,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, including final payment fee</a></td>
<td class="nump">100,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liability</a></td>
<td class="nump">4,127<span></span>
</td>
<td class="nump">6,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">138,485<span></span>
</td>
<td class="nump">47,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December&#160;31, 2025 and December&#160;31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 120,000,000 shares authorized as of December&#160;31, 2025 and December&#160;31, 2024; 14,577,609 and 14,475,904 shares issued and outstanding as of December&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">254,179<span></span>
</td>
<td class="nump">239,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(246,187)<span></span>
</td>
<td class="num">(106,132)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">7,993<span></span>
</td>
<td class="nump">133,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">146,478<span></span>
</td>
<td class="nump">180,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,577,609<span></span>
</td>
<td class="nump">14,475,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,577,609<span></span>
</td>
<td class="nump">14,475,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">113,028<span></span>
</td>
<td class="nump">203,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,297<span></span>
</td>
<td class="nump">127,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">136,325<span></span>
</td>
<td class="nump">331,648<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(135,025)<span></span>
</td>
<td class="num">(331,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Gain related to transaction with Acquirer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,021,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(12,196)<span></span>
</td>
<td class="num">(13,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_InterestIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">7,549<span></span>
</td>
<td class="nump">10,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(381)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="nump">2,019,022<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">(140,053)<span></span>
</td>
<td class="nump">1,687,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (140,055)<span></span>
</td>
<td class="nump">$ 1,687,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (9.04)<span></span>
</td>
<td class="nump">$ 114.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (9.04)<span></span>
</td>
<td class="nump">$ 112.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Shares used in computing earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">14,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">14,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_InterestIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income, Nonoperating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_InterestIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (t)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 43,503<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 657,232<span></span>
</td>
<td class="num">$ (613,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">58,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of shares upon exercise of stock options</a></td>
<td class="nump">71,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock', window );">Acquisition of Former Parent&#8217;s common stock, stock options, and warrants by the Acquirer (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,564,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Acquisition of Former Parent&#8217;s common stock, stock options, and warrants by the Acquirer</a></td>
<td class="num">(1,743,729)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(563,754)<span></span>
</td>
<td class="num">(1,179,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares in Distribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares in Distribution</a></td>
<td class="nump">16,042<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">16,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,687,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">14,475,904<span></span>
</td>
<td class="nump">14,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 133,584<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">239,715<span></span>
</td>
<td class="num">(106,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">11,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with 2025 Loan Agreement</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of shares upon exercise of stock options</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (140,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,055)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">14,577,609<span></span>
</td>
<td class="nump">14,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 7,993<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 254,179<span></span>
</td>
<td class="num">$ (246,187)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholder Equity, Spinoff Transaction, Decrease In Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481423/505-60-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (140,055)<span></span>
</td>
<td class="nump">$ 1,687,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and non-cash interest expense</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">11,138<span></span>
</td>
<td class="nump">58,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_NoncashOperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,803<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet', window );">Non-cash gain on transaction with Acquirer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,998,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">200<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables from related parties</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,301)<span></span>
</td>
<td class="nump">17,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(4,361)<span></span>
</td>
<td class="nump">35,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(1,408)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(129,794)<span></span>
</td>
<td class="num">(194,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(2,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(2,597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="nump">99,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt', window );">Payment of third-party fees associated with debt</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">71,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">101,446<span></span>
</td>
<td class="nump">71,678<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(28,376)<span></span>
</td>
<td class="num">(125,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">152,596<span></span>
</td>
<td class="nump">277,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">124,220<span></span>
</td>
<td class="nump">152,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">11,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement', window );">Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred', window );">Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3)</a></td>
<td class="nump">$ 1,720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Noncash Investing And Financing Items, Warrant Liabilities Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PaymentsOfDebtIssuanceCostsSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of Debt Issuance Costs, Secured Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PaymentsOfDebtIssuanceCostsSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx Biosciences, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#8217;s current pipeline is focused on oncology.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#8217;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Distribution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, Inhibrx, Inc., or the Former Parent, announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. The Former Parent and the Company signed an Agreement and Plan of Merger, dated as of January 22, 2024, or the Merger Agreement, with Aventis Inc., a Pennsylvania corporation, or the Acquirer, and a wholly-owned subsidiary of Sanofi S.A., or Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation, or the Merger Sub, and a wholly-owned subsidiary of Acquirer, along with a Separation and Distribution Agreement, dated as of January 22, 2024, by and among the Former Parent, the Company and Acquirer. The Merger Agreement provided for the acquisition by Acquirer of the Former Parent, or the Merger, to be accomplished through the merger of Merger Sub with and into the Former Parent with the Former Parent continuing as the surviving entity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of common stock of the Company, or the Distribution. On May 30, 2024, the Former Parent completed the Merger, pursuant to which (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer, a wholly-owned subsidiary of Sanofi; and (ii) by way of a series of internal restructuring transactions, or the Separation, the Company acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105. Upon the closing of the Merger, the Company became a stand-alone, publicly traded company.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the foregoing transactions, each Former Parent stockholder received: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">four shares of the Former Parent&#8217;s common stock held. The Acquirer retained an equity interest in the Company of 8% upon the Distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Acquirer paid transaction consideration of $1.9 billion, including the $30.00 per share consideration and the assumption of the Company&#8217;s third-party debt. See Note 3 for further discussion on the extinguishment of the Company&#8217;s Amended 2020 Loans with Oxford (as defined below). In addition, the Acquirer assumed all assets and liabilities under contracts primarily related to INBRX-101 upon close of the Merger. The Acquirer also reimbursed the Company or paid on behalf of the Company $68.0&#160;million in transaction costs. The Acquirer may pay an additional $300.0&#160;million in consideration under the contingent value rights issued upon the achievement of a regulatory milestone.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the legal form of the spin-off, the Separation and Distribution is being treated as a reverse spin-off for financial accounting and reporting purposes in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 505-60,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spinoffs and Reverse Spinoffs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">because (i) a wholly-owned subsidiary of the Acquirer merged with and into the Former Parent immediately following the Distribution; (ii) no senior management of the Former Parent were retained by the Former Parent following the Distribution; and (iii) the size of the Company&#8217;s operations relative to the 101 Business. As a reverse spin-off, the Company considers Inhibrx as the accounting spinnor of the Former Parent, and the accounting successor to the Former Parent. Therefore, for periods prior to the spin-off, the Company&#8217;s financial statements are the historical financial statements of the Former Parent. For such periods, descriptions of historical business activities are presented as if the spin-off had already occurred, and the Former Parent&#8217;s activities related to such assets and liabilities had been performed by the Company. In addition, for all periods prior to the spin-off, all outstanding shares referenced in these financial statements are those shares outstanding of the Former Parent at each respective date, unless otherwise indicated as adjusted for the distribution ratio. Following the spin-off, all outstanding shares referenced are those of the Company, which, as discussed above, were issued on a four-to-one ratio of the Former Parent&#8217;s outstanding shares.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the sale of the 101 Business in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 205-20, Discontinued Operation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">s, and determined that the Separation does not represent a strategic shift and thus does not qualify as a discontinued operation. The Company next evaluated the sale of the 101 Business in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 805, Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, and determined that the 101 Business does not meet the definition of a business, given that substantially all of the fair value of the gross assets transferred is concentrated in one asset. The Company then evaluated the transaction under </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 845, Nonmonetary Transactions</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which contains guidance on the accounting for the distribution of nonmonetary assets to stockholders of an entity in a spin-off. In accordance with this guidance, the disposal of the 101 Business has been accounted for as a dividend-in-kind, with a gain recognized for the difference between the fair value and carrying value of the disposed assets. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain on the transaction of $2.0 billion during the year ended December 31, 2024, which consisted of the following components (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration for common stock, warrants, and stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,727,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of Amended 2020 Loans assumed by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">211,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs paid by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total gain recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,021,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The gain related to the Merger consideration payable to shareholders of $1.7&#160;billion was recorded, net of consideration allocated to the shares issued to Acquirer, through a reduction to retained earnings of $1.2&#160;billion, representing the amount of retained earnings available at the closing of the Merger, with the remaining amount of $563.8&#160;million recorded through additional paid-in capital.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had an accumulated deficit of $246.2 million and cash and cash equivalents of $124.2 million. From its inception and through December&#160;31, 2025, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents, including proceeds from the March 2026 Amendment (see Footnote 11), will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. The Company expects to continue to incur net losses for the foreseeable future until, if ever, the Company has an approved product and can successfully commercialize it. Until such time the Company, if ever, can generate substantial product revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, the Company engages in discussions with potential acquirers regarding the disposition of one or more of its therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its intellectual property on less favorable terms than it would otherwise choose. These actions could materially impact its business, results of operations, financial condition, and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, and the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company&#8217;s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2025 and December&#160;31, 2024, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for credit losses was recorded. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company has never declared or paid any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and office equipment: <span style="-sec-ix-hidden:f-288">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture, fixtures and other: five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: three years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception based on the unique facts and circumstances present in the contract. The Company evaluates classification of leases as either operating or finance at commencement and, as necessary, at modification.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At lease commencement for leases with terms greater than 12 months, the Company records a lease liability determined as the present value of future lease payments over the expected lease term. The Company calculates the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The Company also records an operating right-of-use asset based on the liability as adjusted for any lease incentives or prepaids. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably certain of exercise.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After lease commencement, assumptions made by the Company at the commencement date are re-evaluated upon the occurrence of certain events, including a lease modification. The Company evaluates any change to an existing lease to determine if it constitutes a separate contract or a single contract with the existing lease. For modifications treated as a single contract, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate as of the effective date of the modification, and recognizes the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding right-of-use asset under the lease modification guidance pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional right-of-use asset that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional right-of-use asset. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for lease and non-lease components in its lease agreements as a single lease component in determining lease assets and liabilities. In addition, the Company does not recognize the right-of-use assets and liabilities for leases with lease terms of twelve months or less, instead recognizing lease payments as operating expenses on a straight-line basis over the lease term. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Poplar Therapeutics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Poplar Therapeutics, Inc, or Poplar Therapeutics, formerly Phylaxis Bioscience, LLC., which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company&#8217;s proportionate share of the net income or loss of Poplar Therapeutics is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company&#8217;s share of prior losses of the investee. Following the Company&#8217;s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company&#8217;s investment in Poplar Therapeutics as of December&#160;31, 2025 and December&#160;31, 2024 is zero.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments held during the periods presented consisted principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximated their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximated fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s warrants are equity-classified and carried at the instruments&#8217; fair value upon classification into equity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term outstanding debt is not measured at fair value on a reoccurring basis. As of December&#160;31, 2025 and December&#160;31, 2024, the fair value of the Company&#8217;s long-term outstanding debt approximates fair value using Level 2 inputs. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 835-30, Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments with Characteristics of Both Liabilities and Equity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 480-10, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company&#8217;s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company&#8217;s outstanding warrants are classified as equity as of and for the years ended December&#160;31, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company&#8217;s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change occurs, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the same period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive common shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net earnings (loss) per share when the effect is anti-dilutive.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of shares of common stock used in the basic and diluted net income (loss) per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, outstanding shares during the period consist both of shares of the Former Parent and of the Company. For purposes of computing earnings (loss) per share only, for all periods presented in its consolidated statements of operations, the Company adjusted all outstanding shares of the Former Parent, including potentially dilutive securities, by the four-to-one distribution ratio used in the Distribution. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company has a net loss, basic loss per share and diluted loss per share are identical since the effect of potentially dilutive common shares is anti-dilutive and therefore excluded. Accordingly, for the year ended December 31, 2025, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company&#8217;s market-traded shares best represents its expected volatility. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM, in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM has been identified as the Chief </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer, who reviews financial results at a consolidated level only. The Company views its operations and manages its business as one operating and reportable segment as the Company has devoted substantially all of its resources to drug discovery and development activities through conducting preclinical studies and clinical trials associated with its programs, all of which aim to discover and develop biologic therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM assesses performance for the biologic therapeutic segment and decides how to allocate resources based on the consolidated net income (loss) as reported on its consolidated income statement. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The segment depreciation expense, interest expense, interest income, and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues to date under this segment have been derived from licenses with collaboration partners and grant awards, and the Company has not generated any revenue from the commercial sale of approved therapeutic products (see Note 6). As a result, the Company has incurred operating losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its therapeutic candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval. The CODM evaluates the Company's operating results and allocates resources using net income (loss) and the components of operating expense, together with information on the progression and results of clinical trial activities, to advance the Company's therapeutic pipeline and to best support the long-term growth of the Company&#8217;s overall business. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(5,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,021,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Other segment items consist of the gain on transaction from the Merger, discussed above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other segment expenses include provision for income taxes.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvement to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to enhance the transparency and decision usefulness of income tax disclosures. Two primary enhancements related to this ASU include disaggregating existing income tax disclosures relating to the effective tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025 and applied it prospectively, as disclosed in Note 8, Income Taxes. The adoption did not have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued but Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires additional disclosure about specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this accounting standard update on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company&#8217;s therapeutics. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,093&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for each of the years ended December 31, 2025 and December&#160;31, 2024, and consisted of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,794&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,796&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s usage of third-party CROs for management of clinical trials. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC and other lenders, or collectively, Oxford. Under the original 2020 Loan Agreement and subsequent amendments between November 2020 and October 2022, or collectively, the Amended 2020 Loan Agreement, the Company received an aggregate principal amount of $200.0 million over seven tranches, or Terms A-G.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Separation, the outstanding term loans were to mature on January&#160;1, 2027, or the Amended Maturity Date. Under the Amended 2020 Loan Agreement, and through the Separation, the repayment schedule provided for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount would be due to Oxford. This final payment of $18.0 million was being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company&#8217;s outstanding debt was assumed by the Acquirer. Prior to the close of the Merger, the Company had $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The Acquirer assumed the outstanding debt balance in full, consisting of the $200.0 million in gross principal, the $18.0 million final payment fee, and accrued interest of $2.3&#160;million, net of debt discounts of $9.0&#160;million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the Acquirer&#8217;s assumption and subsequent repayment of the outstanding debt constitutes an extinguishment of the debt as the Company has been legally released from being the primary obligor under the liability. The Company did not make any payment upon the extinguishment of the debt and did not incur any prepayment penalties. Upon the Acquirer&#8217;s assumption of the outstanding debt, the Company recorded a gain of $211.3&#160;million, the net carrying amount of the Amended 2020 Loans upon extinguishment, within the gain related to transaction with Acquirer in its consolidated statements of operations during the year ended December 31, 2024. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Separation, interest expense was calculated using the effective interest method and was inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2024, interest expense was $13.5 million, $2.1 million of which related to non-cash amortization of the debt discount and accretion of the final payment. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2025 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025, the Company entered into a Loan and Security Agreement, or the 2025 Loan Agreement, with Oxford, pursuant to which it received $100.0 million in gross proceeds. The 2025 Loan Agreement provides for an additional tranche of $50.0 million to be funded upon the Company's request and at Oxford&#8217;s sole discretion. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding term loan will mature on January 1, 2030, or the Maturity Date, and bears interest at (1) 5.61% plus (2) the greater of (i) the 1-Month Term Secured Overnight Financing Right as published by the CME Group or (ii) 4.34%. The repayment schedule provides for interest-only payments through February 1, 2028, with principal payments beginning on March 1, 2028. The interest-only period is followed by 23 months of equal payments of principal plus interest. Upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of any term loan under the Term Loan Facility, or (iii) prepayment of any term loan under the Term Loan Facility, the Company will be required to make a final payment of 9.0% of the total principal amount. This final payment of $9.0 million will be accreted over the life of the 2025 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Maturity Date, subject to a prepayment fee ranging from 2.0% to 5.0%, depending on the timing of the prepayment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company&#8217;s outstanding debt balance under the 2025 Loan Agreement consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount and final payment fee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest-only period will continue through February 2028, with principal payments beginning in March 2028. Future principal payments and final fee payments will be made as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43,478&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the 2025 Loan Agreement are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. The 2025 Loan Agreement also requires the Company to maintain a minimum liquidity threshold in the amount of $20.0&#160;million, tested at all times, with such liquidity threshold subject to increase to $50.0&#160;million or $75.0&#160;million based on certain pipeline development changes. As of December&#160;31, 2025, the Company is in compliance with all covenants under the 2025 Loan Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the debt issuance in January 2025, the Company issued to Oxford warrants to purchase shares of the Company&#8217;s common stock equal to 2.0% of the funded amount, or $2.0&#160;million, or the 2025 Oxford Warrants. Upon issuance, the warrants were exercisable for 140,741 shares of common stock at an exercise price of $14.21 per share. The 2025 Oxford Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance. Upon issuance, the warrants were classified as equity and recorded at their fair value of $1.7 million as additional paid-in-capital and as a debt discount which will be accreted over the life of the 2025 Loan Agreement using the effective interest method. See Note 4 for further discussion of these warrants.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div>Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment at an effective interest rate of 12.9%. During the year ended December 31, 2025, interest expense was $12.2 million, $2.4 million of which related to non-cash amortization of the debt discount and accretion of the final payment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, upon effecting the Separation, the Company&#8217;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Distribution and as of May 29, 2024, the Company had 14,475,904 shares of common stock outstanding. The Company issued one SEC-registered, publicly listed, share of Inhibrx for every four shares of the Former Parent&#8217;s common stock held, resulting in 13,316,140 shares of common stock issued to common stockholders of the Former Parent. Upon the Distribution, the Former Parent retained an equity interest in the Company of 8%, or 1,157,926 shares. The Company issued 1,838 shares of common stock to Oxford in connection with the Oxford Warrants (as defined below) in the Distribution.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with certain institutional and other accredited investors, or Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company&#8217;s common stock for $19.35 per share and pre-funded warrants to purchase 6,714,636 shares of the Company&#8217;s common stock in a private placement transaction, or the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The pre-funded warrants were equity-classified and carried at the instruments&#8217; fair value upon issuance. During the second quarter of 2024, certain Purchasers exercised 2,747,245 pre-funded warrants on a cashless basis for a net of 2,746,454 shares of the Former Parent&#8217;s common stock.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Merger Agreement, the Former Parent entered into an Agreement Relating to the Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated as of January 22, 2024, by and between the Former Parent and each holder of the pre-funded warrants purchased in the Private Placement so that on the date of the Distribution, any remaining pre-funded warrants of the Former Parent not already exercised to purchase the Former Parent&#8217;s common stock became exercisable for an equivalent number of shares of the Company&#8217;s common stock at an exercise price of $0.0001 per share, pursuant to certain beneficial ownership limitations. The Company has evaluated the amendment and accounted for this as a modification to the original Purchase Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Separation and Distribution, each holder of outstanding pre-funded warrants received (i) $30.00 per pre-funded warrant in cash, less the applicable exercise price per share, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one pre-funded warrant of Inhibrx for every four of the Former Parent&#8217;s pre-funded warrants held. Following the Separation and Distribution, pre-funded warrants to purchase 991,849 shares of the Company&#8217;s common stock are outstanding at an exercise price of $0.0001 per share. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement, as amended, and will remain outstanding until exercised in full.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oxford Warrants</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended 2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Amended 2020 Loan Agreement, the Company issued equity-classified warrants to Oxford, or the 2020 Oxford Warrants, in two tranches: (i) 7,354 warrants with an exercise price of $17.00 and (ii) 40,000 warrants with an exercise price of $45.00. As part of the Separation and Distribution, each holder of eligible outstanding warrants received (i) $30.00 per warrant in cash, less the applicable exercise price per share (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every four of the Former Parent&#8217;s warrants held. All outstanding warrants with an exercise price which exceeded the total consideration of $35.00 were canceled upon the Merger for no consideration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Separation, no Oxford Warrants were outstanding.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2025 Loan Agreement, the Company issued warrants to Oxford, or the 2025 Oxford Warrants. The Company issued warrants to purchase 140,741 shares of the Company&#8217;s common stock at an exercise price of $14.21 per share. The 2025 Oxford Warrants are exercisable upon issuance and will expire on January&#160;13, 2035. The 2025 Oxford Warrants are equity-classified and carried at the instruments&#8217; fair value upon classification into equity, with no subsequent remeasurements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance as of December&#160;31, 2025 and December&#160;31, 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,660&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future equity grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY COMPENSATION PLAN</a></td>
<td class="text">EQUITY COMPENSATION PLAN <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company&#8217;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provided for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. The 2017 Plan was terminated in connection with the Merger. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, the Company granted options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. The options were subject to four-year vesting with a one-year cliff and had a contractual term of 10 years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $65.3&#160;million. Aggregate intrinsic value of stock options exercised is calculated using the fair value of common stock on the date of exercise. The total fair value of stock options vested during the year ended December 31, 2024 was $42.5&#160;million. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following the Merger, there was no activity under the 2017 Plan and no stock options remained outstanding under the 2017 Plan.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Settlement of Stock Options Upon Merger</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding options with an exercise price less than or equal to the total consideration of $35.00 vested immediately upon the Merger and were settled for the consideration of: (i) $30.00 per share in cash, less the applicable exercise price of their stock option and (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone. In connection with the acceleration of the eligible stock options, affecting 160 grantees, the Company recognized $39.3&#160;million in stock compensation expense.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All outstanding options with an exercise price which exceeded the total consideration of $35.00 were canceled upon the Merger for no consideration. In connection with the cancellation of all unvested options with an exercise price above $35.00, affecting 7 grantees, the Company recognized all remaining stock compensation expense of $1.8&#160;million.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Plan</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company adopted the 2024 Omnibus Incentive Plan, or the 2024 Plan, which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2025, an aggregate of 4.0 million shares of common stock were authorized for issuance under the 2024 Plan, of which 0.4 million remained available for issuance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants options with an exercise price equal to the fair market value of the Company&#8217;s stock on the date of the option grant. All options granted to employees are subject to four-year vesting with a one-year cliff. All options granted to non-employee directors are subject to a one-year vesting term. All options have a contractual term of 10 years. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2024 Plan for the year ended December 31, 2025 is as follows (in thousands, except for per share data and years):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term <br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,660&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">220,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2025 was $4.7 million. The total fair value of stock options vested during the year ended December 31, 2025 was $17.4 million. No stock options were exercised or vested during the year ended December 31, 2024. The Company expects all outstanding stock options to vest. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#8217;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock options granted under the 2024 Plan using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the years ended December 31, 2025 and December&#160;31, 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.91&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.56&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any stock options under the 2017 Plan during the years ended December 31, 2025 and December&#160;31, 2024. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 for further discussion in how the Company determines the assumptions used in the option pricing model.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options under the 2024 Plan and 2017 Plan consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,875&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had $25.9 million of total unrecognized stock-based compensation expense related to its stock options under the 2024 Plan, which is expected to be recognized over a weighted-average period of 2.56 years. As of December&#160;31, 2025, the Company had no remaining unrecognized stock-based compensation expense related to its stock options under the 2017 Plan following the termination of the plan subsequent to the Merger.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LicenseAndGrantRevenueTextBlock', window );">LICENSE REVENUE</a></td>
<td class="text">LICENSE REVENUE<div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Scithera, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scithera License Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2025, the Company entered into a License and Assignment Agreement, or the Scithera License Agreement, with Scithera, Inc., or Scithera, a newly formed biotechnology company that focuses on antibody-based molecules.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Scithera License Agreement, the Company licensed to Scithera the right to use certain assets in the Company&#8217;s antibody library to research, develop, and commercialize antibody-based molecules to certain targets. Additionally, the Company assigned to Scithera its agreement with NorthStar Medical Technologies, LLC for the development of radiopharmaceuticals for the treatment of cancer. The Company also agreed to make available to Scithera certain research materials useful for identifying, generating, and developing antibodies from antibody libraries to enable Scithera&#8217;s use of the assets licensed under the Scithera License Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Contingent upon Scithera&#8217;s achievement of specified funding events, Scithera was required to pay the Company $1.3 million as a non-refundable payment. In addition, Scithera may make additional future milestone payments of up to an aggregate of $41.25 million per target upon the achievement of certain milestone events, and potential royalty payments on net sales in the low- to mid-single digits.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the agreement, the Company identified one performance obligation, which was the transfer of licenses to Scithera for the specified assets and all related materials and know-how. During the second quarter of 2025, Scithera achieved the specified funding event and made a non-refundable payment of $1.3 million to the Company. Upon notice of the achievement of such funding event, the Company re-assessed the transaction price to be $1.3 million, which was allocated to the single performance obligation. All remaining consideration under the agreement is variable consideration associated with the achievement of specified development milestones, and as a result, has been fully constrained (excluded) from the transaction price until such time that the Company </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company completed its single performance obligation and recognized $1.3&#160;million at the point in time upon the completion of the transfer of all licensed materials and know-how. During the year ended December 31, 2025, the Company recognized $1.3 million of revenue and received a payment of $1.3&#160;million under the Scithera License Agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regeneron</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Option and License Agreement with bluebird bio, Inc., or bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retained all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird&#8217;s internal restructuring and subsequent spin-out of 2seventy, and subsequently in April 2024, this agreement, or the 2020 Regeneron Agreement, was assigned to Regeneron Pharmaceuticals, Inc., or Regeneron, in connection with the divestiture of 2seventy&#8217;s oncology and autoimmune pipeline to Regeneron.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee in exchange for a development license and an option in which Regeneron may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which Regeneron exercises its option, Regeneron will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5&#160;million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, pursuant to the option extension terms in the 2020 Regeneron Agreement, Regeneron requested to extend the option term for its third program by an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension at the point in time in which the extension was granted. In November 2024, Regeneron requested a second extension of the option term for an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension at the point in time in which the extension was granted. The $0.2&#160;million related to the option extensions is recorded as accounts receivable in the Company&#8217;s consolidated balance sheet as of December&#160;31, 2024 and was collected in full during the first quarter of the year ended December 31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company recognized $0.2&#160;million of revenue related to this agreement. The Company did not recognize any revenue under this agreement during the year ended December 31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement and Arrangement Other than Collaborative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LicenseAndGrantRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LicenseAndGrantRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#8217;s Board of Directors or a committee thereof pursuant to policy.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Distribution</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, as discussed in Note 1, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of common stock of the Company, or the Distribution. The Former Parent retained an equity interest in the Company of 8%, or 1,157,926 shares upon the Distribution. Accordingly, the Company identified the Acquirer as a related party following the Merger with the Former Parent.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Services Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company also entered into the Transition Services Agreement with the Former Parent under which the Company or one of its affiliates provide the Former Parent or other Sanofi entities with certain transition services for a limited time to ensure an orderly transition following the Separation. The services that the Company agreed to provide to the Former Parent or other Sanofi entities under the Transition Services Agreement include certain finance and accounting, including payroll, tax, and procurement, information technology, legal and intellectual property, clinical study support, technical operations, regulatory, quality assurance, commercial and medical affairs, and other services. The Former Parent pays the Company for any such services received by the Former Parent or other Sanofi entities, as applicable, at agreed amounts as set forth in the Transition Services Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025, the Company substantially completed all obligations under the Transition Services Agreement. The Company has not billed the Former Parent for any services under the Transition Services during the year ended December 31, 2025 and does not expect any future billings. During the year ended December 31, 2024, the Company billed the Former Parent for $0.3 million for services performed under the Transition Services Agreement, which was recognized as other income. The Company received approximately $0.2 million in cash during the year ended December 31, 2024, with the remaining balance of approximately $23,000 received during the year ended December 31, 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Transition Services Agreement required the Former Parent to reimburse the Company for certain severance payments made by the Company to certain Company employees whose employment was terminated as a result of the Merger. During the year ended December 31, 2024, the Company billed the Former Parent for $1.0 million of severance payments to former employees, all of which was received as of December&#160;31, 2024. No further activity occurred during the year ended December 31, 2025.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacovigilance Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Company entered into a Pharmacovigilance Agreement with the Former Parent, pursuant to which the parties agreed to implement processes and procedures for sharing information as required for each party&#8217;s compliance with its regulatory and pharmacovigilance responsibilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income (loss) before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss provision for before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,053)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense were as follows for the years ended December 31, 2025 and December&#160;31, 2024, respectively (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The provision for the years ended December 31, 2025 and December&#160;31, 2024 was related to state income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company made no material income tax payments during 2025 for Federal, state, and foreign jurisdictions.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on January 1, 2025 on a prospective basis. As a result, the Company's rate reconciliation for 2025 is presented in accordance with the new disclosure requirements, while the reconciliation for 2024 continues to be presented under disclosure requirements in effect for that period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(29,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) 50% or more of our state tax provision relates to the California state jurisdiction.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense at federal statutory rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">354,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense, net of federal benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of deferred tax assets and liabilities upon Transaction with Acquirer </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">195,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable gain related to Transaction with Acquirer</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(410,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">336(e) election</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(124,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 research and development capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,721&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,983&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets after valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, the Former Parent retained all rights associated with the unused federal and state NOLs and research tax credit carryforwards as of the date of the transaction to offset its future taxable income. As of December&#160;31, 2025, the Company had unused federal and state NOL carryforwards of approximately $183.1 million and $32.8 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2034 if not utilized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. Following the Separation, the Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company may incur ownership changes in the future. If an ownership change has occurred, the Company&#8217;s ability to use its NOL carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2025. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. Based on this evaluation, as of December&#160;31, 2025, a valuation allowance of $52.5 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#8217;s projections for growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company did not have any gross unrecognized tax benefits. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#8217;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2025 or December&#160;31, 2024, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2025 and December&#160;31, 2024 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in the United States and various state jurisdictions. Following the Separation, the Company&#8217;s tax years from 2024 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law. The OBBBA includes significant changes to U.S. tax and related laws. Some of the provisions of the OBBBA affecting corporations include the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, or TCJA, modifications to the Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income international tax provisions, an increase in the limit of the deduction of interest expense to 30% of earnings before interest, taxes, depreciation, and amortization, and reinstatement of 100% bonus depreciation deduction from the TCJA for eligible property acquired after January 19, 2025. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA&#8217;s financial reporting implications have been recognized in our income tax provision for 2025. The incorporation of these effects resulted in no material impact on the Company&#8217;s effective tax rate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California, which contains an initial base rent of approximately $0.1 million per month with 2% annual escalations. In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020, which contained an initial base rent of approximately $30,000 per month with 2% annual escalations. Each of these leases expired in June 2025 with an option to extend the lease an additional five years, which was not included in the right-of-use asset and lease liabilities. Payments under each of the lease agreements included base rent plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company entered into a new lease agreement for its existing facilities, or the 2024 Lease Agreement, for the period following the expiration of its two existing leases through June 2028, with an option to extend the lease an additional three years, which is not included in the right-of-use asset and lease liabilities. This agreement did not include any additional square footage. The 2024 Lease Agreement contains initial base rent of approximately $0.2 million per month with 3% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. The 2024 Lease Agreement also provided for four months of base rent abatement of $0.2&#160;million per month for the period of October 2024 through January 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the 2024 Lease Agreement contains a lease which should be accounted for as a single modified contract with its existing lease agreements. As a result, the Company remeasured the operating lease liability, resulting in an increase to its operating lease liability and right-of-use asset of $6.3 million as of the lease&#8217;s commencement date, which was determined to be the effective date of the 2024 Lease Agreement. The Company utilized an estimated incremental fully collateralized borrowing rate of 10.2% in its present value calculation as the 2024 Lease Agreement, which does not have a stated rate and did not have a readily determinable implicit rate. The estimated rate was determined using the rate of the 2025 Loan Agreement (as defined below) with Oxford entered into in January 2025.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The operating right-of-use asset and operating lease liability as of December&#160;31, 2025 and December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2025 and December&#160;31, 2024, the Company recognized operating lease expense of $3.9 million and $3.4 million, respectively. During the years ended December 31, 2025 and December&#160;31, 2024, the Company paid $2.3 million and $1.7 million for amounts included in the measurement of the operating lease liability, respectively.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025 and December&#160;31, 2024, the Company&#8217;s operating lease had a remaining term of 2.5 years and 3.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 10.2% as of December&#160;31, 2025 and December&#160;31, 2024.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental commitments for the Company&#8217;s operating leases reconciled to the operating lease liability are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div>Additionally, as of December&#160;31, 2025 and December&#160;31, 2024, Mark P. Lappe, the Company&#8217;s Chief Executive Officer, David Matly, the Company&#8217;s President, and Kelly D. Deck, the Company&#8217;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Loan Agreement with Oxford</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2026, the Company entered into the First Amendment to Loan and Service Agreement with Oxford, or the March 2026 Amendment. The March 2026 Amendment provides for an additional tranche, or the Term B Loans, in an aggregate principal amount of $75.0&#160;million, upsized from $50.0 million originally available under the 2025 Loan Agreement, prior to the March 2026 Amendment, collectively with the prior $100.0 million under the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025 Loan Agreement, the Oxford Term Loans. $75.0 million of the Term B Loans was funded on the date of the March 2026 Amendment.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All obligations under the 2025 Loan Agreement, as amended, and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement, as amended, includes customary events of default, including instances of a material adverse change in the Company&#8217;s operations, that may require prepayment of the outstanding term loans. The March 2026 Amendment updated the minimum liquidity threshold covenant, tested at all times, to $40.0&#160;million, not subject to future increases. All other terms of the 2025 Loan Agreement remain outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the March 2026 Amendment tranche of funding, the Company issued warrants to Oxford to purchase 21,518 shares of the Company&#8217;s common stock at an exercise price of $69.71 per share. The warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity policies, standards, processes and practices are designed to align with recognized frameworks, such as those established by the National Institute of Standards and Technology, or NIST, and the International Organization for Standardization. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use such frameworks as a guide to help us identify, assess and manage cybersecurity risks relevant to our business. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is designed to preserve the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents when they occur.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program designed to ensure our systems are effective and prepared for information security risks, including monitoring for internal and external threats. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services depending on the sensitivity of the information and systems, including network and endpoint monitoring, audits, vulnerability assessments, penetration testing, and threat modeling, which are designed to inform our risk identification and assessment. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our audit committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer, General Counsel, and Director of Information Technology.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also identify cybersecurity risks by engaging experts to attempt to test our information systems. Depending on the sensitivity of the data and systems in question, we may also undertake activities such as:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">monitoring emerging data protection laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">implementing relevant policies, practices, and contracts (as applicable);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">employing technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">providing training for our employees and contractors regarding cybersecurity threats;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">conducting phishing simulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">conducting annual cybersecurity management and incident response training; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">carrying information security risk insurance.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our incident response plan is designed to coordinate the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, and includes processes to triage, assess severity for, escalate, contain, investigate and remediate incidents, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As part of the above processes, we engage with consultants, internal auditors and other third parties, including annually having an independent third-party review of our cybersecurity.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, depending on the nature and sensitivity of the data or systems in question, and monitor cybersecurity threat risks identified through such diligence. Additionally, we generally require certain third parties to agree by contract to </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we may conduct as appropriate.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity breaches could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; which disclosures are incorporated by reference herein.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity policies, standards, processes and practices are designed to align with recognized frameworks, such as those established by the National Institute of Standards and Technology, or NIST, and the International Organization for Standardization. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use such frameworks as a guide to help us identify, assess and manage cybersecurity risks relevant to our business. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is designed to preserve the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents when they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led primarily by our Director of Information Technology, who has several years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, and implementing effective information and cybersecurity programs. Our Director of Information Technology is informed with regard to and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through his management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our management team reports to the audit committee of our board of directors about cybersecurity threat risks, among other cybersecurity related matters, at least annually.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led primarily by our Director of Information Technology, who has<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Director of Information Technology is informed with regard to and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through his management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our management team reports to the audit committee of our board of directors about cybersecurity threat risks, among other cybersecurity related matters, at least annually.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div>The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company had an accumulated deficit of $246.2 million and cash and cash equivalents of $124.2 million. From its inception and through December&#160;31, 2025, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents, including proceeds from the March 2026 Amendment (see Footnote 11), will be sufficient to fund the Company&#8217;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. The Company expects to continue to incur net losses for the foreseeable future until, if ever, the Company has an approved product and can successfully commercialize it. Until such time the Company, if ever, can generate substantial product revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, the Company engages in discussions with potential acquirers regarding the disposition of one or more of its therapeutic candidates. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#8217; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its intellectual property on less favorable terms than it would otherwise choose. These actions could materially impact its business, results of operations, financial condition, and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#8217;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The Company&#8217;s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, and the incremental borrowing rate estimated in relation to the Company&#8217;s operating lease.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company&#8217;s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.</span></div>The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#8217;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2025 and December&#160;31, 2024, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for credit losses was recorded.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Dividends</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company has never declared or paid any dividends on its common stock. </span></div>Any future determination to pay dividends on the Company&#8217;s common stock will be at the discretion of the Company&#8217;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#8217;s board of directors may deem relevant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and office equipment: <span style="-sec-ix-hidden:f-288">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture, fixtures and other: five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: three years.</span></div>Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div>The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception based on the unique facts and circumstances present in the contract. The Company evaluates classification of leases as either operating or finance at commencement and, as necessary, at modification.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At lease commencement for leases with terms greater than 12 months, the Company records a lease liability determined as the present value of future lease payments over the expected lease term. The Company calculates the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The Company also records an operating right-of-use asset based on the liability as adjusted for any lease incentives or prepaids. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably certain of exercise.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After lease commencement, assumptions made by the Company at the commencement date are re-evaluated upon the occurrence of certain events, including a lease modification. The Company evaluates any change to an existing lease to determine if it constitutes a separate contract or a single contract with the existing lease. For modifications treated as a single contract, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate as of the effective date of the modification, and recognizes the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding right-of-use asset under the lease modification guidance pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional right-of-use asset that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional right-of-use asset. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. </span></div>The Company accounts for lease and non-lease components in its lease agreements as a single lease component in determining lease assets and liabilities. In addition, the Company does not recognize the right-of-use assets and liabilities for leases with lease terms of twelve months or less, instead recognizing lease payments as operating expenses on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investment in Poplar Therapeutics</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Poplar Therapeutics</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Poplar Therapeutics, Inc, or Poplar Therapeutics, formerly Phylaxis Bioscience, LLC., which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company&#8217;s proportionate share of the net income or loss of Poplar Therapeutics is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#8217;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company&#8217;s share of prior losses of the investee. Following the Company&#8217;s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company&#8217;s investment in Poplar Therapeutics as of December&#160;31, 2025 and December&#160;31, 2024 is zero.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments held during the periods presented consisted principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximated their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#8217;s debt approximated fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#8217;s warrants are equity-classified and carried at the instruments&#8217; fair value upon classification into equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div>In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Financing Costs and Other Debt-Related Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company&#8217;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 835-30, Imputation of Interest</span>.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_WarrantsPolicyPolicyTextBlock', window );">Financial Instruments with Characteristics of Both Liabilities and Equity</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments with Characteristics of Both Liabilities and Equity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 480-10, and </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company&#8217;s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company&#8217;s outstanding warrants are classified as equity as of and for the years ended December&#160;31, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company&#8217;s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Accrued Research and Development and Clinical Trial Costs</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#8217;s behalf, pursuant to development and consulting agreements in place. The Company&#8217;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company&#8217;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received </span></div>marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div>The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#8220;ownership change&#8221; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change occurs, the Company&#8217;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the same period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive common shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net earnings (loss) per share when the effect is anti-dilutive.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of shares of common stock used in the basic and diluted net income (loss) per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Awards</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company&#8217;s market-traded shares best represents its expected volatility. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend&#8212;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span>The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div>The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM, in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM has been identified as the Chief </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer, who reviews financial results at a consolidated level only. The Company views its operations and manages its business as one operating and reportable segment as the Company has devoted substantially all of its resources to drug discovery and development activities through conducting preclinical studies and clinical trials associated with its programs, all of which aim to discover and develop biologic therapeutic candidates.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The CODM assesses performance for the biologic therapeutic segment and decides how to allocate resources based on the consolidated net income (loss) as reported on its consolidated income statement. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The segment depreciation expense, interest expense, interest income, and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. </span></div>The Company&#8217;s revenues to date under this segment have been derived from licenses with collaboration partners and grant awards, and the Company has not generated any revenue from the commercial sale of approved therapeutic products (see Note 6). As a result, the Company has incurred operating losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its therapeutic candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval. The CODM evaluates the Company's operating results and allocates resources using net income (loss) and the components of operating expense, together with information on the progression and results of clinical trial activities, to advance the Company's therapeutic pipeline and to best support the long-term growth of the Company&#8217;s overall business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvement to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to enhance the transparency and decision usefulness of income tax disclosures. Two primary enhancements related to this ASU include disaggregating existing income tax disclosures relating to the effective tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025 and applied it prospectively, as disclosed in Note 8, Income Taxes. The adoption did not have a material impact on our consolidated financial statements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued but Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, which requires additional disclosure about specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this accounting standard update on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ScheduleOfMergerTransactionTableTextBlock', window );">Schedule of Merger Transaction</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a gain on the transaction of $2.0 billion during the year ended December 31, 2024, which consisted of the following components (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger consideration for common stock, warrants, and stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,727,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of Amended 2020 Loans assumed by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">211,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs paid by Acquirer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total gain recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,021,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Measurements On a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,870&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.342%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December&#160;31, 2025 and December&#160;31, 2024 (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED<br/>DECEMBER&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Segment net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Merger-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">68,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Personnel</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">22,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(5,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,021,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other segment expenses</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Segment and consolidated net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Other segment items consist of the gain on transaction from the Merger, discussed above.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other segment expenses include provision for income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ScheduleOfMergerTransactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Merger Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ScheduleOfMergerTransactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,566&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,382&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company&#8217;s therapeutics. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,519&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,854&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,093&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(11,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,893)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,733&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for each of the years ended December 31, 2025 and December&#160;31, 2024, and consisted of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,794&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,796&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company&#8217;s usage of third-party CROs for management of clinical trials. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company&#8217;s usage of third-party CDMOs for clinical and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company&#8217;s usage of third parties for other research and development efforts. See &#8220;Accrued Research and Development Clinical Trial Costs&#8221; in Note 1 for further discussion of the components of research and development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, the Company&#8217;s outstanding debt balance under the 2025 Loan Agreement consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount and final payment fee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100,559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interest-only period will continue through February 2028, with principal payments beginning in March 2028. Future principal payments and final fee payments will be made as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">DECEMBER 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">43,478&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">52,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">109,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(8,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">100,559&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance as of December&#160;31, 2025 and December&#160;31, 2024 consisted of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,660&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future equity grants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Common Stock Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity under its 2024 Plan for the year ended December 31, 2025 is as follows (in thousands, except for per share data and years):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term <br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,660&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">17.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">220,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">81,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock options granted under the 2024 Plan using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the years ended December 31, 2025 and December&#160;31, 2024 were as follows:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.91&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.56&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">86.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options under the 2024 Plan and 2017 Plan consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,875&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">58,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock', window );">Schedule of License and Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company&#8217;s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Scithera, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement and Arrangement Other than Collaborative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of License And Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income (loss) before income taxes are as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,053)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss provision for before income taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140,053)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,687,574&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense were as follows for the years ended December 31, 2025 and December&#160;31, 2024, respectively (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Federal income taxes at 21%</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(29,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">29,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) 50% or more of our state tax provision relates to the California state jurisdiction.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax expense at federal statutory rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">354,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense, net of federal benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(28,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of deferred tax assets and liabilities upon Transaction with Acquirer </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">195,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable gain related to Transaction with Acquirer</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(410,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">336(e) election</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(124,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 research and development capitalization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">15,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">53,721&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23,983&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(52,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(21,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets after valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,194&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,194)</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to current year tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock', window );">Schedule of Operating Lease, by Balance Sheet Location</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The operating right-of-use asset and operating lease liability as of December&#160;31, 2025 and December&#160;31, 2024 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,338&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Maturity</a></td>
<td class="text"><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental commitments for the Company&#8217;s operating leases reconciled to the operating lease liability are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,453&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset And Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 30, 2024 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th"><div>May 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>distribution</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerExchangeRatioProRateBasisPercentage', window );">Exchange ratio, pro-rate basis</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare', window );">Sale of stock, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare', window );">Sale of stock, right per share, contingency | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare', window );">Sale of stock, price per share, contingency (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Consideration transferred, other</a></td>
<td class="nump">$ 68,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Nonmonetary transaction, gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,021,498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,729,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,187,000<span></span>
</td>
<td class="nump">106,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,220,000<span></span>
</td>
<td class="nump">152,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,870,000<span></span>
</td>
<td class="nump">$ 5,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EarningsDistributionRatio', window );">Distribution ratio | distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,870,000<span></span>
</td>
<td class="nump">$ 5,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870,000<span></span>
</td>
<td class="nump">5,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870,000<span></span>
</td>
<td class="nump">5,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spinoff transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563,754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember', window );">Merger consideration for common stock, warrants, and stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Nonmonetary transaction, gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inbx_AventisIncMember', window );">Aventis Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember', window );">Phylaxis BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod', window );">Equity method investment, ownership percentage, increase during period (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Aventis Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EarningsDistributionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Distribution Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EarningsDistributionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerExchangeRatioProRateBasisPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Exchange Ratio, Pro-Rate Basis, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerExchangeRatioProRateBasisPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (t)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481423/505-60-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inbx_AventisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inbx_AventisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inbx_PhylaxisBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Total gain recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,021,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember', window );">Merger consideration for common stock, warrants, and stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Total gain recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_LoansAssumedByAcquirerMember', window );">Book value of Amended 2020 Loans assumed by Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Total gain recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember', window );">Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Total gain recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_TransactionCostsPaidByAcquirerMember', window );">Transaction costs paid by Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Total gain recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (t)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=inbx_MergerConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_LoansAssumedByAcquirerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=inbx_LoansAssumedByAcquirerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=inbx_TransactionCostsPaidByAcquirerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=inbx_TransactionCostsPaidByAcquirerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 5,870<span></span>
</td>
<td class="nump">$ 5,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">5,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">5,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">5,870<span></span>
</td>
<td class="nump">5,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">3,642<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">3,501<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="nump">2,019,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Gain related to transaction with Acquirer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,021,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(140,055)<span></span>
</td>
<td class="nump">1,687,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=inbx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and development expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ResearchAndDevelopmentExpensePersonnel', window );">Personnel</a></td>
<td class="nump">35,372<span></span>
</td>
<td class="nump">72,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ResearchAndDevelopmentExpenseClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">35,339<span></span>
</td>
<td class="nump">47,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ResearchAndDevelopmentExpenseContractManufacturing', window );">Contract manufacturing</a></td>
<td class="nump">19,590<span></span>
</td>
<td class="nump">55,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility', window );">Equipment, depreciation, and facility</a></td>
<td class="nump">10,227<span></span>
</td>
<td class="nump">9,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">17,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_GeneralAndAdministrativeExpenseMergerRelated', window );">Merger-related</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">68,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_GeneralAndAdministrativeExpensePersonnel', window );">Personnel</a></td>
<td class="nump">14,481<span></span>
</td>
<td class="nump">37,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative</a></td>
<td class="nump">8,816<span></span>
</td>
<td class="nump">22,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(5,028)<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer', window );">Gain related to transaction with Acquirer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,021,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (140,055)<span></span>
</td>
<td class="nump">$ 1,687,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_GeneralAndAdministrativeExpenseMergerRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense, Merger-Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_GeneralAndAdministrativeExpenseMergerRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_GeneralAndAdministrativeExpensePersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense, Personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_GeneralAndAdministrativeExpensePersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ResearchAndDevelopmentExpenseClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ResearchAndDevelopmentExpenseClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ResearchAndDevelopmentExpenseContractManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Contract Manufacturing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ResearchAndDevelopmentExpenseContractManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Equipment, Depreciation, And Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ResearchAndDevelopmentExpensePersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ResearchAndDevelopmentExpensePersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 845<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482864/845-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (t)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=inbx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=inbx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClinicalTrailsPrepaidExpenseCurrent', window );">Clinical trials</a></td>
<td class="nump">$ 4,566<span></span>
</td>
<td class="nump">$ 3,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent', window );">Clinical drug substance and product manufacturing</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_PrepaidLicenseCurrent', window );">Licenses</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent', window );">Outside research and development services</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">$ 8,435<span></span>
</td>
<td class="nump">$ 7,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClinicalTrailsPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trails, Prepaid Expense Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClinicalTrailsPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outside Research And Development Services, Prepaid Expense Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_PrepaidLicenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid License Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_PrepaidLicenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 14,854<span></span>
</td>
<td class="nump">$ 15,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(11,121)<span></span>
</td>
<td class="num">(8,893)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9,519<span></span>
</td>
<td class="nump">9,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,984<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Total depreciation and amortization expense</a></td>
<td class="nump">$ 2,483<span></span>
</td>
<td class="nump">$ 2,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Total depreciation and amortization expense</a></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Total depreciation and amortization expense</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AccruedClinicalTrialsCurrent', window );">Clinical trials</a></td>
<td class="nump">$ 10,794<span></span>
</td>
<td class="nump">$ 14,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">7,450<span></span>
</td>
<td class="nump">7,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent', window );">Clinical drug substance and product manufacturing</a></td>
<td class="nump">5,542<span></span>
</td>
<td class="nump">5,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent', window );">Other outside research and development</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AccruedInterestExpenseCurrent', window );">Interest expense</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 25,529<span></span>
</td>
<td class="nump">$ 29,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Drug Substance and Product Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedClinicalTrialsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedClinicalTrialsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedInterestExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedInterestExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Outside Research And Development, Other, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jan. 22, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,965<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentBalloonPaymentWriteOff', window );">Payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with 2025 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_AmortizationOfDebtDiscountPremiumAndAccretion', window );">Amortization of debt discount and accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding', window );">Percent of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares (in shares) | shares</a></td>
<td class="nump">140,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with 2025 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, final payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrincipalAndInterestTerm', window );">Debt instrument, principal and interest term</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Debt funded</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature', window );">Line of credit facility maximum borrowing capacity accordion feature</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">5.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">4.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent', window );">Percentage of principal amount for final payment</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrincipalAndInterestTerm', window );">Debt instrument, principal and interest term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue', window );">Percentage of principal amount for final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Periodic payment terms, final payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentPrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember', window );">2025 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtLiquidityThreshold', window );">Long term debt, minimum liquidity threshold</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember', window );">2025 Loan Agreement | Secured Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtLiquidityThreshold', window );">Long term debt, minimum liquidity threshold</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember', window );">2025 Loan Agreement | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtLiquidityThreshold', window );">Long term debt, minimum liquidity threshold</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_AmortizationOfDebtDiscountPremiumAndAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Debt Discount (Premium) and Accretion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_AmortizationOfDebtDiscountPremiumAndAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issuance As A Percent Of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentBalloonPaymentWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Balloon Payment, Write-Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentBalloonPaymentWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentPrincipalAndInterestTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal And Interest Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentPrincipalAndInterestTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Maximum Borrowing Capacity Accordion Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LongTermDebtLiquidityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Liquidity Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LongTermDebtLiquidityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Long-Term Debt (Details) - Secured Debt - Line of Credit<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 109,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(8,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, including debt discount and final payment fee</a></td>
<td class="nump">$ 100,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Maturities of Long-Term Debt (Details) - Secured Debt - Line of Credit<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">$ 43,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtMaturityAfterYearFour', window );">2030</a></td>
<td class="nump">13,348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total future minimum payments</a></td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt discount</a></td>
<td class="num">(8,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 100,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 30, 2024 </div>
<div>right </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>right </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 22, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,475,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,577,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,475,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">13,316,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,577,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,475,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOrUnitsAvailableForDistributions', window );">Distribution of shares (in shares)</a></td>
<td class="nump">1,157,926<span></span>
</td>
<td class="nump">1,157,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued/sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares in conversion of convertible securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,746,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant', window );">Sale of stock, right per share, contingency | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue', window );">Contingent payment in cash (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1', window );">Purchase price (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice', window );">Cancelled, threshold exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares of common stock issuable upon exercise of warrants, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember', window );">2020 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsPreFundedMember', window );">Warrants, Pre-Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantsOrRightsWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,747,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate1Member', window );">Class of Warrant or Right, Expiration Date 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate2Member', window );">Class of Warrant or Right, Expiration Date 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued/sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,621,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Warrants, Pre-Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,714,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.3499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Cancelled, Threshold Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Contingent Value Right Per Warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Contingent Value Right Per Warrant, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price of Warrants or Rights1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantsOrRightsWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Rights, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantsOrRightsWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOrUnitsAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock or units eligible for distribution to members or limited partners of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOrUnitsAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2020OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsPreFundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_WarrantsPreFundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=inbx_ClassOfWarrantOrRightExpirationDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">4,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,501<span></span>
</td>
<td class="nump">3,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=inbx_PreFundedWarrantsMember', window );">Pre-funded warrants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for future equity grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=inbx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=inbx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 30, 2024 </div>
<div>USD ($) </div>
<div>right </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice', window );">Merger consideration exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare', window );">Sale of stock, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare', window );">Sale of stock, right per share, contingency | right</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare', window );">Sale of stock, price per share, contingency (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice', window );">Cancelled, threshold exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember', window );">Scithera License Agreement | License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inbx_Plan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inbx_A2024PlanMember', window );">2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,138,000<span></span>
</td>
<td class="nump">$ 58,518,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized, currently available (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares upon exercise of stock options (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inbx_A2017PlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2017 Plan | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2024 Plan | Cliff Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Cancelled, Threshold Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inbx_Plan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inbx_Plan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inbx_A2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inbx_A2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inbx_A2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inbx_A2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inbx_A2024PlanMember', window );">2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,138<span></span>
</td>
<td class="nump">$ 58,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock issued and outstanding | Research and development | 2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
<td class="nump">36,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock issued and outstanding | General and administrative | 2024 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,604<span></span>
</td>
<td class="nump">$ 21,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inbx_A2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inbx_A2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details) - Options to purchase common stock issued and outstanding - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.91%<span></span>
</td>
<td class="nump">4.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.58%<span></span>
</td>
<td class="nump">86.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value (in dollars per share)</a></td>
<td class="nump">$ 13.32<span></span>
</td>
<td class="nump">$ 11.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details) - 2024 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(102,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(435,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">3,501,000<span></span>
</td>
<td class="nump">3,660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">1,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 15.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">17.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">15.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">16.06<span></span>
</td>
<td class="nump">$ 15.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 15.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 220,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, vested and exercisable (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, vested and exercisable</a></td>
<td class="nump">$ 81,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inbx_A2024PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inbx_A2024PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE REVENUE - Schedule of Total Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue | Scithera, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue | Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total license fee revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ScitheraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ScitheraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE REVENUE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundablePayment', window );">Nonrefundable, payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation', window );">Revenue, number of performance obligation, | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Amount allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember', window );">License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable', window );">Development milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember', window );">2seventy bio, Inc. | Initial Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement', window );">Number of programs related to collaborative agreement | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member', window );">Regeneron Pharmaceuticals, Inc. | Initial Programs, Program 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment', window );">Nonrefundable, upfront payment</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member', window );">Regeneron Pharmaceuticals, Inc. | License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember', window );">Scithera License Agreement | License fee revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized related to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number Of Related Programs To Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementDevelopmentMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Milestone Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementDevelopmentMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementNonrefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Nonrefundable Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementNonrefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_CollaborativeArrangementNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Nonrefundable Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_CollaborativeArrangementNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Excluding Assessed Tax, Number Of Performance Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inbx_LicenseNonAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_A2seventyBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_A2seventyBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_RegeneronPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inbx_ScitheraLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 30, 2024</div></th>
<th class="th"><div>May 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerExchangeRatioProRateBasisPercentage', window );">Exchange ratio, pro-rate basis</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_MergerOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOrUnitsAvailableForDistributions', window );">Distribution of shares (in shares)</a></td>
<td class="nump">1,157,926<span></span>
</td>
<td class="nump">1,157,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inbx_ServicesPerformedUnderTransitionServicesAgreementMember', window );">Services Performed Under Transition Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction service amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inbx_ServicesPerformedUnderTransitionServicesAgreementMember', window );">Services Performed Under Transition Services Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=inbx_SeverancePaymentsToFormerEmployeesMember', window );">Severance Payments To Former Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction service amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerExchangeRatioProRateBasisPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Exchange Ratio, Pro-Rate Basis, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerExchangeRatioProRateBasisPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_MergerOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_MergerOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOrUnitsAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock or units eligible for distribution to members or limited partners of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOrUnitsAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inbx_ServicesPerformedUnderTransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inbx_ServicesPerformedUnderTransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=inbx_SeverancePaymentsToFormerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=inbx_SeverancePaymentsToFormerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (140,053)<span></span>
</td>
<td class="nump">$ 1,687,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">$ (140,053)<span></span>
</td>
<td class="nump">$ 1,687,574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax expense at federal statutory rate</a></td>
<td class="num">$ (29,411)<span></span>
</td>
<td class="nump">$ 354,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense, net of federal benefit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Unrecognized tax benefits (FIN 48)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount', window );">Elimination of deferred tax assets and liabilities upon Transaction with Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount', window );">Non-taxable gain related to Transaction with Acquirer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount', window );">336(e) election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">29,552<span></span>
</td>
<td class="num">(124,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21%</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, 336(e) Election, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Elimination Of Deferred Tax Assets And Liabilities Upon Transaction With Acquirer, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-Taxable Gain Related to Transaction With Acquirer, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 40,276<span></span>
</td>
<td class="nump">$ 4,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Section 174 research and development capitalization</a></td>
<td class="nump">8,183<span></span>
</td>
<td class="nump">15,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock compensation</a></td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">1,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">53,721<span></span>
</td>
<td class="nump">23,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(52,508)<span></span>
</td>
<td class="num">(21,789)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">2,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="num">(1,619)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="num">(2,194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax asset valuation allowance</a></td>
<td class="nump">$ 52,508,000<span></span>
</td>
<td class="nump">$ 21,789,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Recognized interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">183,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Increases (decreases) related to current year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases (decreases) related to current year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($) </div>
<div>contract</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth', window );">Initial base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseAnnualEscalations', window );">Annual escalations (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LesseeOperatingLeaseNumberOfContracts', window );">Lessee, operating lease, number of contracts | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OperatingLeaseAnnualEscalationsPercentage', window );">Operating lease, annual escalations percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OperatingLeasesContractAbatementPeriod', window );">Operating leases, contract abatement period</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OperatingLeaseAbatementPeriodAmount', window );">Operating lease, abatement period amount</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement', window );">Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, operating lease, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability', window );">Payments included in measurement of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining term of operating lease (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseAnnualEscalations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Escalations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseAnnualEscalations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Initial Base Rent Expense Per Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LesseeOperatingLeaseNumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LesseeOperatingLeaseNumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OperatingLeaseAbatementPeriodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Abatement Period Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OperatingLeaseAbatementPeriodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OperatingLeaseAnnualEscalationsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Escalations Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OperatingLeaseAnnualEscalationsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Payments Included in Measurement of Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_OperatingLeasesContractAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Contract Abatement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_OperatingLeasesContractAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">$ 5,535<span></span>
</td>
<td class="nump">$ 7,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">4,127<span></span>
</td>
<td class="nump">6,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">$ 6,453<span></span>
</td>
<td class="nump">$ 8,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Operating Lease Liability Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liability</a></td>
<td class="nump">6,453<span></span>
</td>
<td class="nump">$ 8,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liability</a></td>
<td class="num">(2,326)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of operating lease liability</a></td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="nump">$ 6,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 18, 2026</div></th>
<th class="th"><div>Jan. 13, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares (in shares)</a></td>
<td class="nump">21,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share)</a></td>
<td class="nump">$ 69.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember', window );">2025 Loan Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtLiquidityThreshold', window );">Long term debt, minimum liquidity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember', window );">2025 Loan Agreement | Secured Debt | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inbx_LongTermDebtLiquidityThreshold', window );">Long term debt, minimum liquidity threshold</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Debt funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Oxford Term Loans | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Debt funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Oxford Term Loans | Line of Credit | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inbx_LongTermDebtLiquidityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Liquidity Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inbx_LongTermDebtLiquidityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_A2025LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inbx_OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inbx_OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>164</ContextCount>
  <ElementCount>376</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - EQUITY COMPENSATION PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN</Role>
      <ShortName>EQUITY COMPENSATION PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - LICENSE REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEREVENUE</Role>
      <ShortName>LICENSE REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/DEBT</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - EQUITY COMPENSATION PLAN (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables</Role>
      <ShortName>EQUITY COMPENSATION PLAN (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - LICENSE REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEREVENUETables</Role>
      <ShortName>LICENSE REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/LICENSEREVENUE</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/INCOMETAXES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://inhibrx.com/role/LEASES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - DEBT - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails</Role>
      <ShortName>DEBT - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - DEBT - Schedule of Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails</Role>
      <ShortName>DEBT - Schedule of Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails</Role>
      <ShortName>EQUITY COMPENSATION PLAN - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails</Role>
      <ShortName>EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - LICENSE REVENUE - Schedule of Total Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails</Role>
      <ShortName>LICENSE REVENUE - Schedule of Total Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - LICENSE REVENUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LICENSEREVENUENarrativeDetails</Role>
      <ShortName>LICENSE REVENUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails</Role>
      <ShortName>LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>LEASES - Schedule of Operating Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inbx-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inhibrx.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://inhibrx.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="inbx-20251231.htm">inbx-20251231.htm</File>
    <File>inbx-20251231.xsd</File>
    <File>inbx-20251231_cal.xml</File>
    <File>inbx-20251231_def.xml</File>
    <File>inbx-20251231_lab.xml</File>
    <File>inbx-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>inbx-20251231_g1.jpg</File>
    <File>inbx-20251231_g2.jpg</File>
    <File>inbx-20251231_g3.jpg</File>
    <File>inbx-20251231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="560">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inbx-20251231.htm": {
   "nsprefix": "inbx",
   "nsuri": "http://inhibrx.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "inbx-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "inbx-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "inbx-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inbx-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "inbx-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inbx-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 304,
   "keyCustom": 72,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 26,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 1
   },
   "contextCount": 164,
   "entityCount": 1,
   "segmentCount": 58,
   "elementCount": 650,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 560,
    "http://xbrl.sec.gov/dei/2025": 40,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://inhibrx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://inhibrx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://inhibrx.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952156 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATION",
     "longName": "9952157 - Disclosure - OTHER FINANCIAL INFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://inhibrx.com/role/DEBT",
     "longName": "9952158 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952159 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN",
     "longName": "9952160 - Disclosure - EQUITY COMPENSATION PLAN",
     "shortName": "EQUITY COMPENSATION PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://inhibrx.com/role/LICENSEREVENUE",
     "longName": "9952161 - Disclosure - LICENSE REVENUE",
     "shortName": "LICENSE REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inbx:LicenseAndGrantRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inbx:LicenseAndGrantRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "9952162 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://inhibrx.com/role/INCOMETAXES",
     "longName": "9952163 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://inhibrx.com/role/LEASES",
     "longName": "9952164 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952165 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://inhibrx.com/role/SUBSEQUENTEVENTS",
     "longName": "9952166 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-164",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfMergerTransactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfMergerTransactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables",
     "longName": "9955513 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://inhibrx.com/role/DEBTTables",
     "longName": "9955514 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955515 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables",
     "longName": "9955516 - Disclosure - EQUITY COMPENSATION PLAN (Tables)",
     "shortName": "EQUITY COMPENSATION PLAN (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://inhibrx.com/role/LICENSEREVENUETables",
     "longName": "9955517 - Disclosure - LICENSE REVENUE (Tables)",
     "shortName": "LICENSE REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://inhibrx.com/role/INCOMETAXESTables",
     "longName": "9955518 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://inhibrx.com/role/LEASESTables",
     "longName": "9955519 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9955520 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "inbx:MergerExchangeRatioProRateBasisPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredOther1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails",
     "longName": "9955521 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Gain on Transaction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfMergerTransactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails",
     "longName": "9955522 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Fair Value Measurements on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails",
     "longName": "9955523 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Potentially Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails",
     "longName": "9955524 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Significant Expense Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails",
     "longName": "9955525 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "shortName": "OTHER FINANCIAL INFORMATION - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "inbx:ClinicalTrailsPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "inbx:ClinicalTrailsPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails",
     "longName": "9955526 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details)",
     "shortName": "OTHER FINANCIAL INFORMATION - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails",
     "longName": "9955527 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details)",
     "shortName": "OTHER FINANCIAL INFORMATION - Schedule of Depreciation and Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails",
     "longName": "9955528 - Disclosure - OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details)",
     "shortName": "OTHER FINANCIAL INFORMATION - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "inbx:AccruedClinicalTrialsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "inbx:AccruedClinicalTrialsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://inhibrx.com/role/DEBTNarrativeDetails",
     "longName": "9955529 - Disclosure - DEBT - Narrative (Details)",
     "shortName": "DEBT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-33",
      "name": "inbx:DebtInstrumentBalloonPaymentWriteOff",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
     "longName": "9955530 - Disclosure - DEBT - Schedule of Long-Term Debt (Details)",
     "shortName": "DEBT - Schedule of Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
     "longName": "9955531 - Disclosure - DEBT - Schedule of Maturities of Long-Term Debt (Details)",
     "shortName": "DEBT - Schedule of Maturities of Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955532 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
     "longName": "9955533 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
     "longName": "9955534 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details)",
     "shortName": "EQUITY COMPENSATION PLAN - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955535 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "EQUITY COMPENSATION PLAN - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
     "longName": "9955536 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details)",
     "shortName": "EQUITY COMPENSATION PLAN - Schedule of Fair Value of Stock Option Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails",
     "longName": "9955537 - Disclosure - EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details)",
     "shortName": "EQUITY COMPENSATION PLAN - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-126",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails",
     "longName": "9955538 - Disclosure - LICENSE REVENUE - Schedule of Total Revenue (Details)",
     "shortName": "LICENSE REVENUE - Schedule of Total Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
     "longName": "9955539 - Disclosure - LICENSE REVENUE - Narrative (Details)",
     "shortName": "LICENSE REVENUE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-143",
      "name": "inbx:CollaborativeArrangementNonrefundablePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "inbx:CollaborativeArrangementNonrefundablePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "9955540 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-33",
      "name": "inbx:MergerExchangeRatioProRateBasisPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails",
     "longName": "9955541 - Disclosure - INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details)",
     "shortName": "INCOME TAXES - Schedule of Income (Loss) Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955542 - Disclosure - INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "INCOME TAXES - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9955543 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955544 - Disclosure - INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "INCOME TAXES -Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://inhibrx.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9955545 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "9955546 - Disclosure - INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "INCOME TAXES - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://inhibrx.com/role/LEASESNarrativeDetails",
     "longName": "9955547 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails",
     "longName": "9955548 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "shortName": "LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
     "longName": "9955549 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)",
     "shortName": "LEASES - Schedule of Operating Lease Liability Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955550 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inbx-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "inbx_A2017PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "A2017PlanMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan",
        "label": "2017 Plan [Member]",
        "documentation": "2017 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_A2020OxfordTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "A2020OxfordTermLoansMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Loan Agreement",
        "label": "2020 Oxford Term Loans [Member]",
        "documentation": "2020 Oxford Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_A2024PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "A2024PlanMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Plan",
        "label": "2024 Plan [Member]",
        "documentation": "2024 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_A2025LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "A2025LoanAgreementMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Loan Agreement",
        "label": "2025 Loan Agreement [Member]",
        "documentation": "2025 Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_A2seventyBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "A2seventyBioIncMember",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2seventy bio, Inc.",
        "label": "2seventy bio, Inc. [Member]",
        "documentation": "2seventy bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r718"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AccruedClinicalDrugSubstanceAndProductManufacturingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical drug substance and product manufacturing",
        "label": "Accrued Clinical Drug Substance and Product Manufacturing, Current",
        "documentation": "Accrued Clinical Drug Substance and Product Manufacturing, Current"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_AccruedClinicalTrialsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AccruedClinicalTrialsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trials",
        "label": "Accrued Clinical Trials, Current",
        "documentation": "Accrued Clinical Trials, Current"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_AccruedInterestExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AccruedInterestExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Accrued Interest Expense, Current",
        "documentation": "Accrued Interest Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AccruedOutsideResearchAndDevelopmentOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other outside research and development",
        "label": "Accrued Outside Research And Development, Other, Current",
        "documentation": "Accrued Outside Research And Development, Other, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r103",
      "r524"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in-capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r718",
      "r1053"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r920",
      "r921",
      "r922",
      "r923",
      "r994",
      "r1057"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants in connection with 2025 Loan Agreement",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r23",
      "r72"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r815"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r775",
      "r785",
      "r818"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r810",
      "r819",
      "r823",
      "r831"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r361",
      "r370"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r57",
      "r272",
      "r1004"
     ]
    },
    "inbx_AmortizationOfDebtDiscountPremiumAndAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AmortizationOfDebtDiscountPremiumAndAccretion",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and accretion",
        "label": "Amortization of Debt Discount (Premium) and Accretion",
        "documentation": "Amortization of Debt Discount (Premium) and Accretion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of debt discount and non-cash interest expense",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r672",
      "r673",
      "r907",
      "r1004"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r87",
      "r105",
      "r125",
      "r128",
      "r129",
      "r162",
      "r169",
      "r193",
      "r196",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r423",
      "r425",
      "r463",
      "r509",
      "r510",
      "r515",
      "r593",
      "r663",
      "r664",
      "r674",
      "r718",
      "r726",
      "r727",
      "r739",
      "r943",
      "r944",
      "r1011"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r108",
      "r125",
      "r128",
      "r129",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r423",
      "r425",
      "r463",
      "r718",
      "r943",
      "r944",
      "r1011"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://inhibrx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768"
     ]
    },
    "inbx_AventisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "AventisIncMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aventis Inc",
        "label": "Aventis Inc [Member]",
        "documentation": "Aventis Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r419",
      "r691",
      "r692"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, other",
        "label": "Business Combination, Consideration Transferred, Tangible and Intangible Assets, Excluding Cash",
        "documentation": "Amount of tangible and intangible assets other than cash transferred by acquirer as part of consideration transferred in business combination. Includes, but is not limited to, business or subsidiary, or both, of acquirer transferred to former owner of acquiree."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r648"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets measured at fair value",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r995",
      "r996"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r61",
      "r124"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r61"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "inbx_ClassOfWarrantOrRightCancelledThresholdExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightCancelledThresholdExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled, threshold exercise price (in dollars per share)",
        "label": "Class Of Warrant Or Right, Cancelled, Threshold Exercise Price",
        "documentation": "Class Of Warrant Or Right, Cancelled, Threshold Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightContingentValueRightPerWarrant": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightContingentValueRightPerWarrant",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, right per share, contingency",
        "label": "Class Of Warrant Or Right, Contingent Value Right Per Warrant",
        "documentation": "Class Of Warrant Or Right, Contingent Value Right Per Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightContingentValueRightPerWarrantValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightContingentValueRightPerWarrantValue",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payment in cash (in dollars per share)",
        "label": "Class Of Warrant Or Right, Contingent Value Right Per Warrant, Value",
        "documentation": "Class Of Warrant Or Right, Contingent Value Right Per Warrant, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r132",
      "r305"
     ]
    },
    "inbx_ClassOfWarrantOrRightExpirationDate1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightExpirationDate1Member",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right, Expiration Date 1",
        "label": "Class of Warrant or Right, Expiration Date 1 [Member]",
        "documentation": "Class of Warrant or Right, Expiration Date 1"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightExpirationDate2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightExpirationDate2Member",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right, Expiration Date 2",
        "label": "Class of Warrant or Right, Expiration Date 2 [Member]",
        "documentation": "Class of Warrant or Right, Expiration Date 2"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of common stock outstanding",
        "label": "Class Of Warrant Or Right, Issuance As A Percent Of Common Stock Outstanding",
        "documentation": "Class Of Warrant Or Right, Issuance As A Percent Of Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase of shares (in shares)",
        "verboseLabel": "Shares of common stock issuable upon exercise of warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock issuable upon exercise of warrants, outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in dollars per share)",
        "label": "Class of Warrant or Right, Purchase Price of Warrants or Rights",
        "documentation": "Class of Warrant or Right, Purchase Price of Warrants or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in shares)",
        "label": "Class of Warrant or Right, Purchase Price of Warrants or Rights1",
        "documentation": "Class of Warrant or Right, Purchase Price of Warrants or Rights1"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClassOfWarrantsOrRightsWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClassOfWarrantsOrRightsWarrantsExercised",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised (in shares)",
        "label": "Class Of Warrants Or Rights, Warrants Exercised",
        "documentation": "Class Of Warrants Or Rights, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical drug substance and product manufacturing",
        "label": "Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current",
        "documentation": "Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ClinicalTrailsPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ClinicalTrailsPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trials",
        "label": "Clinical Trails, Prepaid Expense Current",
        "documentation": "Clinical Trails, Prepaid Expense Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "CollaborativeAgreementNumberOfRelatedProgramsToAgreement",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of programs related to collaborative agreement",
        "label": "Collaborative Agreement, Number Of Related Programs To Agreement",
        "documentation": "Collaborative Agreement, Number Of Related Programs To Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]",
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_CollaborativeArrangementDevelopmentMilestoneReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "CollaborativeArrangementDevelopmentMilestoneReceivable",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payment receivable",
        "label": "Collaborative Arrangement, Development Milestone Receivable",
        "documentation": "Collaborative Arrangement, Development Milestone Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_CollaborativeArrangementNonrefundablePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "CollaborativeArrangementNonrefundablePayment",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrefundable, payment",
        "label": "Collaborative Arrangement, Nonrefundable Payment",
        "documentation": "Collaborative Arrangement, Nonrefundable Payment"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_CollaborativeArrangementNonrefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "CollaborativeArrangementNonrefundableUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrefundable, upfront payment",
        "label": "Collaborative Arrangement, Nonrefundable Upfront Payment",
        "documentation": "Collaborative Arrangement, Nonrefundable Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 10)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r80",
      "r517",
      "r580"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r233",
      "r234",
      "r642",
      "r934",
      "r939"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r920",
      "r921",
      "r923",
      "r994",
      "r1052",
      "r1057"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r581"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r581",
      "r599",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value, 120,000,000 shares authorized as of December\u00a031, 2025 and December\u00a031, 2024; 14,577,609 and 14,475,904 shares issued and outstanding as of December\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r284",
      "r290",
      "r519",
      "r718"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Comprehensive Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r655"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount allocated to performance obligation",
        "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized related to performance obligation",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r942"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r942"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r910",
      "r915",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r842"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r842"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r844"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r844"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r846"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r844"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r837"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r838"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r838"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r836"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r836"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r836"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r839"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r841"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r841"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r842"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r845"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r843"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r840"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r125",
      "r127",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r239",
      "r240",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r266",
      "r273",
      "r274",
      "r276",
      "r431",
      "r474"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r35",
      "r36",
      "r77",
      "r79",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r707",
      "r910",
      "r911",
      "r912",
      "r919",
      "r935",
      "r936",
      "r937",
      "r1003",
      "r1005",
      "r1020"
     ]
    },
    "inbx_DebtInstrumentBalloonPaymentWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentBalloonPaymentWriteOff",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment fee",
        "label": "Debt Instrument, Balloon Payment, Write-Off",
        "documentation": "Debt Instrument, Balloon Payment, Write-Off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan",
        "totalLabel": "Total future minimum payments",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r277"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r279",
      "r474",
      "r475",
      "r707"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r252"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r431",
      "r512",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r707",
      "r910",
      "r911",
      "r912",
      "r919",
      "r1003",
      "r1005"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r707",
      "r910",
      "r911",
      "r912",
      "r919",
      "r935",
      "r936",
      "r937",
      "r1003",
      "r1005",
      "r1020"
     ]
    },
    "inbx_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number of Tranches",
        "documentation": "Debt Instrument, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment terms, final payment amount",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount for final payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent",
        "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount for final payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value",
        "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_DebtInstrumentPrepaymentFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentPrepaymentFee",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment fee",
        "label": "Debt Instrument, Prepayment Fee",
        "documentation": "Debt Instrument, Prepayment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_DebtInstrumentPrincipalAndInterestTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DebtInstrumentPrincipalAndInterestTerm",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, principal and interest term",
        "label": "Debt Instrument, Principal And Interest Term",
        "documentation": "Debt Instrument, Principal And Interest Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r32",
      "r70",
      "r71",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r431",
      "r512",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r707",
      "r910",
      "r911",
      "r912",
      "r919",
      "r1003",
      "r1005"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: debt discount",
        "negatedLabel": "Less: unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1002",
      "r1003",
      "r1005"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs and Other Debt-Related Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expense and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r78",
      "r394"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets after valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "inbx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 research and development capitalization",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails",
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Valuation allowance",
        "verboseLabel": "Deferred tax asset valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Property and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Total depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r118",
      "r162",
      "r174",
      "r196",
      "r649",
      "r663",
      "r664"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY COMPENSATION PLAN",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r325",
      "r356",
      "r357",
      "r359",
      "r686"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768",
      "r811"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "inbx_EarningsDistributionRatio": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EarningsDistributionRatio",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution ratio",
        "label": "Earnings Distribution Ratio",
        "documentation": "Earnings Distribution Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (loss) per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r116",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r152",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161",
      "r282",
      "r360",
      "r415",
      "r421",
      "r444",
      "r445",
      "r508",
      "r529",
      "r656"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r116",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161",
      "r282",
      "r360",
      "r415",
      "r421",
      "r444",
      "r445",
      "r508",
      "r529",
      "r656"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r160"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r690"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_EffectiveIncomeTaxRateReconciliation336eElectionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliation336eElectionAmount",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "336(e) election",
        "label": "Effective Income Tax Rate Reconciliation, 336(e) Election, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, 336(e) Election, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income taxes at 21%",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r131",
      "r380",
      "r405",
      "r690"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r690",
      "r910",
      "r916",
      "r980"
     ]
    },
    "inbx_EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of deferred tax assets and liabilities upon Transaction with Acquirer",
        "label": "Effective Income Tax Rate Reconciliation, Elimination Of Deferred Tax Assets And Liabilities Upon Transaction With Acquirer, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Elimination Of Deferred Tax Assets And Liabilities Upon Transaction With Acquirer, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-taxable gain related to Transaction with Acquirer",
        "label": "Effective Income Tax Rate Reconciliation, Non-Taxable Gain Related to Transaction With Acquirer, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Non-Taxable Gain Related to Transaction With Acquirer, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "inbx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Items",
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r690",
      "r910",
      "r916",
      "r980"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period of recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding stock options",
        "netLabel": "Options to purchase common stock issued and outstanding",
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r94",
      "r95",
      "r96",
      "r112",
      "r113",
      "r114",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r163",
      "r209",
      "r210",
      "r221",
      "r281",
      "r306",
      "r360",
      "r403",
      "r404",
      "r412",
      "r413",
      "r414",
      "r416",
      "r420",
      "r421",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r476",
      "r478",
      "r489",
      "r528",
      "r553",
      "r554",
      "r555",
      "r568",
      "r622"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r411",
      "r463",
      "r854",
      "r855",
      "r856",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest percentage (as a percent)",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r463"
     ]
    },
    "inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, ownership percentage, increase during period (as a percent)",
        "label": "Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period",
        "documentation": "Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r179",
      "r196",
      "r204",
      "r862",
      "r932"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Poplar Therapeutics",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r206",
      "r463"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r772",
      "r782",
      "r815"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r769",
      "r779",
      "r812"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r455",
      "r700"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r455",
      "r700"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurements On a Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r457",
      "r458",
      "r501",
      "r502",
      "r503",
      "r646",
      "r670",
      "r671",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r702",
      "r706"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r309",
      "r314",
      "r316",
      "r448",
      "r455",
      "r458",
      "r501",
      "r646",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r706"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r309",
      "r314",
      "r316",
      "r318",
      "r448",
      "r449",
      "r455",
      "r458",
      "r502",
      "r646",
      "r670",
      "r671",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r706"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r448",
      "r449",
      "r450",
      "r451",
      "r455",
      "r458",
      "r503",
      "r646",
      "r670",
      "r671",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r702",
      "r706"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r454",
      "r455",
      "r457",
      "r458",
      "r501",
      "r502",
      "r503",
      "r646",
      "r670",
      "r671",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r702",
      "r706"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures and other",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r25"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount",
        "label": "Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff",
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r602"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "inbx_GeneralAndAdministrativeExpenseMergerRelated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "GeneralAndAdministrativeExpenseMergerRelated",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related",
        "label": "General And Administrative Expense, Merger-Related",
        "documentation": "General And Administrative Expense, Merger-Related"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_GeneralAndAdministrativeExpensePersonnel": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "GeneralAndAdministrativeExpensePersonnel",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel",
        "label": "General And Administrative Expense, Personnel",
        "documentation": "General And Administrative Expense, Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r768"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r66"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r379"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r82",
      "r86",
      "r509",
      "r511",
      "r526",
      "r651",
      "r653",
      "r654",
      "r659",
      "r663",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r379"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r229",
      "r230",
      "r427",
      "r428",
      "r429",
      "r430",
      "r452",
      "r453",
      "r456",
      "r464",
      "r465",
      "r466",
      "r550",
      "r552",
      "r607",
      "r645",
      "r646",
      "r691",
      "r692",
      "r698",
      "r699",
      "r701",
      "r706",
      "r992",
      "r993",
      "r1023"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r427",
      "r428",
      "r429",
      "r430",
      "r452",
      "r453",
      "r456",
      "r464",
      "r465",
      "r466",
      "r550",
      "r552",
      "r607",
      "r645",
      "r646",
      "r691",
      "r692",
      "r698",
      "r699",
      "r701",
      "r706",
      "r992",
      "r993",
      "r1023"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r380",
      "r381",
      "r389",
      "r400",
      "r690",
      "r984"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r380",
      "r381",
      "r389",
      "r400",
      "r690",
      "r984"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r131",
      "r374",
      "r380",
      "r385",
      "r386",
      "r387",
      "r392",
      "r398",
      "r406",
      "r408",
      "r409",
      "r410",
      "r514",
      "r559",
      "r564",
      "r690"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/INCOMETAXESScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r93",
      "r125",
      "r150",
      "r151",
      "r162",
      "r177",
      "r196",
      "r378",
      "r380",
      "r407",
      "r530",
      "r651",
      "r653",
      "r654",
      "r690"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r376",
      "r377",
      "r392",
      "r393",
      "r397",
      "r402",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r690",
      "r980"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected income tax expense at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r690"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits (FIN 48)",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r980",
      "r981"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r980",
      "r981"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax expense, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r690",
      "r980"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R&amp;D credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r980",
      "r982"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r123",
      "r399",
      "r400"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Receivables from related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r858",
      "r906"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r810",
      "r819",
      "r823",
      "r831"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r835"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r835"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r835"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r270",
      "r280",
      "r672",
      "r673",
      "r1055"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r651",
      "r654",
      "r864"
     ]
    },
    "inbx_InterestIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "InterestIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Nonoperating",
        "documentation": "Interest Income, Nonoperating"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r122"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r484"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "inbx_LesseeOperatingLeaseAnnualEscalations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LesseeOperatingLeaseAnnualEscalations",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual escalations (as a percent)",
        "label": "Lessee, Operating Lease, Annual Escalations",
        "documentation": "Lessee, Operating Lease, Annual Escalations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LesseeOperatingLeaseInitialBaseRentExpensePerMonth",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial base rent per month",
        "label": "Lessee, Operating Lease, Initial Base Rent Expense Per Month",
        "documentation": "Lessee, Operating Lease, Initial Base Rent Expense Per Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r911",
      "r919",
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r911",
      "r919",
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r911",
      "r919",
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r911",
      "r919",
      "r1020"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "inbx_LesseeOperatingLeaseNumberOfContracts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LesseeOperatingLeaseNumberOfContracts",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, number of contracts",
        "label": "Lessee, Operating Lease, Number Of Contracts",
        "documentation": "Lessee, Operating Lease, Number Of Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining term of operating lease (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r1007"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease extension term (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease agreement term (in years)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://inhibrx.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r35",
      "r36",
      "r37",
      "r40",
      "r41",
      "r42",
      "r45",
      "r125",
      "r128",
      "r129",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r424",
      "r425",
      "r426",
      "r463",
      "r579",
      "r658",
      "r674",
      "r739",
      "r943",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r81",
      "r521",
      "r718",
      "r726",
      "r727",
      "r910",
      "r914",
      "r933",
      "r1001"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r100",
      "r125",
      "r128",
      "r129",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r424",
      "r425",
      "r426",
      "r463",
      "r718",
      "r943",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_LicenseAgreementInitialProgramsAuthorizedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LicenseAgreementInitialProgramsAuthorizedMember",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Programs",
        "label": "License Agreement, Initial Programs Authorized [Member]",
        "documentation": "License Agreement, Initial Programs Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LicenseAgreementInitialProgramsAuthorizedProgramThreeMember",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Programs, Program 3",
        "label": "License Agreement, Initial Programs Authorized, Program Three [Member]",
        "documentation": "License Agreement, Initial Programs Authorized, Program Three"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_LicenseAndGrantRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LicenseAndGrantRevenueTextBlock",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LICENSE REVENUE",
        "label": "License And Grant Revenue [Text Block]",
        "documentation": "License And Grant Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r949"
     ]
    },
    "inbx_LicenseNonAffiliateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LicenseNonAffiliateMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee revenue",
        "label": "License, Non-Affiliate [Member]",
        "documentation": "License, Non-Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39"
     ]
    },
    "inbx_LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility maximum borrowing capacity accordion feature",
        "label": "Line Of Credit Facility Maximum Borrowing Capacity Accordion Feature",
        "documentation": "Line Of Credit Facility Maximum Borrowing Capacity Accordion Feature"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Liquidity [Policy Text Block]",
        "documentation": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_LoansAssumedByAcquirerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LoansAssumedByAcquirerMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book value of Amended 2020 Loans assumed by Acquirer",
        "label": "Loans Assumed By Acquirer [Member]",
        "documentation": "Loans Assumed By Acquirer"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term debt, including debt discount and final payment fee",
        "terseLabel": "Total debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r126",
      "r135",
      "r263",
      "r278",
      "r512",
      "r670",
      "r671",
      "r707",
      "r1021"
     ]
    },
    "inbx_LongTermDebtLiquidityThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LongTermDebtLiquidityThreshold",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term debt, minimum liquidity threshold",
        "label": "Long Term Debt, Liquidity Threshold",
        "documentation": "Long Term Debt, Liquidity Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r126",
      "r135",
      "r268",
      "r512"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r126",
      "r135",
      "r268",
      "r512"
     ]
    },
    "inbx_LongTermDebtMaturityAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "LongTermDebtMaturityAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "documentation": "Long-Term Debt, Maturity, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, including final payment fee",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r22",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r677",
      "r679",
      "r720",
      "r724",
      "r1022",
      "r1024",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r235",
      "r236",
      "r237",
      "r238",
      "r320",
      "r351",
      "r352",
      "r353",
      "r371",
      "r451",
      "r506",
      "r549",
      "r551",
      "r558",
      "r571",
      "r572",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r667",
      "r675",
      "r685",
      "r691",
      "r693",
      "r694",
      "r702",
      "r703",
      "r704",
      "r705",
      "r721",
      "r945",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "inbx_MaximumPotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "MaximumPotentialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum potential milestone payments",
        "label": "Maximum Potential Milestone Payments",
        "documentation": "Maximum Potential Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "inbx_MergerConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "MergerConsiderationMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger consideration for common stock, warrants, and stock options",
        "label": "Merger Consideration [Member]",
        "documentation": "Merger Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_MergerExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "MergerExchangeRatio",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "label": "Merger, Exchange Ratio",
        "documentation": "Merger, Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_MergerExchangeRatioProRateBasisPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "MergerExchangeRatioProRateBasisPercentage",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio, pro-rate basis",
        "label": "Merger, Exchange Ratio, Pro-Rate Basis, Percentage",
        "documentation": "Merger, Exchange Ratio, Pro-Rate Basis, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_MergerOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "MergerOwnershipPercentage",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Merger, Ownership Percentage",
        "documentation": "Merger, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r235",
      "r236",
      "r237",
      "r238",
      "r320",
      "r351",
      "r352",
      "r353",
      "r371",
      "r451",
      "r506",
      "r549",
      "r551",
      "r558",
      "r571",
      "r572",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r667",
      "r675",
      "r685",
      "r691",
      "r693",
      "r694",
      "r702",
      "r703",
      "r704",
      "r721",
      "r945",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r677",
      "r679",
      "r720",
      "r724",
      "r1022",
      "r1024",
      "r1025",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "inbx_NetAssetsAndLiabilitiesAssumedByAcquirerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "NetAssetsAndLiabilitiesAssumedByAcquirerMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer",
        "label": "Net Assets And Liabilities Assumed By Acquirer [Member]",
        "documentation": "Net Assets And Liabilities Assumed By Acquirer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r63",
      "r83",
      "r96",
      "r98",
      "r109",
      "r110",
      "r114",
      "r125",
      "r128",
      "r129",
      "r134",
      "r139",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r155",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r282",
      "r285",
      "r287",
      "r291",
      "r360",
      "r415",
      "r421",
      "r445",
      "r463",
      "r527",
      "r600",
      "r620",
      "r621",
      "r651",
      "r653",
      "r654",
      "r737",
      "r943"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r810",
      "r819"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "inbx_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Noncash Operating Lease Expense",
        "documentation": "Noncash Operating Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonmonetaryTransactionGainLossRecognizedOnTransfer",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain related to transaction with Acquirer",
        "verboseLabel": "Nonmonetary transaction, gain",
        "netLabel": "Total gain recognized",
        "label": "Nonmonetary Transaction, Gain (Loss) Recognized on Transfer",
        "documentation": "Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r487",
      "r488"
     ]
    },
    "inbx_NonmonetaryTransactionGainLossRecognizedOnTransferNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "NonmonetaryTransactionGainLossRecognizedOnTransferNet",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash gain on transaction with Acquirer",
        "label": "Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net",
        "documentation": "Nonmonetary Transaction, Gain (Loss) Recognized On Transfer, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonmonetaryTransactionTypeAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonmonetary Transaction Type [Axis]",
        "label": "Nonmonetary Transaction Type [Axis]",
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r488",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonmonetaryTransactionTypeDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonmonetary Transaction Type [Domain]",
        "label": "Nonmonetary Transaction Type [Domain]",
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r488",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "verboseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r917",
      "r918"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r926"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r666",
      "r926"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r651",
      "r654",
      "r659",
      "r925",
      "r927",
      "r928",
      "r929",
      "r930"
     ]
    },
    "inbx_OperatingLeaseAbatementPeriodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OperatingLeaseAbatementPeriodAmount",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, abatement period amount",
        "label": "Operating Lease, Abatement Period Amount",
        "documentation": "Operating Lease, Abatement Period Amount"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_OperatingLeaseAnnualEscalationsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OperatingLeaseAnnualEscalationsPercentage",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, annual escalations percentage",
        "label": "Operating Lease, Annual Escalations Percentage",
        "documentation": "Operating Lease, Annual Escalations Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "verboseLabel": "Current",
        "negatedTerseLabel": "Less: current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of operating lease liability",
        "verboseLabel": "Non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments included in measurement of lease liability",
        "label": "Operating Lease, Payments Included in Measurement of Lease Liability",
        "documentation": "Operating Lease, Payments Included in Measurement of Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating right-of-use asset",
        "verboseLabel": "Operating right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r709"
     ]
    },
    "inbx_OperatingLeasesContractAbatementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OperatingLeasesContractAbatementPeriod",
     "presentation": [
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, contract abatement period",
        "label": "Operating Leases, Contract Abatement Period",
        "documentation": "Operating Leases, Contract Abatement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r860",
      "r908"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r718"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other general and administrative",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r1056"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants issued to lender in conjunction with 2025 Loan Agreement (as defined in Note 3)",
        "label": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred",
        "documentation": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r697"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "inbx_OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside research and development services",
        "label": "Outside Research And Development Services, Prepaid Expense Current",
        "documentation": "Outside Research And Development Services, Prepaid Expense Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r774",
      "r784",
      "r817"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r777",
      "r787",
      "r820"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r777",
      "r787",
      "r820"
     ]
    },
    "inbx_OxfordTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "OxfordTermLoansMember",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford Term Loans",
        "label": "Oxford Term Loans [Member]",
        "documentation": "Oxford Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "inbx_PaymentsOfDebtIssuanceCostsSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "PaymentsOfDebtIssuanceCostsSecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of third-party fees associated with debt",
        "label": "Payments of Debt Issuance Costs, Secured Debt",
        "documentation": "Payments of Debt Issuance Costs, Secured Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "inbx_PhylaxisBioScienceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "PhylaxisBioScienceLLCMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phylaxis BioScience, LLC",
        "label": "Phylaxis BioScience, LLC [Member]",
        "documentation": "Phylaxis BioScience, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_Plan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "Plan2017Member",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan",
        "label": "Plan 2017 [Member]",
        "documentation": "2017 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "inbx_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants issued and outstanding",
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r293"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r581"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r581",
      "r599",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December\u00a031, 2025 and December\u00a031, 2024",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r284",
      "r289",
      "r518",
      "r718"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expense and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "inbx_PrepaidLicenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "PrepaidLicenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPrepaidExpenseandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses",
        "label": "Prepaid License Current",
        "documentation": "Prepaid License Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt funded",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r562"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of debt",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r507",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r647",
      "r650",
      "r653",
      "r654",
      "r677",
      "r678",
      "r719",
      "r721",
      "r722",
      "r725",
      "r728",
      "r857",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r940",
      "r941",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r507",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r647",
      "r650",
      "r653",
      "r654",
      "r677",
      "r678",
      "r719",
      "r721",
      "r722",
      "r725",
      "r728",
      "r857",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r940",
      "r941",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r484"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r102",
      "r525"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r484",
      "r513",
      "r525",
      "r718"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r91",
      "r92",
      "r523"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r484"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r235",
      "r236",
      "r237",
      "r238",
      "r308",
      "r320",
      "r351",
      "r352",
      "r353",
      "r359",
      "r371",
      "r451",
      "r504",
      "r505",
      "r506",
      "r549",
      "r551",
      "r558",
      "r571",
      "r572",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r667",
      "r675",
      "r685",
      "r691",
      "r693",
      "r694",
      "r702",
      "r703",
      "r704",
      "r705",
      "r721",
      "r731",
      "r938",
      "r945",
      "r998",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r235",
      "r236",
      "r237",
      "r238",
      "r308",
      "r320",
      "r351",
      "r352",
      "r353",
      "r359",
      "r371",
      "r451",
      "r504",
      "r505",
      "r506",
      "r549",
      "r551",
      "r558",
      "r571",
      "r572",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r644",
      "r667",
      "r675",
      "r685",
      "r691",
      "r693",
      "r694",
      "r702",
      "r703",
      "r704",
      "r705",
      "r721",
      "r731",
      "r938",
      "r945",
      "r998",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r769",
      "r779",
      "r812"
     ]
    },
    "inbx_RegeneronPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "RegeneronPharmaceuticalsInc.Member",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regeneron Pharmaceuticals, Inc.",
        "label": "Regeneron Pharmaceuticals, Inc. [Member]",
        "documentation": "Regeneron Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r203",
      "r315",
      "r319",
      "r493",
      "r494",
      "r516",
      "r522",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r630",
      "r1054"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r493",
      "r494",
      "r495",
      "r496",
      "r516",
      "r522",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r630"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction service amount",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r493",
      "r494",
      "r1010"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r1010"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r203",
      "r493",
      "r494",
      "r496",
      "r603",
      "r604",
      "r607"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r203",
      "r315",
      "r319",
      "r493",
      "r494",
      "r516",
      "r522",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r630",
      "r1010",
      "r1054"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r494",
      "r497",
      "r565",
      "r566",
      "r567",
      "r605",
      "r606",
      "r607",
      "r627",
      "r629"
     ]
    },
    "inbx_RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows",
      "http://inhibrx.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of operating lease liability and right-of-use asset in connection with 2024 Lease Agreement",
        "label": "Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement",
        "documentation": "Remeasurement Of Operating Lease Liability And Right-Of-Use Asset In Connection With 2024 Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r645",
      "r651",
      "r652",
      "r663",
      "r1019"
     ]
    },
    "inbx_ResearchAndDevelopmentExpenseClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseClinicalTrials",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trials",
        "label": "Research And Development Expense, Clinical Trials",
        "documentation": "Research And Development Expense, Clinical Trials"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ResearchAndDevelopmentExpenseContractManufacturing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseContractManufacturing",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing",
        "label": "Research And Development Expense, Contract Manufacturing",
        "documentation": "Research And Development Expense, Contract Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, depreciation, and facility",
        "label": "Research And Development Expense, Equipment, Depreciation, And Facility",
        "documentation": "Research And Development Expense, Equipment, Depreciation, And Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ResearchAndDevelopmentExpensePersonnel": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ResearchAndDevelopmentExpensePersonnel",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel",
        "label": "Research And Development Expense, Personnel",
        "documentation": "Research And Development Expense, Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Research and Development and Clinical Trial Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r770",
      "r780",
      "r813"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r771",
      "r781",
      "r814"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r778",
      "r788",
      "r821"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r72",
      "r520",
      "r556",
      "r557",
      "r563",
      "r582",
      "r718"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r209",
      "r210",
      "r221",
      "r281",
      "r360",
      "r403",
      "r404",
      "r412",
      "r413",
      "r414",
      "r416",
      "r420",
      "r421",
      "r432",
      "r434",
      "r435",
      "r437",
      "r443",
      "r476",
      "r478",
      "r553",
      "r555",
      "r568",
      "r1057"
     ]
    },
    "inbx_RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, number of performance obligation,",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Number Of Performance Obligation",
        "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Number Of Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Total license fee revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r115",
      "r125",
      "r128",
      "r129",
      "r162",
      "r170",
      "r171",
      "r191",
      "r196",
      "r200",
      "r201",
      "r202",
      "r208",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r463",
      "r509",
      "r511",
      "r663",
      "r697",
      "r726",
      "r727",
      "r943"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease, by Balance Sheet Location",
        "label": "Right-Of-Use Asset And Operating Lease Liability [Table Text Block]",
        "documentation": "Right-Of-Use Asset And Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, shares issued/sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofFairValueMeasurementsonaRecurringBasisDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuance",
        "label": "Schedule of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule of Common Stock Reserved For Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://inhibrx.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r26",
      "r27",
      "r32",
      "r70",
      "r71",
      "r670",
      "r672",
      "r911",
      "r919",
      "r1003",
      "r1020"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r690",
      "r980"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r411",
      "r463",
      "r854",
      "r855",
      "r856",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r915"
     ]
    },
    "inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ScheduleOfLicenseAndGrantRevenueTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of License and Grant Revenue",
        "label": "Schedule Of License And Grant Revenue [Table Text Block]",
        "documentation": "Schedule Of License And Grant Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "inbx_ScheduleOfMergerTransactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ScheduleOfMergerTransactionTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Merger Transaction",
        "label": "Schedule Of Merger Transaction [Table Text Block]",
        "documentation": "Schedule Of Merger Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofDepreciationandAmortizationExpenseDetails",
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r484"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r133",
      "r134",
      "r493",
      "r494",
      "r496",
      "r603",
      "r604",
      "r607"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate Fair Value",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r689"
     ]
    },
    "inbx_ScitheraInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ScitheraInc.Member",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUEScheduleofTotalRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scithera, Inc.",
        "label": "Scithera, Inc. [Member]",
        "documentation": "Scithera, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ScitheraLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ScitheraLicenseAgreementMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scithera License Agreement",
        "label": "Scithera License Agreement [Member]",
        "documentation": "Scithera License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/DEBTScheduleofLongTermDebtDetails",
      "http://inhibrx.com/role/DEBTScheduleofMaturitiesofLongTermDebtDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r162",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r202",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r231",
      "r232",
      "r418",
      "r419",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r662",
      "r663",
      "r664",
      "r668",
      "r723",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expenses",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r182",
      "r183",
      "r196",
      "r663"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r199",
      "r201",
      "r661",
      "r662",
      "r665"
     ]
    },
    "inbx_ServicesPerformedUnderTransitionServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ServicesPerformedUnderTransitionServicesAgreementMember",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Performed Under Transition Services Agreement",
        "label": "Services Performed Under Transition Services Agreement [Member]",
        "documentation": "Services Performed Under Transition Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_SeverancePaymentsToFormerEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "SeverancePaymentsToFormerEmployeesMember",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Payments To Former Employees",
        "label": "Severance Payments To Former Employees [Member]",
        "documentation": "Severance Payments To Former Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized, currently available (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockBasedCompensationExpenseDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cliff Vesting",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Stock-Based Awards",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r329",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ]
    },
    "inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, per share in cash (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share",
        "documentation": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Cash Price Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share, contingency (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share",
        "documentation": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right, Cash Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, right per share, contingency",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share",
        "documentation": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Contingent Value Right Per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger consideration exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Exercise Price",
        "documentation": "Share-Based Payment Arrangement, Option, Exercise Price Range, Settled, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofFairValueofStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, vested and exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofSignificantExpenseCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r97",
      "r162",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r202",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r231",
      "r232",
      "r418",
      "r419",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r662",
      "r663",
      "r664",
      "r668",
      "r723",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r94",
      "r95",
      "r96",
      "r112",
      "r113",
      "r114",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r163",
      "r209",
      "r210",
      "r221",
      "r281",
      "r306",
      "r360",
      "r403",
      "r404",
      "r412",
      "r413",
      "r414",
      "r416",
      "r420",
      "r421",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r476",
      "r478",
      "r489",
      "r528",
      "r553",
      "r554",
      "r555",
      "r568",
      "r622"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r163",
      "r283",
      "r284",
      "r286",
      "r288",
      "r478",
      "r507",
      "r560",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r602",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r622",
      "r653",
      "r654",
      "r732",
      "r1054"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations",
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r163",
      "r203",
      "r283",
      "r284",
      "r286",
      "r288",
      "r478",
      "r507",
      "r560",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r602",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r622",
      "r653",
      "r654",
      "r732",
      "r1054"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r773",
      "r783",
      "r816"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future equity grants",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares upon exercise of warrants (in shares)",
        "terseLabel": "Issuance of shares in conversion of convertible securities (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r26",
      "r47",
      "r50",
      "r72",
      "r267"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares in Distribution (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r72",
      "r562",
      "r622",
      "r636"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails",
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r72",
      "r335"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of shares in Distribution",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r72",
      "r568",
      "r622",
      "r636",
      "r738"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares upon exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r50",
      "r51",
      "r72"
     ]
    },
    "us-gaap_StockOrUnitsAvailableForDistributions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOrUnitsAvailableForDistributions",
     "presentation": [
      "http://inhibrx.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution of shares (in shares)",
        "label": "Stock or Units Available for Distributions",
        "documentation": "Number of stock or units eligible for distribution to members or limited partners of the limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_StockholderEquitySpinoffTransactionDecreaseInCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "StockholderEquitySpinoffTransactionDecreaseInCommonStock",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of Former Parent\u2019s common stock, stock options, and warrants by the Acquirer (in shares)",
        "label": "Stockholder Equity, Spinoff Transaction, Decrease In Common Stock",
        "documentation": "Stockholder Equity, Spinoff Transaction, Decrease In Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://inhibrx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedBalanceSheets",
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r64",
      "r583",
      "r599",
      "r623",
      "r624",
      "r718",
      "r739",
      "r910",
      "r913",
      "r914",
      "r933",
      "r1001",
      "r1057"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r431",
      "r442",
      "r625",
      "r628",
      "r637"
     ]
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of Former Parent\u2019s common stock, stock options, and warrants by the Acquirer",
        "negatedTerseLabel": "Spinoff transaction",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r626"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r499"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r499"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r499"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r499"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r499"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://inhibrx.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r500"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://inhibrx.com/role/OTHERFINANCIALINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER FINANCIAL INFORMATION",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inhibrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "inbx_TransactionCostsPaidByAcquirerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "TransactionCostsPaidByAcquirerMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofGainonTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs paid by Acquirer",
        "label": "Transaction Costs Paid By Acquirer [Member]",
        "documentation": "Transaction Costs Paid By Acquirer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://inhibrx.com/role/LICENSEREVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r390",
      "r689"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increases (decreases) related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual for interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r689"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r689"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://inhibrx.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increases (decreases) related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r689"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r164",
      "r165",
      "r166",
      "r167",
      "r509",
      "r511",
      "r657"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPotentiallyDilutiveSecuritiesDetails",
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "verboseLabel": "Warrants issued and outstanding",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r733",
      "r734",
      "r735",
      "r736"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails",
      "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise period",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r998",
      "r999"
     ]
    },
    "inbx_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments with Characteristics of Both Liabilities and Equity",
        "label": "Warrants, Policy [Policy Text Block]",
        "documentation": "Warrants, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "inbx_WarrantsPreFundedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://inhibrx.com/20251231",
     "localname": "WarrantsPreFundedMember",
     "presentation": [
      "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Pre-Funded",
        "label": "Warrants, Pre-Funded [Member]",
        "documentation": "Warrants, Pre-Funded"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r158"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r158"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://inhibrx.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing earnings (loss) per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://inhibrx.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "60",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481423/505-60-25-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "845",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0002007919-26-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0002007919-26-000006-xbrl.zip
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M=+5.QG& #2DLCCM)IFTFZ_M()#TE78> &\TA&!AZ>(IU;DR=XD3T>>2&$"S
MY;AF/Z[Q!9DJG>Y0*63WULI^>Q(EJ?],2:H:Q<IO9*P_S9)>40-<&5F^>&0I
M3-\K;=,WC;)ZM])8^-BF2LA9ILZ?[GQ*S'-<7IP_D"$#X<W<0^E+3V"_ C;?
M\B@<*A_WE/_$&&V<[[8+(2_9#%_Y ^[)O[EIW' 2_YHI\V9ZKO/"MMSMH-J%
M16-]&$[VM(\@Z@78;NTEO=SH17LZ@?9 C"!CZ,<N.IF"\<OSQ_>8U.*N4  _
MD(AJ/ $AAD4G\*2((V9#?CQ0VN'0$PNS&"WLI;0GTNX40MJ?U#HNM'1:WAU%
M,K8M=R@-=B4$=PEBD]<XL4C]LL?V80M7YH"-BS&=Q (_9))QW %+<NK#!#UA
M33_>TNB"#"/4!JRT4""90$PW4KEQ%TX2,&<*+#CU,WZ;W15A"KKTY$6/GADY
M<S>5?2U"_"SV+7(&.GF4WK?(LV,&V;3KUA$(:4C/P'@^P[/?G!BP^TT!$SV\
M&RV"YD8X02;JP#MM:,,[-1.0GF-? 1E#,CK45A/$N[5Z*O+(%'!2ZMB'(10H
M;W:F".F9+BL8<YJD4W1,,)7Y62V8E(41/<WC[I.+-B[<$H4P*%GWF5@4K?ZQ
M45DNQ+K#[* XI&AR8.1J/BZS[@S,K-@@^5J7M1IJ7+$'8M:7L-0!^M"!#,+X
M?"<0RK\BX'V"G6L3 E]/:UO<_H857.LN;8QS:TIP<\<(C&*0>>4N9#+.1)M9
MU3,H0.R0%WE?.B85+]#=K<E]V= CKECO56J$Z^?5K),-4*4C3_2N7PB]JU=J
M^SD(.L(AJ4=.-OYE]'&ZMSF&3*B357>:9@LW&2]M,>&1F)'/X@,0J"!,Q\DY
M-1#5UB#P1N:Q<HUBGXRD#S8VSB:N@\'T>MS[[D?CT$;S[P7*!=>"?_LB&R-8
M< NHLF,^C/ L'U"R:)0<'\D"&-/E/G/Y+47Q$";KLXRG>V89F@2],W'L0[ A
M(0XV8);I]4Y\('ZV:5.AT@>U0NBBBU]!9;&6K#MT7XASW QTWTF$3?Q L#(
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M-5/52N,BM^"[_BY<*GV%UZRS6[2%F*[7B;>[>;S=!HD3E:ZF<8K7@.G! -.
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M%'XB'_SRJ\Z_[5L5'F(95^6JRH-?\"S]]-^M[;KOY?X/4$L#!!0    ( !.
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MQR9/GM$W?LO+JCU[2?8W4$L#!!0    ( !. <UP-(?NMX@0  "@3   4
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MV(M$F5"EQ,?Z8NCIIN?^S4XAE.VE0DDSG,45??*NI\;=NS,A*YQ>J1^;/'E
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M12(',@'Y)-,*9$8DWT^)H<&:'$+Z_0Q0^*<W:3">A$@L]-LHP267\+9UF_J
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M1^?/;!)HZ@^IO?9&5:D-0+#0E%25K8VJ4@]HJ#).+'.JJ(92LX>._LB#;-J
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MG-\EH@OBUE=VB?6!8S-1(29-B+0G.?SJD8"]4Y48*"N9#\0A=GH/@U">",X
MF"4"N(;*G44IC5E5 !6LF)5#KBXA![$%S0;\I6M5C%^A/P7[_&:-R( Y5$4E
MB8I;^#&@1J&8 !8.B.5RA+%4\8./F&*>PW@\#L@N+6J(C@X;Q8.$'(ASRCH0
MK+TH*#P4H?';"S%:,7%+GV,-#[4DTN5NU-88O%R?<P]I%A8X4TF08# (<"";
M<I42G*CBGYCC:Y[6;N@ E^6K8W!TIAW(A:1/Z<'Q=9!J?H-7SY/@&G'=.N_/
M\#^*HBXDX;DIM=K;:M4; RMJXE2Q""!: @>#CC)4__'?D1A+U5U2>U'H,F,-
ME6E1EI:*AZ*'A;Q;<3(4D4J: SY]&8>DO;/W#)"%ZK4:UO<8Z\TGN;PLD4J$
M5Y+)9")!%4>LCG/FQ7_]B[O3,S5EO=W.!R>=COLQN@7[=$],6=FF<DT7QG")
MDBPI# UM9X'FV# D2&P7'T&S$74A5::&"1L@O[55R+@E,/3OD8H K*G!)1X4
M,E:4J62(=5^,_8YGO^)@S%(_R!^$?2P\O,4(^+T;#YV5U!9W-[7%CZDMYJ9N
M%<BYY+%OOWE]EEJ],VY#TW(^*A?1X_>X=_\>>[ D]4L63_:[K['ALVL4!O":
M>HNZWU5ZCPD2-4$9  VI'\03$/=CX5$8C.(]7"I,.I)P)L%$XNM0H$4QZ#\F
M(K4PS5CYJ='(3G4J$,K%)) 9JB'C& PXD7#V$4@6B9Y/R6E#.E\V)=T=%2Y*
M=69O-GR?:T2KGC1)MUH+]*6<S"AXJ,90F:K:!$<*@55E"^O7^!BR+ E ;*HW
MCR7JET$Z3DO65HSZ79J#_ ^4WJZ<8)1J"-:)=BT6,H[<V0GIJK V>"N(3O(#
M-YQKH4N]><EJ*2, :F%[+ZWCUX%4+B3R6^>3%<98<O6=\NI[S[1Z>MD^)FT$
MWA(T=2FQ()D=/*C 8S,%T%B N</6ZLT.SB+G"]@CG;V&TVEW>@W=%6"F;4!I
M1V!J@KU"-CE9"A/813P84 ."TX\7_VRZ;1?U8R>>8+74G]A=(9'*^8]4$ *G
M:;KDK<Z2Z01X WWHX. *'LN'17HVD^*4PR88B*:T-I4DC\83J<]4EH6TJTL?
M)G"/Z3U1]3E@"3A+ Q1>4&/)X\)FT-Q637DJ$"OZ\YGZE=> !VR03120KPT>
MH;\PR3A&*,;>5_Q[K_.#-IS ",W)PX:NNLSPH^)9%<(SSQL0?+*^WG(4W+IM
M#;>[EX[8P>^GJLV(/0M9DF-F C'-4N=\TV9#XW7=70@/.@YN10*L-#$[_:+_
M'#@'H)$=>'_D@<K&N\S[FA@$H$D,!GL3+1*L8^ZG@1^@),/GT-X'BZQ$-_2B
M!-]\Y[.7(HH'@7/9.N!'^6_EGF!/J+*IRGLR[HO9K5*8'^&J,E32''23:PXK
M A5,6\YYGJ2YX&!=<0+.V^ =.771R%+>BS#@9 )$(!#= .^ O:XLDV*;Z-6V
MX=]&\4-?82(9P0K[U3X<MD[?!O#I/IF61?\6C7_D<!2><FN1?5B]0,[QUX,/
M@VB0"(WF]$SL!;1L.CE*>XV&,>D;JIM PVQGFZGT3_DUZ*.:_E9?V'O'UC\^
MCC&^F *Z6C^:RPY*)&9-XS=P +5LHF5>N!]3^R3QC1-TK\=Y"F?,[2WHHEI>
ML;JMEG.,LH;T".. Q"^0TJ [P>B,#W(RZB@TMKUQB/> ^1/CDHWGDRQFW^A^
M@]C+,4B" 5MS$/A)<T@-!RA_A!!3(5_TU)=52WVT-7<"':.G"U4VG_"<-3=;
MP#54OL#$N-ZMCCA%71![! /E2L%>26A<8B 9JTU*$G,DX.<0G9Y3=E0G*"NU
ML[-$U"JSK?1^"W-4&YQ*FL"O]*6,M(N2'<,Y:-87Z/;!QT]!CW3<(H7$ZB]4
M9#G.MU+Q[TN#(/D\R!-R@*EXN(K^&Z]K.$7:X# 8(1NG)TRT)^W>U5!82:?W
MP:NTS[PX>N4OMQL85>VJ!'7%$)G[XB(B72!1.)N-VJ=!IA[2D?V^Z1:E&MJH
MAB:TO &(@_B&W<VESUEB=^.U6D"LW34/>=?3D#E4=NJA3B ]5T*MWIS[S,HS
M,;FOMK]B84L:Y>-?4K;9I;UCH.$ 3'.*VE#8#J0^,4+V_DL/RP+H!F]*>55]
M61A$;-&P/=]$&@*N1)H/,!_@SZBCF#!0V:U RFN<*E\"<"P2Z,,X MZ&50C$
MH_8?E'591<[4$;-@&PGPZ29 ,A235.[K?WS0@T."B(!"#WTH?P(_,-L\&K_'
MEQ6Q==N[K0ZCCFIFJ[ZL:+'5-EUQRQ>VVOQ<U;6%#RV^L+.Z=RVYLE7/;)F1
M#^Y69]GFQ,MTGET6>X(QF+2)]].;(.K?-L$BVW([7?=_AV[KWY/A&U!YLI_>
M&&W:^1B*Z"M?F5D]P./V,?CD[G4FMV_8P=QTZ7B*EJ^KZ\#\$D?6J3BR[3N.
M#'?^Y"/K+'5D*T74G27PM*)G,I_?PP%1EP!0I7GYX&;22R+M-WA^AB26/K.5
M8FUOE5AKABK4^\BO9)8(I?E\NMC2RL>K(^V:'-^O\E:?WMD_>^T'']\3\'=A
MG_-J+?YE=< ]^*R[]\-B%?"':CVKU=O=KKS4;KG5CRQZU79K9Z>WFE?MMMK;
MG96\JM?:WMO9O&GSIKV].]^T0$"Y50(JB6_XWQW#+Q1Y<YG9)'/(X^;\Q>_C
M_WU05]%3,7_QL1,M*OEN;V]G\$"^NWL?VR5/SCD[H0V;K6"PBX]EG3=^9?D^
M#A(IOL,3(#?+V_3=^V-RU"P\@4YO=ML)OV9E!'&/NOVRYW)Y=?#+D7-V['PZ
M^L?1Y[-S'%Y1.INE><I2$X=JM??SHG9^(3JLX:Y&V&+9_>9VU%EB1_=0['IM
MN%M%AZ\Q"OH) Z-?^*4+F%6E_]/(N>)U?>%]'29Q'OE-!61LY2/]#TMK1NSP
MU=?1?GR@>!P'OA_*9\2XZF%>E2ZH_UY*35C^^-;Y@,XBCW)$-T=BCN33Q1;%
M/&U?T,&,(^,N[>J>HUE"[5I\<K/#$>_G".[6'2O;;8MV=VO^[?8+]IZ\L\<O
M?@7'^OB/+\#\.UGF>F"X<2S_]T-9X7KL[Y%,;4TV]\]>F_B3Y6Q]"'MZ+G)Y
M,J-YKL&R+\*='O>-C=:[M%]_59&,>XF, AG_._>?Y1JW%8&89^KKM=SR_]O!
M_ZB,IQ!+LGFH$;:<P-Q<3M+Q1G'D)W$J$@\^UG".*&'/_$G+Q!K\$%-\/$KT
MQ@QDU<2""W\9S[-\C,F%T\E=Q:BU/*C_7N*<RB47@)W-=(QYY!XF0H<Y)C^K
M\X%#.+T\_'S()S7"@G_N;N5]==(_<C&.\Y0?\^"4@XC.&1[Z%9XZ7,7)567K
M+5^.V.FL23EBGCB?X7"YD[-S)<6XYC4<OZL^-)C%/.Z'5+>2X;()I:B(CX::
M9L$@\!I69TU*>"_UO<3."0G5TR-NZAQ]JH<HA@BJK'^J'[02!,OM/>$$A$>E
M(T$ZDJ7Y <7:=&<54'U2.9.R5QI>T+^G(WII'@&5M7.'SI9S1G6/S5&,7=(\
M,2FRNPE*U!L#MAE,\%PI-]U4)C2JJB0;3&*J^K'!Y1FAKJW2W43AKI$<8^'1
M=.; 5:$%-1/F@J'#+X?6##^K16%C9O"":H'0<KY([-Y7#&W"\^03LN!'!764
M;#G!5@!V#P6KG=\O,D(G'JZ8ZV]^"4+D+)<S4W"_P!*^.G\5X\D'YS"&'T[C
M:X%@<PY^:3CG T#71!?[P*(O8M@_'WX_%HG/YXH,'YL284\-P(PDH J) :5Z
M7P=^CNTS"2\(CE%Y9$B!PA9B%<V[<5H;7L3*G"*C_6L4WP!!#*55(8;U&8\N
MJNYLK0\7N^16]M.:LR]<JNHQ@YA!K0N9 FVFHTHGL1R@*)_6M8OI*BN"J4)1
MAA-G(N.)[I$3!@/9S$94Z,PE2:9Q+]59<VGXXEIPP=/O<'-J/Z+H7L.553SA
M,T7]A_8!1(!MQ1PL!QF )A1C\0G5%1$OU$V=5"W$'2-WZY5 OZ"R677Q-$.=
MJ-LA)WVK JUY!JF)FCB6*9:J.;I?!K@_BISH$A;>6\,TE*..0D/$-0=+5_VB
M<561I&^J[HP@+02F+MG4!4,W<:D&N"D1P;AX%=M<4Q-+*F:F"M ;6:Z +5Y;
M66K#"U"%F+JJ>%-^LP#ZO34OOWDEHIGDH%1A?$]1O*F<U83 K>7N+%A'L4*>
ME)9S3FAT+:V9O=0_::927K^;FJMA]2F\[PQ4&&R=C(GF1#CV#UQM&T4QMF/T
MU6"2TF=P\95QH[LHE(I>F#%2:[ZQS 16WR'/R"/4.3U..2P;W77GA!^I1JBZ
M@H@9(797I[/#30?8$RN.=,-&U>6-K6@X_.VEMUM/"7@ &LQ4=WI9W-7%ZK=2
MUA\:3H3L38U(+)I L&WFT.@IKDG6$Z4%MF'476I(!\HC0"VJHT(9@T-9ZHY#
MOQ>]^?%D:(N.F=]-TQ>J% <N.+,,3F[+J4^VT#5ITE H;ZDC.(D<,J!H:KN?
MZ%[?6LED W)>RT3Z7>JP21=>IKF/(UE)S&DML%YB<NAFTH,'2'V:FXJI*^[@
MF !J5%&GRG;+;7W6G)B^Z'%KW$D[Y*F' ],!"1LCR%OIY:8(61^AM_S67]G=
M4W:0Y$&(+-3N\:3W3:(-=@9G(1!%+4L:F[<W,T&=,1$W5:O8?DQ3F92P10[<
M]), 3?+)* CC%*R<*1:/!QH/4UV@7<Q2L<F-/!2V81?E8YF@OQ*0'&P_]B@5
M0UFL4E,/2S8-/8;3AF[UJ<8UI9(ZIL_6?*(]AE1F-PD-[(80,Y,NK=6N/>K?
M%E938=16##;6A;[K@O#"\M29.;-<^?O@/9-!E?C<Q*%O+#$RNK#U)O!PEBC<
M%SSVONJF1;IC =42VUXG-? !FS HG[[Q#"@1Q<U)="=:'C8(E,'%UL60)>H;
MBI(HE19;TH-E9)0B4=.6\[%::) 6O9N-0:C'IP%9T*RUEG-@1L\@(>D.I$M.
M/[0:'>'I!9'NRSLG3-6SS%30'0R,*N0.*L1/;,X .,*>5_C&>U3S;%!:3N,2
M5,FCHKR]U1[A*IQ>TL.WNSX>OL5=!I;;:]>]?Z_UY')+E'_6C8V=F24CM>I.
M!\ 0M(*'N&REA57BM5+3D+1\'/[5A+?(20:$LT7!A$\76]@RZ^KT^.+R&)1+
M#!3@M($T)E]X1+V5** :20\L19R@0--DFKHGCIB XH@7, 28X^1+G/@"WZ?W
M7UT<G'RFKG3\U4Z+2QE1.K/504^AX*:P93,%(XU4#25WL8D.15!H^=R!1C=[
M0'YM#ND&5LK"G774$F.PSP8CE;=K+K0_FJ06=.SBB=8;EP\TDC N>XF:6@=
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M;J(JW$JQY)9S,L:;!7( %%]J,HLZ(" 4=+V0[D>#1G7/_G[L3QN:31#1L^5
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M704P@VKE6P$@2D4V[57%[.1G2V6<XIA3S,>:-K3O/!'8 -6:_U!HK!;/-VO
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M+O8ZF[-Q?/;Y^.3BI#I;9;D:S?M<P^0YY=T0=P#CF'*=8#EN6V_ [:HU4Z<
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MG")FE3;!H?U">J"+_*Y#]6!XEG?6:]>"'QR;JC14,2E,12V",0YGMR8HQ:-
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M4/OD3RMZC*E!,44D6-5QFY0!2P:OB<AC)MNS^:K-1JN&\\E%#(*4#N(@2MN
M'8XVC'E%,O)J9#7;QMYM.M-!S6E&.XG"TI8_F-P(VG\E564Q^AE M\EBG#>(
M79>4KPO>A+U\4/W[ ]4;!RZ#)4Y5IVRN)T/8<U&]/]-]IFA;4W?<OQII%V?(
MS0Q5"=F"2L9VIU?F/60ZPX^,\*7A)^C.X.;G:BYZ90:I&:]'W:*(:13=1M!P
MS\@+6;3(T5/>94KCLTLE1-22-K.PP^H!6&YK/3=+BY.::%[W7#]#[I.MAY\X
M*SDSM\>LP5H7-[ O%WA;9Z9JBMA.ON?>2 37RD\W=Z951[C<P6$#R+F#4^E@
M2'?+G)PUHK1(KK([O2?22W*L\RXZO%M#A2B\'0':6WWBL5J1M-Y9).0FD5/%
M"[@S$D5>E-7"41UV>G.&<S%TE.)B>:K5Z9D:2WS0<F?#JC9\_,$*MB4+6\X1
M5>O/MXKC02[<*5J6O1!SLK14<D+QO3[#-]1#9+5'RP:UR87DSBNIR?F970SG
M8)A/!I'5P3I55;V5/@URMRW$)7LM=1<7,X-2MO1H8S5.VFK7=O]HR&ZOU'>P
M4CI8_=GI+V[=K@A]HTZM1ITZGZE33HM^-XK+"N+B"SH8ZLEBU6&/ZA )///I
M3 ^F) :\!IB/'3[5O$\! EB,0]01U;CC]]VJ.>]%]+CLN]^@[FI<-#1C$)LM
M-2D>4+B+Y]OES87+0=%00Q+*QC:I9:5(O5))2E:>FN['40#5 9*[+"T0 9A7
M2OJ4*DFRZAI 0?G<= L190R9U(L3->7U_++AH#%"N;GHLZ:^?JIK=*=-LUO+
M[:=F>MW<R:JW=\L]8 WG[C@H$ZW>$E7-#8G\B\9E_<I>:C0X%VF>&[I:A%\Q
M#TZKU[KPI]QBW9F9(+2HN8_U8MVPL1@.IUYI@&RB"#2Q<G:XW(-&!M$39BY0
MS?G:P*";ZFP)-( =TE0>-YW56$R=/!IJE9F!T-6HH=*XR!W"0UYF1G-:$YH
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MII@*1TQ(C&6I59E([S!9:W[R:(\I3915R5D=BPV0PFZP7'KDSZ69.IA:-$7
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M.&+?TK-G[MKB8;5\\6IIBFTNV06 AB8-.T4V#^/]Q0=G&.IV)<(GJ1.5<]5
M<,A[9TS9['*#F7DT#W/Q]Y^+</IM"Z<Y7:096(+(2:FJT9_AV7:QH]=:,86T
M=RF0<HIX^H&PJE; VKY)[N1,;O1C83X7/[P1HQNNNFM<LU-\HLPAR'JO8.&H
M)&N,DT+ 5W142%NEGB3(XN-6Z:6:>A[<N$J;W='%4( 4W ;"NCBX/8-.A1#
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M[G[DA\>/H\5[&LMNOY53.-DQW351V(FO1S.[O0:ADK6ZTH"O\RUR;(6)EC^
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MO#^XP%)S06Q6[4AP$,_A.0*Y1]A/9&Q9E/8EM@UVD_D^K0RRU6U3T(>]:ME
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MZ#J^CD-K'[F%%6@\'3E6!+7#..8CQ')" L]2NJH>IPO<GT@.C+DJFS!<WR0
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M,!JKW=JZO2EG/"^ZVT*8*(8W-/<W/I5KYB<,:!L]-3TR,D\/G('"R]""Q#@
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MQQX<)/.N=!WHJ>0*!3ND?0P7]U["H%0W95-7<"O7QAJ]0K$G>&<;7#=%B$O
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M=?^%U+RX.=#<LO<["A9)729$&+:+?J*K4G\DH7P-\7I%Z\U>?6EA-C,5(>4
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MW*3<0KO&$[/Q-*!N*8.;[*9D2-F,V^<H.<3/$CNP.(ZZWRIXW/#PDP9([UR
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MUA%6I.R-A_ENI9@>?D5;G,1OP_4+I91+[T'K;!3R1*GA;1=13BP#3B[G:7
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M$S!Q?MQ:C-6/'7HT%&K[%2N_5I&K@SC2AY5RIY6"YFEI$/76A_4>J22M+<.
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MZ%.\HB-92-M#582S>EABU',($WKV] 12#J+CT=.K68IJ^)BN](_U+:V/C+7
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M[R#BJ1I6@S1?>@Y:XJ532].TS3.^$5-@>48VR3VA@LN=/@D0DSY31I#P';-
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M& S8D-Q/>P*FN\@'>(GS!B,='P *B6M5A;JEO2JX(JA$Q)05XVVLY2X\8)B
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MR,V4B%8T0\VB;PKDC5C4BVK*U.F1JJ"^S#RWI3&3QYP\))X@DGC:\4BV5!?
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M!6;1\Y2NRVV8FEC/2V!TYBF\HG1IU6S:U3<FH/+#L'E>K'YL=Q6D3U<_*=W
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MT79=>T/G?QC5@:D%_DLPC,\_"UM_M[.:% ^?B5*;YCLF$"W?.MPF]TKW6/U
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M^-B7^B]7]:YB/K(8!EZ,]6XS@_CYHSZLL:XT'M8IPZLM1>7-I#P60<6T"85
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M,*T/V+,,%N/+WK+5HH=K-[#'15^0Z!Q3<E80,LD;_=;EX;S#\7X;@$> QUT
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M_"__'7%P>&.'<5S+\XO6@= >0MR580(XB5QF5=LAD5K]Q['7"ZS;=V'!6FD
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M'EQ-\ %YF$P[5E1\N0.3!W);0(HZDC$Y[&0CT_X5Y@-.^)'&<*/M'SGU/GL
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M':D:58)1C&);+!.'VH$MFNCZ^I64IH)QMY+F79[F*<:33&=/+?K(BG-CXGR
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M\4UPC N7*^1ZLZ14K*<D$]PXN-&P1-K  J[UE)M!!7X!XRP5F_.JGZS/)0;
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M!RD66R<EXX-F7G-U;KLMO"%*%$"1WLT1Q[*HU!A[52S>;*0^O2V#EY<7WEA
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MEG.6P#"!]6<5;NE?553,:>HHV50< K;QB;8NJ5K4I\40;HF\+GON2)1;Q!^
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M6R>MN&S?ZG4LVZLH>YY;)8>Z_GFCGJ:QBTET(Y/"2DJ)_[,JDC)6M/X;:0Q
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MO(*MD?%VQ(;G,1F><<*2@B=]8,<+54B EJG\K7NCO1H38:3(E:VK*/@_G%>
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M'BDK)5=QZXU**M3(BQA=95?IX<VDQ#]7/#N)1PW;Y%%A:!"70,3?TG"OX<=
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MMNT&3(6Q9]-BCJR4J:1EMCV^Y'688FCO+EN% W[:E(E6',BN@NHOJ1V.(M#
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MOG5VW/HGN*"MOU_UJ&Z_TSOKW^M1JW]_<GB_;^S6HKJ=TU[[G[[QHM93ZHZ
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M1&X&;L'W_ <VS6.SK-(ALZRY<,/6\]O:C>>WL0O/;YWA\DJ^WP(X>E_@B2S
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M=8@=X<A'L11N*#R=,LK%=ODR3%]7*]I;3%^A5Q,44S2/E^(YMD9IM0JB$^Q
M5[88LH:&N1&&U !#.D7!D(^B-1J7PQ,25,HU#8QZ(6,\>!6@4GX3';)N=<A#
M1:#*3I7(!BB1M8+@R$?1(6^S0Q5C<^1W)IA@=<L7Z)82NI<,W+.@3ZH$!]%R
M&>E*SQ2VG&Z[]5JC(!J&U4'?1@=]!4QJ'9VVW%J[6A!,VJ6N6BL?5QO%9;H_
MP@03^;?GKQ($ZV9,'!;%K."]6]$&QL5J5;==VYHZ-KRB/=!G/R:VK>#/6V$;
M1IN:9;?6:>\!MNU(,RXJ;[Z-L!@Y>29%&+,O)ERX$HC$JL O4H$9GK<C+TA
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M3UG?0["_$A&-@6BZB2NG$ODT0@]'8$V\9YKE-! O:PYX\#KK*@$'\/T!X+T
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ME!OMZJ#;;M0[9='[GPKVW9>_&D9I1MF#*'4CX?TL>0,XWHDW>O*>8\15$S(
M%KFG.L-E QA*B)W^K1LA!<R?9!D%O.DT&P+W53#TN]$OYZL?QCU?!#T1N\Y5
MT#MV%F)H 79];M+7O:8J)$!9J \+%I\@>VV5ZEMC?OZA/ET%P#[":0QV"UR"
M^-43P'/A.)R1XL!IO<]KGDFA(O'>E$D0JX>CC+Q)+$[4/[ZHVBP_H%W1C[YD
M'XA4,,/G"63\=4H@F/2'1")M3OEF^?4Q?/7;_.?-YG&YWLK]JGQ<R?U\T:,J
M]>-.M;'1HQ9_WBQO]HNEFUI^OA5V^E)?4&=NV18YM^]+!X0[_WUY=N=<7E]<
M7A24!=$N+R[/+__X>GFGT[QR<KJVN57#]%E?0YMG8T69FH;I<>L4/JYQU@\"
MKGH&7!*59K3$2IVY_&NCUXI'O,:;WBA#"C;S]A;HG7@4P538(7&+7,WK3-1Y
MEYO[[O=PC [VXW0BOD4[)&[AZ0["!52I+O<!26+>M'<*Z/S8 ;^64ZVQMYG*
M%O4/#/5KZZ+^/';CI*+"X/;A=4-9EF;3*JCPY CM K'YXM2&ZH?);:B\DB"J
M[D@0;7H[^Y9$\X$PK?YRQE_;">-_"UQZH^3Q=^&UNE^MGORY5=^I7?AEWF 8
M_9NY%8IMI=Z)6'A1;T@94'V@U5$XP0")+;YZD5AE8)X%_8L4E)=,51O+VCK(
MVDK-+5>WSM6Q)5@%0Z.5,G.7>-1 *5MS6_4]:2!^&.Z_WT4@,-L#^:K7'_N!
M'R<1969\G+*L';)6"4Z@B+,,,%]*%$TL3W2KG5TE3Q7 I6;Q:!W>NFM$PAS_
M:LOME.UX4NO FG5@A7.FE?5E[5HR:/-54O#F3BU,BJ\UW5IU5Z7JUJVU_TBW
M0HQLCW4='(=;<9OU79EWU@'VXLF:<>P,HG"L^'48V#$UFY?!S_'I!67PFG2N
M@EXX%@C]38FG1I-K&FXYAV5O7/=>\ HEBWDO8-:OB'H5YMOU'+Y=*-0[Y*RX
MFV0H(IR #)?H?)*Z]6>;)/<"B;NRF_*K55<M=Y]Y?N!0+9/H.TGH@)4>Q)(5
M//G)T#GK_6OJ1R*R_3%?;#E=A\$8;/+$BYY_I.!%R"-CO!.]\"' ?K\W 7T]
M$-$&[<EKU:+-,[8NMC>RC;;%JS6$,&8.@/8'8KBSJTKV@LC;8D<UKK#R0<2)
M\F=]G##Q=J90ED 4%*7O .A%.PHWI@2,$E?=2J>YA39JX\-%PY\5'':7"(0M
MY&K 1^?[';\Y GV(P+!FH6R^V&CP!@S4#[J_-/*S#;\5[E-+N$9]ZQ['5D,M
M&/HLX)^[QA\,_I;=3GU/BA=VZ_,IEL,@WR7D.F"'?+31=J_CM4?XFL3"Y*/3
M)N:)HWUT6FL70*NP:NE;Q40W1I$.R-\]Z0]?^+R9PF]PLPZB!4_LR94V-FC\
M:N)G"5O93&>KEX].&[E)]86*WMG <0$$VNZ0KD+^ZDH'$&^^4_]6[1IM['AC
M_PLS[5$8QY^=KH";%,XD"A_]&/$%_E1\/?%^[3!A<Z^IZE5X>IJ$\2T*Q^?P
M##^8 DS2OGQ?Z79XW0^\C<M?2>0!5/W BYZO$C&.@4;Q[5$X&A&5LFV_,8%B
M87.][)8;\T4R&QLL19 +=C+ *\J%(B%N#2ORF^V6VVA]H"D#A90LM[L5(H?O
MI5V'RH!ZI-+U501B@#.2YHD YVH5Q 5K??AORH370H]&<=#C\)PX>Z3Z7XM$
M^VQ(_=]",E8^Q*B'S<Y=6+[S.BXID;P\C;S>5 ;'-A4,&UW/.YD;EJ8.DZ9V
MZFC;BI1:J0FTM9A_=8HZ9 -(#395SC4]D&!'_:1F9M(4J9W4RJWM,CVXJ+&Q
MKU[L][:)VQX>E]\/7KY4/[H5T3T2\5(]J;I035),03V&D$2S\7+*QMM'IYWC
M\KP3:Q\31BS2%Q_I7X3S]1FD?R&NX_"V2OVX/)\>5<CDEXW<(4653A<^#CGK
MVR;\"T]76%)]2_DDT22':AOEK254<9S,%NV+C_9O(*&68'L%953UN+DGKO.]
M]DS37<3.-!9]QP\<G"$ZY;YA.S6I#[S70:'5CUSC^ .&^@A[XPUCP?^@1XO^
M&9S.>Q#7TW%71#<#)IN;:1(G7H# D0KW9@[$!B;_--QZVS8#/4#$6N%Z?EW,
MPNR<NMLN'Y@,+32C76#G;9+V=M@4\2*"D%"=HXN-2:*^*V9;'&^?1:WMF.W.
M<*M![+;3WE4FY$[8[6\T)'N=T<3\9#_HPU^O5T9+#SOQ$WAS;SD*T*SQ'T/A
M>#VT2+S@&4V2($S@53AF'';FP[X?L,_]Q(L2'*J>#$4L$"W2J>L#/_""G@^+
M8CU_?<G0>/GV%LY:GX2QC_=W0JW _$>1C@__:[8$60X?+Z<_\;JP!<"KA3_)
MF8/^ML/=\P%>*7=F*I:-_^+V$=O]]L#KM:KUBN?5J_5.I=FMBG*C71UTVXUZ
MIRQZ_U-I@P$O?S74TX G0':E;B2\GR5O ,<[\49/WG.,R&I"!L B]U1GN&P
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MX#X0-1CL[-2&WZ&+!1D8,3M/HPX2-#QD CCI/(@ ^-((^ ]\+R8)_Q8Q_<^
MY $IQ 3R,X*G1RK*[V=GMRS4)8?',H-HBD\T) !Q4W8>.-28E)N"X0K5J0$)
M:NS',2S5NM#]Y3G((/0,L',?;L<+ %A(<$CXR/]QW3<XGE,IE_[?8[IS$Z:G
MV]!:QE182&&=' KK[#^%W::X 3>7 <6AT%E'T=EJTF+A*5@=8 +2&*U$ 4DN
M^/AI& (=E<(GC"J!'A?[?1\U$/Q^/1)%JCIFE^;9:,1U*DJ[UV\G[23R@IA=
MH";Y"U3B B_13T_O;C6)[!F>WB,8^5X1(F"M@P8*RJQ9WE5(A?\J</[3@SL
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M(3S&YQ/V]G47*CXZ<7VT&/".28MC3J&[Y#T15('EQ\C-4 B./!##9$<Z&&1
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M7*W-S#7W>D.L$E ZL8<]!V$;((_0? 'XS-[1G$; NG&6)@W$5,K.;/8==I7
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M?"&NTI5K6J+N/4?%_UIM_>P_ODO$C9YW?/])VU*K3Q)%DLNFV.1,KIT0>*E
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MPX$XA(JB&>B:[7NN.6/I\V^/2C%]ZNZBET[>BLVAE^XX/<@V,! 9REQC(IE
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M-W QX PMQL^7W($D';(>[E")=0;G2OQD@'F[Y&J!J'+ZEV\ZS&EJ$16*OFQ
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MD([1E9*25J,"13F;%]9!O;HA:54P9;7E]*KHRMUX[:+>S3^UZE!SGD@SR'
MCYQUVPE^37IB3#)#**:3F%$D;W*,CBIHS1[%@*F!WNSI1:<_[7LJ5*?3U'O#
MS$>5,V^HX-<J/TN'!CY%^H?J<THZ)W4DEA:;UW3B2!./TBC(,Z1J;R-%.A^C
MU[+PUD^BEW+4R6ZFC!HHER+_-28_H6@_I4X1OE$#-KZ/R2)9E[5-P^2) X9]
M8Z[[.9HKV$K,?$A J4_[X[$_+)'383.92"K,:+VSBV$#'+ 8F_U:M&7YW9GH
MN#0TYC3.R7?G%0^4A@W]FD@2+E8*=2"MGMQ^KLK2]@=4^+N=2F4%59ER*IK
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MR1P-:B<S0A3#_3J9[U@36&Y)H#R?T59^YYJS.0;#/%% I A3GN='H XV$[%
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M-^YR0'8BPD3DK'(TH'>ZQP+!L2]"2SA'(KZ-=*>7"];1U%*ZS(TIHC.$\HO
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M?F>WU:I(NKR$^HN:]D^-]H?;T'Y"1Z="]N6A)NV5\(]0C5;.<MY0S?^$A8)
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M;^/'ZROMQ_C^\=_:X_WX]F%\^7AS=_N@;8-P*=Z1\.8J)DB_DF]%KI.M\<"
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M*T(8]82U#S)AK9YD%IMD5OKT,07O;M3!_W=4\[0*CA]+W^Q'.3"]"#65/JZ
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M4EN;&HY#)="\/)K'!'$UE$9 ('$,'B;'"Y5E9005'39'6SEXJ$/EYTS6ZG$
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MU7;EOS(K1OX0_)3+Z(=N0O*O$I>BNIOZ <'N/ D W?G&;>':BHP^+"E<6OW
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MF=5DMVY[9/C.4Y<PJ_.8IZ(!R5(W9M^$)H*W?-2PL$CG^C-5?7$BCU@Y)AI
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MNK'H)PU$]V7@K?V+>VH>6(<:B&HJ3;4+0/3-A=_FL\]J$%I-$/JT=RG H*8
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MWQJ$21*.CQK9*VP0A_XT6?Y* 7O%T_&81;-C^./>"^KR<SVS7<:?WI09V<2
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M)>,@..MVR&9W/Z$2M_2QTN"T7=4[9."&;5>9P%NZ1M:C2^1T L6OP4W8SF)
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M'N)79R=O?M3T2$&>Y?54D9-593A4)5^LX1I+LL*??_@O4$L#!!0    ( !.
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M8*'>$]8U':Y#ZL0#Z((I*V_ "$?3E(;>0"\,).%Y1J:5S.T;'M_G ?JTYG\
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M/P ?'V<W__ V&OGKXDW\Z'3XE^G\W[\9!S>;*^C!(?RR]A/E)[C^&)1? 67
MZ9^_3N.?_OW??OEE(3DW"9/Q17J?\B_+EW]___H^TN%H]FL<7OZZ_,RO[N("
M$<^_8?;M<_KKGZ;#R\\7Z?IWGR8IKT5_/>0"2A8X_Z-\VZ^],7U"()-PY1/@
M;].H4+PBQE7?WA_SS7=!3-E=7<PJ(K[_W57QCB_=L*: [WUU!;3S+X++=.G3
MI";4'[[W%LYKD'<1#D>?AG[R]<]A?/GK'-GS\6@ZOAC&LJ8^<Q=EL?CP*:79
M]&&4PY'_BE"8I&PQF__'^B^[!0TY,!P-R[+R!G]<?F/!TAMD^CI+HY@6J\KU
MXR[&X8</790U;7RCA OGT\7\MX.K*7QT[O/@PPR?4_8:Q)=>X\OIP!"58K04
MHK"X5QB:P#/%(,NH5?*)69[OJW!Z38GLIGZNQ.4C?BU2^S5=S*;7OYG+<2[#
M]2@60JPPKM^=OT@#DWTD6N%.QH,!D0SNA($+B-PJE:,13/I68YHC^'$\WVEQ
M-KD>V7+Z;+4+Y,GXLJH^9^-J8EQH"D'_Z9?Q)*8)&C[XUGQ._R5<C*<I_O5/
ML\E5^O[+\6B&K'YY,7\@3L/TL;SHRX3WZ:),I7=N,OOV^\2-IBX4P4^??;O]
MSMG7X720@E21. \R)0J"2 LVD@0Z:^U8\(1*5YDEW=%59-"&/7L#HW:@P'@O
MJEC%M(JD>3'?=SHA&MRQ)QJ0Y,6M;;H*&=8:0_>IT$I_&VC20_C[H843R@1B
M&#BK<'5%^H.74H.TQCMON77!/E(Z_&!K'A,;MI%Y Q:\'8\FMT#]-C=(!X8G
M9VP.H"A7Z&)S#D9P I*QS+TER<?:F\=*(#6YL,J2WTR$730TKBW>^SHG-6?^
M$I$*.EG'"!@;&>Z$@8$/.H-!H-P)H133#6?^B6B[IV ;3.^SZ12]K3,_G4UP
M11MH:HS(ED',"0?'C07O* &?I50\>Q)3;=?A1P3[5W%E)Z*'0!O,Y 6:YU>3
M"0[P!A1S 8U:Q*-<+&8M">!UYD"5E]%RH3-9$;>HH.4[0/:O[#[:6:GH/J)M
M,)V?N^FGLU$L?[W\/U?#+^X"P4W/9L_=9/)M./KX#W=QE094"945R<"-MB"L
M,N )<9 <6BQ1>B))[5G>"=BA^-!+B>/6&FBQZH<POD)8[U-("!%=W;=IMI3"
M@"2F NYE$'A.:+\J'#T1 2@SRB1/'1'55X<->$Z!%-7D?9\+K"\7SF>?TN0[
ML.EM9-1ZHHR!1),#+6TNR"($JWC26;%$264FK$=S"CRH).O[+.!]6?!NDCZ[
M87SY]3,ZQ D7L#G4'R0P"#(K1(AV4-(<< $CZ-A&?$6X("S;*(VI3(<.L$Z!
M%[6E?Y\@HJHE.1 :D824@!/T385,Z+4(%L$:3B-ES%L16UJ0IZ#TW25Z7[VR
M__P??T[HE;Z[<#B\42RVR^?B%>$2-0C)&R\#!Y:+RVN"!T=YA)RUQF4IJ!SJ
M3_SU>!ZUVU!-T"U, 43F9FBDODENFMZ7%)OS_'=<D,KP!SX&3;./X#0-N  E
M Y8$"R1)(93F.9O:7L-&0(^:!O5$W< 8N+7[O!V/PG*%\L9J87P&K0FN=9IR
M,)X;8%$Q0ZBC3HD6UN!=((];[[U%VVQO']CHF&:&0@P,48C@P+-R[BF((,9D
M&GSMH/[BR8]:HSL(K\'^_6;H_/ "I9:FN*E\F(W#OSZ-+_"[IV6#F7V[&:K@
M@@<2!!J/7H&(/H!ETD*(4HHL#?Y=.Y#?%=NCC_TV44*#\,\MG'<-6JX"UXYY
MB,7!$#YH-&AQ#R(V$.^DI=RQ=O0X>'RXC0;7TZ2/^!O&!=^Y;R4^<>V;2,($
MET)!8&B1"N4<6.L)*'0\'?$A,E/[V'\UDH,2HI>NU@0$>PBZC?HG5RG>'_.
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MP\![4$Z$/?U$W&#]>IMFMT(YEEG'&7.@9(X@F%.X6%L-A!#)C54ZV-I9#3\
M>/1:WEV<#>X@7M^B>)<F'SZY2;K9B66,TOJ8T+2V980B@>>AW(ZWD?G"R%#[
MA'0=ED>O\2I"7IN67D_YS]QT& ;.XN <%?-[\6@O$X8C509()EEXEXE+M8_
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M OHJF98<Y^+Z!'0'&+4^=S*6']#<#P_=;U.IG<4^KB&SBAF=<R#NZRT@,:;
ME$ZEG!M?A,RM91&T8YDZ:KP5G<RKAY1W^Z&/4'D[RZQ!HN7:K?W9M]_Q*^8+
M3&+*D5P2DZE-('A"5S8%#E9I'Q4EW#"^+Y_A.ZR3-(M:J:5!:N;ZT>,77%^
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MPYA/+32^CE3-U-5@']L.M,Y>&JD(*&9QSI%LP4="P>;(!;X1*:U]:'@$W'K
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M:7NHU?WYS8^X=A3%_@Z\",E<:H%;H,EH-?F@<$?$Y8?P0!QNESZ&VJ6PC^C
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M$NK;*/M82J@OX%_?<&5!$\*3+U4,,HX@,##!44B&J-(>5GA=.R7M!P"/OU3
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M V25E,$W0TKPU(;24X[S0)3ATG>*G_<__Q?%>M-6Q;:4[8/_CW^BQ"?SM1S
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MP/"Q544=3@=60.URFNM4YN5,PD/IQLWT]X*]N<"0:?HMI56MFH[12QT]R%A
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M60L,6<XXMP'__+3*/Y!#'T+WQ\BWC[K!%.X0UF_)/UR0TXSJ;"50'A%0%&6
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MY&W-!606LC5*9%V]#>,V'"_&2>LLY!YN4:QC6EU&;8&J)R=M.Z+3N&C=-7:
M AW$/< NL$2G@\A&8,B8N-<@7!+@@Z1 E%M<6::/FHK^A"0XX)X-Q8%CI-R'
M[D>3,O%WD8I8VB0EJ."VU&<%X4#0) &A"*!4H$U2UFM7^XAW$\7P5K^&?M95
MWDVX?50O;J:(UCP00<';3,"D9"UC4M+UOD\O(??6@[*[B;://.N:([/:Q!9U
M32D&X,R$XL4&,+@V(%)(&3)^$*]^(WL[E!?CXM40=<7A-7M@K:Y2M #6DZ.W
M$]1I?+TJJCM,APYR'V9K6.V /(88 @>?0C%23(,-,H(5(E)C)$FZ=F_1@0EQ
MP.\;E@_'B+M_'JPJZ74.PJ*#2U00(!3NA$9;#UP$W!JE<5;7GK*V%<CP;D$E
M1>U7_Q.DW(,G^-@W79U!+N>^OIDVS?2?H\GMN?L3?S+_ACN2]X*4FS:"),1*
M"'BG""1B+"<\4K\^:JIJ2' (W\F)\K9*-5=O*NF!/N^;:4@ISLJ,ULO9[&XQ
MSB\7M_IFZ59_XH:9E(T"G@/!5R9;L(7JS!&B#..9F-J1Q6%4+X0JE<5?^]SG
M,9"WHW_<C9#1W\J0^MGGZ3BN!T9&ES9$EN/? F.)<Y796H9YQYG!_N?\Y+JN
M+<D>3OO/QVXVN\I_+ZU+)O.KYL/H]O/#M,5%0#PJ!>GG;CQ.\<VWY>_-EK\X
M6P[W5 R2P"\Z<HRW>=80&>4J>F2IEI6WB(Z0?W).G4)Q/1Q?;(5_\34U831+
M[YM1V0S7,=,5: [!>@V:%Q].>@:12J:)5R;[V@GM)P%]R1RKJJ0>4B8K0&>3
M>(_HZFX^F[M)&3=?]N%/P5OM:"0054*S6J(!$U,"EZP2C&F;:>T"MD.87@A?
MJHI^DQIR[R6FY;?+%^]FZ3_^[5]02P,$%     @ %(!S7$=[\&2=&P( RHL"
M !0   !I;F)X+3(P,C4Q,C,Q7V<Q+FIP9^R\!UQ4S9(H?I"D!!$%)(,$11"&
MG&%$)$D&R6&$(0_#D!F08$*4*" @*" B(G%$<@9)2LY#SDGB#''(_\$OW._N
MWMU][_W?[O[>>[>'.E.GNZJZJKJ[JL^9UM.ATRG@TCUE-66 @(  B,1_@--I
M:@$EI*,= &AJ KP  )P'2 DN X1XC #_ 0@8 >)?. !8$S#]B3L1\/Q.@[\2
M" 'G\#@E'MP)A'_A-'AX%.(($/U._QH/GP& Q!G_S?+'MXJ:I@Z[L("0H("0
M*  ("PH+2@M*2 M)L0N)28M(20M+X'G?$_Q-E]\+.1[]72Z^FN#//I8)SOVB
M/=-(F(#P=SX2_(7D+SCM7_3^TS8"R;_91G#[3]OPEIS[4SZ!ZKES?^!4X[\T
M.?_K P"O?M?@U_?IT.DHH B<)R$A)2$^3TI*>N'">3(*&DH*<G(*ALM7J&A8
M&-E861B9F=FY!&ZP<]SB9&;FD;AY2U!(5%24[8:4G*2PK("(J/"9$((+%RY0
MD%/04U+2"U]COB;\/UU.ZP#J\X /\)20X!IPCIJ D)K@M!%@PVM)3/"K_.%3
M@G.$1,0DI.<OD)'C"8HOX>TF)#Q'1$A,3(0WF2  WPX041-?OB:D0')%UXJ4
MPXU&^'%TVGG..P7UM'H]&"X1:_<G%\CHKM(S,')?O\%SDU=43%Q"4DI:\:Z2
MLHJJVCW]^P:&1L8FIE ;6SM[!T<G#T\O;Q^DK]_39\'/0UZ\#(V)?1T7G_ F
M,>E#^L>,3YF?L[*_%A85EY26E5=\:VAL:F[Y_J.UMZ]_8! ]-#PR/3,[-[^P
MN/1S&;NYM;VSNX?;/SBS"S^J!'^4?V@7-=ZN<T1$A$2D9W81G/,Y(Z F(KXF
M1')909?4RNT*A_#C\S1WHM,*ZB]PBNAA:*W=>\CHN$2GN;%GIOVR['_,L"?_
M2Y;]:=C?[!H!* CQ4Y&:D!H  WL'/,"'1]3)NNHRQ+H_N*;(4+  !++W%E5M
M&[L0ZRFPF*$>HZF20Q[OD(VG8]SD4J]0N<_0;#Q3Z.+5!GN8$<:AQ&,F]"Z%
M"OQH%JQK<C^'T6E5<Z@6X4'9'V@#JE9H=HMT,NT1'>C^%OJ 1H= ":"Y#/R0
M//=(,H@>!G/YIE0??+]95;^JX#!#RRU\%I7%F6'ST[2AR8VCC2E=F]K]FB%Y
M50$AL?:UD#*"Z,HY=-B+W.,<-V&$?O?V0)PGSO!!?5U+1W^4GDP ..%>J64C
MJ#7?Z4GH>^&=I?F'E#VB@=9?A-*?;LD'6J:\PTY4]1Z<',R["!CHG;?9C*:^
MXN9_LUU5DD(*&HWF?;_3$AU5D96^9"_7F=J0-.<M' 8;?2(@0)K(Y3+I%HFT
M5*TCS#2G<C9RLRB[]VY[=4]):8G&2%<!;Y .@8XEB;@$ <$MJ#-!_SN]AP2+
M1N)JZ<<?U,LTHK\_U[Z9L! KQ:VE175KF8"!H<7O>U&2R(>?&/JX8OI/A.UQ
M&A'G#2D:%XE<C3C[4JIE>;&>:/[B4^!)KO6VG,J=&)6^2^K)*X_:WJU),ICO
M-3D:%2N5$@UG#_'DD7A8"KQ1<0JU>,U:*3TKQ2E7"G60?;!E;IC&O1>-@%V>
M,ZY4+>-TCF[XXK$9(U2UW34^*VL4$888E?$^!3AONL!_FIHG%3=8<OIZW'W?
M0C%Y+7B?N(YAD92!@?D)I<_.TO1TZ]N:^4:>_"=/0H%]Z,PI$":K]LE?;]!Y
M558A>\2T9<[Y.?DPIU([=6PP*2%7+ Y-=0I<F P'+\'08 Q4XA2@O4UZ="-0
M\!1(0YF? O7ADT<&?J5UH,NPBJX(+_( ?=-^1)JF5#*THL+WOD0B_7<*U<X+
MBQ./Y-(A/0*(A2UXS(2R0[O]&BD[8?@CX&<+ROWA VP$94=DM1?+\L:6O<?Y
M\W>=SX^< N*]- \"U"R3^=J;=/V7M>U.@?9.=?T\S*.RR O0!Y\ 5WJ^BRHL
M!RGE<CA9>]H^M!V#F-IU<V\R/K=WS;6V4M61&ZTB'#>;1:*[IW9;<!=W.GY6
MB.?E.O&XN.3?(E)(UV<E_]),?DC8PKRI3$6[,)!V\W[A\MZU/#7YZTI>T[7!
MTO/C\6FR/JU6PU[D]!]U[,(O,6@IJYA[H1)/@6D9;,@QI=_B"05>JYF<[F>^
M4.O!Q__23RK_TDTZ_\IQ- 2[QS2 [FWB![!/G:0F%.K<]59Q?)7Y)'Z7I V]
M3,-=&EMW63F\OV[&3PAY4;,Z*X3\J%P@=-J9[3N"I3^W2>&.OFB0PRSGI3^^
MRK6N=E\LK &:J2;$37T_/N$KU>*^X0[7+$GW1 MG-O*]>6N)NL<EX]'%5)?[
M0D39<U[64G4M;OT>_4L)\EZ%S;=!3%;)6HI7CLI::%N>-TH7VC0;V6703ACC
ME:,AB)H!TRQ-7.Y+KT6#Y'_ N#[0!MV<:WNE2G];6PD<YWX*8"H#68.Z&TZ!
M&".V(Y='5#B+6BKPDM4I\(,OZD1"Y4A@,B1U&V_Z7%S+*<#T_F)Z0\K-GBJS
M3+6@M(F _$$IC5LG^BTAP&7!*=9PL/2BOXG7PG)H2:FE16O:2_T.WKS^Y#JJ
M-L[/LV6R;WYPWT./)3J[EQPX[UU2M4Y174\+^Y[,QC[KLDJBY\[$T-)'RLRF
MC#DI93FR!LCHZW3"*TT"=6YS+L'"2,'V^G''J"X]Z]6.Y1E9W7R)$>74&I[I
MN*0;,7KW+MYG&=J56HQ\=[ +S9;4<_3JSJJ^Z+2E#5DS_%+TP!0TJ2E2=JM6
MR%:GK!DY'EW?:>:V,H!4T7UZ>.?A^6[?QP3>^LE#MPA3U-JL7K)^-&)E&LM.
M6LG<.7;0\)'AY1L2)3N+R;*3LY#@XM2K2/'.!L7"0XM^OR<:/Q8^(A68'[TK
M)\RAZJSB/*%): 0?7*W=])X\!2)U"$X!,O49MF/RR7T9Q"G0PG,*!'-CJ4Z"
M-XZ22T^!V=<$ZZ< L2Q_+DZEOC2><3YU6.!C/ZNMMAA7*_TL,'^!Y?Z)06DN
M,M"D6&V'_D4I];,?5(]Y@Q$)#AOEA:? 2JX0S?%'@^3<]>OY;E]OPT'Y8B;K
M([05/&2%H#?9BM<>R"D3$M8S6*'%2C_>J_ >7OL4U4J/N/GI1CS[9:8R]BM]
M6<Y&L30#9IDEGP*T*G6JDXO82D:SS!_-*U*\EG]VK)!_[A30+7C:'J.P>.^!
MD:<S(AI)/Q?0]9JN;I;PIX5QX[P+'&_$H_LOMBM5RJHB9\9O^#:J,2]AXR8L
M$M_,CH8SNQ(P+XHM^1D&DT2##P3HB,/:[K;(N;L_W$IM'WCP\WILP#F>??7F
M0 JL 3JR2M$-,9ULY\#=OVXIQ?DE+JZ_M?'2G:DG,H-L1^PI9PM/_VSA>4X>
M:?IQA_RKJLPZ,"5L1"(2E2^F>46OX''1#VJ;BF+DZ]*WU'6W@$Z"V:%NTA[/
M7^E.AT"U-3_#1/$F/7LD)>!^4)(\70;Z\%3'0,)GM)?.-5"AE)0(ZK05U;+L
MQ(0Z;];P":*V^&;>:I'B>_L+HW<>,:2(UQ14[_.#<A23EE+NN_GY1.[()(I1
M>[C&*"$85$WI3RSJ'EV4CNT,W/@L5[!4X17Q/,/6UNV66T"&-=&J18;"[EH+
MP\9(<;)DAZDJW+PX:[GB8IBL_C+Z /[LZV)KS+K#C'TS0;VU2'ADRH>L4^";
MS]0I<,"X#3ZBQR_1)H,AN[DK#5X(VJ:J@@ZBSZQ2G ]:EY45B%P56);O 3SO
MSX7^=N%]GID[Y/"3?%*+PP1B[:K6*=+M$17D=IM-'E?;9#2R@!(VMR!_:Z9V
M/9(DPC]#RC550 J(J^.*[5\L_RG:X(456$!K/<2M?>BSXDV')9J0?C>>.Z=V
MS:/UT)Z4G2+A=H@ZVJ57TE &F?I#%7*1&:C_*">LMH^19LOPK+F,/=<4Q%(>
M*6:183*A ;]-^[)>%HKL8L:& M.UCGPO\M]C<KL+;!#%4W'L&"L6*K&IUP2[
MI\!C\%P*TOZDWK#VX";L_9^&X"]5;3,9$=M;P^,-"/#P6OH8FESB>ZX6<'.'
M+\6WZU"48&OYI_3S=(FCAY=;O>/M&.[X,'^1:O"??F&9JA^]W=+011KT3<(9
M+=Q"'P]#QLB?CQ$ECPFGTF +'/]\+B32DRFC* 9+(WKG3@LT>CZB@85 JI[S
M$2RRL##)1/U6FJG@YYB[9%^ 2SK1R^\)5S:*NDG86G)\2GNJ.+@-3-C68L0;
MZKMBD"WT!T8ONTFS'<%LL@;I#H/2%C6IZ:)TAMC1YE[%F]:?TQ0D7U%,^9&5
MGP*4++-4!R1+07LSB!,9?#X6]<$G'J:T4V#R92UNS8OMXHD8+K9I0J;/4^:0
MGU?&#"7QL)[F<?-0<O.%5Y'9,CJDE3WXL'Z6>-S!EZW4JM@$A2M4N;7YH>RB
MSXXJE547B5*_/9(5[_7X]$/\NZ4,37O6K;Q2;YK+9 \>S!MO$SX=K.:[AXO^
M'*%'4TW=P;P<Y%ZIH+Q*P)R27G!B A1GP]",1:X*/J< :^^]_#N?F9#L/)P^
M$/]-O]G0Q3[-LHJ*1T561'=O71?77WCDJ@!%8X"]'TN $-AAU*OH*R;\_*;T
MA_%'-BM18]AC(4NJ,TV-WOM?QB>7ZK2@T9:3%S&/Y&L_//H54,F>; X(3 W=
M#;1.[I%I9FMSE3<"]F@(MA*:^.47&HRKBM7F*J+'1#/N7T.(+#@#?E9OJ->I
MZ!<O3RQK2C1F#">:FDF$N&D\UZG;:2;Q6'N*LR',+^I?!ZTQ:\KF;PAH] AT
M/$LM(Z<X&GL7?JXC'&L9]WYI)*P%*MOST;4M/I'&RGO]NZ&EL"")Y*P<#V''
M*>"(VH^K7=LX!1S07=MG#O8CK0?M\XU</:X*6GK)0[CR:VO^2W4I;5J<0(MI
M877%$Q+&')Z8FW?SVO(%A<IXONN4'\%:^>49<?F[BQWE!6QV,9);-)&/2%JD
MB!81[%.1Y5.,P,K1#<RNIHQ).6/$JO"]$/?<AZE/(Q5<WC#=GAVL5C/0O?.9
M[/T# +\IER7=33H%$LU.)DZ!W0C_4^ VFSY.>YKTL1B89,EG+^EJHI=79KUH
MUVYY\Z)#?T&=/T6,GV'+T4T0/F.#@N;6\ F;^3TA/BLU=/W*2K/XK&3X_"6F
MM+Z&>9!]H"B9:76OVV5S_O!^5ZE[G*S(*R27.P_AES_&AX<P:O#D)E*B(:GQ
M0"LO]SCE@++&!F*;N+NNTQ!WAXJ(E=(>'Z#6<+ZG@"+5B9IY$+8"T,99!%VL
MYT(^LMD!6Y?ADYQ7X737BQ1:K$LZ]_.0[(#\9<GP]E3[>%EV]BL).M)?CI8(
MV680#2"<\>1P$%;BI.N0].TI(##A<GP('C6'VM>:3H&G$X.674Z!5GP.A;^G
M0G07=:UJ4SDF:2<O!CSOY4-(N(P?7A)8M9F5[!2&W?E#]]\,F*.*J-TT*IX\
MQ,_H'FIT:C>!9?VA)'YOH]@/7J6]<1(1^D@^]6_DI\/ Z325FX.GIZLT".3B
M(6!E@["V%8 BX""DE2M(2$ 0!,B"D:Y64)BM)[NUK;VCBQS'1F4M![NCC1R'
MD9BFH*:KHJV#HZJ?NZV^G]9]J!\,*F7# 9:G))-%2B/AKG!;3RMV)-S9Q4,:
M*<?Q2[HT'C^K!G&P_R+QA,EQ&&OJL"LBW&W9105$!03YE9".WL(<>"$79-UM
M[*3U[BK_+@-_)\?QN[8^/CX"/B(""'=[D)"4E!1(4!@D+,R/I^#W\'7QM$+R
MNWAP_I+QFY"[MAY0=T=73T>$"_O9O94UPLM3CH/C=\GX%J@2TO-/Z6?WOV1[
M>-J U/ WHGA5\00@84%!27Y!87YA*= ?O/@63<T_.?^A%^'P/ZD]/)6\/?]]
M:H_[OJZV(#U;#X27.]16R=O6Q9/S#W979R^/OW)[>=B>5?W2U=G&#H17YI>,
M/^C/WDG]G<_L'>&NOZC/*/^@LH'^2>/JY>[\J]T&"K)UMH7C._? 2Q3ZD]86
MZ6CWC_4_:_F[SO%=_/N6GA'BG2=]%P'U.NM)[:X<QYF"TC8(J*.-]"]4RDK<
M5LQ65(3?2@0JR"\J)"C"+P45$>$7L9(0%164LI*R$I;Z0XZ:BX>GE0O4]DP.
MOD; $2_$2M!.1- */V3B4"$1?E$[(4E^:VLQO"2HG2 4+UQ2&&KU![^VNR-^
MCELY_U6?,SDV>#DB=N+6@G8V$OR"(I)B_*)BXN+\DN(V0OB+A*V@&!0J*"DH
MS,%^YF]I!1TU.0YA <'?;W6<K3SM$.YP_))Q=+%!^'C\7G_?$6ZK[VEUYB0A
M,2DQ(2DA(0E!04$A<7&AWRD,;=T]\#/V3-BOMXH<[#90:66\*"O\%'*$6]G;
M@IQ<;>TYV,]<+ZWCB+1U-KZ+E^KR&Y>0J)3P7]M,_MHF(B[ZRVQI17=;*T^$
M^WT$PEF.X\]WF+^MG0NROZ\,:0T$U.IL]?RBMK7YK?6WM77'RA[T.S7HWR7_
M5\+T'1 ^+O^CHOY"_*<@!7=/'X0[3-M=V]K)%NKY'XGZA^1_"M/#!S@/3W=?
MM?_0NG])*?O;]%'%5R+<??_*K6_K]OOM;_?.CNR_(H"T%=3SUSAX6'G;VG#\
M7@EUL'*QM\7'5M ?-8[_8$;;6(M:V>&G/[^5M0A^'DL)VO!;V0F+\TL(2DH)
MV4A(B$G:"O_![X&P\_2Q<K=5L,=/9_SPXE?4K^%EY_E]+M[\@]+'P?9LH@D*
M"_(+2O +2=W_[:VUB" 'Z ^#0']GD2SH'U@M>Q:-I-7.IJ:^EZNKLZ.M^[]P
MQY_._+<H_R+B]ZGY'TOX.\+?!"@B7'WQR]G!4]O'Y3]0XA^1_B9$PQ&*7S#_
M@09_3R3[:[T9>-BZ*R+@9T'DK[P*SI[_<CK@0Z6T,W[8\>/+;V-K9^7E[,DA
MKP]UM\7+=$!X_N9T9\>_&X,_Q<B"_F%OOU'])>?]2J:@W[/I67H&_9F?\7?L
M_P7EGYW\LY-_=O+/3O[9R3\[^7^HD[\]/MNZV,C=\+D!EC^=.?=%35$1HJ.G
MK:RFH73VDS]P[KTS%.Y!) @ <!=/=SV5.^S&)J;LI', *7 %H &N Y>MH!ZN
MFOK*]X%_L^P._G:HH(__3-:_3?</"Z4-?K,   3L>/PVU-7=$X\_P./B/IZN
M9_B;LT,0^.VI#1[/Q>.WW/$*XO&ALWKKW_#5,]S^%WYV9@*@<;^OIXC'SPY/
ML-O_!;?^"PYU<(?C<5$\SF4#=\'+/V?\&VYSAON?X7!G+^@?/^SC@<+6Q4#_
MK!X/S( *H 9H CH .V -> &.@#/@"?#COUWP-1Z 'K[]SK_!S_B+7P?/98WG
M<@2@>(Z[  *  U:_^(&S,?B7OO6P$Q'^31+%'0 @GC@]W>(& -)8 #A^=7IZ
MF'9Z>OP!  C' *#.Y6_\B/< (+F#KW_UMSJN5 "@>@8 )8U_J[-. (#2$ "@
M'W:U<K?Z575V=..<G1T ;&;BA\D$ *YT P"9V6]^^[T=2$<#P'V\KS0Z " Q
M"0"NV^-EF_\;=I__J]_^79K?_??K ,@Y H*SO]\+(3'A62$A(B(D)B4A)3V#
M\Q?(+YP_3W:>E)2,DHR,G )?2"]<I**DN'B&_SH <L:)Y\+_49PG/4_Q/UU^
M'0 AOD_<3TC \<\#(/\7'  Y/OH0R@/\$_X)_X3_5Z -BWC!B9EX*=;P3CB+
M;R?K]6LCD7.#:7DCCA LUHT9O,%\WU">IV_GIG_EP^^V""4G# RVIC[3G'$K
M9GS?-=\U;\U8NM7)DG+ QWB<UE.*RP<5G7!5=W>B0T5K$308M]M]D!2*K24X
MZ95\R5_,8^-(0OH&2;N4!&KLN&%"7K).:[=$'GH@*VX5DH_24IT0X]BU5U 2
MEZ*[3_%1N)0]<GMY[1;/AU#@_UKX5!5&OY]HM PC;890;T\2#XFBK_"M,8R$
M7\A*5FVRU/K.5+*HH(34F"QRR<J%U.ZZGRS*DEBZ68 ?G4@?UQP[[X@Y++Q:
M(PJG0,=IR]9WH@K"BX4-WH]':7^(9K&Q:/6YN:3$[[>0IG1VWNZ_$2Q%#BV0
MBX>$#24E6*&)3:L"RPZ(W,GP 5%S[\@*3!1QP\7-G.'UQR^]\ZOV^M.20>>1
M$YKRHWN@XK=YCI2:Q>IQCO)VU\L"R+6MBA/B\F<;"NH)<\R_OT+EO#.:-PYU
M?;J@DLSED\3V:+OKTL]4\8%8E@XW\"5_NA/:LG&G]J^$<0^0^:T36YJ%7P_O
M2L>]A;-YV3+DZS>=W(IMNMOB_#';[9U7_JU;F1T=I*6Z'A8./K6%(<UT6-IW
M28$9PKF[<UP/RSH> E*T6,U&B1.&_IC=\= .ZN\M&N@/2)G=] '.Q] J6\2M
M!U-&/Z6\ [2'>=!^^9E>TJTCJ6JZYFP-D,@D1.2<^&'5V^"IC5FQ":.>GCRR
M@L5/ZQ&S7 /=NDJTG[^%GITW^+\%>/,S<\U^7O)-N'P+MN[@,O*%W^@:UFRF
M.+4AXF:2\BF@*CE2EEW#@SM^C_-K59:0^:CC'>Z#2O;WP)+,S@2%GHR[G7P
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M@U]F9%>N/OG6I.,H)0/;3Y>.8S:(GK,$X_K<9D\!NOV1\-5>31X#BG$"R:;
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MTQ"<1Z(S-ZNT()>KU5,G??U>)60&QB=3>> S3'K%TQNH6V^E/T=>1<GL443
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M0!/1=F82=DO(Z>PK3;_)>M%G@L2)S\NTHHH KOE/8A51]1,G#$&O+P#TD(J
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M>*%7LBR$MXRMS\=PC)VHB)0CN<V#>5&14KN3[UZ6GCO<!/*H"HML>6RXJ/0
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M:RT\[S--"AKOT#;J.$N55^!Y,ZHB4*&/][Q],Y"SI=X]3PCC=J0 <^3/#L6
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M')E$T\G?8**)0;129+C:'2V\A2+/@LIF]Y/E1ZA8& L^8^;LNA$^GYNHK3H
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MZYNI4_=% IXG6\C@"F:MF2M_ (7$K3(086+,#2Z+UH\'F<'YIF6163>U7U5
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MG#W10*8?E2CX+@MQ'3DL/3W!&A>IRHDT'1-(^G[]P1M^7J,DWH./\*'D?T,
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MH%^>@&LWW_^%WSI*22M;.$1*C:(&-[$<_;Y3F;V?-X]!A3 (\4%%9<H!M 8
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M6W7G:/:>_CF&L*G&0I[PO7UTUVZG<78JP6,\V@ZT0E^UBZC*6=.4&3Z"$$X
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MTS-0JG?;];/"ID[7Z;2^"FJ%ELX>#\P)N6Y+B3L,2'XTO)N63<I"OQG>3KQ
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MKUWLZ>GJ[2#9)-$=87F</+!0XMH#GM2 PJM'W%H;F>2'[C'']ZHQ3D(;IB<
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M.%A1E<FC97_&W[-Z420$^5R+Z_: 08IJ&;24H^81QIK/?(B .0%8+M_P"'3
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M.+*(4.TE3*+.ZP2-\S;?Y>D.!N3#&%[^[YVNZ'C5.RZRJ/O35C.*49CT<L:
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M8I&:>X<DHD*7RGV\-F6ZQC<HU0DL$KKFXX@ >IG///>IS@WYL9VD?XQU>9C
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M9N9.KV/W9?L\]N%DAY(7C795Q*R%4186]O"YG5.[%?T:UP=*! A[$INGW2$
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M$R5-AZ)>' 3%:/RB!5#=^_"9P]NM-S84N-'#^S$Q[E_$O4X3$M+PR 2%>'0
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M-?I<N9U:/C1QVT199@4WI8/7Q$6HJ[[@1NV.\B)K3X','U2+75=?ZXB*<A^
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M2_^*?D*6<\6R9GU2P6[_=\9E4/! M'N&HD5.H=Q'R)'T",9)LP/AIX9/9K/
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ME]R9TG.PAGXYZS_IH][1I^YGUXZI G#8$NH#V#J]R%Q"\/8-M!%&!=DY(U%
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MR-M'@UL'B;^';G!CMYL^.:%LF " G4$839S")AQJ#2N1S#BT2FC M5E+AM7
ML-VJ?B+9>+:\[:ZPSWM[ FL=.I2OB3:?KOY>M!EMZ7DYZ3.&GXA+!<DI";?
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MF)'DERWGT"_\E')<@E\KL=[GFJO+$K2N9*&<8[0Q83JA<]\JO4;<VT?YHW2
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MC4A(T]7+K% 1UZ]?5RCGL5JX92XP;;H+W3A#E=,)F>4$NH-_G?'F;E*5TDJ
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MMBORE;&:IL6V!!$@X,^5#HEE0JEP_\;2/<-BK$-2B\0NE%0#R;R8\7A&(.6
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M;?W+,$KO5]*P-F?TE/7K_&<\IU&1Z!'(NVU$'VLN>M:AO5U_XG?HUX",?0P
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MSQ33D"Z5GBR5]#2QQ^+8V_SJT*W2*.(OTFW;1PGT2QM-)1568J7QE*"KS =
MH-=,^FG%F_S/#=@G"?1#3G\L^(X@L%0H4JQ<<C4NM(="D!A$R:&;#/+TJT<V
M1+Y($$(.H])K94<X-;)8;T-)5E4HFS>_X'][S=I_@63GNH&K:U35(B0(L/2
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MH.>CA+.(26-!UZM]5LL;'B?4S+")F3_)<9]SC)3K]<ZS%!Z =A<I<M^&8P]
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M%/,AM=]NZH&RS=I.V%'RY K)*A7G)=S^W2;I,] 5D- Z=N4:07S< ,Q=<VH
M6H%Z)\=4\#8S5"HYW\-AMW/&9<C(\]((M934PW;XA0PAE"S28PCKK)LT;(CQ
M/M4L*3XXS!K4/DMHSM>;D5/U<A/NHSXA-@7NRQ8"O+1F%O]4L)R [@$H*KP%
MO<11J\369UNV^R:'O:^X?3GRU"](7I7@0ZFR?RE;BZO#A]ZTX  4OD]C&-//
M*<8$-&^@-CCXV-85@B!"*V !96"S06#(->]#^&1A[7W8EA?K9 Z#S8"AMO08
M1NYK(P^TZSBNYC6H;AOMAVG*,*XO+<G%%62:.)+7+ISBZ&L8N6SV\[QX2)#
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MY631OCZ7M(VVT/XY>6@TGF(")?IODI<[J@?7"VSRF]+XY:>,6'I1[)1_9^[
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M0E-$+G<I,/4A;:CY>RV9'+T^24?V ]7G,V!)@#?]A04BPY0T:@QW0->!, $
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M# N(4+7WR,(I; 0^/?'SV<$<Z2:0]>O?T2V_1>S*M5--"1X]_8]!C$,*M"4
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ME8/:74%NZY*\,.BJB$31?#:(_W]_E[L5S3DD4=ARLB35JR3?]N9?0I:(A44
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M>_;LV;-GSYX]>_ZO=L;^!U!+ P04    "  4@'-<M*?F'Q@( @#X>P( %
M &EN8G@M,C R-3$R,S%?9S(N:G!G[+P'6-/;LBC^ T2DB4CO""@(T@F]J$@3
M 0$A] @AM-!K0(H-4*J"B"!%1)H(B/0N7;KTWD)ODE #!/*"V[W//O>=>\^]
M]_O>N?__>WN%26:M-3-K9JU9LR:_K _<"&X&N'!;54,5(" @ *+P+P W2RVF
M@K"W 0 M+8 ? (!S  G!18 (CQ'@7P !,T#\$P< *P*6/W ' KY?-/AW E&
M$(]3XL&=0.PG3HN'AZ'VP)E?]*_PD T 9QWQGVR_?ZII:-WE%!,2%1$2E0
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MD5FUOFG/I6TRC<@FCQ>N.DP\,]LQ?C1A6R+57W*<IU%WYBI&>BWJW^%5IP7
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MNF>75B4<6UJTL1_N?VX1ZU=-GPQ6E'D-:__R>9<$M+4Q.^@,4BKJ"N"=:J6
M?T:E/@=!0@XG/TE)<<'E,LENS#]281=HO)?+[ 0*3&.]8ZK0%Q;5M^ BF!ZG
MN![&>"]N5^VZK@HM\#\!X"X<P%9]?8H:D_2%GK__XKWA/KK9NI*RAHZ""\HN
MN<:J?:"/R:OIL1;:/L%[&# Y)"?.;OO6]G@JO0:2/,/':6,57H,*R9(P0>"
M.UM0W=B*QX\LU&89Y[PGNHI;7&=2WJQ9@-#DK;5\F!6T]EK#X>6EO<#PC';+
MJA<1+COU= ="T*-<_<R"*^LO%[775"IV7")J.>TM+@]'%DW?6&AQ-9*6X7K_
MI$$VZ/F/,Y*QX^H;_4MTL[)9]:G$6*;^C<5AEQ_5:ZW4N2SOI63RB^I3SUZ[
M7_GD7F_!CTOBE-\LW!O*S1U;S@_,LLE>A1_0=$GLR>DP8)C-*9GH[W]*?R\)
M?_3$W$D /,H#[>S1GWJ+EKN."48-IAJ65(??Z[_G''-N[AIFU3<W]3QQ:FL
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M4IV$\D'1%Z7:\UC[YF1V08>B*)O5UEL8EO219K=S"?<;<^Z+P&=T1D)G)W
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M]6+R5$/)P/E6>WR?*G/ ^RF%H,VM'5^V_4\EUBT0+NP#VFK=-',%>?/[?8L
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M='B%5BPS"39+<F95N9591."[28YX4XG)X(IX-:W=H0^P,ZE-VIUZY3@K=<K
M1,1-ZJH@/]-&A7V'5IPJO_JH:BQ L(S>V)-)ZPD!RY;<JQ_KX@/_J%TEIXL=
M[*X%A09ZE[5(TD7V,(Q0#:"V0&)5G6>"3G]RFY,)J3?6K\"W59XK"*<&^NYH
MP)D"])F9OA[GLN<:\BS/)>97\_;4<KE-[,G>V^I+C-0X<.0B)_<#]"E#DO2Q
M*>2\LVXQ.7QFYC5"=M< !4L1J,H^<D)"V:N39EONOZKW?B"P9N.K43".+;#
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M.%\H[E&::]5NC67@D.(=)031*Q828F[W>P9[RH?O7RWWE^CA -L=>I+= PD
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M^RD$ZHH>] 4OHU&C51W54C?=^]7S0^ _R0%=10)_)SNOE$ 33QDN60SQM6;
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M3!6/SA\Y]<2)"UV5-(EYJ>T9W;^**1P,V3ERR$H-2U(=*M13WV.TJW;7BA9
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MIA/4T*DJ38%N,(FLP#JSVON!(P[-V/KY S5PG80;%VS_Y)\R<%U8 ]N>=,,
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M82&L^/!ENOCN6^KV,,V#3>BWC_/V$EG=V>8(O%<D/>^J>WB>>4O:P3)0G#9
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MS#>>Q9Q1_?LLNOM7FDCK@*-G[3^@OW8K84<O J4]E'6^3G=5!LAZQY"Q\0
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M;>BUR4TA%-]%-P+'D%L8@X8W2>JA![Z3]$=955)W9K]\GVI[!LM$ "WBEGU
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M+PI+YQHF["RP7YF]' 9!LHO[%(B:KKUR@KC#0BLL'I=.!AO?C5T_AQ[=O]R
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M'+Q:X':G_4AV9Y)HTFG[B\7FQ+"4"B6_RZW/:(K.&6J"M6,+#8;51[K#'\X
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MG-I,_BT8/+GO(DI5/0.TB<B!V-R2US%BX_;O#A:V=_BU[X</8YHIAE0@Q?P
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M97$Y6O8@&/[1XMH<YY]3D2!C*LCBG?(GFVN/UZ]N] <GO3MEMW&]WH^"Z*]
ME)K"\A@#@Q77+T'52^8H 4?-'ZS4T,?CQAD]M9?M)BW[ZURF-9P#C(J"(*.[
M9X!X$$EW_@JE<&Y=7VF'5\R"(TX";CR%D2=W;\XO2K\II.J,CKO54%Z/XW*U
M-44+@7M(=;+J7.OKRM]I)2#T-M:+HH<Y/_N*56)\J.9S93J?>1^9CA'OMI"?
M=R,?#1;B235Y!;>C\==$=0A(ZBEO=-5_#!B_-&""FQ>LU'HK3$+%HU3D0D6G
M_%:)G1T2!G!G(C@GQ"4<S4(/>Y1R#+I_35%Q%;+^'\WI/-$^B\6HTZ$[;2.$
MZ[KQ,ZD"8Z1@ 7\5*;F>N&5C/<_TEH&@49^TH6,F^?>\6'OANHAT%9?899AO
MQ04^=\2X)Z'%&"_=R<]&<,&.?WY=4_:U"G'#981]:?Z&I.2(44)&T><NX'Y?
MZ[52?9V-Y4"-(F<_#& ,K0>]HX'9_N3;J=Q1>$S%'J?0")H1U;$-I)7.2DK(
M;\M<G0O2W.S#0>".1H]A6\D9O5H\_=O$S(IG)C8-A,6\1NIO]V/!'*7M-J)0
MYV'(7J"Q9F/WIV>NW<MJZ$70Q4VHWW9L=9"#!>MO2-"R,NP?J414VNV3WRVS
M7(5//-$.E(Q/^57& OC[TCR-]IIB+_VO.L>;9;B7E0L7^_,>G_<=;V5M&SI.
MN[O(TRRD:)RUTU2W,/A0O.<,(/2-DD%"ZE NH$Z^*<_?7MR&,C_Z. /W'Z==
M/_DNJ1(L>B!0ZB\XQ7FB7DF=>]<RTM4*@"E334[[K?27FH>R0\9QDK<7?;Q\
MP5GP.Q07%.TAY==X((L/Q-=%ZI6W-M/@1?-1I_U2Q[3%^*_3V*T6P4EX-G/T
MW)>&1L&*^8M[5S:ADO#1@%R^Y18ZBS\>^TR>=Z'Y8$G2@VWPO=,N)&_%9DVH
M,IB'/7% @X%Q86D^*>189HO :VL@5O;7^2UIU; @+)%.K7UY9B)>&#4;H"3T
MPG!.LW,N,XP4;A9[W%_WI%L*0!TCYC"1GZI)_?G6'$>)Y)W _<.H:VHW=0)S
MRU[[+B6T6NU[3;8:YF#QZT='3,(1.+7(5NT%FD9@ORZ"Y6^ ??ZV4^7JC1<:
M84,3_\/&A[RX[T@+NWH'SWY%>&&_7,=0%^O5-D]]4>&T"4$9FE6\-<UFU&J>
MUR+^K26.<Q#"9M#MX5T<(/KC1E9WS#<R9Q)JF],K PAK*$,EV4E6_H'S\5HL
M,7QWEV'PNS!4C_KU8-/C[EAQ=$JCN4N&E1DTAX& 8ED'U]!U*F^< >CU[\0W
MPAEFZ@;Y6NK9_\+E3[)4C/&"UU Q_E5R8I+;-[A25)LR5-!A@Z30!4;D%;7K
M4ZG @V*L[" R\^U?<WXR9T=C0#@^3'?7*@5T^]XOCB>*"HOA8,$H/(WOJ%J<
M?+)N@]L\#NM6^E;>+WFH@CM GN25-[-0Y:8??I1I>UAY]9VL^KM\^O]8W),E
M.>&2F@/DF-3]_DQ%U@?S?DD.MTGJ2HH91US31#HPI*.KTB9O^ &6,1D4>7PO
MXCVR&IY;>CLB97TVMH%O*1WC16>E>.#%@\[86I-RV?G'5*]:@U4#%+3EB,!%
M46)$&-/.5G4$(98YB(X.U(,AD:*P$_O 4 C0$I#(U8Y2!:!ZD6_4))+:K")P
ML7*2_0&)PQV\V=VB@L,MWZ0I8JK+90?'MEA^8=N^[Q]_ZF*N=D)2EC\%F7<X
MW '!RXA<1Y)JUI>4DHU>AQG6-GOALX$_:S'.N:76C[O) 2AFRENR=7L.,^;T
M#Q0^Z/[NR<JVN1WR<IG:78K[()%GN3B@^BYTF.]C%KKB].<<ZY"?ZQ8J'S)N
MRBB4^=C&? 9?.='S>AQHMTU+''!!^+O"#@E)4T4FE'XOD<_Y6+6/^(DN:3E.
M4&,0]02XW#H%.B@:HMDYD!!1RSJR)RK16X5,R=[K(;%;H(6OH!OE?AH9;0)L
MB?Q*DX]UYB:@,U?6.F'FWV%*'S7B^M$I8/GMAX;&8.F.S%K677LQ@]WTE##.
ME)TM>Z,7(?ZJ@_B^1OV!NL).OY+*_KOFSJJE^W0+@E@H)Q[5'AI<TYG$\QYR
M'PB.$^"BO"-#CB43L,&^>GZ5N$V6=RH(YH\D!^S!J0O0\>LNT0YQT7L?7-9[
M;1RG;2+6E)5U+!^SCY!@ZF%1,1VEV M.RGLP4,Q$WS;K\<]2[V^%9.WIJ*A?
MJ5QO >['/UT?<O_"_-O6-4F,?.>CJ]7,N5"%-;M0JGU[,N6R:LC8^Y"*G-7*
MQOVN8)06Y>/WX R(S)[F *1?37Y&O1@FGRG%K94M#KVXOUPJFR"?85 AY,1Y
MN$>??A"8S!&!UV.9\L+O)VRU.*SXQ2?OK%Q@AX\<^%=2?%^-!'EJ_,B\]B9_
M:]8ZAY'L$GG*1I.JKLPZ9O^L3*I0Z/>U0G:=<)HV YD+1BJX?.R@SY@M/]N;
MJGB\'$.WH X/A=+9A;8MC@(/PLGZW5'^>@6C:5_K+Y+F.U0A+J=7*PD;@P)@
MR!_A^/'DF3?!A 9!REW1;A0]Y$=;P=J0H5J^X&$U5V/28>D0:"'UWI2KP!4<
M2J6RT3(MBB_K2(H=_T7DQ1==!;%0[9I-:C L_OM0@B*U$0F#B:'KAO(TTAX;
M[#>0SQ,&YEA5BUG37FJR"&7MMEZ>@]B)R?!+S0^P,G5<>WTI8(Z!HDA QH24
M/9_%'EC?>>GHD:9BOEHJVC%64:+QH&A2IV=E&'1I_ZA99P%H';.['#80=AE8
M6G8&8 @*$*1?#3AX'O;+Y,)6Z'@$/,U ZI[.5@CPY;=8X*/_[K7)_PH)-7_H
M= -*SYD(PTUW,'459P!/VK.6E#U:SZ.IV=+U6MMUDST5GG^I;G%^<Z/$)B@2
MZHNE6N8O:V?^ *!8U-I,.O!'8EL.5E(O_BPW^X2Z^!<>/=>\ 6T[1'T 0:=#
M4?0P;O*EI9PE<'6E1XCY$%R(5!17 ^71Z^VU6*R+QB<:6I'. %,0RZ0.)$#E
MA9=L,*+RQU_SKNYSU@R:/EFSJFI:XO'?T&J,E$MD(6K U+B<Y!WLRTOK.J@&
M#"],"MD%OU:7U,'&4K7XVBJ'&\%#VS[)@$NX@:^<BK<?I^=X2J2FO;H]6X.;
MKP75:$4YUT0>\/:^];K][IP-%-6G  E_K65G,>/X;270M6?<+F!]0"DH)'#Y
MHS*_X$$@:?O-_N71FFQ%AX88[D/!SPK+S=2%Y4K13M"4D%GKV*GKWL18^9]X
M\7L* \ 1E0M4+8J>I7-=RE%K2(2:1V"%Z,^X E<PI]SWS:+$I_71-YR$4B!$
MGZ!FSO&[]EX"=I[I<P-=PZF*J8:6N"WA,9@Z_;Z10K?NIA\JRF=.O265KSQX
M+CQ4^'@X?>6W@MS&G !9PF?JKI?NP>Y5D\+4EU"CU;]H+T8D\YQ$9<6,H.X6
M3/%27?R>CH<TNQ7#)UH=W7 #(EKMEF:=1)-UBP,-1/G(GD;H(M9],;]C(_G,
M0'#.:E,+F&H8B_ (X\3.T5&*_0O7R(43CMYMADMVR@LL2;TD8%?R>J7,2?:G
M.WW@W6&5O5($Z3DHFG5UOF;_+^26<[,;W[E]U+619GD?0F]MUMH7S94(5+N[
MDV^OSU;^O#2P44'1*FTN:C7JS1G U9((1>#OD6XDE+@=3GQ^/O)2.>>A:DNE
M70)><.HSMO6&I_WIGWI]#J+U2ETVYB4$+ST)ZLX 5Q\F.NQ,(G4:/P3_X2-V
M5P#WV?!>F_L++ G'3K7% D@7!IO;R(=WNP@=OEDGRO\'>>\5UE3718UB>U$0
M4>E=Z5*E@S3+"P@(2)%(C4@G0D1:@!"4WJN %$&DUT@)G00(O??0(?1.0@F!
M!/C]SMTY5^?J__YR,6[6S5[/,]<<<XRU]YY3<+#0^/?V4MKZ#E/ED66!F@*\
MHGX8*H>G#2(#N6=FB0$]N9:R&WE>IEGH=#^A2<4PEY6ZZ-A;.MZKBY6=@;@=
MBP1M;YO@^K/O'Y$VQ V2G=PN'F^Y\VK,0W'/0#WL <W(V?TLK2&&5&-TU^RR
MP2JR3!GY*DGWW4&9IO_2[QF7^*5ZJ_&]CU;%4G=N!&)NVA\/V,.&C4%X\))*
MXK(V/:WK36WZW+MQ#-[P9\02_,$EJQ1:2J-HMI0U^$^[5N !(/NR%5.V @QL
MJ V1H5W0=!F-*YMR9SCTMF7G%&>*ZEM1<3#6<CVI/<M)>Q"5D3.WCEKZN<BQ
MKR2#?PBF7C27J!J_9^C[^===S L\!OL.L\>'KSPY1I@IF@GZNZD,)>5RE+0K
M:4AS_:,B.\!K]9MTLU\JIA-9<9$($W=04<253A*.7G'FL55')X8XR0.9*[AP
MX9&F_&-'-<E4DJAZGJ2ZBPRE=TNJM]Z#GDUF7Y2 <[^JE0I7?!WPH\-ANIZ2
MG^.2\M;28=M\#Q@&M>*> 4!+M)1RL=*>B(:9X==!\C RX#N9XT\5\1K>V@B7
MF2>W[Z(]]R+Q<"V6&9Z;$XQ>8YA04G*^LXEQ=/=7R9]##FQ53$."-)_&>LW/
M2665^5DM\:GADF)3HI%:Q^> /DZIANAWR;(ZO2_8,2@H#3')>EF5VFRVNH^C
M_=%CX[_I>.+"4,9<_])4KF+3*J]^4_HMV^?E")+UG__W[6I.??HNX5#SHD/T
M[.T_7+&7CTR(=%J.!1Y23R_FO->BH;-XZB[6T$B7W+1]>\$]4F%K)Z73/'X2
M>2F%GQ@S?_U&=H]4O8M $]'O:\<0A>1)HPB)^O!-"OA0%70FG[L1/38J0=9E
M19CGV5;<S;Q37S6R/E[.2U(NU;)85;K%<)0 ?0X.6V0Q.#*H/R3+Y:(2>/WK
M1I\LK3<K+OMWD0YB4\!+7-2_N_+10:AF0T1 UJOA_\QJD\/"0V>,L[ [82N'
M[P72^1<LSEUDSD+\,M^%/,Q_@D[[*0K-Q>BIC6-+]&=V;'Q=RO +76]PF@V@
MJ7U11M7X%R0B1PF6=J8$@ >T%XHC!M[JY1)U&1V6:Q-CE5'!W^ YY2JW>[*)
MU"2[SD.V/17ZHYN2?8VQ.K^; (0T?'X9O@";APJ=U8UHO\B7CA'\Q@(T!PRM
MDL':4@5FF>D1$41G#WX"!F-COP><-592)3PGTOCA?3ME=ZT]QY;CI%?A+[;2
M2,*$2MQ YS><#[KM7.23;<+K5NJ+P6MPPXLP?WL.+BP8K<P_^K&D<"[V.+F%
MW8-AG:OV('P?R0X%5"3TG=8,M]:R+&5,)BU70I-S9Q":^R1@07>Y!I7+FZ-Y
M>X+5L$:;_/YZ?<@D85!RCXWS/:;?_S:,5JX3/B/$9JSN+/#FRZ@\J?'[*B ?
MZDLL*BX(F-GIC^=#6<2U%1RPGHI/I2Q%J=(BZ?*S/5BO*!Q!+URTY18LT/%
M+FRFMB%;%*2A[]25;!+"RCZ*>C6/Y(3$+&K6UM8@/FE\*BZ6RGS>87LY>451
M74?TQQ%>)[OR%[EQ=O^F7)^!#+@UE/;A+C5EGO#..KK(]22V,. 6.X SC,!H
M(+/XONG'21_?IOLTBV)SF!US<$R,Q3>/3;*!<6S\=#BTHD$A/?K>SK) ._/C
M^#2SYI?0Z]X*"L7^##!.\4"$MXB-K91:W,HPI@K684D7VY7%DMN<H#SLJ&C[
M*J9 IO5RYOX5A1W49()W'F$7'Q';B1*.T3%64')C7:1?RR/YM\K7<W$GJECC
M=<,_P;@=W%RH)C%.J^LH )*=:+UW14&CI/CY<#]&6\T%<2:'U]!*U!MCQ%LT
M;<Y"%+: N?X50^V*L>' JLM =@/I:/M/\8HWAC';EYS+ B)*1>JF/,-MM2">
M>>D!V<E>OL-<BT73Z6I.=U7I# "#Z]+.CJ*JC%VB_*#4VRW'$IU#%^><J'4D
MP8@>(YDZO.*G ^3:EB5,ZG&N;0TI"Z_HS<2N]*?4TN2U],>;_<P+??D"7BX#
MIIC;9F7\/;@_IL2K+I65AG3'7-YQ1-'#KD,6IDT7%MO//88E4IF%XW($6.!)
MR]M?X$$Q0'4@PZS?;GG\4-B$H%C!X!4%[H\_]E&-F8F8]IS[6B5H$7D/UB<%
M26SM\[\K*GV8OR^\BII.Q(K5XMTZ=VSSNZN<&(^2DDQ(__"< W8 N[ZXOHZ%
M&R SCI>='=G1LAFUEL(XD=F0(U7[OF]!N? 2"UKE$2]],ZZL*PHFY#\OP*ZN
M-!?E?*&%PD> $2!.#Q7@CXLD/O1,8(Q1_%WZZ_SO(H>_G8Y4.^R9L[5!##.C
MS-W'T>J37652+4_--G=$/$=*/7$9W(4MUU%:.,SC?LES!@GYC1+CB+UU#RO'
M7J9/Q\#IR'><=XCA?.G<9UZO>=YJN &->+6YYM\!?\&C8%R0P86^Y<M,,95W
M"4;O5I"@W<U5$WT3W7<A+^";YB&&$##TI%"NKW!;\'=SSH?_=A>]_UGX%17C
M\/NKDCVA":]H C%5%I+1)_QFS_#%]/JS(IG%4+A%0X31Q=KXK<^4IJ<'L^ .
MW!1HQB^-/";M/50@L]Y0DT,XH)7H>JPLO.S6F_B^NN&3ZR0X@SR .VCI=@?2
M69AIVADO*T1@0Q=ZMH4W=:@)V@WU.,VZ1H3#BKOB%\0Q?R*.YSDQM'!F@7F2
M;<I"]YW&H-M"L^%*:(#,;.SUV:DMSTE'A&O<\SU@+]FLU;M?ZLD0M7=K8XFR
MAZ]4=U%HBA1X%:9!''NK%VPITE2;\#:2/=C(\)(1"FH8;K+E6!7EZS3QNKF+
MS&_(FETDF&$N.30$PF02V3TK#[7^#*Z,YEU1!+A#!48-EV(CFJR6[^RMFT5J
M<O\)GV.ZE[M"/=D,+0AQ?5#"^B.R+=<@\;!F,>+VB&_S4-DE+7&9YDOOPE[W
M%846VY2_.Z98?;@'W*! L3+9Y$7P)?K+=*%?>$A6JX)F>6\PMV$LO+*=GODA
M>5*G?!$PDOKO#OT"8]U11_-C3%/B,V%457<_?Y+K/HB?EGK6B;74^6Z$BLOO
M0H=+NJ9).>]$S:PR8_Q-.4N*RH8F.[#8@N1JXAC#M&Y:Y%K0R1.?K'3_6L]T
MD.J>F73,LGJE?6S@MIHI3C8:[*7<\#.;]Q',HQ7Z G^'F$KZ%Y)VKLGZ^G(*
MJ[EQ6+Z"_5EOX3G973^_+J9P"M^X%"\14?\PGEFKC5>:4YN+_9=8@(O0"QW*
M[6_Y@1"$3LURE&RAB ('>_P+MQHBT><9_35'[&92M7BZT2I_)^!UV6R2G(//
M=PF7^M&R)$KV%25,WRE2V9E) S%>9C/K^G'9Z-&QE;EW,B=2+6VD1!.V[^@W
MY'&>JB66,7+>M8)BKQ)6&KVQN8# Z9'IW9:Z)\&?R*ZY;0/<6HPK[%BF(KCM
MQ4^D?,$> ZY+)Y5_WM7^OG:Y][QETK(JQ12QH%5N1KDWIVR57V9^<%1="ECU
M49*L(BQ.\!^L/E1F49/GDKG\&RIJJ!3^!EJXV EPO[0[2\3VCZZ:%Y"BZ8$K
MKI'PK2E9>C;72=];_YR1'^E-]+<J@HH2T240S=R$V]B,2-W/'!IY/AL!*H]W
M5+B)>3E;AXS1SBXY EE-4A&7G_HR>?B&FG]:L'J>2?7%UJL86_X]6 &P/LDA
M]DONT9S'1HSU5))F,D>UNXU+/\'M/OTH7/0< MF8KY"FMIJZ8MCV[0!8?BF%
M\PPM(YJR^:Z;/#R\L5Y^C:6+X>PDFRR!NOCA[ZAL>:3S+H&M>ZJU":LI\ BP
M0XQ2%E&Q9N]X-9>94*M.B)\6/-1+S=(E4Q O7+VQ6.LR-?[X$M/RZ: YL IB
M#840C]AK<EYF]A"GG2\]KTE>-HFRYXOW-3Y%^]]>((-0R.8)I9]BRW2D0_@?
MKNP#$UDY2R:<?8SUZ-Z_7G0ZCV/LK7XN9:J#UH1<5XM74%5\ZJ=9XE(C9XI>
MZBJC9IH.0R^(=)\7V:'LM;B>!@(#EV.DJK3]0D.9"C6<=CN2.7XE32KIP^=K
M<*')<AF]:>L.0T@56K]L,-*S]6 O_,SP3UO$@30\R@?8P8B8$.$U/NH]BU -
MCN6%,9PC;["$)YE8E9!==^;%2DZ>K0C  /7'\-:LJ+X27A_+ O[9]K-WL[&2
MS?]RM"'U)_C,%!T.'H/%ED48K,8!(ZB[2L\7>''!9>B+O6S-DQ;X"-%+-EDH
MO<!P.=9RPX\J1JM_T^%WQ+GAK__GTX/RG8>,U@@CF\29GY9 T@OBY(YV#(WL
MJ'J(9K?(]N?/H'26B!C.J!(]FS>YO\L'1_W#31D0F$3^ J=*>V914_%"LT7'
M2DWVD:8W0?N4-<(;9=I+9$S#)Z_[0QN:CWH^+CXMI^U(4>'&H?9S)O;;_-HR
M[9GA/]KPSD*5:QG.4QLQ @T<*T,,&GG0-^,Y@:+WL-4Q(4V4A!IB&SBO%K<?
M^SC%>)RJY*:"C?I2VO%!&)(OM 5%"T:4'"R8=W&N=?>X60)P3$L6;7VJ,3(=
MCOL'O.*?*MTJ^5?])(!<L>W%4UE6K^:_(\#5_@,9"0E?*A6'O@$I>8F&2^\_
M86C\)->]71.FUYO<")/C!:/D=P4SU5'E(R'F'@(R!TCNBVRH.&Y1\^C$=^V(
M_G/\_7Z5WTU9+6^G+T<6'YIUL.8J5C?*2LSFB-^]ULT+&,2+,:P\]9\B@@1$
ME1_.5PF-K%L."ES#H8R)T0P!&IRIA?[V?]IM.XTB"%<408LW9**!;RW<VA]J
MN$%R[O^*!2<C@P#93@W-N9[Q74Z1X(>N%>H4\#?$5^5;?\R*%X2J?;UY[1D4
M-*BQDE%*UNJBU0?EF(.+3_2;@N^/+/0ZJB#76$&I3758%J45!_@=%-X#M2>
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MS =Y.*1#_%D E+P5<BXZZMK*B\&X>K+FB12I4\\'(U><>@KA/"L# "RR8.6
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MAXTGB7CXVU'^B2N*:F1O6M)$*5M=-) :^ )]-D#UV2.'8[)YS"S'B2%A_/Q
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MVY@4.[GP2RY'2^$1UK;M21YJL1'$<^XFGDY@17!G*LW$8%*AT+]?&SI?=-]
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MQX.6]N!MT4#GLO%$D=@DRC\#4%DP&F\^89UK$K6YY>Z:18=RU#%%+W.,9]K
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ME026N.+,X#L':8?2#\H(:W;&Y^YEUJ5A5G-C7/-1\6D7:(:4XDF#J6-;W8T
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M@^ZJB@!Z/I>;5OQHJ#L(_3DM@+&X$''#+F^H?$0&E\^#SH-,81F5>J[2V>\
M":#CP"7Q;RCL3:*K-?A1^V%GY6N);EYW.--%FJJ]\HTV&']5?8A,0]K\*R:/
MU8?"6PB+DF\M[!3"IW<+GL0\/-P>TC=<^SBBQK!'_Y\_T]Q0]%JTE/,N77/+
M2 8B_(.2WO(3UE=';:7%M)]820(K<F%*1./.Q=/HP/65/_!4I!B4?D*&YJ6.
MH:;SX#0_]Y0ICAAX!_@@9"V[P:OVBU,^U@;BAXJRP_7#G=T>0/#5 ?(R1YZ(
M)7$ZB!DAS *,]KJ;QC$LZNKR#^R+-SR';)^SS2IZJ%%BZJTC,5,6H_IL$G?P
M;6]?J:RN[\-_FA*H1]\L7BXB[5A'=P@4"Y.%\3IK>>/KVIX.T^J0\M$CP[$3
M7 FWD")G4O,2ZI:9"77T2!%5CL!D-*"%<,0(@HS+?KG-4$[+H5[J7=8'?VD^
M9A]^.8:!,8S"6+9]G$_FA+T\'AA%U?;30*V7P;/"ED3KI8K<+:G8N;KW73=W
M&8X%R/1,2Y;UQ0[ 65- *N^D59H-5[MRR9*S\(MQ)<"RU-W)TSO<"<RO@UW/
M 6A7?MNTMYT*"E_&M-4;RD[L135UM ZL][BF$R^I:']#LM[4CI&-\F??;MK'
MMQB ME&W';EP%=5%_&-B/'55=5&%-JOW08?%P  W1[D^N0/FU8>_/@MOBD^G
M$,+QE*W1'QF84NA,Q+6]F;]3CM;C+/D,"QBH+D]/40,W7?U8-E UP%9GT-)&
MQX66-DOJAVXW+GB9!Q?NS=5?/@>A.),R%_3$F#GX[%@HEIM#.U68\')[Z)7&
M+1%W5\I4UF^/#!A\[65V_6_XVX@*$-[C<EZQ/Y$M@RP-"8OWET,>L69RM(EX
MVHN 8NOR(,WI=0:QTF>IH*XL&K(X7L[ X03$G!OC<H="U)NK_8J"R*<>([(Z
MJ43G=R_+N^_,-]R>0 8=*RYY[2;F[B"OD5QR^S& WN>*+PXO.JP@8P0!S'%X
M+IAV4?/S3R/-1^: '984ZHLO"1L1%[K;/V V,!5(02M2GJA7K DJ<JC=8[>_
M_B%+&.:1M\1U&\1%IZ1M#?8&N>9/OU[J\9"THK?Q.H6/Z#T@LXQ+SW_45J6?
MT9#^BH4.I6J>3R@#6\\MT_-DOJ>]BY+=E7>W-$9)=4! @05A&[D7JP?V%1TB
MK'HZ@Y%8RI ]\N.E$F5QS3J23K7@O:792M<!>[(EL=4:-\H;\L[YE7$=5WUU
M- HR?1#KA"\#O,0#OB'4&W#EV:[>K#\7[=-T*B(B"2Z1[:8''>GPA]"7%35'
MG^83)I\N?-R3.4X27/%FD#=<2\;,\ZV=,ZXHFO#DHXA2I5"MQAH\940NR/?U
MXD!$=W24"A*Q9WF-Z%8&J6E;X&#239L<Y)NI=#X#\?MS=BRK,F]][FXL)>,X
M7J^ \_QJEYQ5>M%H1G^K$/D/"4];A%9DCC.4T>-G[,4U:Q/-BT4CK^Z5%1V%
M)))$B#D6]>_!XHQL4&S/&QO <!:-"KL)5!IW["D;(??!.T8UZARCIN:7SW1-
M@[9,VE,]+:95C1Y@]4*-_NVU_YOQ=M%$H\BD!RQY$&$[T[<MY"1XHP7V"-8M
M-5"JX_UK0<.I2L).G66]+O8A;#!3Z*_MGPGT=PA:2Y#> YH.][*\5@ILY42L
M3?;@)MA<9#\-&GT<&E!E(U_7"X.)7 XC#'-VDFV^ K]VS5%Y!:M( "'B[7@(
MN).QTJR_70,,0]L8T@U3$;)FJBQJAV%"+>Y3C#+/%SQ'HA 0KSU-.;)H5L@.
M1Y#0S%J,;4U\W8>+>OC@D7ER&;MV4<!B\>8%P%]JJ$BMR)+RCY.!3%Z@=.(M
M1/SK(ZG6FX 6%.**HC5K%\RE70Q1MIDT=B-M?CB;IU6Z]-C,I,(MMH,?.ICZ
MH<(]M".9]][RW+:;1^U8#BQQW7N_.>EOCZ@)6;9G]LYEMH,+2/4(K1LI!T,$
MT9X+5Q1\ES9:W_-+1\[&G',A&QVL<14(W'IA:1>(,3;H'#,,O'E%L93Z$+)P
M^X26W>D!&[A)9-"HS,]\D28G<^_Q6/;K$^K ^+68DRW+NQ?A3?K%/VPFX&NU
MP;C7)I+/S_7CB6[?"DB]*D<6!+',>XHY&QSB!"^<7)M&# VM7C0T\XZ\TQ$7
M\8E&F-C>Y<VMH_<SU?%FNB;MH.A?]Q#GOOFPK@6V,25A5]M'H-15\[/]P,_<
M2$/\1NL.QT>2$:Z\",S1D9$]SL0R0\O"0%"HT<H.<+<'R3C?B_A>QB9UR(/=
M"$7$1C5,-)P-T)0F")WY=<N<Y^'&EGRAXD1-Z]L>B!#Y9&/[K=$FU4[_/YS-
MI&=F%J %S@J+5YJ:_XX$J#AT^MUR\Z\6V/M;=-@@+ACMH_S1U6_O>&.N X3^
M45A&L?:YY:%/G+H><.S^3AC)6_?&I^?.CXQ#H1<-2N*XB">ESH1MGX2 QF77
M(+#/&1@-K*V-DN%B!DJ?JEC\[$V*9J9-458HM[<@6LM%>6CRI_332-EF')KM
MF&/:54.\+._'R(:PV*Q:?WSH^+%NN4;E=S"+O%REA8J5R*OT2A7,1022FVBG
MN/=ZNTKCHJ!4WNTQU 8S_GK&)9*[A[4T/>5+EC[PVF4KL.J*(JS)=3G2POIM
M",A/<B)02+[5'PK8K E>4N6^/=!NE60DV+TIO$^TJY';]NKG GKE@!J?"=8+
MDC8$5N ,"Y9$'UM$K5#=3FT9M(KT&D+=X4]_<-QHICU4L44X*DVAKHZ5<#NB
M(I48X9I+SV_&=[ >[PKW7SXB^G2A374F3EK>Q=R."L65SZE;O1B:TLUJ&,CA
MG4B3!U)!4I7XEDBBG+U<_&SN4VR3C5QW'"(>4O?PTHBG,=\'K3J;+:^=QBC9
M"VT=*AFOX:DZ(3);67<18'J(ET55_3A?7:*."7T=;QRESZGJ'Z%!B?-*?5-6
M(5/?!JZ"K,J\C1GW5%:]DYA_I"Q[@-)D6N(8EN0+HMX$\T3T/S)Y\2&7W0?0
M1 0M&T<N3\Y:%YKU3PW.K\B<_M%1X_?HGB^_T<55C0J"WO$CF)693I0;87-,
M5&S/,<HD$!0$#@3>.F&+U*1R2GF05$-QE$F$#_V\3J/=[JJ25^2-P0"BUZ7D
MYXPXG8)@R1 O0@AN(W)I/F]!PX\[-DU^5@1QKQDON7[XA >A5X4/,(\@'PS#
M!.:A;'C;GQ/1_<DUVRUSZ@77SCW@5=6T#^"14&7[0M[,CW-MY;J^\2^4.H,'
M1E)_[-O;D?K1B6\#(P1_)681XW$8/6)VSD7RH?RD&F7?9XEJS"",&[>0C8ML
MIP%]B>4K/F+_!?UE'W%>[F7FT*?)ZT!YFL[PS3G;$?70([@Z?=?KBY2S4/^]
MB9NLAVZ?\I.?98D<^S'[JC@//1E1 K%?<GW[A'7<YUTJ/I&IL ?#'9,7'1I&
MP#RU+M!.2PIX49,$3A%MR1*@*J!9?407-_L,H.V=;;(XA:B>Q#?=E=T5[A3N
MRVX[MM*+[^[;WB0&ML=-$XM[0O>G*P)N=Y-!O3('7U58$PWEF$RUI&.\W=_^
M6D?&$4]P3&]Q@/#U<?>ZNVF?NOB8B)1_X(IUD@LF?](&L>\T1#XJ 6*!UX1T
M1DKN.9R5I&HQGIJTH$EW_W*Q[#_:?&::O,Q],G80C<L[Z2#[E=MVXXC;=A6
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MT4+6Z.4$=D/%K]^5KDD-G= :1$-B:T)5O-/(^&5&X:%'N"J,\]L_]3S1B\>
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MN,Z9]9!FF&>6=?JSZA."ON/!O.XWO49Q_QF\&>D3V6NFW6LS^SJA"Q%%'24
MV7_C7*MMO0;$ABRR5;Y[;^\AN([R('++IL(>.>J';U(^V'SLB@R_>]&J&>)*
M*HPEP!)"*)C;98<Y==+=\EG?T-<?3[I%ZP1B3!./ 810 TF>P%"I:$-\?<U
M>411#[NX9I>C?)YH?[JV.E7EDV_^Z%U'&W)E#V:!ZT1OS=G:5H_;Z[CFB@TX
MF*QDA:&[[HE7$L^A@A1OKW"= 82@;I-F0TR"(WW;7)I$"1DW:W,[BWC1A(ND
MS,$P6GDLS_Z&=QSU##E=AI13[KSDP8]HW#M:&ORA'X;PH+J3&O3)HS&*B&KU
M@4LR>JD<(2. 0#)5PD_BCDO"CER(W]<V3"L\'EU?U&MB;).^L)K0_SCCQ<^"
M5+2M7W30M)T!*EU_QU>!Q0I["P$Y>@OSODF\ .+>'$%F4^Y>75DNYF/:@#&#
MW#J4"-*9II=K,-6=X0T2^E$-CODFR1:%TL&:V0EW^3;^X]W6_^V08UU*J/$O
MIFMAE!0"?'UJ' W)1XLW:S;2=\8U:3:7WED:EIM75Y:> S""&3>IX[O]Z$:#
MI'U.J%U*0OK?!M%;?_4CGDZ)/QLP)EN62N5Y*Z1>[^6:,9U7VSH&D"S@+RE%
M+# OS=)G'VZJ?95JN<8"6&VW>D@-#OX8YH"4"Y&O>VG-/'8.L&:-S!X^\_R-
MMI[GND H]":F&+FKH15W1189MDWDH1DJ;>U1 ARLU:9JAE:-U 5VC@'7ZDBC
ME!$2/$E@_G#4[&OSFT5Z!O#-& N,SI>BF]L9*J(372^?Z=CIT$WI*C_*(BI
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M'H9.O*T#SO>AB@H'+[@(S:9:M2VJ>QG_Y4%Z?)UC/ D[(*!^-8HP9WMSN<7
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M>]4IU^L;OWW^;N!UZ(GW4M8"W%(CPP?8IS ,J3E[N? 489?1%E6F51#?'KX
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MO=@K-ZV4-<[=&L6@98\!7MP<#G05LM=O[ 75L>K8X:<!XG<W/)@WE:9#EY]
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MSM-CK'JE8?6X84)-6DWMW$\6#E825KD<CZ?^JE7P [QNNK=61W2,6NPP-I]
M*<ZM:^"7OZ">-O7NC4;L([BIFC31WI3&/^81AV.LZ=31WMOPKD]_5-UB;#$'
M*Q?>$+>\)]&NP-3;IET%$C[W=PB^(ANF2H-SF1JA?1&))X+$W4=V::N5L^;[
ML!B6ZXXLEG_7H!_\\@9$ELRYW^Y:>Z8ZE9_[7FD'(+*R[XC7F+KR-%EH^?6#
MF?0'41/8FJ?4T($0&&?P9I0ZXP<;ZGOA'1WK%2X5^X$M/S*(<4'<L]K7"??E
MM:0"#I5)728I=:&NDI@WS.9J4$BA'SQ0MV*N4Z+\4UH.SJ'/^AKQE;]47G]H
MK5O<U-;LNUZ7%O+-X&+08"TWP6BR7651_+Y=DGA)LRXEU"F!5=O?82T1*8BM
M>?ZGV?=H>FY4]XYXY2NZFO=B_O2VPHQ,\B)'W)J?^":(4!$31=;MU;A@@^\8
MF)G^>*<MS9,]:5^3QW=!A2?=2QRD3Q;L]D:BQO]43IA#0PWZ ^^(:R]$MSL4
M?_BF!?JH>FNQ6J:M*';A=+L)&6SW4G13LP;TT%SX^V^KF[4#%(VCXF"?T-[1
MDLVLIG*^+DN-W-,OO3=O/C4.Z^[_G'P;<(59HVO^?#U)/Y:KR/E"'X>D^.V\
MR?\";_??A7SY*H[GW[LL](VTSP!<J-O=(0QU4LUJ?I!0G[^PF 3U)J*?&Z]"
MN$@"]XX8ZR;H96U5NYIKCT#C&5@0R3R*F:" 7(47#TJ4UESQ>!^T,ZH[ O6B
M;@[<3H3338*KO'A5<ZT>&*N(+087<P-;?JZ\O+6<'?(I+7LZ'2"91P;-+)B
MST%>D%GR*U1#<7[9[?;PHE79C#9<ZW8*F@<)2I:0:R%17BG731#9%8X.U45N
MW$8LR0TC8%[<W!#A?TC;L=6$*>35]V6Y4C[A0ONCRW> 1AOJNRS'@)Q439=5
MU*436LSK6:K*;_/H?YC8'N[_N:"O#6M#=EXZZ/-C]_RR\=ASUVYF5I%<M]MH
M!?<"(F4JEY5$K$\$C"XKOI%FPX]C,QW>OB.A37(G!"^<:!N1F76W6R7U\Z?'
M-<Z]WU,[_$2J)#B^(S5T648XYI\K,Q9IN"Y6)UGHW0-1"%Q<$)XVX(X+VK2+
M,C /SG-->MI_=\5JPE:GD()1KU.>'1;Y-%I[A?DU=;WL(Q4<-BUY\(J^:=K)
MJTO8C@,_MTPU/2?PDO>@XL5MIDW'%/)VUVW3EVAWNY2J?KN:QX_T,C%XT6:H
MQ2[KUH=@8W2* )B4;V]2V57YH_F\-4BY?BT]ZC=S+?46J<ARLAT<NLS-9S?(
M/[OC-[&4\>*9;I>0VL;$^I#"2N#!%\/:AF5P^MZ(;J__]WH[O&V\CKDDQY5:
M:#\%:]\,<LMVTU^^%G@'6 8DF<!F9+N*+D#9<9LBJ^D3\U?NI7>>\8-F4XX!
M"9"KE53-^^G#)LB$'_/*T1G%CPZMU@[HO,< RHA?_*% +J'@X0^UB16SE%N^
M5A/)1QP3B-+)+:>6I#_I+ER5DSQY@+S_W7R/*B]<1U.BD_34Y,\N#F?Y/R_.
MV"#83@(;/>>5@SYSX%ES.?8F+Y^V50< LGP,.'.;NET">?(SB":N%-R;YUWG
M>7?H_:'5"$JLD?'SYX<;=@6?2S,;(788GZT:>0$ULRSE^2@OIV6\MF9/<L:7
MN08 MRV H",#T03SJF;:_/7\9+?+\O.;:A';_M_@5_'QN^Q1YK-_(Z4649HQ
MCI'DTN6*.E*B60,:6:>1^"C@ANGAYYS5M5[4]2_-9*D(K_6#H9=Z.;*#KINC
MF&AM+)BTD*1$#RPV<&GF: I8M4P5NWA05=1HNG4,J-ZP?>YXV=M&_=YI<V7'
ML]N6:-?M- V,X]E6%,9Y+AR2'S"@J6S'N'Y48[NMGWO_J[-:5K#YS1$ 9-^I
M8H:JAEKP$^FY2(O1UQ#9WXYE7)A$*N@O]$I<SBAO,N,PJ]"W^OAMV]&9;&4S
M$8Q@,U)++F_/^1K,OIGWBVY">[Y0&5VSUW83HYD2%N?HX1O&QT31_TH! [TX
M_9Q\+@S<V-IYQ&(JD=U'5Z*Z!R_6Z%K";3.>$SQG/MB@[+DZK0; 9Z":](<8
MB%>61X.CO8GH"IUZ"A43VW,,$- *ES3^;*"V^R P,>N/&6N%0;5B5K7OK(CV
M@ER(&CX,L2P7MFR(G%C=L;AHEFSQXH7<FA"RQHJP_6IIC'ZW34/^@F#@-YG&
M?UO;GN]G)TP5V@#?@+T AZ&+48LDJ]Z1<PQA@;N!+_A?B[VW^LT?C\57+[]5
M7%#6?4I!#(/BU0LOCP?GB]MZX'0K6[*?*?18_89O[9+S\$O;<0(6UH169&]
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M]!,CG?FC:&D/LVXV^-:'8]]]I50=QSW9>P^!W;^<G4?:<WZ4.G:OJE4 K.P
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M5^BY!D::KAJ]T*&+(I-'=6L5?^J/7S\6=IEB,?ZKK<UJ<+$V\V6,IK!'>$[
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MXG1$"UCR>Y]KO@U1N9\'RX@H/_O2&;)+(0F\DF4=H_N8:3@G.@W#%<6L/O9
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M)Z;+4/,K"9/K*&0_1Z9;R/#LB49GW<1Y4B$4YY0&/!6;;Y(2''M@3;AZWJ0
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M[,,^&[_FA#0Z=M)S>4MQRJR;U<!KVF<XSRY9!;L>5VJ)A_3*+.1$YO#K6!V
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M#>I=V_]IBZH0/I[*/\X3/%4&5=GOS^':PD3O7W;W-P<SY0=I&8F/5A_S)QZ
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MBY?U.Q56)!!6%Z<=M>P0&+/99$<T?DU%U&!A5'X3I98/UW;[.99X$_U%(=8
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M>>S[#,>&S%4+Z7M*Z>\TVX[WA2S)Z2G#[MFJF'GCU!UBI4LPXPIQ8)HQ.OH
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M!2E79I>@R]U0\J=F6F!\X]6*OMS:C&">W'7.@CK.8,U.>ZL58Q:?(<,07'T
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M%PX3OR:"U-QU I>,66"=!?D/U?Y-L_^:8L'_3YK]NV+_6R\8X!DZVJ/QT(D
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M'2]?"#B_ H5OV-([^ZOXS,6TXEE4@(3XWMFG7">YU$B+TS,Y]K\5[I>?;?^
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M_6)1P>0C,:IO,9#1KG8[O2,$&_YCL7XL-NX"WU_Z3<ED6!!GM_XE_/-QY9=
M(*7AOH'*=G*EMP_+3([_WOA!H""PNU?^1A[JK[RV2JUO"B&#S4*@@VTULBDS
M;U\'-UIJ4SM 7]W8*SEG:FX%SOT>)=*V&#JK.BVZ4.GH/0X2I.K/%C7>SZ+[
ML?.-:)C;=4C^4LU@8DZ2!9(K10@QN>XBYGK?O^+9I.SWG,FJVVTQLG]:DA*5
MMY8=%1<ESH$!R_[*G)QR+!M-;JO=CC!;?J-*(%R1,"J6C8<*?<6H#%XEV->$
M]9F[--V/,3G:+A8/92?-<4N,9N:!I68"C1427$Q+=CN>^E&6VU$1AATZ*@\
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MZ(.IJ>M\CC^>?I&GFY+--^-Q+IK:'%<IX$U:F\$8]/[[1S3)OU?R3_+;IKB
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M>(^N.39QP/T! ,M0;I\*+11G@Q=-QAZ?_75',NMA8VRI0HY-,M;&:&T[B 2
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M1GO\RRV%I3SJ8R$5A<,#<Q<7DS5V<<USGU]B",W-UICVWM,ALD(W-#I"EU>
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MET9C^6N\*(;+-WGF#&]_N9/]R^)<! %L=<BC)!?I][-ROIZ:7;M5*7?/Z ]
MMZX%Y).2Y$3\%,XI5,%" SQABN*AX9L"_0F?[;=ZS"^LD-<=(_RT^HU6 QJX
MHCX4R7=TX! KL%O*I"[#7DL:Y!RWJ;1*)1 #PSW':R&RK9KOOT8OT:"BVL(.
M/V7 ;\GG&NDR08R1\.X'F!DW*$NPK.6=;!Z^,Q.!P<'CA^MM'ZY9YPBJ^+>!
M-J7JHQ[%%NHNW(I/SL-#GP1@6OB]U&CY::T.9TXG=0K*5W-+][I?#7RZ9EZ
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M<Y4 Q3CA]SEZ#>&@H+M>X5?CQ[5Y%WGJR.0N3!H*]3Q/_U([3ZI7GK>G5D)
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MP+H1Z;4<-OM.F1N 2GW7Y'#NS-@@R4*$I%(X@D1>8* L\ZF59\#Q\]6VJ?.
M'7W)0W^OK'F=US\>LATM=J2O%"T$Z>'</EZS.?:0:TN=9I8(6GRQ3M[?'Z@8
MI=\",4@X-@9+:AGZ!%LZ2#+4U?TZ(NO=N$J=^7'-0!"=NF;;CK:<.C Q0<*D
M;;0N=]VK<F^_OAJWH'>]ZB].L*H<X,1R]A;!0^E@=I?*?KZ^3?LU\!3#)KK
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MYJ8A1ZXA(^.U0Q^9^+ P!D4>"\BWX:6>_2DG4[$]183$BQ@DZ[5--T)]7[C
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M)O=$.Q(&?0*49L6:<0(<GBKO(#< @T;L'P^X@__SK?1($3O/->5#&P5KG>6
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M#?5:A7W*>&A3]]AF]FW!TIE),8,KVXI\492DEI!(X^^]!%?Q^9\FRW$N:]S
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MJC_<\7BJ49D%N,L.>0]#J#KPGAP,/A:1EA'J1!0U;?RM#>G\JZPT\<)*CQY
MI<5.FA+WA5ZM.MAZN"HJK1TBF4$<]>C2#&T%*7]>@^\:M_&#MEDW U:6CIEV
M:FGU:*WU[M.Z\![PJF\9TY<')QG0Q*C7N(2SAW%@-YGKRSL[[*X7"0]0YVH\
M2]Q.>QRZ77R>0_9SDWI$?N3/;97XB2Y>X:K'X[&S#'G3T7Y@Y$OV2E];ZB>:
M'A:)%M%P0(H-\'7*5\B@$B/I_GH_Z'Y+?9*U2U!S'ML*%M6'$*^B*Q:=]"T!
MUI$#3KJ NXCAIWX, K$K#!VIA(IC3L&"!@*JF.BN5C_I\QNSN+:*:"WE68?3
MCNC#O//X4FL7\:+7R*K?@CM,U]XT8^+/SSMPJ(#7I]=@PD&'+QM:VD&,$VNM
M:)%2\S3D :SQE9W?53G%"JJYY6FR&&$ )]CKT'"FU^@TI,UKXO_&<TTYK&DD
MA(/HUH6O&I@^#CZY^-D$Y,^M']-KM!=2.1XXK>I%<!&\MLX,HLV(N<$Q4=9_
M^_R?VD[<1]Z_#D<$-_7I2?H&TPBJP+M%PK"E;#7.:L#.P0>.;R:<%)LJG$ D
MIRKL^-ZR'D0WR=RZW_/.'22EEZG:]J;%4.E<B,8D#Y%ZR1GVVLDYO(V'R_=J
MD!S/PZHMT#WY*50R[LFS3*UG_%*BDOOF]ZQ#L49:M6_'%.C*K>>OP9;R]$ *
MM,YKH14[GMF"*$\53O]NY5@VS3X@_=:T?(:$6*QTRK'7PYC#GJ?!%']/.+Z1
MTPJW_KZF4<]N.$/V O)D]5U62](1#R!"T]/6@L3>@_%_Y_,7_ENR:J[)2F8[
MA]])32S$W(WQ^AMME<TU?EGR!M6:?L2?9/1[A.\7WDRIX:+"*]5?:E"ODSB.
M:BM<LXJR'+YH"V(L5=\>%+2KL3SM"UKR-G/^KW<C_VJF[Q]'-C!U]\%7L L7
MM8*AIP-/OVA:76-=@;C&R-<=X%D9&DB,P^W'^(3/-F_I/=&N,W1R<)<J'W_Z
M26\UC7E>CC=6;JUCV7A\MPFFM(8Z61#9V;-S+H\RS/+EN<(%"S0\ST$(/BS"
M0%$?:\$N "Z>YRV3%K#=OPKVDCU[.!OR )7+\Z)][E&:-0]:J8A-ENL(51S4
M':<$6U:^M4C2UR&B8WV?5$H)5I8+B$(_#0RSFE%;,'@G^=4Z3BEQN5@VPW P
M'4\93(B2]2PTDS9;)<YC8+B[YJ75>=&1/H/MHN(%'"^8++WG[2F=@LD,3?^K
M&=\N5OBWD:%WIF)&@63CK*<1/!])9KU!X(Y*[&8XQF]\6Z#2W<%9Q7"F6;L;
M(\BU9--<6D;V(!['7.0Z?-0Y,<V1<,%8Q\ 0J.^'C+<>:^TF'(6SAG#\(K^6
M3O=>LW6&8YZ#U0M/4I5G5Q/N \36K[SMWDSPCU2BW^"B;X(,ZVLQ)X<&WT#Z
M*B[TY'[&].V_"1327KGX0+&&;4B-1$C5A+"WY9B,[8@D[R[@%T8];S2(5Z=<
MU6:UIO]K<[K%#-':=IYQU)1GFD<;&B0K_" M6Y1RX59!L6KW)<"O(S#<$7BC
MQ_4D.RBVZ\O,<,N"I>664-W"W3?FWUNVO%/$^OW8UGNQP.TBN@9" Z;C<[(S
M44'Z)'5U1ZQYE74]Z?BX! @B18)::R_&Z2 .Y2[R\VV.R1S-TO+SY=P4\_$/
MU &Q(61$"O7; -&>3E%26!>#[UP[IX1&M$$=I,I&62NK2';/+KD>9W[S[I9G
M?Q!?:N=M9V6&&J&:8PI?I\J9]1U,=J%<%)X[* ()KV.2B0KCF O@6$0$-=?!
M] (;=47J_-RNW;A&H0&@*M8!'&!C%ZD(J(]GDK 5#+2HU#OTLS5X?M%:HU8H
M,VTUM^ P#<D9T.\?WE!,3@?2^%\"5&W/KU>)=3D6WZ@^U:8>J8.4V>@XYJO!
MN^SK_!3#5,0I%-+H@H#O0D2=EKKH9S;R_'-/V/G)%2'KBV=>^GP<QR5T7_]/
MGS02N.;>K!NG+MGLL#D4H"&^OC?-] !"=G&\#;?D>+C-NEZ"I+)TVF)?]M"D
M_2.ZK:->'YU![!L2!@^FHFFSV,V7[-:NA(N9,_^9/#7MDC@OAWUR3'G PP<H
M; \=#OL24'423*!)#E&[VEI%\II>-TQD3?>*>NZS6!*!30Z4V8421)';A*)+
M@"4!&P>M/@Z5-]]CW>&^L7]+UD-E"R!'YJ<Z]$9B7$GY:JG@[%7W$"WB):!D
MOJ&8[\4;K[%K9Y1*1G30#?E2B%^8?;I4QXH1B\B]BYWHZ%0[3+V".A089V1[
M9Y/8" 4<NL/POTVW[DUF;2)\F6AF?5T0K-5;;)+?/C?!1#&[F<I"*C5,WN>[
M'>?.E ,G?2"AZ1KNB>/4G2IA)57J<;IZ+5M9$16Y:XI5U]^Z(YX0/THEZ@:S
MWD/00L6U;J@K#%[7Y*9/0BRAAXA;>5\B0LSA1-YILS&=10?8&'2=0_Q'4<DA
M>'?)K(M4B><4M3S8]SF_\\+.4T(B2S>W^S=/DK]A9H8S51-1,\(W] UVUP^S
M36>ZJ-$"5X=KX>B]LUA6Z$-=@5?('NA.!LNMNY;8=YUS7W_$7ZWRV(KY" :\
M_#XO-P +ZHS_]+#U9-Q]MSKOBGBD6+<GUKTC8!2EI^(BCXYI8H4];&FL=^%;
MX A&_^3R$2_N2&FDL-(D_?BRM2@<4]Z*T#JV&'S4&9DNKLUR,V A[WBJK=-J
M2$]")P&_;-66\Z,NH #/P=$ Y6 CVHB@W-_#[T8%RTPH*$*K.K^AT6,Q+841
M@WWO:0;+COF83H [Z-(A6$ ;MB_;+/L;K?[C3_, $XW'/[T+N%07(YY@@63Y
MMO']:E'WM^P&7;Y(3<97V2$A(]ZG\?O@7<(9[OPTL29FYU=G<5G5JQ7<D"B+
MX>:V\=TS@V>)5JWZ4O:V]W_ N@VT9#?D,S/!.,*I=NM8")\3]9*@UVS65(I.
MMES/GQN #1C.*L"(%W>+FDO5:.R_-_;_VS*^^]^#S'\&F!C3XTOYMUA97E7=
MC'H2)6#)3W7@=!(UYA-.LKR0&A>"@9 Z9_;I[Q^+)Q<4EM9G[VZ"U7&%V@B6
MG#;'+DJ,!8>NG:\[NU9ZA:QS#RM/D8K4'[LSH["A4GR98"T)O+B([?=,JX][
ME>@/DA?;8/%[V%(<&_XMN6,T1B0U151$N&D3^[@F7_:1VT</&0^UC,!M%:Y\
M+L;&4%$\9E,>G':_#<&L!!TIJ:O_?8MZ74B3MX@27;OI%V2:^?$\1NTZ+D6V
MNO2]9Z/O/(T19->6*KQ'V2>8?2A7P:QFJ,KJ@!M>I]^0Y.>HL'+VIB.Z6[E^
M'5D;YTV;K*RF.]0/'?*MY&K4ZGJ>!!R,4):4+'QTW/II8M?PR]2>4\HB9L9>
M0H+#CA,R)W4)F,G!@[-.3.#UWZ8SM$Z[,L5K,[#S]_X4>]KZUO9< JYJ+K,@
MC(HXZE)MDUZ+&CVN?F)/@0HEVBC!O(2.VG_,B&E]]'_5X<&8F0 @MQ#VNPN]
M^_*:4(7A-"?6AFX6J[DR(CC4U(#EGZ&EKIV&<LL Z8F12<<$2JM3Z?>5+=%)
M=2N9Q@B^4#9K*WV9?6'$=&[DA5"SREI',>XT7F'8Z^#G;/Z38+P;S( C,H+*
M<T[1F=+])IDO56WR7O:Z0:9!4],3&&Q%Y6M<G>R6>A#=?RC2!;\D/KG0!?8"
M_UQ,AA_%;UD5)_[!6.MQ<-$I&'K4??_.9<_/?B49*?KKN!K:*4R*(PKVR/=C
MWXDH2)4[WUG0ET2?>DIF_&[>O_WU_NTP(DVFQ="B2K )XQ1T*,_7^3^]Q%C/
MA':\\-_V,LI@J#$INN=JL3H@ %5%$#F /CUN/']Z36@EZW,\YW5[WG4GSJIO
MI. EBQ!!1KC,/B?JB\BM-OMW23XFPWY'_Y.Q9QY-&E"9/*VAT?']SZZ4_O\#
ME'<QXJZ/G!*HKVK??3P J*/B&R\+85JQ-QL.YPACF2/Y+3\E"OT9@56YPD$/
M&I_)^#\?L^K;TTZ1O=B@8J0XRM>JJW1\8GPS(X"R"N-JFO?.4=?J+S<#SO*/
M:;(TO](@WY6469OV;P?0]-3/ZT-*M]$'X<Z!(@:C'%HLZBU>%'SIYHL/"2DY
M!'\\'#G7=6WN$F#?4P-6RJIP^:6%8ET63+]G%'90C"\!!F?_65RH$R+VZ7-K
MX;Q_HPO)0<282T#,!?,66V=,2/-INCZE$'$WY&J622R0DR[0-G5?@09V,<8V
M5=M'V^XS(=28#PDVWRO/D/TYTC_ZL^QFQ,*P#Q<;F0^W3W,Q&E3X)687'ZW3
MT@YO35)[HI4A\3-7X.> 7/=^ N#4MDF3KL#(6B=][P:ME@KU^\U16.#=+B+[
M0(XM4U/7-9+^\U_K>B+CM/#,EQG&CK=3<E_.G)ER(?\:0*6"7-EJ$VU@-0@I
MCWOUA."[A@X'R? [5*E2^76H,2LPT_+)5R)N_SS&@;Q!N1^G) :Y"Q*I(\!3
M0^0[.2=];R8K74Q[2A5. )?HIKC.,\&E@5]G73XJS0:Z0[KV?H\+.&UF@L7.
M#'[0315'^52%*+]W0ZB^/6&H%:=^>3; V0U(RG/J'ZJ]&9"(OQ(D1J ;345H
M.]F#S*?=!=C-6>O;<_/=\"]44*$;5/-VZ0]-[#TVD/=RTC0KI(0#-'<ZI/JK
M K :TO \M^+/6\[->38[G7:S@I\M%6?E  =RM?[_3[[;^5=P%:Y#Q+*3::80
M@5]U%=%]G*:T% 'PZ38ORUZ[)M^S?&U6V=V\$QU^JJ%C]V@@WO8JQD5^/?Z8
M3M^BKNW,H?B]-*^9],&Z@+$H"U62?RE2F<:IF>C[)9ZLCT\<979M%FN4OAKL
M X^=88A]%=_C?;X,_JCG]H%BM4B<!".T#2Z;?4/O'U6ZP1+5 IVDNG(EI+$M
MS&[FZ1-,*+(PR<QW673VQ!;HBCI4;>B:M$?4)Z@O"-WM=$4\:FJCI-%7 Q.5
M8CXOV#R8Q(16PW5/G3*8G+@(]R7,-JA&$8:$&JPET3$1'RICU/(+H?KZ?='6
MM-3K0'?4AN-+)+VLHEG3FX#2I<*]AN5=S7Y+LZ1C43HP=JX?(NEGH+%4]@H@
M\W@4#$'SEP"E")H]G(*]08<!L9< PTD%0[Q-K%CEUOCOU-M%56Q'S\]>*I@1
M$@Z-B1^*'A'V$]P5'E7-6PF7SZE!.'NM-;X(Z'11Q)W&!$$9*=8O ;07=Y&$
MQ>V^.P-5BY [$.9'W@KPN>=1*NWFV5S!?,6N1S?^[]83>#G[7P!02P,$%
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M??B3=_F/3ODYE\_UNL2]KM O0>\,6\MI[>%LCA*K3WIOYS8]7L9NM ?%N/_
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MOTQW_PE_Z]'HS_==:4C:&G=(_))DT[2@4)2MW<;;?6).;'G!U*IYYA'01P]
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M"UD3I-14Y3_@ZSZ;_#X>.L::/<-%4H'QB2]S*]*YQ#3IX/57O=NQ6Y)'@,U
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MJ@5>H3!"DM[V$UG+^L+KQ=8P4663]E\153]O4I:>L4G>]1I*-3=G000!R7P
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MT/=4R;DY1U<%?[%D6#XIP$IW%WQ;?#7&7U[H<?S] _N*F\1:<-!<"W!8AC#
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MH>C$)* ")<ZVF$4@F8O*TVFOC+FX55]\9XMZYN<,+-1Y] LO4 *OC7I)D;]
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MWT%I1(JP*+1?>.<202RCV=5[##H=I+!O^0#&$= R3 86[Y'F24;;:X?7V*-
MEYYFZU^V&A13'0NAX26VGK=DU<BQM3!RLE[+FO97^A3YCW[%,$UKFNI@-;HH
M=NCB<E9 ;II 2=BS16$ZZMBN;P&YW1W<+Y8%VRUTUW'XQ48X\FXFTG%?E:E&
MLC*QQ'Z.P!K]KJ%&_7<+QUQ[X]0;BQ)8V9AK<<P=((S.LH6_.L4<PEZ7_,K;
M4*%.WKQ'96.C_S#DLV&!_M'$#].4OU[>?E/7!OD%+^?D:@X]HJ]U<7NR(2*J
M36F^(CE;FMM4!D8?__HU&CS#:_ZQ8;]1H(S=)VIAN':<E"*P@7AXH0>:>3V
MDCX-Z;K5SF@#ZGA)Y55\$X+H%LKMR["F C!,[O"^MUD,KT-W\L+X7'A=2WQL
M^\H(LZA2KTH3=@,-6@H[W=/KNGT^>0= (#5+N.78^[O7Y.\3GUM$^I"MGE=0
M<UT!CW9\E@80U_<@5@&2!VO3"UC2^"CA'3]YJ<^EAMM>E*:2L]+Y,H:]CB[5
MHL]HS8?5( %[^ 7;-% A[.E442&0;B3P2]T/TUG;N Y-5Z,U+YWGU0_.89^Q
M-.$B(V1SV\J5X&"-QT,N$#:L,INY5$0&_5> !_Y4#=(C%[=]I87(^%<FO\=
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M'G)=1G(I%-).1EQ-99O-1YQW;P-4I<HA\Q7"H+>)>V58HL8=;S2]_RU)4<\
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M8:7D]W$'Z.PHI#QD>4#ZM>E?C[D\_ZG4XUIR.^=.LK8X1G)CCXK6\"4RCSL
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MYF9Y^%28,_&)UX$&.9&"BZY/__E<1?C]<=W]D8^Y43QS;_X/^ZI],>,#B2B
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MCG:SC^5<55R'-M&CULC]O8B_;&HP(J.Z&Q2:\.";) ^T!<%+OQN5?FGS&B\
MW@5Q84#U=.5?8;8&P32FN_4*@M_PNN=6'28S8B(BC)$8"T*3@%>)/2Z O<)9
M/6]QY]'OL;S*$G\O$QOI%QY%HX5#PIF^')567+-5R<E/PNLFZ>:%U%V /#99
M=RBQP/YB??Y(#]HW$LF% J[@6>GC'!]X7>+N-WXUD\?R_@V^%30O0-%BRS(/
M6*6>P7,H@_-DASO#OHW6AI+%A#(/06S@W&VEC=%4SO#P_MN;=N)SH5HG^A4@
M_/TE;I;>CX=4BK*SCCI<\XM\I[^HH3VG7B3;YE>*1/<?O @L?G\J?!>D:P'P
M4;E,Z[9G'Z&A<@Z(?#-?YFSWRO:N,]@AN%;JV3/J90S52 .4,T2.9)8XJMN4
M=70K&TE@0? ONW0OI ;2T@>RC9RH;I4=QA3S<PT,&M940L,1"H,>T2+7F-\!
MJH(O PZ8QC?)0=%Q"M#OAD-!OMXTZ.J+]\59(F<3"^A'?YI:C4QY>,S'A$P\
M%'-W\ ;0YY??Q ,0D"ON&WY,=-/MKL#)/GH?"3U9"XFX#D!0#C#<<F:K7HV/
M;W3<TV_-0V.W&7OP*#G4- R3SUR4"J%UNP!&UG(F-SG#KQ#>?OZ^X,AKEE[\
MPA>J/"PXL.Y@2O+VK,>-<A719"G%RE=<>5?SYN.$_8NNS:KNBEIUN<1TC"FY
MU&-]=\$:=W&CY<&%_E'J4I._.D@[Q.T6!@J2!D[9XY8MVN<NW<B#B.,GP_C:
MG;<=_<ND:4ZT*5YS22Q$"Y<\@6.-#Q-%48'RPK6@:F>-QUK51PB3D"!"Q?ZM
M)"IL0CI^%KO-5KW+@^SY[?UR,1L8IFX8U.-;P,1?1TF?E^9"YEL-JEUX[^IL
M-%!\+#E25OJ=)%S'6^U]'1$^E<2VJB&0;9*O4Y5F6?M\XJ%+6WW4>$]7TJ28
MN@[2*U)A[1P0SKT<6^WAW$[L/$M ?X)^<B5^R'0;%>R(1/!$JIAQ;MJ12%..
MR(@[U4.1N<-A]; _K.WO+N(YP;.JRQ%D3>Y7_Y_//_ZQ*.]W_#'4L"C$@$(J
MMW7C4&)QB1>MB>F4T<M^9#K9X6/L\!Z5(QO]H#@9>;U)1/\T68VKF$)8MJX+
MW!=7 ;N:Z->UA7,E&L',@&I 38'<VCR^X;WCGM?R,U=TCX(]X[C E28-<KCN
M,4#BU[@?E11T =*_Z];]]Q;=-S)[4Y>6+CR5[M,7 3,&73XN/OA61[%^%R+-
M41'LY8HHP$B6JBKK?CL'L+J_"VO))YMW'$4>5'J_&U\-R/ GHI+D=-D)#[H6
M3<\62ML7N<[( "TX1M^Y)('96G%@05FQ??'JO>CDGMH/H>)OM@22RM2TYBM8
M*3[K^IR?8[H&\T((^)SY"EK.<@1.@#6?M!E?7>;GH3%>K,^;(;S\3AR8NI)W
M"1AAVL1]#4OY,6^H/S!;6U];X_?Z>3?TY8:$,N G;=,$L@&4*T4G*"T&JDYK
MZ][R"456B&Q''AZ48[UOXGS5;C-T:$\3!Q%/KK1?B.'DXOJ.A\TS/$*:W![V
MLP;%!X=]KLJ6D<UPO?2MX=%15OMI3CFVFA(_NSB4IS<;#TO=6/PS4]EM"IK*
M\NXF#E'M';8;\O=;$#;E$24UZ:4W7U][P2[\\.DDG1?I&O_^B*LJF!_T<W-C
M M;4."1T,U9R*#@K8.J-_^=5_[T/%&*_8;;I\XT^^21+T.YIE&&B>9WR_'NM
M^21N>R1QN7V:^7/=CD0U1NZCAH8SL_@CQT1]]4L%C,MV@Z98O)PI-OQ=94N8
M[%/U>AH$3IU2(39:-!0BMRT4^GEGKW&,.%"VL+88GE.2]BW/,"@JOTRC?@DF
MFM4M[I2HJ&>CK .FNURNSZCB\>Z]-YK5K_FZ )^6U_N5E)X_ Z/WPO2,S<7D
MMS6<+Y.!;/T&@/43(8SA>Q=7-X=$XMS:O92XR=8>B9L=[RJOD7ET+UC5;/6E
M5U#L>O&/%UQK!P!54VP@+V65)Y<$,MF6IH&)R_-@#7!+2W,2[*R]^JJU-4MU
M0ZVFWO'8Q+?CT6(DJ.VHOQ/$H'NHWX2-OT?(4(@;F1<4?B5LZ9VG.!=V?4A-
MWJ%VR*O4PVL?!IIHJ]PH>V)J,3D/453RGHS[I4;[OAU1.(%W4G63@\E.B#4F
M9]8Z"\&C9E.L6B^=2=M2E'3S=9JW3D8S=O""M7'"M+24H50-)W6MBGN4X%GT
MQ35B&C+?$%M7U6CY,G6E3&2C(%L@^*G,QBUCVI)Q[8.#9SKBOU.OWZPZ!R##
MGZ.YJW18J;I/C,X!*5*[9PW_B6=*ZNUCSP'_*Y\AU+LOG-XR[JGW-GH;QHW!
M>AO]DZ;K_XO$Q3N.G/JJ2&3=;WU;8[8VFMMW?9I>C[V\6&8E"B21$0=6VQB;
M<\#CGF(BG-NO^P_7DU[-KZ<D8=0C^.),7#[CX%<E*UQTTQUB9!KQTZY07:-S
M'"?N9C=RLF[%_K-$X:N([^J8G7/  <FZ_RJ* (,C-0:=W(5 K+=]+E@<BJ;Q
M)V3\9<C'2BJ@)%U5\\(_32M$U3JX>9:YT[@EEVJA+*'\^C>I'JD^_8)V_K[9
M!"6= ZY8N7%<#^:2<JBI1WZXM93  F*GW0K ^]KSGH@KC+R<!A.6X!Y/.[FO
M8_+W8B8?%0!3)X>]PEI8DKX%"(,D[_N!)$WNQ1O+OAIC-O5)%>TW+HX##!&R
MM;=KTC 45!^1J&[UC;W6$AR.<N*B&IVH'6DZ/D"W-M12$CY9&NV O2<4ON D
M7M[3X<PM$.AKF(F=9AYNNH&Y.V]_*3K#5-A0]Z>PIOML.LY4Z"/93JLB1%LU
MJ1,*8:-X=A8TZ:5",;?#N+ZV+_/Y,(H"URA+*;;+LI5^./IEA( 10^!,?--C
MC*N=:"NW+1Z?V_OS+IPU@\#FT_EEM;A>C<KV89[D8)/7[.O-$/JU&WL&0GGB
M!?=G4Z(L+="!B)6X* B;RS3/ 'D?PC%>.+1'J-11;V"H-:%FW*.MXS,$!/>W
M!9?=;FNAK1X,T4Q)T-=/]Y02'BOD/6D<V_>>:4:<0;:>9I9:M2EGW4:CY5/:
MP"XV;!**)<DH39C!#F8SUJJ"?&&.076)AZX)0H+3T0AON%(]1?PL05\5PO"G
MKUL9EK+8STQ#$3<R4D@4A^=L"6<P%11"G/= GNI&'\9CJ_@NP==U;RVS.?GW
M@T@AOY[\>8?QAZ/O*4P='&?,>@N#(L$JTBC]WMB6Z<4DL)@Z#R\OPB8JJ7AU
M6JXIS79HG?O0N"6M#_OR TN/$$A0A/-^3I*)O=V)",60]1Q +S+0!"WN>K!]
M\OUG16^T)[#B67NY"Q!?79LX_Z"^F= 1A"KY$EK#.3FG8D.O9L"D(SXQTEPQ
M6QXAV1)U1/X^CBC)E_$8_I*LRTG66@U.LS-'',M3OO3)/Y\P&=PL-),I+;>]
ML=//D_T<1+5BKXL,@')+13PNCC(_EA=G7YQEODC'2E7\%[@AOGWK[]C*(DKD
M[]B*Z;^5K?RUC]DRP'R)%F<(AVZ/=GK%F*!=#=]C)GF09_VO N]9 #;.V+]7
M#'%OM\;F?\D/0PG+'\JMM(X=E1)^5WQ<P?6DC.U/JBJB7E']3BJQ7,'SI4]U
MU)HSNQ:^<6RXJ1U6/]U=</&1JH)W RJ3/3V (^8%>CSKSD[^3;Q^@%GRH^[3
M5$4U,A^3PA'M]O$!9"LS0H-E-0@7298N&JZF#"_LBKB&4'9H(M-X<_B'MX0_
MSFS%6A5=#<P,,BH\B[Y079%?U7UR$\.?DK/#9  @2V-O\RJQZ(.?Z;(RIR2_
M??".ZB$:.1J#//ZJ:EM>]J<+L*,?_RAJM!>KJS*EK^HR4B-P%#(,/417@_/
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MCQ+CM7Z<WL23:\, >,;!&5 \6"QZ!M 9& !^ ;&;BR-8@"\M X8*QQ04"VO
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M-7H$"2\(C&@6TY"@&".C#,.#HT^L0CI:#5A7X%Y>\U4%/&E;S5>7]+;3+_O
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MF6KL2;(PA @E'!:"(!CB/"FR@.:(F9<4MZ<_>7):1PR4BII%J4,'*(=5P@P
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M=Y]5@.TA\%8)V(+TS-6 [4%Y61'888P3^R;LIR;JM/*=<. B86D1"<0@Q7$
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MK03>REW3O:"$^C0 \'+IBX&XK#0:#(A5"72OD";ESJ<7F+RTN5>.4V7,_2_
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M($S\3)DJC/4E#P])&L?,ASE$?=3&/L$UI*S&*?7#9.CVN!(>Z.@8RFTQKMM
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MPX'1R$D#6B,KK";NZ7P\CROR5][S?#E_WCQ[BY81Y9LUG !<A@'X#%PN=Z#
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MP>  ,QZT,".B^&B;S"M.NLV:O887[]T.,IMC#! [P%%F/ SMCC,P+!T=:.Q
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M=>SKR)H'[VXI5\6S1<=I,^@,+QA= P*\3FRPV-*?ILDJ2&I7]X1&-*>]%83
M<'0'"'K9>=QI%H6$9"QB*)91BG#@9XB&(4'$EURF<1@+";[\.T-K@GO ;J2$
M[45*?OF\6@LO\*&S*GN@NSB0]$91HTFB0].%@GZ:N(]%D.?2W5][$U2GN.LF
MONIH4VV#G3SW=Z^[1]HL^+])P>O\]_(/42J?Y&[Y((KYBF_GKP<S%D6!+T2
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MFQKEO9RGLDUVNJ9D7:EK[:TH<Y1DE"E+Q#AE",<R0B0A5:!(9'DB<\:-CH0
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MJDP#FD0(9\K.)R&72 @<QBGGB4B-JG6/86)JAT)#U=NQY55\>7O&O-TS.]9
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M(8',*2+"U[%M08"R. L138(D266><6*4G6A,<6*]W^922P%1.D90&6AOUP
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MMO2 /G&ZV0&]SUGZ'\_?;.PZS-(@BAG)!$I]'BHK.O%1EL4^"F+BDXQD*4Y
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MDDJ$8\D0S7& 0MTYCX0^I]2HKL@0H8F7<4VZS4+MQ)_4U*&-C2Z U;^(74(
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MH8C2/ PP8I3I4+ H1)F(8D1B(7!.<))%1H;()0)3GY4:6E[E/0<LDG-8&&B
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M#>^:0W B<2 8RU&6INKPPF.),I%D2$:AB$3JBPQ'((U\B=+$FK7VF&BKJV$
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M:G./T4$NW 3#6Q;I/O#G'I5(JH[Y2H_K=L$-Y84(@B3B*4."L1#A0/HHEWZ
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MJ+,7DK%,<$22*&/F];[A]"?6-@UQC^I-NM#A/;HBSJ.F#+BBLH#5X#YO6K"
M/IOSB:#:F5P#J#GR-$M>PU-57.?S]$ "[OVF!=3N#G 28&%W@O:P]-X/6@P[
MWUVAO<P']X8CAK&S$SM&Y^M]0=8EJ7HC-<Y?'*61CSE!C-$88=UTE?(L05G*
M@IC'&8D34+)]+[6)-7/W:/3J=:A;.L_[D3,S!)WA 5.^(Z  FWE&(CHRZ_II
MS6K&&8E];+:9O619">>9EN+?SUJ!O&BO+[#A^:77I_N2[BEZ-<E)&I,/R>6J
MR,LE,O/6>!D0]J3$R]#S\#RSNY>GRC>^OPHPS#8[>7'B[>*.O'HO5<5RN2D>
MJTZ".O!QM=&.X"MH>]-3L?N7W6B)86OMC+!37&'T2F65N'8ZVFSI:Q<%Z2:Q
M77[(12Q_8PHN))5<8)$AB@E#.,:Q^HDSE F>2)GYJ<\R^X#]ALK$ZVU_7EE5
M#FY14QT3?]_"8[;#C18:MN1.SF<?!@0>&2E_)- DX? MC3>,>3\2LS^P_?AA
MNS6I8SWW6P/0KCK_\G1?NRI$>$]P$INJ7R9'W[P+1&;]ZO4+>OS=&W@:;DM]
M5'QOUN*K8)L74;R^?Q;WF[\O-ZNF?<9_;A[%.YVH4;Q^(G]>/VY-32WHN!/O
M# T[7LN/QY^%[A*Q8TE?6&BFO(8K3[$UV&!F/)K#%MR40,*6_308@@P_6S"L
M[$(PL=G,1EL8NE:E]1@6-SP?I-3MTE_$+JI7YWUITFNV7"TKDE\V:_6YMG-_
M(\MUX\6XWW1<&/]8;K]?LW\_+PM1-.VPXBC.* XQ"O(D0)C$3,>R"!3%G 4R
M3+(L)X!8EDF9G2?R17&&MC5KWH/B;1?YHA9JUTE7]:UO&01<ADPVE09W3V\Z
M,U8J<\=Q-[]!,^T=<GWEZ7EK&/<TY[LHG*-Y^T=WWF ;U+3S![CR^AGFT>YB
M[*WG$W:'-C7.O3=MDQ&?[SYN:OP.;NTF)S9S&Y-N].OSXY-^J_RZ+/_UL1"B
MS>/1$BZR)/(33#$*PSA7>SB7*(^$C\(\36B8\3 3L"+Z4W,\]1VC(HFDHKG/
M-"R,JP?/-VV&5SX_TV0 [X[&MSWI)$MTQ+CRM"">EF2?W?C52:WDV6%_Z]8H
MQOS^-5JE0.%WUCH%3!C>]_'#>KO<OJK]ZX8KJDNY9/6>5L45+H*<D"A.$\2)
MTOTXI3'*)(U02**4Q&$4<9F;]H'LI32Q]JYI5W;A(?4F,-:\4V0_7OWJURD*
MP"./+0"@WI)&PEGUFNP?>;;>DT8"=GM1FKU@X;QIL_]NY:<ETU<=UVO^FU(H
MVZ_B1:R?Q=&==(J#0*9YC)*0IPCS2" :T@"1/!=4K?),4*-[1 O:$R_M;AID
MPTY5H:!BR&LX AS%@< :.$BF@PMH.K5(W>Z1NCY&"A(=,!H\@'=B.A#M? Y&
M8#KR&-C)WNL'  XYW^G>3M:#,[OE$/97Q/MR0+^OR>.FV.JJ&6TM-9V&3OTT
M\%'F"X'2B$F4I7&(XCR+6*+T<AR&%IF=@X3G\6SKL.;_\+B^>VZ++<+.Q
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MIVE[FK@[G3!*=D<:PXZ'6?7)*)B.M<VXP=[F<KJ*02IOUG7#V-^*35DN%*&
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M3*<LZ8TB#1%)98@$I6& N8PE-<H+N$1@ZOVA(>FU-#U-U/SF_"PF_6O1A:3
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M^?'735%L_M3QMN1)_67[NJ TI4G*$L2S)$8XCV-$PY"AF)(LD5A2'A!0?2@
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M]?UL]MNWM%Q-%_-__@O]*_G+;VD>%G$Z__S/?_GCTVLP?_E?__(/__!/_Q?
M?[XX??/;JT4X/TOS]6\OE\FM4_SMS^GZRV_K+^FW_U@L_S[]YG[[,'/KO%B>
M ?Q+]\]>+K[^6$X_?UG_Q@A3E[]V^=/E/QI*D^:>@W/2@V#4@).$@?*)\."\
M(LS^/Y__D7BEB0@4#"$<A%<9+)$29(S$^AA(XK[[T-ET_O=_+/_Q;I5^0_;F
MJ^ZO__R7+^OUUW_\_?<___SSK]_]<O;7Q?+S[PP_[??+W_[+Q:]_O_?[?_+N
MMZFU]O?NIU>_NIH^](OXL?3W_WS[YF/XDLX<3.>KM9N'LL!J^H^K[IMO%L&M
M.ZD_2==O6W^C_ TN?PW*MX RX/2OWU?Q+__R#[_]MA''<C%+IRG_5O[\X_3D
M:LGI_,O4+[__-2S.?B\_^_WE K& 5';_:OWC:_KGOZRF9U]GZ?)[7Y8I__-?
MIG/_'5=CDK+-6O_WYA_^?KWDUV5:(4XZ%M_@-R[^?5EEI^73]W6:Q[3AYO+#
M9XMPZY=F19:+JW\Y<S[-NN].8II.ND\]\JOUTH7UA(1,.#<!N-0:A+8.(64M
M^"25S3PQ(NAM;@NU*R2W$_TJA;]^7GS['3_X]R*!\D4GBDX,]Y;;B&0_NB_W
MVB?\W8FS2CF:)?!$<)N8$,'(E$'J[!EE62FC!I%]<[7;5-]4Y=$R_+98QK1$
M8W&YG%N&6VJ]#].+W_C]JUOB!T'X,IW%RW^=EXNS&KI:+RI(;J,6)/<OOR'7
M.2V7*;[9:&4K<QUG:S2AJ?O-&AH_FL_/W>PT?5TLUY.D#4^)9\A4HN6S.8#-
M@H)+2CLIN5,A5='\S55[(8"UCX"])=D($CZDY701C^?Q%9ZV$V,HT]P14-8B
ME'V08!Q#/.-)Z&A @416!0JWENV%!=X^%O:7Y<A@>'F^+))Z/5T%-_NOY):7
M/%#F&0G40_#9@N"*@3'*@Q1161.-LE(..\NVK-P+$J)=2%21:",FXM/2S5?3
M(OL+,Z=\L,(Z#2KC,2>2%6!3T$"L849;G2FOY"K<6;D7*F2[J*@BT9%1<3Q?
M3]<_7D]GZ=WYF4_+"=7*1BL$R(!'G7 >A<$8@RYNRIKQ9/D@--Q=L1<*5+LH
M&"3!)K1_FCY/BQ#FZW?N+$VD]-YIC)4YTQ)$% $,1U>8),=,C%IFIRL@X/:J
MO5"@6T?! $DV@823>5@LT81U@O^(\D\O%^?S]?+'RT5,$US3D20X>$X3^L,B
MHVP21_>86.E5B(X/<Q]Z$-$+)Z9UG-23<Q.P^>2^GT04WS1/-Y=4%Y8P>2\T
MTP1<3 1$#AA ";2)!D_'0#AZ3DI4 ,R6Y7M!Q;8.E1JR;0(D1S&B"E87?[R9
MSA.=,"F2MQ2#*IHPJ+(R883-$D3%= R.B%C%HCRP=+\K*](Z.H8*M5%D,'2B
MC')2*=!"&Q2+YF E,> 8%X%IYYCW!T$&ZX>,AF\SZPBU)62\Q"_?+S\M_IQ/
M!,_&N:3!6M>!&^7AN ;-@O#"$^UXC2/EWL+]4-'P#6<-@;:$B<YK>K_\L%Q\
MF\X#.DV9>9Z9A<1<1%^;<3"11PR\K0J:>\T'WFT]MGH_=#1\YUE-M"U!Y,-B
MM7:S_SW]VGG57F1O,E<@J5$@J/)@C-= I7.$XPGI0XV+C8?6[@>/AN\_*XEU
M['OQPL,RN8YN'IGDA'MPA@<0P6&011F:0<VCPPB+6SOLF>SF:OT T/!5Y]ZB
M&UGE)6MB]N'+8GYY.2>I#2QBL!02_D<HG<'1%$ 2RQB/48J!3V)W5^RG^H;O
M-P>)<&3U?TSA?(G0I<Q_FJYGY2CS1I@D()F('G"2#BP7&I@D+N'Q%@(W@]1_
M=\5^ZF_X8G.0"$=6_Z>E*YEI'W^<^<5LH@DS@0D*05J&$@@$/$4)*&NUCX)E
M;8:%#K>6ZZ?XAF\J]Q=>(YO^^'OXXN:?4W<5[[DOO$:@R D(HB18DS.@'ZLR
MH823..RX?VC5?AAH^ IRL"B;" ?^(\UF_S;'8/=C<BL\Q^+):G6.!YGQV?NL
M(QBE4"K91'#2*<@QVRPM-9H.P\2CR_=+F6K^!K*&<)M R;\O9N>H@&7WE+M<
M31QU(7)T:X..&/5:G< +EX K;UC.Q'-I*Z#CSK+]4-'\[>,083:!AHN,GTU"
M1SD&40GGJPF2&H,E HPHSH]@":R+ 8A"MT=G+>+ ;.#'5N^'C>;O("N(M@F(
MG,SQTU <TV_IE5N["[8F ATEFE4 GXT$X:@&KS('Y"TI%JCS _-O'UN]'T2:
MOXBL(-HF(-)9OY=NG3XOEC\F,G#A%<>#4*'I$PS/14NX &)<EC$CD:9&8LVM
M1?L!HOFKQ_T%V00./IZYV>S%^6HZ3ZO5Q*@8O=46.'$9'6BF '&-_W%*<F^3
MSCY7P,&M1?OAH.$;R*&"; ('QV=I^1F/O+\M%W^NO[Q<G'UU\Q\3[YD(U N0
M0@D0- FP,>-7)4<L..NUJ7%B/+AX/UPT?#U92[!MX./[=2[QIOQ@$FVB)60"
MV>42TV3!*F. R1QX20)R;%AV]K:5^R&CX9O+*B(=&18G(2^/SN,4?^-HO4ZK
MC0)>S]SG20C9:T0PD"#Q$*26@!,B@8RNF#^691[VGKE][7[0:/ANLY)8&ZGH
M>#V=?UR?K8^7R\7RY0*)"%?<$*-XDJ0\QY8,9">[ISH#&%)9(XVG5 Y[[WB:
MAGY@:?@2M+*8FSAH/GY)L]GE,9FH*8+@P(QG(++J[*&&P+S+,3LN0XU+C9MK
M]JL1;/[R<V\Q-@&"#^=^-@VO9PN'H760V5J6("?A092K.B,= 1&LYR&EQ$2-
M?,L;2_:#0/,WG?L*L0D$('3/2@'"(OS]XQ<4V^K]^;JTGB@/?Q-"-$])1^!>
M(YX%LF1= 75F) L50TS#4B6>IJ$?1MJ_\:PEYD8<CM5U_4J*+WZ<%DK2/*1/
MZ?OZ!?[RWR?>*:*=B9!80*8L<^""+3?_243M.!>FCM_Q)"G](-3PC>AAA#XR
MDHZ0H]@Y5<5]LHX*GR4''@NYT3*PTGE0"OTGW!TQQV&AS*WE^B&BX2O1_877
MQJ&#E"_=[&0>T_=_2S\F'B-P4TIE41;H/$O#$+8>3TT1B4K<.Y=JN!YWENV'
M@N8O1(<(LY'3Y+JKPFO\SFKBK$N)8/3$K"B^$[* 3E6 1)SUA%-!!F;R;UFX
M'R(:O@JM(="F,+&YK]LPP7Q.B1L%6F9DPG$!%K\'6JCLJ74FNUHW&7>6[H>+
MAB]"ZPBU&C+^Z?=[@GR#W]BC_5QWA7<R+^T#NX^Y36J_3G3W/F-H4[K'B1K8
MGZ[0/[F[PA5 :,!=CMX>)%?>PV+B&$K("(Y&+0F/3HG\E#P>76&0R[>Y;^U2
M" 7ECCLO@.143BF)@7),B#M"K,R"42'=,(?O>K%QFM/54]0MSV]/&8[M[6_(
M?G/1PG)BE-6TD,XY0;.3T.P8'<M?.<-H.-L8AGE\=Q8<ISO=02&PERS;@,'K
MZ?+L)$YL,M8)G2$E#%F%,A1,*LD\F<CH&-,V#7OUOK7<.$WI#@J!/>38X!G^
M<C%?+6;3V-UJN%EI>_OQ2TKKU3Z'^?8/&]YJMA>9 X_W\Q5\=N[KI*O +2[;
M^_QZ.L?%INBW+3:/V%?PL1CJ41T#:%,>G6QQ!PV-P"A#Q4M."7W,(\YNY3LM
M7RRZV45IMEY=?N=Z.^U"U[X6XMX:GYR?I8G)/A*M)$@>2KF1X1C0HI&+W"J5
MHQ%,/G96#.*RHV <_^%@2+@T)!7$/>)Q<DG]:9J5'?G!+=<_NCP/USW*KLK]
MZ/5/CKY/5Y,4I(K$>9 I4<"8UX*-)('.6CL6/*&/^IS[ *D_=8V ; \,+)Y%
M(8U![=7BS$WG$X>G;2#EBLTJ7U+6)?CBATMKO/.66Q<>*Q$9"JD-%>-"YU#Z
M?@16>PB_ ?B\6\R7-YAXF[I::L.3,Z6QM*)<@6"<@Q&<@&0L<V])\K&V47J0
MD'9 M(]V%[5%W0!>3N]SH().UC$"QD:&=CDP\ $=?X.,<2>$4NRQ^H&AYF8'
MI%2/I0^$E(%";@ F5T<W1C+I!+]<30Q1*49+(8K2J=S0!)XI!EE&K9)/S/+'
MR@L&><Q75(P+DXH.S4 !-P"1H]4*X]2K8$%38T2V#&(N[0&Y*0V_* &?I50\
M>Q(??6[=!QZW*6C$U]U3GXMJPFT&&A?E=5=,,!=PLR#]RG4=/D@ KS,'JKR,
MI==')H_=S.V/D#N$C N4(9I]$"1#Q-P 5EZZU9>C>2Q_'/_W^?2;FY6DI*/U
M2[=<_IC./_^[FYVG"55"944R<*,M"*L,>$(<)(=.?Y2>2%+;NO0BK 4L#0+
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MA-(\9U,[.GN4H!8<H"H0JB?V%C!T?<*^6\S#A27UQFIA2G*P)F5X!.5@/#?
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M9LZT9PGU=Q)V T=;Z;DW77>-TTJ>W&)>-D&:A\**="HCJC40Y34(DVF91D-
M6Q]+M&DHKYZDN)V<<:^PGP5'M931@/VY(Y4H*#IX"@]FF3T(*@3@OT'7CXA
MA<XV/#I#;!\H[7%[7;UIU;.B9X#(&P#,A\MU.^EL\G)%:=%B;0:-C&/4P0A8
MYQE(DX+&2,3*4/O*^@$RQKU>'*+5^SEB@T3< $INM(C=T&^5#TDJ"8FQTIHK
M"_#$6]#:,NN%T2S4OD:\2\.XT5=%? P2;@/@.(JQ:_C@9A_<-)[,7[JO4_23
M)H9P&QR70$(NR6VQO#<K#E)9IKC)/N?:_N\64L:-I"I"I8:H&T#,:5J[Z3S%
M8[><HZNU.@KA_.R\*W9]E?(T3->3,@-%,Q5 )I8QVJ,9/#IBP*2,Q)ELS*/S
M+?>K)GZ*JG%CJHHXJJR !B!UW[F;R,@5=YQ#=A;%XHT%BRX[!"*8T<A%?G0:
MYGZ5QG>I&#=\J@B9@0)N(.9^*AJ8H)&TJO2J-E'DTK/0@_'9H!6E,2I-6=*U
M2].?HJD7?*HW=QWK%F>X6JK![!E:R'WH=/ EK:<!791;# SL)W?[DP_67.X1
M!IZSTYS*)EJ/P9/F>%R)3'W)9#; C A&">&XJ9WZ^QR=YFZ'C2CK]\MNV=@%
M"1_2LAO6,;'$:6*U!PP-2J/5S, 8AT8X:T^HC8RFVJ]A_2AKI)%"+>0\'M57
M44\#;M1MKC;C8([.UU\6R^G_I#BQ+ABTZP*D+K,)N4=33%V$1&VV/CGE7>W[
MQ,<I:B0[]GE -D@=C8+KYJRA%#VWWGFP2J 7D6T9,Q0#F,R0(6.)LK7]KR=(
M&O?B8!1X[:N0!O!UXR)MJSWV.CI&J +"2@DNHX4;8< F;JQU40C]V,#:@1>7
M@\[*@UTL'!QGM173%M;NF67N.5&"9N">J-+PEH#A:):=,YDF;S5Y=&#40(SM
M=40>[ ;B.;$U2!$M8NIDM3I'-@S3*20F2VN3!,+A66\"4R@M'[(G1D9;NP9_
M"RGC/N<^/Y;V4$"+.+IYII>W1J-\@G(5B#ZCH^!-Z2"I/'=))1/\(;)+!LW0
M/-@%U_,C:E]5-#X;X4J0JT6^2.K#GPZ]U-KRJ34OM/H07NDRJTS(/$M7"U[A
MRZ<<G'4<5"ZI:YP*L"6)OS2NBA0C.V-K!]5;2*D\'$%Z(84C'&349>,DC2<O
ME<"84$%:JI6IG53;TG"$&OI^8A["+A(>\6!:+=>EC4D\#VMT_M/RVS2DKNFZ
MLE&2:#7P,EA8.!6A]!< KHV**JL4>*\G.ES@!CKP;]?(V+9V(]>3>^AQ45&H
M;8"B>_C9<+"ZZIO-D U1.B-UQ7)&H>MN..I51A6]2IKWNM;NAXS[!(P#CSHZ
MO0^0@0)NP*=]@Z3/5^FB#;H+*9!,.1!J7,EWB:5;O@*630J4&)%H_:+Z&P2,
MCHZA"KWW!KNO=!N Q@,]*D@0T5!J2U42P<"_R"+(#,*8S#G5//G:^&B\R?P^
M)TPE 3< D=/T+<W/TW4OG*1,ECJ2T@%'@4""P6&0#R0$KA-Q5*C:3PUW:6C$
M =E3I_<2R@8(N"& 3*(6:"LE1O>!)4"!H.W+QJ.'SO$'^)6HGK1ZN?;84VZ&
M:' +''829P,PN*I'O&CH>BT-1LK$TA !K661!D9NSED+PNN@O%)"IMKO1EN)
M:>1@J6,YZHB\ >R<HAJ0@-+W_A7"?[;HFG1><#5A5(9 N(!@><2-4 H^&%'
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MG>@VI+\Z7Z)_L]EW&[>G^^'[KUV5RO'WM Q3W+03Q:*U+!$(4E.,%R6'4CD
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MYD ]"UXDSV@^R''?@[9QBR/&O>"JH*W6#_=WZ<_N1ZN)2(EKH01X7_J91I?
MTRRA-%,*VB>17/UWQ3Z4];NV)[\,!.NJJHD\FL<<Z&NVLC?2Q"#0V: >!%4*
MA98PJLL2/8_L@_2UZYY[$=8/@+_$PU%]136!O]M] DR*1JD80&:'Y ?NP$6"
M[JT42B-"N(ZUPY7=6S#07^+1:'_!-X&;1]]132#"")<AZJ1*^R9>^@\2L$9)
M;IU30M8NN!_^NOU+/-)44\O 1\GC>3S4XS8ZE)E&@V<Z!N @=)D\*X("M+HN
MV^1U$O7KA/9ZW*:_Q#O)0!54!=+A:_M>NM67U[/%GU7']%Y_Z*$J^;:07;^
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MKY*_,O@:&;(2-/$"O+8"=W.(DCH90JI]N_@D44UZC=50\<CI/%Q%8Z=R7_K
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M)VAA5A<3@6_4>IQL2MPNQP,["U$1!3HD#B;;"%)%3UGP(?4<E3>4DG%=A/&
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MZ>L3M*,O3X[>G+Q[_?[T;6=8]SH.MG[88)/?C\RFS#I!]7%!/41AR@A 4T8
M4@K*,Z.C)T*DVM-"FS#K-Z^&7KA9R3'[^"6E]?7NNKE]C"2XK3-D17$/L9#
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MUM?^AU<8M]'N>!"J)_8&;-8?J_0^'Z_6TS.4S6JB&/?9> ?!)0\BZ#(XSP1
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M8UQ5+^H^&#/CWA0WL3G&A$>#;O.;DY?H@AZ?EE%Y?QSO[RX_^#F#YQ4_2=Q
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MMJ; P2KMHZ*$&U9[S$</LL:-[ _J-!Q*.2WCK3#T:G'FIO,)L39JH0/@&6M
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MZ?6HN=/9MS^]XYZ0M3!S[YA\)@4V -:W>"[\>.N6?T_KU^?S>,F%I!@G$^/
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M$#G-W 4;&:U=?/P,.<,F+/I&5"T]- "IK:+Z<-<*.7N3K%4@;=(@E%+@!<N
M/H]07*.;DVNG(%ZFJI5664/XAONIIF6P_6U:JA)UN9H;/ $K\(MP:"4N=F/D
M+;E B*#N:%[A@J)&K?8]]=\57KLKHP%HG85P<WVSN!!YO[D ?G^55F'$L^M2
M6[L,,6YE_D)G%@7U*%)A(XA@ S@M'2!;3 060XRUNW#5HKU1KZ .7 =1\.[
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M:6=A&21JLK%<*1$[=6?"I]Y#!OYTAXH'+QRVZJ>6/;*_#%M0_ JOVIKH"%5
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M)3%;4CM#OPM]W8*_Y+7"LR]-MH723]-1N.<^1^Y5E@2H2KC[+S+6G' (087
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M#XDNVJ<+A;1K 7BZE3&;04GM,].IVXI^].!A\_(5-;VWM!HXS_^>9N4B[^(
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MA G%IX] >>"&V9R%?'2#8XNW]/Q[A@-$)2U.^A'IP#O(I^DDWH3Y^?1+FOY
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M3,H*E"?*6BNS?)Q8;6L5;6;KY&<4-;..*L#FM:ZDWT<_1C&-XR:!>*E*RIT
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M@:.:] ]\;:$-\VAP8#2P*%91;#0A%(K).PJ*VXAT1XMT!XEL*/1QC=4N^LJ
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M:FK@Z*U:UD$$28ZG"-R;#"(ZM)PS]<#0FG;:.D55[89?1Z_VZJ]]5UN&Y6#
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M(005 D_203(\@(B*@!>,09(ZT<"<S;+;(*^^*!RV6^NIK(S>=7^HL?/U>.N
M<Y7>7J5[Q><7P4<AB+>XP(,&=#0DRCX@IYXX)3C-+NMJ*'_Z_F%;NYX*A@_4
M6[LNXWI.PY,3Z^_NZF8IX*NKR5^EZ\>%5+CPB/=X"BD\E()FX",ZR<:F[+-F
M5/': PH.IWK8/K%MF_!]*;]=N"^<EMM?C2]7C5(7HD6I.D8C:%H,+5G&HUIT
M6=!S4>AG']$!?4S?P#UIV\;PX1IM":V/RY!RIBX8!S:@7RU02&!\Y, 3\X%)
M[VWU#GR'U._0?YO,W0%ZJE;OLS_<-EL\FX2YT1AZ+,H,5,92&A\\>",T>!T-
M3U9SZVI?9ZU$>B,YN\I5%D/HM8'=LXL!_U(6?75@4,B,X-:0@@&O' 6I/:%*
M1:--[3Q)!;*'+:<8!&Z=(-^?[D\$[EOS[BM>&4C!D%>6RZAWFR"@+ULX3?QQ
M&/HH.&^SMN)4 %Y%VR>"[%U\UA7['(+R%'1 X9NL/?H#@06CK,^A=M.[RBP,
M6\QQ*OCO"Q,GLB0VNL"K]DUK?@6H)$.1/05#<RA=G&2T7'E3O4K\4)J'K0LY
M%=!7TWJS*-\D\SO.T*E&L686P$BF@.OH4R(Q:5J[N+\[=</6B[2+W(,U>2J7
MI)Z<0.Y!XK_V_:B.K^OE:M0^K![A5I24S$H1(QB78QG%H<"*C%^TH$Y+*YC5
ME?>''F]%/1'RWZ:3V=T4)<FT)HR7AL4A@V!:@F6X7)/B(?J<**>UO;GG*6KD
M?L>!N'B\J5740@.'[1-N5GOR^+)TC7CCIM-?>3+]RTWC[,(X)JAA96RIXR!,
MX.!(")"8S2*3%#FKG8#8@;QAT583%2\!KI**6D3?;:7S [9NJYZU<\B 9J!Y
M4KAND4=7QEE2X225J5P:J>W#[TCBL#&J8Z*PHJH:1>+Z=ZO\7NF4@O]=*G,<
M5^F^V45DAC%B!=!L2Z-(R<$[F\!&[V66WGO>^[;8F=IA8TA'QF</"CP-J)95
M./V12J7Q60C3&W<UNW"&$^=8!!IH+/=$!)AB @651.DB97+U;CK[43ILQ&=8
MB!ZJN*'+OY^Q59+#%]RYA!>6LA0]94"))&BJH._O=-9 $QK@4EG.'G<CWE+J
MVOV=PT9D>D!6GS)O<:?[VV02_QI=7>'R>(^:&U^._%5:_NF".\:B)VQI9@AE
M-?B$FSHA6L>@(W)7N[W1+O0->W'FF+M:+26U",!/TPDNKOFO3U=N/$<&W_[K
M9O3]^EZ0W8)-UH#.M+1I3!D8)9X*1B1/O1^O6ZD;]F[*,<%71T$M0F^1XKD@
MUE%73 "*NW>9ING 9=S&C5<V<&)B\K6KDS=3,NQ5D:.&6W86?(OP60CH(CM'
MN+<, M=EH"]!KSP$"P3W8\(C42K6KFS;3,FP-S&.>ASN+/@&BH*[%$^4F@GC
M A[>I6&+$!H7@S,*N"))<J>(T[V?>'L6R?1W/^*8R#I0)\/?E-S*V<<TOQ!&
M69%,*+7/*"I=5HR,'D$1@S&><5Z]"'<3'0/?=3@FGG:5>EO[U#T_]TX\V;MD
M:2J+((%(TH.G7B_FURM%<4'0VAWRGJ>HW:L&E5*BAVJA+=/I'C?;'0N71(C2
M<X@\6A"<.K!2>W!.X!](0!9K%QGL2&(SJ=&#T=$)>'54U>3Q>(_+$MP;C2_/
MIM-2[[KLNB/1K66!4H@ZZ3):S(,UE$&6400EM="VQU34\\0UDQD]#@@/54][
M\+L]/>Y'E-$%-C)I!B0R7%$I:BBR D)R*&W/J8M]Q2,VT=-,>K,OD!VLA(-Q
MU9^/>8^E8HH:&Q-3(4 65(*P7J#+["($&P7+1B'3/1IOFTAJI)MFWP5M!^BA
M69?@0CI#G'$4B([(A8H4/!$,O!(N9L]4)N(H1V,CC2Z/X@+L)/6VR[H_NFE)
MJOY(=<JVGSRN8EGV\Z0>8Q@%\VA/>P*I]'T4WN-!I_#'K%-V> @ZF6H/,>JQ
M['ICH=O7TL+L0A.9>&8.0K;(:(ZN'.89E$B&"DL%JS[,<3LU[99;[X*'QQM+
M)>DW$%>XE=#9S?S;9#J:_SK[.9I=>!IH4MJ4&4.E)@-/5FN, F)<8.B7*FMK
ME^UOIF18_-32\[8F+?L+O4GH_#ZY=J/Q!?>:!N,LH+F/1[84Z%$RK<%*GFU4
M.?GJ%^"VT=+(]G. GE^$SAY";P \ZR'+;TJGPNFO/]*U+_EL:J.DTN$JX@8M
MLX!^*$.S+Z1(/2F-9:IO.QL):0TV^^CXL2U\L, ;0,V#-A+_[\UT-(NC1<?+
M%3N<.)LY;LH\EZ;$D93QKY*"9([*I)RWHG:YW0LD-9);J8FDFDIH %,;SWCT
M<-*R3Y\PP;F0'6I>*!""X@J1!(]]215/65(?:[L-SU,T+*)ZLH@J*J$!2#UW
M%\Y013FZ&;J4^0EF3;G1(<$$8;@D07M;.W[8ZNW$FCJ?]** !J#4J6&,5YJK
MK'&E48N2DJ0TOBTA?)NSH1HW]-Z+S/>L>3KN/E4'7+55LC?*?J2IGU3"V9_C
M:0J3R_'H?Q:,K:^AW1H0G]+872T21XL"^H3JG"\N Z5XH2+-PG&.QH3SI=['
M@K5"@.(T>R8B[OVU&_@<0.ZP^9(><7DL%3:P*^[#ZNHRVX6DR$\R'&CIN2R$
M#Z43+@&N)..*V41U;8/N '*'3<PTAM9]5%@-K3WWY=DBC\^3JZMW2[G7;LW3
M_8V]=.?9D^$C9(H$CYH%+D$;QT $P<OA+2%$)7+PC"E;NZ%#CYFB1SW9MLG]
M[<]P=1-+<=!B>$CITX;2'^,OOD[>_G37N.C+QS^G^<UT?%]+%[+<4A)HW"B=
M5;&H&?CRHY0N1VT4'AZUD]A]\]1(_.] ;#[><IM"0KM6Q(4)-C/B*:A$\7AA
MT:",@P>NE0U4<TYU[2CT%E*&Q6%;>.EF/^RDO+TQ^#U-1Y/X9>ZF\SZ1^'L*
MTW);OC2PN;DJ\8QWJ*0W-].BO4\+&HJE-)F-EOT*C?:EF@]]3:MS&?*P&$E&
MP=)(=&3)L% [\U^'\F%C!:>(\SZAT4Z5[W8G82?FE;2:XM$(NO3Q%-ZP(H8(
M.="H@J5>5A]24X?R86,5I[@N^H1&\^OB(HLH4E *)2A*"F91QQTC_FAB4MP:
M96H7OA]BN?06MSA%Y.ZDO ,ME[?CV$MDX\/;LR]UJE*W/.G02$07 BM%&!9]
MCN[N663%B<PT@>)9H^.F"%B3.7#\96D]J)FM/4+^(06'[CD?TFR6TL,V3KBC
M79_GTCM[Z9PJS6+F#A(MM=K::'"Z;*9HD NJ%=H9M>W/EZD:UH<Z  6/]XW*
M"ABZ*]LF=MZ/\5AV5[^YTG1NO([WXK;\!W+X[4(ZGJ4D%D@J);M9EYD!)N#6
M2[(4RCF6NDVHW_W=PWHH%5!T#)FW"*FS\?C&7;V=!7>UZNHOB*%9XOI(JD0(
MB!%@<6& X$Y$;ASE+.^-HB>O&]:$[Q,XATFV@?C?)J9P":2_W%795R]L:2W!
M2 ";2IUN$KB;2N: LF1ET,IS5CNO_0))PUK5/9]E^XJ^Q5WGXTTIA;P[F6<7
ME#*JM9?@H[/H,011FJ!G,$*2&((-6?*]=YTGKQNVJ6B?N\YADFU@UWG(SCJE
MK9C5CG,%VJ$'*$K_4T-+2COFZ#+CT:?:>\U&0H;M"%IQASE<S$/O*R^<MJM!
M6NXR723IA+&9 6>)EBI^ MX3"A%)D@0--VY5I[VE\RN'[=U9:W_I1\)MX6:V
MWBC/O)LO6GXLHZ 7@@:JA"O-_XJO*)4%BR8;4)TDLS;P*+J9P=W>-VQKSGX0
M4T6V;<'E$2?+P.A%TE%&HSA0$QD(ISP4,PSM?"M,8#H()_?98#:];-@FG#UM
M+0=+=6B4?$;R7:E$*5R<Y\W=W'^=C>/GT>4W_,"?LV5W[?=C7"/CM+@?](_1
M_!M"0BQ%<CE-BX==>.:T=]0"]UR R":#)S:6K18E3'6,'4^O_F@<N']G+5 V
MHL0&C/!-GD6IMBKK<C%Q/3%?@J8&9!D7)/"P!\\$!70_N3.".>./X?O?IVG@
MII\]>_][2W_HG?$A&Y_<KT5;M??CDEHLK;'^N+_D'JZT"\ZS(Z*X(Y26JY(V
MHQ"MP@,A$>_PCU3H/<[5G8CH!JOF0]O'4D.CFQ=N[<O,]6U:Z")Q@IP$!X$0
M"8)P%&7*!LT+[Z0WUD=3NRZW&V7=$-=R3+Q'332 KX?\_",58R#%LQ_XV\L'
M^_1ZEK=EUD5G''AM+?(G&-AB ;B8*">&HY=<NV!^5QJ[8>X40N>]:J?!VS++
MDHV[>R./;%,WCEOLV(.K3PYX9YTZE5I,]U/1XD.FA.(QB18_*]D^5_H\E-"J
MIY)'DUFLW6*Z;D7+HWW[H8@O4G9!)N0L..9 B!RA3,6 A+NV*C9H-+5O53]+
M4%-U++OH_OD-[!"Q-W%S>IL7O1:58UHKDQ1D4QKL,JK!$.WQ1Y9SCB:J4/N^
MZ0LD-57+4@])AXF^.;OKEIU5\?*%55%:7F(JP> Y'DKG"A,8R!QH5EH*^;CZ
MJ2\@K2@:=D>JJOQNP-I'$RWO41\GX[!B29A T!XT0+PMD\3,HA&8PA]5UIY:
M(F7MP_Q%HH;=IP; UY[Z:!EB%R10KY+/D!Q3(%1.8 R-0 PMK0,\BZIVW?,6
M4H:MQ!L 3CO)OL%&UX^=H"UL_N'F-].Z_E['-]7V\O9AL!_?+A)2AH\Z<+S,
M9):&(')L!A^%S31R%43]V&'?MQ5N!;J.#O]^DSZB_+[^E:Y^I$6Y\^PB*6=L
M,@J<B;@.G8C@J*<@D^;.!B]#]4*L?6EMRB/<!3%=PJC5E=6 @=^5SW\F-_WZ
MU^3"!IX#=PF8CV@$2*[!^=*=55/NL@B</RZ[.!H65R0VY4H> X+[J.;4D(=0
M2A<\"192X+!HM"0<#6!T=(""#%)Z146H'=/?F<BF[E8<#7T[J^>$\'=!O+',
M)@&6T,5L%C199;* SI 70J0@[5!;7E.7+XZ!MIV4T<"0I6?Y^G,<5[FQ%-_^
M#/C1515><$1)H2-(IU"26J),O<[ M# \XS)S01T3<=L(;>I*1V_PJZ*F=AHU
M;//,DS4I."N!25:Z%,F,WKYBH%PRS@1.+*T-ND.B(L>Z\'$(K&J(NH%-[(70
M,Z.&&<4T:,61FU"F=2IC(?B4N9<Y*]U?__"]DP#'N@G2 W[V$7SS^\^]0'.F
MP03%!#!32BV=M> #R9 H$5(X0[,[$J!V#/P?ZZY(#YC:4_P-%N=\^?.W+V__
MSY]O/WY]^W?\\N6 &.RV1QT:9.U$8J4HZI<;/TO_NBEM%'X4(_H61$D81:DU
MX'7T(&BF:$E;-*=MMC91X;RO'4_=1LO!,W@>/G<Y^\-1PDETI;A16EPDUI60
M7 3T$Y+5)F<A:F=Y-M$Q;$2TBO:?3-LY5-P->/_+'N+O7%BFO,H,-&IRB$FB
M:YFU03;*#+3B7UK#%,N<!ZIR9< \I:(IN.RAV4E5,3<'E-6LJJC*8#Q2ZE=+
M%(*B%6\9GI.LU,ER;@/^7Z]0:6&4X*&Z?18J>PBZ ;!\26A$I?A[\O/U-#O-
MJ,[HZE%>!CM'X<'PE "W5TFC\9G)VDAY0D1+,-E'KX^/GX.$W !*"N7OQW@0
MWY2PYF+AH+NF _$,$B\]U%7*:-M3!CD$KDE4)K/J4R:?4#%LYJSZV7.@F)L#
MRD=WG5;+1VK"DI(9,H\*Q>(-6)T=9,E3)IE9QVIGPK;1,NSF<JB.GX7,G@(?
M_/;GSXQB+[>\/DS<>+;:(W&+E4+@THF.1Q0+KBF?-(6@M62<),EYMV9/&Q_?
M$@KV5=NDJ@R'1L%9T5PA_O9"_-U\W1 C+@W'D7YM>0:#]$,NK1]DRM(^/FJV
M &';&X8]1NICH8HD&SA-/DS&E_BTZR*AK_AO%KNE34XYI<M<5%W:LPJ!/' !
MF85LC1)9^]JQUDUT#%LV4=WT.%C4#<)EM8QT$-D(M+ 3]QJ$2P)\D!2(<L)&
M;BA5U:_8;:1DX%+#@S7\ F3V$'<+H!F-TWE>NGRK75()*K@M([U#Z2%/DP0D
M70"E G=)9;UVM2^;/:6B+;#LH]O'<#E,T U 98,;_^@\%12\S01,2M8R)B7E
MM0.P^\5*^JL>K0^4P\3< DX>'<[KS78QMSC% )R94.RY  9E 40**<M5DL1K
M=_;?0LJP57C5C9<: F\3-^OEQ&.((7!TWD+9+9D&&V0$B[X=-4:6WIG](Z<%
M*Z:*JE^&SQYR;P] J]V3ZQQ$&<=$5! @%*XLHZT'+@(N-6F<U;7+Y#82TAQP
M]E'R\]#90^+MP>;#W6AJ8@PNGP124-R3DU1@I+>09?(I!1],ZKG@XI:680MW
M^SZQ]A-Y ]"Y;]2O$V9_N)^CZYOKWR;3Z>2OT?CRC?N.?YG_NHC)>T&"+F-/
M$BX+0L"7.N1$C.6$1^JE[]&O>HF^IO:G/1'QC,]553T-0._3=!)2BK,RFO#]
M;';CQ@%Y+?[(UY4_<L$-,RD;!3P'@CM[MF#+CLP<(<HPGHFI[9Z]3%53.<LZ
M,*NLBJ$3$?<)_S#ZU\T(5\^O<F-L]FUR%1][HT9+,-9R_"XPECA7F3T*0&\;
M0O+L>YH*,!^&D]I2;6#W>7/E9K/S_(\R!'$\/Y\N.G"MQZHL(ABC^2C-WKBK
MJQ1_^[7ZW&SUP5EA-Q*I&"2!7W3D GQI8Q@9Y2IZ7!&Z]A6] TEN*F909]\Z
MIA);Q>S;GVD:1K/T:3HJF_9C'NF:20[!>@V:%_=(>@:12J:)5R;[VNF3O0AM
MRD/H$9]5%=8 *M<,K#OFS\YOYK/2G'.T/"\N@K?:E?E"4:4RQ@R==!-3 I>L
M$HQIFVGM2K.7:!KVOE\O6*NJAN$OV2R>/4OA?UU.?OP_2.OR\6=E[O37T37R
M5)K\7DU*-_.'1&^Z9_, 3_<?NH022N(609O?L./UF[V)/_ &#K[J8OF6Z\4K
M[J(O^XIC^Q/WW#7N/_"/\?=1>>A79/LW_.-_5R'SZ5,'B0N\J(OU NXDD0'W
M^0?TI?FW2:RLKT?/',2]WD];FZ71B*X^X6OGT^MQ?'?E+JMHZN$3!W%O]]+3
M1DDTHJ6RXM^,9W%:3TV/'CF(V[?W[O=4%HTHZG]/_KJCK^X.N.71@_A#>RGN
M>=D,K,#;,W5TG>*[R?3-Y/K[W]W5P<OMN><.XE[LI+H.4FEAX<W>H)F<ODYN
MR2V9NXJK[X7G#]+68_<EV$U*S>JS)S4.TT"CDO8:4=K[<1S]&,4;=[4H.SM$
M48\>-:Q3]KS,)R\)8.BE='5U1]?Z/M1!BVC3 P?3T!:93[H)H(&0Z'+]KVLU
MZX8V'SY[6&>YTRIZ5B@-*.O+-V3V-S=+L=A :3Q;R6_JQI>+NU>SWW[=?6;5
M&7+!S!U'X_CIRHWO75&MJ_->2!RT6F8S&!X76?6HF0: ]_;Z^]7D5TI?YFBD
MG7\OO+VXE>^#GNWO&;9@JD_M3G84=0-P6-!V]AU?'T8+42S3.%_./G_I!18O
MOV_80J<CPJ.SZ(>V^S8=NF@(%0[K.U'K!W>!@>W-QMC;C7HDEQ94]^<X3J]^
M7=Y5IIQ=SP_7V\:G=MK:R?!:>TXD+:CL[<]I6%1J'*ZGNT<-,\-^=^4\8;X%
MC?RME#G\[N;IG1M-_^ZN;BJH9L,SAQD(O[N.MHMC8&4]7-F__OCO^0)*;[Z-
M+S^%P[:]%QX]S&3UG53733BMEN&\G2[R!3V5X#Q]>I7RFQ>(KE!Z\SF%R8\T
M_76>G[SK"1CVPGVG%QRP9%=/7;_F\.#\Q@<.%E?<13_W%^MS8AEXD_V<9BB[
MA3]4SH"#@_2;GC>8OIZ5^Z23$/ZMTR>]6"==E?*?Q,E_$B<[Z>;C9/PQ36HH
MY>&3ADLT/B?KR0N,-W2NI-(?9C1>R*SLK]4.F"</'FQ3V]<RZ"*FH;>\R\OY
MBJF#HTT/'S58 >B^VMHLBH'ULR9H[*Y^S4:S.K5-6Q\Z6#'H@;;W5O$,K+TO
M\__^- WGTZ^SZ=O9?'3MEJFE>E7RG5XP6*7HOEK=16P#:_C>-:J*6^GVIPY6
M.KJO+E\44#L'X,?)_)_I]J1.M<JXN[Q@L$K2"H?EBV(;6,/O\*&3<5IS6B,A
MNN61@U64[JO%YT73EMY^OTE?)V]_EEQ_0C['>3(-"]/ZT,UVE_<,ENRNI.$N
M0FQ0[7\?3:X68C[/_WMRG=Z4:;?37Q_<7WWH_MF7#9<XKXF +O)L$ ;(\;]N
MW-4HC\**^J_NYV]IG/)H?G"QQ%XO'"Y57Q,.7>7:%B1P&[MRXQ7![Z^_ES&"
MR,!R?&@=VVV_-PY7&U )%+M)MAT/K*:)]\QCARL@J."$M6GK;2"PLA_]^+&=
ME-A4K.ME&364%9BD&?J%G]._;D;3VWVESJ:\PVLZ*;FIT-?N,FRU"NC3_VWO
MBGH;1X'P^_V:W=7>ZTG9IJDJG9JHS5;JHV.<U"=B<D"R[;\_<%(W<3#&,+F9
ME?)25:WT,7P?C&$8AMVE,H!.D4&R?SS& F3^S++W9S4KI-EMK6WQ3.C$GQ#\
MA'EMR$G/]6E T Y<!ZAP/"/;O<<^$'HK\JTN=\6-<1,K(=^34T?<B'@RM?D6
M@9W'#B1SWC:O+("22+J!\;*OO%*(8;P@2S<K!(!.GRB8.27]7 M/Q_&3?(Q)
M#R!RM+'P[D(/%*6#A&NNXO_YI;GF)U[S$X=IP_Z9BWH_GCH]3I'0TJA\L\/9
M66P!.&_,@ID:;3B\S[J3;A'2=VQ15BM=WUJJ5/6<F<G[M%VO]W$KI:OY@D^$
M'&WX@K](",T&MX:Y4NM23 #01T!V:[/IHGK:Y3=* ZGK!,5<V06*Z",#>_,#
MK5.T1I>9:'WLBS JB*@TDQ)<J#8FWGR*T*J#$.PHW;_Z??1+,F5-!)#*A8=7
M83G([7DHH"+.A9<C0]K!B^-Y9'*I^=NL04XZ=ON6\Y5903UNI&;G78">H6'-
MX5W2'*CY8 :1I7^1MQ6;V'(7TV73B3M96<-O=I*]2'N6SJK5J&(_JYW2#&
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M/S7HD?\/YP\O8!]VD)*40EF!9*%_-EM+N%0=G8!!XE&*9/AHP2YU:K_,MD=
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M?ACFLO-!Z(.I,/'^\%:(A/\3=?;P=WF/?OB'_;'(5/'7'_\!4$L! A0#%
M  @ $X!S7/AY'Q&[&0  KB ! !X              ( !     &5X:&EB:70Q
M,#$R+6]X9F]R9&9I<G-T86UE+FAT;5!+ 0(4 Q0    ( !. <US%?+_#>0(
M #L(   4              "  ?<9  !E>&AI8FET,C,Q<30R,#(U+FAT;5!+
M 0(4 Q0    ( !. <USTJ0H6W0<  #8G   4              "  :(<  !E
M>&AI8FET,S$Q<30R,#(U+FAT;5!+ 0(4 Q0    ( !. <UQ?;0JDWP<  $ G
M   4              "  ;$D  !E>&AI8FET,S$R<30R,#(U+FAT;5!+ 0(4
M Q0    ( !. <URM3TTZV@0  "L3   4              "  <(L  !E>&AI
M8FET,S(Q<30R,#(U+FAT;5!+ 0(4 Q0    ( !. <UP-(?NMX@0  "@3   4
M              "  <XQ  !E>&AI8FET,S(R<30R,#(U+FAT;5!+ 0(4 Q0
M   ( !. <UQ.LW& W6L# %\T&P 1              "  >(V  !I;F)X+3(P
M,C4Q,C,Q+FAT;5!+ 0(4 Q0    ( !. <UPCQN,&=Q,  -C6   1
M      "  >ZB P!I;F)X+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( !. <URK
MSUD+VB$  .U/ 0 5              "  92V P!I;F)X+3(P,C4Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    "  3@'-<G3A2%O%B   9E00 %0
M@ &AV , :6YB>"TR,#(U,3(S,5]D968N>&UL4$L! A0#%     @ %(!S7$=[
M\&2=&P( RHL" !0              ( !Q3L$ &EN8G@M,C R-3$R,S%?9S$N
M:G!G4$L! A0#%     @ %(!S7+2GYA\8" ( ^'L" !0              ( !
ME%<& &EN8G@M,C R-3$R,S%?9S(N:G!G4$L! A0#%     @ %(!S7.T"FJ9U
MH0  8*L  !0              ( !WE\( &EN8G@M,C R-3$R,S%?9S,N:G!G
M4$L! A0#%     @ %(!S7%=Y9;C$F   0J(  !0              ( !A0$)
M &EN8G@M,C R-3$R,S%?9S0N:G!G4$L! A0#%     @ %(!S7)D#B1PL% $
M0-@* !4              ( !>YH) &EN8G@M,C R-3$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( !2 <US6QM>?Q*<  ' *"  5              "  =JN"@!I
J;F)X+3(P,C4Q,C,Q7W!R92YX;6Q02P4&     !  $  H!   T58+

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>inbx-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:inbx="http://inhibrx.com/20251231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inbx-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2026-03-11</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2024-05-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inbx:AventisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inbx:AventisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:MergerConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:LoansAssumedByAcquirerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:NetAssetsAndLiabilitiesAssumedByAcquirerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">inbx:TransactionCostsPaidByAcquirerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inbx:PhylaxisBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inbx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">inbx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:WarrantsPreFundedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2020OxfordTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:ClassOfWarrantOrRightExpirationDate1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">inbx:ClassOfWarrantOrRightExpirationDate2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inbx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">inbx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-30</startDate>
            <endDate>2024-05-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:A2024PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inbx:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:ScitheraLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inbx:LicenseNonAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:A2seventyBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inbx:RegeneronPharmaceuticalsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:ServicesPerformedUnderTransitionServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">inbx:SeverancePaymentsToFormerEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:OxfordTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inbx:A2025LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-18</startDate>
            <endDate>2026-03-18</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-18</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <instant>2025-01-13</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007919</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="right">
        <measure>inbx:right</measure>
    </unit>
    <unit id="distribution">
        <measure>inbx:distribution</measure>
    </unit>
    <unit id="segment">
        <measure>inbx:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>inbx:tranche</measure>
    </unit>
    <unit id="obligation">
        <measure>inbx:obligation</measure>
    </unit>
    <unit id="program">
        <measure>inbx:program</measure>
    </unit>
    <unit id="contract">
        <measure>inbx:contract</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0002007919</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-37">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-40" id="f-288">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-42031</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">INHIBRX BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">99-0613523</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">11025 N. Torrey Pines Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 140</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">795-4220</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">INBX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-27">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-28">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-31" unitRef="usd">174600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-32" unitRef="shares">14607036</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-33">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant&#x2019;s Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1 contextRef="c-4" decimals="INF" id="f-38" unitRef="shares">991849</inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-5" decimals="INF" id="f-39" unitRef="shares">140741</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-42">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity policies, standards, processes and practices are designed to align with recognized frameworks, such as those established by the National Institute of Standards and Technology, or NIST, and the International Organization for Standardization. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use such frameworks as a guide to help us identify, assess and manage cybersecurity risks relevant to our business. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is designed to preserve the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management and Strategy; Effect of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program designed to ensure our systems are effective and prepared for information security risks, including monitoring for internal and external threats. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services depending on the sensitivity of the information and systems, including network and endpoint monitoring, audits, vulnerability assessments, penetration testing, and threat modeling, which are designed to inform our risk identification and assessment. As discussed in more detail under &#x201c;Cybersecurity Governance&#x201d; below, our audit committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer, General Counsel, and Director of Information Technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also identify cybersecurity risks by engaging experts to attempt to test our information systems. Depending on the sensitivity of the data and systems in question, we may also undertake activities such as:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;monitoring emerging data protection laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;implementing relevant policies, practices, and contracts (as applicable);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;employing technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated through vulnerability assessments and cybersecurity threat intelligence;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;providing training for our employees and contractors regarding cybersecurity threats;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;conducting phishing simulations;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt"&gt;conducting annual cybersecurity management and incident response training; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;carrying information security risk insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incident response plan is designed to coordinate the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, and includes processes to triage, assess severity for, escalate, contain, investigate and remediate incidents, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the above processes, we engage with consultants, internal auditors and other third parties, including annually having an independent third-party review of our cybersecurity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, depending on the nature and sensitivity of the data or systems in question, and monitor cybersecurity threat risks identified through such diligence. Additionally, we generally require certain third parties to agree by contract to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we may conduct as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cybersecurity breaches could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; which disclosures are incorporated by reference herein.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-40">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity policies, standards, processes and practices are designed to align with recognized frameworks, such as those established by the National Institute of Standards and Technology, or NIST, and the International Organization for Standardization. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use such frameworks as a guide to help us identify, assess and manage cybersecurity risks relevant to our business. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is designed to preserve the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and responding to cybersecurity incidents when they occur.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-45">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-46">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led primarily by our Director of Information Technology, who has several years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, and implementing effective information and cybersecurity programs. Our Director of Information Technology is informed with regard to and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through his management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our management team reports to the audit committee of our board of directors about cybersecurity threat risks, among other cybersecurity related matters, at least annually.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-49">The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-50">At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes which may cover topics such as data security posture, results from third-party assessments, progress towards predetermined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-51">In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our efforts to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives information regarding cybersecurity incidents that meet certain thresholds.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-52">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led primarily by our Director of Information Technology, who has</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-53">Our Director of Information Technology is informed with regard to and monitors the prevention, mitigation, detection, and remediation of cybersecurity incidents through his management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our management team reports to the audit committee of our board of directors about cybersecurity threat risks, among other cybersecurity related matters, at least annually.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-54">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorName contextRef="c-1" id="f-55">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-56">San Diego, California</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-57">243</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">124220000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-59" unitRef="usd">152596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-60" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="-3" id="f-61" unitRef="usd">200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">177000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-7" decimals="-3" id="f-63" unitRef="usd">197000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-3" id="f-64" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-65" unitRef="usd">23000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">8435000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-67" unitRef="usd">7382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">132832000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-69" unitRef="usd">160398000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">3733000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-71" unitRef="usd">6200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">5535000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-73" unitRef="usd">7338000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">4378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-75" unitRef="usd">6831000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">146478000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-77" unitRef="usd">180767000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">5944000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-79" unitRef="usd">9245000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">25529000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-81" unitRef="usd">29890000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">2326000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-83" unitRef="usd">1595000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">33799000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-85" unitRef="usd">40730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-86" unitRef="usd">100559000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-7" decimals="-3" id="f-87" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">4127000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-89" unitRef="usd">6453000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">138485000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">47183000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-92" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-93" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-96" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-98" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-99" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-103"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-104" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-105" unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-106" unitRef="shares">14577609</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-107" unitRef="shares">14577609</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-108" unitRef="shares">14475904</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-109" unitRef="shares">14475904</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">254179000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">239715000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">-246187000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">-106132000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">7993000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">133584000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">146478000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">180767000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-120" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-121" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-123" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">113028000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-125" unitRef="usd">203743000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">23297000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-127" unitRef="usd">127905000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">136325000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-129" unitRef="usd">331648000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-135025000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-131" unitRef="usd">-331448000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-14" decimals="-3" id="f-133" unitRef="usd">2021498000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">12196000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">13491000</us-gaap:InterestExpenseNonoperating>
    <inbx:InterestIncomeNonoperating contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">7549000</inbx:InterestIncomeNonoperating>
    <inbx:InterestIncomeNonoperating contextRef="c-14" decimals="-3" id="f-137" unitRef="usd">10940000</inbx:InterestIncomeNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-381000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-139" unitRef="usd">75000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-5028000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-141" unitRef="usd">2019022000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-140053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-143" unitRef="usd">1687574000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-145" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">-140055000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">1687572000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-9.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">114.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-9.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">112.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-152" unitRef="shares">15487000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-153" unitRef="shares">14802000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-154" unitRef="shares">15487000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-155" unitRef="shares">14984000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-15" decimals="-3" id="f-156" unitRef="shares">47369000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-158" unitRef="usd">657232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-159" unitRef="usd">-613734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-160" unitRef="usd">43503000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-161" unitRef="usd">58518000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-162" unitRef="usd">58518000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-20" decimals="-3" id="f-163" unitRef="shares">3449000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-164" unitRef="usd">71678000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-165" unitRef="usd">71678000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-20" decimals="-3" id="f-166" unitRef="shares">2746000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <inbx:StockholderEquitySpinoffTransactionDecreaseInCommonStock contextRef="c-20" decimals="-3" id="f-167" unitRef="shares">53564000</inbx:StockholderEquitySpinoffTransactionDecreaseInCommonStock>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-20" decimals="-3" id="f-168" unitRef="usd">-5000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-19" decimals="-3" id="f-169" unitRef="usd">-563754000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-21" decimals="-3" id="f-170" unitRef="usd">-1179970000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">-1743729000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-20" decimals="-3" id="f-172" unitRef="shares">14476000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-173" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-174" unitRef="usd">16041000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-175" unitRef="usd">16042000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-176" unitRef="usd">1687572000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-177" unitRef="usd">1687572000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-22" decimals="-3" id="f-178" unitRef="shares">14476000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-179" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-180" unitRef="usd">239715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-181" unitRef="usd">-106132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-182" unitRef="usd">133584000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-183" unitRef="usd">11138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">11138000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-25" decimals="-3" id="f-185" unitRef="usd">1720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">1720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-26" decimals="-3" id="f-187" unitRef="shares">102000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-188" unitRef="usd">1606000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">1606000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-190" unitRef="usd">-140055000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-140055000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-28" decimals="-3" id="f-192" unitRef="shares">14578000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-193" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-194" unitRef="usd">254179000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-195" unitRef="usd">-246187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-196" unitRef="usd">7993000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-140055000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">1687572000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">2483000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">2285000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">2439000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">2065000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">11138000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">58518000</us-gaap:ShareBasedCompensation>
    <inbx:NoncashOperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">1803000</inbx:NoncashOperatingLeaseExpense>
    <inbx:NoncashOperatingLeaseExpense contextRef="c-14" decimals="-3" id="f-206" unitRef="usd">1897000</inbx:NoncashOperatingLeaseExpense>
    <inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">0</inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet>
    <inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet contextRef="c-14" decimals="-3" id="f-208" unitRef="usd">1998809000</inbx:NonmonetaryTransactionGainLossRecognizedOnTransferNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-212" unitRef="usd">185000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-20000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-14" decimals="-3" id="f-214" unitRef="usd">-566000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-23000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c-14" decimals="-3" id="f-216" unitRef="usd">23000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-1400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-14" decimals="-3" id="f-218" unitRef="usd">-2982000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-14" decimals="-3" id="f-220" unitRef="usd">3667000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-3301000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-222" unitRef="usd">17903000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-4361000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-14" decimals="-3" id="f-224" unitRef="usd">35883000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-1595000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-226" unitRef="usd">-1408000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-129794000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-228" unitRef="usd">-194409000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-230" unitRef="usd">2597000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-232" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">-28000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-234" unitRef="usd">-2597000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">99965000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-14" decimals="-3" id="f-236" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:PaymentsOfDebtIssuanceCostsSecuredDebt contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">125000</inbx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <inbx:PaymentsOfDebtIssuanceCostsSecuredDebt contextRef="c-14" decimals="-3" id="f-238" unitRef="usd">0</inbx:PaymentsOfDebtIssuanceCostsSecuredDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">1606000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-14" decimals="-3" id="f-240" unitRef="usd">71678000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">101446000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-242" unitRef="usd">71678000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">-28376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-244" unitRef="usd">-125328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-245" unitRef="usd">152596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-246" unitRef="usd">277924000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">124220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">152596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">8900000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-250" unitRef="usd">11506000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-14" decimals="-3" id="f-252" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">0</inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement>
    <inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement contextRef="c-14" decimals="-3" id="f-254" unitRef="usd">6283000</inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement>
    <inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">1720000</inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred contextRef="c-14" decimals="-3" id="f-256" unitRef="usd">0</inbx:OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-257">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inhibrx Biosciences, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company&#x2019;s current pipeline is focused on oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company&#x2019;s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separation and Distribution&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, Inhibrx, Inc., or the Former Parent, announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. The Former Parent and the Company signed an Agreement and Plan of Merger, dated as of January 22, 2024, or the Merger Agreement, with Aventis Inc., a Pennsylvania corporation, or the Acquirer, and a wholly-owned subsidiary of Sanofi S.A., or Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation, or the Merger Sub, and a wholly-owned subsidiary of Acquirer, along with a Separation and Distribution Agreement, dated as of January 22, 2024, by and among the Former Parent, the Company and Acquirer. The Merger Agreement provided for the acquisition by Acquirer of the Former Parent, or the Merger, to be accomplished through the merger of Merger Sub with and into the Former Parent with the Former Parent continuing as the surviving entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 29, 2024, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of common stock of the Company, or the Distribution. On May 30, 2024, the Former Parent completed the Merger, pursuant to which (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer, a wholly-owned subsidiary of Sanofi; and (ii) by way of a series of internal restructuring transactions, or the Separation, the Company acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105. Upon the closing of the Merger, the Company became a stand-alone, publicly traded company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the foregoing transactions, each Former Parent stockholder received: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;four shares of the Former Parent&#x2019;s common stock held. The Acquirer retained an equity interest in the Company of 8% upon the Distribution. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Acquirer paid transaction consideration of $1.9 billion, including the $30.00 per share consideration and the assumption of the Company&#x2019;s third-party debt. See Note 3 for further discussion on the extinguishment of the Company&#x2019;s Amended 2020 Loans with Oxford (as defined below). In addition, the Acquirer assumed all assets and liabilities under contracts primarily related to INBRX-101 upon close of the Merger. The Acquirer also reimbursed the Company or paid on behalf of the Company $68.0&#160;million in transaction costs. The Acquirer may pay an additional $300.0&#160;million in consideration under the contingent value rights issued upon the achievement of a regulatory milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notwithstanding the legal form of the spin-off, the Separation and Distribution is being treated as a reverse spin-off for financial accounting and reporting purposes in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 505-60,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spinoffs and Reverse Spinoffs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;because (i) a wholly-owned subsidiary of the Acquirer merged with and into the Former Parent immediately following the Distribution; (ii) no senior management of the Former Parent were retained by the Former Parent following the Distribution; and (iii) the size of the Company&#x2019;s operations relative to the 101 Business. As a reverse spin-off, the Company considers Inhibrx as the accounting spinnor of the Former Parent, and the accounting successor to the Former Parent. Therefore, for periods prior to the spin-off, the Company&#x2019;s financial statements are the historical financial statements of the Former Parent. For such periods, descriptions of historical business activities are presented as if the spin-off had already occurred, and the Former Parent&#x2019;s activities related to such assets and liabilities had been performed by the Company. In addition, for all periods prior to the spin-off, all outstanding shares referenced in these financial statements are those shares outstanding of the Former Parent at each respective date, unless otherwise indicated as adjusted for the distribution ratio. Following the spin-off, all outstanding shares referenced are those of the Company, which, as discussed above, were issued on a four-to-one ratio of the Former Parent&#x2019;s outstanding shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the sale of the 101 Business in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 205-20, Discontinued Operation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s, and determined that the Separation does not represent a strategic shift and thus does not qualify as a discontinued operation. The Company next evaluated the sale of the 101 Business in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and determined that the 101 Business does not meet the definition of a business, given that substantially all of the fair value of the gross assets transferred is concentrated in one asset. The Company then evaluated the transaction under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 845, Nonmonetary Transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which contains guidance on the accounting for the distribution of nonmonetary assets to stockholders of an entity in a spin-off. In accordance with this guidance, the disposal of the 101 Business has been accounted for as a dividend-in-kind, with a gain recognized for the difference between the fair value and carrying value of the disposed assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a gain on the transaction of $2.0 billion during the year ended December 31, 2024, which consisted of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration for common stock, warrants, and stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Book value of Amended 2020 Loans assumed by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs paid by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gain recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain related to the Merger consideration payable to shareholders of $1.7&#160;billion was recorded, net of consideration allocated to the shares issued to Acquirer, through a reduction to retained earnings of $1.2&#160;billion, representing the amount of retained earnings available at the closing of the Merger, with the remaining amount of $563.8&#160;million recorded through additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had an accumulated deficit of $246.2 million and cash and cash equivalents of $124.2 million. From its inception and through December&#160;31, 2025, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents, including proceeds from the March 2026 Amendment (see Footnote 11), will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. The Company expects to continue to incur net losses for the foreseeable future until, if ever, the Company has an approved product and can successfully commercialize it. Until such time the Company, if ever, can generate substantial product revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, the Company engages in discussions with potential acquirers regarding the disposition of one or more of its therapeutic candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company raises additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its intellectual property on less favorable terms than it would otherwise choose. These actions could materially impact its business, results of operations, financial condition, and prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#x2019;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, and the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company&#x2019;s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2025 and December&#160;31, 2024, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for credit losses was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company has never declared or paid any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;laboratory and office equipment: &lt;span style="-sec-ix-hidden:f-288"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture, fixtures and other: five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception based on the unique facts and circumstances present in the contract. The Company evaluates classification of leases as either operating or finance at commencement and, as necessary, at modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At lease commencement for leases with terms greater than 12 months, the Company records a lease liability determined as the present value of future lease payments over the expected lease term. The Company calculates the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The Company also records an operating right-of-use asset based on the liability as adjusted for any lease incentives or prepaids. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After lease commencement, assumptions made by the Company at the commencement date are re-evaluated upon the occurrence of certain events, including a lease modification. The Company evaluates any change to an existing lease to determine if it constitutes a separate contract or a single contract with the existing lease. For modifications treated as a single contract, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate as of the effective date of the modification, and recognizes the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding right-of-use asset under the lease modification guidance pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 842, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional right-of-use asset that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional right-of-use asset. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for lease and non-lease components in its lease agreements as a single lease component in determining lease assets and liabilities. In addition, the Company does not recognize the right-of-use assets and liabilities for leases with lease terms of twelve months or less, instead recognizing lease payments as operating expenses on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in Poplar Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Poplar Therapeutics, Inc, or Poplar Therapeutics, formerly Phylaxis Bioscience, LLC., which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company&#x2019;s proportionate share of the net income or loss of Poplar Therapeutics is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company&#x2019;s share of prior losses of the investee. Following the Company&#x2019;s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company&#x2019;s investment in Poplar Therapeutics as of December&#160;31, 2025 and December&#160;31, 2024 is zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments held during the periods presented consisted principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximated their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#x2019;s debt approximated fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#x2019;s warrants are equity-classified and carried at the instruments&#x2019; fair value upon classification into equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term outstanding debt is not measured at fair value on a reoccurring basis. As of December&#160;31, 2025 and December&#160;31, 2024, the fair value of the Company&#x2019;s long-term outstanding debt approximates fair value using Level 2 inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 835-30, Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 480-10, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company&#x2019;s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company&#x2019;s outstanding warrants are classified as equity as of and for the years ended December&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company&#x2019;s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development and Clinical Trial Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change occurs, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the same period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive common shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net earnings (loss) per share when the effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average number of shares of common stock used in the basic and diluted net income (loss) per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, outstanding shares during the period consist both of shares of the Former Parent and of the Company. For purposes of computing earnings (loss) per share only, for all periods presented in its consolidated statements of operations, the Company adjusted all outstanding shares of the Former Parent, including potentially dilutive securities, by the four-to-one distribution ratio used in the Distribution. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company has a net loss, basic loss per share and diluted loss per share are identical since the effect of potentially dilutive common shares is anti-dilutive and therefore excluded. Accordingly, for the year ended December 31, 2025, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company&#x2019;s market-traded shares best represents its expected volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM, in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM has been identified as the Chief &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Officer, who reviews financial results at a consolidated level only. The Company views its operations and manages its business as one operating and reportable segment as the Company has devoted substantially all of its resources to drug discovery and development activities through conducting preclinical studies and clinical trials associated with its programs, all of which aim to discover and develop biologic therapeutic candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM assesses performance for the biologic therapeutic segment and decides how to allocate resources based on the consolidated net income (loss) as reported on its consolidated income statement. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The segment depreciation expense, interest expense, interest income, and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues to date under this segment have been derived from licenses with collaboration partners and grant awards, and the Company has not generated any revenue from the commercial sale of approved therapeutic products (see Note 6). As a result, the Company has incurred operating losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its therapeutic candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval. The CODM evaluates the Company's operating results and allocates resources using net income (loss) and the components of operating expense, together with information on the progression and results of clinical trial activities, to advance the Company's therapeutic pipeline and to best support the long-term growth of the Company&#x2019;s overall business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, depreciation, and facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment and consolidated net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Other segment items consist of the gain on transaction from the Merger, discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Other segment expenses include provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvement to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to enhance the transparency and decision usefulness of income tax disclosures. Two primary enhancements related to this ASU include disaggregating existing income tax disclosures relating to the effective tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025 and applied it prospectively, as disclosed in Note 8, Income Taxes. The adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued but Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires additional disclosure about specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this accounting standard update on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-258">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-259">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP.&#160;All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <inbx:MergerExchangeRatioProRateBasisPercentage contextRef="c-31" decimals="2" id="f-260" unitRef="number">0.92</inbx:MergerExchangeRatioProRateBasisPercentage>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
      contextRef="c-32"
      decimals="2"
      id="f-261"
      unitRef="usdPerShare">30.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare contextRef="c-32" decimals="INF" id="f-262" unitRef="right">1</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
      contextRef="c-32"
      decimals="2"
      id="f-263"
      unitRef="usdPerShare">5.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare>
    <inbx:MergerExchangeRatio
      contextRef="c-33"
      decimals="INF"
      id="f-264"
      unitRef="number">4</inbx:MergerExchangeRatio>
    <inbx:MergerOwnershipPercentage contextRef="c-32" decimals="2" id="f-265" unitRef="number">0.08</inbx:MergerOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-34" decimals="-8" id="f-266" unitRef="usd">1900000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
      contextRef="c-32"
      decimals="2"
      id="f-267"
      unitRef="usdPerShare">30.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1 contextRef="c-33" decimals="-5" id="f-268" unitRef="usd">68000000.0</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-35" decimals="-5" id="f-269" unitRef="usd">300000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <inbx:ScheduleOfMergerTransactionTableTextBlock contextRef="c-1" id="f-270">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a gain on the transaction of $2.0 billion during the year ended December 31, 2024, which consisted of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger consideration for common stock, warrants, and stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Book value of Amended 2020 Loans assumed by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Book value of net assets and liabilities related to INBRX-101 assumed by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transaction costs paid by Acquirer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gain recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inbx:ScheduleOfMergerTransactionTableTextBlock>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-14" decimals="-8" id="f-271" unitRef="usd">2000000000.0</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-36" decimals="-3" id="f-272" unitRef="usd">1727687000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-37" decimals="-3" id="f-273" unitRef="usd">211315000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-38" decimals="-3" id="f-274" unitRef="usd">14496000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-39" decimals="-3" id="f-275" unitRef="usd">68000000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-14" decimals="-3" id="f-276" unitRef="usd">2021498000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-36" decimals="-8" id="f-277" unitRef="usd">1700000000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-21" decimals="-8" id="f-278" unitRef="usd">-1200000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="c-19" decimals="-5" id="f-279" unitRef="usd">-563800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <inbx:LiquidityPolicyTextBlock contextRef="c-1" id="f-280">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had an accumulated deficit of $246.2 million and cash and cash equivalents of $124.2 million. From its inception and through December&#160;31, 2025, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its existing cash and cash equivalents, including proceeds from the March 2026 Amendment (see Footnote 11), will be sufficient to fund the Company&#x2019;s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of conducting preclinical studies and testing therapeutic candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. The Company expects to continue to incur net losses for the foreseeable future until, if ever, the Company has an approved product and can successfully commercialize it. Until such time the Company, if ever, can generate substantial product revenue, the Company expects to finance its cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, the Company engages in discussions with potential acquirers regarding the disposition of one or more of its therapeutic candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company raises additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders&#x2019; rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises additional capital through strategic licensing, collaboration or other similar agreements, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its intellectual property on less favorable terms than it would otherwise choose. These actions could materially impact its business, results of operations, financial condition, and prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rules and regulations of the SEC or any other regulatory agencies may restrict the Company&#x2019;s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.&lt;/span&gt;&lt;/div&gt;</inbx:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-5" id="f-281" unitRef="usd">-246200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-282" unitRef="usd">124200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-283">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The Company&#x2019;s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, and the incremental borrowing rate estimated in relation to the Company&#x2019;s operating lease.&#160;The Company bases its estimates on historical experience, known trends and other&#160;market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.&#160;The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-284">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep, and money market accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-285">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or the FDIC, of up to $250,000. The Company&#x2019;s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/div&gt;The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company&#x2019;s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December&#160;31, 2025 and December&#160;31, 2024, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for credit losses was recorded.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-286">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company has never declared or paid any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;Any future determination to pay dividends on the Company&#x2019;s common stock will be at the discretion of the Company&#x2019;s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company&#x2019;s board of directors may deem relevant.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation.&#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;laboratory and office equipment: &lt;span style="-sec-ix-hidden:f-288"&gt;three&lt;/span&gt; to five years; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;furniture, fixtures and other: five years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;computer software: three years.&lt;/span&gt;&lt;/div&gt;Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term.&#160;The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-41" id="f-289">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-42" id="f-290">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-291">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.&#160;If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception based on the unique facts and circumstances present in the contract. The Company evaluates classification of leases as either operating or finance at commencement and, as necessary, at modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At lease commencement for leases with terms greater than 12 months, the Company records a lease liability determined as the present value of future lease payments over the expected lease term. The Company calculates the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The Company also records an operating right-of-use asset based on the liability as adjusted for any lease incentives or prepaids. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After lease commencement, assumptions made by the Company at the commencement date are re-evaluated upon the occurrence of certain events, including a lease modification. The Company evaluates any change to an existing lease to determine if it constitutes a separate contract or a single contract with the existing lease. For modifications treated as a single contract, the Company reassesses the lease classification, remeasures the related lease liability using an updated discount rate as of the effective date of the modification, and recognizes the amount of the remeasurement of the lease liability for the modified lease as an adjustment to the corresponding right-of-use asset under the lease modification guidance pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 842, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If a lease continues to exist, the lease modification is determined to be a separate contract when the modification grants the lessee an additional right-of-use asset that is not included in the original lease and the lease payments increase commensurate with the standalone price for the additional right-of-use asset. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease. &lt;/span&gt;&lt;/div&gt;The Company accounts for lease and non-lease components in its lease agreements as a single lease component in determining lease assets and liabilities. In addition, the Company does not recognize the right-of-use assets and liabilities for leases with lease terms of twelve months or less, instead recognizing lease payments as operating expenses on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-294">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in Poplar Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Poplar Therapeutics, Inc, or Poplar Therapeutics, formerly Phylaxis Bioscience, LLC., which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company&#x2019;s proportionate share of the net income or loss of Poplar Therapeutics is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company&#x2019;s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company&#x2019;s share of prior losses of the investee. Following the Company&#x2019;s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company&#x2019;s investment in Poplar Therapeutics as of December&#160;31, 2025 and December&#160;31, 2024 is zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-44" decimals="2" id="f-295" unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-45" decimals="2" id="f-296" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-46" decimals="INF" id="f-297" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <inbx:EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod contextRef="c-47" decimals="2" id="f-298" unitRef="number">0.05</inbx:EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod>
    <us-gaap:EquityMethodInvestments contextRef="c-48" decimals="INF" id="f-299" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-49" decimals="INF" id="f-300" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-301">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments held during the periods presented consisted principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximated their related fair values due to the short-term nature of these instruments. The carrying value of the Company&#x2019;s debt approximated fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company&#x2019;s warrants are equity-classified and carried at the instruments&#x2019; fair value upon classification into equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-302">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;In certain cases, the inputs used to measure fair value may fall into different&#160;levels of the fair value hierarchy.&#160;In such&#160;cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement&#160;in its entirety.&#160;The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific&#160;to the asset or liability.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type are presented in the following table (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-304" unitRef="usd">5870000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-307" unitRef="usd">5870000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-308" unitRef="usd">5870000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-6" decimals="-3" id="f-311" unitRef="usd">5870000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-312" unitRef="usd">5093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-314" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-315" unitRef="usd">5093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-316" unitRef="usd">5093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-7" decimals="-3" id="f-319" unitRef="usd">5093000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-320">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs and Other Debt-Related Costs &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs are capitalized, recorded as an offset to the Company&#x2019;s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 835-30, Imputation of Interest&lt;/span&gt;.&#160;If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.</us-gaap:DeferredChargesPolicyTextBlock>
    <inbx:WarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-321">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments with Characteristics of Both Liabilities and Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 480-10, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company&#x2019;s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company&#x2019;s outstanding warrants are classified as equity as of and for the years ended December&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</inbx:WarrantsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-322">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research, Development, and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2)&#160;nonrefundable up-front fees; (3)&#160;payments for reimbursement of research costs; (4)&#160;payments associated with achieving specific development, regulatory, or commercial milestones; and (5)&#160;royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company&#x2019;s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-323">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development and Clinical Trial Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company&#x2019;s behalf, pursuant to development and consulting agreements in place. The Company&#x2019;s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company&#x2019;s purchases of&#160;in-process&#160;research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received &lt;/span&gt;&lt;/div&gt;marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method.&#160;Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.&#160;Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse.&#160;A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. &lt;/span&gt;&lt;/div&gt;The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. The Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company has already incurred ownership changes and may incur additional ownership changes in the future. If an ownership change occurs, the Company&#x2019;s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-325">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common stock outstanding during the same period. Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive common shares outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net earnings (loss) per share when the effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average number of shares of common stock used in the basic and diluted net income (loss) per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <inbx:EarningsDistributionRatio
      contextRef="c-14"
      decimals="INF"
      id="f-326"
      unitRef="distribution">4</inbx:EarningsDistributionRatio>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-327">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In periods in which the Company has net income, the Company applies the treasury stock method to determine the dilutive effect of potentially dilutive securities. Potentially dilutive securities included in the diluted earnings per share are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.342%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="-3" id="f-328" unitRef="shares">3501000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="-3" id="f-329" unitRef="shares">141000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-330" unitRef="shares">3642000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="-3" id="f-331" unitRef="shares">182000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="-3" id="f-332" unitRef="shares">182000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-333">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. The Company determines the assumptions used in the option pricing model in the following manner:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company&#x2019;s market-traded shares best represents its expected volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&#x2014;&lt;/span&gt;The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM, in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM has been identified as the Chief &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Officer, who reviews financial results at a consolidated level only. The Company views its operations and manages its business as one operating and reportable segment as the Company has devoted substantially all of its resources to drug discovery and development activities through conducting preclinical studies and clinical trials associated with its programs, all of which aim to discover and develop biologic therapeutic candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM assesses performance for the biologic therapeutic segment and decides how to allocate resources based on the consolidated net income (loss) as reported on its consolidated income statement. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The segment depreciation expense, interest expense, interest income, and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s revenues to date under this segment have been derived from licenses with collaboration partners and grant awards, and the Company has not generated any revenue from the commercial sale of approved therapeutic products (see Note 6). As a result, the Company has incurred operating losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its therapeutic candidates through all stages of development and clinical trials and, ultimately, seeks regulatory approval. The CODM evaluates the Company's operating results and allocates resources using net income (loss) and the components of operating expense, together with information on the progression and results of clinical trial activities, to advance the Company's therapeutic pipeline and to best support the long-term growth of the Company&#x2019;s overall business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-336"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-337"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-338">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the significant segment revenue and significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net income (loss) for the years ended December&#160;31, 2025 and December&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED&lt;br/&gt;DECEMBER&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, depreciation, and facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merger-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,021,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment and consolidated net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Other segment items consist of the gain on transaction from the Merger, discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Other segment expenses include provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-67" decimals="-3" id="f-339" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-68" decimals="-3" id="f-340" unitRef="usd">200000</us-gaap:Revenues>
    <inbx:ResearchAndDevelopmentExpensePersonnel contextRef="c-67" decimals="-3" id="f-341" unitRef="usd">35372000</inbx:ResearchAndDevelopmentExpensePersonnel>
    <inbx:ResearchAndDevelopmentExpensePersonnel contextRef="c-68" decimals="-3" id="f-342" unitRef="usd">72790000</inbx:ResearchAndDevelopmentExpensePersonnel>
    <inbx:ResearchAndDevelopmentExpenseClinicalTrials contextRef="c-67" decimals="-3" id="f-343" unitRef="usd">35339000</inbx:ResearchAndDevelopmentExpenseClinicalTrials>
    <inbx:ResearchAndDevelopmentExpenseClinicalTrials contextRef="c-68" decimals="-3" id="f-344" unitRef="usd">47665000</inbx:ResearchAndDevelopmentExpenseClinicalTrials>
    <inbx:ResearchAndDevelopmentExpenseContractManufacturing contextRef="c-67" decimals="-3" id="f-345" unitRef="usd">19590000</inbx:ResearchAndDevelopmentExpenseContractManufacturing>
    <inbx:ResearchAndDevelopmentExpenseContractManufacturing contextRef="c-68" decimals="-3" id="f-346" unitRef="usd">55643000</inbx:ResearchAndDevelopmentExpenseContractManufacturing>
    <inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility contextRef="c-67" decimals="-3" id="f-347" unitRef="usd">10227000</inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility>
    <inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility contextRef="c-68" decimals="-3" id="f-348" unitRef="usd">9693000</inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-67" decimals="-3" id="f-349" unitRef="usd">12500000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-68" decimals="-3" id="f-350" unitRef="usd">17952000</us-gaap:OtherResearchAndDevelopmentExpense>
    <inbx:GeneralAndAdministrativeExpenseMergerRelated contextRef="c-67" decimals="-3" id="f-351" unitRef="usd">0</inbx:GeneralAndAdministrativeExpenseMergerRelated>
    <inbx:GeneralAndAdministrativeExpenseMergerRelated contextRef="c-68" decimals="-3" id="f-352" unitRef="usd">68061000</inbx:GeneralAndAdministrativeExpenseMergerRelated>
    <inbx:GeneralAndAdministrativeExpensePersonnel contextRef="c-67" decimals="-3" id="f-353" unitRef="usd">14481000</inbx:GeneralAndAdministrativeExpensePersonnel>
    <inbx:GeneralAndAdministrativeExpensePersonnel contextRef="c-68" decimals="-3" id="f-354" unitRef="usd">37649000</inbx:GeneralAndAdministrativeExpensePersonnel>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-67" decimals="-3" id="f-355" unitRef="usd">8816000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c-68" decimals="-3" id="f-356" unitRef="usd">22195000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-67" decimals="-3" id="f-357" unitRef="usd">-5028000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-68" decimals="-3" id="f-358" unitRef="usd">-2476000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-67" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer contextRef="c-68" decimals="-3" id="f-360" unitRef="usd">2021498000</us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-67" decimals="-3" id="f-361" unitRef="usd">2000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-68" decimals="-3" id="f-362" unitRef="usd">2000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-67" decimals="-3" id="f-363" unitRef="usd">-140055000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-68" decimals="-3" id="f-364" unitRef="usd">1687572000</us-gaap:NetIncomeLoss>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-365">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adoption of New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvement to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to enhance the transparency and decision usefulness of income tax disclosures. Two primary enhancements related to this ASU include disaggregating existing income tax disclosures relating to the effective tax rate reconciliation and income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025 and applied it prospectively, as disclosed in Note 8, Income Taxes. The adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued but Not Yet Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires additional disclosure about specific expense categories in the notes to financial statements. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this accounting standard update on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-366">OTHER FINANCIAL INFORMATION &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expense and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical drug substance and product manufacturing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Relates primarily to the Company&#x2019;s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company&#x2019;s therapeutics. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Relates primarily to the Company&#x2019;s usage of third-party CDMOs for clinical and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Relates to the Company&#x2019;s usage of third parties for other research and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for each of the years ended December 31, 2025 and December&#160;31, 2024, and consisted of the following (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical drug substance and product manufacturing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other outside research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Relates primarily to the Company&#x2019;s usage of third-party CROs for management of clinical trials. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Relates primarily to the Company&#x2019;s usage of third-party CDMOs for clinical and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Relates to the Company&#x2019;s usage of third parties for other research and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-367">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expense and other current assets were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical drug substance and product manufacturing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside research and development services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Relates primarily to the Company&#x2019;s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company&#x2019;s therapeutics. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Relates primarily to the Company&#x2019;s usage of third-party CDMOs for clinical and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Relates to the Company&#x2019;s usage of third parties for other research and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <inbx:ClinicalTrailsPrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-368" unitRef="usd">4566000</inbx:ClinicalTrailsPrepaidExpenseCurrent>
    <inbx:ClinicalTrailsPrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-369" unitRef="usd">3544000</inbx:ClinicalTrailsPrepaidExpenseCurrent>
    <inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-370" unitRef="usd">1880000</inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent>
    <inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-371" unitRef="usd">1998000</inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent>
    <inbx:PrepaidLicenseCurrent contextRef="c-6" decimals="-3" id="f-372" unitRef="usd">1303000</inbx:PrepaidLicenseCurrent>
    <inbx:PrepaidLicenseCurrent contextRef="c-7" decimals="-3" id="f-373" unitRef="usd">816000</inbx:PrepaidLicenseCurrent>
    <inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-374" unitRef="usd">448000</inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent>
    <inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-375" unitRef="usd">642000</inbx:OutsideResearchAndDevelopmentServicesPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-376" unitRef="usd">238000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-377" unitRef="usd">382000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-378" unitRef="usd">8435000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-379" unitRef="usd">7382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-380">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net were comprised of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for each of the years ended December 31, 2025 and December&#160;31, 2024, and consisted of the following (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-69" decimals="-3" id="f-381" unitRef="usd">9519000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="-3" id="f-382" unitRef="usd">9758000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-383" unitRef="usd">3984000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-72" decimals="-3" id="f-384" unitRef="usd">3984000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-42" decimals="-3" id="f-385" unitRef="usd">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-386" unitRef="usd">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-387" unitRef="usd">795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-75" decimals="-3" id="f-388" unitRef="usd">795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-389" unitRef="usd">14854000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-390" unitRef="usd">15093000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-391" unitRef="usd">11121000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-392" unitRef="usd">8893000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-393" unitRef="usd">3733000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-394" unitRef="usd">6200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-76" decimals="-3" id="f-395" unitRef="usd">2304000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-77" decimals="-3" id="f-396" unitRef="usd">1881000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-78" decimals="-3" id="f-397" unitRef="usd">179000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-79" decimals="-3" id="f-398" unitRef="usd">404000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">2483000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-14" decimals="-3" id="f-400" unitRef="usd">2285000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-401">&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical drug substance and product manufacturing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other outside research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Relates primarily to the Company&#x2019;s usage of third-party CROs for management of clinical trials. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Relates primarily to the Company&#x2019;s usage of third-party CDMOs for clinical and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Relates to the Company&#x2019;s usage of third parties for other research and development efforts. See &#x201c;Accrued Research and Development Clinical Trial Costs&#x201d; in Note 1 for further discussion of the components of research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inbx:AccruedClinicalTrialsCurrent contextRef="c-6" decimals="-3" id="f-402" unitRef="usd">10794000</inbx:AccruedClinicalTrialsCurrent>
    <inbx:AccruedClinicalTrialsCurrent contextRef="c-7" decimals="-3" id="f-403" unitRef="usd">14796000</inbx:AccruedClinicalTrialsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-404" unitRef="usd">7450000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-405" unitRef="usd">7726000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent contextRef="c-6" decimals="-3" id="f-406" unitRef="usd">5542000</inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent>
    <inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent contextRef="c-7" decimals="-3" id="f-407" unitRef="usd">5642000</inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent>
    <inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent contextRef="c-6" decimals="-3" id="f-408" unitRef="usd">111000</inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent>
    <inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent contextRef="c-7" decimals="-3" id="f-409" unitRef="usd">632000</inbx:AccruedOutsideResearchAndDevelopmentOtherCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-410" unitRef="usd">447000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-411" unitRef="usd">629000</us-gaap:AccruedProfessionalFeesCurrent>
    <inbx:AccruedInterestExpenseCurrent contextRef="c-6" decimals="-3" id="f-412" unitRef="usd">857000</inbx:AccruedInterestExpenseCurrent>
    <inbx:AccruedInterestExpenseCurrent contextRef="c-7" decimals="-3" id="f-413" unitRef="usd">0</inbx:AccruedInterestExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-414" unitRef="usd">328000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-415" unitRef="usd">465000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-416" unitRef="usd">25529000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-417" unitRef="usd">29890000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-418">DEBT&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC and other lenders, or collectively, Oxford. Under the original 2020 Loan Agreement and subsequent amendments between November 2020 and October 2022, or collectively, the Amended 2020 Loan Agreement, the Company received an aggregate principal amount of $200.0 million over seven tranches, or Terms A-G.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Separation, the outstanding term loans were to mature on January&#160;1, 2027, or the Amended Maturity Date. Under the Amended 2020 Loan Agreement, and through the Separation, the repayment schedule provided for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount would be due to Oxford. This final payment of $18.0 million was being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company had the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, the Company&#x2019;s outstanding debt was assumed by the Acquirer. Prior to the close of the Merger, the Company had $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The Acquirer assumed the outstanding debt balance in full, consisting of the $200.0 million in gross principal, the $18.0 million final payment fee, and accrued interest of $2.3&#160;million, net of debt discounts of $9.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the Acquirer&#x2019;s assumption and subsequent repayment of the outstanding debt constitutes an extinguishment of the debt as the Company has been legally released from being the primary obligor under the liability. The Company did not make any payment upon the extinguishment of the debt and did not incur any prepayment penalties. Upon the Acquirer&#x2019;s assumption of the outstanding debt, the Company recorded a gain of $211.3&#160;million, the net carrying amount of the Amended 2020 Loans upon extinguishment, within the gain related to transaction with Acquirer in its consolidated statements of operations during the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Separation, interest expense was calculated using the effective interest method and was inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2024, interest expense was $13.5 million, $2.1 million of which related to non-cash amortization of the debt discount and accretion of the final payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2025 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 13, 2025, the Company entered into a Loan and Security Agreement, or the 2025 Loan Agreement, with Oxford, pursuant to which it received $100.0 million in gross proceeds. The 2025 Loan Agreement provides for an additional tranche of $50.0 million to be funded upon the Company's request and at Oxford&#x2019;s sole discretion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding term loan will mature on January 1, 2030, or the Maturity Date, and bears interest at (1) 5.61% plus (2) the greater of (i) the 1-Month Term Secured Overnight Financing Right as published by the CME Group or (ii) 4.34%. The repayment schedule provides for interest-only payments through February 1, 2028, with principal payments beginning on March 1, 2028. The interest-only period is followed by 23 months of equal payments of principal plus interest. Upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of any term loan under the Term Loan Facility, or (iii) prepayment of any term loan under the Term Loan Facility, the Company will be required to make a final payment of 9.0% of the total principal amount. This final payment of $9.0 million will be accreted over the life of the 2025 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loan in full prior to the Maturity Date, subject to a prepayment fee ranging from 2.0% to 5.0%, depending on the timing of the prepayment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company&#x2019;s outstanding debt balance under the 2025 Loan Agreement consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount and final payment fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s interest-only period will continue through February 2028, with principal payments beginning in March 2028. Future principal payments and final fee payments will be made as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the 2025 Loan Agreement are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company&#x2019;s operations, that may require prepayment of the outstanding term loans. The 2025 Loan Agreement also requires the Company to maintain a minimum liquidity threshold in the amount of $20.0&#160;million, tested at all times, with such liquidity threshold subject to increase to $50.0&#160;million or $75.0&#160;million based on certain pipeline development changes. As of December&#160;31, 2025, the Company is in compliance with all covenants under the 2025 Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the debt issuance in January 2025, the Company issued to Oxford warrants to purchase shares of the Company&#x2019;s common stock equal to 2.0% of the funded amount, or $2.0&#160;million, or the 2025 Oxford Warrants. Upon issuance, the warrants were exercisable for 140,741 shares of common stock at an exercise price of $14.21 per share. The 2025 Oxford Warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance. Upon issuance, the warrants were classified as equity and recorded at their fair value of $1.7 million as additional paid-in-capital and as a debt discount which will be accreted over the life of the 2025 Loan Agreement using the effective interest method. See Note 4 for further discussion of these warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment at an effective interest rate of 12.9%. During the year ended December 31, 2025, interest expense was $12.2 million, $2.4 million of which related to non-cash amortization of the debt discount and accretion of the final payment.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-80" decimals="-5" id="f-419" unitRef="usd">200000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:DebtInstrumentNumberOfTranches
      contextRef="c-81"
      decimals="INF"
      id="f-420"
      unitRef="tranche">7</inbx:DebtInstrumentNumberOfTranches>
    <inbx:DebtInstrumentPrincipalAndInterestTerm contextRef="c-82" id="f-421">P23M</inbx:DebtInstrumentPrincipalAndInterestTerm>
    <inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue
      contextRef="c-83"
      decimals="INF"
      id="f-422"
      unitRef="number">0.090</inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-83" decimals="-5" id="f-423" unitRef="usd">18000000.0</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="c-84"
      decimals="INF"
      id="f-424"
      unitRef="number">0.010</inbx:DebtInstrumentPrepaymentFee>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="c-85"
      decimals="INF"
      id="f-425"
      unitRef="number">0.030</inbx:DebtInstrumentPrepaymentFee>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-80" decimals="-5" id="f-426" unitRef="usd">200000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-80" decimals="-5" id="f-427" unitRef="usd">200000000.0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <inbx:DebtInstrumentBalloonPaymentWriteOff contextRef="c-33" decimals="-5" id="f-428" unitRef="usd">18000000.0</inbx:DebtInstrumentBalloonPaymentWriteOff>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-82" decimals="-5" id="f-429" unitRef="usd">2300000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost contextRef="c-82" decimals="-5" id="f-430" unitRef="usd">9000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-82" decimals="-5" id="f-431" unitRef="usd">211300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-86" decimals="-5" id="f-432" unitRef="usd">13500000</us-gaap:InterestExpenseDebt>
    <inbx:AmortizationOfDebtDiscountPremiumAndAccretion contextRef="c-86" decimals="-5" id="f-433" unitRef="usd">2100000</inbx:AmortizationOfDebtDiscountPremiumAndAccretion>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-87" decimals="-5" id="f-434" unitRef="usd">100000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <inbx:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature contextRef="c-88" decimals="-5" id="f-435" unitRef="usd">50000000.0</inbx:LineOfCreditFacilityMaximumBorrowingCapacityAccordionFeature>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-87"
      decimals="INF"
      id="f-436"
      unitRef="number">0.0561</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-88"
      decimals="INF"
      id="f-437"
      unitRef="number">0.0434</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inbx:DebtInstrumentPrincipalAndInterestTerm contextRef="c-87" id="f-438">P23M</inbx:DebtInstrumentPrincipalAndInterestTerm>
    <inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent
      contextRef="c-88"
      decimals="INF"
      id="f-439"
      unitRef="number">0.090</inbx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercent>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c-89" decimals="-5" id="f-440" unitRef="usd">9000000.0</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="c-90"
      decimals="INF"
      id="f-441"
      unitRef="number">0.020</inbx:DebtInstrumentPrepaymentFee>
    <inbx:DebtInstrumentPrepaymentFee
      contextRef="c-91"
      decimals="INF"
      id="f-442"
      unitRef="number">0.050</inbx:DebtInstrumentPrepaymentFee>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-443">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company&#x2019;s outstanding debt balance under the 2025 Loan Agreement consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including debt discount and final payment fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-92" decimals="-3" id="f-444" unitRef="usd">109000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-92" decimals="-3" id="f-445" unitRef="usd">8441000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-92" decimals="-3" id="f-446" unitRef="usd">100559000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s interest-only period will continue through February 2028, with principal payments beginning in March 2028. Future principal payments and final fee payments will be made as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DECEMBER 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-92" decimals="-3" id="f-448" unitRef="usd">43478000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-92" decimals="-3" id="f-449" unitRef="usd">52174000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <inbx:LongTermDebtMaturityAfterYearFour contextRef="c-92" decimals="-3" id="f-450" unitRef="usd">13348000</inbx:LongTermDebtMaturityAfterYearFour>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-92" decimals="-3" id="f-451" unitRef="usd">109000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-92" decimals="-3" id="f-452" unitRef="usd">8441000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-92" decimals="-3" id="f-453" unitRef="usd">100559000</us-gaap:LongTermDebt>
    <inbx:LongTermDebtLiquidityThreshold contextRef="c-93" decimals="-5" id="f-454" unitRef="usd">20000000.0</inbx:LongTermDebtLiquidityThreshold>
    <inbx:LongTermDebtLiquidityThreshold contextRef="c-94" decimals="-5" id="f-455" unitRef="usd">50000000.0</inbx:LongTermDebtLiquidityThreshold>
    <inbx:LongTermDebtLiquidityThreshold contextRef="c-95" decimals="-5" id="f-456" unitRef="usd">75000000.0</inbx:LongTermDebtLiquidityThreshold>
    <inbx:ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding
      contextRef="c-96"
      decimals="INF"
      id="f-457"
      unitRef="number">0.020</inbx:ClassOfWarrantOrRightIssuanceAsAPercentOfCommonStockOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-6" decimals="-5" id="f-458" unitRef="shares">2000000.0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-5" decimals="INF" id="f-459" unitRef="shares">140741</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-5"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">14.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-97" id="f-461">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-98" decimals="-5" id="f-462" unitRef="usd">1700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-92" decimals="3" id="f-463" unitRef="number">0.129</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt contextRef="c-99" decimals="-5" id="f-464" unitRef="usd">12200000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-99" decimals="-5" id="f-465" unitRef="usd">2400000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-466">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 29, 2024, upon effecting the Separation, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 120,000,000 shares of common stock and 15,000,000 shares of preferred stock, each with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Distribution and as of May 29, 2024, the Company had 14,475,904 shares of common stock outstanding. The Company issued one SEC-registered, publicly listed, share of Inhibrx for every four shares of the Former Parent&#x2019;s common stock held, resulting in 13,316,140 shares of common stock issued to common stockholders of the Former Parent. Upon the Distribution, the Former Parent retained an equity interest in the Company of 8%, or 1,157,926 shares. The Company issued 1,838 shares of common stock to Oxford in connection with the Oxford Warrants (as defined below) in the Distribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with certain institutional and other accredited investors, or Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company&#x2019;s common stock for $19.35 per share and pre-funded warrants to purchase 6,714,636 shares of the Company&#x2019;s common stock in a private placement transaction, or the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The pre-funded warrants were equity-classified and carried at the instruments&#x2019; fair value upon issuance. During the second quarter of 2024, certain Purchasers exercised 2,747,245 pre-funded warrants on a cashless basis for a net of 2,746,454 shares of the Former Parent&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Merger Agreement, the Former Parent entered into an Agreement Relating to the Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated as of January 22, 2024, by and between the Former Parent and each holder of the pre-funded warrants purchased in the Private Placement so that on the date of the Distribution, any remaining pre-funded warrants of the Former Parent not already exercised to purchase the Former Parent&#x2019;s common stock became exercisable for an equivalent number of shares of the Company&#x2019;s common stock at an exercise price of $0.0001 per share, pursuant to certain beneficial ownership limitations. The Company has evaluated the amendment and accounted for this as a modification to the original Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Separation and Distribution, each holder of outstanding pre-funded warrants received (i) $30.00 per pre-funded warrant in cash, less the applicable exercise price per share, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one pre-funded warrant of Inhibrx for every four of the Former Parent&#x2019;s pre-funded warrants held. Following the Separation and Distribution, pre-funded warrants to purchase 991,849 shares of the Company&#x2019;s common stock are outstanding at an exercise price of $0.0001 per share. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement, as amended, and will remain outstanding until exercised in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Oxford Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amended 2020 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Amended 2020 Loan Agreement, the Company issued equity-classified warrants to Oxford, or the 2020 Oxford Warrants, in two tranches: (i) 7,354 warrants with an exercise price of $17.00 and (ii) 40,000 warrants with an exercise price of $45.00. As part of the Separation and Distribution, each holder of eligible outstanding warrants received (i) $30.00 per warrant in cash, less the applicable exercise price per share (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx for every four of the Former Parent&#x2019;s warrants held. All outstanding warrants with an exercise price which exceeded the total consideration of $35.00 were canceled upon the Merger for no consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Separation, no Oxford Warrants were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2025 Loan Agreement, the Company issued warrants to Oxford, or the 2025 Oxford Warrants. The Company issued warrants to purchase 140,741 shares of the Company&#x2019;s common stock at an exercise price of $14.21 per share. The 2025 Oxford Warrants are exercisable upon issuance and will expire on January&#160;13, 2035. The 2025 Oxford Warrants are equity-classified and carried at the instruments&#x2019; fair value upon classification into equity, with no subsequent remeasurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance as of December&#160;31, 2025 and December&#160;31, 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future equity grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-100"
      decimals="INF"
      id="f-467"
      unitRef="shares">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-100"
      decimals="INF"
      id="f-468"
      unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-100"
      decimals="INF"
      id="f-469"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-100"
      decimals="INF"
      id="f-470"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-100"
      decimals="INF"
      id="f-471"
      unitRef="shares">14475904</us-gaap:CommonStockSharesOutstanding>
    <inbx:MergerExchangeRatio
      contextRef="c-31"
      decimals="INF"
      id="f-472"
      unitRef="number">4</inbx:MergerExchangeRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-32"
      decimals="INF"
      id="f-473"
      unitRef="shares">13316140</us-gaap:CommonStockSharesIssued>
    <inbx:MergerOwnershipPercentage contextRef="c-32" decimals="2" id="f-474" unitRef="number">0.08</inbx:MergerOwnershipPercentage>
    <us-gaap:StockOrUnitsAvailableForDistributions contextRef="c-31" decimals="0" id="f-475" unitRef="shares">1157926</us-gaap:StockOrUnitsAvailableForDistributions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-31"
      decimals="INF"
      id="f-476"
      unitRef="shares">1838</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-477"
      unitRef="shares">3621314</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-102"
      decimals="INF"
      id="f-478"
      unitRef="usdPerShare">19.35</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-103"
      decimals="INF"
      id="f-479"
      unitRef="shares">6714636</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="c-103"
      decimals="INF"
      id="f-480"
      unitRef="usdPerShare">19.3499</inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-104"
      decimals="INF"
      id="f-481"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inbx:ClassOfWarrantsOrRightsWarrantsExercised
      contextRef="c-105"
      decimals="INF"
      id="f-482"
      unitRef="shares">2747245</inbx:ClassOfWarrantsOrRightsWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-106"
      decimals="INF"
      id="f-483"
      unitRef="shares">2746454</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-104"
      decimals="INF"
      id="f-484"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-107"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">30.00</us-gaap:SaleOfStockPricePerShare>
    <inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant contextRef="c-32" decimals="INF" id="f-486" unitRef="right">1</inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant>
    <inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue
      contextRef="c-6"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">5.00</inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue>
    <inbx:MergerExchangeRatio
      contextRef="c-33"
      decimals="INF"
      id="f-488"
      unitRef="number">4</inbx:MergerExchangeRatio>
    <inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1 contextRef="c-4" decimals="INF" id="f-489" unitRef="shares">991849</inbx:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-104"
      decimals="INF"
      id="f-490"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inbx:DebtInstrumentNumberOfTranches
      contextRef="c-108"
      decimals="INF"
      id="f-491"
      unitRef="tranche">2</inbx:DebtInstrumentNumberOfTranches>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-109"
      decimals="INF"
      id="f-492"
      unitRef="shares">7354</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-109"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-110"
      decimals="INF"
      id="f-494"
      unitRef="shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-110"
      decimals="2"
      id="f-495"
      unitRef="usdPerShare">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-107"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">30.00</us-gaap:SaleOfStockPricePerShare>
    <inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant contextRef="c-6" decimals="INF" id="f-497" unitRef="right">1</inbx:ClassOfWarrantOrRightContingentValueRightPerWarrant>
    <inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue
      contextRef="c-6"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">5.00</inbx:ClassOfWarrantOrRightContingentValueRightPerWarrantValue>
    <inbx:MergerExchangeRatio contextRef="c-1" decimals="INF" id="f-499" unitRef="number">4</inbx:MergerExchangeRatio>
    <inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">35.00</inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-501" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-5" decimals="INF" id="f-502" unitRef="shares">140741</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-5"
      decimals="2"
      id="f-503"
      unitRef="usdPerShare">14.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance as of December&#160;31, 2025 and December&#160;31, 2024 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future equity grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-111"
      decimals="-3"
      id="f-505"
      unitRef="shares">3501000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-112"
      decimals="-3"
      id="f-506"
      unitRef="shares">3660000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-113"
      decimals="-3"
      id="f-507"
      unitRef="shares">992000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="-3"
      id="f-508"
      unitRef="shares">992000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="-3"
      id="f-509"
      unitRef="shares">499000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-116"
      decimals="-3"
      id="f-510"
      unitRef="shares">340000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-117"
      decimals="-3"
      id="f-511"
      unitRef="shares">141000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-118"
      decimals="-3"
      id="f-512"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-6" decimals="-3" id="f-513" unitRef="shares">5133000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-7" decimals="-3" id="f-514" unitRef="shares">4992000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-515">EQUITY COMPENSATION PLAN &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, the Company&#x2019;s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provided for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. The 2017 Plan was terminated in connection with the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Plan, the Company granted options with an exercise price equal to the fair market value of the Company&#x2019;s stock on the date of the option grant. The options were subject to four-year vesting with a one-year cliff and had a contractual term of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised during the year ended December 31, 2024 was $65.3&#160;million. Aggregate intrinsic value of stock options exercised is calculated using the fair value of common stock on the date of exercise. The total fair value of stock options vested during the year ended December 31, 2024 was $42.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Merger, there was no activity under the 2017 Plan and no stock options remained outstanding under the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Settlement of Stock Options Upon Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All outstanding options with an exercise price less than or equal to the total consideration of $35.00 vested immediately upon the Merger and were settled for the consideration of: (i) $30.00 per share in cash, less the applicable exercise price of their stock option and (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone. In connection with the acceleration of the eligible stock options, affecting 160 grantees, the Company recognized $39.3&#160;million in stock compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All outstanding options with an exercise price which exceeded the total consideration of $35.00 were canceled upon the Merger for no consideration. In connection with the cancellation of all unvested options with an exercise price above $35.00, affecting 7 grantees, the Company recognized all remaining stock compensation expense of $1.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, the Company adopted the 2024 Omnibus Incentive Plan, or the 2024 Plan, which provides for the issuance of incentive stock options, restricted and unrestricted stock awards, and other stock-based awards. As of December&#160;31, 2025, an aggregate of 4.0 million shares of common stock were authorized for issuance under the 2024 Plan, of which 0.4 million remained available for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants options with an exercise price equal to the fair market value of the Company&#x2019;s stock on the date of the option grant. All options granted to employees are subject to four-year vesting with a one-year cliff. All options granted to non-employee directors are subject to a one-year vesting term. All options have a contractual term of 10 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2024 Plan for the year ended December 31, 2025 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term &lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options exercised during the year ended December 31, 2025 was $4.7 million. The total fair value of stock options vested during the year ended December 31, 2025 was $17.4 million. No stock options were exercised or vested during the year ended December 31, 2024. The Company expects all outstanding stock options to vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company&#x2019;s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock options granted under the 2024 Plan using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the years ended December 31, 2025 and December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any stock options under the 2017 Plan during the years ended December 31, 2025 and December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 1 for further discussion in how the Company determines the assumptions used in the option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options under the 2024 Plan and 2017 Plan consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company had $25.9 million of total unrecognized stock-based compensation expense related to its stock options under the 2024 Plan, which is expected to be recognized over a weighted-average period of 2.56 years. As of December&#160;31, 2025, the Company had no remaining unrecognized stock-based compensation expense related to its stock options under the 2017 Plan following the termination of the plan subsequent to the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-119" id="f-516">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-120" id="f-517">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-119" id="f-518">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-14" decimals="-5" id="f-519" unitRef="usd">65300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-14" decimals="-5" id="f-520" unitRef="usd">42500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice
      contextRef="c-32"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">35.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare
      contextRef="c-32"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">30.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledCashPricePerCommonShare>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare contextRef="c-32" decimals="INF" id="f-523" unitRef="right">1</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightPerCommonShare>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare
      contextRef="c-32"
      decimals="2"
      id="f-524"
      unitRef="usdPerShare">5.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledContingentValueRightCashPerCommonShare>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-5" id="f-525" unitRef="usd">39300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice
      contextRef="c-32"
      decimals="2"
      id="f-526"
      unitRef="usdPerShare">35.00</inbx:ShareBasedPaymentArrangementOptionExercisePriceRangeSettledExercisePrice>
    <inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice
      contextRef="c-32"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">35.00</inbx:ClassOfWarrantOrRightCancelledThresholdExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-33" decimals="-5" id="f-528" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-122"
      decimals="-5"
      id="f-529"
      unitRef="shares">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-122"
      decimals="-5"
      id="f-530"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-123" id="f-531">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-124" id="f-532">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-125" id="f-533">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-123" id="f-534">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity under its 2024 Plan for the year ended December 31, 2025 is as follows (in thousands, except for per share data and years):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term &lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-126"
      decimals="-3"
      id="f-536"
      unitRef="shares">3660000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-126"
      decimals="2"
      id="f-537"
      unitRef="usdPerShare">15.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-125"
      decimals="-3"
      id="f-538"
      unitRef="shares">378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">17.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-125"
      decimals="-3"
      id="f-540"
      unitRef="shares">102000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">15.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-125"
      decimals="-3"
      id="f-542"
      unitRef="shares">435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">15.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-122"
      decimals="-3"
      id="f-544"
      unitRef="shares">3501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-122"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">16.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-125" id="f-546">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-122" decimals="-3" id="f-547" unitRef="usd">220342000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c-122"
      decimals="-3"
      id="f-548"
      unitRef="shares">1295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-122"
      decimals="2"
      id="f-549"
      unitRef="usdPerShare">15.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-125" id="f-550">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-122" decimals="-3" id="f-551" unitRef="usd">81773000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-125" decimals="-5" id="f-552" unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-125" decimals="-5" id="f-553" unitRef="usd">17400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-127"
      decimals="INF"
      id="f-554"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-555">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used by the Company to estimate the fair value of stock options granted under the 2024 Plan using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value, for the years ended December 31, 2025 and December&#160;31, 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-128" decimals="4" id="f-556" unitRef="number">0.0391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-129" decimals="4" id="f-557" unitRef="number">0.0456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-128" decimals="4" id="f-558" unitRef="number">0.8658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-129" decimals="4" id="f-559" unitRef="number">0.8632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-128" decimals="2" id="f-560" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-129" decimals="2" id="f-561" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-128" id="f-562">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-129" id="f-563">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-128"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">13.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-129"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">11.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-130" decimals="0" id="f-566" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-131" decimals="0" id="f-567" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for stock options under the 2024 Plan and 2017 Plan consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-569" unitRef="usd">6534000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-570" unitRef="usd">36875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-571" unitRef="usd">4604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-572" unitRef="usd">21643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="-3" id="f-573" unitRef="usd">11138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="-3" id="f-574" unitRef="usd">58518000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-122" decimals="-5" id="f-575" unitRef="usd">25900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-125" id="f-576">P2Y6M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-136" decimals="INF" id="f-577" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <inbx:LicenseAndGrantRevenueTextBlock contextRef="c-1" id="f-578">LICENSE REVENUE&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scithera, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Scithera License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2025, the Company entered into a License and Assignment Agreement, or the Scithera License Agreement, with Scithera, Inc., or Scithera, a newly formed biotechnology company that focuses on antibody-based molecules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Scithera License Agreement, the Company licensed to Scithera the right to use certain assets in the Company&#x2019;s antibody library to research, develop, and commercialize antibody-based molecules to certain targets. Additionally, the Company assigned to Scithera its agreement with NorthStar Medical Technologies, LLC for the development of radiopharmaceuticals for the treatment of cancer. The Company also agreed to make available to Scithera certain research materials useful for identifying, generating, and developing antibodies from antibody libraries to enable Scithera&#x2019;s use of the assets licensed under the Scithera License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent upon Scithera&#x2019;s achievement of specified funding events, Scithera was required to pay the Company $1.3 million as a non-refundable payment. In addition, Scithera may make additional future milestone payments of up to an aggregate of $41.25 million per target upon the achievement of certain milestone events, and potential royalty payments on net sales in the low- to mid-single digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the effective date of the agreement, the Company identified one performance obligation, which was the transfer of licenses to Scithera for the specified assets and all related materials and know-how. During the second quarter of 2025, Scithera achieved the specified funding event and made a non-refundable payment of $1.3 million to the Company. Upon notice of the achievement of such funding event, the Company re-assessed the transaction price to be $1.3 million, which was allocated to the single performance obligation. All remaining consideration under the agreement is variable consideration associated with the achievement of specified development milestones, and as a result, has been fully constrained (excluded) from the transaction price until such time that the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be reassessed at each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025, the Company completed its single performance obligation and recognized $1.3&#160;million at the point in time upon the completion of the transfer of all licensed materials and know-how. During the year ended December 31, 2025, the Company recognized $1.3 million of revenue and received a payment of $1.3&#160;million under the Scithera License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regeneron&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Option and License Agreement with bluebird bio, Inc., or bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retained all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird&#x2019;s internal restructuring and subsequent spin-out of 2seventy, and subsequently in April 2024, this agreement, or the 2020 Regeneron Agreement, was assigned to Regeneron Pharmaceuticals, Inc., or Regeneron, in connection with the divestiture of 2seventy&#x2019;s oncology and autoimmune pipeline to Regeneron.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee in exchange for a development license and an option in which Regeneron may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which Regeneron exercises its option, Regeneron will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5&#160;million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, pursuant to the option extension terms in the 2020 Regeneron Agreement, Regeneron requested to extend the option term for its third program by an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension at the point in time in which the extension was granted. In November 2024, Regeneron requested a second extension of the option term for an additional six months in exchange for an option extension fee of $0.1&#160;million. The Company recognized the $0.1&#160;million of revenue related to this extension at the point in time in which the extension was granted. The $0.2&#160;million related to the option extensions is recorded as accounts receivable in the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2024 and was collected in full during the first quarter of the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company recognized $0.2&#160;million of revenue related to this agreement. The Company did not recognize any revenue under this agreement during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;</inbx:LicenseAndGrantRevenueTextBlock>
    <inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock contextRef="c-1" id="f-579">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total revenue recorded in the Company&#x2019;s consolidated statements of operations (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;License fee revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scithera, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total license fee revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-137" decimals="-3" id="f-580" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-138" decimals="-3" id="f-581" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-139" decimals="-3" id="f-582" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-140" decimals="-3" id="f-583" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-141" decimals="-3" id="f-584" unitRef="usd">1300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-142" decimals="-3" id="f-585" unitRef="usd">200000</us-gaap:Revenues>
    <inbx:CollaborativeArrangementNonrefundablePayment contextRef="c-143" decimals="-5" id="f-586" unitRef="usd">1300000</inbx:CollaborativeArrangementNonrefundablePayment>
    <inbx:MaximumPotentialMilestonePayments contextRef="c-6" decimals="-4" id="f-587" unitRef="usd">41250000</inbx:MaximumPotentialMilestonePayments>
    <inbx:RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation
      contextRef="c-1"
      decimals="INF"
      id="f-588"
      unitRef="obligation">1</inbx:RevenueFromContractWithCustomerExcludingAssessedTaxNumberOfPerformanceObligation>
    <inbx:CollaborativeArrangementNonrefundablePayment contextRef="c-143" decimals="-5" id="f-589" unitRef="usd">1300000</inbx:CollaborativeArrangementNonrefundablePayment>
    <inbx:CollaborativeArrangementNonrefundablePayment contextRef="c-143" decimals="-5" id="f-590" unitRef="usd">1300000</inbx:CollaborativeArrangementNonrefundablePayment>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="c-143" decimals="-5" id="f-591" unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-144" decimals="-5" id="f-592" unitRef="usd">1300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <inbx:CollaborativeArrangementNonrefundablePayment contextRef="c-1" decimals="-3" id="f-593" unitRef="usd">1300000</inbx:CollaborativeArrangementNonrefundablePayment>
    <inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement
      contextRef="c-145"
      decimals="INF"
      id="f-594"
      unitRef="program">2</inbx:CollaborativeAgreementNumberOfRelatedProgramsToAgreement>
    <inbx:CollaborativeArrangementDevelopmentMilestoneReceivable contextRef="c-146" decimals="-5" id="f-595" unitRef="usd">51500000</inbx:CollaborativeArrangementDevelopmentMilestoneReceivable>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment contextRef="c-147" decimals="-5" id="f-596" unitRef="usd">100000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment contextRef="c-147" decimals="-5" id="f-597" unitRef="usd">100000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment contextRef="c-147" decimals="-5" id="f-598" unitRef="usd">100000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <inbx:CollaborativeArrangementNonrefundableUpfrontPayment contextRef="c-147" decimals="-5" id="f-599" unitRef="usd">100000</inbx:CollaborativeArrangementNonrefundableUpfrontPayment>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-148" decimals="-5" id="f-600" unitRef="usd">200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Revenues contextRef="c-140" decimals="-5" id="f-601" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-139" decimals="0" id="f-602" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-603">RELATED PARTY TRANSACTIONS &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business. These agreements are ratified by the Company&#x2019;s Board of Directors or a committee thereof pursuant to policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separation and Distribution&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, as discussed in Note 1, the Former Parent completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of common stock of the Company, or the Distribution. The Former Parent retained an equity interest in the Company of 8%, or 1,157,926 shares upon the Distribution. Accordingly, the Company identified the Acquirer as a related party following the Merger with the Former Parent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transition Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, the Company also entered into the Transition Services Agreement with the Former Parent under which the Company or one of its affiliates provide the Former Parent or other Sanofi entities with certain transition services for a limited time to ensure an orderly transition following the Separation. The services that the Company agreed to provide to the Former Parent or other Sanofi entities under the Transition Services Agreement include certain finance and accounting, including payroll, tax, and procurement, information technology, legal and intellectual property, clinical study support, technical operations, regulatory, quality assurance, commercial and medical affairs, and other services. The Former Parent pays the Company for any such services received by the Former Parent or other Sanofi entities, as applicable, at agreed amounts as set forth in the Transition Services Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025, the Company substantially completed all obligations under the Transition Services Agreement. The Company has not billed the Former Parent for any services under the Transition Services during the year ended December 31, 2025 and does not expect any future billings. During the year ended December 31, 2024, the Company billed the Former Parent for $0.3 million for services performed under the Transition Services Agreement, which was recognized as other income. The Company received approximately $0.2 million in cash during the year ended December 31, 2024, with the remaining balance of approximately $23,000 received during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Transition Services Agreement required the Former Parent to reimburse the Company for certain severance payments made by the Company to certain Company employees whose employment was terminated as a result of the Merger. During the year ended December 31, 2024, the Company billed the Former Parent for $1.0 million of severance payments to former employees, all of which was received as of December&#160;31, 2024. No further activity occurred during the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmacovigilance Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, the Company entered into a Pharmacovigilance Agreement with the Former Parent, pursuant to which the parties agreed to implement processes and procedures for sharing information as required for each party&#x2019;s compliance with its regulatory and pharmacovigilance responsibilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <inbx:MergerExchangeRatioProRateBasisPercentage contextRef="c-33" decimals="2" id="f-604" unitRef="number">0.92</inbx:MergerExchangeRatioProRateBasisPercentage>
    <inbx:MergerOwnershipPercentage contextRef="c-32" decimals="2" id="f-605" unitRef="number">0.08</inbx:MergerOwnershipPercentage>
    <us-gaap:StockOrUnitsAvailableForDistributions contextRef="c-33" decimals="0" id="f-606" unitRef="shares">1157926</us-gaap:StockOrUnitsAvailableForDistributions>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-149" decimals="-5" id="f-607" unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-150" decimals="-5" id="f-608" unitRef="usd">200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-151" decimals="-3" id="f-609" unitRef="usd">23000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-152" decimals="-5" id="f-610" unitRef="usd">1000000.0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-611">INCOME TAXES &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income (loss) before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss provision for before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax expense were as follows for the years ended December 31, 2025 and December&#160;31, 2024, respectively (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for the years ended December 31, 2025 and December&#160;31, 2024 was related to state income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made no material income tax payments during 2025 for Federal, state, and foreign jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, on January 1, 2025 on a prospective basis. As a result, the Company's rate reconciliation for 2025 is presented in accordance with the new disclosure requirements, while the reconciliation for 2024 continues to be presented under disclosure requirements in effect for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.726%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) 50% or more of our state tax provision relates to the California state jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (FIN 48)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of deferred tax assets and liabilities upon Transaction with Acquirer &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable gain related to Transaction with Acquirer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336(e) election&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 research and development capitalization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Separation, the Former Parent retained all rights associated with the unused federal and state NOLs and research tax credit carryforwards as of the date of the transaction to offset its future taxable income. As of December&#160;31, 2025, the Company had unused federal and state NOL carryforwards of approximately $183.1 million and $32.8 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to expire in 2034 if not utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The utilization of NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an &#x201c;ownership change&#x201d; may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50 percentage points or more in the ownership positions of certain stockholders or groups of stockholders during a rolling three-year period. Following the Separation, the Company has not completed a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 have occurred. It is possible that the Company may incur ownership changes in the future. If an ownership change has occurred, the Company&#x2019;s ability to use its NOL carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December&#160;31, 2025. Such objective evidence limits the ability to consider other subjective evidence such as the Company&#x2019;s projections for future growth. Based on this evaluation, as of December&#160;31, 2025, a valuation allowance of $52.5 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company&#x2019;s projections for growth. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, the Company did not have any gross unrecognized tax benefits. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company&#x2019;s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December&#160;31, 2025 or December&#160;31, 2024, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2025 and December&#160;31, 2024 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in the United States and various state jurisdictions. Following the Separation, the Company&#x2019;s tax years from 2024 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law. The OBBBA includes significant changes to U.S. tax and related laws. Some of the provisions of the OBBBA affecting corporations include the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, or TCJA, modifications to the Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income international tax provisions, an increase in the limit of the deduction of interest expense to 30% of earnings before interest, taxes, depreciation, and amortization, and reinstatement of 100% bonus depreciation deduction from the TCJA for eligible property acquired after January 19, 2025. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA&#x2019;s financial reporting implications have been recognized in our income tax provision for 2025. The incorporation of these effects resulted in no material impact on the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income (loss) before income taxes are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss provision for before income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-613" unitRef="usd">-140053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-3" id="f-614" unitRef="usd">1687574000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-617" unitRef="usd">-140053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-618" unitRef="usd">1687574000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-619">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax expense were as follows for the years ended December 31, 2025 and December&#160;31, 2024, respectively (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-620" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-621" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-622" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-623" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-624">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the income tax expense computed at the U.S. federal statutory income tax rate to the Company's income tax expense is as follows (in thousands) (after the adoption of ASU 2023-09):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.726%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.167%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) 50% or more of our state tax provision relates to the California state jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized as follows (in thousands) (prior to the adoption of ASU 2023-09): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;YEAR ENDED DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected income tax expense at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (FIN 48)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Elimination of deferred tax assets and liabilities upon Transaction with Acquirer &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable gain related to Transaction with Acquirer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336(e) election&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-625" unitRef="usd">-29411000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-626" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-627" unitRef="usd">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-628" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-629" unitRef="usd">29552000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-630" unitRef="number">-0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-3" id="f-631" unitRef="usd">-140000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-632" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-633" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-634" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="-3" id="f-635" unitRef="usd">354390000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="-3" id="f-636" unitRef="usd">10106000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <inbx:EffectiveIncomeTaxRateReconciliationPermanentItems contextRef="c-14" decimals="-3" id="f-637" unitRef="usd">6842000</inbx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-14" decimals="-3" id="f-638" unitRef="usd">28602000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-14" decimals="-3" id="f-639" unitRef="usd">-4651000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <inbx:EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount contextRef="c-14" decimals="-3" id="f-640" unitRef="usd">195694000</inbx:EffectiveIncomeTaxRateReconciliationEliminationOfDeferredTaxAssetsAndLiabilitiesUponTransactionWithAcquirerAmount>
    <inbx:EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount contextRef="c-14" decimals="-3" id="f-641" unitRef="usd">410226000</inbx:EffectiveIncomeTaxRateReconciliationNonTaxableGainRelatedToTransactionWithAcquirerAmount>
    <inbx:EffectiveIncomeTaxRateReconciliation336eElectionAmount contextRef="c-14" decimals="-3" id="f-642" unitRef="usd">665000</inbx:EffectiveIncomeTaxRateReconciliation336eElectionAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="-3" id="f-643" unitRef="usd">-124216000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-644" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-645">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 research and development capitalization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-646" unitRef="usd">40276000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-647" unitRef="usd">4726000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-648" unitRef="usd">8183000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-649" unitRef="usd">15718000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-6" decimals="-3" id="f-650" unitRef="usd">2355000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-7" decimals="-3" id="f-651" unitRef="usd">809000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-6" decimals="-3" id="f-652" unitRef="usd">1427000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-7" decimals="-3" id="f-653" unitRef="usd">893000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <inbx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-6" decimals="-3" id="f-654" unitRef="usd">1414000</inbx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <inbx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-7" decimals="-3" id="f-655" unitRef="usd">1776000</inbx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-656" unitRef="usd">46000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-7" decimals="-3" id="f-657" unitRef="usd">56000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-658" unitRef="usd">18000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-660" unitRef="usd">2000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-661" unitRef="usd">5000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-662" unitRef="usd">53721000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-663" unitRef="usd">23983000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-664" unitRef="usd">52508000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-665" unitRef="usd">21789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-666" unitRef="usd">1213000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-667" unitRef="usd">2194000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-668" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-669" unitRef="usd">575000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-6" decimals="-3" id="f-670" unitRef="usd">1213000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-7" decimals="-3" id="f-671" unitRef="usd">1619000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-672" unitRef="usd">1213000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-673" unitRef="usd">2194000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-677" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-153" decimals="-5" id="f-678" unitRef="usd">183100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-154" decimals="-5" id="f-679" unitRef="usd">32800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-680" unitRef="usd">52500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-681">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to current year tax positions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-682" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-3" id="f-683" unitRef="usd">4651000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-14" decimals="-3" id="f-685" unitRef="usd">4651000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-686" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-687" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="INF" id="f-688" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="INF" id="f-689" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-690" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-14" decimals="INF" id="f-691" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-692">LEASES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California, which contains an initial base rent of approximately $0.1 million per month with 2% annual escalations. In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020, which contained an initial base rent of approximately $30,000 per month with 2% annual escalations. Each of these leases expired in June 2025 with an option to extend the lease an additional five years, which was not included in the right-of-use asset and lease liabilities. Payments under each of the lease agreements included base rent plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Company entered into a new lease agreement for its existing facilities, or the 2024 Lease Agreement, for the period following the expiration of its two existing leases through June 2028, with an option to extend the lease an additional three years, which is not included in the right-of-use asset and lease liabilities. This agreement did not include any additional square footage. The 2024 Lease Agreement contains initial base rent of approximately $0.2 million per month with 3% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. The 2024 Lease Agreement also provided for four months of base rent abatement of $0.2&#160;million per month for the period of October 2024 through January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the 2024 Lease Agreement contains a lease which should be accounted for as a single modified contract with its existing lease agreements. As a result, the Company remeasured the operating lease liability, resulting in an increase to its operating lease liability and right-of-use asset of $6.3 million as of the lease&#x2019;s commencement date, which was determined to be the effective date of the 2024 Lease Agreement. The Company utilized an estimated incremental fully collateralized borrowing rate of 10.2% in its present value calculation as the 2024 Lease Agreement, which does not have a stated rate and did not have a readily determinable implicit rate. The estimated rate was determined using the rate of the 2025 Loan Agreement (as defined below) with Oxford entered into in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating right-of-use asset and operating lease liability as of December&#160;31, 2025 and December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2025 and December&#160;31, 2024, the Company recognized operating lease expense of $3.9 million and $3.4 million, respectively. During the years ended December 31, 2025 and December&#160;31, 2024, the Company paid $2.3 million and $1.7 million for amounts included in the measurement of the operating lease liability, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025 and December&#160;31, 2024, the Company&#x2019;s operating lease had a remaining term of 2.5 years and 3.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 10.2% as of December&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental commitments for the Company&#x2019;s operating leases reconciled to the operating lease liability are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-155" id="f-693">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth contextRef="c-155" decimals="-5" id="f-694" unitRef="usd">100000</inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inbx:LesseeOperatingLeaseAnnualEscalations
      contextRef="c-155"
      decimals="INF"
      id="f-695"
      unitRef="number">0.02</inbx:LesseeOperatingLeaseAnnualEscalations>
    <inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth contextRef="c-156" decimals="-3" id="f-696" unitRef="usd">30000</inbx:LesseeOperatingLeaseInitialBaseRentExpensePerMonth>
    <inbx:LesseeOperatingLeaseAnnualEscalations
      contextRef="c-156"
      decimals="INF"
      id="f-697"
      unitRef="number">0.02</inbx:LesseeOperatingLeaseAnnualEscalations>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-155" id="f-698">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <inbx:LesseeOperatingLeaseNumberOfContracts
      contextRef="c-157"
      decimals="INF"
      id="f-699"
      unitRef="contract">2</inbx:LesseeOperatingLeaseNumberOfContracts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-158" id="f-700">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseExpense contextRef="c-157" decimals="-5" id="f-701" unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <inbx:OperatingLeaseAnnualEscalationsPercentage
      contextRef="c-157"
      decimals="INF"
      id="f-702"
      unitRef="number">0.03</inbx:OperatingLeaseAnnualEscalationsPercentage>
    <inbx:OperatingLeasesContractAbatementPeriod contextRef="c-157" id="f-703">P4M</inbx:OperatingLeasesContractAbatementPeriod>
    <inbx:OperatingLeaseAbatementPeriodAmount contextRef="c-157" decimals="-5" id="f-704" unitRef="usd">200000</inbx:OperatingLeaseAbatementPeriodAmount>
    <inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement contextRef="c-157" decimals="-3" id="f-705" unitRef="usd">6300000</inbx:RemeasurementOfOperatingLeaseLiabilityAndRightOfUseAssetInConnectionWith2024LeaseAgreement>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-6" decimals="3" id="f-706" unitRef="number">0.102</us-gaap:LesseeOperatingLeaseDiscountRate>
    <inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock contextRef="c-1" id="f-707">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating right-of-use asset and operating lease liability as of December&#160;31, 2025 and December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-708" unitRef="usd">5535000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-709" unitRef="usd">7338000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-710" unitRef="usd">2326000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-711" unitRef="usd">1595000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-712" unitRef="usd">4127000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-713" unitRef="usd">6453000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-714" unitRef="usd">6453000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-715" unitRef="usd">8048000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-716" unitRef="usd">3900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-14" decimals="-5" id="f-717" unitRef="usd">3400000</us-gaap:OperatingLeaseExpense>
    <inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability contextRef="c-1" decimals="-5" id="f-718" unitRef="usd">2300000</inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability>
    <inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability contextRef="c-14" decimals="-5" id="f-719" unitRef="usd">1700000</inbx:OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-6" id="f-720">P2Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-7" id="f-721">P3Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-722" unitRef="number">0.102</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-723" unitRef="number">0.102</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-724">&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum rental commitments for the Company&#x2019;s operating leases reconciled to the operating lease liability are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AS OF DECEMBER 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-725" unitRef="usd">2855000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-726" unitRef="usd">2941000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-727" unitRef="usd">1492000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-728" unitRef="usd">7288000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-729" unitRef="usd">835000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-730" unitRef="usd">6453000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-731" unitRef="usd">2326000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-732" unitRef="usd">4127000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-733">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;Additionally, as of December&#160;31, 2025 and December&#160;31, 2024, Mark P. Lappe, the Company&#x2019;s Chief Executive Officer, David Matly, the Company&#x2019;s President, and Kelly D. Deck, the Company&#x2019;s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-734">SUBSEQUENT EVENTS &lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;First Amendment to Loan Agreement with Oxford&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;18, 2026, the Company entered into the First Amendment to Loan and Service Agreement with Oxford, or the March 2026 Amendment. The March 2026 Amendment provides for an additional tranche, or the Term B Loans, in an aggregate principal amount of $75.0&#160;million, upsized from $50.0 million originally available under the 2025 Loan Agreement, prior to the March 2026 Amendment, collectively with the prior $100.0 million under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025 Loan Agreement, the Oxford Term Loans. $75.0 million of the Term B Loans was funded on the date of the March 2026 Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All obligations under the 2025 Loan Agreement, as amended, and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all present and future assets of the Company, subject to certain exceptions. The 2025 Loan Agreement, as amended, includes customary events of default, including instances of a material adverse change in the Company&#x2019;s operations, that may require prepayment of the outstanding term loans. The March 2026 Amendment updated the minimum liquidity threshold covenant, tested at all times, to $40.0&#160;million, not subject to future increases. All other terms of the 2025 Loan Agreement remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the March 2026 Amendment tranche of funding, the Company issued warrants to Oxford to purchase 21,518 shares of the Company&#x2019;s common stock at an exercise price of $69.71 per share. The warrants are immediately exercisable, and the exercise period will expire 10 years from the date of issuance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-159" decimals="-5" id="f-735" unitRef="usd">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-160" decimals="-5" id="f-736" unitRef="usd">50000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-87" decimals="-5" id="f-737" unitRef="usd">100000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <inbx:LongTermDebtLiquidityThreshold contextRef="c-161" decimals="-5" id="f-738" unitRef="usd">40000000.0</inbx:LongTermDebtLiquidityThreshold>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-162" decimals="0" id="f-739" unitRef="shares">21518</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-162"
      decimals="2"
      id="f-740"
      unitRef="usdPerShare">69.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-163" id="f-741">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-164" id="f-742">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-164" id="f-743">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-164" id="f-744">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-164" id="f-745">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-746">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
